Associations and Affiliations еЌЏеЉћеЌ•дЅЌ PCR Complex Cardiovascular Therapeutics European Association of Percutaneous Cardiovascular Intervention European Society of Cardiology Sociedad Latinoamericana de CardiologГa Intervencionista Angioplasty Summit - TCTAP Cardiovascular Research Technologies Asian Interventional Cardiovascular Therapeutics New Cardiovascular Horizons Division of Medicine and Health, Chinese Academy of Engineering Asian-Pacific Society of Interventional Cardiology Cardiovascular Society of Cross-Straits Medicine Exchange Association China Cardiovascular Promotive Association, China International Exchange and Promotive Association for Medicine and Health Care Hong Kong College of Cardiology Chinese Medical Journal Toyohashi Heart Center, Toyohashi, Japan National Taiwan University Hospital, Taiwan, China Guangdong Provincial Cardiovascular Institute, China Affiliated Ruijin Hospital of Shanghai Jiao Tong University School of Medicine, China Affiliated Zhongshan Hospital of Fudan University, China Affiliated Nanjing First Hospital of Nanjing Medical University, China Affiliated Xijing Hospital of the Fourth Military Medical University, China Shenyang Northern Hospital, China Affiliated Chaoyang Hospital of Capital Medical University, China Peking University PeopleвЂ™s Hospital, China Chinese PLA General Hospital, China Affiliated An Zhen Hospital of Capital Medical University, China National Center for Cardiovascular Diseases and Fu Wai Hospital, China PCR ж—Ґжњ¬е¤Ќжќ‚еїѓиЎЂз®ЎжІ»з–—е¦е¤§дјљ ж¬§жґІеїѓиЎЂз®Ўд»‹е…ҐжІ»з–—еЌЏдјљ ж¬§жґІеїѓи„Џз—…е¦дјљ ж‹‰дёЃзѕЋжґІд»‹е…Ґеїѓи„Џз—…е¦дјљ йџ©е›ЅAngioplasty Summit - TCTAP зѕЋе›ЅеїѓиЎЂз®Ўз ”з©¶жЉЂжњЇдјљи®® дєљжґІеїѓиЎЂз®Ўд»‹е…ҐжІ»з–—е¦дјљи®® зѕЋе›ЅеїѓиЎЂз®Ўж–°ењ°е№ізєїдјљи®® дёе›Ѕе·ҐзЁ‹й™ўеЊ»иЌЇеЌ«з”џе¦йѓЁ дєље¤Єд»‹е…Ґеїѓи„Џз—…е¦дјљ жµ·еіЎдё¤еІёеЊ»иЌЇеЌ«з”џдє¤жµЃе¦дјљеїѓиЎЂз®Ўдё“дёље§”е‘�дјљ дёе›ЅеЊ»з–—дїќеЃҐе›Ѕй™…дє¤жµЃдїѓиї›дјљеїѓиЎЂз®Ўз–ѕз—…з®Ўзђ†е§”е‘�дјљ й¦™жёЇеїѓи„Џз—…е¦й™ў дёеЌЋеЊ»е¦жќ‚еї—и‹±ж–‡з‰€ ж—Ґжњ¬дё°жЎҐеїѓи„Џдёеїѓ дёе›Ѕе›Ѕз«‹еЏ°ж№ѕе¤§е¦еЊ»й™ў е№їдёњзњЃеїѓиЎЂз®Ўз—…з ”з©¶ж‰Ђ дёЉжµ·дє¤йЂље¤§е¦еЊ»е¦й™ўй™„е±ћз‘ћй‡‘еЊ»й™ў е¤Ќж—¦е¤§е¦й™„е±ћдёе±±еЊ»й™ў еЌ—дє¬еЊ»з§‘е¤§е¦й™„е±ћеЌ—дє¬з¬¬дёЂеЊ»й™ў з¬¬е››е†›еЊ»е¤§е¦й™„е±ћиҐїдє¬еЊ»й™ў жІ€й�іе†›еЊєжЂ»еЊ»й™ў й¦–йѓЅеЊ»з§‘е¤§е¦й™„е±ћжњќй�іеЊ»й™ў еЊ—дє¬е¤§е¦дєєж°‘еЊ»й™ў дёе›Ѕдєєж°‘и§Јж”ѕе†›жЂ»еЊ»й™ў й¦–йѓЅеЊ»з§‘е¤§е¦й™„е±ће®‰иґћеЊ»й™ў е›Ѕе®¶еїѓиЎЂз®Ўз—…дёеїѓй�ње¤–еЊ»й™ў Transcatheter Cardiovascular Therapeutics 2012 T H E WO R L DвЂ™S PR EM IER INT ERVENT IO NA L EXP ER IENCE TCT Comes to Miami in 2012 SAVE THE DATE October 22-26, 2012 Miami Beach Convention Center MIAMI, FLORIDA www.tctconference.com Join the session PCR@CIT How Should I Treat on High risk acute coronary syndrome in patients with multivessel disease Friday 16th March at 2:00pm, Function B Chairpersons: Jean Marco, Run-Lin Gao Presenters: Shaoliang Chen, Yundai Chen, Thomas Cuisset, Junbo Ge, Kari NiemelГ¤, Goran Stankovic On a case-based format, this session will involve 3 diЖЎerent cardiovascular physicians who will discuss what they would have done with a speciпѓћc patient case, with the aim of understanding the various treatment rationales. Two cases will be discussed: ACS patient with MVD involving bifurcation / LM ACS patient with MVD involving CTO DonвЂ™t miss EAPCI-EuroPCR/ESC@CIT Current Management of NSTEMI-ACS 8:30am-10:30am, Saturday, March 17th, 2012 - Room309A Moderators: Jean Fajadet, Hongbin Yan CIT 2012 www.citmd.com TABLE OF CONTENTS Venue and Floor Plan 001 Welcome Message 004 Organization 005 General Information 016 Program at a Glance 019 Live Case Sites 021 Detailed Program 022 Thursday, March 15, 2012 022 Friday, March 16, 2012 040 Saturday, March 17, 2012 052 Sunday, March 18, 2012 072 Poster Program еЈЃжЉҐдє¤жµЃ 083 ж¬ўиїЋиѕћ 090 е¤§дјљз»„з»‡з»“жћ„ 091 дјљи®®дїЎжЃЇ 101 ж—ҐзЁ‹дёЂи§€иЎЁ 103 з¤єж•™жј”з¤єдёеїѓ 105 дјљи®®иЇ¦з»†ж—ҐзЁ‹ 106 2012е№ґ3жњ€15ж—Ґ ж�џжњџе›› 106 2012е№ґ3жњ€16ж—Ґ ж�џжњџдє” 122 2012е№ґ3жњ€17ж—Ґ ж�џжњџе… 133 2012е№ґ3жњ€18ж—Ґ ж�џжњџж—Ґ 150 CIT Hands-on Center е®ћд№ дёеїѓ 158 Exhibit Floor Plan е±•дЅЌе›ѕ 166 Exhibitors еЏ‚е±•еЌ•дЅЌ 167 Acknowledgment 1 188 Sponsored Services 189 Acknowledgment 2 190 Acknowledgment 3 191 Map ењ°е›ѕ 192 CIT 2012 www.citmd.com VENUE AND FLOOR PLAN дјљењєе№ійќўе›ѕ L1 Poster Area Cyber Station дёЉзЅ‘еЊє еЈЃжЉҐеЊє Function Hall C е¤љеЉџиѓЅC B Function Hall B е¤љеЉџиѓЅB Function Hall A е¤љеЉџиѓЅA A C D N A B D Faculty Lounge /Speaker Ready Room (SRR) дё»еёе›ўж€ђе‘�дј‘жЃЇеЊє/иЇ•з‰‡е®¤ Scientiп¬Ѓc Exhibition Hall е¦жњЇе±•и§€ Functional Areas еЉџиѓЅеЊє - Industrial Exhibition дјЃдёље±•и§€ - Registration жіЁе†ЊеЊє - Cyber Station дёЉзЅ‘еЊє - Express Registration и‡ЄеЉ©жіЁе†ЊеЊє - Poster Area еЈЃжЉҐеЊє - CIT On-demand Service CITж—ҐзЁ‹е®ћж—¶е›ћж”ѕжµЏи§€еЊє D-Dining Area и‡ЄеЉ©й¤ђз”Ёй¤ђеЊє LocationпјљExhibition Hall 5, CNCC з”Ёй¤ђењ°з‚№пјљ е›Ѕе®¶дјљи®®дёеїѓењ°дё‹дёЂе±‚5еЏ·е±•еЋ… 001 C - CIT App Help Center CITи‹№жћњзЁ‹еєЏжЉЂжњЇж”ЇжЊЃдёеїѓ CIT 2012 www.citmd.com VENUE AND FLOOR PLAN дјљењєе№ійќўе›ѕ L3 жґІй™…й…’еє—иїће»Љ Walkway to InterContinental Hotel VIP-2 305 303 AB 302 жґІй™…й…’еє—иїће»Љ Walkway to Inter Continental Hotel 309A E 308 309B 310 307 AB AB 306 301 311 AB AB AB VIP-1 F Auditorium жЉҐе‘ЉеЋ… йЂљеѕЂе›Ѕе®¶дјљи®®дёеїѓе¤§й…’еє— To Indoor walkway to CNCC Grand Hotel N E CIT Hands-on Center CITе®ћд№ дёеїѓ - 301AB Abbott - 302A Boston Scientiп¬Ѓc - 302B Medtronic - 303A Terumo F дё‰е±‚е±•еЊє - GE Total Solution Booth йЂљз”Ёз”µж°”е±•еЊє - CIT 10-year Exhibit Area CITеЌЃе‘Ёе№ґе±•з¤єеЊє - 303B St.Jude - 305 Media Room еЄ’дЅ“е·ҐдЅњй—ґ 002 CIT 2012 www.citmd.com VENUE AND FLOOR PLAN дјљењєе№ійќўе›ѕ L4 дё»дјљењє G йЂљеѕЂе›Ѕе®¶дјљи®®дёеїѓе¤§й…’еє— The Outdoor walkway to CNCC Grand Hotel N G Plenary Hall A (Main Arena, for the morning of March 16 ONLY) е¤§дјље ‚AеЊє (дё»дјљењєпјЊ3жњ€16ж—ҐдёЉеЌ€) Plenary Hall (Welcome Banquet, March 16) е¤§дјље ‚ (3жњ€16ж—Ґж¬ўиїЋж™ље®ґ) 003 CIT 2012 www.citmd.com WELCOME MESSAGE Dear colleagues and friends, It gives me great pleasure to announce to you all that CIT will be celebrating its 10 th anniversary at China Interventional Therapeutics (CIT) 2012 in partnership with TCT on Thursday, March 15th through Sunday, March 18th, 2012 at the China National Convention Center (CNCC). CIT2012 is organized by Chinese Medical Association, CIT Board of Directors, Chinese Society of Cardiology, and Cardiovascular Research Foundation / Transcatheter Cardiovascular Therapeutics (TCT), and co-sponsored by PCR, Complex Cardiovascular Therapeutics, European Association of Percutaneous Cardiovascular Intervention, European Society of Cardiology, Sociedad Latinoamericana de CardiologГa Intervencionista, Angioplasty Summit - TCTAP, Cardiovascular Research Technologies, Asian Interventional Cardiovascular Therapeutics, New Cardiovascular Horizons, Division of Medicine and Health, Chinese Academy of Engineering, Asian-Pacific Society of Interventional Cardiology, Cardiovascular Society of Cross-Straits Medicine Exchange Association, China Cardiovascular Promotive Association, China International Exchange and Promotive Association for Medicine and Health Care, Hong Kong College of Cardiology, and Chinese Medical Journal. CIT2012 will provide more than 360 hours' education courses, 1100 didactic presentations in 150 sessions at 18 meeting rooms, and 50 live cases transmission during its three-and-half-day program. The grand opening and plenary CIT-TCT session will take place in the morning of March 16th, and the results of late-breaking clinical trials will be released on March 16th and 17th. Comprehensive program will feature the four major areas of interventional cardiology: coronary, endovascular, structural heart disease, and heart rhythm. Sessions are designed to provide information and resources that can be immediately translated into improved patient care. PCR, CCT, EAPCI, SOLACI, Angioplasty Summit, CRT, AICT, NCVH, and HKSTENT will organize more productively joint sessions at CIT 2012. Original researches are presented in the forms of oral and poster abstracts, late-breaking clinical trials, topicoriented symposia, workshops, and concurrent sessions. The basic research, advanced interventional techniques, interventional pharmacology, cardiovascular prevention, and cardiovascular imaging are also covered in-depth. As the largest interventional cardiology meetings and one of the most educational teaching courses in Asia Pacific region, there are more than 5,500 experts, cardiologists, radiologists, vascular medicine specialists, industrial partners and other health care professionals with a special interest in the field of interventional cardiology will attend the meeting. Participants will have the opportunities to share scientific information and the latest advances, to exchange expertise in interventional cardiology, to renew our friendship, and to increase worldwide collaboration. The congress will also provide a unique opportunity for the industries to exhibit their new products and to contact with the cardiologists more closely. The meeting venue of CIT 2012 is still the CNCC, China's largest and the most modern international conference center with primary location and completed facilities. It is located in the heart of Beijing Olympic Green, standing right next to the Bird Nest (China National Stadium), Water Cube (National Aquatic Center) and National Indoor Stadium. Beijing is a highly civilized and ancient city rich in historical sites and full of cultural events. The city is also an international metropolis with modern and efficient tourist systems. I cordially welcome you to CIT2012 in partnership with TCT and to join us to celebrate the 10th anniversary of CIT! Sincerely Yours, Run-Lin Gao, MD, FACC, FSCAI Professor of Medicine Chairman, China Interventional Therapeutics (CIT) 004 CIT 2012 www.citmd.com ORGANIZATION Honorary Chairman Weifeng Shen, MD Baoqi Jiang, MD Zhu Chen, MD Gregg W. Stone, MD Ruoyi Ke, MD Takahiko Suzuki, MD Yuannan Ke, MD Chairman Haichang Wang, MD Huatai Li, MD Run-Lin Gao, MD Weimin Wang, MD Shuguang Lin, MD Yuejin Yang, MD Guoshu Liu, MD Co-Chairman Shu Zhang, MD Yili Liu, MD Martin B. Leon, MD Guoying Zhu, MD Yuqing Liu, MD Jieming Mao, MD Chairman of Scientific Committee Dayi Hu, MD Honorary Co-Chairmen of Organizing Committee Shengshou Hu, MD Course Co-Directors Jilin Chen, MD Jiyan Chen, MD Yanfei Liu, MD Guoming Qi, MD Shengli Yang, MD Shaoliang Chen, MD Junbo Ge, MD Yaling Han, MD Secretary General Bo Xu, MBBS Dejia Huang, MD Yong Huo, MD Guoliang Jia, MD Shiliang Jiang, MD Osamu Katoh, MD Yean-Leng Lim, MD, PhD Shuzheng Lu, MD Changsheng Ma, MD Jean Marco, MD Seung-Jung Park, MD, PhD Shubin Qiao, MD Shigeru Saito, MD Patrick W. Serruys, MD, PhD 005 Advisory Committee Haozhu Chen, MD Youfang Ni, MD Luhua Shen, MD Fangzheng Wang, MD Fengzhi Wang, MD Yinsheng Wu, MD Xifu Yan, MD Dingyi Zeng, MD Aiqing Zhou, MD Jintai Zhou, MD Bingrang Zhao, MD Wenling Zhu, MD Junzhu Chen, MD Mingzhe Chen, MD Shulan Chen, MD Zaijia Chen, MD Changcong Cui, MD Yuhua Dai, MD Fusheng Gu, MD Jingxuan Guo, MD Congxin Huang, MD Zhenwen Huang, MD Scientific Committee Alexandre Abizaid, MD, PhD Maurice Buchbinder, MD Kejiang Cao, MD Fang Chen, MD Yundai Chen, MD Chung-Seung Chiang, MD Antonio Colombo, MD Costantino R. Costantini, MD, PhD Donald E. Cutlip, MD CIT 2012 www.citmd.com ORGANIZATION Zhimin Du, MD Huay Cheem Tan, MD Haibo Liu, MD Eric Eeckhout, MD, PhD Etsuo Tsuchikane, MD, PhD Jian Liu, MD Jean Fajadet, MD Renu Virmani, MD Xuebo Liu, MD Quan Fang, MD Ron Waksman, MD Yuyang Liu, MD Weiyi Fang, MD Craig M. Walker, MD Jianfang Luo, MD Xianghua Fu, MD Jian'an Wang, MD Raghotham R. Patlola, MD Luyue Gai, MD Lefeng Wang, MD Jie Qian, MD Wei Gao, MD Stephan Windecker, MD Juying Qian, MD Liliana R. Grinfeld, MD Yawei Xu, MD Xiantao Song, MD Eberhard Grube, MD Hongbing Yan, MD Ning Tan, MD Wenyi Guo, MD Xinchun Yang, MD Yongjian Wu, MD Ben He, MD Yanzong Yang, MD Jinqing Yuan, MD David E. Kandzari, MD Alan C. Yeung, MD Bin Zhang, MD Adnan Kastrati, MD Bo Yu, MD Qi Zhang, MD Spencer B. King III, MD Ruiyan Zhang, MD Ajay J. Kirtane, MD, SM Yujie Zhou, MD Mitchell W. Krucoff, MD Eisho Kyo, MD Organizing Committee Alexandra J. Lansky, MD Jue Chen, MD Jianjun Li, MD Lei Ge, MD Weimin Li, MD Wei Guo, MD Zhanquan Li, MD Wei Hua, MD Roxana Mehran, MD Yongmao Jiang, MD Ian T. Meredith, MBBS, PhD Xiongjing Jiang, MD Gary S. Mintz, MD Zening Jin, MD Marie-Claude Morice, MD Quanmin Jing, MD Jeffrey W. Moses, MD Paul Hsien-Li Kao, MD Thach Nguyen, MD Michael Kang-Yin Lee, MD Masahiko Ochiai, MD Lang Li, MD Xuewen Qin, MD Yi Li, MD Horst Sievert, MD Yue Li, MD 006 CIT 2012 www.citmd.com ORGANIZATION International Faculty Alexandre Abizaid, MD, PhD Brazil Praveer Agarwal, MD India Frank Ahmann, MBA USA Tamzeed Ahmed, MD Bangladesh Takashi Akasaka, MD Japan Erol Akgul, MD Turkey Thomas Alexander, MD India Dominic Allocco, MD USA Yaron Almagor, MD Israel Brigadier S. Aziz, MBBS Pakistan Joseph D. Babb, MD USA Jacek Bialkowski, MD Poland Vikas Bisne, MD India Maurice Buchbinder, MD USA Davide Capodanno, MD Italy Chong-Guan Chan, MD Malaysia Praveen Chandra, MD India 007 Paul TL Chiam, MBBS Singapore Alfredo R. Galassi, MD Italy David E. Kandzari, MD USA Kenneth Chin, MBBS Malaysia Michael Gertner, MD USA Soo-Jin Kang, MD, PhD South Korea Gim-Hooi Choo, MD Malaysia Liliana R. Grinfeld, MD Argentina Elias Kassab, MD USA Antonio Colombo, MD Italy Eberhard Grube, MD Germany Adnan Kastrati, MD Germany Costantino O. Costantini, MD Brazil Sema GГјneri, MD Turkey Osamu Katoh, MD Japan Costantino R. Costantini, MD, PhD Brazil Yuji Hamazaki, MD Japan Pham Gia Khai, MD, PhD Vietnam Thomas Cuisset, MD, PhD France Chip B. Hance, BS, MBA USA Ferdinand Kiemeneij, MD, PhD The Netherlands Donald E. Cutlip, MD USA Tetsuya Hata, MD Japan Spencer B. King III, MD USA Debabrata Dash, MD India Dongming Hou, MD, PhD USA Yoshihisa Kinoshita, MD Japan Keith D. Dawkins, MD USA Pham Manh Hung, MD, PhD Vietnam Ajay J. Kirtane, MD, SM USA Giuseppe De Luca, MD, PhD Italy Seung-Ho Hur, MD, PhD South Korea Bon-Kwon Koo, MD, PhD South Korea Ajit G. Desai, MD India Hweung Kon Hwang, MD, PhD South Korea Jan Kovac, MD UK Devang Desai, MD India Fumiaki Ikeno, MD Japan Mitchell W. Krucoff, MD USA W. Britton Eaves, MD USA Mohammad Ishaq, MBBS Pakistan Eisho Kyo, MD Japan Javier Escaned, MD, PhD Spain Atilla Iyisoy, MD Turkey Kai Huat Lam, MD Malaysia Jean Fajadet, MD France Rajneesh Jain, MD India Alexandra J. Lansky, MD USA William F. Fearon, MD USA Yangsoo Jang, MD, PhD South Korea Nae Hee Lee, MD, PhD South Korea Fausto Feres, MD Brazil Haizal Haron Kamar, MBBS Malaysia Martin B. Leon, MD USA CIT 2012 www.citmd.com ORGANIZATION Michael Lim, MD Singapore Sundeep Mishra, MD India Kenan Ovunc, MD Turkey Patrick W. Serruys, MD, PhD The Netherlands Richard Lim, MBBS, MD Australia Rosli Mohd Ali, MD Malaysia Ramazan Г–zdemir, MD Turkey Imad Sheiban, MD Italy Yean-Leng Lim, MD, PhD Australia Marie-Claude Morice, MD France Seung-Jung Park, MD, PhD South Korea Won-Heum Shim, MD, PhD South Korea Yean-Teng Lim, MD Singapore Jeffrey W. Moses, MD USA Raghotham R. Patlola, MD USA Eak-Kyun Shin, MD, PhD South Korea Sidney Tsz Ho Lo, MD Australia Martin MГ¶ckel, MD Germany Jayesh S. Prajapati, MD India Toshiro Shinke, MD Japan William L. Lombardi, MD USA Michael A. Mussallem USA Jenny Zhen Qin, MS USA Horst Sievert, MD Germany Josef Ludwig, MD Germany Jihad Mustapha, MD USA Sufia Rahman, MD Bangladesh Charles A. Simonton, MD USA Yasuhiro Makita, MD Japan Muhammad Munawar, MD Indonesia Sudhir Rathore, MD UK Pieter C. Smits, MD, PhD The Netherlands Fazila Tun Nesa Malik, MD Bangladesh Toshiya Muramatsu, MD Japan Johan H. C. Reiber, PhD The Netherlands Goran Stankovic, MD Serbia Jean Marco, MD France Yoshinobu Murasato, MD, PhD Japan Jason H. Rogers, MD USA Pieter R. Stella, MD The Netherlands Motomaru Masutani, MD, PhD Japan Aravinda Nanjundappa, MD USA Manoj Kumar Rohit, MD India Gregg W. Stone, MD USA Samuel K. Mathew, MD India Swee Choon Ng, MD Malaysia Martin T. Rothman, MD USA Neil E. Strickman, MD USA Fina Mauri, MD, PhD Spain Quang Tuan Nguyen, MD Vietnam Carlos E. Ruiz, MD, PhD USA Satoru Sumitsuji, MD Japan Roxana Mehran, MD USA Thach Nguyen, MD, PhD USA Witold Ruzyllo, MD Poland Harry Suryapranata, MD, PhD The Netherlands Sameer Mehta, MD USA Kari NiemelГ¤, MD Finland Shigeru Saito, MD Japan I Gde Rurus Suryawan, MD Indonesia Carlos Mena, MD USA Masahiko Ochiai, MD, PhD Japan Gustavo Samaja, MD Argentina Malgorzata Szkutnik, MD Poland Ian T. Meredith, MBBS, PhD Australia Masaaki Okutsu, MD Japan Teguh Santoso, MD, PhD Indonesia Seung-Jea Tahk, MD, PhD South Korea Gary S. Mintz, MD USA Yoshinobu Onuma, MD Japan Markus P. Schlaich, MD, PhD Australia Akihiko Takahashi, MD Japan 008 CIT 2012 www.citmd.com ORGANIZATION Huay Cheem Tan, MD Singapore Stephan Windecker, MD Switzerland Ching-Chang Fang, MD Taiwan, China Tak-Fu Tse, MD Hong Kong, China Damras Tresukosol, MD Thailand Joo-Young Yang, MD South Korea William Kongto Hau, PhD Hong Kong, China Chuen-Den Tseng, MD, PhD Taiwan, China Etsuo Tsuchikane, MD, PhD Japan Yee Guan Yap, MD Malaysia Duncan Hung-Kwong Ho, MD Hong Kong, China Wei-Kung Tseng, MD Taiwan, China Wasan Udayachalerm, MD Thailand Alan C. Yeung, MD USA I-Chang Hsieh, MD Taiwan, China Kin-Lam Tsui, MD Hong Kong, China Kinzo Ueda, MD, PhD Japan Hiroyoshi Yokoi, MD Japan Chien-Ming Huang, MD Taiwan, China Ping-Tim Tsui, MBBS, MBA Hong Kong, China Yuichi Ujiie, MD Japan Fuminobu Yoshimachi, MD, PhD Japan Paul Hsien-Li Kao, MD Taiwan, China Shih-Pu Wang, MD Taiwan, China Mujeeb Ul-Haq, MD Pakistan Robaayah Zambahari, MD Malaysia Vincent On-Hing Kwok, MD Hong Kong, China Chris Kwok-Yiu Wong, MD Hong Kong, China Joseph Varon, MD USA David X. M. Zhao, MD USA Simon Cheung-Chi Lam, MD Hong Kong, China Philip Hung-Chung Wong, MD Hong Kong, China U Po Lam, MD Macau, China Chee-Wo Wu, MD Hong Kong, China Kathy Lai Fun Lee, MD Hong Kong, China Chiung-Jen Wu, MD Taiwan, China Michael Kang-Yin Lee, MD Hong Kong, China Wei-Hsian Yin, MD Taiwan, China Dobrin Vasilev, MD, PhD Bulgaria Renu Virmani, MD USA Kenji Wagatsuma, MD, PhD Japan Ron Waksman, MD USA Craig M. Walker, MD USA Wan Azman Wan Ahmad, MD Malaysia Jie Wang, MD, PhD USA Kai Wang, MD, PhD USA John G. Webb, MD Canada Franz Weidinger, MD Austria 009 Chinese Faculty: Hong Kong, Macau and Taiwan Chi-Kin Chan, MD Hong Kong, China Kam-Tim Chan, MD Hong Kong, China Kelvin Chan, MD Hong Kong, China Wai-Kwong Chan, MD Hong Kong, China Yat-Sun Chan Hong Kong, China Heng-Chia Chang, MD Taiwan, China Chung-Seung Chiang, MD Hong Kong, China Xiwei Deng, MD Macau, China Stephen-Wai Luen Lee, MD Hong Kong, China Wen-Lieng Lee, MD, PhD Taiwan, China Steven Li, MD Hong Kong, China Ping-Han Lo, MD Taiwan, China Ju-Pin Pan, MD Taiwan, China Li-Wah Tam, MBBS Hong Kong, China CIT 2012 www.citmd.com ORGANIZATION Chinese Faculty Cheng Xiaoshu, MD Jiangxi Gao Wei, MD Beijing An Yi, MD Shandong Cheng Yingzhang, MD Jiangxi Gao Ying, MD Beijing Bai Feng, MD Gansu Chu Jianmin, MD Beijing Gao Zhan, MD Beijing Bao Junmin,MD Shanghai Cong Hongliang, MD Tianjin Ge Junbo, MD Shanghai Cai Lin, MD Sichuan Cui Junyu, MD Beijing Ge Lei, MD Shanghai Cai Shanglang, MD Shandong Cui Lianqun, MD Shandong Gong Fangqi, MD Zhejiang Cao Feng, MD Shaanxi Dai Jun, MD Beijing Gong Jianbin, MD Jiangsu Cao Kejiang, MD Jiangsu Dang Qun, MD Tianjin Guan Ruijin, MD Fujian Cao Xuebin, MD Hebei Deng Hua, MD Beijing Guan Jun, MD Shandong Chang Lianfang, MD Beijing Ding Yansheng, MD Beijing Guang Xuefeng, MD Yunnan Chang Qian, MD Beijing Dong Jianzeng, MD Beijing Guo Jihong, MD Beijing Chen Buxing, MD Beijing Dong Pingshuan, MD Henan Guo Jincheng, MD Beijing Chen Can, MD Guangdong Dong Yugang, MD Guangdong Guo Jun, MD Beijing Chen Fang, MD Beijing Dou Kefei, MD Beijing Guo Lijun, MD Beijing Chen Fengrong, MD Beijing Du Yuhuan, MD Beijing Guo Ning, MD Shaanxi Chen Hong, MD Beijing Du Zhimin, MD Guangdong Guo Tao, MD Yunnan Chen Jilin, MD Beijing Fan Bing, MD Shanghai Guo Wei, MD Beijing Chen Jiyan, MD Guangdong Fan Jie, MD Yunnan Guo Wenyi, MD Shaanxi Chen Jue, MD Beijing Fan Zhongjie, MD Beijing Han Lixian, MD Hebei Chen Keping, MD Beijing Fang Pihua, MD Beijing Han Yaling, MD Liaoning Chen Lianglong, MD Fujian Fang Quan, MD Beijing Hang Jingyu, MD Shanghai Chen Lin, MD Fujian Fang Weiyi, MD Shanghai Hao Hengjian, MD Beijing Chen Minglong, MD Jiangsu Feng Yanguang, MD Hebei He Ben, MD Shanghai Chen Shaoliang, MD Jiangsu Fu Guosheng, MD Zhejiang He Guoxiang, MD Chongqing Chen Silin, MD Guangdong Fu Weiguo, MD Shanghai He Jiangui, MD Guangdong Chen Yuguo, MD Shandong Fu Xianghua, MD Hebei He Qing, MD Beijing Chen Yundai, MD Beijing Gai Luyue, MD Beijing He Zuoxiang, MD Beijing Chen Zhong, MD Beijing Gan Xuedong, MD Hubei He Yong, MD Sichuan Chen Zhujun, MD Guangdong Gao Chuanyu, MD Henan Hong Lang, MD Jiangxi Cheng Biao, MD Sichuan Gao Lianjun, MD Liaoning Hong Tao, MD Beijing Gao Run-Lin, MD Beijing Hou Jingbo, MD Heilongjiang Cheng Guanchang, MD Henan 010 CIT 2012 www.citmd.com ORGANIZATION Hou Yuqing, MD Guangdong Jin Huigen, MD Shanghai Li Weijie, MD Shaanxi Hou Zishan, MD Shandong Jin Linjun, MD Guangdong Li Weimin, MD Heilongjiang Hu Chengheng, MD Guangdong Jin Mei, MD Beijing Li Weiming, MD Shanghai Hu Dayi, MD Beijing Jin Qinhua, MD Beijing Li Xiaoying, MD Beijing Hu Fenghuan, MD Beijing Jin Zening, MD Beijing Li Xinming, MD Shanghai Hu Shenjiang Zhejiang Jing Quanmin, MD Liaoning Li Xuebin, MD Beijing Hu Shengshou, MD Beijing Jing Zaiping, MD Shanghai Li Xueqi, MD Heilongjiang Hua Wei, MD Beijing Kong Xiangqing, MD Jiangsu Li Yan, MD Shaanxi Hua Yimin, MD Sichuan Li Bao, MD Shanxi Li Yi, MD Guangdong Huang Chaolian, MD Beijing Li Chengxiang, MD Shaanxi Li Yigang, MD Shanghai Huang Dejia, MD Sichuan Li Chunlin, MD Beijing Li Yongjun, MD Hebei Huang He, MD Hubei Li Fen, MD Shanghai Li Yue, MD Heilongjiang Huang Lan, MD Chongqing Li Guangwei, MD Beijing Li Zhanquan, MD Liaoning Huang Shi'an, MD Guangdong Li Guangping, MD Tianjin Li Zhizhong, MD Beijing Huang Weijian, MD Zhejiang Li Guishuang, MD Shandong Li Zhongjie, MD Zhejiang Hui Yongming, MD Beijing Li Guoqing, MD Xinjiang Liang Yanchun, MD Liaoning Huo Yong, MD Beijing Li Hongwei, MD Beijing Liang Zhaoguang, MD Heilongjiang Ji Zhenguo, MD Hebei Li Hui, MD Heilongjiang Lin Yingzhong, MD Guangxi Jia Dalin, MD Liaoning Li Jianjun, MD Beijing Liu Bin, MD Jilin Jia Jianxiong, MD Beijing Li Jianping, MD Beijing Liu Bing, MD Shaanxi Jia Shaobin, MD Ningxia Li Jifu, MD Shandong Liu Chaozhong, MD Beijing Jia Yongping, MD Shanxi Li Kang, MD Beijing Liu Haibo, MD Beijing Jiang Chenyang, MD Zhejiang Li Lang, MD Guangxi Liu Heping, MD Jilin Jiang Dongju, MD Liaoning Li Li, MD Shanghai Liu Hong, MD Beijing Jiang Hong, MD Hubei Li Li, MD Gansu Liu Hongbin, MD Beijing Jiang Jinfa, MD Shanghai Li Ling, MD Henan Liu Hongxu, MD Beijing Jiang Shiliang, MD Beijing Li Lu, MD Liaoning Liu Hualin, MD Beijing Jiang Shisen, MD Jiangsu Li Shumei, MD Jilin Liu Hui, MD Henan Jiang Tiemin, MD Tianjin Li Shufeng, MD Heilongjiang Liu Huiliang, MD Beijing Jiang Xiongjing, MD Beijing Li Tianchang, MD Beijing Liu Jian, MD Beijing Jiang Yongmao, MD Beijing Li Wei, PhD Beijing Liu Jianping, MD Chongqing 011 CIT 2012 www.citmd.com ORGANIZATION Liu Jinghua, MD Beijing Ma Genshan, MD Jiangsu Qin Yongwen, MD Shanghai Liu Junming, MD Xinjiang Ma Hong, MD Guangdong Qiu Chunguang, MD Henan Liu Meilin, MD Beijing Ma Jian, MD Beijing Qu Peng, MD Liaoning Liu Qiming, MD Hunan Ma Kanghua, MD Chongqing Qu Xinkai, MD Shanghai Liu Quan, MD Jilin Ma Likun, MD Anhui Qu Xiufen, MD Heilongjiang Liu Renguang, MD Liaoning Ma Liping, MD Henan Ren Jingyi, MD Beijing Liu Shaowen, MD Shanghai Ma Yitong, MD Xinjiang Ren Xuejun, MD Beijing Liu Tongku, MD Jilin Ma Yingyan, MD Liaoning Ru Leisheng, MD Hebei Liu Xingbin, MD Sichuan Mao Jialiang, MD Shanghai Shan Shoujie, MD Jiangsu Liu Xingpeng, MD Beijing Miao Lifu, MD Beijing Shang Xiaoming, MD Hebei Liu Xing, MD Jiangxi Mu Chaowei, MD Beijing Shen Farong, MD Zhejiang Liu Xu, MD Shanghai Nie Ruqiong, MD Guangdong Shen Weifeng, MD Shanghai Liu Xuebo, MD Shanghai Nie Shaoping, MD Beijing Shen Xiangqian, MD Hunan Liu Yin, MD Tianjin Niu Guodong, MD Beijing Shen Zhujun, MD Beijing Liu Yin, MD Qinghai Pan Xin, MD Shanghai Sheng Guotai, MD Jiangxi Liu Yuyang, MD Beijing Pang Wenyue, MD Beijing Shi Haiming, MD Shanghai Liu Zhenyu, MD Beijing Peng Jianjun, MD Beijing Shi Xinli, MD Beijing Lu Anlin, MD Shaanxi Pu Jielin, MD Beijing Shu Chang, MD Hunan Lu Bin, MD Beijing Pu Kui, MD Tianjin Song Xiantao, MD Beijing Lu Caiyi, MD Beijing Pu Xiaoqun, MD Hunan Song Xiaoming, MD Chongqing Lu Changlin, MD Beijing Pu Zhongjie, PhD Beijing Song Zhiyuan, MD Chongqing Lu Chengzhi, MD Tianjin Qi Guoxian, MD Liaoning Su Xi, MD Hubei Lu Jiyuan, MD Shanxi Qi Xiangqian, MD Tianjin Su Yangang, MD Shanghai Lu Shuzheng, MD Beijing Qi Xiaoyong, MD Hebei Sun Fucheng, MD Beijing Lu Guoping, MD Shanghai Qian Jie, MD Beijing Sun Yingxian, MD Liaoning Lu Xiuzhang, MD Beijing Qian Juying, MD Shanghai Tan Ning, MD Guangdong Luan Ronghua, MD Shaanxi Qiao Shubin, MD Beijing Tang Baopeng, MD Xinjiang Luo Jianfang, MD Guangdong Qin Jun, MD Chongqing Tang Chaoshu, MD Beijing Luo Qiyi, PhD Shanghai Qin Lei, MD Henan Tang Fakuan, MD Beijing Luo Xiaoliang, MD Beijing Qin Qin, MD Tianjin Tang Jifei, MD Zhejiang Ma Changsheng, MD Beijing Qin Xuewen, MD Beijing Tang Liangqiu, MD Guangdong 012 CIT 2012 www.citmd.com ORGANIZATION Tang Min, MD Beijing Wang Weimin, MD Beijing Xu Bo, MBBS Beijing Tang Yida, MD Beijing Wang Xiaozeng, MD Liaoning Xu Feng, MD Beijing Tao Guizhou, MD Liaoning Wang Yan, MD Fujian Xu Geng, MD Zhejiang Tao Jun, MD Guangdong Wang Yu, MD Beijing Xu Jing, MD Tianjin Tian Jun, MD Tianjin Wang Yulin, MD Shandong Xu Kai, MD Liaoning Tian Lei, MD Beijing Wang Yutang, MD Beijing Xu Lishu, MD Xinjiang Tian Ye, MD Heilongjiang Wang Zhen, MD Hebei Xu Wei, MD Jiangsu Wan Zheng, MD Tianjin Wang Zhiyi, MD Tianjin Xu Yan, MD Anhui Wang Bin, MD Beijing Wang Zulu, MD Liaoning Xu Yanmin, MD Tianjin Wang Changqian, MD Shanghai Wei Meng, MD Shanghai Xu Yawei, MD Shanghai Wang Dongmei, MD Hebei Wen Shangyu, MD Heilongjiang Xu Yingjia, MD Shanghai Wang Dongqi, MD Shaanxi Wu Bingxiang, MD Heilongjiang Xu Zesheng, MD Hebei Wang Fang, MD Shanghai Wu Chun, MD Guangdong Xu Zhongying, MD Beijing Wang Guangyi, MD Beijing Wu Keng, MD Guangdong Xue Yusheng, MD Shaanxi Wang Guisong, MD Beijing Wu Liqun, MD Shanghai Yan Hongbing, MD Beijing Wang Haichang, MD Shaanxi Wu Lirong, MD Guizhou Yan Ji, MD Anhui Wang Hao, MD Beijing Wu Ming, MD Hainan Yang Bing, MD Jiangsu Wang Hongyu, MD Shanxi Wu Qiming, MD Beijing Yang Chengming, MD Chongqing Wang Huifeng, MD Shanxi Wu Shulin, MD Guangdong Yang Jiefu, MD Beijing Wang Jian' an, MD Zhejiang Wu Tongguo, MD Guangdong Yang Jingang, MD Beijing Wang Jicheng, PhD Shandong Wu Weifeng, MD Guangxi Yang Junguo, MD Hubei Wang Jingfeng, MD Guangdong Wu Xiaofan, MD Beijing Yang Junqing, MD Guangdong Wang Kai, MD Neimenggu Wu Yangfeng, MD Beijing Yang Lixia, MD Yunnan Wang Lefeng, MD Beijing Wu Yongjian, MD Beijing Yang Ming, MD Beijing Wang Lei, MD Beijing Wu Yueping, MD Fujian Yang Ping, MD Jilin Wang Li, MBA Shanghai Xia Ran, RT Beijing Yang Pingzhen, MD Guangdong Wang Liming, MD Qinghai Xia Yunlong, MD Liaoning Yang Shengli, MD Beijing Wang Mingsheng, MD Beijing Xiang Dingcheng, MD Guangdong Yang Shusen, MD Heilongjiang Wang Ningfu, MD Zhejiang Xiao Chun, MD Guangdong Yang Tianhe, MD Guizhou Wang Qingsheng, MD Hebei Xin Shuanli, MD Hebei Yang Tianlun, MD Hunan Wang Shouli, MD Beijing Xu Biao, MD Jiangsu Yang Tingshu, MD Beijing 013 CIT 2012 www.citmd.com ORGANIZATION Yang Xiangjun, MD Jiangsu Zhang Haicheng, MD Beijing Zhong Guoqiang, MD Guangxi Yang Xinchun, MD Beijing Zhang Jianjun, MD Beijing Zhou Binquan, MD Zhejiang Yang Yanzong, MD Liaoning Zhang Jinlin, MD Hubei Zhou Bingfeng, MD Anhui Yang Yongjian, MD Sichuan Zhang Jun, MD Shaanxi Zhou Daxin, MD Shanghai Yang Yuejin, MD Beijing Zhang Jun, MD Beijing Zhou Lijun, MD Heilongjiang Yang Zhijian, MD Jiangsu Zhang Junjie, MD Jiangsu Zhou Shenghua, MD Hunan Yang Zhiming, MD Shanxi Zhang Ming, MD Liaoning Zhou Xiaofang, MD Sichuan Yao Min, MD Beijing Zhang Minzhou, MD Guangdong Zhou Xuchen, MD Liaoning Yao Yan, MD Beijing Zhang Pei, MD Beijing Zhou Yingling, MD Guangdong Yao Zhuhua, MD Tianjin Zhang Ping, MD Beijing Zhou Yujie, MD Beijing Ye Fei, MD Jiangsu Zhang Qi, MD Shanghai Zhu Guoying, MD Hubei Ye Honghua, MD Zhejiang Zhang Ruiyan, MD Shanghai Zhu Jianhua, MD Zhejiang Ye Ping, MD Beijing Zhang Shu, MD Beijing Zhu Xianyang, MD Liaoning Yi Qijian, MD Chongqing Zhang Shulin, MD Beijing Zhu Yonghong, MD Guangdong Yin Rongxiu, MBA Beijing Yin Yuehui, MD Chongqing Zhang Shutian, MD Beijing Zhuang Baixi, MD Beijing You Shijie, MD Beijing Zhang Shuyang, MD Beijing Zhuang Shaowei, MD Shanghai Yu Bo, MD Heilongjiang Zhang Weihua, MD Yunnan Zou Jiangang, MD Jiangsu Yu Bo, MD Liaoning Zhang Weize, MD Gansu Zou Yangchun, MD Beijing Yu Zhuo, MD Yunnan Zhang Yushun, MD Shaanxi Zou Yinghua, MD Beijing Yuan Hong, MD Hunan Zhang Zheng, MD Gansu Yuan Jinqing, MD Beijing Zhang Zhiwei, MD Guangdong Yuan Yong, MD Guangdong Zhao Quanming, MD Beijing Faculty for Nurse and Technologist Yuan Zuyi, MD Shaanxi Zhao Shihua, MD Beijing Feng Qi, RN Zeng Hesong, MD Hubei Zhao Xianxian, MD Shanghai Gu Xiaofang, RN Beijing Zeng Yujie, MD Beijing Zhao Xingsheng, MD Neimenggu Hou Guihua, RN Beijing Zeng Zhi, MD Sichuan Zhao Yingxin, MD Beijing Jin Jianfen, RN Zhejiang Zhang Bin, MD Guangdong Zhao Yongqiang, MD Beijing Kan Jing, RT Jiangsu Zhang Dadong, MD Shanghai Zheng Jingang, MD Beijing Kim Chan, RT South Korea Zhang Daifu, MD Shanghai Zheng Liangrong, MD Zhejiang Li Fei, RN Liaoning Zhang Gaoxing, MD Guangdong Zheng Qiangsu, MD Shaanxi Li Huizhu, RN Beijing Zhang Gejun, MD Beijing Zheng Yang, MD Jilin Li Jie, RN Beijing Shanghai 014 CIT 2012 www.citmd.com ORGANIZATION Li Li, RN Xinjiang Li Shurong, MD Hebei Li Zhaohui, RN Beijing Liang Tao, RN Beijing Liu Hong, RN Tianjin Liu Jing, RN Beijing Liu Jun, RN Beijing Liu Yan, RN Beijing Qiu Yuehong, RN Beijing Shim Myeong-Bo, RT South Korea Tong Sumei, RN Beijing Tsai Pei-Lan, RN Taiwan, China Wang Xiaoyan, RN Shaanxi Wang Ying, RN Hubei Xie Zhen, RN Beijing Xu Liang, RT Beijing Yang Yuzhen, RN Beijing Yao Suyu, RN Gansu Yue Jihua, RN Tianjin Zhang Hongmei, RN Henan Zhao Xia, RN Beijing Secretariat Chen Kai Deputy Secretary General Dai Lifeng Gao Yan Feng Zhiyong Li Qingmin Zhu Yanyan 015 CIT 2012 www.citmd.com REGISTRATION 1. Registration Office and Opening Hours Lobby, China National Convention Center Tel: +86 10 84379013 / 84379015 Opening Hours: March 14, 2012 0800-1800 March 15, 2012 0800-1800 March 16-17, 2012 0800-1730 Language English is the official language. Sessions with the Signпј€see leftпј‰at the meeting rooms entrance will be provided with simultaneous interpretation from English to Chinese. 2. On-Site Registration Fees (in RMB) Full Participant 3,600 Nurse/Technologist 1,800 Student 2,800 Accompanying Person 2,000 Note: if you register as a student, a verification letter is required. 3. Registration Entitlements Delegate Nurse/ Technologist Student Accompanying Person Scientific Sessions * * * Abstracts Book & Program Book * * * Exhibition * * * Congress Bag * * * Certificate of Attendance * * * Sponsored Symposia * * * * Welcome Banquet * * * * * 4. Participant Identification Please wear your Congress badge for all Congress activities. Red: Faculty Blue: Delegate Green: Exhibitor & Accompanying Person Yellow: Staff General Information Dates: Venue: March 15-18, 2012 China National Convention Center (CNCC) е›Ѕе®¶дјљи®®дёеїѓ No. 7 Tianchen East Road, Chaoyang District, Beijing 100105, China Tel: +86 10 84372008 Website: http://www.cnccchina.com Banks and Currency Major credit cards like Master, American Express and Visa are acceptable in most big shopping centers and hotels. Major foreign currencies can be changed to the Chinese currency RMB at the airport, Bank of China or hotels. Business Center There is a business center on the level 3 of the CNCC that provides services such as copying, fax transmittal and receiving and general office supplies. Certificate of Attendance All registered delegate will be provided a Certificate of Attendance. The certificate will be found inside the congress bag. Coffee Break Coffee, tea will be provided at 10:15-10:45 and 15:45-16:15 in the lobby, Level 3 from March 15-18, 2012 & Level 4 in the morning on March 16, 2012 in the CNCC. Cyber Station & WIFI Service The Cyber Station will be located in the Exhibition Hall, Level 1 of the CNCC that provide access to internet. WIFI service will be provided at Level 1, 3 and 4. Meals All luncheon industrial satellite symposia provide meals for participants. Please use the lunch coupons in your registration envelop for admission. On March 15-18, 2012, breakfast meetings will be held on Level 3 from 07:00-08:00. Breads, juices and yogurts will be provided outside the meeting room for participants. Exhibition Ballroom A+B+C, Level 1, CNCC Exhibit Hours: 14:00-18:00 09:00-17:00 March 15, 2012 March 16-17, 2012 016 CIT 2012 www.citmd.com REGISTRATION Faculty Lounge Faculty Lounge located at the Lobby of CNCC is prepared for all faculty members and invited guests to have a rest during the Congress. Coffee, tea, snacks and Internet service will be served in the room. It will open at: Open: Wednesday, March 14th Thursday, March 15 Friday, March 16 th Thursday, March 15th 08:00 AM вЂ“ 5:30 PM Saturday, March 17 Friday, March 16th 08:00 AM вЂ“ 5:30 PM Sunday, March 18th th Saturday, March 17 th Sunday, March 18 4:00 PM вЂ“ 6:00 PM 7:00 AM вЂ“ 6.00 PM 7:00 AM вЂ“ 6:00 PM th 7:00 AM вЂ“ 6:00 PM 7:00 AM вЂ“ 11:00 AM 08:00 AM вЂ“5:30 PM 08:00 AM вЂ“11:30 PM Accommodations For any enquires about hotel rooms, please go to Registration Desk for information (see Opening Hours at Registration). Post-Congress Inquiry CIT2012 CMA Meeting Planner Chinese Medical Association 42 Dongsi Xidajie, Beijing 100710, China Tel.: +86 10 8515 8473 Fax: +86 10 6512 3754 Email: [email protected] Social Events 1. Opening Ceremony & Plenary Session Place: Plenary Hall A, Level 4, CNCC Time: 08:00 AM-12:30 PM, Friday, March 16, 2012 2. Welcome Banquet 1) Place: Plenary Hall AB, Level 4, CNCC 2) Time: 06:30 PM-08:30 PM, Friday, March 16, 2012 3) Admission: All registered participants are invited to participate in the event. Scientific Information To All Chairs and Speakers Please refer to relevant parts in this section for information on Speaker Ready Room and AV equipment. Speaker Ready Room (Slides and MS PowerPoint Preview) Lobby, CNCC Tel: +86 10 84379018 017 th Please hand in your slides to the staff in the Speaker Ready Room at least 3 hours before your presentation. AV Equipment LCD projector will be available in the meeting room. Poster Exhibition Poster Area for CIT2012 locates at Level 1, Scietifiic Exhibit Hall, CNCC. Poster exhibit time is: 02:00 PM -06:00 PM March 15, 2012 09:00 AM - 05:00 PM March 16-17, 2012 02:00 PM -06:00 PM on March 15, 2012 is a special session for Poster Discussion, during which, the author of the poster will present in front of his/her poster to answer questions that visitors may ask. CIT On-demand, did you miss a session or a talk? At CIT all participants will receive a complimentary 24 hour access card at the registration. With the card and the printed individual access code all participants will be able to review all presentations that have been held during the conference. CIT on-demand booth will be located at the Lobby, CNCC which includes eight computer terminals and qualified service personnel, the participants will be guided through the easy and free registration process. 019 Friday, March 16, 2012 Thursday, March 15, 2012 AM 0 :3 07 AM AM 0 :0 09 AM 09 AM 0 :0 10 AM 10 0 :3 AM 0 :0 11 4th Clinical Research Workshop 0 :3 AM 0 :3 11 AM 0 :0 12 PM PM 0 :0 01 PM 0 :3 01 PM Luncheon Symposium MicroPort 0 :3 12 HKSTENT at CIT Master Lecture Room 308 PM 0 :3 02 PM PM 0 :3 03 PM 0 :0 04 PM 0 :3 04 Interventional Innovation Summit 0 :0 03 PM OCT Workshop Part I PM 0 :3 05 PM 0 :0 06 Practical Course on PCI Part I: How to Treat FFR Workshop Luncheon Symposium Medtronic Master Lecture Room 311B Exhibition CIT Hands-on Center Level 3 Pharmacologic Satellite Symposium-Pп¬Ѓzer Pharmacologic Satellite Symposium -AstraZeneca Heart Rhythm Structural Heart Disease STEMI Summit (AICT and LUMEN) Luncheon Symposium Kinhely Master Lecture Room 311A Basics and Medical Therapies Comprehensive Management of Cardiovascular Disease in Diabetics Left Main and Bifurcation Summit Luncheon Symposium Lifetech Level 1 PM PM 0 :0 07 PM Welcome Banquet 0 :3 06 Live Case 8: Beijing Live Case 7: Taipei Mini-Symposium Late Breaking Clinical Trials on Bioabsorbable Scaffolds and First Report Investigations I Peripheral and Endovascular Therapy: NCVH at CIT PCR at CIT Live Case 6: Beijing Heart Rhythm Cardiac Catheterization Basics Sino-European Interventional Cardiology Hot Topics Pharmacologic Satellite Symposium-Sanoп¬Ѓ Aventis Pharmacologic Satellite Symposium-Bayer CIT Educational Case Award: Case Presentations Left Main and Bifurcation Summit Master Lecture Auditorium 0 :0 05 The Final of CIT Young Investigator Award / PCI Technique and Outcome Research (2 meeting rooms: A and B) Room 310 Room 309B Luncheon Symposium Lake Region Medical Luncheon Symposium BraccoSine Luncheon Symposium Star Progress & Asahi Luncheon Symposium Johnson & Johnson Medical Master Lecture Room 307AB Room 309A Luncheon Symposium GE Master Lecture Room 306AB Luncheon Symposium JW Medical Luncheon Symposium Sino Medical Function C Live Case 5: Beijing (Structural) Luncheon Symposium Boston Scientiп¬Ѓc Function B Function A Live Case 4: Beijing (Peripheral) CIT Hands-on Center Level 3 Special Live Case Session, Opening of CIT in Partnership with TCT, and CIT-TCT Plenary Session Exhibition Luncheon Symposium Lepu Medical Luncheon Symposium Abbott Vascular Luncheon Symposium Siemens Luncheon Symposium GE Level 1 Contemporary Electrocardiology Room 311B Breakfast Case Reviews CIT Educational Case Award: Case Presentations SOLACI at CIT IVUS Workshop Part I Abstract Oral Presentation (2 meeting rooms: A and B) Cardiac Catheterization Basics Plenary Hall A 0 :0 02 2 Sino-Japanese Friendship Interventional Cardiology Forum (Live Case Session 1: Toyohashi, 8:30 am-10:00 am; Live Case Session 2: Shanghai, 11:45 am-1:15 pm; Live Case Session 3: Beijing, 2:45 pm-4:45 pm) nd 0 :3 08 Non-Invasive Cardiovascular Imaging Symposium AM Room 310 Breakfast Case Reviews 0 :0 08 Room 311A Breakfast Case Reviews Room 309B Breakfast Case Reviews Room 309A Breakfast Case Reviews Room 308 Breakfast Case Reviews Room 307AB Breakfast Case Reviews Room 306AB Function C Function B Function A 0 :0 07 CIT 2012 www.citmd.com PROGRAM AT A GLANCE Sunday, March 18, 2012 Saturday, March 17, 2012 AM 08 0 :0 AM 08 0 :3 AM 0 :0 09 AM 0 :0 10 AM 0 :3 10 AM AM 0 :3 11 AM 0 :0 12 PM 3rd Rotablation Mini-Symposium DES Summit PM 0 :0 01 PM 0 :3 01 PM Structural Heart Disease Case Reviews (Call-for-Cases) Heart Rhythm Room 310 Breakfast Case Reviews Room 311B Breakfast Case Reviews Pharmacologic Satellite Symposium - Servier Room 311A Breakfast Case Reviews Room 309B Breakfast Case Reviews Case Reviews (Call-for-Cases) IVUS Workshop Part II Case Reviews (Call-for-Cases) Room 308 Breakfast Case Reviews Room 309A Breakfast Case Reviews Endovascular Forum on Aortic Aneurysm Repair Room 307AB Breakfast Case Reviews Practical Course on PCI Part IV: Chronic Total Occlusion Room 306AB Breakfast Case Reviews Function C GAP-CCBC at CIT: Guideline and Practice - Clinical Case Reviews Function B Closing Exhibition CIT Hands-on Center Level 3 4th PCI Complications Forum PM 0 :0 03 PM PM 0 :0 04 PM 0 :3 04 PM 0 :0 05 PM 0 :3 05 PM 0 :0 06 PM Case Reviews with CIT Live Case 14: Beijing and TCT Master Operators Late Breaking Clinical Trials Live Case 15: Beijing and First Report Investigations III 0 :3 03 Left Main and Bifurcation Summit OCT Workshop Part II Peripheral and Endovascular Therapy Practical Course on PCI Part III: Chronic Total Occlusion Live Case 13: Xi'an 7th Annual Symposium for Nurse and Technologist Function A 0 :3 02 Live Case 12: Beijing PM Heart Rhythm DES Summit Structural Heart Disease (Transcather Valve Therapies) CCC/CISC at CIT: Difп¬Ѓcult Patients and Dilemmas in Clinical Practice Pharmacologic Satellite Symposium Pharmacologic Satellite Symposium - Daiichi Sankyo - Salubris Pharmaceuticals 0 :0 02 Level 1 Luncheon Symposium Edwards Lifesciences Luncheon Symposium MicroPort Luncheon Symposium Lepu Medical Luncheon Symposium Abbott Vascular Luncheon Symposium Medfavour Luncheon Symposium Essen Luncheon Symposium Volcano Luncheon Symposium Terumo Luncheon Symposium Star Progress & Kaneka Luncheon Symposium St. Jude 0 :3 12 Auditorium Heart Rhythm Structural Heart Disease Interventional Pharmacology EAPCI-EuroPCR/ESC at CIT Left Main and Bifurcation Summit TRI Club Peripheral and Endovascular Therapy Room 310 Breakfast Case Reviews JW Medical Room 311B Breakfast Meeting Medtronic 0 :0 11 Live Case 10: Beijing Angioplasty Summit - TCTAP at CIT Late Breaking Clinical Trials Live Case 11: Beijing and First Report Investigations II 0 :3 09 Practical Course on PCI Part II: Controversial Case Reviews: Why, When, and How AM Room 311A Breakfast Meeting Room 309B Room 309A Room 308 Breakfast Case Reviews Room 306AB Breakfast Meeting Boston Scientiп¬Ѓc Breakfast Meeting Room 307AB Terumo Function C Live Case 9: Beijing 0 :3 07 Function B AM CRT at CIT 0 :0 Function A 07 0 :3 06 PM 0 :0 07 PM CIT 2012 www.citmd.com PROGRAM AT A GLANCE 020 CIT 2012 www.citmd.com LIVE CASE SITES Fu Wai Hospital, National Center for Cardiovascular Diseases, China Affiliated Xijing Hospital of the Fourth Military Medical University, China Operators: Jun Dai, Kefei Dou, Zhan Gao, Fenghuan Hu, Xiongjing Jiang, Chaowei Mu, Jie Qian, Hong Qiu, Wenhui Wu, Zhongying Xu, Weixian Yang, Yuejin Yang, Mengyue Yu, Gejun Zhang, Pei Zhang, Jinglin Zhao Guest Operators: Yaron Almagor, Jacek Bialkowski, Maurice Buchbinder, Antonio Colombo, Osamu Katoh, William L. Lombardi, Gary S. Mintz, Jeffrey W. Moses, Masahiko Ochiai, Seung-Jung Park, Raghotham R. Patlola, Shigeru Saito, Horst Sievert, Satoru Sumitsuji, Malgorzata Szkutnik, Etsuo Tsuchikane, Yuichi Ujiie, Craig M. Walker Operators: Wenyi Guo, Chengxiang Li, Weijie Li, Ronghua Luan Guest Operator: Toshiya Muramatsu Affiliated An Zhen Hospital of Capital Medical University, China Operators: Fang Chen, Xin Chen, Yuechun Gao, Zhizhong Li, Xinmin Liu, Yuyang Liu, Hong Liu, Jinghua Liu, Shuzheng Lu, Taiyang Luo, Shaoping Nie, Yan Qiao, Bin Que, Dongmei Shi, Gong Su, Tao Sun, Rui Tian, Jian Wang, Su Wang, Zheng Wu, Fei yuan, Xiaoling Zhang, Yuchen Zhang, Donghui Zhao, Quanming Zhao, Yingxin Zhao, Yujie Zhou, Yuan Zhou Guest Operators: Jean Fajadet, Ferdinand Kiemeneij, Mitchell W. Krucoff, Samuel K. Mathew, Marie-Claude Morice, Imad Sheiban, Robaayah Zambahari Affiliated Chaoyang Hospital of Capital Medical University, China Operators: Weiming Li, Zhuhua Ni, Hao Sun, Hongshi Wang, Lefeng Wang, Kun Xia, Li Xu Guest Operators: Fausto Feres, David E. Kandzari, Costantino O. Costantini, Costantino R. Costantini, Teguh Santoso, Alan C. Yeung 021 Affiliated Zhongshan Hospital of Fudan University, China Operators: Junbo Ge, Dong Huang, Hao Lu, Kang Yao, Feng Zhang Guest Operators: Alfredo R. Galassi, Etsuo Tsuchikane National Taiwan University Hospital, Taiwan, China Operator: Paul Hsien-Li Kao Toyohashi Heart Center, Toyohashi, Japan Operators: Takahiko Suzuki, Yoshihisa Kinoshita, Kenya Nasu CIT 2012 www.citmd.com Thursday, March 15th, 2012 9:20 AM - How to Be Effective at Publishing and Presenting Your Research? Ajay J. Kirtane Function A, Level 1 The 4th Clinical Research Workshop 8:15 AM-12:30 PM Part I: The Basics of Clinical Research Programs - What You Need to Be Successful Moderators: Alexandra J. Lansky, Ajay J. Kirtane Discussants: Dominic Allocco, Yaling Han, Mitchell W. Krucoff, Wei Li, David Liu, Roxana Mehran, Jenny Zhen Qin, Xinli Shi, Haichang Wang (This session will focus on the basics of starting and sustaining a successful research program. The general audience can be physicians, investigators, coordinators, and managers of programs. The main topics will focus on the needed infrastructure, guidelines and tips for being successful in the program.) 9:32 AM - Panel Discussion: Focused on Specific Challenges and Tips for Succeeding in Your Program 9:52 AM - Featured Lecture: The Rewards of Setting up Collaborative Research Initiatives Martin B. Leon 10:07 AM - Break Part II: Clinical Trial Interpretation - Pitfalls and Practical Lessons Moderators: Ajay J. Kirtane, Roxana Mehran Discussants: Alexandre Abizaid, Davide Capodanno, Shaoliang Chen, Yundai Chen, Donald E. Cutlip, Alexandra J. Lansky, Wei Li, Xinli Shi, Ruiyan Zhang 8:15 AM - Welcome Address Run-Lin Gao (The session aims to provide PRACTICAL, rather than theoretical examples of specific topics in clinical trial design and interpretation. Each talk should use several case examples to illustrate the major points germane to the lecture.) 8:17 AM - Goals and Objectives Alexandra J. Lansky 10:17 AM - Goals and Objectives Ajay J. Kirtane 8:20 AM - How to Start and Set up a Research Program: The Basic Tools Roxana Mehran 10:20 AM - Randomized Trials vs. Observational Studies: Both Are Good, Both Can Be Bad Alexandra J. Lansky 8:32 AM - National and International Trials: How to Succeed in Both? How Are They Different? Mitchell W. Krucoff 8:44 AM - Guiding Principles in Clinical Research: The Basic Rules (GCP, IRB, Informed Consent, Training, etc) Yaling Han 8:56 AM - Quality Control, Monitoring Visits, and Audits: What Each Investigator Must Know? Jenny Zhen Qin 9:08 AM - SFDA Regulations for Sites Conducting Clinical Research Xinli Shi 10:30 AM - Panel Discussion with Audience Q&A 10:35 AM - Practicalities and Misapplications of Composite Endpoints in Clinical Trials Ajay J. Kirtane 10:45 AM - Panel Discussion with Audience Q&A 11:00 AM - Panel Discussion with Audience Q&A 11:05 AM - Non-Inferiority Explained and Exposed: Uses and Abuses Donald E. Cutlip 11:15 AM - Panel Discussion with Audience Q&A 11:20 AM - Subgroup Analyses and Risk Groups within Clinical Trials: Uses and Abuses Davide Capodanno 11:30 AM - Panel Discussion with Audience Q&A 11:35 AM - Pros and Cons of Globally Conducted Studies Roxana Mehran 11:45 AM - Future of Research in China: The Next Frontier Run-Lin Gao 11:55 AM - Panel Discussion with Audience Q&A Part III: Keynote Debate - The Finale Moderator: Roxana Mehran Discussants: Donald E. Cutlip, Ajay J. Kirtane, Wei Li Debate: Alpha Error and the вЂњMagicalвЂќ P<0.05 Threshold 12:00 PM - P-Values Are ImportantвЂ¦and Significant! Donald E. Cutlip 12:12 PM - Down with P-Values! Ajay J. Kirtane 12:24 PM - Panel Discussion 12:30 PM - Adjourn 10:50 AM - Importance of Adequately Powered Studies in Clinical Medicine: Case Studies Wei Li 022 00 CIT 2012 www.citmd.com Thursday, March 15th, 2012 Luncheon Symposium Sponsored by MicroPort Experiencing FIREHAWK, Targeting the Future 12:40 PM-1:55 PM Chairman: Martin B. Leon Co-Chairmen: Fausto Feres, Changsheng Ma, Weifeng Shen, Bo Xu 12:40 PM - Opening Address 12:43 PM - FIREHAWK Bioabsorbable Polymer Sirolimus-Eluting Stent: Update on the Firstin-Man, TARGET I, and TARGET II Trials Run-Lin Gao 12:58 PM - Angioscopic Findings of FIREHAWK vs. XIENCE V from TARGET I Trial Shaoliang Chen 1:13 PM - IVUS Findings of FIREHAWK from TARGET I Trial Ruiyan Zhang Moderators: Martin B. Leon, Xinli Shi, Bo Xu 4:25 PM - Percutaneous Mitral Valve Therapies Maurice Buchbinder 2:30 PM - Safety and Effectiveness Considerations of Bioabsorbable Polymer DES Technology Stephan Windecker 4:35 PM - Transcatheter Renal Nerve Denervation for Refractory Hypertension: Current Perspectives Markus P. Schlaich 2:40 PM - Safety and Effectiveness Considerations of Polymer-Free DES Technology Adnan Kastrati 4:45 PM - Transcatheter Renal Nerve Denervation for Refractory Hypertension: Future Expectations Horst Sievert 2:50 PM - Vascular Reparative Therapy with Bioabsorbable Drug-Eluting Scaffolds Are the Future! The Science Behind the Dream Patrick W. Serruys 4:55 PM - External and Non-Invasive Strategies to Treat Hypertension Michael Gertner Part II: Innovation in DES 3:00 PM - New Stent Technologies on the Horizon: The Abbott Vascular Pipeline Charles A. Simonton 3:10 PM - New Stent Technologies on the Horizons: The Boston Scientific Pipeline Keith D. Dawkins 5:05 PM - Panel Discussion with Audience Q&A Discussants: Maurice Buchbinder, Yundai Chen, Michael Gertner, Jianxiong Jia, Michael A. Mussallem, Markus P. Schlaich, Weifeng Shen, Horst Sievert, Jie Wang Moderator: Eberhard Grube 1:28 PM - Single Center Experience of FIREHAWK and Case Reviews from TARGET I and II Trials Yaling Han 3:20 PM - New Stent Technologies on the Horizons: The Medtronic Pipeline Martin T. Rothman 5:15 PM - Biopolymer Based Restoration of Left Ventricular Mechanics in Advanced Heart Failure Frank Ahmann 1:43 PM - Panel Discussion with Audience Q&A 3:30 PM - New Stent Technologies on the Horizons: The JW and Biosensors Pipeline Jack Wang 5:25 PM - Endovascular Approach to Erectile Dysfunction: Results of the ZEN Trial Jason H. Rogers 3:40 PM - New Stent Technologies on the Horizons: The Lepu Pipeline Zhongjie Pu 5:35 PM - Cath Lab of the Future and Telemanipulation Ferdinand Kiemeneij 3:50 PM - New Stent Technologies on the Horizons: The MicroPort Pipeline Qiyi Luo 5:45 PM - Registration of 3D QCA and IVUS or OCT in Percutaneous Coronary Intervention Johan H. C. Reiber 1:55 PM - Adjourn Interventional Innovation Summit 2:00 PM-6:15 PM Part I: Featured Lecture Moderators: Run-Lin Gao, Martin B. Leon 2:00 PM - Innovation in Perspective: Past, Present, and Future Martin B. Leon 2:15 PM - Panel Discussion: Innovation Therapies: Impact and Opportunities in Global and Emerging Markets Discussants: Alexandre Abizaid, Yaron Almagor, Eberhard Grube, Ian T. Meredith, Patrick W. Serruys, Philip Li Wang, Yuejin Yang 4:00 PM - Panel Discussion: Challenges and Opportunities for DES Innovation: Industry Perspective Discussants: Keith D. Dawkins, Qiyi Luo, Zhongjie Pu, Martin T. Rothman, Xinli Shi, Charles A. Simonton, Jack Wang, Bo Xu Moderator: Martin B. Leon Part III: Novel (non-DES) Therapies Moderators: Eberhard Grube, Weifeng Shen, Yundai Chen, Jianxiong Jia 4:15 PM - Percutaneous Aortic Valve Therapies Michael A. Mussallem 023 00 5:55 PM - Examples of Clinical Research and Translational Medicine: Role of Chinese Physicians in Medical Device Venture Jie Wang 6:05 PM - Panel Discussion with Audience Q&A Discussants: Frank Ahmann, Yundai Chen, Jianxiong Jia, Ferdinand Kiemeneij, Weifeng Shen, Johan H. C. Reiber, Jason H. Rogers, Jie Wang Moderator: Eberhard Grube 6:15 PM - Adjourn CIT 2012 www.citmd.com Thursday, March 15th, 2012 11:05 AM - CTO-PCI in China and Case Presentation Jiyan Chen Function B, Level 1 The 2nd Sino-Japanese Friendship Interventional Cardiology Forum CCT at CIT 8:25 AM-6:00 PM 8:25 AM - Opening Remarks Eisho Kyo, Run-Lin Gao Live Case Session 1 Chronic Total Occlusions Toyohashi Heart Center, Toyohashi, Japan 8:30 AM-10:00 AM Moderators: Osamu Katoh, Yong Huo Discussants: Quanmin Jing, Weijie Li, Yue Li, Motomaru Masutani, Xiantao Song, Kinzo Ueda, Yuichi Ujiie, Shouli Wang, Yu Wang, Jingang Zheng Operators: Takahiko Suzuki, Yoshihisa Kinoshita, Kenya Nasu Lectures and Case Presentations I Chronic Total Occlusions Moderators: Eisho Kyo, Shuzheng Lu Discussants: Jiyan Chen, Osamu Katoh, Toshiya Muramatsu, Yuichi Ujiie, Haichang Wang, Yongjian Wu, Hiroyoshi Yokoi, Yujie Zhou 10:00 AM - Keynote Lecture: What to Learn from the Past History of Japanese CTO-PCI? Osamu Katoh 10:30 AM - Panel Discussion with Audience Q&A 10:35 AM - My Approach to CTO: Case Presentation Toshiya Muramatsu 10:50 AM - Clinical Results of Retrograde Approach in CTO-PCI: Japanese Registry Data from Retrograde Summit Yuichi Ujiie 11:20 AM - Peripheral Endovascular CTO and Complex Lesions Hiroyoshi Yokoi 11:35 AM - Panel Discussion with Audience Q&A Live Case Session 2 Chronic Total Occlusions Affiliated Zhongshan Hospital of Fudan University, Shanghai, China 11:45 AM-1:15 PM Moderators: Kinzo Ueda, Hongbing Yan Discussants: Weiyi Fang, Xuefeng Guang, Wenyi Guo, Nae Hee Lee, Xuebo Liu, Toshiya Muramatsu, Masaaki Okutsu, Toshiro Shinke, Wasan Udayachalerm, Wei-Hsian Yin Operators: Junbo Ge, Etsuo Tsuchikane, Alfredo R. Galassi Lectures and Case Presentations II Imaging and Physiology for Complex PCI Moderators: Motomaru Masutani, Juying Qian Discussants: Buxing Chen, Shaoliang Chen, Luyue Gai, Huiliang Liu, Masaaki Okutsu, Jie Qian, Toshiro Shinke 1:15 PM - Physiology: FFR / Pressure Wire Toshiro Shinke Live Case Session 3 Chronic Total Occlusions Fu Wai Hospital, National Center for Cardiovascular Diseases, Beijing, China 2:45 PM-4:45 PM Moderators: Eisho Kyo, Yuejin Yang Discussants: Lei Ge, Guosheng Fu, Hweung Kon Hwang, Ping-Han Lo, William L. Lombardi, Ronghua Luan, Jianfang Luo, Yoshinobu Murasato, Fuminobu Yoshimachi, Bin Zhang Operators: Osamu Katoh, Shigeru Saito, Satoru Sumitsuji IVUS Interpreter: Yuichi Ujiie Lectures and Case Presentations III Complex PCI Moderators: Masahiko Ochiai, Fang Chen Discussants: Yoshinobu Murasato, Shaoping Nie, Kenji Wagatsuma, JianвЂ™an Wang, Fuminobu Yoshimachi, Qi Zhang 4:45 PM - Complex Bifurcated Lesions Yoshinobu Murasato 5:00 PM - Slender Catheter System in Complex Lesions Fuminobu Yoshimachi 5:15 PM - Rotational Atherectomy in Severely Calcified Lesions JianвЂ™an Wang 1:28 PM - IVUS Motomaru Masutani 5:30 PM - Enhancing Backup Support in PCI by Transradial Approach Qi Zhang 1:41 PM - OCT Jie Qian 5:45 PM - Panel Discussion with Audience Q&A 1:54 PM - CT Masaaki Okutsu 6:00 PM - Adjourn 2:07 PM - Rotational Angiography Huiliang Liu 2:20 PM - Angioscopy Shaoliang Chen 2:33 PM - Panel Discussion with Audience Q&A 024 00 CIT 2012 www.citmd.com Thursday, March 15th, 2012 Session II: Cardiac Arrhythmias Room 306A, Level 3 Abstract Oral Presentation Part I 8:30 AM-12:30 PM Session I: Fundamental Research Moderators: Jianjun Li, Jie Wang, Dongming Hou, Hong Yuan 8:30 AM - AS-0196: FTY720 Protects Cardiac Microvessels of Diabetic Rats via Suppression of the PKCОІII-Dependant Signaling Pathway by Regulating S1P1 and S1P3 Zhiyong Yin 8:38 AM - Q&A 8:42 AM - AS-0209: Protection of Cellular Repressor of E1A Stimulated Genes Against TNF-О± Mediated Inflammatory Injury of Endothelial Cells Yan Duan 8:50 AM - Q&A Moderators: Yinsheng Wu, Yingxian Sun, Jielin Pu 9:30 AM - AS-0156: NOS1AP Variations and Idiopathic Ventricular Tachycardia (IVT) Rongfeng Zhang 9:38 AM - Q&A 9:42 AM - AS-0234: Left Atrial Epicardial Adipose Tissue and Atrial Fibrillation Jieyu Liu 9:50 AM - Q&A 9:54 AM - AS-0242: The Electrophysiologic Characteristics and Radiofrequency Catheter Ablation of Idiopathic Ventricular Arrhythmias Originating from the Papillary Muscles Shibei Li 10:02 AM - Q&A 10:06 AM - AS-0430: Comparative Study of Pocket Hemorrhage After Pacemaker Implantation in Patients with Warfarin Anticoagulation Jiwen Li 8:54 AM - AS-0210: Association Between Polymorphism in the Cytochrome P450 3A5 Gene rs3800959 and Clopidogrel Resistance in Chinese Han Population Xueyao Feng 10:14 AM - Q&A 9:02 AM - Q&A 10:26 AM - Q&A 9:06 AM - AS-0213: Downregulation of Adiponectin Induced by Tumor Necrosis Factor О± Is Involved in the Aggravation of Post-Traumatic Myocardial Ischemia/ Reperfusion Injury Shaowei Liu 9:14 AM - Q&A 9:18 AM - AS-0218: CREG Prevents Human Umbilical Vein Endothelial Cell from Apoptosis by Inhibiting p38 MAPK Activation Na Wang 9:26 AM - Q&A 025 00 10:18 AM - AS-0523: Clinical Analysis of Arrhythmia in 297 Ebstein's Anomaly Patients Yu Hou Session III: Structural Heart and Peripheral Vascular Disease Moderators: Shihua Zhao, Xinming Li, Xiongjing Jiang 10:30 AM - AS-0262: Transcatheter Closure of Membraneous Ventricular Septal Defects in Children Xianyang Zhu 10:38 AM - Q&A 10:42 AM - AS-0403: Transcatheter Closure of Coronary Artery Fistula with Coil Device or Occluder Songhua Li 10:50 AM - Q&A 10:54 AM - AS-0327: Carotid Artery Stenting in Surgically High-Risk Patients: Early and Long-Term Results Hui Dong 11:02 AM - Q&A 11:06 AM - AS-0190: Transcatheter Renal Denervation for the Treatment of Refractory Hypertension: Early China Experience Chengzhi Lu 11:14 AM - Q&A 11:18 AM - AS-0167: Understanding the Effects of Psychological Intervention in Patients with Coronary Heart Disease Senlin Li 11:26 AM - Q&A Session IV: Coronary Artery Disease V Moderators: Xianghua Fu, Kai Huat Lam, Biao Xu 11:30 AM - AS-0212: A Gene Polymorphism Inhibits the Therapeutic Actions of Clopidogrel in Chinese After Drug-Eluting Stent Implantation Zhenyang Liang 11:38 AM - Q&A 11:42 AM - AS-0239: Relationship Between Renal Dysfunction and Severity of Coronary Artery Disease in a Large Cohort of Catheterized Patients Lei Zhang 11:50 AM - Q&A 11:54 AM - AS-0489: The Value of Combining CYP2C19*2 Polymorphism with Classic Risk Factors in Prediction of Clinical Prognosis in Acute Coronary Syndrome Patients Yuanning Xu 12:02 PM - Q&A 12:06 PM - AS-0027: Safety and Efficacy of Anisodamine on Prevention of Contrast Induced Nephropathy in Patients with Acute Coronary Syndrome Xianghua Fu CIT 2012 www.citmd.com Thursday, March 15th, 2012 12:14 PM - Q&A 12:18 PM - AS-0619: A Multicenter Randomized Comparison of Drug-Eluting Balloon plus Bare Metal Stent vs. Bare Metal Stent vs. Drug-Eluting Stent in Primary Percutaneous Coronary Intervention: 6-Month Angiographic, Intravascular, Functional and Clinical Results of the DEBAMI Trial Pieter R. Stella 12:26 PM - Q&A 12:30 PM - Adjourn The Final of CIT Young Investigator Award 2:00 PM-4:20 PM Moderator: Roxana Mehran Panelists: Joseph D. Babb, Davide Capodanno, Donald E. Cutlip, Liliana R. Grinfeld, Fumiaki Ikeno, Spencer B. King III, Ajay J. Kirtane, Mitchell W. Krucoff, Yean-Leng Lim, Jean Marco 3:20 PM - ApplicantвЂ™s Presentation 5 Qi Zhang Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 3:32 PM - Q&A Room 306B, Level 3 3:40 PM - ApplicantвЂ™s Presentation 6 Kai Xu Shenyang Northern Hospital, Shenyang Abstract Oral Presentation Part II 8:30 AM-12:30 PM 3:52 PM - Q&A Session I: Coronary Artery Disease I 4:00 PM - ApplicantвЂ™s Presentation 7 Kefei Dou Fu Wai Hospital, National Center for Cardiovascular Diseases of China, Beijing Moderators: Guoshu Liu, Yongming Hui, Daifu Zhang 4:12 PM - Q&A 4:20 PM - Adjourn 8:30 AM - AS-0102: Multimodality Imaging Evaluation of Functional and Clinical Benefits of Percutaneous Coronary Intervention in Patients with Chronic Total Occlusion Lesion: Role of SPECT/CTCA Fusion Imaging as a Gatekeeper to Evaluate LAD CTO PatientsвЂ™ Outcomes Dongdong Sun 8:38 AM - Q&A Lei Ge Zhongshan Hospital, Fudan University, Shanghai 8:42 AM - AS-0174: Angioscopy Study from a Large Patient Population Comparing Sirolimus-Eluting Stent with Biodegradable vs. Durable Polymer Shaoliang Chen 2:12 PM - Q&A 8:50 AM - Q&A 2:20 PM - ApplicantвЂ™s Presentation 2 Jingbo Hou The 2nd Affiliated Hospital, Harbin Medical University, Harbin 8:54 AM - AS-0204: Natural History of Dissection and Tissue Prolapse Following Sirolimus-Eluting Stent: 6-Month OCT Follow-up Study Xingtao Huang 2:00 PM - ApplicantвЂ™s Presentation 1 2:32 PM - Q&A 2:40 PM - ApplicantвЂ™s Presentation 3 Zhan Gao Fu Wai Hospital, National Center for Cardiovascular Diseases of China, Beijing 2:52 PM - Q&A 3:00 PM - ApplicantвЂ™s Presentation 4 Ning Guo The 1st Affiliated Hospital, XiвЂ™an Jiaotong University, XiвЂ™an 3:12 PM - Q&A 9:02 AM - Q&A 9:06 AM - AS-0555: Characterization of Coronary Plaque Assessed by Optical Coherence Tomography in Diabetic Subjects with Coronary Artery Disease Peng Gao 9:14 AM - Q&A 9:18 AM - AS-0140: Decreased Serum esRAGE Level Is Associated with Coronary Artery Remodeling in Patients with Type 2 Diabetes: An Intravascular Ultrasound Study Run Du 9:26 AM - Q&A 026 00 CIT 2012 www.citmd.com Thursday, March 15th, 2012 Session II: Coronary Artery Disease II Moderators: Junzhu Chen, Guoxiang He, Luyue Gai 9:30 AM - AS-0056: A Meta-Analysis of Early Percutaneous Coronary Intervention within 24 Hours of Thrombolysis in Acute STSegment Elevation Myocardial Infarction Buchun Zhang 9:38 AM - Q&A 9:42 AM - AS-0142: Effect of the Chronic Kidney Disease on Formation of Coronary Collateral Vessels in Patients with Acute Myocardial Infarction Run Du 9:50 AM - Q&A 9:54 AM - AS-0275: Clinical Investigation of Effects of Intravenous vs. Intracoronary Injection of Tirofiban During Primary PCI Yingyan Ma 10:02 AM - Q&A 10:06 AM - AS-0573: Beneficial Effects of Intracoronary Tirofiban Bolus Administration Following Upstream Intravenous Treatment in Patients with ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: The ICT-AMI Study Tianqi Zhu 10:14 AM - Q&A 10:18 AM - AS-0622: Influence of Dietary Patterns on the Risk of Acute Myocardial Infarction (AMI) in China Population: The INTERHEART China Study Jin Guo Compared to FIREBIRD 2 Sirolimus-Eluting Stent with Durable Coating in Patients with Coronary Artery Disease: 9-Month Angiographic and 18-Month Clinical Results Kefei Dou 11:42 AM - AS-0028: Effect of High Dose Rosuvastatin Loading Before Percutaneous Coronary Intervention in Female Patients with Non-ST-Segment Elevation Acute Coronary Syndrome Yuan Gao 10:38 AM - Q&A 11:50 AM - Q&A 10:42 AM - AS-0183: Double Kissing (DK) Crush vs. Culotte Stenting for the Treatment of Unprotected Distal Left main Bifurcation Lesions: DKCRUSH-III, A Multicenter Randomized Study Comparing Double-Stent Techniques Shaoliang Chen 11:54 AM - AS-0266: Effects of Intensive Antiplatelet Therapy for Patients with High On-Treatment Platelet Reactivity After Coronary Stent Implantation Shaoyi Guan 10:50 AM - Q&A 12:06 PM - AS-0068: Same-Day Discharge Following Effective PCI: 10 Year Single Center Experience Zhihua Zhang 10:54 AM - AS-0295: TIVOLI BiodegradablePolymer-Based Sirolimus-Eluting Stents in Treating Patients with Coronary Artery Disease: 8-Month Angiographic and 3-Year Clinical Follow-up Results - A Prospective, Parallel Control, Multicenter Study Kefei Dou 11:02 AM - Q&A 12:18 PM - AS-0066: Risk Score for Prediction of Contrast Induced Nephropathy in Patients underwent Percutaneous Coronary Intervention Dongxia Jin 12:26 PM - Q&A 11:14 AM - Q&A PCI Technique and Outcome Research 2:00 PM-6:00 PM 11:18 AM - AS-0168: Distal Protection Devices in Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials Bo Jin 11:26 AM - Q&A Session IV: Coronary Artery Disease IV Session III: Coronary Artery Disease III Moderators: Xiangqian Qi, Changqian Wang, Yin Liu 10:30 AM - AS-0293: NOYA I: A Prospective Randomized Trial of NOYA Sirolimus -Eluting Stent with Biodegradable Coating 12:14 PM - Q&A 11:06 AM - AS-0286: Incidence, Predictors, and Clinical Outcome of Stent Thrombosis After Stent Implantation Quanyu Zhang 10:26 AM - Q&A Moderators: Weifeng Shen, Jianjun Li, Shisen Jiang 12:02 PM - Q&A 11:30 AM - AS-0284: Long-Term Efficacy of PCI vs. CABG for Patients with Multiple Coronary Chronic Total Occlusions Jian Zhang 11:38 AM - Q&A 12:30 PM - Adjourn Session I Moderators: Guoxiang He, Wei-Kung Tseng, Kefei Dou 2:00 PM - Developing a STEMI System of Care in India: The Challenges Thomas Alexander 2:10 PM - Q&A 2:12 PM - Stent Thrombosis: Is It an Important Issue in 2012? Chris Kwok-Yiu Wong 2:22 PM - Q&A 2:24 PM - Effect of Myocardial Bridging on PCI Shih-Pu Wang 2:34 PM - Q&A 027 00 CIT 2012 www.citmd.com Thursday, March 15th, 2012 2:36 PM - The Use of Rotablation in Complex and CTO Lesion PCI in DES Era Wen-Lieng Lee 2:46 PM - Q&A 2:48 PM - Tips and Tricks in Managing Coronary Perforations Sundeep Mishra 2:58 PM - Q&A Session II Moderators: Feng Cao, U Po Lam, Yonghong Zhu 3:00 PM - Drug-Coated Balloon Prior to BMS Stenting: Insights from the PIONEER Trial Pieter C. Smits 3:10 PM - Q&A 3:12 PM - Update on the PAPA Trial: DrugCoated Balloon in Acute MI Ferdinand Kiemeneij 3:22 PM - Q&A 3:24 PM - Clinical Experience in a 6 French Intra-Aortic Balloon Pumping Catheter Akihiko Takahashi 3:34 PM - Q&A 3:36 PM - Kissing Microcatheter Technique for CTO Intervention Wasan Udayachalerm 3:46 PM - Q&A 3:48 PM - Percutaneous Coronary Intervention for Ischemic Cardiomyopathy Thach Nguyen 3:58 PM - Q&A Session III (Language: Chinese) Moderators: Lijun Jin, Xuewen Qin, Yingzhong Lin 4:00 PM - Pros and Cons with the Utility of DES or BMS in Large Coronary Vessel Weiyi Fang 4:10 PM - Q&A 4:12 PM - Update on Small Vessel PCI Genshan Ma 4:22 PM - Q&A 4:24 PM - PCI Strategy for SVG Lesions Yin Liu 4:34 PM - Q&A 4:36 PM - Long-Term Outcomes of PCI for Unprotected Left Main Coronary Artery Disease Bing Fan 4:46 PM - Q&A 4:48 PM - Benefits from PCI in Patients with Cardiac Functional Insufficiency Wenyi Guo 4:58 PM - Q&A Session IV (Language: Chinese) Moderators: Caiyi Lu, Guizhou Tao, Xiaofan Wu 5:00 PM - Clinical Utility of FFR via Microcatheter Ningfu Wang 5:10 PM - Q&A 5:12 PM - Retrospective Analysis of VH-IVUS Findings in 450 CAD Patients Yan Wang 5:22 PM - Q&A Room 307AB, Level 3 Breakfast Case Reviews 1 Acute Coronary Syndrome 7:00 AM-8:00 AM Moderators: Lei Ge, Yanguang Feng, Liping Ma 7:00 AM - CS-0067: AMI in Patient with Thrombotic Trifurcation Lesion Yawei Xu 7:10 AM - Q&A 7:12 AM - CS-0070: Use of ZEEK Thrombus Aspiration Device to Avoid Thrombosis Migration in Emergency PCI Jinming Zhu 7:22 AM - Q&A 7:24 AM - CS-0285: Primary PTCA of Unprotected Left Main Sanjay Kumar 7:34 AM - Q&A 7:36 AM - CS-0289: Revascularization vs. Reperfusion Shuanli Xin 7:46 AM - Q&A 5:24 PM - A Single Center Experience of CTO PCI: Acute Procedural Results and Long-Term Clinical Outcomes Xueqi Li 7:48 AM - CS-0356: Thrombosis in AMI: How to Treat? Jun Chen 5:34 PM - Q&A 7:58 AM - Q&A 5:36 PM - Establishment and Evaluation of the Clinical Pathway by Integrating Traditional and Western Medicine in AMI Minzhou Zhang 8:00 AM - Adjourn 5:46 PM - Q&A 5:48 PM - Importance of High Pressure Post-Dilatation After DES Implantation Caiyi Lu 5:58 PM - Q&A 6:00 PM - Adjourn 028 00 CIT 2012 www.citmd.com Thursday, March 15th, 2012 IVUS Workshop Part I 8:30 AM-12:30 PM Pre-Intervention Moderators: Javier Escaned, Philip HungChung Wong Discussants: William Kongto Hau, Soo-Jin Kang, Gary S. Mintz 8:30 AM - Pre-Intervention IVUS Gary S. Mintz Case Presentations Illustrating the Use of IVUS Either in a Diagnostic Setting or Prior to PCI (15 minutes each including Q&A) 9:00 AM - Case 1: Patient with Acute Coronary Syndrome Ning Guo 9:15 AM - Case 2: Patient with Spontaneous Dissection Jie Qian 9:30 AM - Case 3: Diabetic Patient Junqing Yang 9:45 AM - Case 4: Assessment of a Coronary Aneurysm Xiaofan Wu 10:00 AM - Case 5: Assessment of an Angiographic Filling Defect Xuebo Liu 10:15 AM - Virtual Histology and Its Clinical Utilities William Kongto Hau Case Presentations Illustrating the Use of IVUS During PCI Procedures (15 minutes each including Q&A) 11:00 AM - Case 6: Routine Stent Sizing Kai Xu 11:15 AM - Case 7: Use of IVUS to Identify and Resolve Acute Underexpansion Jun Guo 11:30 AM - Case 8: Use of IVUS to Identify and Resolve Acute Malapposition Jian Liu 11:45 AM - Case 9: Abrupt Closure During Stent Implantation or Shortly Thereafter Shoujie Shan OCT Before and During PCI Moderators: Takashi Akasaka, William F. Fearon Discussants: Yundai Chen, Javier Escaned, Michael Kang-Yin Lee, Yoshinobu Onuma, Ron Waksman 2:00 PM - Basics of OCT Imaging Interpretation Takashi Akasaka 2:20 PM - Diagnostic and Pre-PCI Uses of OCT Yoshinobu Onuma 2:40 PM - OCT to Guide Interventions and Assess Complications Yundai Chen 12:00 PM - Case 10: Perforation Yingjia Xu 3:00 PM - Panel Discussion: IVUS or OCT During PCI - Which Should I Use? 12:15 PM - Case 11: Distal LMCA Bifurcation Stenting Yong He 3:15 PM - Break 12:30 PM - Adjourn Luncheon Symposium Sponsored by GE Healthcare How Do You Manage Cardiorenal Risk Reduced by Contrast Medium? 12:40 PM-1:55 PM Chairmen: Haichang Wang, Yawei Xu 12:40 PM - Opening Address Interventional Imaging - Focusing on What ItвЂ™s Important 12:45 PM - Focusing on Contrast Medium Induced Cardiorenal Risk for Diabetes Yaling Han Moderators: Fina Mauri, Gary S. Mintz Discussants: Takashi Akasaka, Costantino O. Costantini, Soo-Jin Kang, Satoru Sumitsuji 1:15 PM - Cardiac Safety of Contrast Medium Lefeng Wang 10:30 AM - Use of IVUS During LMCA Intervention Soo-Jin Kang 1:35 PM - Panel Discussion with Audience Q&A 10:45 AM - IVUS Guided Stenting and Recognition / Assessment of Complications Costantino O. Costantini OCT Workshop Part I 2:00 PM-6:00 PM 1:50 PM - Take-Home Message 1:55 PM - Adjourn Case Presentations Illustrating the Use of OCT Either in a Diagnostic Setting or Prior to PCI or During PCI (15 minutes each including Q&A) Moderators: Gary S. Mintz, Ron Waksman Discussants: Takashi Akasaka, Javier Escaned, Seung-Ho Hur, Stephen Wai-Luen Lee, Yoshinobu Onuma 3:30 PM - Case 1 Jingbo Hou 3:45 PM - Case 2 Jie Qian 4:00 PM - Case 3 Xiantao Song 4:15 PM - Case 4 Binquan Zhou 4:30 PM - Case 5 Feng Tian 4:45 PM - Case 6 Chengzhi Lu 5:00 PM - Case 7 Fei Ye 5:15 PM - Case 8 Kelvin Chan 5:30 PM - Case 9 Hongzhi Xie 5:45 PM - Case 10 Fei Gao 6:00 PM - Adjourn 029 00 CIT 2012 www.citmd.com Thursday, March 15th, 2012 Room 308, Level 3 Breakfast Case Reviews 2 Bifurcation 7:00 AM-8:00 AM Moderators: Ronghua Luan, Quan Liu, Chun Xiao 7:00 AM - CS-0112: A Complex MultiBifurcation Case Huai Yu 7:10 AM - Q&A 7:12 AM - CS-0153: PCI for Ostial Lesion with Szabo Technique Shengli Yang 7:22 AM - Q&A 7:24 AM - CS-0208: A Complex Ostial Lesion Treated by Transradial Approach with 6Fr Homemade Sheathless Guiding Catheter Binquan Zhou 7:34 AM - Q&A 7:36 AM - CS-0272: Culotte Stenting in a High-Lateral AMI Patient Involving Diagonal 1 and Chronic Occluded LAD Jun Jiang 7:46 AM - Q&A 7:48 AM - CS-0371: Crush Stenting in Patient with Acute Myocardial Infarction Chaoyang Zhang 7:58 AM - Q&A 8:00 AM - Adjourn SOLACI at CIT 8:30 AM-10:30 AM HKSTENT at CIT 10:30 AM-12:30 PM Part I: TAVR Moderators: Michael Kang-Yin Lee, Martin B. Leon, Eberhard Grube Moderators: Martin B. Leon, Liliana R. Grinfeld 8:30 AM - How to Improve Safety on TAVR Procedures? Alexandre Abizaid 8:45 AM - Novel TAVR Devices Eberhard Grube 9:00 AM - TAVR Case Presentation Michael Kang-Yin Lee 10:30 AM - HKSTENT: Where Are We Heading for? Michael Kang-Yin Lee Part I: Cardiac Imaging and Physiology 10:35 AM - FFR in Clinical Practice Chi-Kin Chan 10:47 AM - Discussion 9:15 AM - Panel Discussion with Audience Q&A Discussants: Alexandre Abizaid, Yundai Chen, Eberhard Grube, Michael Kang-Yin Lee, Sudhir Rathore, Yongjian Wu 10:50 AM - Impact on PCI Practice and Research from OCT Perspective Stephen Wai-Luen Lee Part II: Controversies in Left Main 11:05 AM - The Practical Applications of FFR, IVUS and OCT in Current PCI Practice Philip Hung-Chung Wong Moderators: Alexandre Abizaid, Jiyan Chen 9:30 AM - Left Main Stenting: IVUS for All Costantino R. Costantini 9:45 AM - Left Main Stenting: Selective Use of IVUS Fausto Feres 10:00 AM - Left Main Stenting Case Presentation Guosheng Fu 10:15 AM - Panel Discussion with Audience Q&A Discussants: Costantino O. Costantini, Costantino R. Costantini, Fausto Feres, Guosheng Fu, Sema GГјneri 11:02 AM - Discussion 11:17 AM - Discussion 11:20 AM - Take-Home Message Martin B. Leon Part II: HKSTENT Cardiovascular Interventional Complication Forum (CICF) 2012 - How Would You Treat? Discussants: Kam-Tim Chan, Antonio Colombo, Yong Huo, Kin-Lam Tsui, Ping-Tim Tsui, Yuejin Yang Best CICF 2012 Complication Case 1 11:25 AM - Case Presentation: A вЂњSuboptimallyвЂќ Positioned Ostial Stent Kin-Lam Tsui 11:30 AM - Panel Discussion: How Would I Treat? 11:40 AM - How Did I Treat? Kin-Lam Tsui 030 00 CIT 2012 www.citmd.com Thursday, March 15th, 2012 Best CICF 2012 Complication Case 2 11:45 AM - Case Presentation: The вЂњRetrogradeвЂќ Complication Tei-Kei Ng 11:50 AM - Panel Discussion: How Would I Treat? 12:00 PM - How Did I Treat? Tei-Kei Ng Best CICF 2012 Complication Case 3 12:05 PM - Case Presentation: A Million Dollar Procedure Michael Chan 12:10 PM - Panel Discussion: How Would I Treat? 12:20 PM - How Did I Treat? Michael Chan 12:25 PM - Wrap up and HKSTENT Future Events Li-Wah Tam 12:30 PM - Adjourn Left Main and Bifurcation Summit Part I 2:00 PM-6:07 PM Session I: Core Concepts Moderators: Alexandra J. Lansky, Haichang Wang 2:00 PM - How Are Left Main and Non-Left Main Bifurcations Unique, and How Should These Observations Affect the Interventional Approach 1: Insights from Pathology Renu Virmani 2:12 PM - How Are Left Main and Non-Left Main Bifurcations Unique, and How Should These Observations Affect the Interventional Approach 2: Insights from Imaging Gary S. Mintz 2:24 PM - Coronary Bifurcation Treatment: Update from the European Bifurcation Club Goran Stankovic Session II: Anatomical and Diagnostic Considerations of Bifurcation Lesions Moderators: Shaoliang Chen, Jean Fajadet Discussants: Kam-Tim Chan, Alexandra J. Lansky, Thach Nguyen, Teguh Santoso, Dobrin Vassilev, Chris Kwok-Yiu Wong 2:58 PM - Flow Dynamics, Shear Stress, and Plaque Distribution: Implications on Bifurcation Treatment Strategies, Acute and Long-Term Safety and Effectiveness Outcomes Thach Nguyen 3:10 PM - Limitations of Routine Angiography: Novel 3-D Angiography and Other Modalities Alexandra J. Lansky 3:22 PM - Practical Approach to Performing and Interpreting Diagnostic FFR in Bifurcation Lesions Shaoliang Chen 3:34 PM - Panel Discussion with Audience Q&A 3:44 PM - Bifurcation Angle and Implications on Outcomes Teguh Santoso 3:54 PM - Case Presentation: Narrow Angle and Technique Selection (Medina 111) Jingyu Hang 4:00 PM - Discussion 4:06 PM - Case Presentation: Wider Angle and Technique Selection (Medina 111) Junjie Zhang 4:12 PM - Discussion 4:18 PM - Carina / Plaque Shift and Implications on Outcomes Dobrin Vassilev 2:36 PM - Predictors of Restenosis and Stent Thrombosis After One- and Two-Stent Techniques in Left Main and Non-Left Main Bifurcations Antonio Colombo 4:28 PM - Case Presentation: Side Branch Preservation Strategy - Predilation or Jailed Wire Only? Kam-Tim Chan 2:48 PM - Panel Discussion with Audience Q&A Discussants: Antonio Colombo, Gary S. Mintz, Goran Stankovic, Renu Virmani 4:34 PM - Discussion 031 00 4:40 PM - Case Presentation: Tips and Tricks of Rewiring and Final Kissing Balloon Technique Jinghua Liu 4:46 PM - Discussion 4:52 PM - Case Presentation: How to Treat Pinched Side Branch? Chris Kwok-Yiu Wong 4:58 PM - Discussion Session III: Management of Complex NonLeft Main Bifurcations Moderators: Jilin Chen, Marie-Claude Morice Discussants: Tamzeed Ahmed, Yaron Almagor, Lianglong Chen, Antonio Colombo, Jinghua Liu, Yasuhiro Makita 5:04 PM - MasterвЂ™s Lecture: My Top 10 Techniques to Surviving Complex Non-Left Main Bifurcations Antonio Colombo 5:19 PM - Case Presentation: How Did I Treat This Complex Non-Left Main Bifurcation? (Medina 111) Sundeep Mishra 5:25 PM - Discussion 5:31 PM - Case Presentation: How Did I Treat This Complex Non-Left Main Bifurcation? Yi Li 5:37 PM - Discussion 5:43 PM - Case Presentation: How Did I Treat This Complex Non-Left Main Bifurcation? (Medina 011) Li Li 5:49 PM - Discussion 5:55 PM - Case Presentation: Unprotected Left Main PCI Treated with T-Stenting and Kissing Balloon Technique in a Bangladeshi Patient with Hepatocellular Carcinoma Tamzeed Ahmed 6:01 PM - Discussion 6:07 PM - Adjourn CIT 2012 www.citmd.com Thursday, March 15th, 2012 Room 309A, Level 3 Breakfast Case Reviews 3 Left Main Coronary Artery Disease 7:00 AM-8:00 AM Moderators: Weijie Li, ShiвЂ™an Huang, Liangqiu Tang 7:00 AM - CS-0068: Utility of JR4 Guiding Catheter in Ostial Left Main PCI Ling Ma 7:10 AM - Q&A 7:12 AM - CS-0195: Simple Strategy for Left Main plus Triple Vessel Disease Jingtao Guo 7:22 AM - Q&A 7:24 AM - CS-0264: IVUS-Guided PCI in Left Main Bifurcation Combined with Severe Triple Vessel Disease Weigang Qi 7:34 AM - Q&A 7:36 AM - CS-0284: PCI in Patient with Left Main plus Triple Vessel Disease Liangqiu Tang 7:46 AM - Q&A 7:48 AM - CS-0369: A Case of Left Main Bifurcation PCI Liqing Jiang 7:58 AM - Q&A 8:00 AM - Adjourn CIT Educational Case Award Case Presentations Part I 8:15 AM-12:30 PM 10:00 AM - CS-0090: Emergency PCI in a Patient with AMI After Thrombolysis Failure: Culprit or Complete Revascularization? Keng Wu Session I 10:10 AM - Q&A Moderator: Shubin Qiao Panelists: Shanglang Cai, Xuefeng Guang, Tongku Liu, Guizhou Tao, Ming Yang, Yujie Zeng 10:15 AM - CS-0092: A Case of CAD with Granulocytopenia Yonggang Sui 8:15 AM - CS-0219: Coronary Perforation: How to Bail out? Takuro Takama 10:25 AM - Q&A 8:25 AM - Q&A 8:30 AM - CS-0030: Striking One Snag After Another After Acute Anterior Wall Myocardial Infarction Zhaofang Yin 8:40 AM - Q&A 8:45 AM - CS-0031: Successful Retrieval of the Fractured Guidewire Zhaoqing Sun 8:55 AM - Q&A 9:00 AM - CS-0046: Using VSD Occluder in Ventricular Septum Rupture After Acute Myocardial Infarction Dangsheng Huang 9:10 AM - Q&A 9:15 AM - CS-0048: Left Main Occlusion Caused by Aortic Dissection Zhiguo Zhang 9:25 AM - Q&A 9:30 AM - CS-0066: LCX Aneurysm with Fistula to Right Atrium Hongyong Wang 9:40 AM - Q&A 9:45 AM - CS-0081: Which Was the Culprit Vessel for AMI? Jingbo Hou 9:55 AM - Q&A Session II Moderator: Weimin Wang Panelists: Yuguo Chen, Hengjian Hao, Likun Ma, Yaoming Song, Qingsheng Wang, Daifu Zhang 10:30 AM - CS-0111: PCI in Patient with Syphilis Coronary Artery Inflammation Jing Liu 10:40 AM - Q&A 10:45 AM - CS-0140: Recanalization of RCA CTO with Retrograde Approach: Tricks and Solutions Guowei Zhou 10:55 AM - Q&A 11:00 AM - CS-0146: Recanalizing Total Occlusion of Left Anterior Descending Artery Using Retrograde Technique Jianying Ma 11:10 AM - Q&A 11:15 AM - CS-0154: Reverse Crush PCI for the Left Main Bifurcation AMI Patient in Postpartum Shengli Yang 11:25 AM - Q&A 11:30 AM - CS-0160: Large Tortuous Epicardial or Small But Straight Septal Collateral: Successful Treatment with Retrograde Approach with Rendezvous Technique in a LAD CTO Case Tse-Min Lu 11:40 AM - Q&A 032 00 CIT 2012 www.citmd.com Thursday, March 15th, 2012 11:45 AM - CS-0169: Rotablation and Crush Stenting in a Severe Calcified Left Main Bifurcation Lesion After CABG Jun Jiang 11:55 AM - Q&A 12:00 PM - CS-0190: Stent Dislodgment in Calcified Lesion Ruijin Guan 12:10 PM - Q&A 12:15 PM - CS-0191: FFR-Guided PCI for Multivessel Disease Yongzhen Zhang 12:25 PM - Q&A 12:30 PM - Adjourn CIT Educational Case Award Case Presentations Part II 2:00 PM-6:00 PM Session III Moderator: Wenyi Guo Panelists: Biao Cheng, Anlin Lu, Jianjun Peng, Liangqiu Tang, Shouli Wang, Shulin Zhang 2:00 PM - CS-0339: PCI for Diffuse LAD CTO with IVUS Guidance YiвЂ™an Yao 2:10 PM - Q&A 2:15 PM - CS-0142: Acute Occlusion in RCA Complicating Acute In-Stent Occlusion in LAD Hao Sun 2:25 PM - Q&A 2:30 PM - CS-0252: RCA CTO: Retrograde PCI Using Wire Capturing Technique Lang Hong 2:40 PM - Q&A 2:45 PM - CS-0257: PCI for Sudden Cardiac Death Survivor with Left Main Trifurcation, LAD CTO, and COPD Hu Li 033 00 2:55 PM - Q&A 4:55 PM - Q&A 3:00 PM - CS-0268: Left Main Trifurcation PCI: Simultaneous Triple-Balloon Inflation Technique Anek Kanoksilp 5:00 PM - CS-0366: Death Induced by Severely Multiple Thrombosis in Abdominal Aorta After IABP Placement Tao Qu 3:10 PM - Q&A 5:10 PM - Q&A 3:15 PM - CS-0282: RCA Dissection After LAD PCI Fengxia Hou 5:15 PM - CS-0373: Dilemma in Management of High Risk and Emergency ACS Patients Jian Liu 3:25 PM - Q&A 5:25 PM - Q&A 3:30 PM - CS-0326: A Case of Re-PCI for LAD-CTO Treated by Retrograde Approach Through Homolateral Branch Quanmin Jing 5:30 PM - CS-0375: Retrograde Technique Helps Pass Through CTO Lesion with Balloon Bin Zhang 3:40 PM - Q&A 5:40 PM - Q&A 3:45 PM - CS-0242: A Case of Longitudinal Stent Deformation Tamon Kato 5:45 PM - CS-0354: A Candidate of Heart Transplantation, Found to Have Total Occlusion of LMCA Ping-Han Lo 3:55 PM - Q&A 5:55 PM - Q&A Session IV Moderator: Weimin Li Panelists: Guanchang Cheng, Dongju Jiang, Ling Li, Yu Wang, Yusheng Xue, Xingsheng Zhao 4:00 PM - CS-0342: A Case of PCI in a Patient with Heart and Renal Failure Huaimin Guan 4:10 PM - Q&A 4:15 PM - CS-0349: IVUS-Induced Acute Left Main Artery Closure You-Chun Huang 4:25 PM - Q&A 4:30 PM - CS-0363: One for ALL: One Lesion Involved RCA and LAD Qing Yang 4:40 PM - Q&A 4:45 PM - CS-0365: Heavy Calcification and Angulated Lesion with Coronary Perforation Nailiang Tian 6:00 PM - Adjourn CIT 2012 www.citmd.com Thursday, March 15th, 2012 2:05 PM - BARC Bleeding Definitions and Strategy of Bleeding Prevention Thomas Cuisset Room 309B, Level 3 2:30 PM - Update of ACC/AHA and ESC Guidelines for Anti-Thrombotic Therapy in ACS Jingxuan Guo Breakfast Case Reviews 4 Complications 7:00 AM-8:00 AM 2:50 PM - Update of Anticoagulant Therapy in STEMI Jinqing Yuan Moderators: Ruijin Guang, Jingyu Hang, Lei Qin 3:10 PM - Optimizing Antithrombotic Therapy in PCI Periprocedural Period Shuyang Zhang 7:00 AM - CS-0003: Sudden Death After Emergent PCI for AMI: Who Is the ArchCriminal? Zhonglong Deng 7:10 AM - Q&A 3:30 PM - Balancing the Benefit of Antithrombotic Therapy and the Bleeding Risk in ACS Yundai Chen 7:12 AM - CS-0004: A New Method to Retrieve the Lost Stent Jinhua Feng 3:50 PM - Panel Discussion with Audience Q&A 7:22 AM - Q&A Pharmacologic Satellite Symposium Supported by Bayer 4:00 PM-5:30 PM 7:24 AM - CS-0023: Big Intracoronary Thrombus Before PCI Jingjin Che 7:34 AM - Q&A 7:36 AM - CS-0028: A Case of Recurrent Stent Thrombosis Chunmei Wang Moderators: Run-Lin Gao, Yaling Han 4:00 PM - Opening Address Run-Lin Gao 7:46 AM - Q&A 4:05 PM - Stroke Prevention in Atrial Fibrillation Patients with Prior MI: ROCKET AF Subgroup Analysis Shu Zhang 7:48 AM - CS-0052: Delayed Intracoronary Hematoma Hongyu Shi 4:25 PM - Current and Future of Secondary Prevention After ACS: ATLAS ACS 2 TIMI 51 Yujie Zhou 7:58 AM - Q&A 8:00 AM - Adjourn 4:45 PM - Application of Aspirin: New Guideline Recommendations for Percutaneous Coronary Intervention Ben He Pharmacologic Satellite Symposium Supported by Sanofi 2:00 PM-4:00 PM 5:05 PM - The Mechanism of Aspirin in AntiAtherosclerosis Xiaoying Li Moderators: Yong Huo, Xiaoying Li, Jiyan Chen, Jingxuan Guo, Wei Gao 5:25 PM - Take-Home Message Yaling Han 2:00 PM - Opening Address 5:30 PM - Adjourn Room 310, Level 3 Breakfast Case Reviews 5 Complications 7:00 AM-8:00 AM Moderators: Quanmin Jing, Xi Su, Jun Guan 7:00 AM - CS-0096: A New Option to Close the Perforation Junqing Yang 7:10 AM - Q&A 7:12 AM - CS-0099: Successful Retrieval of the Dislodged Guidewire from Coronary During PCI via Radial Approach Yitong Ma 7:22 AM - Q&A 7:24 AM - CS-0113: Combined Use of OCT and IVUS to Diagnose the Abrupt Closure After PCI Zhigang Han 7:34 AM - Q&A 7:36 AM - CS-0128: A Case of No-Reflow and "Electrical Storm" During PCI Lei Zhang 7:46 AM - Q&A 7:48 AM - CS-0134: A Case of Refractory Hypotension After PCI Bingfeng Zhou 7:58 AM - Q&A 8:00 AM - Adjourn 034 00 CIT 2012 www.citmd.com Thursday, March 15th, 2012 Non-Invasive Cardiovascular Imaging Symposium 8:30 AM-12:30 PM Session l Moderators: Zuoxiang He, Hao Wang, Shihua Zhao, Jun Zhang, Xiuzhang Lu 8:30 AM - Adhere to Consensus and Guideline: How to Promote the Standardized Development of Cardiovascular Imaging in China? Shihua Zhao 8:45 AM - Discussion 8:50 AM - Update on Detection of Vulnerable by PET/CT Quanming Zhao 9:05 AM - Discussion 9:10 AM - The Diagnosis of Acute Chest Pain: What We Can Learn from Echocardiography? Lianglong Chen 9:25 AM - Discussion 9:30 AM - The Role of Echocardiography in Transcatheter Closure for ASD and VSD Xiuzhang Lu 9:45 AM - Discussion 9:50 AM - The Role of Real Time 3-Dimension Echocardiography in Transcatheter Closure for Congenital Heart Disease Jun Zhang 10:30 AM - Update of Invasive and NoInvasive Diagnosis for Coronary Artery Spasm Dingcheng Xiang 1:05 PM - Clinical Significance of MRI in Cardiovascular Diseases Zhong Wang 10:45 AM - Discussion 1:25 PM - Siemens' Total Solutions for Integrations of 3D Images in the Cath Lab Janina Beilner 10:50 AM - Application of Coronary CTA in China: An Interventional CardiologistsвЂ™ Perspective Hongbin Yan 11:05 AM - Discussion 11:10 AM - Reducing Complications and Improving Outcomes with CT Guided PCI Michael Lim 11:25 AM - Discussion 11:30 AM - Automated Assessment of Coronary Plaque Burden by MSCT Johan H. C. Reiber 11:45 AM - Discussion 11:50 AM - Acute Chest Pain Investigation: Utility of Cardiac CT Angiography in Guiding Troponin Measurement Ian T. Meredith 12:05 PM - Discussion 12:10 PM - Transcatheter Mitral Valve Repair: Is It Necessary to Use MSCT to Evaluate Coronary Sinus and Adjacent Structure? Xinming Li 12:25 PM - Discussion 12:30 PM - Adjourn 10:05 AM - Discussion 10:10 AM - Multimodality Imaging Integration for Structural Heart Disease Interventions Carlos E. Ruiz 10:25 AM - Discussion Session II Moderators: Bin Lu, Michael Lim, Shih-Pu Wang, Buxing Chen, Wenyue Pang 035 00 Luncheon Symposium Sponsored by Siemens Healthcare Image Guided Percutaneous Cardiovascular Interventions: From Diagnosis, Therapy, to Prognosis 12:40 PM-1:55 PM 1:45 PM - Panel Discussion with Audience Q&A 1:55 PM - Adjourn Sino-European Interventional Cardiology Hot Topics Supported by B Braun and Bayer 2:00 PM-6:00 PM Part I Moderators: Franz Weidinger, Shuzheng Lu Discussants: Ben He, Jinghua Liu, Shubin Qiao, Yujie Zhou 2:00 PM - Introduction and Objectives Shuzheng Lu 2:05 PM - Europe Perspective on the Clinical Utility of Drug-Coated Balloon Franz Weidinger 2:25 PM - China Perspective on the Clinical Utility of Drug-Coated Balloon JianвЂ™an Wang 2:40 PM - Discussion 2:45 PM - Current Status of In-Stent Restenosis and the Early Experience of Drug-Coated Balloon Yongjian Wu 3:00 PM - Discussion 3:05 PM - Case Presentation: 9-Month FollowUp After DCB Treatment in ISR Lesion Qinhua Jin 3:15 PM - Discussion Chairman: Shiliang Jiang 12:40 PM - Opening Address 12:45 PM - Applications of Dual Source CT in the Diagnosis and Treatment of Coronary Artery Disease Fanghong Wu 3:20 PM - Case Presentation: Treatment of Side Branch Restenosis Xiantao Song 3:30 PM - Discussion CIT 2012 www.citmd.com Thursday, March 15th, 2012 3:35 PM - Case Presentation: Management of Multiple Stent Thrombosis Xiangqian Qi 3:45 PM - Discussion 3:50 PM - Case Presentation: Complex Bifurcation Lesion Xuebo Liu 4:00 PM - Discussion 4:05 PM - Take-Home Message Shuzheng Lu Part II Moderators: Martin MГ¶ckel, Yong Huo Discussants: Haichang Wang, Lefeng Wang, Meng Wei 4:10 PM - Introduction and Objectives Yong Huo 4:15 PM - Mechanisms of CIN: Evidence and Controversy Martin MГ¶ckel 4:50 PM - Discussion 4:55 PM - Case Presentation: Modified Culotte Technique Yi An 5:05 PM - Discussion 5:10 PM - Case Presentation: Stent Thrombosis Zhuo Yu 5:20 PM - Discussion 5:25 PM - Case Presentation: Treatment of Bifurcation Lesion in Small Vessel Xi Su 5:35 PM - Discussion 5:40 PM - Case Presentation: Treatment of In-Stent Restenosis Yue Li 5:50 PM - Discussion 5:55 PM - Take-Home Message Yong Huo Cardiac Catheterization Basics Part I 8:30 AM-12:30 PM Room 311A, Level 3 Breakfast Case Reviews 6 Complications 7:00 AM-8:00 AM Moderators: Lang Li, Lixian Han, Jifei Tang 7:00 AM - CS-0163: ST-Segment Elevation Myocardial Infarction Caused by Very Late Stent Thrombosis Due to Drug-Eluting Stent Fracture Lang Li 7:10 AM - Q&A 7:12 AM - CS-0199: Stent Fracture Complicated with Very Late Stent Thrombosis Yingwu Liu 7:22 AM - Q&A 7:24 AM - CS-0215: Right Coronary Dissection During Percutaneous Coronary Intervention Hongxu Liu 7:34 AM - Q&A 7:36 AM - CS-0223: Thrombosis in Left Main and LCX After Recanalization of Ostial LAD Total Occlusion Zhenguo Ji 7:46 AM - Q&A 7:48 AM - CS-0307: No-Reflow During PCI for Late Stent Thrombosis Qinhua Jin 7:58 AM - Q&A 8:00 AM - Adjourn Session I Moderators: Weimin Wang, Xuewen Qin, Dongju Jiang, Kang Li 8:30 AM - Cardiovascular Anatomy and Physiology Lei Ge 8:45 AM - Q&A 8:50 AM - Indications and Contraindications for Coronary Angiography Yingling Zhou 9:05 AM - Q&A 9:10 AM - Radial Artery Puncture: Tips, Common Difficulties, and Complications Xianghua Fu 9:25 AM - Q&A 9:30 AM - Catheter Manipulation via Radial Approach: Tips and Tricks Jue Chen 9:45 AM - Q&A 9:50 AM - Basic Skill of Diagnostic Catheterization: Coronary Anatomic Variants Shaoping Nie 10:05 AM - Q&A 10:10 AM - How to Interpret Coronary Angiogram? Xinkai Qu 10:25 AM - Q&A Session II Moderators: Wei Gao, Dadong Zhang, Qiming Wu, Qin Qin 10:30 AM - How to Perform Qualitative and Quantitative Coronary Angiography? Ran Xia 6:00 PM - Adjourn 036 00 CIT 2012 www.citmd.com Thursday, March 15th, 2012 10:45 AM - Q&A 10:50 AM - How to Utilize and Interpret IVUS? Xiaofan Wu 11:05 AM - Q&A 11:10 AM - How to Utilize and Interpret OCT? Jingbo Hou 1:28 PM - CTO Case Reviews Kefei Dou 1:38 PM - CTO Case Reviews Fei Ye 4:00 PM - PTSMA for HOCM: Patient Selections, Techniques, and Complications Shijie You 1:55 PM - Adjourn 4:15 PM - Q&A Cardiac Catheterization Basics Part II 2:00 PM-6:00 PM Session III 11:50 AM - IABP: Indication, Implantation, and Management Chengxiang Li Moderators: Changcong Cui, Lianjun Gao, Hongliang Cong, Zhongjie Fan 12:05 PM - Q&A 2:00 PM - Basic Skill of Subclavian Vein Puncture and Complications Yan Yao 12:25 PM - Q&A 12:30 PM - Adjourn 2:15 PM - Q&A 2:20 PM - Basic Skill of Septum Atrioventriculare Puncture Xuebin Li 2:35 PM - Q&A Luncheon Symposium Sponsored by Abbott Vascular New Weapon for CTO, No More Challenge to Overcome 12:40 PM-1:55 PM 2:40 PM - Right Heart Catheterization: Techniques and Clinical Significance Gejun Zhang Chairmen: Jiyan Chen, Ben He, Weimin Wang, Yujie Zhou 3:00 PM - Bedside Hemodynamic Monitoring: Indications, Management, and Complications Hongliang Cong 12:40 PM - Opening Address 12:43 PM - CTO Angioplasty: Antegrade or Retrograde? When and How to Make a Decision? William L. Lombardi 12:58 PM - TREK: No Environment Too Challenging Jianping Li 1:13 PM - PROGRESS: New Weapon to Challenge CTO Lang Li 037 00 4:20 PM - Prevention and Management of CIN Hongbin Liu 4:35 PM - Q&A 11:45 AM - Q&A 12:10 PM - How to Use Thrombus Aspiration Catheter: Tip and Tricks Lefeng Wang Moderators: Shubin Qiao, Zhanquan Li, Lianqun Cui, Yang Zheng 1:48 PM - Panel Discussion with Audience Q&A 11:25 AM - Q&A 11:30 AM - How to Utilize and Interpret FFR? Guisong Wang Session IV 2:55 PM - Q&A 3:15 PM - Q&A 3:20 PM - Endomyocardial Biopsy: Indications, Procedure, and Complications Zhujun Shen 3:35 PM - Q&A 3:40 PM - Temporary Pacemaker Implantation: Indications and Techniques Keping Chen 3:55 PM - Q&A 4:40 PM - How to Monitor, Avoid and Manage the High Radiation Dose? Shouli Wang 4:55 PM - Q&A 5:00 PM - Tip and Tricks of Haemostatic Closure Device Implantation Hong Liu 5:15 PM - Q&A 5:20 PM - Common Complications in the Cath Lab: Identification, Prevention, and Management Shaobin Jia 5:35 PM - Q&A 5:40 PM - New Model of Information System Construction in Contemporary Catheterization Lab Jian Liu 5:55 PM - Q&A 6:00 PM - Adjourn CIT 2012 www.citmd.com Thursday, March 15th, 2012 Contemporary Electrocardiology 8:30 AM-12:30 PM 11:15 AM - Advances on Research of T Wave Hongyu Wang Moderators: Pihua Fang, Junguo Yang, Hong Ma 11:30 AM - Electrocardiographic Characteristics of Sudden Cardiac Death Syndrome Junguo Yang Breakfast Case Reviews 7 Complications 7:00 AM-8:00 AM 8:30 AM - Identification and Management of the Abnormal CRT Electrocardiogram Yat-Sun Chan 11:45 AM - Assessment of Acute Pulmonary Embolism by ECG Guangping Li Moderators: Hong Jiang, Yue Li, Leisheng Ru 8:45 AM - Analysis of Abnormal Pacemaker Electrocardiogram Wei Hua 12:00 PM - Comparison of the Noninvasive ECG Methods in Stratification of Sudden Cardiac Death Risk Pihua Fang Room 311B, Level 3 7:00 AM - CS-0308: LAD CTO Angioplasty Complicated with Acute Left Main Thrombus and Shock Guowei Zhou 7:10 AM - Q&A 7:12 AM - CS-0323: Coronary Artery Perforation Caused by Wire or Congenital Fistula? Shaoyi Guan 7:22 AM - Q&A 7:24 AM - CS-0334: LAD Stent Fracture Shuo Sun 7:34 AM - Q&A 7:36 AM - CS-0353: Catheter-Induced Dissection During PCI Bei Ge 7:46 AM - Q&A 7:48 AM - CS-0360: Subacute Stent Thrombosis After CTO Recanalization Leisheng Ru 7:58 AM - Q&A 8:00 AM - Adjourn Session I 9:00 AM - Application of Ladder Diagram in Diagnosis of Arrhythmias Zhiyi Wang 9:15 AM - Esophageal Electrophysiological Testing in Tachyarrhythmias Zhongjie Li 9:30 AM - New Knowledge of Pre-Excitation Syndrome Renguang Liu 9:45 AM - Differential Diagnosis of Wide QRS Tachycardia on ECG Haicheng Zhang 10:00 AM - Differential Diagnosis of Narrow QRS Tachycardia on ECG Quan Fang 10:15 AM - Audience Q&A Session II Moderators: Yat-Sun Chan, Renguang Liu, Haicheng Zhang 10:30 AM - ECG Diagnosis of Acute Myocardial Infarction Bin Wang 10:45 AM - ECG Characteristics of Acute Myocardial Infarction with Bundle Branch Block and Its Clinical Significance Hong Ma 12:15 PM - Audience Q&A 12:30 PM - Adjourn Luncheon Symposium Sponsored by Lepu Medical Direction of New Generation DES 12:40 PM-1:55 PM Chairmen: Xiaoshu Cheng, Ruqiong Nie, Yongjian Wu, Hong Zhang 12:40 PM - Multiple Considerations on DES Selection in Clinical Practice Yingzhong Lin 12:55 PM - Excellence of NANO PolymerFree DES in Clinical Utility Jianbin Gong 1:10 PM - The Direction of DES Development Jinghua Liu 1:25 PM - A Large-Scale Clinical Trial of NANO Polymer-Free DES Ming Yang 1:40 PM - Panel Discussion with Audience Q&A 1:55 PM - Adjourn 11:00 AM - Advances of J Wave Syndrome Ping Zhang 038 00 CIT 2012 www.citmd.com Thursday, March 15th, 2012 Heart Rhythm Part I Ablation Technologies 2:00 PM-6:00 PM Session I Moderators: Zulu Wang, Jian Ma, Yingxian Sun, Bin Liu, Guoqiang Zhong 2:00 PM - Diagnostic Difficulties and Catheter Ablation of Special Supraventricular Tachycardia Xingpeng Liu 2:15 PM - Q&A 2:20 PM - Approaches and Techniques for Repeated Catheter Ablation of Atrial Fibrillation Xu Liu 2:35 PM - Q&A 2:40 PM - The Long Term Effect of Catheter Ablation of Atrial Fibrillation and Mechanisms of Recurrence Jian Ma 2:55 PM - Q&A 3:00 PM - Optimal Strategy of Catheter Ablation for Chronic Atrial Fibrillation Jianzeng Dong 3:15 PM - Q&A 3:20 PM - Mapping and Ablation of the Special Atrial Tachycardia Shaowen Liu 3:35 PM - Q&A 3:40 PM - Strategies of Mapping and Ablation for the Atrial Tachycardia Post Atrial Fibrillation Ablation Yansheng Ding 3:55 PM - Q&A 039 00 Session II Moderators: Yansheng Ding, Xu Liu, Xingpeng Liu, Lianjun Gao, Zhaoguang Liang 4:00 PM - Identification and Ablation of Ventricular Tachycardia Originated from Special Locations Zulu Wang 4:15 PM - Q&A 4:20 PM - The Substrate and Ablation Methods of Ventricular Tachycardia with Structural Heart Disease Shulin Wu 4:35 PM - Q&A 4:40 PM - The Types of Recurrent Arrhythmias After Ablation of Fascicular Ventricular Tachycardia Yan Yao 4:55 PM - Q&A 5:00 PM - Catheter Ablation of Ventricular Tachycardias Post-Myocardial Infarction Minglong Chen 5:15 PM - Q&A 5:20 PM - The Timing and Strategy of Catheter Ablation for Patients with ICD Pingzhen Yang 5:35 PM - Q&A 5:40 PM - The Electrophysiological Mechanisms and Catheter Ablation of Ventricular Fibrillation and Its Catheter Ablation Hong Jiang 5:55 PM - Q&A 6:00 PM - Adjourn вЂѓ CIT 2012 www.citmd.com Friday, March 16th, 2012 Plenary Hall A, Level 4 Special Live Case Session 8:00 AM-8:35 AM Transcatheter Renal Nerve Denervation for Refractory Hypertension Fu Wai Hospital, National Center for Cardiovascular Diseases of China, Beijing Moderator: Martin B. Leon Discussants: Shaoliang Chen, Run-Lin Gao, David E. Kandzari, Steven Li, Jianfang Luo, Martin T. Rothman, Markus P. Schlaich, Alan C. Yeung, Robaayah Zambahari, Ruiyan Zhang Operators: Horst Sievert, Xiongjing Jiang Opening of CIT 2012 in Partnership with TCT 8:35 AM-9:40 AM Moderators: Run-Lin Gao, Martin B. Leon Discussants: Junbo Ge, Dayi Hu, Shengshou Hu, Yong Huo, Osamu Katoh, Shuzheng Lu, Jean Marco, Seung-Jung Park, Patrick W. Serruys, Gregg W. Stone, Yuejin Yang, Shu Zhang 8:35 AM - Opening Video: Looking back at the 10 Years of CIT 8:45 AM - Welcome Address by VIPs 9:00 AM - Celebrating the 10th Anniversary: The Journey of Percutaneous Cardiovascular Interventions in China Run-Lin Gao 9:15 AM - History of Percutaneous Coronary Intervention: What We Should Know from the Past 35 Years? Spencer B. King III 9:30 AM - Panel Discussion CIT-TCT Plenary Session 9:40 AM-12:30 PM Part IV - Complex PCI: CTOs, Bifurcations, and MVD Part I - The Asia Pacific Region: An Emerging Center of Growth and Worldwide Leadership in Interventional Cardiovascular Therapeutics! Moderators: Antonio Colombo, David E. Kandzari, Jeffrey W. Moses Discussants: Maurice Buchbinder, Costantino R. Costantini, Jean Fajadet, Junbo Ge, Osamu Katoh, William L. Lombardi, Marie-Claude Morice, Charles A. Simonton, Etsuo Tsuchikane, Yuejin Yang Moderators: Martin B. Leon, Patrick W. Serruys Discussants: Chung-Seung Chiang, Run-Lin Gao, Yean-Leng Lim, Sundeep Mishra, Masahiko Ochiai, Seung-Jung Park, Teguh Santoso, Huay Cheem Tan, Damras Tresukosol, Robaayah Zambahari 11:20 AM - Case Presentation Lei Ge 9:40 AM - Panel Discussion: Clinical Demographics, Education, and Research 11:50 AM - Synthesis Antonio Colombo Part II - Acute MI: State of the Art Part V - Future Visions: WhatвЂ™s Next Moderators: Gregg W. Stone, Harry Suryapranata Discussants: Joseph D. Babb, Kenneth Chin, Fausto Feres, Yong Huo, Mitchell W. Krucoff, Alexandra J. Lansky, Sameer Mehta, Weifeng Shen, Pieter C. Smits, Alan C. Yeung Moderators: Gary S. Mintz, Eberhard Grube Co-Moderator: Martin B. Leon Discussants: Alexandre Abizaid, Shaoliang Chen, Keith D. Dawkins, William F. Fearon, Ian T. Meredith, Martin T. Rothman, Renu Virmani, Ron Waksman, Haichang Wang, John G. Webb 10:10 AM - Case Presentation Jian Liu 10:15 AM - Panel Discussion 10:40 AM - Synthesis Gregg W. Stone 11:25 AM - Panel Discussion 11:55 AM - Case Presentation Eberhard Grube 12:00 PM - Panel Discussion 12:25 PM - Synthesis Martin B. Leon Part III - DAPT Issues: Duration and Dilemmas After PCI 12:30 PM - Adjourn Moderators: Roxana Mehran, Stephan Windecker Discussants: Jiyan Chen, Donald E. Cutlip, Liliana R. Grinfeld, Yaling Han, David E. Kandzari, Adnan Kastrati, Ajay J. Kirtane, Jean Marco, Samuel K. Mathew, David X. M. Zhao Welcome Banquet 6:45 PM-9:00 PM 10:45 AM - Case Presentation Zening Jin 10:50 AM - Panel Discussion 11:15 AM - Synthesis Roxana Mehran 040 00 CIT 2012 www.citmd.com Friday, March 16th, 2012 Function A, Level 1 Live Case Session 4 Peripheral Vascular Intervention Fu Wai Hospital, National Center for Cardiovascular Diseases of China, Beijing, China 9:30 AM-11:00 AM Moderators: Neil E. Strickman, Jianfang Luo Discussants: Junmin Bao, W. Britton Eaves, Haizal Haron Kamar, Elias Kassab, Carlos Mena, Jihad Mustapha, Aravinda Nanjundappa, Yan Wang, Ruiyan Zhang, Yinghua Zou Operators: Craig M. Walker, Raghotham R. Patlola, Xiongjing Jiang Live Case Session 5 Structural Heart Disease Intervention Fu Wai Hospital, National Center for Cardiovascular Diseases of China, Beijing, China 11:00 AM-12:30 PM Moderators: Jan Kovac, Shiliang Jiang Discussants: Kelvin Chan, Pham Manh Hung, Atilla Iyisoy, Xiangqing Kong, Jason H. Rogers, Carlos E. Ruiz, Witold Ruzyllo, Zhiwei Zhang, Xianxian Zhao Operators: Horst Sievert, Jacek Bialkowski, Malgorzata Szkutnik, Zhongying Xu Luncheon Symposium Sponsored by Boston Scientific The Power of PtCr: Real World Excellence and Clinical Trial Evidence 12:40 PM-1:55 PM Chairmen: Jean Marco, Yuejin Yang, Fang Chen, Dejia Huang, Jianhua Zhu 12:40 PM - Opening Address 12:45 PM - The Power of PtCr: EvidenceBased Clinical Trial Updates Ian T. Meredith 1:05 PM - PROMUS Element: Real World Experience and Practical Tips Huay Cheem Tan 041 00 1:25 PM - Innovation: Defining the New DES Standard and Shaping the Future of Interventional Cardiology Keith D. Dawkins 1:45 PM - Panel Discussion with Audience Q&A 1:55 PM - Adjourn Live Case Session 6 Non-Left Main Bifurcation or Ostial Lesion Fu Wai Hospital, National Center for Cardiovascular Diseases of China, Beijing, China 2:00 PM-3:30 PM Moderators: Gregg W. Stone, Alan C. Yeung Discussants: Alexandre Abizaid, Thomas Alexander, Donald E. Cutlip, Xianghua Fu, Adnan Kastrati, Jian Liu, Fina Mauri, Pieter C. Smits, Franz Weidinger, Stephan Windecker Operators: Jeffrey W. Moses, Maurice Buchbinder, Yaron Almagor IVUS Interpreter: Gary S. Mintz Live Case Session 7 CTO and / or TAVR National Taiwan University Hospital, Taipei, China 3:30 PM-5:00 PM Moderators: Junbo Ge, Eberhard Grube Discussants: Paul TL Chiam, Zhimin Du, Ching-Chang Fang, Richard Lim, Huiliang Liu, Masahiko Ochiai, Sudhir Rathore, Etsuo Tsuchikane, Lefeng Wang, John G. Webb Operators: Paul Hsien-Li Kao and Colleagues Live Case Session 8 Left Main Bifurcation Fu Wai Hospital, National Center for Cardiovascular Diseases of China, Beijing, China 5:00 PM-6:30 PM Moderators: Jeffrey W. Moses, Ajay J. Kirtane Discussants: Giuseppe De Luca, Ben He, Yuqing Hou, Kai Huat Lam, Imad Sheiban, Goran Stankovic, Pieter R. Stella, Seung-Jea Tahk, Lei Wang, Bin Zhang Operators: Antonio Colombo, Seung-Jung Park, Yuejin Yang IVUS Interpreter: Gary S. Mintz Function B, Level 1 Luncheon Symposium Sponsored by JW Medical Biodegradable for Natural Health 12:40 PM-1:55 PM Chairmen: Antonio Colombo, Run-Lin Gao, Eberhard Grube, Haichang Wang 12:40 PM - Opening Address 12:45 PM - LEADERS 4-Year Follow-up Results: A Prospective, Randomized Trial of Biolimus A9-Eluting Stents with Biodegradable Polymer vs. SirolimusEluting Stents with Durable Polymer Stephan Windecker 1:05 PM - CREATE 5-Year Update: MultiCenter Registry of EXCEL Biodegradable Polymer Drug-Eluting Stent Yaling Han 1:25 PM - OCT in Drug-Eluting Stent Era Yundai Chen 1:45 PM - Panel Discussion with Audience Q&A 1:55 PM - Adjourn PCR at CIT How Should I Treat on High Risk Acute Coronary Syndrome in Patients with Multivessel Disease 2:00 PM-3:30 PM Moderators: Jean Marco, Run-Lin Gao Discussants: Shaoliang Chen, Yundai Chen, Thomas Cuisset, Junbo Ge, Kari NiemelГ¤, Goran Stankovic 2:00 PM - Introduction and Objectives Jean Marco CIT 2012 www.citmd.com Friday, March 16th, 2012 Case 1: ACS Patient with MVD Involving Bifurcation / LM 2:05 PM - Case Presentation 1 Yundai Chen 2:10 PM - How Would I Treat? Shaoliang Chen 2:17 PM - How Would I Treat? Goran Stankovic 2:24 PM - How Did I Treat? Yundai Chen 2:29 PM - Panel Discussion with Audience Q&A 2:41 PM - Consensus Case 2: ACS Patient with MVD Involving a CTO 2:46 PM - Case Presentation 2 Thomas Cuisset 2:51 PM - How Would I Treat? Junbo Ge 2:58 PM - How Would I Treat? Kari NiemelГ¤ 3:05 PM - How Did I Treat? Thomas Cuisset 3:10 PM - Panel Discussion with Audience Q&A 3:25 PM - Consensus Mini-Symposium on Bioabsorbable Scaffolds 3:30 PM-5:00 PM Moderators: Run-Lin Gao, Ian T. Meredith Discussants: Jiyan Chen, Fausto Feres, Yoshinobu Onuma, Patrick W. Serruys, Renu Virmani, Ron Waksman, Yujie Zhou 3:30 PM - Introduction and Objectives Ian T. Meredith 3:32 PM - Why Will Bioabsorbable Scaffold Replace Metallic Drug-Eluting Stent? Patrick W. Serruys 3:39 PM - The Promise and Challenge of Bioabsorbable Scaffolds (as I see it)! Renu Virmani 3:49 PM - Pre-Clinical and Clinical Evaluation of Drug Eluting Bioabsorbable Metal Scaffold Ron Waksman 3:59 PM - Imaging Bioabsorbable Scaffolds: IVUS, VH, OCT, CTA, and More Yoshinobu Onuma 4:09 PM - Assessment and Potential Clinical Benefits of Restored Late Endothelial Function After Scaffold Bioabsorption Ian T. Meredith 4:19 PM - BVS in Simple Lesions: 5-Year Cohort A and 2-Year Cohort B Results Integrated Insights Patrick W. Serruys 4:34 PM - BVS in Complex Lesions: Early Results from ABSORB Extend Fausto Feres 4:44 PM - Panel Discussion 5:22 PM - DK-CRUSH III: A Multicenter, Randomized Trial Comparing Double Kissing (DK) Crush vs. Culotte Stenging for the Treatment of Unprotected Distal Left Main Bifurcation Lesions Shaoliang Chen 5:34 PM - Discussion 5:44 PM - DOCA-TRI: A Randomized Trial Assessing the Utility of 5-in-6 Double Catheter Technique in Treating Complex Coronary Lesions via Transradial Approach Qi Zhang 5:54 PM - Discussion 6:00 PM - SUIT-AMI: A Multicener, Randomized Trial Assessing the Impacts of Super-Selective Infarct-Related Artery Infusion with Tirofiban on Myocardial Reperfusion and Bleeding Complications in Acute Myocardial Infarction Patients Hongbing Yan 6:10 PM - Discussion 6:15 PM - Adjourn 4:58 PM - Take-Home Message Run-Lin Gao Late Breaking Clinical Trials and First Report Investigations I 5:00 PM-6:15 PM Moderators: Martin B. Leon, Patrick W. Serruys, Gregg W. Stone Discussants: Shaoliang Chen, Donald E. Cutlip, Jean Fajadet, Adnan Kastrati, Mitchell W. Krucoff, Roxana Mehran, Ian T. Meredith, Marie-Claude Morice, Stephan Windecker 5:00 PM - TRACK-D: A Large-Scale, Multicenter, Randomized Trial Assessing the Safety and Efficacy for Rosuvastatin to Prevent Contrast-Induced Acute Kidney Injury in Patients with Diabetes Yaling Han 5:12 PM - Discussion 042 00 CIT 2012 www.citmd.com Friday, March 16th, 2012 Case 1: Ostial Lesion Function C, Level 1 Luncheon Symposium Sponsored by Sino Medical BuMA: A New Drug-Eluting Stent with Excellent Performance and Perfect ReEndothelialization 12:40 PM-1:55 PM Chairmen: Yong Huo, Renu Virmani, Yongjian Wu, Tiemin Jiang 12:40 PM - Opening Address 12:45 PM - Comparison of Endothelial Response Following Different DES Implants Renu Virmani 1:05 PM - First Report Investigation: Evaluating Re-Endothelialization of BuMA vs. XIENCE V by OCT 3-Month After Implantations Bo Yu 1:20 PM - Case Review 1: Challenging the Complex Lesion with BuMA Changjiang Hong 1:35 PM - Case Review 2: Challenging the Complex Lesion with BuMA Shangyu Wen 1:50 PM - Panel Discussion with Audience Q&A 1:55 PM - Adjourn Practical Course on PCI Part I How to Treat? 2:00 PM-6:00 PM Session I Moderators: Jilin Chen, Hongbing Yan Discussants: Lianglong Chen, Lijun Jin, Yin Liu, Kai Wang, Zesheng Xu, Hesong Zeng 2:00 PM - Case Introduction Fenghua Ding 2:05 PM - How Would I Treat? Lianglong Chen 2:10 PM - How Would I Treat? Lijun Jin 2:15 PM - Case Presentation: How Did I Treat? Fenghua Ding 2:20 PM - Tips and Tricks in Treating Coronary Ostial Lesion Jilin Chen 2:30 PM - Panel Discussion with Audience Q&A Case 2: Thrombus-Containing Lesion 2:40 PM - Case Introduction Yue Li 2:45 PM - How Would I Treat? Yin Liu 2:50 PM - How Would I Treat? Hesong Zeng 2:55 PM - Case Presentation: How Did I Treat? Yue Li 3:00 PM - Tips and Tricks in Treating Thrombus-Containing Lesion Hongbing Yan 3:10 PM - Panel Discussion with Audience Q&A 3:30 PM - How Would I Treat? Wenyi Guo 3:35 PM - Case Presentation: How Did I Treat? Jingyu Hang 3:40 PM - Tips and Tricks in Treating Small Vessel Disease Shubin Qiao 3:50 PM - Panel Discussion with Audience Q&A Case 4: Long Diffuse Lesion 4:00 PM - Case Introduction Yan Li 4:05 PM - How Would I Treat? Chaozhong Liu 4:10 PM - How Would I Treat? Ruqiong Nie 4:15 PM - Case Presentation: How Did I Treat? Yan Li 4:20 PM - Tips and Tricks in Treating Long Diffuse Lesion Weiyi Fang 4:30 PM - Panel Discussion with Audience Q&A Session III Moderators: Shuzheng Lu, Weimin Wang Discussants: Lang Hong, Jinfa Jiang, Lang Li, Haiming Shi, Huifeng Wang, Lishu Xu Session II Moderators: Weiyi Fang, Shubin Qiao Discussants: Zhujun Chen, Wenyi Guo, Chaozhong Liu, Hongxu Liu, Ruqiong Nie, Dadong Zhang Case 3: Small Vessel Disease 3:20 PM - Case Introduction Jingyu Hang 043 00 3:25 PM - How Would I Treat? Dadong Zhang Case 5: Calcified Lesion 4:40 PM - Case Introduction Junjie Zhang 4:45 PM - How Would I Treat? Jinfa Jiang 4:50 PM - How Would I Treat? Lang Hong CIT 2012 www.citmd.com Friday, March 16th, 2012 2:15 PM - Aorto-Iliac Intervention: Tips, Tricks, and Safeguards Raghotham R. Patlola 4:55 PM - Case Presentation: How Did I Treat? Junjie Zhang 5:00 PM - Tips and Tricks in Treating Calcified Lesion Weimin Wang 5:10 PM - Panel Discussion with Audience Q&A Case 6: DES In-Stent Restensis 5:20 PM - Case Introduction Xiantao Song 5:25 PM - How Would I Treat? Lang Li 5:30 PM - How Would I Treat? Haiming Shi 5:35 PM - Case Presentation: How Did I Treat? Xiantao Song 5:40 PM - Tips and Tricks in Treating DES InStent Restensis Shuzheng Lu 5:50 PM - Panel Discussion with Audience Q&A 6:00 PM - Adjourn Room 306AB, Level 3 Master Lecture 1 Learning PCI Techniques from Dr. ChenвЂ™s Cases Supported by JCIC 7:00 AM-7:45 AM Moderator and Lecturer: Jiyan Chen Luncheon Symposium Sponsored by GE Healthcare Leading the Healthcare (R)evolution: Advanced Image Guided Complex Cardiac Procedure 12:40 PM-1:55 PM Chairmen: Qing He, Marie-Claude Morice 12:40 PM - Opening Address 12:45 PM - Imaging Solutions for Complex PCI Procedures Marie-Claude Morice 1:05 PM - Multi-Modality Guidance Application for CTO Junbo Ge 1:25 PM - 3D Guided Interventions for Structural Heart Disease Ashok Tirouvanziam 1:45 PM - Panel Discussion with Audience Q&A 1:55 PM - Adjourn Peripheral and Endovascular Therapy NCVH at CIT 2:00 PM-6:00 PM Moderators: Craig M. Walker, Raghotham R. Patlola Discussants: Chip B. Hance, Aravinda Nanjundappa 2:00 PM - Opening Remarks / Keynote Address: Why Every Cardiologist Should Understand and Intervene in PAD? Craig M. Walker 2:30 PM - Aortic Intervention: Case Presentation Zaiping Jing 2:40 PM - Aorto-Iliac Intervention: Panel Discussion 2:45 PM - Crossing Total Occlusions: Subintimal Technique, Crossing Tools, and Access Site Importance Jihad Mustapha 3:00 PM - SFA / Popliteal Atherectomy Elias Kassab 3:15 PM - SFA / Popliteal Stenting: New Stent Designs, Covered Stents, Drug Eluting Stents, and Bioabsorbable Stents Carlos Mena 3:30 PM - SFA / Popliteal Intervention: Case Presentation Xiongjing Jiang 3:40 PM - SFA / Popliteal Intervention: Panel Discussion 3:45 PM - Infrapopliteal Intervention: The Role of Transpedal Access, Pedal Arch Reconstruction, and Transcollateral Crossing Jihad Mustapha 4:00 PM - Infrapopliteal Intervention: Case Presentation Wei Guo 4:10 PM - Infrapopliteal Intervention: Panel Discussion 4:15 PM - The Role of Distal Protection and Clot Aspiration W. Britton Eaves 4:30 PM - Carotid Intervention Elias Kassab 4:45 PM - Carotid Intervention: Case Presentation Jianfang Luo 4:55 PM - Carotid Intervention: Panel Discussion 044 00 CIT 2012 www.citmd.com Friday, March 16th, 2012 2:30 PM - Use of FFR During PCI Procedures: From Multivessel Disease to Bifurcations Bon-Kwon Koo 5:00 PM - Renal Artery Stenting and Renal Artery Denervation Raghotham R. Patlola 5:15 PM - Renal Artery Intervention: Case Presentation Ruiyan Zhang Room 307AB, Level 3 5:25 PM - Renal Artery Intervention: Panel Discussion Master Lecture 2 Learning PCI Techniques from Dr. GeвЂ™s Cases Supported by JCIC 7:00 AM-7:45 AM 5:30 PM - Subclavian and Vertebral Artery Intervention Carlos Mena Case Presentations (15 minutes each including Q&A) 2:45 PM - Case 1 JianвЂ™an Wang 3:00 PM - Case 2 Lijun Guo Moderator and Lecturer: Junbo Ge 3:15 PM - Case 3 Ningfu Wang 3:30 PM - Case 4 Fei Ye 5:55 PM - Subclavian Intervention: Panel Discussion Luncheon Symposium Sponsored by BraccoSine The Latest Evidences of Contrast MediaвЂ™s Administration in PCI 12:40 PM-1:55 PM 6:00 PM - Closing Remarks / Adjourn Chairman: Weifeng Shen 4:00 PM - Break 12:40 PM - Opening Address The Future 12:45 PM - Prevention and Treatment of Contrast Media Induced Acute and Delayed Adverse Reaction in PCI Juying Qian Moderators: William F. Fearon, Yongjian Wu Discussants: Javier Escaned, Jianping Li, Sidney Tsz Ho Lo, Bon-Kwon Koo 5:45 PM - Subclavian Intervention: Case Presentation Yan Wang 1:15 PM - Perioperative Management of Chronic Kidney Disease in PCI: Update on 2011 ACCF/AHA Guideline Hongbing Yan 1:45 PM - Panel Discussion with Audience Q&A 1:55 PM - Adjourn FFR Workshop 2:00 PM-6:00 PM The Present Moderators: Javier Escaned, Seung-Jea Tahk Discussants: William F. Fearon, Bon-Kwon Koo, Seung-Jung Park 2:00 PM - Keynote: How I Use FFR and Why? Basics, Practice, and Pitfalls William F. Fearon 2:15 PM - Use of FFR to Defer Interventions Seung-Jung Park 045 00 3:45 PM - Panel Discussion with Audience Q&A 4:15 PM - iFR: What Is It and How Will It Make My Life Easier? Javier Escaned 4:30 PM - CT-FFR: Is This the Future? Bon-Kwon Koo Case Presentations (15 minutes each including Q&A) 4:45 PM - Case 5 Zhujun Shen 5:00 PM - Case 6 Ruqiong Nie 5:15 PM - Case 7 Guisong Wang 5:30 PM - Case 8 Yongjian Wu 5:45 PM - Panel Discussion with Audience Q&A 6:00 PM - Adjourn CIT 2012 www.citmd.com Friday, March 16th, 2012 Room 308, Level 3 Master Lecture 3 Learning PCI Techniques from Dr. HanвЂ™s Cases Supported by JCIC 7:00 AM-7:45 AM Moderator and Lecturer: Yaling Han Luncheon Symposium Sponsored by Star Progress & Asahi Learning the Experiences of Asahi Devices from the Specialists 12:40 PM-1:55 PM Chairmen: Jiyan Chen, Lefeng Wang, Jian'an Wang 12:40 PM - Opening Address 12:45 PM - Tips and Tricks of Retrograde Approach in CTO-PCI Etsuo Tsuchikane 12:55 PM - The Use of Corsair Micro Catheter Osamu Katoh 1:05 PM - New Front Line Guidewire from Asahi Intecc Eisho Kyo 1:15 PM - Personal Experience of Using Asahi Guidewire in PCI Hui Chen 1:30 PM - Utilization of AsahiвЂ™s New Devices in PCI Junbo Ge 1:45 PM - Panel Discussion with Audience Q&A 1:55 PM - Adjourn Left Main and Bifurcation Summit Part II 2:00 PM-6:02 PM Session IV: Left Main Revascularization: PCI vs. CABG Moderators: Eberhard Grube, Yaling Han 2:00 PM - PCI vs. CABG for Left Main Disease: Today's Data from Randomized Trials and Large Registries Marie-Claude Morice 2:15 PM - Left Main PCI and CABG: Trends from U.S. David E. Kandzari 2:27 PM - Left Main Disease in Acute Coronary Syndromes Patients: PCI or CABG? Imad Sheiban 4:13 PM - Comparison Among Various DESs in Treating Left Main Bifurcation Lesions Wei-Hsian Yin 4:25 PM - Panel Discussion with Audience Q&A Discussants: Costantino R. Costantini, Debabrata Dash, Quanmin Jing, Haichang Wang, Wei-Hsian Yin Session VI: Left Main Bifurcation PCI Techniques 2:39 PM - Left Main Bifurcation with Massive Calcification: PCI or CABG? Teguh Santoso Moderators: Jilin Chen, Kenneth Chin Discussants: Akihiko Takahashi, Joo-Young Yang 2:51 PM - PCI Could Be an Alternative Therapy for Most Left Main Disease: A Practical Perspective from Chinese Interventionalist Juying Qian 4:35 PM - One Stent vs. Two Stents: Evidence-Based Medicine and Cath Lab Practicalities Jean Fajadet 3:03 PM - Reflections on the Ideal RiskStratification Tool: Beyond the Syntax Score Davide Capodanno 3:15 PM - Panel Discussion with Audience Q&A Discussants: Davide Capodanno, David E. Kandzari, Marie-Claude Morice, Juying Qian, Teguh Santoso, Imad Sheiban Session V: Regional Left Main PCI Experiences Moderators: Fang Chen, Thach Nguyen, Sema GГјneri 3:25 PM - Left Main Stenting: Indian Experience and Long-Term Results Debabrata Dash 3:37 PM - Left Main Stenting: Brazilian Experience and Long-Term Results Costantino R. Costantini 4:47 PM - Can IVUS Help Determine Whether One vs. Two Stents Are Necessary? Shoujie Shan 4:59 PM - Can FFR Help Determine Whether One vs. Two Stents Are Necessary? Bon-Kwon Koo 5:11 PM - Case Presentation: Integrated Use of IVUS and FFR During Complex Left Main PCI Fei Ye 5:17 PM - Discussion 5:23 PM - The Spectrum of Two-Stent Techniques (and how to choose) Guosheng Fu 5:38 PM - Case Presentation: How to Treat This Complex Left Main Trifurcation? Teguh Santoso 5:44 PM - Discussion 3:49 PM - Left Main Stenting: A Large Chinese CenterвЂ™s Experience and LongTerm Results Quanmin Jing 5:50 PM - Dedicated Left Main Bifurcation Stents: Rationale, Development, and Experience Dobrin Vassilev 4:01 PM - Left Main Stenting: A Large Chinese CenterвЂ™s Experience and LongTerm Results Haichang Wang 6:02 PM - Adjourn 046 00 CIT 2012 www.citmd.com Friday, March 16th, 2012 Room 309A, Level 3 Luncheon Symposium Sponsored by Johnson & Johnson Medical From Basic to Great: New Frontier, New Ideas, New Cordis 12:40 PM-1:55 PM Chairmen: Shubin Qiao, Guosheng Fu 12:40 PM - Opening Address 12:45 PM - Tips and Cases: The Cornerstone of PCI - How to Choose Guiding Catheter via Radial Approach? Yue Li 1:05 PM - Tips and Cases: How to Utilize High Pressure Balloon to Ensure the Safety and Efficacy of PCI? Binquan Zhou 1:25 PM - Tips and Cases: How to Treat Renal Artery Stenosis via Radial Approach? Yawei Xu 1:45 PM - Panel Discussion with Audience Q&A 1:55 PM - Adjourn Comprehensive Management of Cardiovascular Disease in Diabetics Educationally Supported by Medtronic 2:00 PM-6:00 PM Part I Moderators: Jiyan Chen, Ben He, Caiyi Lu, Fucheng Sun Discussants: Junmin Bao, Xuedong Gan, Chunlin Li, Xuebo Liu, Yongjian Wu, Baixi Zhuang 2:00 PM - Opening Lecture: It's Time for Cross-Disciplinary Collaboration to Manage Diabetes Jiyan Chen 2:05 PM - Management of Glucose in CVD Patients with Different Risk Stratifications Chunlin Li 4:55 PM - Case Presentation: NSTEMI-ACS PCI for a Diabetic Patient Zhizhong Li 2:25 PM - Enhanced PCI for Diabetics with Coronary Angiogram: Facts and Fantasy Yongjian Wu 5:05 PM - Discussion 2:40 PM - Discussion 2:45 PM - Case Presentation: PCI for a Type II Diabetic Patient Xuebo Liu 2:55 PM - Discussion 3:00 PM - Case Presentation: PCI for Diabetic Patient with Bifurcation Xuedong Gan 3:10 PM - Discussion 3:15 PM - Case Presentation: BTK Intervention in Diabetic Patient Baixi Zhuang 3:30 PM - Case Presentation: BTK Intervention in Diabetic Patient Junmin Bao 3:45 PM - Discussion Part II Moderators: Chuanyu Gao, Lijun Guo, JianвЂ™an Wang, Zuyi Yuan Discussants: Ning Guo, Guangwei Li, Jifu Li, Zhizhong Li, Chaowei Mu, Alan C. Yeung 4:00 PM - Comprehensive Management of Cardiovascular Disease in Diabetics: Evidence and Practice Guangwei Li 4:20 PM - Enhanced PCI with Latest Intracoronary Imaging Technologies: Facts and Fantasy Ning Guo 4:35 PM - Discussion 4:40 PM - Case Presentation: CTO in a Diabetic Patient Chaowei Mu 4:50 PM - Discussion 047 00 5:10 PM - Case Presentation: STEMI PCI for a Diabetic Patient Jifu Li 5:20 PM - Discussion 5:25 PM - Percutaneous Coronary Intervention in Diabetics: State of the Art Alan C. Yeung 5:45 PM - Panel Discussion with Audience Q&A 5:55 PM - Take-Home Message Zuyi Yuan 6:00 PM - Adjourn CIT 2012 www.citmd.com Friday, March 16th, 2012 2:40 PM - Inflammation-Related Biomarkers in Atherosclerosis Ye Tian Room 309B, Level 3 Luncheon Symposium Sponsored by Lake Region Medical New Guidewire Technology Meets Complex Lesions 12:40 PM-1:55 PM Chairmen: Shuzheng Lu, Yingling Zhou, Zheng Wan, Ben He, Zheng Ji, Yu Cao 12:40 PM - Opening Address 12:45 PM - New Guidewire Technology from Lake Region Medical Meets Complex Lesions Ron Amanda 12:55 PM - Use of Regatta Frontline Guidewire for Complex Lesions Jun Chen 1:10 PM - Regatta SB: Side Branch Access by Using Lake Region MedicalвЂ™s Deflector Technology Jianfang Luo 1:25 PM - Regatta HS: Crossing CTO by Using Lake Region MedicalвЂ™s Wedge Technology Zheng Ji 1:40 PM - Panel Discussion with Audience Q&A 1:55 PM - Adjourn 2:55 PM - Q&A 3:00 PM - Keynote Lecture: Retrospect of Lipid Disorder and Clinics in 2011 Jianjun Li 3:25 PM - New Opinion in LowDensity Lipoprotein Cholesterol and Atherosclerosis Ping Ye 3:40 PM - Novel Insight into HighDensity Lipoprotein Cholesterol and Atherosclerosis Hong Chen 3:55 PM - Q&A Master Lecture 4 Learning PCI Techniques from Dr. LuвЂ™s Cases Supported by JCIC 7:00 AM-7:45 AM Moderator and Lecturer: Shuzheng Lu Luncheon Symposium Sponsored by Lifetech Revolution for Congenital Heart Disease Intervention 12:40 PM-1:55 PM Chairman: Shiliang Jiang Session II Moderators: Dejia Huang, Yuannan Ke, Zhenwen Huang, Biao Xu, Ming Zhang, Feng Cao 4:00 PM - Keynote Lecture: Retrospect of Myocardial Ischemia and Infarction in 2011 Ben He 4:25 PM - Application of Ischemic Preconditioning and Postconditioning Xiangjun Yang 4:40 PM - Molecular Mechanisms and Clinical Intervention of Coronary No-Reflow Phenomenon Lan Huang 4:55 PM - Q&A Basics and Medical Therapies Part I 2:00 PM-6:00 PM Room 310, Level 3 Session I 5:00 PM - Keynote Lecture: Retrospect of Stem Cell Therapy in 2011 Junbo Ge Moderators: Haozhu Chen, Wenling Zhu, Junzhu Chen, Baoqi Jiang, Luyue Gai, Guangping Li 5:25 PM - Misconceptions in Stem Cell Therapy Jie Wang 2:00 PM - Keynote Lecture: Retrospect of Mechanisms of Atherosclerosis in 2011 Chaoshu Tang 5:40 PM - Stem Cell Therapy in Ischemic Cardiomyopathy Zhijian Yang 2:25 PM - Regulation of Gene Expression for Endothelial Healing Function Jun Tao 5:55 PM - Q&A 12:40 PM - Opening Address 12:45 PM - Use of FuStar Steerable Catheter in Facilitating Structural Heart Interventions Yat-Yin Lam 1:05 PM - Follow-up Results of Cera Occluder from China and Global Use Report Zhiwei Zhang 1:25 PM - PDA Device Closure: My Experience and Difficulties - Does the Device Matter? Manoj Kumar Rohit 1:45 PM - Panel Discussion with Audience Q&A 1:55 PM - Adjourn 6:00 PM - Adjourn 048 00 CIT 2012 www.citmd.com Friday, March 16th, 2012 Structural Heart Disease Part I 2:00 PM-6:00 PM Session I Moderators: Aiqing Zhou, Carlos E. Ruiz, Xiangqing Kong, Shihua Zhao, Dongming Hou, Atilla Iyisoy Discussants: Dominic Allocco, Jacek Bialkowski, Xin Pan, Horst Sievert, David X. M. Zhao 2:00 PM - LAA Closure: State of the Art Horst Sievert 2:15 PM - Discussion 2:20 PM - Stent Implantation in Coarctation of the Aorta: Polish Experience Jacek Bialkowski 2:35 PM - Discussion 2:40 PM - PFO Closure for Stroke Prevention David X. M. Zhao 2:55 PM - Discussion 3:00 PM - Clinical Data and the Role of the Watchman LAAC Device Dominic Allocco 3:15 PM - Discussion 3:20 PM - Paravalvular Leak Closure Xin Pan 3:35 PM - Discussion 3:40 PM - Percutaneous Transapical LV Access and Closure for SHD Interventions Carlos E. Ruiz 3:55 PM - Discussion 4:00 PM - Percutaneous Mitral Commissurotomy Nondeflating Balloon: A Rare Complication Vikas Bisne 4:15 PM - Discussion 049 00 Session II Moderators: Shiliang Jiang, Pham Gia Khai, Huatai Li, Guangyi Wang, Gejun Zhang, Ajit G. Desai Discussants: Xiwei Deng, Pham Manh Hung, Hweung Kon Hwang, Witold Ruzyllo, Malgorzata Szkutnik Room 311A, Level 3 4:20 PM - Percutaneous Closure of Ruptured Sinus of Valsalva Malgorzata Szkutnik Master Lecture 5 Learning PCI Techniques from Dr. WangвЂ™s Cases Supported by JCIC 7:00 AM-7:45 AM 4:35 PM - Discussion Moderator and Lecturer: Weimin Wang 4:40 PM - Antegrade Aortic Balloon Valvuloplasty Using Inoue Balloon After Retrograde Aortic Valvuloplasty for Easy Access of Inoue Balloon Using Externized Wire from Femoral Vein to Femoral Artery Hweung Kon Hwang Luncheon Symposium Sponsored by Kinhely The Start of New Heart: HELIOS 12:40 PM-1:55 PM 4:55 PM - Discussion Chairmen: Zhanquan Li, Weimin Wang, Weiyi Fang 5:00 PM - Transcatheter Pulmonary Valve Implantation with Melody and SapienEdwards Valves Witold Ruzyllo 5:15 PM - Discussion 5:20 PM - Percutaneous Balloon Mitral Valvuloplasty for Patients with Rheumatic Mitral Stenosis in Vietnam Pham Manh Hung 5:35 PM - Discussion 5:40 PM - How to Manage the Complication with Snare Device During Intervention? Xiwei Deng 5:55 PM - Discussion 6:00 PM - Adjourn 12:40 PM - Opening Address 12:45 PM - HOPE: A Prospective Multicenter Randomized Trial of HELIOS Biodegradable Polymer Sirolimus-Eluting Stent - 24-Month Results Shuzheng Lu 1:15 PM - The First DES Randomized Trial in China: A Statistical Consideration Wei Li 1:35 PM - Panel Discussion with Audience Q&A 1:55 PM - Adjourn STEMI Summit AICT and LUMEN in Partnership with CIT 2:00 PM-6:05 PM STEMI Overview Moderators: Dayi Hu, Weifeng Shen, Huay Cheem Tan Discussants: Giuseppe De Luca, Roxana Mehran, Sameer Mehta, Damras Tresukosol, Lefeng Wang, Robaayah Zambahari CIT 2012 www.citmd.com Friday, March 16th, 2012 2:00 PM - Opening Remarks Dayi Hu, Huay Cheem Tan 4:05 PM - Cardiogenic Shock Praveen Chandra 2:03 PM - Burgeoning STEMI Epidemic in Asia Robaayah Zambahari 4:15 PM - Discussion 2:15 PM - Current Status of STEMI Therapy in China and Guideline Update Weifeng Shen 4:20 PM - No-Reflow Fazila Tun Nesa Malik 4:30 PM - Discussion 2:27 PM - How to Improve D2B Outcomes? Sameer Mehta 4:35 PM - Left Main Acute Closure Rosli Mohd Ali 2:42 PM - Critical Lessons from HORIZONSAMI: Bivalirudin and DES Roxana Mehran 4:45 PM - Discussion 2:57 PM - Panel Discussion with Audience 4:50 PM - Multivessel Disease Meng Wei Q&A 5:00 PM - Discussion Global STEMI Processes 5:05 PM - Thrombus Aspiration Hongbing Yan Moderators: Yean-Leng Lim, Wei Gao Discussants: Joseph D. Babb, Chung-Seung Chiang, Yong Huo, Harry Suryapranata, Huay Cheem Tan, Chuen-Den Tseng 5:15 PM - Discussion 3:07 PM - Europe Harry Suryapranata 5:30 PM - Discussion 3:19 PM - U.S. Joseph D. Babb Final Debate: What Is the Best Global Strategy for STEMI Therapy? 3:31 PM - Asia Huay Cheem Tan Moderators: Sameer Mehta, Huay Cheem Tan Discussants: Liliana R. Grinfeld, Lefeng Wang 3:43 PM - Update on China STEMI-PCI Program 5:35 PM - Primary PCI Remains the Gold Yong Huo Standard Lefeng Wang 3:55 PM - Panel Discussion with Audience Q&A STEMI PCI Case Reviews: Learn from Illustrated Examples Moderators: Sameer Mehta, Hongbing Yan Discussants: Devang Desai, Seung-Ho Hur, Mohammad Ishaq, Rajneesh Jain, Vincent On-Hing Kwok, Muhammad Munawar, Quang Tuan Nguyen 5:20 PM - Vein Graft Praveer Agarwal Room 311B, Level 3 Master Lecture 6 Learning PCI Techniques from Dr. YangвЂ™s Cases Supported by JCIC 7:00 AM-7:45 AM Moderator and Lecturer: Yuejin Yang Luncheon Symposium Sponsored by Medtronic Solution for a Better Heart 12:40 PM-1:55 PM Chairman: Martin B. Leon Co-Chairmen: Shaoliang Chen, Martin T. Rothman, Bo Xu, Yujie Zhou 12:40 PM - Opening Address 12:43 PM - RESOLUTE: Top Choice for Diabetes Jinghua Liu 1:03 PM - Case Presentation 1: PCI in Diabetic Yan Wang 1:15 PM - Case Presentation 2: PCI in Diabetic Meng Wei 1:27 PM - RESOLUTE Clinical Evidence and the Future for Interventional Cardiology David E. Kandzari 5:45 PM - Pharmaco-Invasive Management 1:42 PM - Panel Discussion with Audience Q&A Will Be the Preferred Reperfusion Strategy Liliana R. Grinfeld 1:55 PM - Adjourn 5:55 PM - Panel Discussion and Take-Home Message 6:05 PM - Adjourn Heart Rhythm Part II Management of Atrial and Ventricular Tachycardias 2:00 PM-6:00 PM Session I Moderators: Fangzheng Wang, Congxin Huang, Kejiang Cao, Xinchun Yang, Yawei Xu 050 00 CIT 2012 www.citmd.com Friday, March 16th, 2012 2:00 PM - The Current Status and Future of Catheter Ablation for Atrial Fibrillation in China Congxin Huang 2:15 PM - Q&A 2:20 PM - Advances in Anti-Coagulation Therapy for Atrial Fibrillation Shu Zhang 2:35 PM - Q&A 2:40 PM - The Difficulties and Promises of Catheter Ablation for Atrial Fibrillation Changsheng Ma 2:55 PM - Q&A 3:00 PM - The New Techniques and Strategies in Catheter Ablation of Atrial Fibrillation Yanzong Yang 4:45 PM - Q&A 5:00 PM - The Reevaluation and Treatment Strategy of Functional Premature Ventricular Contraction Jiefu Yang 5:15 PM - Q&A 5:20 PM - Premature Ventricular Contraction and Heart Failure Quan Fang 5:35 PM - Q&A 5:40 PM - Current Problems in Ventricular Tachycardia Ablation Yigang Li 5:55 PM - Q&A 6:00 PM - Adjourn Session II Moderators: Shu Zhang, Changsheng Ma, Yanzong Yang, Qiangsun Zheng, Xiufen Qu 4:00 PM - Ventricular Arrhythmias Originated from Upper Pulmonary Valve Kejiang Cao Auditorium, Level 3 Pharmacologic Satellite Symposium Supported by Pfizer Optimized Statins Treatment in CHD Patients: Investigation and Practice 2:00 PM-4:00 PM Moderators: Guoying Zhu, Shuzheng Lu, Shuyang Zhang 4:15 PM - Q&A 2:00 PM - Opening: Continuously Improve Prognosis After PCI by Optimized Medication Shuzheng Lu 4:20 PM - Current Status of Treatment for Ventricular Tachycardia Xinchun Yang 2:05 PM - Intensive Statins Treatment PeriPCI: Evidence of Chinese Population Jianping Li 4:35 PM - Q&A 2:30 PM - Blind Spot and Breakthrough of Statins Treatment Guoping Lu 4:40 PM - Catheter Ablation for Brugada Syndrome Ventricular Tachycardia Yan Yao 051 00 3:35 PM - Time to Benefit: An Emerging Concept When Considering of Statins Prescription in High Risk Patients Yundai Chen 3:55 PM - Take-Home Message Pharmacologic Satellite Symposium Supported by AstraZeneca New Exploration of Pharmacotherapy in Peri-Percutaneous Coronary Intervention 4:00 PM-5:30 PM 4:00 PM - Opening Address 3:35 PM - Q&A 3:40 PM - Break 3:15 PM - Statins in CIN Prevention Weimin Wang Moderators: Dayi Hu, Weifeng Shen 3:15 PM - Q&A 3:20 PM - What Has AF Registry Study Brought to Us? Shulin Wu 2:55 PM - Reversal of Coronary Tree Atherosclerotic Lesion with Lipid Lowering Therapy: An Imaging Study in Patients with Moderate Lesions (RETARD) Fei Ye 4:05 PM - 2011 NSTEMI/UA Guideline Review Weifeng Shen 4:25 PM - Surveying the Landscape of Antiplatelet Therapy Yaling Han 4:45 PM - Utility of Beta-Blocker in PCI Yundai Chen 5:05 PM - New Progress of Lipid Study Shuyang Zhang 5:25 PM - Take-Home Message 5:30 PM - Adjourn CIT 2012 www.citmd.com Saturday, March 17th, 2012 Function A, Level 1 CRT at CIT Multivessel Disease Management 8:00 AM-9:30 AM Moderators: Ron Waksman, Run-Lin Gao 8:00 AM - Multivessel Disease: The Impact of the Syntax Score on the Choice of Revascularization Patrick W. Serruys 8:12 AM - Why I Don't Use the Syntax Score for Multivessel Disease? Maurice Buchbinder 8:24 AM - Multivessel Disease: Should We Stage the Procedure? Imad Sheiban 8:36 AM - Multivessel Disease: The Use of FFR - Does It Make a Difference? Ron Waksman 8:48 AM - Future Directions for the Treatment of Multivessel Disease: Will the Second Generation DES Change the Outcome? Gregg W. Stone 9:00 AM - Future Directions for the Treatment of Multivessel Disease: Will the Hybrid Revascularization Play an Important Role? Shengshou Hu 9:12 AM - Panel Discussion Discussants: Maurice Buchbinder, Shengshou Hu, Patrick W. Serruys, Imad Sheiban, Gregg W. Stone Live Case Session 10 Left Main Bifurcation Affiliated An Zhen Hospital of Capital Medical University, Beijing, China 9:30 AM-11:00 AM Moderators: Patrick W. Serruys, Jiyan Chen Discussants: Lianqun Cui, William F. Fearon, Sema GГјneri, Yangsoo Jang, Mitchell W. Krucoff, Shubin Qiao, Eak-Kyun Shin, Fucheng Sun, Dobrin Vassilev Operators: Marie-Claude Morice, Shuzheng Lu, Imad Sheiban Angioplasty Summit - TCTAP at CIT Left Main and Bifurcation Stenting: Optimization with FFR and IVUS 11:00 AM-12:30 PM Moderators: Seung-Jung Park, Gregg W.Stone 11:00 AM - Welcome and Introductory Remarks Seung-Jung Park 11:03 AM - IVUS and FFR to Guide Non Left Main Bifurcation PCI Soo-Jin Kang 11:15 AM - Distal Left Main Bifurcation Cases 1: My Solutions Marie-Claude Morice 11:27 AM - Distal Left Main Bifurcation Cases 2: My Solutions Jeffrey W. Moses 11:39 AM - IVUS and FFR to Guide Left Main PCI: Decision Making and Optimization Seung-Jung Park 11:51 AM - Integrated Clinical Trial Insights into the Appropriateness of Left Main Intervention Patrick W. Serruys Luncheon Symposium Sponsored by Abbott Vascular DES Summit: Sharing Global Expertise 12:40 PM-1:55 PM Chairmen: Yuejin Yang, Junbo Ge, Fang Chen, Zhimin Du 12:40 PM - Opening Address 12:45 PM - Development and Future of DES Patrick W. Serruys 1:00 PM - DAPT Interruption: Are All Stents Equally Safe? Gregg W. Stone 1:15 PM - Is Newer Stent Design Always Better? Mitchell W. Krucoff 1:30 PM - SEEDS Registry Update Yuejin Yang 1:45 PM - Panel Discussion with Audience Q&A 1:55 PM - Adjourn Live Case Session 12 MVD, SVG, and Calcified Lesions Affiliated An Zhen Hospital of Capital Medical University, Beijing, China 2:00 PM-3:30 PM Moderators: Jean Fajadet, Yaling Han Discussants: Praveer Agarwal, Brigadier S. Aziz, Praveen Chandra, Qing He, Hui Li, Xiangqian Qi, Li-Wah Tam, Renu Virmani, Franz Weidinger, Yangchun Zou Operators: Samuel K. Mathew, Robaayah Zambahari, Mitchell W. Krucoff 12:03 PM - EXCEL Trial Gregg W. Stone 12:15 PM - Panel Discussion with Audience Q&A Discussants: Soo-Jin Kang, Patrick W. Serruys, Marie-Claude Morice, Jeffrey W. Moses 12:30 PM - Adjourn 052 00 CIT 2012 www.citmd.com Saturday, March 17th, 2012 Live Case Session 14 Unusual Complex PCI Affiliated Chaoyang Hospital of Capital Medical University, Beijing, China 3:30 PM-5:00 PM Moderators: Shaoliang Chen, Liliana R. Grinfeld Discussants: Chung-Seung Chiang, Kefei Dou, Yong He, Weiming Li, Sidney Tsz Ho Lo, Quang Tuan Nguyen, Gustavo Samaja, Zheng Zhang, Qi Zhang, Binquan Zhou Operators: David E. Kandzari, Costantino R. Costantini, Fausto Feres IVUS Interpreter: Costantino O. Costantini Case Reviews with CIT and TCT Master Operators 5:00 PM-6:00 PM Moderators: Run-Lin Gao, Jeffrey W. Moses Discussants: Junbo Ge, Yaling Han, David E. Kandzari, Roxana Mehran, Gary S. Mintz, Alan C. Yeung 5:00 PM - CS-0217: A Case Report of Left Main Primary PCI Ning Guo 5:15 PM - CS-0232: Bailout Use of 5-in-6 Double Catheter Technique in a Complex CTO Angioplasty with Retrograde Approach Qi Zhang 5:30 PM - CS-0170: A Case of Very Late Stent Thrombosis Caused by Aneurysm Formation Associated with Stent Fracture Junjie Zhang 5:45 PM - CS-0377: Massive Hemorrhage of the Upper Alimentary Tract Due to MalloryWeiss Syndrome After Emergent PCI for AMI Yongjian Wu 6:00 PM - Adjourn 10:10 AM - Discussion Function B, Level 1 Live Case Session 9 Non-Left Main Bifurcation or Ostial Lesion Affiliated Chaoyang Hospital of Capital Medical University, Beijing, China 8:00 AM-9:30 AM Moderators: Yean-Leng Lim, Roxana Mehran Discussants: Joseph D. Babb, I-Chang Hsieh, Tiemin Jiang, Yi Li, Sameer Mehta, Rosli Mohd Ali, Chunguang Qiu, Harry Suryapranata, Zuyi Yuan, Xuchen Zhou Operators: Lefeng Wang, Alan C. Yeung, Teguh Santoso Late Breaking Clinical Trials and First Report Investigations II 9:30 AM-11:00 AM Moderators: Donald E. Cutlip, Alexandra J. Lansky Discussants: Fausto Feres, Liliana R. Grinfeld, Jan Kovac, Wei Li, Weifeng Shen, Xinli Shi, Huay Cheem Tan, Damras Tresukosol, Ron Waksman 9:30 AM - CREATE: A Prospective, LargeScale, Multicenter Registry of EXCEL Biodegradable Polymer Drug-Eluting Stents - Final 5-Year Clinical Results Yaling Han 9:40 AM - Discussion 9:45 AM - TARGET I Long Cohort: A Prospective, Multicenter Clinical Trial Assessing the Safety and Effectiveness of FIREHAWK Biodegradable Polymer Target Release Rapamycin-Eluting Stent for the Treatment of Long Coronary Artery Disease - 9-Month Angiographic and 1-Year Clinical Results Run-Lin Gao 9:55 AM - Discussion 10:00 AM - FOCUS: A Prospective, LargeScale, Multicenter Registry of FIREBIRD 2 Cobalt-Chromium Alloyed SirolimusEluting Stent - 2-Year Clinical Results Junbo Ge 053 00 10:15 AM - NOYA I: A Multicenter, Randomized Trial of NOYA SirolimusEluting Stent with Biodegradable Coating Compared to FIREBIRD 2 Sirolimus-Eluting Stent with Durable Coating in Patients with Coronary Artery Disease - 2-Year Clinical Results Yuejin Yang 10:25 AM - Discussion 10:30 AM - FIRE2-DIABETES: A Prospective, Multicenter Registry Examining the Efficacy and Safety of FIREBIRD 2 Cobalt-Chromium Alloyed Sirolimus-Eluting Stent for the Treatment of Complex Coronary Lesions in Patients with Diabetes - 6-Month Clinical Results Yan Li 10:40 AM - Discussion 10:45 AM - SERY I: A Prospective, Multicenter Registry of YINYI Polymer-Free Paclitaxel-Eluting Stent for the Treatment of Coronary Artery Disease - 2-Year Clinical Results Weifeng Shen 10:55 AM - Discussion Live Case Session 11 Chronic Total Occlusions Fu Wai Hospital, National Center for Cardiovascular Diseases of China, Beijing, China 11:00 AM-12:30 PM Moderators: Maurice Buchbinder, David E. Kandzari Discussants: Chi-Kin Chan, Shaoliang Chen, Yundai Chen, Tetsuya Hata, Duncan HungKwong Ho, Fumiaki Ikeno, Eisho Kyo, JianвЂ™an Wang, Mei Wei, Joo-Young Yang Operators: Etsuo Tsuchikane, Masahiko Ochiai, William L. Lombardi CIT 2012 www.citmd.com Saturday, March 17th, 2012 Luncheon Symposium Sponsored by Medfavour Medical Small Stent, Big Impact 12:40 PM-1:55 PM Chairmen: Jiyan Chen, Shubin Qiao, Lefeng Wang 12:40 PM - Opening Address 12:45 PM - Technical Characteristics of NOYA Co-Cr Biodegradable Polymer Sirolimus-Eluting Stent Haofei Wang 1:05 PM - NOYA I: A Multicenter, Randomized Trial of NOYA SirolimusEluting Stent with Biodegradable Coating Compared to FIREBIRD 2 Sirolimus-Eluting Stent with Durable Coating in Patients with Coronary Artery Disease - 2-Year Clinical Results Bo Xu 1:25 PM - Clinical Application of NOYA DES Yundai Chen 1:45 PM - Panel Discussion with Audience Q&A 1:55 PM - Adjourn Live Case Session 13 Unusual Complex PCI Affiliated Xijing Hospital of the 4th Military Medical University, Xi'an, China 2:00 PM-3:30 PM Late Breaking Clinical Trials and First Report Investigations III 3:30 PM-5:00 PM Moderators: Jean Marco, Alan C. Yeung Discussants: William F. Fearon, Fumiaki Ikeno, Michael Lim, Richard Lim, Thach Nguyen, Imad Sheiban, Pieter C. Smits, Pieter R. Stella, Chuen-Den Tseng, Yee Guan Yap 3:30 PM - CREST-MI Update: A Multicenter, Randomized Trial Comparing Safety and Efficacy of CYPHER vs. ENDEAVOR in Patients with Acute ST-Segment Elevation Myocardial Infarction Lefeng Wang 3:40 PM - Discussion 3:45 PM - A Multicenter, Randomized Trial Assessing the Safety and Efficacy of Recombinant Human Pro-Urokinase Before Emergent Percutaneous Coronary Intervention in Patients with Acute STSegment Elevation Myocardial Infarction Kai Xu 4:45 PM - A Large-Scale, Single Center Study Examining the Impact of Depressed Left Ventricular Function on Outcomes in Patients with Three-Vessel Coronary Disease Undergoing Percutaneous Coronary Intervention Zhan Gao 4:55 PM - Discussion Live Case Session 15 TRI, ISR, or Magnetic Navigation Assisted PCI Affiliated An Zhen Hospital of Capital Medical University, Beijing, China 5:00 PM-6:30 PM Moderators: Jean Marco, Ron Waksman Discussants: Feng Cao, Zhan Gao, Paul HsienLi Kao, Marie-Claude Morice, Xinkai Qu, I Gde Rurus Suryawan, Huay Cheem Tan, Mujeeb Ul-Haq, Yee Guan Yap, Yonghong Zhu Operators: Jean Fajadet, Ferdinand Kiemeneij 3:55 PM - Discussion 4:00 PM - A Prospective, Multicenter Study Investigating Diagnostic Accuracy of Quantitative Angiographic and Intravascular Ultrasound Parameters to Predict the Functional Significance for Single De Novo Lesion Junjie Zhang 4:10 PM - Discussion Moderators: Ian T. Meredith, Haichang Wang Discussants: Debabrata Dash, Mohammad Ishaq, Yan Li, Haibo Liu, Kenan Ovunc, Teguh Santoso, Ning Tan, Chee-Wo Wu, Chiung-Jen Wu, Feng Xu Operators: Toshiya Muramatsu, Wenyi Guo, and Colleagues 4:15 PM - A Single Center Registry of PCI for Left Main Coronary Artery Disease from a Developing Country Fazila Tun Nesa Malik 4:25 PM - Discussion 4:30 PM - A Single Center Registry Examining Prolonged Clopidogrel Use After Drug-Eluting Stent Implantation Fang Chen 4:40 PM - Discussion 054 00 CIT 2012 www.citmd.com Saturday, March 17th, 2012 10:00 AM - Panel Discussion with Audience Q&A Function C, Level 1 Practical Course on PCI Part II Controversial Case Reviews: Why, When, and How? 8:30 AM-12:30 PM Case 1 Moderator: Junbo Ge Panelists: Feng Bai, Weiming Li, Ning Tan, Ruiyan Zhang 8:30 AM - CS-0037: Intervene Unusually Concomitant Ostial and Severe Tortuous Lesion Jun Dai 10:25 AM - Take-Home Message Guoying Zhu Case 4 Moderator: Ben He Panelists: Chaolian Huang, Jiyuan Lu, Peng Qu, Lijun Zhou 10:30 AM - CS-0274: Cardiac Arrest Complicating Thrombosis in Left Main During PCI Yuquan He 10:40 AM - Panel Discussion with Audience Q&A 11:05 AM - Take-Home Message Ben He 8:40 AM - Panel Discussion with Audience Q&A Case 5 9:05 AM - Take-Home Message Guoliang Jia Moderator: Yong Huo Panelists: Huiliang Liu, Jian Liu, Chun Wu, Feng Xu Case 2 11:10 AM - CS-0034: IVUS as an Important Tool in PCI for Ostial Left Main Occlusion Hong Wang Moderator: Weimin Wang Panelists: Chengheng Hu, Leisheng Ru, Yanmin Xu, Shengli Yang 11:20 AM - Panel Discussion with Audience Q&A 9:10 AM - CS-0352: PCI in LAD MultiBifurcations and Tortuous RCA Caiyi Lu 11:45 AM - Take-Home Message Yong Huo 9:20 AM - Panel Discussion with Audience Q&A Case 6 9:45 AM - Take-Home Message Weimin Wang Moderator: Jiyan Chen Panelists: Pingshuan Dong, Weijian Huang, Anlin Lu, Fei Ye Case 3 11:50 AM - CS-0057: A "Complicated" CTO Lin Wang Moderator: Guoying Zhu Panelists: Kui Pu, Xuewen Qin, Fakun Tang, Yongjian Yang 12:00 PM - Panel Discussion with Audience Q&A 9:50 AM - CS-0224: Sudden Death After PCI 12:25 PM - Take-Home Message Jiyan Chen Weiqing Wang 12:30 PM - Adjourn 055 00 Luncheon Symposium Sponsored by Essen Technology Time for TIVOLI, Experiencing the Innovation 12:40 PM-1:55 PM Chairmen: Yaling Han, Haichang Wang, Xueqi Li 12:40 PM - Opening Address 12:45 PM - LAD CTO Recanalization with Combined Use of Multiple Techniques: A Case Review Guowei Zhou 1:00 PM - Challenging Case Reviews Wenyue Pang 1:15 PM - Will the Bioabsorbable Polymer DES Reduce the Risk of Late Stent Malapposition? Feng Zhang 1:30 PM - Complex PCI with TIVOLI: A Case of RCA CTO and Left Main Lesions Yan Li 1:45 PM - Panel Discussion with Audience Q&A 1:55 PM - Adjourn Practical Course on PCI Part III Chronic Total Occlusions 2:00 PM-6:00 PM Session I: CTO Angioplasty 2012: MasterвЂ™s Perspective Moderators: Jiyan Chen, Hweung Kon Hwang Discussants: William L. Lombardi, Jeffrey W. Moses, Etsuo Tsuchikane, Sudhir Rathore 2:00 PM - Rationale and Techniques of CTO Angioplasty Jeffrey W. Moses 2:15 PM - Update on Retrograde Approach in CTO Angioplasty Etsuo Tsuchikane 2:30 PM - CS-0364: Challenging Case of the Year in China: A Successfully Antegrade Approach to LAD CTO Junbo Ge CIT 2012 www.citmd.com Saturday, March 17th, 2012 2:45 PM - Retrograde CTO Techniques: Predictors of Success and Failure Sudhir Rathore 3:00 PM - Hybrid Approach to CTO Revascularization William L. Lombardi 3:15 PM - Panel Discussion with Audience Q&A Session III: CTO Angioplasty Strategies Moderators: Fang Chen, Tiemin Jiang Discussants: Huigen Jin, Tianchang Li, Changqian Wang, Shusen Yang 4:45 PM - How to Plan Your Strategy with Angiographic Findings? Weimin Wang 4:57 PM - Q&A Session II: Basics of CTO Angioplasty Moderators: JianвЂ™an Wang, Lianqun Cui Discussants: Bao Li, Shouli Wang, Shangyu Wen, Shuanli Xin 3:30 PM - Evidence-Based Rationale of CTO Angioplasty Zhimin Du 3:42 PM - Q&A 3:45 PM - Impact of CTO Pathology on PCI Strategy Haichang Wang 3:57 PM - Q&A 4:00 PM - Guidewire Selections in CTO Angioplasty JianвЂ™an Wang 4:12 PM - Q&A 4:15 PM - How to Handle the CTO Unable to Cross with Balloons? Shouli Wang 4:27 PM - Q&A 4:30 PM - Management of Complications in CTO PCI Yujie Zhou 4:42 PM - Q&A 5:00 PM - CTA Is Helpful in CTO Angioplasty Luyue Gai Room 306AB, Level 3 Breakfast Meeting Sponsored by Boston Scientific How to Manage the Complex Left Main and Calcified Lesion in PCI? 7:00 AM-8:00 AM Chairmen: Weimin Wang, Meng Wei, Bo Yu 5:12 PM - Q&A 7:00 AM - Opening Address 5:15 PM - The Role of IVUS Guidance in CTO Angioplasty Jie Qian 7:03 AM - Guiding Catheter Optimization in Complex PCI Cases Guosheng Fu 5:27 PM - Q&A 7:18 AM - Insights from China IVUS Academy: Why IVUS Is Becoming More Critical in Modern Left Main PCI - Clinical Update and Case Reviews Jie Qian 5:30 PM - The Most Common Errors in CTO Angioplasty Jiyan Chen 5:42 PM - Q&A 5:45 PM - Importance of Contralateral Injection Should Be Mainly Emphasized! Yawei Xu 5:57 PM - Q&A 6:00 PM - Adjourn 7:33 AM - Rotablator: Personal Experiences and Case Reviews Jianfang Luo 7:48 AM - Panel Discussion with Audience Q&A 8:00 AM - Adjourn Peripheral and Endovascular Therapy Part I 8:30 AM-12:30 PM Carotid Artery Disease Moderators: Neil E. Strickman, Xiongjing Jiang 8:30 AM - Essentials of Carotid Artery Diseases: Guidelines, Assessment, and Outcomes Xiongjing Jiang 8:45 AM - Carotid Stenting Update 2012: Where Have We Come from and Where Are We Going? Neil E. Strickman 056 00 CIT 2012 www.citmd.com Saturday, March 17th, 2012 9:00 AM - Transradial Sheathless Approach for Carotid Artery Stenting Chiung-Jen Wu 11:45 AM - Advances in Intervention for Refractory Hypertension Yinghua Zou 9:15 AM - How to Recanalize Carotid Total Occlusion? Aravinda Nanjundappa 12:00 PM - Transcatheter Renal Nerve Denervation for Refractory Hypertension: Early Experience and Case Report Chengzhi Lu 9:30 AM - Carotid Stenting for Standard Surgical Risk Patients: Update from the CREST Trial Charles A. Simonton 9:45 AM - Intervention for Acute Ischemic Stroke: Yes or No? Yan Wang 10:00 AM - Jasper Detachable Coils in the Treatment of Intracranial Aneurysms Erol Akgul 10:15 AM - Panel Discussion with Audience Q&A Discussants: Erol Akgul, Aravinda Nanjundappa, Charles A. Simonton, Yan Wang, Chiung-Jen Wu Renal Artery Disease Moderators: Aravinda Nanjundappa, Yinghua Zou 10:30 AM - Essentials of Renal Artery Disease: Guidelines, Assessment, and Outcomes Ruiyan Zhang 10:45 AM - Role of Renal Artery Stenting in 2012 Aravinda Nanjundappa 11:00 AM - Renal Stenting Is Effective in Selected Patients with Severe Atherosclerotic Renal Artery Stenosis: 6-Year Follow-Up Outcomes from a Single Center Xiongjing Jiang 11:15 AM - How to Perform Renal Stenting by Transradial Approach? Jianfang Luo 11:30 AM - Sympathetic Nervous System and Cardiorenal Disease Markus P. Schlaich 057 00 12:15 PM - Panel Discussion with Audience Q&A Discussants: Xiongjing Jiang, Chengzhi Lu, Jianfang Luo, Markus P. Schlaich, Ruiyan Zhang 12:30 PM - Adjourn Luncheon Symposium Sponsored by Volcano Advances in Coronary Imaging and Physiology 12:40 PM-1:55 PM Chairmen: Shaoliang Chen, Hongbing Yan, Lijun Guo, Gary S. Mintz 12:40 PM - Opening Address 12:45 PM - The Exploding World of Invasive Imaging: Rational Assimilation of IVUS, VHIVUS, OCT, and More into the Cath Lab Gary S. Mintz 1:05 PM - iFR: A New Pressure-Based Adenosine-Free Method to Assess Stenosis Severity Javier Escaned 1:25 PM - Radio Frequency Analysis of Coronary Plaque and Its Clinical Applications William Kongto Hau 1:45 PM - Panel Discussion with Audience Q&A 1:55 PM - Adjourn Peripheral and Endovascular Therapy Part II 2:00 PM-6:00 PM Lower Extremity Artery Disease and Venous Disease Moderators: Zhong Chen, Craig M. Walker 2:00 PM - Essentials of Lower Extremity Artery Disease: Guidelines, Assessment, and Outcomes Xiaozeng Wang 2:15 PM - The Role of Pedal Access and Transcollateral Crossing to Improved Interventional Outcomes in Critical Limb Ischemia Craig M. Walker 2:30 PM - Comparing PTA, Bare Metal Stent, Drug-Eluting Stent, and Drug-Coated Balloon in the Treatment of SFA Disease Haizal Haron Kamar 2:45 PM - BTK Intervention: Clinical Experience and Challenging Case Reviews Rosli Mohd Ali 3:00 PM - Current Status and Future Perspective on Peripheral Artery Disease Intervention Chengming Yang 3:15 PM - Vascular Access Complications Aravinda Nanjundappa 3:30 PM - Ultrasound-Guided IVC Filter Placement: When, How, and Who Should Place It? Joseph Varon 3:45 PM - Panel Discussion with Audience Q&A Discussants: Haizal Haron Kamar, Rosli Mohd Ali, Aravinda Nanjundappa, Joseph Varon, Xiaozeng Wang, Chengming Yang CIT 2012 www.citmd.com Saturday, March 17th, 2012 Aortic Disease Access Difficulties Moderators: Wei Guo, Weiguo Fu Moderators: Huiliang Liu, Jianping Li, Shaoping Nie, Xiaoyong Qi 4:00 PM - Critical Issues in TEVAR for Aortic Dissection Weiguo Fu Room 307AB, Level 3 4:15 PM - Minimally Invasive Endovascular Therapies for Aortic Disease: Current Status and Future Perspectives Zaiping Jing Breakfast Meeting Sponsored by Terumo TRI Solution: How to HOLD TRI in Complex Lesion? 7:00 AM-8:00 AM 4:30 PM - Endovascular Reconstruction of Visceral Arteries: Techniques and Results Wei Guo Chairmen: Haichang Wang, Chiung-Jen Wu, Yujie Zhou 4:45 PM - Combined Surgical and Endovascular Repair for Aortic Arch Disease: Intermediate Outcomes and Complications Eak-Kyun Shin 7:00 AM - Opening Address 7:03 AM - How to HOLD TRI in Left Main Lesion? Yongjian Wu 5:00 PM - Totally Percutaneous Aortic Aneurysm Repair (EVAR) Neil E. Strickman 7:18 AM - How to HOLD TRI in Bifurcation Lesion? Qing Zhang 5:15 PM - Application of Suprarenal Fixation Devices in EVAR for AAA with Severe Neck Angulation: Rationale, Technical Tips, and Case Examples Won-Heum Shim 7:33 AM - How to HOLD Sheathless TRI Technique in Complex Coronary Artery Lesion? Yong He 5:30 PM - Treatment of Coronary Artery Disease Combined with Aorta Dissection Hesong Zeng 5:45 PM - Panel Discussion with Audience Q&A Discussants: Zaiping Jing, Won-Heum Shim, Eak-Kyun Shin, Neil E. Strickman, Hesong Zeng 6:00 PM - Adjourn 7:48 AM - Panel Discussion with Audience Q&A 8:42 AM - Radial Access as the Default Approach for PCI: Current State of the Evidence Weimin Li 8:52 AM - Q&A 8:54 AM - Is Transulnar PCI Indispensable for Interventional Cardiologists? Xianghua Fu 9:04 AM - Q&A 9:06 AM - How to Overcome Access Difficulties During Catheterization via Radial Approach? Quanmin Jing 9:16 AM - Q&A 9:18 AM - The "Coronary Guidewire Trick" for Radial Access in Patients with Vascular Tortuosity Gustavo Samaja 9:28 AM - Q&A Challenging TRI Moderators: Zhanquan Li, Tianchang Li, Jun Dai, Yongming Hui, Hesong Zeng, Yingxin Zhao TRI Club 8:00 AM-12:30 PM Featured Lectures Moderators: Fina Mauri, Shubin Qiao, Yujie Zhou Discussants: Ferdinand Kiemeneij, Mitchell W. Krucoff, Yuejin Yang 9:30 AM - Bilateral Transradial Sheathless Approach for CTO Lesions Chiung-Jen Wu 9:40 AM - Q&A th 8:00 AM - Celebrating the 20 Anniversary of TRI: Past Accomplishment and Future Opportunity Ferdinand Kiemeneij 8:12 AM - Complex PCI via Radial Approach in China: Where Are We Going? Yuejin Yang 8:24 AM - TRI in the USA: What Data Is Needed? Mitchell W. Krucoff 9:42 AM - LM PCI via Radial Approach (with case examples) Yawei Xu 9:52 AM - Q&A 9:54 AM - PCI for Bifurcations via Radial Approach (with case examples) Josef Ludwig 10:04 AM - Q&A 8:36 AM - Panel Discussion 058 00 CIT 2012 www.citmd.com Saturday, March 17th, 2012 10:06 AM - PCI for Graft Lesions via Radial Approach (with case examples) Guosheng Fu 10:16 AM - Q&A 10:18 AM - Unusual Complex PCI via Radial Approach (with case examples) Ramazan Г–zdemir 10:28 AM - Q&A 10:30 AM - TRI for STEMI: Current Evidence and Practical Experience Lei Wang 11:40 AM - Q&A 11:42 AM - Major Concerns of the Radial Approach: Radial Artery Spasm, Stroke, and Radiation Injury Haichang Wang 11:52 AM - Q&A 11:54 AM - Prevention and Management of Severe Bleeding Complications in TRI Lang Li 12:04 PM - Q&A 10:40 AM - Q&A 12:06 PM - How to Avoid Radial Injury and Occlusion? Jue Chen Device Selections 12:16 PM - Q&A Moderators: Lefeng Wang, Lang Hong, Shaobin Jia, Wenyue Pang, Jinfa Jiang 12:18 PM - Complications in TRI (with case examples) Zhimin Du 10:42 AM - Essentials of Guiding Catheter Selections in TRI Min Yao 10:52 AM - Q&A 10:54 AM - Mother-Child Catheter Technique in TRI Kenji Wagatsuma 11:04 AM - Q&A 11:06 AM - PCI for LM/Bifurcations via Radial Approach: Device Selections and Manipulation Tips Shubin Qiao 11:16 AM - Q&A 11:18 AM - Rotablation for Severe Calcified Lesions via Radial Approach Teimin Jiang 11:28 AM - Q&A Complications Moderators: Chuanyu Gao, Bin Liu, Guoxian Qi, Yujie Zeng, Lifu Miao 11:30 AM - Prevention and Management of Complications for Radial Access Yujie Zhou 059 00 12:28 PM - Q&A 12:30 PM - Adjourn Luncheon Symposium Sponsored by Terumo CTO Solution: How to HOLD the Success Rate of CTO? 12:40 PM-1:55 PM Chairmen: Guosheng Fu, Yuqing Hou, Shuzheng Lu 12:40 PM - Opening Address 12:45 PM - Before: Preprocedural Preparation for CTO Lei Ge 1:05 PM - During: Conventional Techniques for CTO Lian Chen 1:25 PM - After: Why Failed? Lang Li 1:45 PM - Panel Discussion with Audience Q&A 1:55 PM - Adjourn OCT Workshop Part II 2:00 PM-6:00 PM Late Stent Complications Moderators: Yangsoo Jang, Yuejin Yang Discussants: Kelvin Chan, Jie Qian, Bo Yu 2:00 PM - OCT Assessment of Stent Thrombosis Bo Yu 2:25 PM - OCT Assessment of In-Stent Restenosis and Neoatherosclerosis Yangsoo Jang 2:50 PM - Panel Discussion with Audience Q&A Case Presentations (15 minutes each including Q&A) 3:00 PM - Case 1: Early Stent Thrombosis Jie Qian 3:15 PM - Case 2: Late / Very Late Stent Thrombosis Caused by Malapposition Qinhua Jin 3:30 PM - Case 3: Late / Very Late Stent Thrombosis Caused by Neointima Rupture Mengyue Yu 3:45 PM - Break Late Stent Complications Moderators: Yudai Chen, Yangsoo Jang Discussants: Buxing Chen, Guosheng Fu, Zhanquan Li 4:00 PM - Case 4: In-Stent Restenosis Caused by Neointimal Hyperplasia Jingbo Hou 4:15 PM - Case 5: In-Stent Restenosis Caused by Stent Fracture Yangsoo Jang 4:30 PM - Case 6: In-Stent Restenosis Caused by Chronic Stent Underexpansion Guosheng Fu CIT 2012 www.citmd.com Saturday, March 17th, 2012 4:45 PM - Case 7: In-Stent Restenosis Cause by In-Stent Neoatherosclerosis Jun Guo 5:00 PM - Case 8: Treatment of Stent Thrombosis Chengzhi Lu Room 308, Level 3 5:15 PM - Case 9: Treatment of In-Stent Restenosis Shiwei Yang Breakfast Case Reviews 8 Peripheral and Endovascular Disease 7:00 AM-8:00 AM 5:30 PM - Case 10: Late Stent Complication Simon Cheung-Chi Lam Moderators: Zaiping Jing, Ruiyan Zhang, Jianping Liu 5:45 PM - Panel Discussion with Audience Q&A 7:00 AM - CS-0094: Use of IVUS to Confirm the True Lumen During EVAR Wenhui Huang 6:00 PM - Adjourn 8:45 AM - Lesion Preparation of the Calcified Left Main: PTCA vs. Scoring Balloons vs. Rotational Atherectomy Samuel K. Mathew 9:00 AM - Hemodynamic Support Considerations: Provisional vs. Prophylactic and Support Options Yuji Hamazaki 9:12 AM - Role of Staging and Hybrid Procedures in Patients with Left Main and Multivessel Disease David X. M. Zhao 7:12 AM - Q&A 9:24 AM - Follow-up Surveillance After Left Main PCI: Angiography vs. Stress Testing, Timing, and Avoiding Unnecessary Reintervention Jinghua Liu 7:15 AM - CS-0135: Recurrent Refractory Hypertension After Renal Artery Stenting Songyuan Luo 9:36 AM - Management and Outcomes for Left Main In-Stent Restenosis Gim-Hooi Choo 7:27 AM - Q&A 9:48 AM - Panel Discussion with Audience Q&A Discussants: Jilin Chen, Gim-Hooi Choo, Yuji Hamazaki, Jinghua Liu, Samuel K. Mathew, David X. M. Zhao 7:30 AM - CS-0299: A Stent to Relieve Brain Drain and Arm Pain: Application of Interventional Cardiology Tools for Challenging Peripheral CTOs Andrew D. Wisneski 7:42 AM - Q&A 7:45 AM - CS-0340: Percutaneous Carotid Stenting with Sheathless Guiding Catheter by Transradial Approach Binquan Zhou 7:57 AM - Q&A 8:00 AM - Adjourn Left Main and Bifurcation Summit Part III 8:30 AM-12:30 PM Session VII: Left Main PCI Techniques (Others) Session VIII: Left Main PCI Case Reviews I: Problem Solving or Complications (Language: Chinese) Moderators: Weimin Wang, Weiyi Fang Discussants: Xuebin Cao, Hengjian Hao, Guoqing Li, Haibo Liu, Jinghua Liu, Zheng Zhang 10:00 AM - Left Main PCI Challenging Case 1 Xuchen Zhou 10:10 AM - Discussion 10:15 AM - Left Main PCI Challenging Case 2 Genshan Ma 10:25 AM - Discussion Moderators: Shaoliang Chen, Davide Capodanno 10:30 AM - Left Main PCI Challenging Case 3 Tongku Liu 8:30 AM - Treatment of Ostial LAD or LCx Lesion: My Approach Jilin Chen 10:40 AM - Discussion 060 00 CIT 2012 www.citmd.com Saturday, March 17th, 2012 10:45 AM - Left Main PCI Challenging Case 4 Dadong Zhang 10:55 AM - Discussion 11:00 AM - Left Main PCI Challenging Case 5 Anlin Lu 11:10 AM - Discussion Luncheon Symposium Sponsored by Star Progress & Kaneka Learning the Experiences of Kaneka Devices from the Specialists 12:40 PM-1:55 PM Chairmen: Weijian Huang, genshan Ma, Weimin Wang 12:40 PM - Opening Address Session IX: Left Main PCI Case Reviews II: Problem Solving or Complications (Language: Chinese) 12:45 PM - Use of Thrombus Aspiration Catheter (Thrombuster II) in AMI Dadong Zhang Moderators: Dadong Zhang, Ning Tan Discussants: Jun Dai, Bing Fan, Jincheng Guo, Yongjun Li, Keng Wu, Lixia Yang 1:00 PM - The Application of Thrombus Aspiration Catheter in STEMI Jincheng Guo 11:15 AM - Left Main PCI Challenging Case 6 Likun Ma 11:25 AM - Discussion 11:30 AM - Left Main PCI Challenging Case 7 Junjie Zhang 11:40 AM - Discussion 11:45 AM - Left Main PCI Challenging Case 8 Binquan Zhou 1:15 PM - The Use of Thrombus Aspiration Catheter in STEMI: Case Reviews Yi Li 1:30 PM - The Use of Bifurcation MicroCatheter in PCI Eisho Kyo 1:45 PM - Panel Discussion with Audience Q&A 1:55 PM - Adjourn 11:55 AM - Discussion 12:00 PM - Left Main PCI Challenging Case 9 Xinkai Qu 12:10 PM - Discussion 12:15 PM - Left Main PCI Challenging Case 10 Wenyue Pang 12:25 PM - Discussion 12:30 PM - Adjourn Left Main and Bifurcation Summit Part IV 2:00 PM-6:00 PM Session X: Complications of PCI for NonLeft Main Bifurcations Moderators: Weifeng Shen, Yean-Teng Lim Discussants: Devang Desai, Lei Ge, Jian Liu, Goran Stankovic, Guisong Wang, Tingshu Yang 2:00 PM - How to Prevent Complications During and After PCI for Non-Left Main Bifurcation Lesions? Goran Stankovic 2:15 PM - Case Presentation: Bifurcation Treatment with Nilepax Stent (Medina 111) Devang Desai 2:21 PM - Discussion 061 00 2:27 PM - IVUS Criteria in Guiding Bifurcation Lesion Stenting: Stent Symmetry, Recoil and Expansion, and Implications on Safety and Effectiveness Outcomes Gary S. Mintz 2:42 PM - Case Presentation: Provisional T-Stenting for Medina 110 Lesion Lei Ge 2:48 PM - Discussion 2:54 PM - Utility of MurrayвЂ™s and FinetвЂ™s Bifurcation Laws: Clinical Utility and Implications in the Treatment and Outcomes of Bifurcation Lesions Sidney Tsz Ho Lo 3:09 PM - Case Presentation: How to Select Stent Size in a LAD/Diagonal Medina 111 Bifurcation? (difference between visual estimation, QCA and IVUS) Jian Liu 3:15 PM - Discussion 3:21 PM - Why In-Stent Restenosis Is Commonly Seen at Lateral Wall of Bifurcation Site? Gim-Hooi Choo 3:36 PM - Case Presentation: Side Branch In-Stent Restenosis Wan Azman Wan Ahmad 3:42 PM - Discussion 3:48 PM - Impacts of Bifurcation Anatomy and Plaque Burden on PCI Complications Dobrin Vassilev 4:03 PM - Case Presentation: Side Branch Lost After Stenting Main Vessel (Medina 110) Sufia Rahman 4:09 PM - Discussion CIT 2012 www.citmd.com Saturday, March 17th, 2012 10:42 AM - Tips and Tricks in Rotablation Wei Gao Session XI: Non-Left Main Bifurcation Stenting - Lessons from Clinical Trials Moderators: Alexandra J. Lansky, Lang Li Discussants: Hongliang Cong, Giuseppe De Luca, Josef Ludwig, Jayesh S. Prajapati, Zhujun Shen, Swee Choon Ng 4:15 PM - Meta Analysis of Provisional vs. Dual Stenting of the Bifurcation Lesion: Case Selection and Outcomes Jan Kovac 4:30 PM - Side Branch Jailing: Who Is at Risk and How Does It Impact Outcomes? Alexandra J. Lansky 4:45 PM - Case Presentation: To Kiss or Not to Kiss (Medina 111, after main vessel stenting) Li Li 4:51 PM - Discussion 4:57 PM - The DK-CRUSH Trials: Understanding the Key Results and Relevance to Clinical Practice Junjie Zhang 5:12 PM - Case Presentation: How Would You Treat Multiple Bifurcation Lesions in One Patient? Ning Tan 5:18 PM - Discussion Room 309A, Level 3 EAPCI-EuroPCR/ESC at CIT Current Management of NSTEMI-ACS 8:30 AM-10:30 AM Moderators: Jean Fajadet, Hongbing Yan 8:35 AM - Risk Stratification Kari NiemelГ¤ 11:19 AM - Case 2: Rotablation in the Lesion Unable Pass with Balloon Shangyu Wen 8:47 AM - Which Antiplatelet Therapy for Which Patient? Thomas Cuisset 8:59 AM - Timing and Results of Invasive Management Goran Stankovic 9:11 AM - NSTEMI-ACS Management in China Yangfeng Wu 9:23 AM - Live in-a-Box Case and Discussion Discussants: Thomas Cuisset, Ben He, YeanTeng Lim, Kari NiemelГ¤, Goran Stankovic, Franz Weidinger 5:30 PM - Discussion 10:25 AM - Take-Home Message Jean Fajadet 5:36 PM - Case Presentation: LAD CTO with Proximally Medina 111 Bifurcation Lesion Zhujun Shen The 3rd Rotablation Mini-Symposium 10:30 AM-12:30 PM 5:54 PM - Discussion 6:00 PM - Adjourn 11:06 AM - Case 1: Rotablation in Complex Calcified Lesion Yuji Hamazaki 11:16 AM - Discussion 10:13 AM - What Do the Guidelines Say? Franz Weidinger 5:48 PM - Case Presentation: AMI with True Bifurcation Lesion Yingyan Ma Challenging Case Reviews 8:30 AM - Introduction Jean Fajadet 5:24 PM - Case Presentation: One- or TwoStent for Medina 101 Lesion? Fei Ye 5:42 PM - Discussion 10:54 AM - Management of Complications During Rotabaltion Samuel K. Mathew Moderators: Wei Gao, Juying Qian Discussants: Yuji Hamazaki, Chien-Ming Huang, Wen-Lieng Lee, Samuel K. Mathew, Jun Tian, Shangyu Wen, Wei-Hsian Yin, Robaayah Zambahari 11:29 AM - Discussion 11:32 AM - Case 3: Rotablation in Complex CTO Lesion Wen-Lieng Lee 11:42 AM - Discussion 11:45 AM - Case 4: Rotablation in Small Vessel Disease Jun Tian 11:55 AM - Discussion 11:58 AM - Case 5: Rotablation by Transradial Approach Chien-Ming Huang 12:08 PM - Discussion 12:11 PM - Case 6: How to Retrieve a Stuck Rotablator Burr? Wei-Hsian Yin 12:21 PM - Discussion 12:24 PM - Audience Q&A and Take-Home Message 12:30 PM - Adjourn 10:30 AM - The Role of Rotational Atherectomy in the Treatment of Complex Lesions Robaayah Zambahari 062 00 CIT 2012 www.citmd.com Saturday, March 17th, 2012 Luncheon Symposium Sponsored by St. Jude FFR and OCT: Can I Have Both? 12:40 PM-1:55 PM Chairmen: William F. Fearon, Yongjian Wu, Juying Qian, Yingling Zhou 12:40 PM - Opening Address 12:45 PM - Clinical Utilities of FFR and OCT William F. Fearon 1:05 PM - OCT Case Review Jie Qian 1:20 PM - FFR Case Review Junjie Zhang 1:30 PM - FFR Case Review Jianfang Luo Session II: Tripartite Dialogue: Heart, Brain, and Kidney Moderators: Jingxuan Guo, Xiaoying Li, Lan Huang Room 309B, Level 3 3:20 PM - Anticoagulant and Antithrombotic Therapy for ACS Patients Complicated with Stroke Xiaoyong Qi Basics and Medical Therapies Part II 8:30 AM-12:30 PM 3:40 PM - Anticoagulant Therapy in ACS Patients Complicated with Renal Insufficiency Yundai Chen 4:00 PM - Revascularization Therapy in ACS Patients Complicated with End-Stage Nephropathy Ruiyan Zhang Session I Moderators: Shuguang Lin, Dingyin Zeng, Shumei Li, Qing He, Yingling Zhou, Dalin Jia 8:30 AM - Keynote Lecture: Retrospect of Anticoagulant and Antithrombotic Therapy of Coronary Artery Disease in 2011 Shuzheng Lu 4:20 PM - Panel Discussion with Audience Q&A 8:55 AM - Drug Interactions of Anticoagulant Therapy Tianlun Yang 1:55 PM - Adjourn Session III: Interventional Cardiology and Clinical Practice: Healing the Gap 9:10 AM - Two Sides of Clopidogrel: AntiIschemia and Bleeding Jinqing Yuan CCC/CISC at CIT Difficult Patients and Dilemmas in Clinical Practice 2:00 PM-6:00 PM Moderators: Guoying Zhu, Luhua Shen, Hongwei Li, Xueqi Li 9:25 4:40 PM - Revascularization in CAD Patients Complicated withThrombocytopenia or Leukopenia Jianping Li 9:30 AM - Keynote Lecture: Retrospect of Pharmacological Therapy of Acute Coronary Syndrome in 2011 Wei Gao Moderators: Shuzheng Lu, Fusheng Gu, Wei Gao, Shutian Zhang 5:00 PM - Revascularization in CAD Patients Complicated with Malignant Tumor Guisong Wang 9:55 AM - Application of IIb/IIIa Receptor Antagonist in Acute Coronary Syndrome Xinchun Yang 2:00 PM - Anticoagulant and Antithrombotic Medications in ACS Patients Complicated with UGH Shuyang Zhang 5:20 PM - Antithrombotic Medications in CAD Patients Who Received PCI Complicated with AF Yuyang Liu 10:10 AM - Antithrombotic Therapy for Non-ST-Segment Elevation Acute Coronary Syndrome Yitong Ma 2:20 PM - Antithrombotic Medications in CAD Patients Complicated with Abnormal Blood Clotting Mechanism Yongqiang Zhao 5:40 PM - Panel Discussion with Audience Q&A 10:25 6:00 PM - Adjourn Session II 1:40 PM - Panel Discussion with Audience Q&A Session I: Bleeding and Thrombosis: How to Avoid the Risk? 2:40 PM - Antithrombotic Medications in Patients with PCI Who Need Emergency Non-Cardiac Surgery Jinqing Yuan 3:00 PM - Panel Discussion with Audience Q&A 063 00 AM - Q&A AM - Q&A Moderators: Jieming Mao, Jianhua Zhu, Youfang Ni, Hui Li, Kai Wang, Zhuhua Yao 10:30 AM - Keynote Lecture: Retrospect of Pharmacological Therapy After Successful PCI Hong Ma CIT 2012 www.citmd.com Saturday, March 17th, 2012 10:55 AM - Optimizing Oral Pharmacological Therapy After Successful PCI Meilin Liu 11:10 AM - Application of New Antiplatelet Drugs in PCI Kai Wang 11:25 AM - Q&A 11:30 AM - Keynote Lecture: Special Forms of Coronary Artery Disease Jianhua Zhu Pharmacologic Satellite Symposium Supported by Salubris Pharmaceuticals All You Need to Know About Talcom and Taijianing 4:00 PM-6:00 PM Part I: Didactic Lectures Moderators: Yuejin Yang, Jiefu Yang, Shuyang Zhang 4:00 PM - Opening Address 11:55 AM - Clinical Significance of Slow Coronary Flow Shaoping Nie 4:05 PM - ItвЂ™s Time for Bivalirudin! Hongbing Yan 12:10 PM - Mechanisms and Clinics of Coronary Spasm Dingcheng Xiang 4:30 PM - The Study of Dynamic Change for Clopidogrel in Human Body Lei Tian 12:25 PM - Q&A 4:50 PM - Panel Discussion with Audience Q&A 12:30 PM - Adjourn Pharmacologic Satellite Symposium Supported by Daiichi Sankyo From Evidence to Real-World Practice: ACS DAPT Forum 2:00 PM-4:00 PM Moderators: Yujie Zhou, Shuyang Zhang, Yundai Chen Room 310, Level 3 Part II: Case Reviews Breakfast Case Reviews 9 Structural Heart Disease 7:00 AM-8:00 AM Moderators: Xiaoqun Pu, Zhongying Xu, Liming Wang 7:00 AM - CS-0220: Treatment of Restenosis After Surgical Repair for Left Pulmonary Artery Stenosis Associated Absent Right Pulmonary Artery Using CP Stent Zhongying Xu 7:12 AM - Q&A 7:15 AM - CS-0302: Hemolysis After Transcatheter Closure of Large Patent Ductus Arteriosus Mei Jin Moderators: Shuzheng Lu, Shubin Qiao, Hongbing Yan 7:27 AM - Q&A 5:00 PM - Case Presentation: Cerebral Hemorrhage After PCI Jingmei Zhang 7:30 AM - CS-0341: Antegrade Device Closure of Coronary Fistula to Right Ventricle Using ADO2 Vascular Plug Manoj Kumar Rohit 2:00 PM - Opening Address 5:10 PM - Discussion 2:05 PM - Integrated Management of ACS/ PCI Patients Yundai Chen 5:15 PM - Case Presentation: Triple Vessel Disease with CTO in Elderly Meng Zhang 7:45 AM - CS-0372: Use of Coronary Guidewire to Treat Ventricular Septal Defect Bingxiang Wu 2:25 PM - Update on 2011 ACS DAPT Guideline Yujie Zhou 5:25 PM - Discussion 7:57 AM - Q&A 5:30 PM - Case Presentation: Successful RePCI One Week After First PCI Failure and Enhanced DAPT with Talcom Naikun Fu Structural Heart Disease Part II 8:00 AM-12:30 PM 2:45 PM - Predictable Morbidity and Mortality Benefit for STEMI/PCI Patients Zhenyu Liu 3:05 PM - Consistent Antithrombotic Protection for UA/NSTEMI Patients Jianping Li 3:25 PM - Perspective on ACS Antithrombotic Therapy Yongjian Wu 3:45 PM - Q&A with Lottery 3:55 PM - Take-Home Message 5:40 PM - Discussion 5:45 PM - Case Presentation: Huge Thrombus Burden During Emergent PCI for AMI Patient Zhi Liu 5:55 PM - Discussion 6:00 PM - Adjourn 7:42 AM - Q&A Session I Moderators: Shiliang Jiang, Bo Yu, Fen Li, Mei Jin, Guishuang Li, Qijian Yi, Yulin Wang, Zhen Wang 8:00 AM - The Technical Essentials of Transcatheter Closure for Perimembranous Ventricular Septal Defects in Children Xianyang Zhu 8:15 AM - Discussion 064 00 CIT 2012 www.citmd.com Saturday, March 17th, 2012 8:20 AM - Transcatheter Closure of OutletType Ventricular Septal Defects Yongwen Qin 8:35 AM - Discussion 8:40 AM - Management of Device Embolization of Interventional Therapy for Congenital Heart Disease Zhongying Xu 8:55 AM - Discussion 9:00 AM - Interventional Therapy for Congenital Heart Disease with Severe Pulmonary Hypertension: A Single Center Experience from Southwest Hospital, Third Military Medical University Zhiyuan Song 9:10 AM - Discussion 9:15 AM - Interventional Therapy for Congenital Heart Disease with Severe Pulmonary Hypertension: A Single Center Experience from First Affiliated Hospital, Medical College of XiвЂ™an Jiao-Tong University Yushun Zhang 9:25 AM - Discussion 9:30 AM - Interventional Therapy for Congenital Heart Disease with Severe Pulmonary Hypertension: A Single Center Experience from First Affiliated Hospital of Harbin Medical University Bingxiang Wu 9:40 AM - Discussion 9:45 AM - Interventional Therapy for Congenital Heart Disease with Severe Pulmonary Hypertension: A Single Center Experience from Guangdong Provincial PeopleвЂ™s Hospital Zhiwei Zhang 9:55 AM - Discussion 10:00 AM - Interventional Therapy for Congenital Heart Disease with Severe Pulmonary Hypertension: A Single Center Experience from Huaxi Second Hospital, Sichuan University Yimin Hua 10:10 AM - Discussion 065 00 Session II Moderators: Xianyang Zhu, Xianxian Zhao, Daxin Zhou, Yushun Zhang, Yan Xu, Jun Qin, Xiangqian Shen, Xin Pan 10:15 AM - Interventional Therapy for Congenital Heart Disease with Severe Pulmonary Hypertension: A Single Center Experience from First Affiliated Hospital of Nanjing Medical University Xiangqing Kong 10:25 AM - Discussion 10:30 AM - Interventional Therapy for Congenital Heart Disease with Severe Pulmonary Hypertension: A Single Center Experience from First Affiliated Hospital, Xinjiang Medical University Yitong Ma 10:40 AM - Discussion 10:45 AM - Interventional Therapy for Congenital Heart Disease with Severe Pulmonary Hypertension: A Single Center Experience from First Affiliated Hospital of Guangxi Medical University Weifeng Wu 10:55 AM - Discussion 11:00 AM - Interventional Therapy for Congenital Heart Disease with Severe Pulmonary Hypertension: A Single Center Experience from Guizhou Provincial PeopleвЂ™s Hospital Tianhe Yang 11:10 AM - Discussion 11:15 AM - Interventional Therapy for Congenital Heart Disease with Severe Pulmonary Hypertension: A Single Center Experience from Kunming YanвЂ™an Hospital Weihua Zhang 11:25 AM - Discussion 11:30 AM - Interventional Therapy for Congenital Heart Disease with Severe Pulmonary Hypertension: A Single Center Experience from Huaxi Hospital, Sichuan University Zhi Zeng 11:40 AM - Discussion 11:45 AM - Interventional Therapy for Congenital Heart Disease with Severe Pulmonary Hypertension: A Single Center Experience from the Second Affiliated Hospital of Nan Chang University Yingzhang Cheng 11:55 AM - Discussion 12:00 PM - Interventional Therapy for Congenital Heart Disease with Severe Pulmonary Hypertension: A Single Center Experience from Zhejiang ChildrenвЂ™s Hospital Fangqi Gong 12:10 PM - Discussion 12:15 PM - Interventional Therapy for Congenital Heart Disease with Severe Pulmonary Hypertension: A Single Center Experience from Linyi PeopleвЂ™s Hospital Zishan Hou 12:25 PM - Discussion 12:30 PM - Adjourn Luncheon Symposium Sponsored by Edwards Lifesciences Current Status of TAVR and Pillars of Success 12:40 PM-1:55 PM Chairmen: Run-Lin Gao, Shengshou Hu 12:40 PM - Opening Address 12:45 PM - Edwards TAVR Clinical Program Overview and WhatвЂ™s Coming Next Martin B. Leon 1:05 PM - Components of a Successful TAVR Program and North American Models John G. Webb 1:25 PM - Asian Perspective in Starting TAVR Practice Seung-Jung Park 1:45 PM - Panel Discussion with Audience Q&A 1:55 PM - Adjourn CIT 2012 www.citmd.com Saturday, March 17th, 2012 Structural Heart Disease Part III Transcatheter Valve Therapies 2:00 PM-6:00 PM Session I: Therapy Alternatives for Aortic Stenosis Moderators: Eberhard Grube, Run-Lin Gao 2:00 PM - Current Status of Surgical Aortic Valve Replacement in China Shengshou Hu 2:10 PM - A Multicenter Survey of Aortic Stenosis in China: Indications for Balloon Aortic Valvuloplasty and Early TAVR Experiences Yongjian Wu 2:20 PM - Lessons from Recent Balloon Aortic Valvuloplasty Studies: Clinical Outcomes and Revived Use in the TAVR Era Ron Waksman 2:30 PM - A Multi-Disciplinary вЂњHeart Valve TeamвЂќ Is Required to Achieve Optimal Therapy for Aortic Stenosis Jan Kovac 2:40 PM - Perspectives on Creating a Successful Global Transcatheter Aortic Valve Program: вЂњThe Agony and the EcstasyвЂќ Michael A. Mussallem 2:50 PM - Panel Discussion with Audience Q&A Discussants: Shengshou Hu, Jan Kovac, Michael A. Mussallem, Ron Waksman, Yongjian Wu, Ruiyan Zhang Session II: TAVR Clinical Updates Moderators: John G. Webb, Junbo Ge 3:00 PM - Overview of Self-Expanding TAVR Clinical Outcomes Eberhard Grube 3:10 PM - Overview of Balloon-Expandable TAVR Clinical Outcomes John G. Webb 3:30 PM - Vascular Access and Adjunctive Imaging (Echo and MSCT): The Cornerstones of Successful TAVR? Stephan Windecker 5:10 PM - Percutaneous Mitral Valvuloplasty II: Procedural Tips and Tricks to Optimize Success Pham Manh Hung 3:40 PM - Survey of New TAVR Devices Ian T. Meredith 5:20 PM - Percutaneous вЂњEdge-to-EdgeвЂќ Mitral Valve Repair: Current Status of the MitraClip Procedure Charles A. Simonton 3:50 PM - Survey of Upcoming TAVR Clinical Trials Patrick W. Serruys 4:00 PM - Panel Discussion with Audience Q&A Discussants: Eberhard Grube, Ian T. Meredith, Patrick W. Serruys, Stephan Windecker Session III: TAVR Challenging Cases and Regional Experiences Moderators: Eberhard Grube, Yaling Han 4:10 PM - Early Experiences with TAVR in Taiwan Paul Hsien-Li Kao 4:20 PM - TAVR in Woman: European Experience Marie-Claude Morice 5:30 PM - Challenging Case: MitraClip for High-Risk Functional MR (case and topic review) Jason H. Rogers 5:40 PM - Survey of New Transcatheter Mitral Valve Therapies: Projections for the Future Maurice Buchbinder 5:50 PM - Panel Discussion with Audience Q&A Discussants: Pham Manh Hung, Jason H. Rogers, Charles A. Simonton, Zhi Zeng 6:00 PM - Adjourn 4:30 PM - Challenging Case: Trans-Aortic Access for TAVR (case and topic review) David X. M. Zhao 4:40 PM - Challenging Case: TAVR in a Bicuspid Aortic Valve Paul TL Chiam 4:50 PM - Panel Discussion with Audience Q&A Discussants: Paul TL Chiam, Paul Chien-Li Kao, Xiangqing Kong, Marie-Claude Morice, David X. M. Zhao Session IV: Transcatheter Mitral Valve Therapies Moderators: Maurice Buchbinder, Yuejin Yang 5:00 PM - Percutaneous Mitral Valvuloplasty I: Indications and Results (short and longterm) - The China Experience Zhi Zeng 3:20 PM - Complications After TAVR: Frequency and Clinical Importance Patrick W. Serruys 066 00 CIT 2012 www.citmd.com Saturday, March 17th, 2012 Room 311A, Level 3 Breakfast Meeting Sponsored by JW Medical Mature Technology Leads the Future 7:00 AM-8:00 AM Chairmen: Zhimin Du, Shubin Qiao 7:00 AM - Opening Address 7:03 AM - Complex Case Reviews Wei Mao 8:39 AM - Biodegradable Polymer-Based Biolimus A9-Eluting Stents: Past, Present and Future Stephan Windecker 8:51 AM - Is Stent Surface Modification an Answer to Avoid Permanent Polymer in DES? Adnan Kastrati 9:03 AM - Cre8 Polymer-Free DES Giuseppe De Luca 9:15 AM - BioFreedom Polymer-Free DES Eberhard Grube 9:27 AM - Panel Discussion: How to Pick a DES Around the World - Sifting Through All the Data? 7:18 AM - Complex Case Reviews Chunguang Qiu Current Chinese DES Platforms: Everything You Need to Know and More 7:33 AM - A Large Angioscope Study Investigating Endothelization After Implantation of EXCEL Biodegradable Polymer Compared to CYPHER Durable Polymer Sirolimus-Eluting Stent Shaoliang Chen Moderators: Ajay J. Kirtane, Bo Xu Discussants: Kefei Dou, Lei Ge, Ning Guo, Zening Jin, Lang Li, Yan Li, Xuebo Liu, Xiantao Song, Qi Zhang 7:48 AM - Panel Discussion with Audience Q&A DES Summit Part I Current DES Platforms 8:00 AM-12:30 PM Update on Current Worldwide DES Platforms Moderators: Ian T. Meredith, Haichang Wang Discussants: Giuseppe De Luca, Eberhard Grube, David E. Kandzari, Adnan Kastrati, Pieter C. Smits, Stephan Windecker 8:00 AM - Opening Lecture - Historical Perspectives on DES Development: Past, Present, and Future Ian T. Meredith 8:15 AM - Zotarolimus-Eluting Stents: Past, Present and Future David E. Kandzari 8:27 AM - Everolimus-Eluting Stents: Past, Present and Future Pieter C. Smits 067 00 9:42 AM - FIREBIRD 2: Durable Polymer Cobalt Chromium Sirolimus-Eluting Stent Yan Li 9:52 AM - EXCEL: Biodegradable Polymer Sirolimus-Eluting Stent Xuebo Liu 10:02 AM - PARTNER: Durable Polymer Sirolimus-Eluting Stent Ning Guo 10:12 AM - YINYI: Polymer-Free PaclitaxelEluting Stent Qi Zhang 10:22 AM - TIVOLI: Biodegradable Polymer Cobalt Chromium Sirolimus-Eluting Stent Lei Ge 10:32 AM - BuMA: Biodegradable Polymer Sirolimus-Eluting Stent Xiantao Song 10:42 AM - NANO: Polymer-Free SirolimusEluting Stent Lang Li 10:52 AM - HELIOS: Biodegradable Polymer Sirolimus-Eluting Stent Zening Jin 11:02 AM - NOYA: Biodegradable Polymer Cobalt Chromium Sirolimus-Eluting Stent Kefei Dou 11:12 AM - Panel Discussion with Audience Q&A The Anti-DES: Drug-Coated Balloons Moderators: Jean Marco, Shubin Qiao Discussants: Feng Cao, Kenneth Chin, GimHooi Choo, Rosli Mohd Ali, Pieter R. Stella, Renu Virmani 11:27 AM - Similarities and Critical Differences Between DCB and DES Technologies Renu Virmani 11:39 AM - 2012 Overview of Current DCB Programs and Prior Clinical Data Pieter R. Stella 11:54 AM - Case Reviews of Strategies for Coronary DCB Use (ISR, Bifurcations, Small Vessels, De Novo Lesions) Kenneth Chin 12:06 PM - Case Reviews of Strategies for Peripheral DCB Use Rosli Mohd Ali 12:18 PM - Panel Discussion with Audience Q&A 12:30 PM - Adjourn Luncheon Symposium Sponsored by MicroPort Smoothing the Artery with Proven Evidence: A FIREBIRD 2 Data Review 12:40 PM-1:55 PM Chairmen: Yong Huo, Yujie Zhou, Bo Yu, Costantino R. Costantini, Yin Liu 12:40 PM - Opening Address 12:45 PM - 2-Year Follow-up Results of FOCUS Study Junbo Ge CIT 2012 www.citmd.com Saturday, March 17th, 2012 1:00 PM - Efficacy and Safety of FIREBIRD 2 Co-Cr Sirolimus-Eluting Stent in Complex Coronary Lesions for the Treatment of Complex Coronary Lesions in Patients with Diabetes: 6-Month Clinical Results of FIRE2DIABETES Yan Li 1:15 PM - Protocol Design and Preliminary Data of FIREBIRD 2 Diabetes Registry in Argentina Liliana R. Grinfeld 1:30 PM - FOCUS-T Registry: Two-Year Clinical Outcomes of FIREBIRD 2 stent at Siriraj Hospital Suwatchai Pornrattanarungsri 1:45 PM - Panel Discussion with Audience Q&A 1:55 PM - Adjourn DES Summit Part II Clinical Use of DES 2:00 PM-6:00 PM Use of DES in Complex Lesions Moderators: Jilin Chen, Duncan Hung-Kwong Ho Discussants: Heng-Chia Chang, Swee Choon Ng, Sufia Rahman, Jifei Tang, Wan Azman Wan Ahmad, Xuchen Zhou 2:00 PM - When and How I Choose DES in Complex Disease? Marie-Claude Morice 2:12 PM - Case Presentation 1: DES in Multivessel Disease (non-LMCA with one CTO) Chien-Ming Huang 2:20 PM - Discussion 2:27 PM - Case Presentation 2: DES in LMCA Disease Wen-Lieng Lee 2:35 PM - Discussion 2:57 PM - Take-Home Massage Jilin Chen DES Failures Use of DES in High Risk Patients Moderators: Weimin Li, Tak-Fu Tse Discussants: Brigadier S. Aziz, Wai-Kwong Chan, Jingyu Hang, Yue Li, Chee-Wo Wu, Pei Zhang Moderators: Yong Huo, Fina Mauri Discussants: Yuqing Hou, Jinghua Liu, Ju-Pin Pan, I Gde Rurus Suryawan, Mujeeb Ul-Haq, Kai Wang 3:00 PM - When Should DES Be Used in STEMI Patients? Fina Mauri 3:12 PM - Case Presentation 4: DES in Simple STEMI Lesion Richard Lim 3:20 PM - Discussion 3:27 PM - Case Presentation 5: DES in a Complex STEMI Lesion Fenghuan Hu 3:35 PM - Discussion 3:42 PM - Use of DES in Complex Clinical Scenarios: Non-Cardiac Surgery, High Bleeding Risk, Questions of Adherence Roxana Mehran 3:54 PM - Current State of the Evidence for Discontinuation of DAPT After DES Alexandra J. Lansky 4:06 PM - Case Presentation 6: PCI Prior to Elective Non-Cardiac Surgery Yi Li 4:14 PM - Discussion 4:41 PM - Managing DES Failures When They Occur (ISR, thrombosis, mechanical issues) Jeffrey W. Moses 4:56 PM - Case Presentation 8: DES Restenosis (recurrent) Sema GГјneri 5:04 PM - Discussion 5:11 PM - Case Presentation 9: DES Restenosis / Thrombosis (strut fracture) Juying Qian 5:19 PM - Discussion 5:26 PM - Case Presentation 10: Subacute Stent Thrombosis (underexpansion) Chris Kwok-Yiu Wong 5:34 PM - Discussion 5:41 PM - Case Presentation 11: Late / Very Late Stent Thrombosis (unknown cause) Brigadier S. Aziz 5:49 PM - Discussion 5:56 PM - Take-Home Massage Weimin Li 6:00 PM - Adjourn 4:21 PM - Case Presentation 7: PCI of Complex Lesion in Patient at High-Risk for Bleeding Jinghua Liu 4:29 PM - Discussion 4:36 PM - Take-Home Massage Yong Huo 2:42 PM - Case Presentation 3: DES in a Complex Long Lesion Jue Chen 2:50 PM - Discussion 068 00 CIT 2012 www.citmd.com Saturday, March 17th, 2012 Room 311B, Level 3 Breakfast Meeting Sponsored by Medtronic Innovative Zero-Fold Technology: The New Era in Balloon Production 7:00 AM-8:00 AM Chairmen: Yuejin Yang, Fang Chen, Yundai Chen, Jifu Li 8:45 AM - Mild-to-Moderate Chronic Heart Failure: ICD or CRT-D? 2010 ESC Guidelines on Device Therapy in Heart Failure Wei Hua 9:00 AM - From Experience to Standard: Management of Pacemaker and ICD Infections - 2010 AHA Guidelines Interpretation Jian Ma 9:15 AM - Primary Prevention of SCD: Guidelines and Reality Kathy Lai Fun Lee 7:00 AM - Opening Address Session II: Guidelines and Practice - Case Discussion 7:02 AM - Innovative Zero-Fold Technology: The New Era in Balloon Production Yundai Chen Moderators: Farong Shen, Yangang Su, Li Li, Haicheng Zhang 7:14 AM - Side Branch Saving Technique with Sprinter Legend Chengxiang Li 9:30 AM - Case 1: MI with Low EF: Is ICD Timely Help or Just Icing on the Cake? Wei Xu Discussants: Shu Zhang, Liqun Wu 7:26 AM - Sprinter Legend OTW: Challenging the Ultimate Complex Lesions Dingcheng Xiang 7:38 AM - Optimization of Stenting Result with NC Sprinter Juying Qian 7:50 AM - Panel Discussion with Audience Q&A 8:00 AM - Adjourn Heart Rhythm Part III Device Therapy 8:30 AM-12:30 PM Session I: Guidelines Interpretation Moderators: Fangzheng Wang, Mingzhe Chen, Shenghua Zhou, Ming Wu 8:30 AM - From ABC to CAB: The Priority of Chest Compression in CPR of SCD - 2010 AHA Guidelines for CPR and ECC Dejia Huang 069 00 10:00 AM - Case 2: MI Accompanied by VT: PCI or ICD? - Strategy and Opportunity Jiangang Zou Discussants: Dejia Huang, Guangping Li Session III: CRT Forum Didactic Lectures Moderators: Lan Huang, Qiangsun Zheng, Xingbin Liu, Lin Cai 10:30 AM - CRT-P Replacement: Is There a Need to Upgrade to CRT-D? Dongmei Wang 10:45 AM - CRT Therapy in HF Patients with AF: The Position and Evaluation of AV Node Ablation Yangang Su 11:00 AM - Diaphragm Nerve Stimulation After CRT Implantation: Treatment Options Other Than Reoperation Farong Shen 11:15 AM - CRT Non-Response: Causes and Strategies Keping Chen Case Discussion - CRT Implantation Technique: Difficulties and Challenges Moderators: Ji Yan, Jing Xu, Chunguang Qiu, Yin Liu 11:30 AM - Case 1 Lin Cai 11:40 AM - Q&A 11:45 AM - Case 2 Dongqi Wang 11:55 AM - Q&A 12:00 PM - Case 3 Yanchun Liang 12:10 PM - Q&A 12:15 PM - Case 4 Xingbin Liu 12:25 PM - Q&A 12:30 PM - Adjourn Luncheon Symposium Sponsored by Lepu Medical Device Selections in Complex Intervention for Congenital Heart Disease 12:40 PM-1:55 PM Chairmen: Shiliang Jiang, Xianyang Zhu, Yushun Zhang, Zhiwei Zhang 12:40 PM - Special ASD Intervention Yongwen Qin 12:55 PM - Essentials in PDA Intervention Wei Gao 1:10 PM - Utility of Snare in Dislodged Occluder Daxin Zhou 1:25 PM - Patient Selection of VSD Intervention in Children Yimin Hua 1:40 PM - Panel Discussion with Audience Q&A 1:55 PM - Adjourn CIT 2012 www.citmd.com Saturday, March 17th, 2012 Heart Rhythm Part IV 2:00 PM-6:00 PM Management of ICD Complications Didactic Lectures Pacing Therapy Forum - Didactic Lectures Moderators: Jingfeng Wang, Xi Su, Can Chen, Lirong Wu Auditorium, Level 3 Moderators: Jihong Guo, Xiaoyong Qi, Li Li, Xiufen Qu 4:00 PM - IIВ°AVB: When to Choose Pacing Therapy? Geng Xu 2:00 PM - Management of Electrical Storm After ICD Implantation Liqun Wu 4:15 PM - AF with Long R-R Interval: When Is Pacing Therapy Needed? Lin Chen 2:15 PM - Strategy for Elevation of DFT During ICD Implantation Jingfeng Wang 4:30 PM - Right Ventricular Septal Pacing: When, Where, Why? Ji Yan Session I: Keynote Lecture 2:30 PM - How to Reduce Inappropriate Shock of ICD? Silin Chen 4:45 PM - Remote Monitoring of Pacemaker: Future Direction Baopeng Tang 2:45 PM - Re-Implantation of ICD After Infection: In Situ or Contralaterally? Tao Guo Pacing Therapy Forum - Debate 8:30 AM - WhatвЂ™s New in the Cath Lab of the Future: Focusing on Bioabsorbable Scaffolds, Transcatheter Aortic Valve Replacement, and Transcatheter Renal Denervation for Refractory Hypertension Jian Liu Management of ICD Complications - Case Discussion Moderators: Wei Hua, Silin Chen, Junming Liu, Tao Guo 3:00 PM - Case 1 Bo Yu 3:10 PM - Q&A 3:15 PM - Case 2 Liangrong Zheng 8:25 PM - Welcome Address Bo Xu Moderators: Jingxuan Guo, Tan Liang, Yan Liu Moderators: Yugang Dong, Zheng Wan Discussants: Jian Ma, Xiaoshu Cheng 8:55 AM - Q&A Leads Extraction Must Be Implemented in All Cases of Pocket Infection Session II: International Exchange 5:00 PM - Pro Xuebin Li 5:10 PM - Con Bing Liu 5:20 PM - Panel Discussion 3:25 PM - Q&A Pacing Therapy Forum - Pacemaker Complications Case Reviews 3:30 PM - Case 3 Moderators: Bo Yu, Qiming Liu, Weize Zhang Jie Fan The 7th Annual Symposium for Nurse and Technologist 8:25 AM-5:00 PM Moderators: Jingxuan Guo, Tan Liang, Yan Liu 9:05 AM - Personnel Management of the Cath Lab Pei-Lan Tsai 9:20 AM - Experience of TAVR (Core Valve) Chan Kim 9:35 AM - Balloon Fracture in Coronary Artery Myeong-Bo Shim 9:50 AM - Q&A 10:00 AM - Break 3:40 PM - Q&A 5:30 PM - Case 1 Xuejun Ren 3:45 PM - Case 4 Jialiang Mao 5:40 PM - Case 2 Jing Xu Moderators: Yuezhen Yang, Fei Li, Hong Liu 3:55 PM - Q&A 5:50 PM - Case 3 Shufeng Li 10:20 AM - Current Status of Interventional Nursing in China Guihua Hou 6:00 PM - Adjourn Session III: Learning from the Specialists 10:40 AM - Data Management and Followup Skill Liang Xu 070 00 CIT 2012 www.citmd.com Saturday, March 17th, 2012 11:00 AM - How to Perform IVUS Analysis? Jing Kan 11:20 AM - Paper Writing in Nursing Research Zhen Xie 11:40 AM - Q&A Session IV: Luncheon Activity Moderators: Guihua Hou, Yan Liu 12:00 PM - Hemodynamic Monitoring in the Cath Lab Ying Wang 12:25 PM - Q&A 12:30 PM - Utility of IABP Jianfen Jin 12:55 PM - Q&A Session VI: Experience Exchange Moderators: Xia Zhao, Xiaoyan Wang, Zhaohui Li 3:00 PM - Support of Coronary Angiogram in Children Jing Liu 3:15 PM - Nursing Experience Sharing in Stent Dislodgement Jihua Yue 3:30 PM - Special EP Case Jun Liu 3:45 PM - Emergent PCI Complicating Cardiac Arrhythmia Yuehong Qiu 4:00 PM - Nursing Strategy for Cardiac Rupture in AF Ablation Li Li 1:00 PM - Use of Contrast Medium Suyu Yao 4:15 PM - Connections of Emergent Patient Between Different Departments Shurong Li 1:25 PM - Q&A 4:30 PM - Q&A Session V: Cath Lab Management 4:50 PM - Take-Home Message Yan Liu, Guihua Hou Moderators: Jie Li, Qi Feng, Huizhu Li 1:30 PM - Human Resource Management in the Cath Lab Yan Liu 1:50 PM - Analysis of Pressure Source for Cath Lab Nurse Xiaofang Gu 2:10 PM - Risk Management of the Cath Lab Hongmei Zhang 2:30 PM - Joint Management in Cath Lab and Ward Sumei Tong 2:50 PM - Q&A 071 00 5:00 PM - Adjourn вЂѓ CIT 2012 www.citmd.com Sunday, March 18th, 2012 Session II Function A, Level 1 th The 4 PCI Complications Forum 8:30 AM-12:30 PM Session I Moderators: Guoying Zhu, Yean-Leng Lim, Yujie Zhou, Ning Tan, Shangyu Wen, Haibo Liu, Shaoping Nie, Shijie You 8:30 AM - Case 1: Stent Dislodgement Induced by Inappropriate Manipulation Baiying Wang 8:38 AM - Discussion 8:50 AM - Case 2: Intensified Coronary Dissection Fenghua Ding 8:58 AM - Discussion 9:10 AM - Case 3: Coronary Aneurysm, Stent Fracture, and Stent Thrombosis Junjie Zhang 9:18 AM - Discussion 9:30 AM - Case 4: Guidewire Stuck During CTO Intervention Xiantao Song 9:38 AM - Discussion 9:50 AM - Case 5: Acute Compartment Syndrome After Transradial Coronary Intervention Lang Li 9:58 AM - Discussion 10:10 AM - Case 6: Spontaneous or Catheter Induced LM Dissection? Quanmin Jing 10:18 AM - Discussion Moderators: Yuejin Yang, Shuzheng Lu, Weimin Wang, Yundai Chen, Yongjian Wu, Jianhua Zhu, Lijun Guo, Yuyang Liu Function B, Level 1 10:30 AM - Case 7: Acquired Stent Malapposition, Stent Thrombosis, and Multiple Stent Fracture After DES Implantation Juying Qian GAP-CCBC at CIT Guideline and Practice - Clinical Case Reviews 8:30 AM-12:30 PM 10:38 AM - Discussion Moderators: Yuejin Yang, Chung-Seung Chiang, Fengrong Chen, Yawei Xu, Ben He, Ping Zhang, Yunlong Xia, Yida Tang 10:50 AM - Case 8: A Series of Consequences After a Slight Oversight Xuebo Liu 10:58 AM - Discussion 11:10 AM - Case 9: Recurrent Angina Shortly After LM Stenting Yue Li 11:18 AM - Discussion 11:30 AM - Case 10: A Rare Complication of Angioseal Closure Device Jie Zhao 11:38 AM - Discussion 11:50 AM - Case 11: Butterfly Effect in Cath Lab Lang Hong 11:58 AM - Discussion 12:10 PM - Case 12: Acute Coronary Closure After PCI Yuangang Qiu 12:18 PM - Discussion Closing of CIT 2012 in Partnership with TCT 12:30 PM-12:45 PM Moderator: Bo Xu Discussants: Jiyan Chen, Shaoliang Chen, Run-Lin Gao, Junbo Ge, Yaling Han, Shiliang Jiang, Shuzheng Lu, Weimin Wang, Yuejin Yang, Guoying Zhu 12:30 PM - Conclusion of CIT 2012 and Announcement of CIT 2013 Run-Lin Gao 12:45 PM - Adjourn Session I 8:30 AM - Case 1: A Case of Patient with Lumbago, Hematuria, Hematochezia, and Dyspnea Xing Liu 8:50 AM - Case 2: A Case of Recurrent Atrial Flutter After Pacemaker Implantation Lianfang Chang 9:10 AM - Case 3: A Case of Severe Ostial Left Main Stenosis Combined with LAD and RCA CTOs Bingfeng Zhou 9:30 AM - Case 4: Understanding About a Mistake After 15 Years Clinical Practice Jianjun Zhang 9:50 AM - Case 5: A Case of Acute Myocardial Infarction with Subacute Cardiac Rupture Jun Zhang 10:10 AM - Case 6: Strategy for IIb/IIIa Antagonist Induced Thrombocytopenia in Patient After PCI Yida Tang Session II Moderators: Hong Chen, Chuen-Den Tseng, Changlin Lu, Yan Wang, Jun Tian, Jianjun Zhang, Yueping Wu, Jingang Yang 10:30 AM - Case 7: A Case of Chest Pain with Syncope in Young Woman Ying Gao 10:50 AM - Case 8: A Patient Died with Acute Inferior Myocardial Infarction Caused by Suspected Aortic Dissection Shaowei Zhuang 072 00 CIT 2012 www.citmd.com Sunday, March 18th, 2012 11:10 AM - Case 9: Diagnosis and Treatment of a Patient with Paroxysmal Chest Pain and Syncope Lianglong Chen 11:30 AM - Case 10: Strategy Selection for Patient with Complex Atherosclerotic Lesions Involving Both Coronary and Peripheral Arteries Yan Wang 11:50 AM - Case 11: Primary Aldosteronism in Patient with Fever of Unknown Cause Jingyi Ren 12:10 PM - Case 12: A Case of Tako-Tsubo Cardiomyopathy Xiaoliang Luo 12:30 PM - Adjourn 10:15 AM - Q&A Function C, Level 1 Practical Course on PCI Part IV Chronic Total Occlusions 8:30 AM-12:30 PM Session IV: Antegrade Approach Moderators: Weifeng Shen, Haichang Wang Discussants: Shaobin Jia, Shouli Wang, Yu Wang, Xuchen Zhou 8:30 AM - Entry Point Judgment and Wire Crossing Technique Shuzheng Lu 8:45 AM - Q&A 8:48 AM - How to Manipulate Wire to Cross CTO Lesion: Feeling or Direction? Yaling Han 10:18 AM - Retrograde Channel Selections Lei Ge 10:33 AM - Q&A 10:36 AM - How to Manipulate the Wire to Cross Collateral Channel? Jiyan Chen 10:51 AM - Q&A 10:54 AM - Connecting the Channels: Kissing-Wire, CART, Reverse CART, Rendezvous, and Other Techniques Bin Zhang 11:09 AM - Q&A 11:12 AM - Antegrade vs. Retrograde Decision-Making: Hybrid Thinking and Changing Course Junbo Ge 11:27 AM - Q&A 9:03 AM - Q&A 9:06 AM - How to Control the Wire to Cross the Exit Point with Multiple View Angiography? Jianfang Luo 9:21 AM - Q&A 9:24 AM - How Often and How Do I Judge the Wire in False Lumen? Shaoliang Chen Session VI: Challenging CTO Case Reviews Moderators: Jiyan Chen, Yaling Han Discussants: Chengxiang Li, Xeuqi Li, Yue Li, Jingang Zheng 11:30 AM - My вЂњMostвЂќ Challenging CTO Xeuqi Li 11:40 AM - Q&A 9:39 AM - Q&A 11:45 AM - My вЂњMostвЂќ Challenging CTO Jingang Zheng 9:42 AM - Dual-Wire Technique in CTO Angioplasty Yongjian Wu 11:55 AM - Q&A 9:57 AM - Q&A 12:00 PM - My вЂњMostвЂќ Challenging CTO Chengxiang Li 12:10 PM - Q&A Session V: Retrograde Approach Moderators: Junbo Ge, Weiyi Fang Discussants: Tianchang Li, Chaowei Mu, Dongqi Wang, Zheng Zhang 10:00 AM - Indication and Device Preparations Guosheng Fu 073 00 12:15 PM - My вЂњMostвЂќ Challenging CTO Yue Li 12:25 PM - Q&A 12:30 PM - Adjourn CIT 2012 www.citmd.com Sunday, March 18th, 2012 Room 306AB, Level 3 Breakfast Case Reviews 10 Chronic Total Occlusion 7:00 AM-8:00 AM Moderators: Ning Tan, Dalin Jia, Yi Li 7:00 AM - CS-0043: Tips and Tricks for Recanalization of CTO by Retrograde Approach Haojian Dong 7:10 AM - Q&A 7:12 AM - CS-0065: A CTO TRI Case: Different Guidewire Choices Rongchong Huang 7:22 AM - Q&A 7:24 AM - CS-0186: A CTO Case Treated by Trans-Epicardial Retrograde Technique Ning Guo Peripheral and Endovascular Therapy Part III Endovascular Forum on Aortic Aneurysm Repair 8:30 AM-12:00 PM Moderators: Qian Chang, Ruiyan Zhang, Chang Shu, Weiguo Fu, Wei Guo, Zhong Chen 8:30 AM - Clinical Experience from Fu Wai Hospital and Challenging Case Reviews Qian Chang 9:00 AM - Clinical Experience from Shanghai Ruijin Hospital and Challenging Case Reviews Ruiyan Zhang 9:30 AM - Clinical Experience from Xiangya Second Hospital and Challenging Case Reviews Chang Shu 10:00 AM - Clinical Experience from Shanghai Zhongshan Hospital and Challenging Case Reviews Weiguo Fu 7:34 AM - Q&A 10:30 AM - Clinical Experience from the PLA General Hospital and Challenging Case Reviews Wei Guo 7:36 AM - CS-0201: Retrograde Rendezvous Technique for Coronary Chronic Total Occlusion Longhao Yu 11:00 AM - Clinical Experience from Beijing An Zhen Hospital and Challenging Case Reviews Zhong Chen 7:46 AM - Q&A 11:30 AM - Panel Discussion with Audience Q&A 7:48 AM - CS-0213: Successful Recanalization of LAD CTO by Antegrade Approach in Patient 10 Years After CABG Dong Huang 12:00 PM - Adjourn Room 307AB, Level 3 Breakfast Case Reviews 11 Chronic Total Occlusion 7:00 AM-8:00 AM Moderators: Keng Wu, Qi Zhang, Yongping Jia 7:00 AM - CS-0239: A Case of Emergency CTO Yan Lai 7:10 AM - Q&A 7:12 AM - CS-0241: Complex Multivessel Disease with CTO Tao Hu 7:22 AM - Q&A 7:24 AM - CS-0245: Collateral Vessel Rupture in Retrograde PCI Xintian Zheng 7:34 AM - Q&A 7:36 AM - CS-0319: A Case of RCA CTO Recanalized with Parallel Wire Technique Bin Wang 7:46 AM - Q&A 7:48 AM - CS-0336: Acute Total Occlusion of LAD Combined with Chronic Total Occlusion Hongbing Yan 7:58 AM - Q&A 8:00 AM - Adjourn 7:58 AM - Q&A 8:00 AM - Adjourn 074 00 CIT 2012 www.citmd.com Sunday, March 18th, 2012 IVUS Workshop Part II 8:30 AM-12:00 PM Stent Complications Moderators: Gary Mintz, Jeffrey W. Moses Discussants: Ning Guo, Yong He, Xuebo Liu, Juying Qian 8:30 AM - IVUS Assessment of In-Stent Restenosis Jie Qian 11:15 AM - Case 8: вЂњSpontaneousвЂќ Dissection and Thrombosis Yining Yang 11:30 AM - Case 9: Plaque Rupture Lin Wang 11:45 AM - Panel Discussion with Audience Q&A 12:00 PM - Adjourn Room 308, Level 3 Breakfast Case Reviews 12 Left Main and Imaging 7:00 AM-8:00 AM Moderators: Guoqing Li, Zhenguo Ji, Zesheng Xu 8:50 AM - IVUS Assessment of Stent Thrombosis Jian Liu 7:00 AM - CS-0064: Left Main PCI in Patient with Dexiocardia Yongjun Li Case Presentations (15 minutes each including Q&A) 7:10 AM - Q&A 9:10 AM - Case 1: Subacute Stent Thrombosis Kai Cui 9:25 AM - Case 2: Very Late Stent Thrombosis Caused by Malapposition Zhenyu Liu 9:40 AM - Case 3: Very Late Stent Thrombosis Minghui Wang 9:55 AM - Case 4: Stent Fracture, Restenosis, and Thrombosis Yingxin Zhao 10:10 AM - Break Stent Complications Moderators: Gary Mintz, Jeffrey W. Moses Discussants: Jian Liu, Jie Qian, Xiaofan Wu, Kai Xu 10:30 AM - Case 5: In-Stent Restenosis Caused by Stent Fracture Jun Pu 10:45 AM - Case 6: In-Stent Restenosis Caused by Chronic Stent Underexpansion Lijian Gao 11:00 AM - Case 7: Stent Fracture and Restenosis Yin Zhang 075 00 7:12 AM - CS-0139: Treatment of Acute Left Main Occlusion Li Yin 7:22 AM - Q&A 7:24 AM - CS-0280: The Value of IVUS and FFR in PCI Xianghua Fu 7:34 AM - Q&A 7:36 AM - CS-0331: PCI for Borderline Lesion Yongqing Lin 7:46 AM - Q&A 7:48 AM - CS-0332: A Case of Acute Left Main Occlusion Zesheng Xu 7:58 AM - Q&A 8:00 AM - Adjourn CIT 2012 www.citmd.com Sunday, March 18th, 2012 Case Reviews (Call-for-Cases) Part I 8:30 AM-12:30 PM Session II: Left Main, Bifurcation, and Imaging Session I: Acute Coronary Syndrome Moderator: Guosheng Fu Panelists: Zhujun Chen, Qun Dang, Pingshuan Dong, Yanmin Xu, Lixia Yang, Shusen Yang Moderator: Xianghua Fu Panelists: Yi An, Feng Bai, Xuebin Cao, Tongguo Wu, Zhuhua Yao, Minzhou Zhang 8:30 AM - CS-0061: A Case of Tako-Tsuboe Syndrome Yuan Gao 8:40 AM - Q&A 8:45 AM - CS-0091: Emergent Intervention of the Occluded Saphenous Vein Graft Hao Sun 8:55 AM - Q&A 9:00 AM - CS-0093: Three Days After MI: Open It or Not? Junqing Yang 9:10 AM - Q&A 9:15 AM - CS-0174: Successfully Rescuing AMI Induced by Type A Dissection of Aorta Xinjun Lei 9:25 AM - Q&A 9:30 AM - CS-0235: STEMI with Huge Thrombus in Culprit Vessel: How to Treat? Qi Zhang 9:40 AM - Q&A 9:45 AM - CS-0296: Acute Inferior Myocardial Infarction Induced by Coronary Spasm Ke Wang 9:55 AM - Q&A 10:00 AM - CS-0338: High Risk ACS Intervention Min Shen 10:10 AM - Q&A 10:30 AM - CS-0044: Unprotected Left Main Stenting Chong-Guan Chan 10:40 AM - Q&A 10:45 AM - CS-0007: Unprotected Left Main and Multivessel PCI Yanmin Xu 10:55 AM - Q&A 11:00 AM - CS-0133: Revascularization of Left Main and Triple Vessel Disease Huaimin Guan 11:10 AM - Q&A 11:15 AM - CS-0165: DK Crush for Left Main Bifurcation Lesion Lang Li 11:25 AM - Q&A Room 309A, Level 3 Breakfast Case Reviews 13 Special Cases 7:00 AM-8:00 AM Moderators: Ningfu Wang, Lu Li, Shuanli Xin 7:00 AM - CS-0035: A Case of Hypertrophic Cardiomyopathy in the Period of Dilation Xuewen Wang 7:10 AM - Q&A 7:12 AM - CS-0082: Nursing Care for Patient with Spontaneous Coronary Dissection Juntao Duan 7:22 AM - Q&A 7:24 AM - CS-0086: A Case of Severe Myocarditis Zhangqiang Chen 7:34 AM - Q&A 11:30 AM - CS-0185: Vulnerable Plaque and Thrombosis Inside DES Honghua Ye 7:36 AM - CS-0109: Drug Dependence of BNP Therapy in Patient with CAD Complicating HF Ningfu Wang 11:40 AM - Q&A 7:46 AM - Q&A 11:45 AM - CS-0305: Jailed Balloon Technique and Reverse Crush Stenting Qinhua Jin 7:48 AM - CS-0118: Myocardial Enzyme Diversity Senlin Li 11:55 AM - Q&A 7:58 AM - Q&A 12:00 PM - CS-0324: A Case of PCI for Trifurcation Lesion in LAD Quanmin Jing 8:00 AM - Adjourn 12:10 PM - Q&A 10:15 AM - CS-0346: Strategies for AMI Zhuhua Yao 12:15 PM - CS-0328: A Case of IUVS Guided SKS Technique in Left Main Bifurcation Kai Xu 10:25 AM - Q&A 12:25 PM - Q&A 12:30 PM - Adjourn 076 00 CIT 2012 www.citmd.com Sunday, March 18th, 2012 Case Reviews (Call-for-Cases) Part II 8:30 AM-12:30 PM Session I: Calcified Lesion and Chronic Total Occlusion Moderator: Wei Gao Panelists: Chengheng Hu, Kang Li, Yongjun Li, Mingsheng Wang, Chun Wu, Yongjian Yang 8:30 AM - CS-0005: Severely Calcified and Diffuse Lesions in Elderly with TVD Underwent PCI Bing Liu 8:40 AM - Q&A 8:45 AM - CS-0006: A Case of PCI for Severely Calcified Lesion Runtao Gan 8:55 AM - Q&A 9:00 AM - CS-0147: Double Microcatheter Technique to Open LAD Total Occlusion Lei Hou 9:10 AM - Q&A 9:15 AM - CS-0159: Retrograde Recanalization of a Chronically Occluded RCA: Reverse CART with Wire Externalization Liting Zhang 9:25 AM - Q&A 9:30 AM - CS-0246: Retrograde PCI for CTO Lijun Guo 9:40 AM - Q&A 9:45 AM - CS-0287: Retrograde Recanalization of Chronic Total Occlusion Using Bilateral Radial Approach with Only 5Fr Guiding Catheters Yoshihide Fujimoto 9:55 AM - Q&A 10:00 AM - CS-0329: PCI for Multivessel CTOs Yining Yang 10:10 AM - Q&A 10:15 AM - CS-0345: Crusade Catheter Used for a CTO Lesion with a Very Sharp Angulation Fei Ye 12:15 PM - CS-0317: Inserting PTCA Guidewire into RCA by Using Diagnostic Angiographic Catheter Geng Wang 10:25 AM - Q&A 12:25 PM - Q&A Session II: Special Cases Moderator: Fang Chen Panelists: Jiyuan Lu, Lifu Miao, Kui Pu, Huifeng Wang, Zhijian Yang, Quanming Zhao 10:30 AM - CS-0020: PCI in Patient with Previous CABG Mengqi Li 10:40 AM - Q&A 10:45 AM - CS-0021: Myocardial Infarction and Subacute In-Stent Thrombosis Induced by Hypercoagulable Condition Qian Wang 10:55 AM - Q&A 11:00 AM - CS-0079: Golden Standard for PCI: Angiography? IVUS? FFR? Jiancheng Xiu 11:10 AM - Q&A 11:15 AM - CS-0166: A Case of PCI for Thrombus in RCA Dong Yin 11:25 AM - Q&A 11:30 AM - CS-0198: A Case of PCI for Coronary Artery Dissection Jingyu Zhou 11:40 AM - Q&A 11:45 AM - CS-0209: Traumatic Myocardial Infarction in a Young Patient with Angiographically Normal Coronary Arteries Shiwei Yang 11:55 AM - Q&A 12:00 PM - CS-0256: Assistance of PTCA Guidwire Dongxing Ma 12:10 PM - Q&A 077 00 12:30 PM - Adjourn CIT 2012 www.citmd.com Sunday, March 18th, 2012 Room 309B, Level 3 Pharmacologic Satellite Symposium Supported by Servier Metabolic Therapy Advance in CAD Management 8:30 AM-10:30 AM Room 310, Level 3 Moderator: Run-Lin Gao Breakfast Case Reviews 14 Special Cases 7:00 AM-8:00 AM Moderators: Fei Ye, Heping Liu, Ping Yang 7:00 AM - CS-0127: A Case of Takayasu Arteritis Bo Yu 7:10 AM - Q&A 7:12 AM - CS-0168: Sudden Death Induced by PTCA of Mid LCX and Successfully Saved by CPR Yi Mao 7:22 AM - Q&A 7:24 AM - CS-0197: Anomalous Origin of RCA and Hypoxemia After PCI Hao Xu 7:34 AM - Q&A 7:36 AM - CS-0221: Treatment of Ventricular Aneurysm with Mural Thrombus After AMI Qingsheng Wang 7:46 AM - Q&A 7:48 AM - CS-0227: A Case of Cardiac Amyloidosis Yujie Zhou 7:58 AM - Q&A 8:30 AM - Opening Address 8:35 AM - Metabolic Therapy Advance in CAD Management Xiaoying Li 9:00 AM - Metabolic Therapy in PCI Patients: From Evidence to Practice Yundai Chen 9:25 AM - Metabolic Therapy in LVD Patients Shenjiang Hu 9:50 AM - Vasorel MR: New Formulation, More Benefits Xiaofang Zhou 10:15 AM - Panel Discussion with Audience Q&A 10:30 AM - Adjourn Breakfast Case Reviews 15 Special Cases 7:00 AM-8:00 AM Moderators: Bin Zhang, Hui Liu, Zhiming Yang 7:00 AM - CS-0250: A Case of PCI in Patient with Primary Aldosteronism Song Cui 7:10 AM - Q&A 7:12 AM - CS-0255: A Case of PCI with LAD Dissection Fenghuan Hu 7:22 AM - Q&A 7:24 AM - CS-0294: Tako-Tsubo Syndrome Xianbo Liu 7:34 AM - Q&A 7:36 AM - CS-0310: A Case of Coronary Artery Spasm Maoru Ma 7:46 AM - Q&A 7:48 AM - CS-0320: Coronary Lesions in Young Female Patient with Heavy Smoking History Haiwei Liu 7:58 AM - Q&A 8:00 AM - Adjourn 078 00 CIT 2012 www.citmd.com Sunday, March 18th, 2012 Structural Heart Disease Part IV 8:00 AM-12:26 PM Session I Moderators: Yongwen Qin, Yushun Zhang, Zhongying Xu, Zhiyuan Song, Yimin Hua, Zhiwei Zhang, Bingxiang Wu, Guotai Sheng 8:00 AM - Interventional Therapy for Congenital Heart Disease with Severe Pulmonary Hypertension: A Single Center Experience from Changhai Hospital, Second Military Medical University Xianxian Zhao 8:10 AM - Discussion 8:14 AM - Interventional Therapy for Congenital Heart Disease with Severe Pulmonary Hypertension: A Single Center Experience from Fu Wai Hospital Gejun Zhang 8:24 AM - Discussion 8:28 AM - Interventional Therapy for Congenital Heart Disease with Severe Pulmonary Hypertension: A Single Center Experience from Zhongshan Hospital of Fudan University Daxin Zhou 8:38 AM - Discussion 8:42 AM - Interventional Therapy for Congenital Heart Disease with Severe Pulmonary Hypertension: A Single Center Experience from Second Affiliated Hospital of Harbin Medical University Bo Yu 8:52 AM - Discussion 8:56 AM - Interventional Therapy for Congenital Heart Disease with Severe Pulmonary Hypertension: A Single Center Experience from First Affiliated Hospital, Anhui Medical University Yan Xu 9:06 AM - Discussion 079 00 9:10 AM - Interventional Therapy for Congenital Heart Disease with Severe Pulmonary Hypertension: A Single Center Experience from Xinqiao Hospital, Third Military Medical University Jun Qin 9:20 AM - Discussion 9:24 AM - Interventional Therapy for Congenital Heart Disease with Severe Pulmonary Hypertension: A Single Center Experience from Shenyang Northern Hospital Xianyang Zhu 9:34 AM - Discussion 9:38 AM - Interventional Therapy for Congenital Heart Disease with Severe Pulmonary Hypertension: A Single Center Experience from Qing Hai Cardiovascular Hospital Liming Wang 9:48 AM - Discussion 9:52 AM - Interventional Therapy for Congenital Heart Disease with Severe Pulmonary Hypertension: A Single Center Experience from Xiangya Second Hospital, Central South University Xiangqian Shen 10:02 AM - Discussion 10:06 AM - Interventional Therapy for Congenital Heart Disease with Severe Pulmonary Hypertension: A Single Center Experience from Shanghai Chest Hospital Affiliated to Shanghai Jiaotong University Xin Pan 10:16 AM - Discussion Session II Moderators: Zhi Zeng, Shiliang Jiang, Yitong Ma, Weifeng Wu, Zishan Hou, Weihua Zhang, Tianhe Yang, Fangqi Gong 10:20 AM - Interventional Therapy for Congenital Heart Disease with Severe Pulmonary Hypertension: A Single Center Experience from Chinese PLA General Hospital Guangyi Wang 10:30 AM - Discussion 10:34 AM - Interventional Therapy for Congenital Heart Disease with Severe Pulmonary Hypertension: A Single Center Experience from Shanghai Children Medical Center Fen Li 10:44 AM - Discussion 10:48 AM - Interventional Therapy for Congenital Heart Disease with Severe Pulmonary Hypertension: A Single Center Experience from Beijing An Zhen Hospital Mei Jin 10:58 AM - Discussion 11:02 AM - Interventional Therapy for Congenital Heart Disease with Severe Pulmonary Hypertension: A Single Center Experience from Qilu Hospital, Qilu University Guishuang Li 11:12 AM - Discussion 11:16 AM - Interventional Therapy for Congenital Heart Disease with Severe Pulmonary Hypertension: A Single Center Experience from Chongqing ChildrenвЂ™s Hospital Qijian Yi 11:26 AM - Discussion 11:30 AM - Interventional Therapy for Congenital Heart Disease with Severe Pulmonary Hypertension: A Single Center Experience from Shandong Provincial PeopleвЂ™s Hospital Yulin Wang CIT 2012 www.citmd.com Sunday, March 18th, 2012 11:40 AM - Discussion 11:44 AM - Interventional Therapy for Congenital Heart Disease with Severe Pulmonary Hypertension: A Single Center Experience from First Affiliated Hospital of Hebei Medical University Zhen Wang 11:54 AM - Discussion 11:58 AM - Interventional Therapy for Congenital Heart Disease with Severe Pulmonary Hypertension: A Single Center Experience from Jiangxi Provincial PeopleвЂ™s Hospital Guotai Sheng Case Reviews (Call-for-Cases) Part III 8:30 AM-12:30 PM Room 311A, Level 3 Breakfast Case Reviews 16 Unusual Complex Cases 7:00 AM-8:00 AM Moderators: Huigen Jin, Junjie Zhang, Yong Yuan 7:00 AM - CS-0019: One-Layer Vessel, FiveLayer Stents Songhua Li 12:08 PM - Discussion 7:10 AM - Q&A 12:12 PM - Interventional Therapy for Congenital Heart Disease with Severe Pulmonary Hypertension: A Single Center Experience from Xiangya Hospital, Central South University Xiaoqun Pu 7:12 AM - CS-0049: Biopsy First or PCI First? Dilemma in Decision Weiming Li 12:22 PM - Discussion Approach to Complex Coronary Artery Disease Xinyang Hu 12:26 PM - Adjourn 7:22 AM - Q&A 7:24 AM - CS-0200: One-Stop Hybird 7:34 AM - Q&A 7:36 AM - CS-0253: An Unfavorable Emergent PCI Zheng Wu 7:46 AM - Q&A 7:48 AM - CS-0298: Hardly Fighting Against Calcified Lesion Huiping Zhang Session I: Complication and Unusual Cases Moderator: Weimin Li Panelists: Jun Dai, Fenghuan Hu, Changlin Lu, Guoxian Qi, Qin Qin, Xiaoming Shang 8:30 AM - CS-0025: A Case of Antithrombotic Therapy for Complex PCI Yawei Luo 8:40 AM - Q&A 8:45 AM - CS-0029: Stent Dislodged in the Ostium of Right Coronary Artery Wenyue Pang 8:55 AM - Q&A 9:00 AM - CS-0059: Coronary Artery Rupture Ruiping Zhao 9:10 AM - Q&A 9:15 AM - CS-0132: Coronary Aneurysm and Stent Fracture Following Stenting of a Myocardial Bridge Hao Lu 9:25 AM - Q&A 9:30 AM - CS-0162: One Case of Iatrogenic Left Main Dissection Chengming Yang 9:40 AM - Q&A 7:58 AM - Q&A 9:45 AM - CS-0202: Acute Pericardial Tamponade After Percutaneous Coronary Intervention Yutong Cheng 8:00 AM - Adjourn 9:55 AM - Q&A 10:00 AM - CS-0237: Entrapped Rotablator Burr During PCI for Calcified CTO Lesion in LAD Bin Wang 10:10 AM - Q&A 10:15 AM - CS-0238: Acute Myocardial Infarction with Ventricular Electrical Storm Lihui Ren 10:25 AM - Q&A 080 00 CIT 2012 www.citmd.com Sunday, March 18th, 2012 Session II: Complication and Unusual Cases Moderator: Shaoliang Chen Panelists: Chaolian Huang, Peng Qu, Leisheng Ru, Pei Zhang, Yang Zheng, Lijun Zhou 10:30 AM - CS-0251: Application of DrugCoated Balloon in In-Stent Restenosis Xianbao Liu 10:40 AM - Q&A 10:45 AM - CS-0267: Acute Subintimal Hematoma After Stent Implantation Weigang Qi 10:55 AM - Q&A 11:00 AM - CS-0297: Global Myocardial Ischemia Occurred During PCI Due to Aortic Valve Regurgitation Induced by Guiding Catheter Fangyi Xiao 11:10 AM - Q&A 11:15 AM - CS-0205: Recurrent Subacute Stent Thrombosis After DES Implantation in Patient with AMI Yujie Zhou 11:25 AM - Q&A 11:30 AM - CS-0315: A Case of Ventricular Fibrillation Caused by Angiography Xiaozeng Wang 11:40 AM - Q&A 11:45 AM - CS-0327: PCI and Transcatheter Closure of Ventricular Septal Defects in Patient with AMI Yingyan Ma 11:55 AM - Q&A 12:00 PM - CS-0337: Successful Retrieval of Fractured Guiding Catheter from Femoral Sheath Guizhou Tao 12:10 PM - Q&A 12:15 PM - CS-0361: Spiral Dissection Distal to the Stent: Management and Lesson Xiaoyong Qi 12:25 PM - Q&A 12:30 PM - Adjourn 081 00 Room 311B, Level 3 Breakfast Case Reviews 17 Unusual Complex Cases 7:00 AM-8:00 AM Moderators: Xuebo Liu, Kanghua Ma, Gaoxing Zhang Heart Rhythm Part V Progress in Arrhythmia Research and Case Reviews 8:00 AM-12:30 PM Session I: Progress in Arrhythmia Research Moderators: Jielin Pu, Guangpin Li, Yuehui Yin, Fang Wang, He Huang 8:30 AM - New Insights of Fatal Arrhythmia Jielin Pu 8:45 AM - Q&A 7:00 AM - CS-0301: AMI Induced by Multiple Spontaneous Coronary Artery Dissections Boyu Li 8:50 AM - Progress in Mechanisms of Atrial Fibrillation Yutang Wang 7:10 AM - Q&A 9:05 AM - Q&A 7:12 AM - CS-0306: Complex and Embarrassing Image and Lesion Xuebo Liu 9:10 AM - Recent Advances in Cryoablation of Atrial Fibrillation Pihua Fang 7:22 AM - Q&A 9:25 AM - Q&A 7:24 AM - CS-0313: A Case of Calcified and Angled Lesion with Difficulties for Wire Passing Through Ming Yuan 9:30 AM - Magnetic Navigation System in Electrophysiological Interventional Therapy Bing Yang 7:34 AM - Q&A 7:36 AM - CS-0335: PCI in High Risk Patient with Multivessel Diffuse Lesions Yong He 7:46 AM - Q&A 7:48 AM - CS-0367: Treatment of Heavily Calcified Coronary Lesion Jie Zhao 7:58 AM - Q&A 8:00 AM - Adjourn 9:45 AM - Q&A 9:50 AM - Epicardial Catheter Ablation of Ventricular Arrhythmia Hua Deng 10:05 AM - Q&A 10:10 AM - Recent Advances in Catheter Ablation of Atrial Tachycardia Jiangui He 10:25 AM - Q&A CIT 2012 www.citmd.com Sunday, March 18th, 2012 Session II: Case Reviews Moderators: Yigang Li, Jiangui He, Weize Zhang, Junyu Cui, Jianmin Chu 10:30 AM - Case 1 Jinlin Zhang 10:40 AM - Q&A 10:45 AM - Case 2 He Huang 10:55 AM - Q&A 11:00 AM - Case 3 Bing Yang 11:10 AM - Q&A 11:15 AM - Case 4 Qiming Liu 11:25 AM - Q&A 11:30 AM - Case 5 Yunlong Xia 11:40 AM - Q&A 11:45 AM - Case 6 Guodong Niu 11:55 AM - Q&A 12:00 PM - Case 7 Chenyang Jiang 12:10 PM - Q&A 12:15 PM - Case 8 Min Tang 12:25 PM - Q&A 12:30 PM - Adjourn 082 00 CIT 2012 www.citmd.com POSTER PROGRAM еЈЃжЉҐ AS-0001: Elevated Admission Microalbuminuria Predicts Poor Myocardial Blood Flow and Six-Month Mortality in STSegment Elevation Myocardial Infarction Patients AS-0046: Atorvastatin Combining with Probucol Can Reduce Serum Uric Acid's Level During Perioperative Period of Intervention Yiran Wang, et al Jiawei Chen, et al AS-0021: Microarray Gene Expression Profiling Identifies Pathophysiological Vascular Responses to Implantation of Overlapping Drug-Eluting Stents into Porcine Coronary Arteries Jing Chen, et al AS-0026: Characterization of Culprit lesions in Acute Coronary Syndromes Compared to Stable Angina Pectoris by Dual-Source Computed Tomography Xia Yang, et al Hongmei Dong, et al AS-0039: A Meta-Analysis About Angiotensin-Converting Enzyme InhibitorвЂ™s Effect on Contrast-Induced Nephropathy Tingting Li, et al AS-0040: The Prognostic Significance of Depression for Patients with Coronary Heart Disease Undergoing Revascularization Sen Lei, et al AS-0052: A Meta-analysis on the Association of Adiponectin Gene Polymorphisms with Coronary Heart Disease in Chinese Han Population Buchun Zhang, et al AS-0053: High-Dose Statin Pretreatment for the Prevention of Contrast-Induced Nephropathy: A Meta-Analysis AS-0054: PI3K/AKT Signal Pathway Modulates Vascular Smooth Muscle Cells Migration under Cyclic Mechanical Strain Buchun Zhang, et al AS-0061: Takayasu's Arteritis with Aortic Dissection: Analysis of Clinical Feature Linghong Shen, et al 083 AS-0073: Probucol Inhibit Vascular Smooth Muscle Cell Proliferation via Up-Regulation of KLF4 After Balloon Injure of Rat Carotid Arteries AS-0093: Efficacy of Pitavastatin in Acute Myocardial Infarction after Primary PCI AS-0063:Hyperhomocysteinemia Induced by Methionine Supplementation Independently Cause and Promotes Atherosclerosis in LDL Receptor-Deficient Mice Fukang Xu, et al AS-0068: Same-Day Discharge Following Effective PCI: 10 Year Single Center Experience Zhihua Zhang, et al Lin Wang, et al Lin Wang, et al Hongmei Dong, et al AS-0080: Role of the Angiogenic Factor Cyr61 in Endothelial Progenitor Cells Migration and Tube Formation in Vitro Yu Yang, et al AS-0082: Transplantation of Cryopreserved Human Umbilical Cord Blood-Derived Endothelial Progenitor Cell Induces Recovery of Carotid artery Injury in Mice Xiaohui Zhao, et al AS-0084: Use of Mother-andChild Catheter in Complex Percutaneous Coronary Intervention Jia'an Sun, et al Teng Sun, et al Tingting Li, et al AS-0042: Early Percutaneous Coronary Intervention After Thrombolysis in STEMI: The EARLY-PCI Pilot Feasibility Study AS-0092: Propensity Score Adjusted Analysis of 12-Month Clinical Outcomes Following Pitavastatin Administration in Patients with Acute Myocardial Infarction Hongmei Dong, et al AS-0048: Frequency Spectra Analysis Predicts Outcomes in Patients with Paroxysmal Atrial Fibrillation Buchun Zhang, et al AS-0029: Association Between Coronary Local Oxidized LDL Levels and Smoking in Patients with Coronary Heart Disease in Chinese Men AS-0072: Kruppel-Like Factor 4 Promotes Differentiation of Endothelial Progenitor Cells into Endothelial Cells by UpRegulating Endothelial Nitric Oxide Synthase AS-0087: Forecasting Major Adverse Cardiac Events by Coronary Computed Tomography Angiography Bin He, et al AS-0089: Long-Term Clinical Outcomes of Medical Therapy versus Coronary Revascularisation in Patients with Intermediate Stenoses Guided by Pressure Wire Hongyu Shi, et al AS-0094: The Influence of Previous Myocardial Infarction on 12-Month Clinical Outcomes in Patients with Recurrent ST-Segment Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention Lin Wang, et al AS-0095: The Influence of Previous Myocardial Infarction on Clinical Characteristics and In-hospital Outcomes in Patients with Recurrent Acute Myocardial Infarction Lin Wang, et al AS-0098: Impact of Statins on 12-Month Clinical Outcomes in Patients with Acute Myocardial Infarction Lin Wang, et al AS-0099: Impact of Statins on 12-Month Clinical Outcomes in Acute ST-Segment Elevation Myocardial Infarction Patients Who Received Thrombolytic Therapy Lin Wang, et al CIT 2012 www.citmd.com POSTER PROGRAM еЈЃжЉҐ AS-0106: Liposomal Prostaglandin E1 Decreases CD29 and CD31 Expression in a Catheter-Based Porcine Model of Myocardial Infarction Reperfusion No-Reflow AS-0137: A Novel PolymerCoated Sirolimus-Eluting Stent Preserves Endothelialization in a Porcine Coronary Artery Model AS-0163: Neointimal Coverage of Drug-Eluting Stent After 3 Months Followup: Evaluation Using Optical Coherence Tomography AS-0138: All-Trans Retinoic Acid Prevent Reperfusion Injury Post-Myocardial Infartion in Diabetic Mice by Incresing RAGE Cut AS-0164: Compliance and Potential Influencing Factors of Secondary Prevention in Patients with Coronary Artery Disease Post Coronary Revascularization Jinzhou Zhu, et al Tianjie Wang, et al Xianlun Li, et al AS-0107: Efficacy and Safety of Prolonged Antiplatelet Therapy Before On-Pump and OffPump Coronary Artery Bypass Grafting Shaoliang Chen, et al Zhengbin Zhu, et al Sergey Altarev, et al AS-0109: Revascularization of Chronic Total Occlusion under the Guidance of Mobile CT Workstation: A Prospective Randomized Study Luyue Gai, et al AS-0112: Safety and Efficacy of Early Application of Tirofiban in STEMI PPatients Undergoing Primary Percutaneous Coronary Intervention Xianghua Fu, et al AS-0115: Prediction of Platelet Distribution Width on No-Reflow Phenomenon in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention Wenlin Ren, et al AS-0143: Impact of Insulin Resistance on Coronary Plaque Progression Dong Yu, et al AS-0165: Anatomic Similarity Between Human Coronary Artery and Renal Artery AS-0145: Influence of Albuminuria on the Real Time Coronary Arterial Lesions Xuanqi An, et al AS-0146: Intravascular Ultrasound Study in Patients Aged over 75 Years with Sirolimus-Eluting Stent Implantation Run Du, et al AS-0150: Role of All-Trans Retinoic Acid in preventing Ischemia/Reperfusion Injury in Aldose Reductase Transgenic Mice Zhengbin Zhu, et al AS-0119: Preventive Effects of Intracoronary Administration of Anisodamine on Myocardial Microcirculation Perfusion After Primary PCI in STEMI Patients AS-0155: Higher Atrial Fibrillation Termination Rate During Ablation of Nonparoxysmal Atrial Fibrillation Based on Application of Amiodarone, and Its Improved Outcome AS-0134: Association between Low-Grade Microalbuminuria and Artery Elasticity and Blood Pressure in Essential Hypertension AS-0160: The Early Diagnosis and Drug Intervention of Contrast-Induced Nephropathy in Patients Undergoing Coronary Intervention Rongfeng Zhang, et al AS-0169: The Impact of VKORC1 -1639G>A Genetic Polymorphism upon Warfarin Dose Requirement in Caucasians and Asians Bo Jin, et al AS-0170: Analysis of in Situ and Ex Vivo О±VОІ3 Integrin Expression During Experimental Carotid Atherogenesis Yibo Jiang, et al AS-0171: Insulin Protects Cardiac Microvascular Endothelital Cells Against Ischemia/Reperfusion Injury: The Key Role of Survivin Shaoliang Chen, et al AS-0178: Comparison of a Five-Year Clinical Outcome Between Chinese Women and Men with De Novo Coronary Disease Treated by Implantation of a DrugEluting stent: A Three-Center, Prospective, Registry Study Shaoliang Chen, et al AS-0179: Acute Effects of Nicardipine and Esmolol on the Cardiac Cycle, Hemodynamic and Endothelial Shear Stress in Patients with unstable Angina Pectoris and Moderate Coronary Stenosis: Results from Single Center, Randomized Study Shaoliang Chen, et al Yanli Gao, et al AS-0172: Clinical Outcomes after Percutaneous Coronary Intervention in Patients with Chronic Total Occlusions Shaoliang Chen, et al Shuxia Yao, et al AS-0177: Comparison of Long-Term Clinical Outcome Between Female versus Male Patients with Firstly Diagnosed De Novo Coronary Disease Treated by Implantation of Drug-Eluting Stent: A Multicenter, Prospective, Registry (LATER) Study Bin Zheng, et al Xianghua Fu, et al Xianghua Fu, et al AS-0173: Serial Intravascular Ultrasound Analysis Comparing Double Kissing (DK) and Classical Crush Stenting for Coronary Bifurcation Lesions AS-0181: Optimized Parameters and Cutoff Values in Quantitative Angiographic and Intravascular Ultrasound for Predicting the Functional Significance of Myocardial Ischemia in Patients with Single De Novo Stenosis Shaoliang Chen, et al Wenhua Li, et al 084 CIT 2012 www.citmd.com POSTER PROGRAM еЈЃжЉҐ AS-0182: Fractional Flow Reserve After DK Crush versus One Stent with Kissing Balloon Inflation for True Coronary Bifurcation Lesions: DKCRUSHIV, A Multicenter, Prospective, Randomized Study AS-0217: CREG Promotes Vasculogenesis of Yolk Sac Derived from Embryonic Stem Cells AS-0235: CREG Gene Silence Induces Spontaneous Apoptosis of Embryonic Stem Cell derived Embryoid Bodies AS-0259: Initial Experience of Occluding Special Type Patent Ductus Arteriosus Using the Amplatzer Vascular Plug AS-0184: Effect and Mechanisms of Coronary Bifurcation Angle from 3-D on Clinical Outcomes After Percutaneous Treatment with Stents: Results from DKCRUSHII Trial AS-0225: SNP rs3825214 in the TBX5 Gene Is Associated with Lone Atrial Fibrillation Xiaobiao Zang, et al AS-0236: The Value of Chest Pain Symptoms in the Diagnosis of Coronary Artery Disease AS-0261: Estimation of Haemodynamics Parameters to Transcatheter Closure of Patent Ductus Arteriosus Complicated Severe Pulmonary Arterial Hypertension Shaoliang Chen, et al Xiaoxiang Tian, et al Guijun Wu, et al AS-0226: CREG Regulates Formation of Endothelial Tip Cells in Angiogenesis via VEGF/ Flk-1/CDC42 Pathway Chenghui Yan, et al Shaoliang Chen, et al AS-0194: Two-Steps Kissing Crush Has the Same Effects as Direct Kissing Crush AS-0227: The Value of Ibutilide for Conversion of Persistent Atrial Fibrillation During Radio Frequency Ablation AS-0199: The Explore of Relation Between Renal Sympathetic Denervation and Angiotensin Converting Enzyme 2 for Hypertensive Dogs AS-0228: Overexpression of CREG Attenuates Atherosclerotic Endothelium Apoptosis via VEGF/PI3K/AKT Pathway AS-0208: Anatomical Characteristics of Pulmonary Vein in Patients with Atrial Fibrillation Analyzed by Multi-detector Computed Tomography AS-0229: CREG Reduces Atherosclerosis in Apolipoprotein E Deficient Mice Bin Wu, et al Chengzhi Lu, et al Qian Yang, et al AS-0211: Association of Activating 5-Lipoxygenase Haplotypes with Susceptibility to Coronary Artery Disease in Chinese Han Population Zhidong li, et al AS-0216: Association of P2Y12 T744C Polymorphism and Clopidogrel Resistance in Coronary Artery Disease in Northern Chinese Ying Sun, et al Na Zhang, et al Xiaochen Tian, et al Chenghui Yan, et al Yaling Han, et al AS-0230: Astragali Radix Extract Shows Antiatherosclerosis Function by Downregulating the Adhesion Molecules Expression in vivo and in vitro AS-0237: Variation of Lipoprotein (a) As a New Predictor for Acute Coronary Syndrome Prognosis After Percutaneous Coronary Intervention Haojian Dong, et al Yang You, et al Yanchun Liang, et al AS-0245: CARTO ThreeDimensional Mapping System Guided Catheter Ablation of Macro-Reentrant Atrial Tachycardia Following Cardiac Surgery in Patients with Structural Heart Disease Shuyin Shi, et al AS-0252: Clinical Analysis of Transcatheter Closure of Atrial Septal Defects in Elderly Patients Huoyuan Chen, et al AS-0254: Screening All the Exons of Nkx2.5 and ISLet1 Gene and Family Survey of New Variant Gene Site Qiguang Wang, et al 085 Xianyang Zhu, et al AS-0263: Experiment of Cellular Repressor of E1AStimulated Genes (CREG) Delivery via Nanoporous Stent in a Porcine Coronary Mode Jie Deng, et al AS-0244: Clinical Characteristics and the Efficacy of Radiofrequency Catheter Ablation of Ventricular Fibrillation/Polymorphic Ventricular Tachycardia Triggered by Idiopathic Premature Ventricular Contraction Originating from the Right Ventricular Outflow Tract Yang You, et al AS-0231: Effects of Astragali Radix Extract on the Expression of MMP-9 and the Formation of Atherosclerotic Plaque in ApoE Gene-Deficient Mice Po Zhang, et al AS-0270: Novel Miniature Mobile Cardiac Catheterization Laboratory for ST-Elevation Myocardial Infarction Following Natural Disaster: A Feasibility Study Zhuo Liang, et al AS-0271: Characteristics of STSegment Elevation Myocardial Infarction Treated by Primary Angioplasty in Shenyang During the 2010 FIFA World Cup in South Africa Haiwei Liu, et al AS-0272: Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction Caused by Unprotected Left Main Coronary Artery Lesions: A Single Centre Study Haiwei Liu, et al AS-0273: Thrombus Aspiration Followed by Direct Stenting During Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction Haiwei Liu, et al CIT 2012 www.citmd.com POSTER PROGRAM еЈЃжЉҐ AS-0282: Prognostic Value of a New Post-Procedural Intravascular Ultrasound Scoring Schemes in Patients Undergoing Coronary DrugEluting Stents Implantation Kai XU, et al AS-0287: Optimal Antiplatelet Strategy and Prognostic Predictors for Patients with Stent Thrombosis: An Observational Study of 140 Patients Yaling Han, et al AS-0288: Clinical Efficacy of Intra-Aortic Balloon Pump in Treating Patients with Left Main Coronary Artery Disease Xin Zhao, et al AS-0289: The Efficacy and Security Analysis of Interventional Therapy Supported by Intra-Aortic Balloon Pump for Patients with High Risk Coronary Heart Disease Xin Zhao, et al AS-0292: Comparison of Human Amniotic Fluid-Derived C-kit+ Stem Cells and C-kitStem Cells: Characterization and Myocardial Differentiation Capacity Jing Bai, et al AS-0296: Safety and Efficacy of Cobalt Chromium Alloy Based Sirolimus-Eluting Stent with Bioabsorbable Polymer in Porcine Model Shen Li, et al AS-0299: IVUS Assessment of Chitosan/Heparin Layerby-Layer Self Assembly Coating Stent on Late Stent Malappoisition and Vessel Remodeling in Porcine Model AS-0307: The Short-Term Effects of Pre-Treatment of Statins on Reperfusion and Short-Term Clinical Prognosis After Percutanous Coronary Intervention in Patients with Non ST-Segment Elevation Acute Coronary Syndrome Chao Ding, et al AS-0308: Transplantation of Endothelial Progenitor Cells Overexpressing Endothelial Nitric Oxide Synthase Enhances Inhibition of Neointimal Hyperplasia and Restores Endothelium-Dependent Vasodilatation Bin Cui, et al AS-0309: Early Clinical Experience with the New Amplatzer Ductal Occluder II for Closure of Varied Congenital Heart Defects AS-0315: A Single Transradial Guiding Catheter for Coronary Angiography and Intervention in Patients with ST Elevation Myocardial Infarciton Jincheng Guo, et al AS-0325: Comparison of Percutaneous-Endocardial Transplantation of Bone Marrow Derived Mesenchymal Stem Cell and Bone Marrow Mononuclear Cells in Porcine Ischemic Reperfusion Hearts Mingliang Cui, et al AS-0331: Impact of Postoperative QRS Duration on Effect of Cardiac Resynchronization Therapy Dongmei Wang, et al AS-0333: Clincal Evaluation of Pacing Therapy via Axillary Vein Shuying Qi, et al AS-0347: Impact of Elevated Serum Glycated Albumin Levels on Contrast-Induced Acute Kidney Injury in Diabetic Patients with Moderate to Severe Renal Insufficiency Undergoing Coronary Angiography Fenghua Ding, et al AS-0349: Declination of Postoperative Complications of Ttranscatheter Closure of Congenital Perimembranous Ventricular Septal Defects: A Single Center and Longitudinal Study from 2002 to 2010 Youpeng Jin, et al AS-0352: CREG Inhibits Angiotensin II-Induced Adventitial Fibroblasts Phenotype Modulation through p38MAPK Pathway Yang Li, et al Hu Haibo, et al AS-0310: Demographic and Clinical Characteristic Predictors of Left Ventricular Dysfunction in Patients with Triple Vessel Coronary Disease Zhan Gao, et al AS-0311: Impact of Depressed Left Ventricular Function on Outcomes in Patients with Three-Vessel Coronary Disease Undergoing Percutaneous Coronary Intervention Zhan Gao, et al AS-0312: Gene Polymorphisms for Clopidogrel Metabolism in Chinese Acute Coronary Syndrome Patients Yan Liang, et al AS-0313: Acute Effect Study of Catheter-Based Renal Sympathetic Denervation in Swine Xiaoqing Liu, et al AS-0335: Procedural Results and 30-Day Outcome Following Transcatheter Aortic Valve Implantation in 48 Consecutive Patients in the Transition Time from the Old Generation to the New Generation Edwards Prosthetic Aortic Valve Quanming Zhao, et al AS-0353: The Initial Evaluation of Moning Times during Atrial Fibrillation Ablation Bailing Dai, et al AS-0354: Animal Experiment Study of A New AntiCalcification Transcatheter Valve for Transcatheter Aortic Valve Implantation Jianming Wang, et al AS-0339: Death Cause Analysis of Procedure and Hospitalization following Transcatheter Aortic Valve Implantation with Edwards Prosthetic Valve in 48 Consecutive Patients AS-0357: Long-Term Syndecan-4 Expression Preserves Cardiac Function in a Rat Model of Myocardial Infarction Jun Xie, et al Quanming Zhao, et al AS-0359: To Investigate the Methode of Radiofrequency Ablation of Focal Atrial Tachycardia Arising from NonCoronary Cusp of the Aortic Valve Shubin Jiang, et al Yizhe Wu, et al 086 CIT 2012 www.citmd.com POSTER PROGRAM еЈЃжЉҐ AS-0366: Efficiency and Safety of Percutaneous Endovascular Graft Exclusion in the Treatment of Patients with Acute and Chronic Type B Aortic Dissections Jiangang Jiang, et al AS-0367: Prognostic Value of Circulating Catestatin Levels in In-Hospital Outcomes of Patients with Acute Coronary Syndromes Zhiqiang Pei, et al AS-0372: Inhibition of Angiotensin II? Induced Cardiomyocyte Apoptosis by Growth Hormone through the Endoplasmic Reticulum Stress Response Pathway Chunyan Yang, et al AS-0383: Stent for Treatment of Infrapopliteal Artery Occlusive Disease AS-0417: Comparison of Different Atrial Stimulating Protocols in AF Inducibility Wen Huang, et al Jinwei Tian, et al AS-0418: Atrial Substrates of Chronic Atrial Fibrillation Detected by Domain Frequency Activation Mapping Wen Huang, et al Prenali Dwisthi, et al AS-0388: Impacts of Tirofiban Infusion through Aspiration Catheter versus through Guiding Catheter on 30 Days' Prognosis in Patients Undergoing Primary Percutaneous Coronary Intervention Hongbing Yan, et al AS-0392: Cold Stress-Induced Endoplasmic Reticulum Stress Increases the Instability of Atherosclerotic Plaque Xiaohui Zheng, et al AS-0454: Long-Term Outcomes of Emergent and Elective PCI in the Unprotected Left Main Disease Bing Fan, et al AS-0419: The Clinical Outcomes of the Patients undergoing Repeated Percutaneous Coronary Intervention with DrugeEluting Stents for In-Stent Restenosis Wenguang Zhang, et al AS-0455: The Effects of High Loading and High Maintenance Doses of Atorvastatin on Platelet Activity and Vascular Endothelium Function as well as Prognosis in Patients with ACS Undergoing PCI Zhangqiang Chen, et al AS-0421: Coronary Artery Disease in Chinese Patients with Abdominal Aortic Aneurysm: Prevalence and Impact on Operative Mortality Tao Sun, et al Bo Shi, et al AS-0384: Participation of Teenagers for Preventing Coronary Artery Disease in Bantul, Indonesia: Implementing Both Peer Education and Community Empowerment AS-0449: Tissue Property of Optical Coherence Tomography in Rabbit Model of Atherosclerotic Plaques AS-0459: Clinical Efficacy of Intervention Therapy in Patients with Acute Myocardial Infarction Complicating Complete Atrioventricular Block Zhangqiang Chen, et al AS-0426: Associations among the CHA2DS2-VASc Score, Different Type of Atrial Fibrillation, and Outcome of Catheter Ablation in Patients with Atrial Fibrillation AS-0461: The Investigation of the Relation Between Coronary Artery Calcium and Acute Myocardial Infarction Hui Xiong, et al Feifei Han, et al AS-0441: Early Identification of High Risk Patients with Intermediate NonCulprit Lesions Prone to Revascularization During Priamry Percutaneous Coronary Intervetion Rongqiang Yan, et al AS-0447: Quantification of Vascular Wall Stress Using Finite Element Modeling: A Pulmonary Autograft Model Andrew D. Wisneski, et al AS-0466: Isolation or Delayed Activation of the Left Atrial Appendage following Ablation of Chronic Atrial Fibrillation Yonghua Zhang, et al AS-0468: sPLA2-IIA Affect Cytokines Production in Human Umbilical Vein Endothelial Cells via Signal Pathway Activation Wei Song, et al AS-0471: VEGF Expression Regulated by rAAV1 Pseudotyped Vectors Mediating Hypoxia-Responsive Elements In Oxygen-Varied Conditions in Vivo and in Vitro Hua Yan, et al AS-0475: A Novel Chemically Defined Condition for Human Menstrual Blood-Derived Stem Cells Rongrong Wu, et al AS-0476: The Effect of Hypoxia on Global Gene Expression and Alternative Splicing of Human Mesenchymal Stem Cells Xinyang Hu, et al AS-0477: Rb and p130 Control the Post-Mitotic Phenotype in Adult Heart Muscle by Recruiting the Heterochromatin Promoting Factor HP1Оі to Growth Associated Genes Yaping Wang, et al AS-0478: Up-Regulation of Endogenous Leptin Improves Human Mesenchymal Stem Cell Survival Ability in Vitro and This Cells Prtect Fatal Cardial Myocytes from Apoptosis Huang, Xin, et al AS-0483: Combination of Percutaneous Coronary Intervention (PCI) and Cell Infusion Is Superior to PCI Alone in Treatment of Patients with Chronic Coronary Total Occlusion Lianru Gao, et al AS-0485: Benefit of Using Endovascular Aneurysm Repair versus Open Surgery for Abdominal Aortic Aneurysms: A Meta-Analysis Yitong Ma, et al 087 CIT 2012 www.citmd.com POSTER PROGRAM еЈЃжЉҐ AS-0487: The Relationship Between Platelet Activation Distribution and Clinical Events in Chinese High-Risk Patients with Acute Coronary Syndrome AS-0515: Percutaneous Intervention for Pulmonary Stenosis Due to Takayasu's Arteritis AS-0539: The Value of Prenatal Echocardiographic Diagnosis of Fetal Ventricular Septal Defect AS-0516: A New Method Using Single-Catheter Technique to Evaluate BiDirectional Conduction Block for Pulmonary Vein Antrum Ablation AS-0543: Different Effect of Follistatin-Related Protein (FRP) in ox-LDL induced Endothelial Cell and Vascular Smooth Muscle Cell Apoptosis Qingxue LI, et al Hui Du, et al Yihong Ren, et al AS-0501: The Safety of Human Umbilical Cord Blood Mononuclear Cells Transplantation in Patients with Myocardial Infarction and Heart Failure Ming Zhang, et al AS-0502: Long-Term Outcome After Intracoronary Autologous Peripheral Blood Stem Cell Transplantation in Old Patients with Acute Myocardial Infarction Ming Zhang, et al AS-0504: Plasma ThrombinCleaved N-Half Osteopontin Is Not Associated with Coronary Artery Disease in Patients with Type 2 Diabetes AS-0518: Leads Location of Right Ventricular Mid-Septal Pacing: A Clinical Study from a Single Center Qiang Li, et al AS-0526: A Clinical Evaluation of the XIENCE V EverolimusEluting Stent in the Treatment of Patients with Complex De Novo Coronary Artery Lesions: Analysis of Chinese Subset from the SPIRIT V Study Yuejin Yang, et al Xiaoxiang Yan, et al AS-0505: Elevated Serum Glycated Albumin and Low Soluble RAGE Levels Are Associated with Albuminuria in Type 2 Diabetic Patients AS-0529: Prognostic Value of Resting Heart Rate in Patients with ST-Segment Elevation Myocardial Infarction with and without Diabetes Han Zhang, et al Lijin Pu, et al AS-0511: The Efficacy of IVUS-Guided Reverse CART (Controlled Antegrade and Retrograde Subintimal Tracking) in Chronic Total Occlusion of the Coronary Arteries AS-0530: Clinical Characteristics Related with High On-Treatment Platelet Reactivity Receiving Clopidogrel Undergoing Percutaneous Coronary Intervention Xumin Hou, et al Leisheng Ru, et al AS-0514: Effects of Termination as a Procedural Endpoint on Catheter Ablation of Persistent Atrial Fibrillation Ping Wang, et al Hua Shen, et al Ping Wang, et al AS-0532: A Clinical Study of Transradial versus Transfemoral Approach for Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction AS-0546: Duration of Dual Antiplatelet Therapy and Outcomes After Left Main Percutaneous Coronary Intervention Tao Hu, et al AS-0547: The Effect of Statins in Chronic Heart Failure: Beyond Its CholesterolLowering Effect Tao Hu, et al AS-0550: The Incidence and Characteristics of Vagal Response During Catheter Ablation of Atrial Fibrillation and the Effect on the Ablation Results Rui Shi, et al AS-0551: The Relation of Arrhythmia Type After Persistent Atrial Fibrillation Catheter Ablation and the Success of Repeat Procedure Rui Shi, et al AS-0552: Uric Acid Predicted Risk of Recurrence of Paroxysmal Atrial Fibrillation after catheter ablation Xiaonan He, et al AS-0556: Mesenchymal Stem Cells Overexpressing IntegrinLinked Kinase Attenuate Left Ventricular Remodeling and Improve Cardiac Function After Myocardial Infarction Qing Mao, et al AS-0557: The Effect of Intravenous Vitamin C Infusion on Short-Term Prognosis for Patients Undergoing Eclective Percutanous Coronary Intervetion Yingxin Zhao, et al AS-0558: Incidence and Risk Factors of Acute Raidal Artery Occlusion in Elderly Paitents Following Transradial Coronary Intervention Yingxin Zhao, et al AS-0559: Predictive Value of Admission Electrocardiogram for Multivessel Disease in Acute Anterior and Anterior-Inferior Myocardial Infarction Qin Ma, et al AS-0560: Changes and Clinical Significances of the Levels of Serum NO and oxLDL in Patients with Obstructive Sleep Apner-Hypopner Syndrome Yulin Jia, et al AS-0561: The Clinical Analysis of Antegrade Puncture in the Treatment of Occlusion in the Beginning of Superficial Femoral Artery Baixi zhuang, et al AS-0562: Activation of NF-ОєB in Circulating Monocular Cells in Apparently Healthy People Fangfang Jiao, et al Jian Liu, et al 088 CIT 2012 www.citmd.com POSTER PROGRAM еЈЃжЉҐ AS-0568: Glycated Albumin Is a Better Indicator Than HbA1c for Evaluating Coronary Artery Disease in Patients with Type 2 Diabetes AS-0585: Catheter Ablation of Ventricular Tachycardia in Patients with Idiopathic Dilated Cardiomyopathy Guided by Non-Contact Mapping System AS-0569: Increased Glycated Albumin and Decreased esRAGE Levels But Not Gly82Ser Polymorphism of RAGE Gene Is Associated with In-Stent Restenosis in Chinese Diabetic Patients AS-0587: Incidence and Predictors of Sinus Node Dysfunction Following Successful Catheter Ablation of Persistent Atrial Flutter Lijin Pu, et al Lin Lu, et al AS-0570: Correlation of Serum Levels of vWF and sVCAM with Late and Very Late Stent Thrombosis Wen Lu, et al AS-0579: Clinical Characteristics and Incidence of All-Cause Mortality and Overall MACCE During InHosptial in Patients with Prior Stroke Undergoing Percutaneous Coronary Intervention Ming Zhang, et al AS-0584: Comparison of Percutaneous Coronary Intervention versus Coronary Artery Bypass Grafting Stratified by Global Risk Classification Score for Unprotected Left Main Disease in Patients with Diabetes Mellitus Fei Gao, et al AS-0613: Preconditioning with High Density Liporotein Enhances Mesenchymal Stem Cell Survival in Infarcted Myocardium Jianfeng Xu, et al Rui Shi, et al AS-0590: Impact of Left Ventricular Scar Burden and Cardiac Dissynchrony on CRT Efficacy: A Single-Center Retrospective Observational Study AS-0614: MAPK/ERK Signaling Pathway Invovles in Mechanism of Oxidative Stress-Induced Apoptosis of Mesenchymal Stem Cell Jianfeng Xu, et al Xiaofeng Hou, et al AS-0591: Combining Neutrophil Gelatinase-Associated Lipocalin with Cystatin C to Early Diagnose Contrast Induced Acute Kidney Injury AS-0615: PI3K/AKT Signaling Pathway Involves in High Density Liporotein-Induced Proliferation of Mesenchymal Stem Cell Jianfeng Xu, et al Xiaoli Liu, et al AS-0595: Rapamycin Regulates the Expression of KrГјppel-Like Transcription Factor 2 in Human Umbilical Vein Endothelial Cells Qian Ma, et al AS-0608: Relationship Between Hemoglobin A1C and Clopidogrel Resistance De'an Jia, et al AS-0609: Vaso-Active Substances and Radial Artery Spasm: A Matched CaseControl Study De'an Jia, et al AS-0610: Acute Rosuvastatin for Preventing Myocardial Damage in Patients with ACS Shujuan Cheng, et al 089 Jianfeng Xu, et al Rui Shi, et al Cao Jin, et al AS-0576: Overexpression of ILK Improves Heart Function After Myocardium Infarction in Pig Model AS-0612: Transforming Growth Factor-ОІ2 Released by Mesenchymal Stem Cells Preconditioned with High Density AS-0616: Impact of Successful Staged Revascularization of a Chronic Total Occlusion in the Non-Infarct-Related Artery on Long-Term Outcome in Patients with Acute STSegment Elevation Myocardial Infarction Qi Zhang, et al AS-0618: Transcatheter Intervention of Fenestration After Modified Fontan Silin Pan, et al CIT 2012 www.citmd.com ж¬ўиїЋиѕћ еђ„дЅЌдё“е®¶гЂЃеђ„дЅЌеђЊд»Ѓпјљ з”±дёеЌЋеЊ»е¦дјљгЂЃдёе›Ѕд»‹е…Ґеїѓи„Џз—…е¦е¤§дјљзђ†дє‹дјљгЂЃдёеЌЋеЊ»е¦дјљеїѓиЎЂз®Ўз—…е¦е€†дјљеЏЉзѕЋе›ЅеїѓиЎЂз®Ўз ”з©¶еџєй‡‘дјљдё» еЉћпјЊPCRгЂЃж—Ґжњ¬е¤Ќжќ‚еїѓиЎЂз®ЎжІ»з–—е¦е¤§дјљгЂЃж¬§жґІеїѓиЎЂз®Ўд»‹е…ҐжІ»з–—еЌЏдјљгЂЃж¬§жґІеїѓи„Џз—…е¦дјљгЂЃж‹‰дёЃзѕЋжґІд»‹е…Ґеїѓи„Џз—… е¦дјљгЂЃйџ©е›ЅAngioplasty Summit - TCTAPгЂЃзѕЋе›ЅеїѓиЎЂз®Ўз ”з©¶жЉЂжњЇдјљи®®гЂЃдєљжґІеїѓиЎЂз®Ўд»‹е…ҐжІ»з–—е¦дјљи®®гЂЃзѕЋе›ЅеїѓиЎЂ з®Ўж–°ењ°е№ізєїдјљи®®гЂЃдёе›Ѕе·ҐзЁ‹й™ўеЊ»иЌЇеЌ«з”џе¦йѓЁгЂЃдєље¤Єд»‹е…Ґеїѓи„Џз—…е¦дјљгЂЃжµ·еіЎдё¤еІёеЊ»иЌЇеЌ«з”џдє¤жµЃе¦дјљеїѓиЎЂз®Ўдё“дёљ е§”е‘�дјљгЂЃдёе›ЅеЊ»з–—дїќеЃҐе›Ѕй™…дє¤жµЃдїѓиї›дјљеїѓиЎЂз®Ўз–ѕз—…з®Ўзђ†е§”е‘�дјљгЂЃй¦™жёЇеїѓи„Џз—…е¦й™ўгЂЃдёеЌЋеЊ»е¦жќ‚еї—и‹±ж–‡з‰€гЂЃж—Ґ жњ¬дё°жЎҐеїѓи„ЏдёеїѓгЂЃдёе›Ѕе›Ѕз«‹еЏ°ж№ѕе¤§е¦еЊ»й™ўгЂЃе№їдёњзњЃеїѓиЎЂз®Ўз—…з ”з©¶ж‰ЂгЂЃдёЉжµ·дє¤йЂље¤§е¦еЊ»е¦й™ўй™„е±ћз‘ћй‡‘еЊ»й™ўгЂЃе¤Ќ ж—¦е¤§е¦й™„е±ћдёе±±еЊ»й™ўгЂЃеЌ—дє¬еЊ»з§‘е¤§е¦й™„е±ћеЌ—дє¬з¬¬дёЂеЊ»й™ўгЂЃз¬¬е››е†›еЊ»е¤§е¦й™„е±ћиҐїдє¬еЊ»й™ўгЂЃжІ€й�іе†›еЊєжЂ»еЊ»й™ўгЂЃй¦– йѓЅеЊ»з§‘е¤§е¦й™„е±ћзєўеЌЃе—жњќй�іеЊ»й™ўгЂЃеЊ—дє¬е¤§е¦дєєж°‘еЊ»й™ўгЂЃй¦–йѓЅеЊ»з§‘е¤§е¦й™„е±ће®‰иґћеЊ»й™ўгЂЃе›Ѕе®¶еїѓиЎЂз®Ўз—…дёеїѓй�ње¤– еЊ»й™ўе…±еђЊеЌЏеЉћзљ„з¬¬еЌЃе±Љдёе›Ѕд»‹е…Ґеїѓи„Џз—…е¦е¤§дјље°†дєЋ2012е№ґ3жњ€15-18ж—ҐењЁеЊ—дє¬е›Ѕе®¶дјљи®®дёеїѓеЏ¬ејЂгЂ‚ж€‘и°Ёд»ЈиЎЁе¤§ дјљз»„е§”дјљиЇљжЊљењ°ж¬ўиїЋж‚ЁеЏ‚еЉ ж¤ж¬Ўз››дјљгЂ‚ CIT2012е°†дёєж‚ЁжЏђдѕ›е€†еёѓењЁ18дёЄдјљењє4е¤©зґЇи®Ў360дёЄе°Џж—¶д»ҐдёЉзљ„ж•™и‚ІиЇѕзЁ‹пјЊи¶…иї‡150ењєе¦жњЇдјљи®®1100дёЄи®І еє§еЏЉ50дѕ‹з¤єж•™жј”з¤єиЅ¬ж’пј›з››е¤§ејЂе№•ејЏе’ЊCIT-TCTе…ЁдЅ“е¤§дјље°†дєЋ3жњ€16ж—ҐдёЉеЌ€дёѕиЎЊпјЊз”±дё–з•ЊйЎ¶зє§еїѓиЎЂз®Ўдё“е®¶е’Ње¦ жњЇз ”з©¶дё“е®¶дё»жЊЃе’Њз‚№иЇ„зљ„CITе№ґеє¦жњЂж–°дёґеєЉиЇ•йЄЊе°†дєЋ3жњ€16гЂЃ17ж—Ґй¦–ж¬Ўе…¬еёѓпј›дј—е¤ље›Ѕй™…зџҐеђЌе¦жњЇз»„з»‡е°†дёЋCIT дёѕиЎЊзІѕеЅ©зљ„иЃ”еђ€е¦жњЇжґ»еЉЁпј›е†…е®№ж¶‰еЏЉе† еїѓз—…гЂЃеїѓеѕ‹е¤±еёёгЂЃз»“жћ„жЂ§еїѓи„Џз—…гЂЃе¤–е‘ЁиЎЂз®Ўз–ѕз—…еЏЉз›ёе…іиЌЇз‰©жІ»з–—иЇёйў† еџџзљ„з‰№й‚ЂжњЂж–°иї›е±•е¦жњЇжЉҐе‘ЉгЂЃеђЊжҐе€†дјљгЂЃе¦жњЇз ”и®ЁдјљгЂЃдё“йў�еі°дјљгЂЃи®єж–‡дє¤жµЃгЂЃз—…дѕ‹и®Ёи®єгЂЃеђ„з§Ќеџ№и®ж•™зЁ‹еЏЉ CITе®ћд№ дёеїѓз‰е°†ењЁдёЌеђЊзљ„дјљењєдёеђЊжҐиї›иЎЊпј›дЅњдёєе¤§дјљж ёеїѓе¦жњЇе†…е®№д№‹дёЂзљ„з¤єж•™жј”з¤єе°†дјљж›ґеЉ зЄЃе‡єе®ћз”ЁжЂ§пјЊ CIT2012е°†иї›иЎЊ25дёЄе°Џж—¶жќҐи‡Єе›Ѕе†…е¤–7е®¶еїѓи„Џдёеїѓзљ„иЅ¬ж’пјЊд»ҐеЏЉе¤ље®¶еЊ»й™ўзљ„з‰№и‰ІеЅ•ж’з—…дѕ‹дё“ењєгЂ‚ д»Ље№ґж�ЇCITзљ„еЌЃе‘ЁеІЃз”џж—ҐгЂ‚ењЁе›Ѕе†…гЂЃе¤–дё“е®¶еЏЉеђЊиЎЊзљ„е…±еђЊеЏ‚дёЋе’Ње¤§еЉ›ж”ЇжЊЃдё‹пјЊCITењЁиї‡еЋ»зљ„еЌЃе№ґдёеѕ—е€°дє†еї« йЂџзљ„еЏ‘е±•е’ЊеЈ®е¤§гЂ‚CITе¤§дјље·Із»Џж€ђдёєдєље¤Єењ°еЊєд»‹е…Ґеїѓи„Џз—…е¦йў†еџџи§„жЁЎжњЂе¤§зљ„е›Ѕй™…е¦жњЇдјљи®®е’ЊжњЂе…·ж•™и‚Іж„Џд№‰зљ„ж•™ е¦иЇѕзЁ‹д№‹дёЂгЂ‚еЌЃе№ґжќҐпјЊCITеЇ№ж€‘е›Ѕд»‹е…ҐжІ»з–—зљ„еї«йЂџеЏ‘е±•гЂЃж™®еЏЉгЂЃжЏђй«�д»ҐеЏЉи§„иЊѓеЊ–иµ·дє†еѕ€е¤§зљ„дїѓиї›дЅњз”ЁгЂ‚ж€‘иЎ·еїѓ еёЊжњ›CITењЁеђ„дЅЌеђЊйЃ“гЂЃеђ€дЅњдј™дјґеЏЉдјЃдёљеЌ•дЅЌзљ„её®еЉ©е’Ње…±еђЊж”ЇжЊЃдё‹пјЊењЁдё‹дёЂдёЄеЌЃе№ґиѓЅе¤џеЏ–еѕ—ж›ґеЉ иѕ‰з…Њзљ„ж€ђз»©гЂ‚ ж€‘зѓжѓ…ењ°жњџеѕ…ењЁ2012е№ґзљ„CITе¤§дјљдёЉж¬ўиїЋж‚Ёзљ„е€°жќҐпјЃ й«�ж¶¦йњ– ж•™жЋ€ CITе¤§дјљдё»её 090 CIT 2012 www.citmd.com е¤§дјљз»„з»‡з»“жћ„ еђЌиЄ‰дё»её зЋ‹жµ·ж�Њ е€�зЋ‰жё… й™€гЂЂз«є зЋ‹дјџж°‘ жЇ›иЉ‚ж�Ћ жќЁи·ѓиї› еЂЄе№јж–№ е¤§дјљдё»её еј гЂЂжѕЌ жІ€жЅћеЌЋ й«�ж¶¦йњ– жњ±е›Ѕи‹± зЋ‹ж–№жЈ зЋ‹йЈЋиЉќ е…±еђЊдё»её з»„з»‡е§”е‘�дјљеђЌиЄ‰дё»её еђґеЌ°з”џ Martin B. Leon иѓЎз››еЇї й�ЋиҐїи‰ґ е€�й›ЃйЈћ ж›ѕе®ље°№ зҐЃе›Ѕж�Ћ е‘Ёз€±еЌї жќЁиѓње€© е‘Ёй‡‘еЏ° е¦жњЇе§”е‘�дјљдё»её иѓЎе¤§дёЂ иЃ”еђ€дё»её (жЊ‰е§“ж°Џж‹јйџіжЋ’еєЏ) й™€зєЄжћ— иµµз‚іи®© з§�д№¦й•ї жњ±ж–‡зЋІ еѕђгЂЂжіў е¦жњЇе§”е‘�дјљ й™€зєЄиЁЂ й™€з»Ќи‰Ї дё“е®¶жЊ‡еЇје§”е‘�дјљ Alexandre Abizaid и‘›еќ‡жіў й™€зЃЏзЏ Maurice Buchbinder йџ©й›…зЋІ й™€еђ›жџ± ж›№е…‹е°† й»„еѕ·е�‰ й™€ж�Ће“І й™€гЂЂж–№ йњЌгЂЂе‹‡ й™€ж ‘е…° й™€йџµеІ± иґѕе›Ѕи‰Ї й™€ењЁе�‰ Chung-Seung Chiang и’‹дё–и‰Ї еґ”й•їзђ® Antonio Colombo Osamu Katoh ж€ґзЋ‰еЌЋ Costantino R. Costantini Yean-Leng Lim йЎѕе¤Ќз”џ Donald E. Cutlip еђ•ж ‘й“® йѓйќ™иђ± жќњеї—ж°‘ й©¬й•їз”џ й»„д»Ћж–° Eric Eeckhout Jean Marco й»„жЊЇж–‡ Jean Fajadet Seung-Jung Park и’‹е®ќзђ¦ ж–№гЂЂе…Ё д№”ж ‘е®ѕ жџЇи‹Ґд»Є ж–№е”ЇдёЂ Shigeru Saito жџЇе…ѓеЌ— е‚…еђ‘еЌЋ Patrick W.Serruys жќЋеЌЋжі° з›–йІЃзІ¤ жІ€еЌ«еі° жћ—ж›™е…‰ й«�гЂЂз‚њ Gregg W. Stone е€�е›Ѕж ‘ Liliana R. Grinfeld Takahiko Suzuki е€�дјЉдёЅ Eberhard Grube 091 CIT 2012 www.citmd.com е¤§дјљз»„з»‡з»“жћ„ йѓж–‡жЂЎ дєЋгЂЂжіў дЅ•гЂЂеҐ” еј з‘ћеІ© David E. Kandzari е‘ЁзЋ‰жќ°дјљ (жЊ‰е§“ж°Џж‹јйџіжЋ’еєЏ) Adnan Kastrati Spencer B. King III з»„з»‡е§”е‘�дјљ Ajay J. Kirtane й™€гЂЂзЏЏ Mitchell W. Krucoff и‘›гЂЂй›· Eisho Kyo йѓгЂЂдјџ Alexandra J. Lansky еЌЋгЂЂдјџ жќЋе»єе†› е§њж°ёиЊ‚ жќЋдёєж°‘ и’‹й›„дє¬ жќЋеЌ е…Ё й‡‘жіЅе®Ѓ Roxana Mehran иЌ†е…Ёж°‘ Ian T. Meredith Paul Hsien-Li Kao Gary S. Mintz Michael Kang-Yin Lee Marie-Claude Morice жќЋгЂЂжµЄ Jeffrey W. Moses жќЋгЂЂжЂЎ Thach Nguyen жќЋгЂЂж‚¦ Masahiko Ochiai е€�жµ·жіў з§¦е¦ж–‡ е€�гЂЂеЃҐ Horst Sievert е€�е¦жіў Huay Cheem Tan е€�е®‡ж‰¬ Etsuo Tsuchikane зЅ—е»єж–№ Renu Virmani Raghotham R. Patlola Ron Waksman й’±гЂЂжќ° Craig M. Walker й’±иЏЉи‹± зЋ‹е»єе®‰ е®‹зЋ°ж¶› зЋ‹д№ђдё° и°гЂЂе®Ѓ Stephan Windecker еђґж°ёеЃҐ еѕђдєљдјџ иўЃж™‹йќ’ йўњзєўе…µ еј гЂЂж–Њ жќЁж–°ж�Ґ еј гЂЂеҐ‡ жќЁе»¶е®— Alan C. Yeung 092 CIT 2012 www.citmd.com е¤§дјљз»„з»‡з»“жћ„ е›Ѕе¤–дё»еёе›ў Alexandre Abizaid е·ґиҐї Praveer Agarwal еЌ°еє¦ Frank Ahmann зѕЋе›Ѕ Tamzeed Ahmed еџеЉ ж‹‰е›Ѕ Takashi Akasaka ж—Ґжњ¬ Erol Akgul ењџиЂіе…¶ Thomas Alexander еЌ°еє¦ Dominic Allocco зѕЋе›Ѕ Yaron Almagor д»Ґи‰Іе€— Brigadier S. Aziz е·ґеџєж–Їеќ¦ Joseph D. Babb зѕЋе›Ѕ Jacek Bialkowski жіўе…° Vikas Bisne еЌ°еє¦ Maurice Buchbinder зѕЋе›Ѕ Davide Capodanno ж„Џе¤§е€© Chong-Guan Chan й©¬жќҐиҐїдєљ Praveen Chandra еЌ°еє¦ 093 Paul TL Chiam ж–°еЉ еќЎ Alfredo R. Galassi ж„Џе¤§е€© David E. Kandzari зѕЋе›Ѕ Kenneth Chin й©¬жќҐиҐїдєљ Michael Gertner зѕЋе›Ѕ Soo-Jin Kang йџ©е›Ѕ Gim-Hooi Choo й©¬жќҐиҐїдєљ Liliana R. Grinfeld й�їж №е»· Elias Kassab зѕЋе›Ѕ Antonio Colombo ж„Џе¤§е€© Eberhard Grube еѕ·е›Ѕ Adnan Kastrati еѕ·е›Ѕ Costantino O. Costantini е·ґиҐї Sema GГјneri ењџиЂіе…¶ Osamu Katoh ж—Ґжњ¬ Costantino R. Costantini е·ґиҐї Yuji Hamazaki ж—Ґжњ¬ Pham Gia Khai и¶ЉеЌ— Thomas Cuisset жі•е›Ѕ Chip B. Hance зѕЋе›Ѕ Ferdinand Kiemeneij иЌ·е…° Donald E. Cutlip зѕЋе›Ѕ Tetsuya Hata ж—Ґжњ¬ Spencer B. King III зѕЋе›Ѕ Debabrata Dash еЌ°еє¦ Dongming Hou зѕЋе›Ѕ Yoshihisa Kinoshita ж—Ґжњ¬ Keith D. Dawkins зѕЋе›Ѕ Pham Manh Hung и¶ЉеЌ— Ajay J. Kirtane зѕЋе›Ѕ Giuseppe De Luca ж„Џе¤§е€© Seung-Ho Hur йџ©е›Ѕ Bon-Kwon Koo йџ©е›Ѕ Ajit G. Desai еЌ°еє¦ Hweung Kon Hwang йџ©е›Ѕ Jan Kovac и‹±е›Ѕ Devang Desai еЌ°еє¦ Fumiaki Ikeno ж—Ґжњ¬ Mitchell W. Krucoff зѕЋе›Ѕ W. Britton Eaves зѕЋе›Ѕ Mohammad Ishaq е·ґеџєж–Їеќ¦ Eisho Kyo ж—Ґжњ¬ Javier Escaned иҐїзЏз‰™ Atilla Iyisoy ењџиЂіе…¶ Kai Huat Lam й©¬жќҐиҐїдєљ Jean Fajadet жі•е›Ѕ Rajneesh Jain еЌ°еє¦ Alexandra J. Lansky зѕЋе›Ѕ William F. Fearon зѕЋе›Ѕ Yangsoo Jang йџ©е›Ѕ Nae Hee Lee йџ©е›Ѕ Fausto Feres е·ґиҐї Haizal Haron Kamar й©¬жќҐиҐїдєљ Martin B. Leon зѕЋе›Ѕ CIT 2012 www.citmd.com е¤§дјљз»„з»‡з»“жћ„ Michael Lim ж–°еЉ еќЎ Sundeep Mishra еЌ°еє¦ Kenan Ovunc ењџиЂіе…¶ Patrick W. Serruys иЌ·е…° Richard Lim жѕіе¤§е€©дєљ Rosli Mohd Ali й©¬жќҐиҐїдєљ Ramazan Г–zdemir ењџиЂіе…¶ Imad Sheiban ж„Џе¤§е€© Yean-Leng Lim жѕіе¤§е€©дєљ Marie-Claude Morice жі•е›Ѕ Seung-Jung Park йџ©е›Ѕ Won-Heum Shim йџ©е›Ѕ Yean-Teng Lim ж–°еЉ еќЎ Jeffrey W. Moses зѕЋе›Ѕ Raghotham R. Patlola зѕЋе›Ѕ Eak-Kyun Shin йџ©е›Ѕ Sidney Tsz Ho Lo жѕіе¤§е€©дєљ Martin MГ¶ckel еѕ·е›Ѕ Jayesh S. Prajapati еЌ°еє¦ Toshiro Shinke ж—Ґжњ¬ William L. Lombardi зѕЋе›Ѕ Michael A. Mussallem зѕЋе›Ѕ Jenny Zhen Qin зѕЋе›Ѕ Horst Sievert еѕ·е›Ѕ Josef Ludwig еѕ·е›Ѕ Jihad Mustapha зѕЋе›Ѕ Sufia Rahman еџеЉ ж‹‰е›Ѕ Charles A. Simonton зѕЋе›Ѕ Yasuhiro Makita ж—Ґжњ¬ Muhammad Munawar еЌ°еє¦е°јиҐїдєљ Sudhir Rathore и‹±е›Ѕ Pieter C. Smits иЌ·е…° Fazila Tun Nesa Malik еџеЉ ж‹‰е›Ѕ Toshiya Muramatsu ж—Ґжњ¬ Johan H. C. Reiber иЌ·е…° Goran Stankovic еЎће°”з»ґдєљ Jean Marco жі•е›Ѕ Yoshinobu Murasato ж—Ґжњ¬ Jason H. Rogers зѕЋе›Ѕ Pieter R. Stella иЌ·е…° Motomaru Masutani ж—Ґжњ¬ Aravinda Nanjundappa зѕЋе›Ѕ Manoj Kumar Rohit еЌ°еє¦ Gregg W. Stone зѕЋе›Ѕ Samuel K. Mathew еЌ°еє¦ Swee Choon Ng й©¬жќҐиҐїдєљ Martin T. Rothman зѕЋе›Ѕ Neil E. Strickman зѕЋе›Ѕ Fina Mauri иҐїзЏз‰™ Quang Tuan Nguyen и¶ЉеЌ— Carlos E. Ruiz зѕЋе›Ѕ Satoru Sumitsuji ж—Ґжњ¬ Roxana Mehran зѕЋе›Ѕ Thach Nguyen зѕЋе›Ѕ Witold Ruzyllo жіўе…° Harry Suryapranata иЌ·е…° Sameer Mehta зѕЋе›Ѕ Kari NiemelГ¤ иЉ¬е…° Shigeru Saito ж—Ґжњ¬ I Gde Rurus Suryawan еЌ°еє¦е°јиҐїдєљ Carlos Mena зѕЋе›Ѕ Masahiko Ochiai ж—Ґжњ¬ Gustavo Samaja й�їж №е»· Malgorzata Szkutnik жіўе…° Ian T. Meredith жѕіе¤§е€©дєљ Masaaki Okutsu ж—Ґжњ¬ Teguh Santoso еЌ°еє¦е°јиҐїдєљ Seung-Jea Tahk йџ©е›Ѕ Gary S. Mintz зѕЋе›Ѕ Yoshinobu Onuma ж—Ґжњ¬ Markus P. Schlaich жѕіе¤§е€©дєљ Akihiko Takahashi ж—Ґжњ¬ 094 CIT 2012 www.citmd.com е¤§дјљз»„з»‡з»“жћ„ Huay Cheem Tan ж–°еЉ еќЎ Stephan Windecker з‘ћеЈ« William Kongto Hau й¦™жёЇпјЊдёе›Ѕ Wei-Kung Tseng еЏ°ж№ѕпјЊдёе›Ѕ Damras Tresukosol жі°е›Ѕ Joo-Young Yang йџ©е›Ѕ Duncan Hung-Kwong Ho й¦™жёЇпјЊдёе›Ѕ Kin-Lam Tsui й¦™жёЇпјЊдёе›Ѕ Etsuo Tsuchikane ж—Ґжњ¬ Yee Guan Yap й©¬жќҐиҐїдєљ I-Chang Hsieh еЏ°ж№ѕпјЊдёе›Ѕ Ping-Tim Tsui й¦™жёЇпјЊдёе›Ѕ Wasan Udayachalerm жі°е›Ѕ Alan C. Yeung зѕЋе›Ѕ Chien-Ming Huang еЏ°ж№ѕпјЊдёе›Ѕ Shih-Pu Wang еЏ°ж№ѕпјЊдёе›Ѕ Kinzo Ueda ж—Ґжњ¬ Hiroyoshi Yokoi ж—Ґжњ¬ Paul Hsien-Li Kao еЏ°ж№ѕпјЊдёе›Ѕ Chris Kwok-Yiu Wong й¦™жёЇпјЊдёе›Ѕ Yuichi Ujiie ж—Ґжњ¬ Fuminobu Yoshimachi ж—Ґжњ¬ Vincent On-Hing Kwok й¦™жёЇпјЊдёе›Ѕ Philip Hung-Chung Wong й¦™жёЇпјЊдёе›Ѕ Mujeeb Ul-Haq е·ґеџєж–Їеќ¦ Robaayah Zambahari й©¬жќҐиҐїдєљ Simon Cheung-Chi Lam й¦™жёЇпјЊдёе›Ѕ Chee-Wo Wu й¦™жёЇпјЊдёе›Ѕ Joseph Varon зѕЋе›Ѕ David X. M. Zhao зѕЋе›Ѕ U Po Lam жѕій—ЁпјЊдёе›Ѕ Chiung-Jen Wu еЏ°ж№ѕпјЊдёе›Ѕ Dobrin Vasilev дїќеЉ е€©дєљ жёЇжѕіеЏ°дё»еёе›ў Kathy Lai Fun Lee й¦™жёЇпјЊдёе›Ѕ Wei-Hsian Yin еЏ°ж№ѕпјЊдёе›Ѕ Renu Virmani зѕЋе›Ѕ Chi-Kin Chan й¦™жёЇпјЊдёе›Ѕ Michael Kang-Yin Lee й¦™жёЇпјЊдёе›Ѕ Kenji Wagatsuma ж—Ґжњ¬ Kam-Tim Chan й¦™жёЇпјЊдёе›Ѕ Stephen-Wai Luen Lee й¦™жёЇпјЊдёе›Ѕ Ron Waksman зѕЋе›Ѕ Kelvin Chan й¦™жёЇпјЊдёе›Ѕ Wen-Lieng Lee еЏ°ж№ѕпјЊдёе›Ѕ Craig M. Walker зѕЋе›Ѕ Wai-Kwong Chan й¦™жёЇпјЊдёе›Ѕ Steven Li й¦™жёЇпјЊдёе›Ѕ Wan Azman Wan Ahmad й©¬жќҐиҐїдєљ Yat-Sun Chan й¦™жёЇпјЊдёе›Ѕ Ping-Han Lo еЏ°ж№ѕпјЊдёе›Ѕ Jie Wang зѕЋе›Ѕ Heng-Chia Chang еЏ°ж№ѕпјЊдёе›Ѕ Ju-Pin Pan еЏ°ж№ѕпјЊдёе›Ѕ Kai Wang зѕЋе›Ѕ Chung-Seung Chiang й¦™жёЇпјЊдёе›Ѕ Li-Wah Tam й¦™жёЇпјЊдёе›Ѕ John G. Webb еЉ ж‹їе¤§ Xiwei Deng жѕій—ЁпјЊдёе›Ѕ Tak-Fu Tse й¦™жёЇпјЊдёе›Ѕ Franz Weidinger еҐҐењ°е€© Ching-Chang Fang еЏ°ж№ѕпјЊдёе›Ѕ Chuen-Den Tseng еЏ°ж№ѕпјЊдёе›Ѕ 095 CIT 2012 www.citmd.com е¤§дјљз»„з»‡з»“жћ„ е›Ѕе†…дё»еёе›ў зЁ‹е† ж�Њпј€жІіеЌ—пј‰ й«�иїћеђ›пј€иѕЅе®Ѓпј‰ жґЄгЂЂжµЄпј€ж±џиҐїпј‰ е®‰гЂЂжЇ…пј€е±±дёњпј‰ зЁ‹ж™“ж›™пј€ж±џиҐїпј‰ й«�ж¶¦йњ–пј€еЊ—дє¬пј‰ жґЄгЂЂж¶›пј€еЊ—дє¬пј‰ з™ЅгЂЂй”‹пј€з”�и‚ѓпј‰ зЁ‹еє”жЁџпј€ж±џиҐїпј‰ й«�гЂЂз‚њпј€еЊ—дє¬пј‰ дѕЇйќ™жіўпј€й»‘йѕ™ж±џпј‰ еЊ…дїЉж•Џпј€дёЉжµ·пј‰ жҐље»єж°‘пј€еЊ—дє¬пј‰ й«�гЂЂи‹±пј€еЊ—дє¬пј‰ дѕЇзЋ‰жё…пј€е№їдёњпј‰ и”ЎгЂЂзђіпј€е››е·ќпј‰ дё›жґЄи‰Їпј€е¤©жґҐпј‰ й«�гЂЂе±•пј€еЊ—дє¬пј‰ дѕЇеђе±±пј€е±±дёњпј‰ и”Ўе°љйѓЋпј€е±±дёњпј‰ еґ”дїЉзЋ‰пј€еЊ—дє¬пј‰ и‘›еќ‡жіўпј€дёЉжµ·пј‰ иѓЎж‰їжЃ’пј€е№їдёњпј‰ ж›№гЂЂдё°пј€й™•иҐїпј‰ еґ”иїћзѕ¤пј€е±±дёњпј‰ и‘›гЂЂй›·пј€дёЉжµ·пј‰ иѓЎе¤§дёЂпј€еЊ—дє¬пј‰ ж›№е…‹е°†пј€ж±џи‹Џпј‰ ж€ґгЂЂе†›пј€еЊ—дє¬пј‰ йѕљж–№ж€љпј€жµ™ж±џпј‰ иѓЎеҐ‰зЋЇпј€еЊ—дє¬пј‰ ж›№й›Єж»Ёпј€жІіеЊ—пј‰ е…љгЂЂзѕ¤пј€е¤©жґҐпј‰ е®«е‰‘ж»Ёпј€ж±џи‹Џпј‰ иѓЎз”іж±џпј€жµ™ж±џпј‰ еёёиїћиЉіпј€еЊ—дє¬пј‰ й‚“гЂЂеЌЋпј€еЊ—дє¬пј‰ е…із‘ћй”¦пј€з¦Џе»єпј‰ иѓЎз››еЇїпј€еЊ—дє¬пј‰ еёёгЂЂи°¦пј€еЊ—дє¬пј‰ дёЃз‡•з”џпј€еЊ—дє¬пј‰ з®ЎгЂЂе†›пј€е±±дёњпј‰ еЌЋгЂЂдјџпј€еЊ—дє¬пј‰ й™€жҐж�џпј€еЊ—дє¬пј‰ и‘Је»єеўћпј€еЊ—дє¬пј‰ е…‰й›Єеі°пј€дє‘еЌ—пј‰ еЌЋз›Љж°‘пј€е››е·ќпј‰ й™€гЂЂзЃїпј€е№їдёњпј‰ и‘Је№іж “пј€жІіеЌ—пј‰ йѓз»§йёїпј€еЊ—дє¬пј‰ й»„и¶…иЃ”пј€еЊ—дє¬пј‰ й™€гЂЂж–№пј€еЊ—дє¬пј‰ и‘ЈеђЃй’ўпј€е№їдёњпј‰ йѓй‡‘ж€ђпј€еЊ—дє¬пј‰ й»„еѕ·е�‰пј€е››е·ќпј‰ й™€е‡¤иЌЈпј€еЊ—дє¬пј‰ зЄ¦е…‹йќћпј€еЊ—дє¬пј‰ йѓгЂЂе†›пј€еЊ—дє¬пј‰ й»„гЂЂй№¤пј€ж№–еЊ—пј‰ й™€гЂЂзєўпј€еЊ—дє¬пј‰ жќњзЋ‰зЋЇпј€еЊ—дє¬пј‰ йѓдёЅеђ›пј€еЊ—дє¬пј‰ й»„гЂЂеІљпј€й‡Ќеє†пј‰ й™€зєЄжћ—пј€еЊ—дє¬пј‰ жќњеї—ж°‘пј€е№їдёњпј‰ йѓгЂЂе®Ѓпј€й™•иҐїпј‰ й»„зџіе®‰пј€е№їдёњпј‰ й™€зєЄиЁЂпј€е№їдёњпј‰ жЁЉгЂЂе†°пј€дёЉжµ·пј‰ йѓгЂЂж¶›пј€дє‘еЌ—пј‰ й»„дјџе‰‘пј€жµ™ж±џпј‰ й™€гЂЂзЏЏпј€еЊ—дє¬пј‰ иЊѓгЂЂжґЃпј€дє‘еЌ—пј‰ йѓгЂЂдјџпј€еЊ—дє¬пј‰ жѓ ж°ёж�Ћпј€еЊ—дє¬пј‰ й™€жџЇиђЌпј€еЊ—дє¬пј‰ иЊѓдёжќ°пј€еЊ—дє¬пј‰ йѓж–‡жЂЎпј€й™•иҐїпј‰ йњЌгЂЂе‹‡пј€еЊ—дє¬пј‰ й™€и‰Їйѕ™пј€з¦Џе»єпј‰ ж–№дё•еЌЋпј€еЊ—дє¬пј‰ йџ©з«‹е®Єпј€жІіеЊ—пј‰ з±ЌжЊЇе›Ѕпј€жІіеЊ—пј‰ й™€гЂЂжћ—пј€з¦Џе»єпј‰ ж–№гЂЂе…Ёпј€еЊ—дє¬пј‰ йџ©й›…зЋІпј€иѕЅе®Ѓпј‰ иґѕе¤§жћ—пј€иѕЅе®Ѓпј‰ й™€ж�Ћйѕ™пј€ж±џи‹Џпј‰ ж–№е”ЇдёЂпј€дёЉжµ·пј‰ жќйќ–е®‡пј€дёЉжµ·пј‰ иґѕеЃҐй›„пј€еЊ—дє¬пј‰ й™€з»Ќи‰Їпј€ж±џи‹Џпј‰ е†Їз‡•е…‰пј€жІіеЊ—пј‰ йѓќжЃ’е‰‘пј€еЊ—дє¬пј‰ иґѕз»Ќж–Њпј€е®Ѓе¤Џпј‰ й™€жі—жћ—пј€е№їдёњпј‰ е‚…е›Ѕиѓњпј€жµ™ж±џпј‰ дЅ•гЂЂеҐ”пј€дёЉжµ·пј‰ иґѕж°ёе№іпј€е±±иҐїпј‰ й™€зЋ‰е›Ѕпј€е±±дёњпј‰ з¬¦дјџе›Ѕпј€дёЉжµ·пј‰ дЅ•е›ЅзҐҐпј€й‡Ќеє†пј‰ и’‹ж™Ёй�іпј€жµ™ж±џпј‰ й™€йџµеІ±пј€еЊ—дє¬пј‰ е‚…еђ‘еЌЋпј€жІіеЊ—пј‰ дЅ•е»єжЎ‚пј€е№їдёњпј‰ е§њдёњз‚¬пј€иѕЅе®Ѓпј‰ й™€гЂЂеї пј€еЊ—дє¬пј‰ з›–йІЃзІ¤пј€еЊ—дє¬пј‰ дЅ•гЂЂйќ’пј€еЊ—дє¬пј‰ ж±џгЂЂжґЄпј€ж№–еЊ—пј‰ й™€з«№еђ›пј€е№їдёњпј‰ е№Іе¦дёњпј€ж№–еЊ—пј‰ дЅ•дЅњзҐҐпј€еЊ—дє¬пј‰ и’‹й‡‘жі•пј€дёЉжµ·пј‰ зЁ‹гЂЂж ‡пј€е››е·ќпј‰ й«�дј зЋ‰пј€жІіеЌ—пј‰ иґєгЂЂе‹‡пј€е››е·ќпј‰ и’‹дё–и‰Їпј€еЊ—дє¬пј‰ 096 CIT 2012 www.citmd.com е¤§дјљз»„з»‡з»“жћ„ ж±џж—¶жЈ®пј€ж±џи‹Џпј‰ жќЋгЂЂжЅћпј€иѕЅе®Ѓпј‰ е€�зєўж—пј€еЊ—дє¬пј‰ еђ•ж ‘й“®пј€еЊ—дє¬пј‰ е§њй“Ѓж°‘пј€е¤©жґҐпј‰ жќЋж·‘жў…пј€еђ‰жћ—пј‰ е€�еЊ–жћ—пј€еЊ—дє¬пј‰ еђ•з§Ђз« пј€еЊ—дє¬пј‰ и’‹й›„дє¬пј€еЊ—дє¬пј‰ жќЋиї°еі°пј€й»‘йѕ™ж±џпј‰ е€�гЂЂж…§пј€жІіеЌ—пј‰ ж ѕиЌЈеЌЋпј€й™•иҐїпј‰ е§њж°ёиЊ‚пј€еЊ—дє¬пј‰ жќЋз”°ж�Њпј€еЊ—дє¬пј‰ е€�жѓ дє®пј€еЊ—дє¬пј‰ зЅ—е»єж–№пј€е№їдёњпј‰ й‡‘жѓ ж №пј€дёЉжµ·пј‰ жќЋгЂЂеЌ«пј€еЊ—дє¬пј‰ е€�гЂЂеЃҐпј€еЊ—дє¬пј‰ зЅ—дёѓдёЂпј€дёЉжµ·пј‰ йќіз«‹е†›пј€е№їдёњпј‰ жќЋдјџжќ°пј€й™•иҐїпј‰ е€�е»єе№іпј€й‡Ќеє†пј‰ зЅ—ж™“дє®пј€еЊ—дє¬пј‰ й‡‘гЂЂжў…пј€еЊ—дє¬пј‰ жќЋдёєж°‘пј€й»‘йѕ™ж±џпј‰ жџіж™ЇеЌЋпј€еЊ—дє¬пј‰ й©¬й•їз”џпј€еЊ—дє¬пј‰ й‡‘зђґиЉ±пј€еЊ—дє¬пј‰ жќЋдјџж�Ћпј€дёЉжµ·пј‰ е€�дїЉж�Ћпј€ж–°з–†пј‰ й©¬ж №е±±пј€ж±џи‹Џпј‰ й‡‘жіЅе®Ѓпј€еЊ—дє¬пј‰ жќЋе°Џй№°пј€еЊ—дє¬пј‰ е€�жў…жћ—пј€еЊ—дє¬пј‰ й©¬гЂЂи™№пј€е№їдёњпј‰ иЌ†е…Ёж°‘пј€иѕЅе®Ѓпј‰ жќЋж–°ж�Ћпј€дёЉжµ·пј‰ е€�еђЇж�Ћпј€ж№–еЌ—пј‰ й©¬гЂЂеќљпј€еЊ—дє¬пј‰ ж™ЇењЁе№іпј€дёЉжµ·пј‰ жќЋе¦ж–Њпј€еЊ—дє¬пј‰ е€�гЂЂе…Ёпј€еђ‰жћ—пј‰ й©¬еє·еЌЋпј€й‡Ќеє†пј‰ е”зҐҐжё…пј€ж±џи‹Џпј‰ жќЋе¦еҐ‡пј€й»‘йѕ™ж±џпј‰ е€�д»Ѓе…‰пј€иѕЅе®Ѓпј‰ й©¬з¤јеќ¤пј€е®‰еѕЅпј‰ жќЋгЂЂдїќпј€е±±иҐїпј‰ жќЋгЂЂе¦Ќпј€й™•иҐїпј‰ е€�е°‘зЁіпј€дёЉжµ·пј‰ й©¬е€©е№іпј€жІіеЌ—пј‰ жќЋж€ђзҐҐпј€й™•иҐїпј‰ жќЋгЂЂжЂЎпј€е№їдёњпј‰ е€�еђЊеє“пј€еђ‰жћ—пј‰ й©¬дѕќеЅ¤пј€ж–°з–†пј‰ жќЋж�Ґйњ–пј€еЊ—дє¬пј‰ жќЋжЇ…е€љпј€дёЉжµ·пј‰ е€�е…ґж–Њпј€е››е·ќпј‰ й©¬йў–и‰іпј€иѕЅе®Ѓпј‰ жќЋгЂЂеҐ‹пј€дёЉжµ·пј‰ жќЋж‹Ґе†›пј€жІіеЊ—пј‰ е€�е…ґй№Џпј€еЊ—дє¬пј‰ жЇ›е®¶дє®пј€дёЉжµ·пј‰ жќЋе…‰дјџпј€еЊ—дє¬пј‰ жќЋж‚¦пј€й»‘йѕ™ж±џпј‰ е€�гЂЂж�џпј€ж±џиҐїпј‰ и‹—з«‹е¤«пј€еЊ—дє¬пј‰ жќЋе№їе№іпј€е¤©жґҐпј‰ жќЋеЌ е…Ёпј€иѕЅе®Ѓпј‰ е€�гЂЂж—пј€дёЉжµ·пј‰ ж…•жњќдјџпј€еЊ—дє¬пј‰ жќЋиґµеЏЊпј€е±±дёњпј‰ жќЋеї—еї пј€еЊ—дє¬пј‰ е€�е¦жіўпј€дёЉжµ·пј‰ иЃ‚е¦‚зђјпј€е№їдёњпј‰ жќЋе›Ѕеє†пј€ж–°з–†пј‰ жќЋеї жќ°пј€жµ™ж±џпј‰ е€�гЂЂеЇ…пј€е¤©жґҐпј‰ иЃ‚з»Ќе№іпј€еЊ—дє¬пј‰ жќЋи™№дјџпј€еЊ—дє¬пј‰ жўЃе»¶ж�Ґпј€иѕЅе®Ѓпј‰ жџігЂЂиЊµпј€йќ’жµ·пј‰ з‰›е›Ѕж ‹пј€еЊ—дє¬пј‰ й»ЋгЂЂиѕ‰пј€й»‘йѕ™ж±џпј‰ жўЃе…†е…‰пј€й»‘йѕ™ж±џпј‰ е€�е®‡ж‰¬пј€еЊ—дє¬пј‰ жЅ�гЂЂж¬Јпј€дёЉжµ·пј‰ жќЋе»єе†›пј€еЊ—дє¬пј‰ жћ—и‹±еї пј€е№їиҐїпј‰ е€�йњ‡е®‡пј€еЊ—дє¬пј‰ еєћж–‡и·ѓпј€иѕЅе®Ѓпј‰ жќЋе»єе№іпј€еЊ—дє¬пј‰ е€�гЂЂж–Њпј€еђ‰жћ—пј‰ еђ•е®‰жћ—пј€й™•иҐїпј‰ еЅе»єе†›пј€еЊ—дє¬пј‰ жќЋз»§з¦Џпј€е±±дёњпј‰ е€�гЂЂе…µпј€й™•иҐїпј‰ еђ•гЂЂж»Ёпј€еЊ—дє¬пј‰ жµ¦д»‹йєџпј€еЊ—дє¬пј‰ жќЋгЂЂеє·пј€еЊ—дє¬пј‰ е€�жњќдёпј€еЊ—дє¬пј‰ еЌўж‰Ќд№‰пј€еЊ—дє¬пј‰ жµ¦гЂЂеҐЋпј€е¤©жґҐпј‰ жќЋгЂЂжµЄпј€е№їиҐїпј‰ е€�жµ·жіўпј€еЊ—дє¬пј‰ еЌўй•їжћ—пј€еЊ—дє¬пј‰ и’Іж™“зѕ¤пј€ж№–еЌ—пј‰ жќЋгЂЂиЋ‰пј€дёЉжµ·пј‰ е€�е’Ње№іпј€еђ‰жћ—пј‰ еЌўж€ђеї—пј€е¤©жґҐпј‰ и’Іеї жќ°пј€еЊ—дє¬пј‰ жќЋгЂЂдёЅпј€з”�и‚ѓпј‰ жџігЂЂеј�пј€еЊ—дє¬пј‰ й™†е›Ѕе№іпј€дёЉжµ·пј‰ йЅђе›Ѕе…€пј€иѕЅе®Ѓпј‰ жќЋгЂЂе‡Њпј€жІіеЌ—пј‰ е€�е®Џж–Њпј€еЊ—дє¬пј‰ еђ•еђ‰е…ѓпј€е±±иҐїпј‰ йЅђеђ‘е‰Ќпј€е¤©жґҐпј‰ 097 CIT 2012 www.citmd.com е¤§дјљз»„з»‡з»“жћ„ йЅђж™“е‹‡пј€жІіеЊ—пј‰ е®їз‡•еІ—пј€дёЉжµ·пј‰ зЋ‹ж™Їеі°пј€е№їдёњпј‰ дјЌдјџеі°пј€е№їиҐїпј‰ й’±гЂЂжќ°пј€еЊ—дє¬пј‰ е™з¦Џж€ђпј€еЊ—дє¬пј‰ зЋ‹гЂЂе‡Їпј€е†…и’™еЏ¤пј‰ еђґе°Џе‡Ўпј€еЊ—дє¬пј‰ й’±иЏЉи‹±пј€дёЉжµ·пј‰ е™и‹±иґ¤пј€иѕЅе®Ѓпј‰ зЋ‹д№ђдё°пј€еЊ—дє¬пј‰ ж¦й�ідё°пј€еЊ—дє¬пј‰ д№”ж ‘е®ѕпј€еЊ—дє¬пј‰ и°гЂЂе®Ѓпј€е№їдёњпј‰ зЋ‹гЂЂй›·пј€еЊ—дє¬пј‰ еђґж°ёеЃҐпј€еЊ—дє¬пј‰ и¦ѓгЂЂе†›пј€й‡Ќеє†пј‰ ж±¤е®ќй№Џпј€ж–°з–†пј‰ ж±ЄгЂЂз«‹пј€дёЉжµ·пј‰ еђґеІіе№іпј€з¦Џе»єпј‰ з§¦гЂЂй›·пј€жІіеЌ—пј‰ е”ђжњќжћўпј€еЊ—дє¬пј‰ зЋ‹й»Ћж�Ћпј€йќ’жµ·пј‰ е¤ЏгЂЂз„¶пј€еЊ—дє¬пј‰ з§¦гЂЂе‹¤пј€е¤©жґҐпј‰ е”ђеЏ‘е®Ѕпј€еЊ—дє¬пј‰ зЋ‹ж�Ћз”џпј€еЊ—дє¬пј‰ е¤Џдє‘йѕ™пј€иѕЅе®Ѓпј‰ з§¦е¦ж–‡пј€еЊ—дє¬пј‰ е”ђз–ѕйЈћпј€жµ™ж±џпј‰ зЋ‹е®Ѓе¤«пј€жµ™ж±џпј‰ еђ‘е®љж€ђпј€е№їдёњпј‰ з§¦ж°ёж–‡пј€дёЉжµ·пј‰ е”ђи‰Їз§‹пј€е№їдёњпј‰ зЋ‹еє†иѓњпј€жІіеЊ—пј‰ и‚–гЂЂзєЇпј€е№їдёњпј‰ й‚±ж�Ґе…‰пј€жІіеЌ—пј‰ е”ђгЂЂй—Ѕпј€еЊ—дє¬пј‰ зЋ‹е®€еЉ›пј€еЊ—дє¬пј‰ дїЎж “еЉ›пј€жІіеЊ—пј‰ ж›ІгЂЂй№Џпј€иѕЅе®Ѓпј‰ е”ђз† иѕѕпј€еЊ—дє¬пј‰ зЋ‹дјџж°‘пј€еЊ—дє¬пј‰ еѕђгЂЂж ‡пј€ж±џи‹Џпј‰ ж›Іж–°е‡Їпј€дёЉжµ·пј‰ й™¶иґµе‘Ёпј€иѕЅе®Ѓпј‰ зЋ‹ж•€еўћпј€иѕЅе®Ѓпј‰ еѕђгЂЂжіўпј€еЊ—дє¬пј‰ ж›Із§ЂиЉ¬пј€й»‘йѕ™ж±џпј‰ й™¶гЂЂе†›пј€е№їдёњпј‰ зЋ‹гЂЂз„±пј€з¦Џе»єпј‰ и®ёгЂЂй”‹пј€еЊ—дє¬пј‰ д»»ж™ЇжЂЎпј€еЊ—дє¬пј‰ з”°гЂЂе†›пј€е¤©жґҐпј‰ зЋ‹гЂЂз¦№пј€еЊ—дє¬пј‰ еѕђгЂЂиЂ•пј€жµ™ж±џпј‰ д»»е¦е†›пј€еЊ—дє¬пј‰ з”°гЂЂи•ѕпј€еЊ—дє¬пј‰ зЋ‹зЋ‰жћ—пј€е±±дёњпј‰ и®ёгЂЂйќ™пј€е¤©жґҐпј‰ ж±ќзЈЉз”џпј€жІіеЊ—пј‰ з”°гЂЂй‡Ћпј€й»‘йѕ™ж±џпј‰ зЋ‹зЋ‰е ‚пј€еЊ—дє¬пј‰ еѕђгЂЂе‡Їпј€иѕЅе®Ѓпј‰ еЌ•е®€жќ°пј€ж±џи‹Џпј‰ дё‡гЂЂеѕЃпј€е¤©жґҐпј‰ зЋ‹гЂЂйњ‡пј€жІіеЊ—пј‰ и®ёеЉ›и€’пј€ж–°з–†пј‰ е°љж™“ж�Ћпј€жІіеЊ—пј‰ зЋ‹гЂЂж–Њпј€еЊ—дє¬пј‰ зЋ‹еї—жЇ…пј€е¤©жґҐпј‰ еѕђгЂЂдјџпј€ж±џи‹Џпј‰ жІ€жі•иЌЈпј€жµ™ж±џпј‰ зЋ‹й•їи°¦пј€дёЉжµ·пј‰ зЋ‹зҐ–з¦„пј€иѕЅе®Ѓпј‰ еѕђгЂЂеІ©пј€е®‰еѕЅпј‰ жІ€еЌ«еі°пј€дёЉжµ·пј‰ зЋ‹е†¬жў…пј€жІіеЊ—пј‰ йЏгЂЂз›џпј€дёЉжµ·пј‰ еѕђе»¶ж•Џпј€е¤©жґҐпј‰ жІ€еђ‘е‰Ќпј€ж№–еЌ—пј‰ зЋ‹дёњзђ¦пј€й™•иҐїпј‰ жё©е°љз…њпј€й»‘йѕ™ж±џпј‰ еѕђдєљдјџпј€дёЉжµ·пј‰ жІ€зЏ е†›пј€еЊ—дє¬пј‰ ж±ЄгЂЂиЉіпј€дёЉжµ·пј‰ еђґз‚ізҐҐпј€й»‘йѕ™ж±џпј‰ еѕђиїЋдЅіпј€дёЉжµ·пј‰ з››е›Ѕе¤Єпј€ж±џиҐїпј‰ зЋ‹е№їд№‰пј€еЊ—дє¬пј‰ еђґгЂЂж·іпј€е№їдёњпј‰ еѕђжіЅеЌ‡пј€жІіеЊ—пј‰ ж–Ѕжµ·ж�Ћпј€дёЉжµ·пј‰ зЋ‹иґµжќѕпј€еЊ—дє¬пј‰ еђґгЂЂй“їпј€е№їдёњпј‰ еѕђд»Іи‹±пј€еЊ—дє¬пј‰ еЏІж–°з«‹пј€еЊ—дє¬пј‰ зЋ‹жµ·ж�Њпј€й™•иҐїпј‰ еђґз«‹зѕ¤пј€дёЉжµ·пј‰ и–›зЋ‰з”џпј€й™•иҐїпј‰ и€’гЂЂз•…пј€ж№–еЌ—пј‰ зЋ‹гЂЂжµ©пј€еЊ—дє¬пј‰ еђґз«‹иЌЈпј€иґµе·ћпј‰ йўњзєўе…µпј€еЊ—дє¬пј‰ е®‹зЋ°ж¶›пј€еЊ—дє¬пј‰ зЋ‹зєўе®‡пј€е±±иҐїпј‰ еђґгЂЂж�Ћпј€жµ·еЌ—пј‰ дёҐгЂЂжїЂпј€е®‰еѕЅпј‰ е®‹иЂЂж�Ћпј€й‡Ќеє†пј‰ зЋ‹ж…§еі°пј€е±±иҐїпј‰ еђґе…¶ж�Ћпј€еЊ—дє¬пј‰ жќЁгЂЂе…µпј€ж±џи‹Џпј‰ е®‹жІ»иїњпј€й‡Ќеє†пј‰ зЋ‹е»єе®‰пј€жµ™ж±џпј‰ еђґд№¦жћ—пј€е№їдёњпј‰ жќЁж€ђж�Ћпј€й‡Ќеє†пј‰ и‹ЏгЂЂж™ћпј€ж№–еЊ—пј‰ зЋ‹еђ‰ж€ђпј€е±±дёњпј‰ еђґеђЊжћњпј€е№їдёњпј‰ жќЁжќ°ељпј€еЊ—дє¬пј‰ 098 CIT 2012 www.citmd.com е¤§дјљз»„з»‡з»“жћ„ жќЁиї›е€љпј€еЊ—дє¬пј‰ е–»гЂЂеЌ“пј€дє‘еЌ—пј‰ еј еЌ«жіЅпј€з”�и‚ѓпј‰ й‚№е»єе€љпј€ж±џи‹Џпј‰ жќЁй’§е›Ѕпј€ж№–еЊ—пј‰ иўЃгЂЂжґЄпј€ж№–еЌ—пј‰ еј зЋ‰йЎєпј€й™•иҐїпј‰ й‚№й�іж�Ґпј€еЊ—дє¬пј‰ жќЁеі»йќ’пј€е№їдёњпј‰ иўЃж™‹йќ’пј€еЊ—дє¬пј‰ еј гЂЂй’Іпј€з”�и‚ѓпј‰ й‚№и‹±еЌЋпј€еЊ—дє¬пј‰ жќЁдёЅйњћпј€дє‘еЌ—пј‰ иўЃгЂЂе‹‡пј€е№їдёњпј‰ еј ж™єдјџпј€е№їдёњпј‰ жќЁгЂЂж�Ћпј€еЊ—дє¬пј‰ иўЃзҐ–иґ»пј€й™•иҐїпј‰ иµµе…Ёж�Ћпј€еЊ—дє¬пј‰ жЉ¤еЈ«дёЋжЉЂжњЇдєєе‘�дё»еёе›ў жќЁгЂЂиђЌпј€еђ‰жћ—пј‰ ж›ѕе’Њжќѕпј€ж№–еЊ—пј‰ иµµдё–еЌЋпј€еЊ—дє¬пј‰ е†ЇгЂЂ зҐєпј€дёЉжµ·пј‰ жќЁе№ізЏЌпј€е№їдёњпј‰ ж›ѕзЋ‰жќ°пј€еЊ—дє¬пј‰ иµµд»™е…€пј€дёЉжµ·пј‰ иѕње°ЏиЉіпј€еЊ—дє¬пј‰ жќЁиѓње€©пј€еЊ—дє¬пј‰ ж›ѕгЂЂж™єпј€е››е·ќпј‰ иµµе…ґиѓњпј€е†…и’™еЏ¤пј‰ дѕЇжЎ‚еЌЋпј€еЊ—дє¬пј‰ еј гЂЂж–Њпј€е№їдёњпј‰ иµµиїЋж–°пј€еЊ—дє¬пј‰ й‡‘е»єиЉ¬пј€жµ™ж±џпј‰ еј е¤§дёњпј€дёЉжµ·пј‰ иµµж°ёејєпј€еЊ—дє¬пј‰ й�љгЂЂйќ™пј€ж±џи‹Џпј‰ еј д»ЈеЇЊпј€дёЉжµ·пј‰ йѓ‘й‡‘е€љпј€еЊ—дє¬пј‰ Kim Chanпј€йџ©е›Ѕпј‰ еј й«�ж�џпј€е№їдёњпј‰ йѓ‘и‰ЇиЌЈпј€жµ™ж±џпј‰ жќЋгЂЂиЏІпј€иѕЅе®Ѓпј‰ еј ж€€е†›пј€еЊ—дє¬пј‰ йѓ‘ејєиЌЄпј€й™•иҐїпј‰ жќЋжѓ зЏ пј€еЊ—дє¬пј‰ еј жµ·жѕ„пј€еЊ—дє¬пј‰ йѓ‘гЂЂжќЁпј€еђ‰жћ—пј‰ жќЋгЂЂжќ°пј€еЊ—дє¬пј‰ еј е»єе†›пј€еЊ—дє¬пј‰ й’џе›Ѕејєпј€е№їиҐїпј‰ жќЋгЂЂиЋ‰пј€ж–°з–†пј‰ еј еЉІжћ—пј€ж№–еЊ—пј‰ е‘Ёж–Ње…Ёпј€жµ™ж±џпј‰ жќЋж·‘иЌЈпј€жІіеЊ—пј‰ еј гЂЂе†›пј€й™•иҐїпј‰ е‘Ёз‚іе‡¤пј€е®‰еѕЅпј‰ жќЋжњќиѕ‰пј€еЊ—дє¬пј‰ еј гЂЂеі»пј€еЊ—дє¬пј‰ е‘Ёиѕѕж–°пј€дёЉжµ·пј‰ жўЃгЂЂж¶›пј€еЊ—дє¬пј‰ еј дїЉжќ°пј€ж±џи‹Џпј‰ е‘Ёз«‹еђ›пј€й»‘йѕ™ж±џпј‰ е€�гЂЂжґЄпј€е¤©жґҐпј‰ еј гЂЂж�Ћпј€иѕЅе®Ѓпј‰ е‘ЁиѓњеЌЋпј€ж№–еЌ—пј‰ е€�гЂЂйќ™пј€еЊ—дє¬пј‰ еј ж•Џе·ћпј€е№їдёњпј‰ е‘Ёж™“иЉіпј€е››е·ќпј‰ е€�гЂЂеђ›пј€еЊ—дє¬пј‰ еј гЂЂжІ›пј€еЊ—дє¬пј‰ е‘Ёж—ж™Ёпј€иѕЅе®Ѓпј‰ е€�гЂЂз„±пј€еЊ—дє¬пј‰ еј гЂЂиђЌпј€еЊ—дє¬пј‰ е‘Ёйў–зЋІпј€е№їдёњпј‰ й‚±жњ€зєўпј€еЊ—дє¬пј‰ еј гЂЂеҐ‡пј€дёЉжµ·пј‰ е‘ЁзЋ‰жќ°пј€еЊ—дє¬пј‰ Shim Myeong-Boпј€йџ©е›Ѕпј‰ еј з‘ћеІ©пј€дёЉжµ·пј‰ жњ±е›Ѕи‹±пј€ж№–еЊ—пј‰ з«Ґзґ жў…пј€еЊ—дє¬пј‰ еј гЂЂжѕЌпј€еЊ—дє¬пј‰ жњ±е»єеЌЋпј€жµ™ж±џпј‰ Tsai Pei-Lanпј€дёе›ЅеЏ°ж№ѕпј‰ ж®·и·ѓиѕ‰пј€й‡Ќеє†пј‰ еј ж ‘жћ—пј€еЊ—дє¬пј‰ жњ±йІњй�іпј€иѕЅе®Ѓпј‰ зЋ‹ж™“з‡•пј€й™•иҐїпј‰ е°¤еЈ«жќ°пј€еЊ—дє¬пј‰ еј жѕЌз”°пј€еЊ—дє¬пј‰ жњ±ж°ёе®Џпј€е№їдёњпј‰ зЋ‹гЂЂи‹±пј€ж№–еЊ—пј‰ дєЋгЂЂжіўпј€й»‘йѕ™ж±џпј‰ еј жЉ’ж‰¬пј€еЊ—дє¬пј‰ еє„з™ѕжєЄпј€еЊ—дє¬пј‰ и°ўгЂЂиґћпј€еЊ—дє¬пј‰ дєЋгЂЂжіўпј€иѕЅе®Ѓпј‰ еј дјџеЌЋпј€дє‘еЌ—пј‰ еє„е°‘дјџпј€дёЉжµ·пј‰ и®ёгЂЂдє®пј€еЊ—дє¬пј‰ жќЁж ‘жЈ®пј€й»‘йѕ™ж±џпј‰ жќЁе¤©е’Њпј€иґµе·ћпј‰ жќЁе¤©дј¦пј€ж№–еЌ—пј‰ жќЁеєж ‘пј€еЊ—дє¬пј‰ жќЁеђ‘е†›пј€ж±џи‹Џпј‰ жќЁж–°ж�Ґпј€еЊ—дє¬пј‰ жќЁе»¶е®—пј€иѕЅе®Ѓпј‰ жќЁж°ёеЃҐпј€е››е·ќпј‰ жќЁи·ѓиї›пј€еЊ—дє¬пј‰ жќЁеї—еЃҐпј€ж±џи‹Џпј‰ жќЁеї—ж�Ћпј€е±±иҐїпј‰ е§љгЂЂж°‘пј€еЊ—дє¬пј‰ е§љгЂЂз„°пј€еЊ—дє¬пј‰ е§љжњ±еЌЋпј€е¤©жґҐпј‰ еЏ¶гЂЂйЈћпј€ж±џи‹Џпј‰ еЏ¶зєўеЌЋпј€жµ™ж±џпј‰ еЏ¶гЂЂе№іпј€еЊ—дє¬пј‰ ж�“еІ‚е»єпј€й‡Ќеє†пј‰ е°№иЌЈз§Ђпј€еЊ—дє¬пј‰ 099 CIT 2012 www.citmd.com е¤§дјљз»„з»‡з»“жћ„ жќЁзЋ‰зЏЌпј€еЊ—дє¬пј‰ иЌЇзґ жЇ“пј€з”�и‚ѓпј‰ еІіз»§еЌЋпј€е¤©жґҐпј‰ еј зєўжў…пј€жІіеЌ—пј‰ иµµгЂЂйњћпј€еЊ—дє¬пј‰ з§�д№¦е¤„ й™€гЂЂе‡Ї е‰Їз§�д№¦й•ї ж€ґдёЅеі° й«�гЂЂе¦Ќ е†Їеї—е‹‡ жќЋжё…ж•Џ жњ±з‡•е«Ј 100 CIT 2012 www.citmd.com дјљи®®дїЎжЃЇ 1. дјљи®®ж—¶й—ґ 2012е№ґ3жњ€15-18ж—Ґ 2. дјљи®®ењ°з‚№ е›Ѕе®¶дјљи®®дёеїѓ 7. з”Ёй¤ђ жњ¬ж¬Ўдјљи®®иї›й¤ђењ°з‚№е¦‚дё‹пјЊиЇ·е‡й¤ђе€ёе°±й¤ђгЂ‚ ж—©й¤ђ еЌ€й¤ђ ж™љй¤ђ е›Ѕе®¶дјљи®®дёеїѓдє” еЏ·е±•еЋ…и‡ЄеЉ©й¤ђ е›Ѕе®¶дјљи®®дёеїѓдє” еЏ·е±•еЋ…и‡ЄеЉ©й¤ђ е›Ѕе®¶дјљи®®дёеїѓеЌ€ й¤ђз›’ е›Ѕе®¶дјљи®®дёеїѓдє” еЏ·е±•еЋ…и‡ЄеЉ©й¤ђ еЊ—дє¬её‚жњќй�іеЊєе¤©иѕ°дёњи·Ї7еЏ· й‚®зј–пјљ100105 з”µиЇќпјљ010- 8437 2008 3жњ€14ж—Ґ 3. д»ЈиЎЁжЉҐе€° д»ЈиЎЁж‰ЂењЁй…’еє—з”Ёй¤ђ жіЁе†ЊеЏ°ејЂж”ѕж—¶й—ґ 3жњ€15ж—Ґ еЏ‚еЉ ж—©й—ґдјљзљ„д»Ј иЎЁеЏЇењЁдјљењєе†…з”Ё ж—©й¤ђ 08:00AM вЂ“ 06:00 PM д»ЈиЎЁж‰ЂењЁй…’еє—з”Ёй¤ђ 08:00AM вЂ“ 12:00 PM 3жњ€16ж—Ґ еЏ‚еЉ ж—©й—ґдјљзљ„д»Ј иЎЁеЏЇењЁдјљењєе†…з”Ё ж—©й¤ђ 3жњ€17ж—Ґ еЏ‚еЉ ж—©й—ґдјљзљ„д»Ј иЎЁеЏЇењЁдјљењєе†…з”Ё ж—©й¤ђ 3жњ€18ж—Ґ еЏ‚еЉ ж—©й—ґдјљзљ„д»Ј иЎЁеЏЇењЁдјљењєе†…з”Ё ж—©й¤ђ 2012е№ґ3жњ€14ж—Ґ 08:00AM вЂ“ 10:00 PM 2012е№ґ3жњ€15ж—Ґ 07:30AM вЂ“ 08:00 PM 2012е№ґ3жњ€16-17ж—Ґ 2012е№ґ3жњ€18ж—Ґ зЋ°ењєжіЁе†Њиґ№ж ‡е‡†пјљRMB1300.00 е›Ѕе®¶дјљи®®дёеїѓеЌ€ й¤ђз›’ е›Ѕе›Ѕе®¶дјљи®®дёеїѓ е››е±‚е¤§дјље ‚ ж¬ўиїЋж™ље®ґ д»ЈиЎЁж‰ЂењЁй…’еє—з”Ёй¤ђ 4. дјљи®®иЇиЁЂ CIT2012дјљи®®жЈејЏиЇиЁЂдёєи‹±гЂЃдёеЏЊиЇпјЊдјљи®®жњџй—ґпјЊ е‡Ўж�ЇењЁй—ЁеЏЈжњ‰ж”ѕзЅ®пј€еђЊеЈ°дј иЇ‘ж ‡и®° и§Ѓе·¦е›ѕпј‰зљ„дјљ ењєпјЊиЎЁз¤єиЇҐдјљењєдјљжЏђдѕ›дё“дёљзє§зљ„зЋ°ењєи‹±дёеђЊеЈ°зї» е›Ѕе®¶дјљи®®дёеїѓеЌ€ й¤ђз›’ е›Ѕе®¶дјљи®®дёеїѓдє” еЏ·е±•еЋ…и‡ЄеЉ©й¤ђ д»ЈиЎЁж‰ЂењЁй…’еє—з”Ёй¤ђ иЇ‘пјЊе±Љж—¶иЇ·ењЁдјљи®®еЋ…й—ЁеЏЈеЉћзђ†еђЊдј иЂіжњєз§џз”Ёж‰‹з»гЂ‚ е›Ѕе®¶дјљи®®дёеїѓдє” еЏ·е±•еЋ…и‡ЄеЉ©й¤ђ 5. д»ЈиЎЁж ‡иЇ† иѓёеЌЎж�ЇеЏ‚дјљд»ЈиЎЁзљ„ж ‡иЇ†гЂ‚иЇ·ењЁеЏ‚еЉ дјљи®®жґ»еЉЁе’ЊдЅїз”ЁиЊ¶з‚№ж—¶дЅ©ж€ґ иѓёеЌЎгЂ‚жІЎжњ‰дЅ©её¦иѓёеЌЎзљ„д»ЈиЎЁе°†ж— жі•иї›е…Ґдјљењєеђ¬дјљгЂ‚ 8. е±•и§€ жњ¬ж¬Ўдјљи®®жњџй—ґеђЊж—¶дёѕиЎЊеїѓи„Џд»‹е…Ґз›ёе…іеЊ»иЌЇе™Ёжў°з‰ж–№йќўзљ„е±•и§€гЂ‚ дЅ©ж€ґзєўи‰ІиѓёеЌЎзљ„дёєдјљи®®дё»еёе›ўж€ђе‘� дЅ©ж€ґи“ќи‰ІиѓёеЌЎзљ„дёєдјљи®®жЈејЏд»ЈиЎЁ е±•и§€ењ°з‚№пјљ е›Ѕе®¶дјљи®®дёеїѓдёЂе±‚е®ґдјљеЋ…A+B+C е±•и§€ж—¶й—ґпјљ 3жњ€15ж—Ґ 3жњ€16-17ж—Ґ дЅ©ж€ґз»їи‰ІиѓёеЌЎзљ„дёєеЏ‚е±•е…¬еЏёд»ЈиЎЁ дЅ©ж€ґй»„и‰ІиѓёеЌЎзљ„дёєдјљи®®е·ҐдЅњдєєе‘�гЂ‚ 14:00-18:00 09:00-17:00 9. дјљи®®й‡Ќи¦Ѓжґ»еЉЁе®‰жЋ’ 6. иЊ¶ж‡ ејЂе№•ејЏеЏЉе…ЁдЅ“е¤§дјљ е¤§дјље°†ењЁдјљи®®жњџй—ґдёЉеЌ€10:15-10:45е’Њдё‹еЌ€15:45-16:15ењЁе›Ѕе®¶дјљ ењ° з‚№пјљеЊ—дє¬е›Ѕе®¶дјљи®®дёеїѓе››е±‚е¤§дјље ‚AеЊє и®®дёеїѓдё‰е±‚е¤§еЋ…жЏђдѕ›иЊ¶ж‡гЂ‚3жњ€16ж—ҐдёЉеЌ€10:15-10:45пјЊењЁе›Ѕе®¶дјљ ж—¶ й—ґпјљ2012е№ґ3жњ€16ж—Ґ 8:00 AM-12:30 PM и®®дёеїѓе››е±‚е¤§еЋ…жЏђдѕ›иЊ¶ж‡гЂ‚ жіЁж„Џдє‹йЎ№пјљеЋ…е†…дёЌеѕ—еђёзѓџ ж¬ўиїЋж™ље®ґ ењ°з‚№пјљеЊ—дє¬е›Ѕе®¶дјљи®®дёеїѓе››е±‚е¤§дјље ‚ ж—¶й—ґпјљ2012е№ґ3жњ€16ж—Ґ 6:30 PM-8:30 PM жіЁж„Џдє‹йЎ№пјљиЇ·е‡иЇ·жџ¬е…ҐењєпјЊеЋ…е†…дёЌеѕ—еђёзѓџ 101 CIT 2012 www.citmd.com дјљи®®дїЎжЃЇ 10пјЋе¦жњЇдє¤жµЃ 13. CIT On-demandжњЌеЉЎеЊє/CITењЁзєїпјЊд»Ће®№еЏ‚дјље†ЌдёЌвЂње€†иє«д№ЏжњЇвЂќ AпјЋе¦жњЇдє¤жµЃж—ҐзЁ‹ йљЏзќЂCITдјљи®®и§„жЁЎзљ„дёЌж–ж‰©е¤§пјЊе¦жњЇдјљењєзљ„дёЌж–еўће¤љпјЊењЁеђЊдёЂж—¶ е¦жњЇдє¤жµЃе®Ње…ЁжЊ‰е¤§дјљжњЂз»€ж—ҐзЁ‹е†Ње®‰жЋ’иї›иЎЊпјЊиЇ·еЏ‘иЁЂзљ„д»ЈиЎЁжіЁж„Џ й—ґпјЊд»ЈиЎЁйѓЅдјљйќўдёґеЏЄиѓЅеЏ‚еЉ дёЂдёЄдјљењєиЂЊй”™иї‡е…¶д»–дјљењєзІѕеЅ©ж—ҐзЁ‹ и‡Єе·±зљ„еЏ‘иЁЂж—Ґжњџе’Њж—¶й—ґе№¶жЏђе‰ЌдЅњеҐЅе‡†е¤‡гЂ‚ зљ„е›°йљѕпјЊдёєдє†ж›ґеҐЅзљ„и§Је†іиї™дёЂй—®йў�пјЊCIT2012е¤§дјље°†й¦–ж¬ЎеђЇз”Ёж—Ґ зЁ‹е®ћж—¶и§†йў‘е›ћж”ѕзі»з»џпјЊж—ЁењЁеё®еЉ©д»ЈиЎЁж›ґеЉ е…Ёйќўзљ„дє†и§ЈењЁCITеђ„дјљ BпјЋе№»зЃЇз‰‡ ењєеЏ‘еёѓзљ„еђ„йЎ№жњЂж–°е¦жњЇе†…е®№пјЊд»ЋиЂЊиѕѕе€°еЏ‚дјље¦д№ зљ„з›®зљ„гЂ‚ жњ¬ж¬Ўе¤§дјље¤‡жњ‰иЇ•з‰‡е®¤пј€е›Ѕе®¶дјљи®®дёеїѓдёЂе±‚е¤§еЋ…пј‰пјЊиЇ·еЏ‘иЁЂзљ„д»Ј иЎЁењЁеЏ‘иЁЂе‰Ќи‡іе°‘дё‰е°Џж—¶еЋ»иЇ•з‰‡е®¤йЂ’дє¤ж‚Ёзљ„е№»зЃЇз‰‡пј€ж€–е…‰з›�гЂЃU д»Ћ2012е№ґ3жњ€16ж—ҐејЂе§‹пјЊд»ЈиЎЁеЏЇењЁCIT On-demandжњЌеЉЎеЊєйЂљиї‡з™» з›�гЂЃиЅЇз›�пј‰иї›иЎЊиЇ•з‰‡пј€дёЉеЌ€еЏ‘иЁЂзљ„иЇ·дєЋе‰ЌдёЂе¤©дё‹еЌ€иЇ•з‰‡пј‰гЂ‚ еЅ•зЅ‘з«™www.citondemand.org иѕ“е…Ґз™»еЅ•еЌЎдёЉзљ„еЇ†з ЃжќҐжµЏи§€CITе‰Ќ дёЂе¤©зљ„ж‰Ђжњ‰е¦жњЇдјљењєзљ„е®ћж—¶ж—ҐзЁ‹е›ћж”ѕгЂ‚д»ЈиЎЁеЏЇд»Ґжњ‰йЂ‰ж‹©зљ„жµЏи§€ CпјЋиЇ•з‰‡е®¤ејЂж”ѕж—¶й—ґ е› дёєж—¶й—ґе…ізі»й”™иї‡зљ„зІѕеЅ©ж—ҐзЁ‹гЂ‚ 3жњ€14ж—Ґ 4:00 PM вЂ“ 6:00 PM 3жњ€15ж—Ґ 7:00 AM вЂ“ 6.00 PM 3жњ€16ж—Ґ 7:00 AM вЂ“ 6:00 PM 3жњ€17ж—Ґ 7:00 AM вЂ“ 6:00 PM 3жњ€18ж—Ґ 7:00 AM вЂ“ 11:00 PM з”µиЇќ: (010) 84379018 жіЁж„Џпјљ 1. д»ЈиЎЁж‰‹жЊЃзљ„з™»еЅ•еЌЎеќ‡й…Ќе¤‡з™»еЅ•еЇ†з ЃпјЊеЏЇйљЏж—¶з™»еЅ• www.citondemand.orgжџҐзњ‹ж—ҐзЁ‹и§†йў‘е›ћж”ѕпј€е№¶дёЌеЏЄй™ђдєЋењЁдјљи®®жњџ й—ґпј‰пјЊдЅ†ж�ЇиЇҐз™»еЅ•еЌЎдёЂж—¦дЅїз”ЁпјЊеЏЄиѓЅењЁ24е°Џж—¶е†…е…Ќиґ№жµЏи§€CITж—Ґ зЁ‹и§†йў‘е®ћж—¶е›ћж”ѕпјЊи¶…иї‡24е°Џж—¶пјЊз™»еЅ•з ЃеЌідјље¤±ж•€пјЊд»ЈиЎЁе¦‚жћњиї� жѓіз»§з»жµЏи§€пјЊйњЂи¦Ѓж”Їд»�дёЂе®љзљ„иґ№з”ЁжќҐиЋ·еЏ–ж–°зљ„з™»еЅ•еЇ†з ЃгЂ‚ DпјЋе…Ќиґ№дёЉзЅ‘е’ЊWIFI 2. CITзљ„е®ћж—¶ж—ҐзЁ‹е›ћж”ѕе°†дјљењЁwww.citondemand.orgзЅ‘з«™дїќз•™дёЂ е¤§дјљењЁдёЂе±‚е±•еЋ…и®ѕз«‹дє†е…Ќиґ№дёЉзЅ‘еЊєпјЊж¬ўиїЋеЏ‚дјљд»ЈиЎЁдЅїз”ЁгЂ‚еђЊ ж—¶пјЊењЁе›Ѕе®¶дјљи®®дёеїѓзљ„дёЂе±‚гЂЃдё‰е±‚е’Ње››е±‚жЏђдѕ›е…Ќиґ№WIFIзЅ‘з»њгЂ‚ 11. дё»еёе›ўдј‘жЃЇе®¤ е№ґзљ„ж—¶й—ґпјЊд»ЈиЎЁйЂљиї‡д»�иґ№иЂЊиЋ·еЏ–зљ„еЇ†з ЃењЁдё‹дёЂе±ЉCITдјљи®®еЏ¬ејЂд№‹ е‰Ќеќ‡еЏЇд»ҐйљЏж—¶з™»еЅ•иЇҐзЅ‘з«™жµЏи§€гЂ‚ 3. жњ‰йњЂи¦Ѓзљ„д»ЈиЎЁпјЊеЏЇе‰ЌеѕЂе¤§дјљжіЁе†ЊеЏ°зљ„M EventsжњЌеЉЎеЏ°е’ЁиЇўз›ёе…і дё»еёе›ўдј‘жЃЇе®¤дЅЌдєЋе›Ѕе®¶дјљи®®дёеїѓдёЂе±‚е¤§еЋ…пјЊеЇ№е¤§дјљдё»еёе›ўж€ђе‘� д»�иґ№жѓ…е†µгЂ‚ е’Њз‰№й‚Ђе�‰е®ѕејЂж”ѕгЂ‚е№¶е…Ќиґ№жЏђдѕ›иЊ¶ж°ґгЂЃе’–е•ЎгЂЃз”њз‚№еЏЉдёЉзЅ‘жњЌеЉЎгЂ‚ 12. еЈЃжЉҐдє¤жµЃеЊє CIT2012е¤§дјљеЈЃжЉҐдє¤жµЃеЊєи®ѕењЁе›Ѕе®¶дјљи®®дёеїѓдёЂе±‚зљ„вЂње¦жњЇе±•и§€вЂќ е±•еЋ…е†…пјЊеЈЃжЉҐзљ„е±•е‡єж—¶й—ґе¦‚дё‹пјљ 2012е№ґ3жњ€15ж—Ґ 14:00-18:00 2012е№ґ3жњ€16-17ж—Ґ 09:00-17:00 3жњ€15ж—Ґ14:00-18:00ж�Їе¤§дјљдё“й—Ёи®ѕз«‹зљ„еЈЃжЉҐй›†дёи®Ёи®єж—¶й—ґпјЊиї™жњџ й—ґпјЊеЏ‚и§‚еЈЃжЉҐзљ„д»ЈиЎЁжњ‰жњєдјљдёЋеЈЃжЉҐдЅњиЂ…йќўеЇ№йќўдє¤жµЃгЂ‚ 14. иї”зЁ‹зҐЁйў„е®љ е¤§дјље°†ењЁжЉҐе€°зЋ°ењєдёєд»ЈиЎЁжЏђдѕ›еЉћзђ†жњєзҐЁе’ЊзЃ«иЅ¦зҐЁзљ„д»Јзђ†е•†зљ„иЃ” зі»ж–№ејЏпјЊиЇ·йњЂи¦Ѓзљ„д»ЈиЎЁдєЋжЉҐе€°еЅ“ж—Ґе€°е¤§дјљжіЁе†ЊеЏ°е’ЁиЇўгЂ‚ 102 103 2012е№ґ 3жњ€16ж—Ґ ж�џжњџдє” 2012е№ґ 3жњ€15ж—Ґ ж�џжњџе›› е¤љеЉџиѓЅA еЋ… 30 : 09 0 :0 10 AM 0 :3 10 AM 0 :0 11 AM 0 :3 11 з¬¬е››е±ЉдёґеєЉз ”з©¶дё“йў�з ”и®Ёеі°дјљ AM AM 0 :0 12 PM 0 :3 12 0 :0 01 PM 0 :3 01 PM еЌ€й—ґеЌ«ж�џдјљ-еѕ®е€› PM PM 0 :3 02 PM 0 :0 03 PM PM 04 :0 0 PM д»‹е…Ґе€›ж–°еі°дјљ 0 :3 03 04 :3 0 PM 05 :0 0 иЅ¬ж’5: еЊ—дє¬ (з»“жћ„) CITе®ћд№ дёеїѓ дё‰е±‚ PM PCR at CIT е† и„‰д»‹е…Ґе®ћз”Ёж•™зЁ‹з¬¬дёЂйѓЁе€†: жЂЋд№€еЃљпјџ еЌ€й—ґеЌ«ж�џдјљ-еђ‰еЁЃ еЌ€й—ґеЌ«ж�џдјљ-иµ›иЇє е¤љеЉџиѓЅB еЋ… е¤љеЉџиѓЅC еЋ… STж®µжЉ¬й«�ећ‹еїѓи‚Њжў—ж»еі°дјљ (AICTдёЋLUMENеЌЏеЉћ) еїѓеѕ‹е¤±еёё еЌ€й—ґеЌ«ж�џдјљ-й‡‘з‘ће‡Їе€© еЌ€й—ґеЌ«ж�џдјљ-зѕЋж•¦еЉ› е¤§её€и®Іеє§ е¤§её€и®Іеє§ 311A е®¤ 311B е®¤ е±•и§€ CITе®ћд№ дёеїѓ дё‰е±‚ иЌЇз‰©е¦з ”и®Ёдјљ-й�їж–Їе€©еє· еџєзЎЂдёЋиЌЇз‰© з»“жћ„жЂ§еїѓи„Џз—… еЌ€й—ґеЌ«ж�џдјљ-ж·±ењіе…€еЃҐ е¤§её€и®Іеє§ 310 е®¤ иЌЇз‰©е¦з ”и®Ёдјљ-иѕ‰з‘ћ еїѓиЎЂз®Ўз–ѕз—…еђ€е№¶зі–е°їз—…ж‚ЈиЂ…зљ„з»јеђ€з®Ўзђ† еЌ€й—ґеЌ«ж�џдјљ-ејєз”џ еЌ€й—ґеЌ«ж�џдјљ-й›·з§‘еЊ»з–— е¤§её€и®Іеє§ 308 е®¤ 309A е®¤ FFRеџ№и®иЇѕзЁ‹ е·¦дё»е№Іе’Ње€†еЏ‰з—…еЏ�еі°дјљ еЌ€й—ґеЌ«ж�џдјљ-ж�џеі°/Asahi е¤§её€и®Іеє§ 307AB е®¤ 309B е®¤ е¤–е‘Ёе’Њи…”е†…иЎЂз®ЎжІ»з–—: NCVH at CIT еЌ€й—ґеЌ«ж�џдјљ-GE еЌ€й—ґеЌ«ж�џдјљ-еЌљиЋ±з§‘дїЎи°Љ е¤§её€и®Іеє§ 306AB е®¤ дёЂе±‚ :0 0 PM 06 :3 з”џз‰©еЏЇеђёж”¶ж”Їжћ¶з ”и®Ёеі°дјљжњЂж–°дёґеєЉиЇ•йЄЊдёЋз‰№и‰Із ”з©¶й¦–ж¬Ўе…¬еёѓ(дёЂ) иЅ¬ж’6: еЊ—дє¬ иЅ¬ж’7: еЏ°еЊ— еїѓеѕ‹е¤±еёё еїѓеЇјз®ЎжњЇеџєзЎЂ 06 иЅ¬ж’8: еЊ—дє¬ иЌЇз‰©е¦з ”и®Ёдјљ-ж‹њиЂі дёж¬§д»‹е…Ґеїѓи„Џз—…е¦зѓз‚№и®єеќ› иЌЇз‰©е¦з ”и®Ёдјљ-иµ›иЇєиЏІе®‰дё‡з‰№ CITжњЂе…·ж•™и‚Іж„Џд№‰з—…дѕ‹з«ћиµ› е·¦дё»е№Іе’Ње€†еЏ‰з—…еЏ�еі°дјљ еЌ€й—ґеЌ«ж�џдјљ-жіўеЈ«йЎїз§‘е¦ иЅ¬ж’4: еЊ—дє¬ (е¤–е‘Ё) ејЂе№•ејЏе’Ње…ЁдЅ“е¤§дјљ е±•и§€ дёЂе±‚ еЌ€й—ґеЌ«ж�џдјљ-д№ђж™® еЌ€й—ґеЌ«ж�џдјљ-й›…еџ№еїѓиЎЂз®Ў з—…дѕ‹ж—©й¤ђдјљ зЋ°д»Јеїѓз”µе›ѕе¦ еїѓеЇјз®ЎжњЇеџєзЎЂ з—…дѕ‹ж—©й¤ђдјљ 311A е®¤ 311B е®¤ CITжњЂе…·ж•™и‚Іж„Џд№‰з—…дѕ‹з«ћиµ› HKSTENT at CIT еЌ€й—ґеЌ«ж�џдјљ-иҐїй—Ёеђ жЉҐе‘ЉеЋ… 0 OCTеџ№и®иЇѕзЁ‹з¬¬дёЂйѓЁе€† :3 CITйќ’е№ґеЊ»её€з ”з©¶еҐ–е†іиµ› / PCIжЉЂжњЇдёЋз–—ж•€з ”з©¶дё“ењє (дјљењєAе’ЊB) еЌ€й—ґеЌ«ж�џдјљ-GE 05 и®єж–‡дє¤жµЃ (дјљењєAе’ЊB) еїѓиЎЂз®Ўж— е€›еЅ±еѓЏз ”и®Ёдјљ е¤љеЉџиѓЅA еЋ… PM IVUSеџ№и®иЇѕзЁ‹з¬¬дёЂйѓЁе€† з—…дѕ‹ж—©й¤ђдјљ е¤§дјље ‚A еЊє 0 :0 02 з¬¬дєЊе±Љдёж—ҐеЏ‹еҐЅд»‹е…ҐжЂ§еїѓи„Џз—…е¦и®єеќ› (иЅ¬ж’1: Toyohashi, 8:30 am-10:00 am; иЅ¬ж’2: дёЉжµ·, 11:45 am-1:15 pm; иЅ¬ж’3: еЊ—дє¬, 2:45 pm-4:45 pm) AM SOLACI at CIT 0 :0 09 з—…дѕ‹ж—©й¤ђдјљ AM 310 е®¤ 0 :3 08 з—…дѕ‹ж—©й¤ђдјљ AM 309A е®¤ 0 :0 08 309B е®¤ з—…дѕ‹ж—©й¤ђдјљ AM 308 е®¤ 30 : 07 з—…дѕ‹ж—©й¤ђдјљ AM 307AB е®¤ 306AB е®¤ е¤љеЉџиѓЅC еЋ… е¤љеЉџиѓЅB еЋ… 0 :0 07 0 07 :0 0 PM ж¬ўиїЋж™ље®ґ PM CIT 2012 www.citmd.com ж—ҐзЁ‹дёЂи§€иЎЁ 2012е№ґ 3жњ€18ж—Ґ ж�џжњџж—Ґ 2012е№ґ 3жњ€17ж—Ґ ж�џжњџе… AM 08 0 :3 AM 09 0 :0 AM 0 :3 09 AM 0 :0 10 AM 10 0 :3 AM PM 0 :3 12 PM 0 :0 01 PM 0 :3 01 PM 0 :0 02 PM 0 :3 02 PM 0 :0 03 PM PM 0 :3 04 иЅ¬ж’14: еЊ—дє¬ 0 :0 04 з—…дѕ‹и®Ёи®є (з—…дѕ‹еѕЃй›†) з—…дѕ‹и®Ёи®є (з—…дѕ‹еѕЃй›†) з—…дѕ‹ж—©й¤ђдјљ з—…дѕ‹ж—©й¤ђдјљ з—…дѕ‹ж—©й¤ђдјљ 308 е®¤ 309A е®¤ 309B е®¤ з—…дѕ‹и®Ёи®є (з—…дѕ‹еѕЃй›†) еїѓеѕ‹е¤±еёё з—…дѕ‹ж—©й¤ђдјљ з—…дѕ‹ж—©й¤ђдјљ з—…дѕ‹ж—©й¤ђдјљ 310 е®¤ 311A е®¤ 311B е®¤ з»“жћ„жЂ§еїѓи„Џз—… иЌЇз‰©е¦з ”и®Ёдјљ-ж–Ѕз»ґй›… дё»еЉЁи„‰з�¤д»‹е…Ґи®єеќ› IVUSеџ№и®иЇѕзЁ‹з¬¬дєЊйѓЁе€† з—…дѕ‹ж—©й¤ђдјљ 307AB е®¤ е† и„‰д»‹е…Ґе®ћз”Ёж•™зЁ‹з¬¬е››йѓЁе€†: ж…ўжЂ§е®Ње…Ёй—еЎћз—…еЏ� з—…дѕ‹ж—©й¤ђдјљ е¤љеЉџиѓЅC еЋ… 306AB е®¤ з¬¬е››е±Ље† и„‰д»‹е…ҐжІ»з–—вЂњзІѕйЂ‰вЂќе№¶еЏ‘з—‡и®єеќ› GAP-CCBC at CIT: жЊ‡еЌ—е’Ње®ћи·µ - дёґеєЉз—…дѕ‹и®Ёи®єдјљ й—е№•ејЏ дё‰е±‚ е¤љеЉџиѓЅA еЋ… е±•и§€ CITе®ћд№ дёеїѓ дёЂе±‚ е¤љеЉџиѓЅB еЋ… з¬¬дёѓе±ЉжЉ¤еЈ«е’ЊжЉЂжњЇдєєе‘�з ”и®Ёдјљ еЌ€й—ґеЌ«ж�џдјљ-д№ђж™® еїѓеѕ‹е¤±еёё жЉҐе‘ЉеЋ… еЌ€й—ґеЌ«ж�џдјљ-еѕ®е€› иЌЇз‰©жґ—и„±ж”Їжћ¶еі°дјљ ж—©й¤ђдјљ-еђ‰еЁЃ ж—©й¤ђдјљ-зѕЋж•¦еЉ› еЌ€й—ґеЌ«ж�џдјљ-з€±еѕ·еЌЋ еџєзЎЂдёЋиЌЇз‰© з»“жћ„жЂ§еїѓи„Џз—… 311A е®¤ з—…дѕ‹ж—©й¤ђдјљ 311B е®¤ 310 е®¤ 309B е®¤ еЌ€й—ґеЌ«ж�џ-ењЈзЉ№иѕѕ 0 :3 05 иЌЇз‰©е¦з ”и®Ёдјљ - дїЎз«‹жі° еїѓеѕ‹е¤±еёё иЌЇз‰©жґ—и„±ж”Їжћ¶еі°дјљ з»“жћ„жЂ§еїѓи„Џз—… (з»ЏеЇјз®Ўз“Ји†њжІ»з–—) иЌЇз‰©е¦з ”и®Ёдјљ - з¬¬дёЂдё‰е…± PM 0 :0 06 иЅ¬ж’15: еЊ—дє¬ CCC/CISC at CIT: зЄЃз ґдёґеєЉе®ћи·µзљ„е›°еўѓ - з–‘йљѕз—…дєєзљ„е¤„зђ† е·¦дё»е№Іе’Ње€†еЏ‰з—…еЏ�еі°дјљ з¬¬дё‰е±Љж—‹зЈЁжЉЂжњЇе°Џећ‹з ”и®Ёдјљ еЌ€й—ґеЌ«ж�џдјљ-ж�џеі°/Kaneka е·¦дё»е№Іе’Ње€†еЏ‰з—…еЏ�еі°дјљ з—…дѕ‹ж—©й¤ђдјљ EAPCI-EuroPCR/ESC at CIT: йќћSTж®µжЉ¬й«�жЂҐжЂ§е† и„‰з»јеђ€еѕЃ TRIдї±д№ђйѓЁ е¤–е‘Ёе’Њи…”е†…иЎЂз®ЎжІ»з–— OCTеџ№и®иЇѕзЁ‹з¬¬дєЊйѓЁе€† еЌ€й—ґеЌ«ж�џдјљ-зЃ«е±± еЌ€й—ґеЌ«ж�џдјљ-жі°е°”иЊ‚ е¤–е‘Ёе’Њи…”е†…иЎЂз®ЎжІ»з–— ж—©й¤ђдјљ-жі°е°”иЊ‚ 308 е®¤ PM з—…дѕ‹и®Ёи®є-дёЋCITе’ЊTCTе¤§её€йќўеЇ№йќў 0 :0 05 е† и„‰д»‹е…Ґе®ћз”Ёж•™зЁ‹з¬¬дё‰йѓЁе€†: ж…ўжЂ§е®Ње…Ёй—еЎћз—…еЏ� ж—©й¤ђдјљ-жіўеЈ«йЎїз§‘е¦ 309A е®¤ PM жњЂж–°дёґеєЉиЇ•йЄЊдёЋз‰№и‰Із ”з©¶й¦–ж¬Ўе…¬еёѓ(дё‰) 0 :3 03 307AB е®¤ е† и„‰д»‹е…Ґе®ћз”Ёж•™зЁ‹з¬¬дєЊйѓЁе€†: дє‰и®®з—…дѕ‹дё“ењєпјљдёєд»Ђд№€пјџдЅ•ж—¶пјџжЂЋж ·пјџ еЌ€й—ґеЌ«ж�џдјљ-ж�“з”џз§‘жЉЂ иЅ¬ж’11: еЊ—дє¬ PM 306AB е®¤ е¤љеЉџиѓЅC еЋ… 0 :0 12 иЅ¬ж’13: иҐїе®‰ AM иЅ¬ж’12: еЊ—дє¬ 0 :3 11 еЌ€й—ґеЌ«ж�џдјљ-дё‡з‘ћйЈћйёї AM Angioplasty Summit - TCTAP at CIT еЌ€й—ґеЌ«ж�џдјљ-й›…еџ№еїѓиЎЂз®Ў 0 :0 11 иЅ¬ж’10: еЊ—дє¬ 0 :0 08 жњЂж–°дёґеєЉиЇ•йЄЊдёЋз‰№и‰Із ”з©¶й¦–ж¬Ўе…¬еёѓ(дєЊ) AM CRT at CIT 0 :3 07 иЅ¬ж’9: еЊ—дє¬ AM е¤љеЉџиѓЅA еЋ… 0 :0 е¤љеЉџиѓЅB еЋ… 07 PM 0 :3 06 PM 0 :0 07 PM CIT 2012 www.citmd.com ж—ҐзЁ‹дёЂи§€иЎЁ 104 CIT 2012 www.citmd.com LIVE CASE SITES е›Ѕе®¶еїѓиЎЂз®Ўз—…дёеїѓй�ње¤–еЊ»й™ў е¤Ќж—¦е¤§е¦й™„е±ћдёе±±еЊ»й™ў жњЇиЂ…пјљж€ґе†›, зЄ¦е…‹йќћ, й«�е±•, иѓЎеҐ‰зЋЇ, и’‹й›„дє¬, ж…•жњќдјџ, й’±жќ°, й‚±жґЄ, еђґж–‡иѕ‰, еѕђд»Іи‹±, жќЁдјџе®Є, жќЁи·ѓиї›, дїћжў¦и¶Љ, еј ж€€е†›, еј жІ›, иµµдє¬жћ— з‰№й‚ЂжњЇиЂ…пјљYaron Almagor, Jacek Bialkowski, Maurice Buchbinder, Antonio Colombo, Osamu Katoh, William L. Lombardi, Gary S. Mintz, Jeffrey W. Moses, Masahiko Ochiai, Seung-Jung Park, Raghotham R. Patlola, Shigeru Saito, Horst Sievert, Satoru Sumitsuji, Malgorzata Szkutnik, Etsuo Tsuchikane, Yuichi Ujiie, Craig M. Walker жњЇиЂ…пјљи‘›еќ‡жіў, й»„дёњ, й™†жµ©, е§љеє·, еј еі° з‰№й‚ЂжњЇиЂ…пјљAlfredo R. Galassi, Etsuo Tsuchikane й¦–йѓЅеЊ»з§‘е¤§е¦й™„е±ће®‰иґћеЊ»й™ў жњЇиЂ…пјљй™€ж–№, й™€ж–°, й«�й�…ж�Ґ, жќЋеї—еї , е€�ж–°ж°‘, е€�е®‡ж‰¬, жџіе®Џ, жџіж™ЇеЌЋ, еђ•ж ‘й“®, зЅ—е¤Єй�і, иЃ‚з»Ќе№і, д№”еІ©, й�™ж–Њ, еЏІе†¬жў…, и‹Џе·Ґ, е™ж¶›, з”°й”ђ, зЋ‹еЃҐ, зЋ‹и‹Џ, еђґй“®, и‹‘йЈћ, еј ж™“зЋІ, еј е®‡ж™Ё, иµµдёњж™–, иµµе…Ёж�Ћ, иµµиїЋж–°, е‘ЁзЋ‰жќ°, е‘ЁжёЉ з‰№й‚ЂжњЇиЂ…пјљJean Fajadet, Ferdinand Kiemeneij, Mitchell W. Krucoff, Samuel K. Mathew, Marie-Claude Morice, Imad Sheiban, Robaayah Zambahari й¦–йѓЅеЊ»з§‘е¤§е¦й™„е±ћжњќй�іеЊ»й™ў жњЇиЂ…пјљжќЋжѓџй“, еЂЄзҐќеЌЋ, е™ж�Љ, зЋ‹зєўзџі, зЋ‹д№ђдё°, е¤Џж�†, еѕђз«‹ з‰№й‚ЂжњЇиЂ…пјљFausto Feres, David E. Kandzari, Costantino O. Costantini, Costantino R. Costantini, Teguh Santoso, Alan C. Yeung з¬¬е››е†›еЊ»е¤§е¦й™„е±ћиҐїдє¬еЊ»й™ў жњЇиЂ…пјљйѓж–‡жЂЎ, жќЋж€ђзҐҐ, жќЋдјџжќ°, ж ѕиЌЈеЌЋ з‰№й‚ЂжњЇиЂ…пјљToshiya Muramatsu 105 дёе›Ѕе›Ѕз«‹еЏ°ж№ѕе¤§е¦еЊ»й™ў жњЇиЂ…пјљPaul Hsien-Li Kao ж—Ґжњ¬дё°жЎҐеїѓи„Џдёеїѓ жњЇиЂ…пјљTakahiko Suzuki, Yoshihisa Kinoshita, Kenya Nasu CIT 2012 www.citmd.com 2012е№ґ3жњ€15ж—Ґ ж�џжњџе›› 9:52 AM - з‰№и‰Іжј”и®Іпјљи®ѕи®ЎгЂЃе®ћж–ЅеЌЏдЅњжЂ§ дёґеєЉиЇ•йЄЊзљ„з›Ље¤„ Martin B. Leon дёЂе±‚е¤љеЉџиѓЅAеЋ… з¬¬е››е±ЉдёґеєЉз ”з©¶дё“йў�з ”и®Ёеі°дјљ 8:15 AM-12:30 PM з¬¬дёЂйѓЁе€†пјљдёґеєЉз ”з©¶йЎ№з›®еџєзЎЂ - иЋ·еѕ—ж€ђеЉџ зљ„и¦Ѓзґ дё»жЊЃдєєпјљAlexandra J. Lansky, Ajay J. Kirtane и®Ёи®єдё“е®¶пјљDominic Allocco, йџ©й›…зЋІ, Mitchell W. Krucoff, жќЋеЌ«, David Liu, Roxana Mehran, Jenny Zhen Qin, еЏІж–°з«‹, зЋ‹жµ·ж�Њ пј€жњ¬ењєдјљи®®е°†иЃљз„¦дєЋеђЇеЉЁе’Њж”Їж’‘дёЂйЎ№ж€ђ еЉџз ”з©¶зљ„еџєжњ¬и¦Ѓзґ гЂ‚еђ¬дј—еЊ…ж‹¬е†…з§‘еЊ» её€гЂЃз ”з©¶иЂ…гЂЃйЎ№з›®еЌЏи°ѓдєєе‘�еЏЉйЎ№з›®з®Ўзђ† иЂ…з‰гЂ‚е…¶дё»и¦Ѓи®®йў�е°†зќЂй‡ЌдєЋиЋ·еѕ—йЎ№з›®ж€ђ еЉџж‰Ђеї…йњЂзљ„з ”з©¶еџєзЎЂз»„з»‡жћ„йЂ гЂЃжЊ‡еЌ—еЏЉ иїђиЎЊжЉЂе·§з‰гЂ‚пј‰ 8:15 AM - ж¬ўиїЋи‡ґиѕћ й«�ж¶¦йњ– 8:17 AM - з›®зљ„з®Ђд»‹ Alexandra J. Lansky 10:07 11:55 AM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” AM - иЊ¶ж‡ з¬¬дё‰йѓЁе€†пјљдё»ж—Ёиѕ©и®є - з»€ж›І з¬¬дєЊйѓЁе€†пјљдёґеєЉиЇ•йЄЊи§ЈиЇ» - зјєй™·дёЋе®ћз”Ё ж•™и® дё»жЊЃдєєпјљAjay J. Kirtane, Roxana Mehran и®Ёи®єдё“е®¶пјљAlexandre Abizaid, Davide Capodanno, й™€з»Ќи‰Ї, й™€йџµеІ±, Donald E. Cutlip, Alexandra J. Lansky, жќЋеЌ«, еЏІж–°з«‹, еј з‘ћеІ© пј€жњ¬ењєдјљи®®з›®ж ‡ж�ЇжЏђдѕ›ењЁдёґеєЉиЇ•йЄЊи®ѕи®ЎдёЋ и§ЈиЇ»дёз‰№е®љдё»йў�зљ„е®ћз”ЁжЂ§иЂЊйќћзђ†и®єжЂ§зљ„е®ћ дѕ‹гЂ‚жЇЏдёЂдёЄеЏ‘иЁЂеќ‡еє”дЅїз”Ёи‹Ґе№Іе®ћдѕ‹жќҐй�ђж�Ћ дёЋе…¶жј”и®ІеЇ†е€‡з›ёе…ізљ„дё»и¦Ѓи§‚з‚№гЂ‚пј‰ 10:17 AM - з›®зљ„з®Ђд»‹ Ajay J. Kirtane 10:20 AM - еЇ№жЇ”йљЏжњєеЇ№з…§иЇ•йЄЊдёЋи§‚еЇџжЂ§з ” з©¶пјљдё¤иЂ…еќ‡еЏЇеѕ€еҐЅпјЊдє¦еЏЇеѕ€е·® Alexandra J. Lansky 10:30 AM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 8:20 AM - жЂЋж ·ејЂе§‹е’Њи®ѕз«‹дёЂйЎ№з ”з©¶пјљеџє жњ¬е·Ґе…· Roxana Mehran 10:35 AM - дёґеєЉиЇ•йЄЊдёе¤Ќеђ€з»€з‚№зљ„е®ћз”ЁжЂ§ дёЋиЇЇз”Ёж»Ґз”Ё Ajay J. Kirtane 8:32 AM - е›Ѕе†…зљ„е’Ње›Ѕй™…зљ„дёґеєЉиЇ•йЄЊпјљжЂЋ ж ·еќ‡еЏ–еѕ—ж€ђеЉџпјџе®ѓд»¬жњ‰дЅ•дёЌеђЊпјџ Mitchell W. Krucoff 10:45 AM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 8:44 AM - дёґеєЉз ”з©¶зљ„жЊ‡еЇјеЋџе€™пјљеџєжњ¬и§„е€™ пј€GCPгЂЃIRBгЂЃзџҐжѓ…еђЊж„ЏгЂЃеџ№и®еЏЉе…¶д»–пј‰ йџ©й›…зЋІ 11:45 AM - дёе›Ѕз ”з©¶зљ„жњЄжќҐпјљдё‹дёЂдёЄе‰ЌжІї й«�ж¶¦йњ– 10:50 AM - дёґеєЉеЊ»е¦дёе……и¶іжЉЉжЏЎеє¦з ”з©¶зљ„ й‡Ќи¦ЃжЂ§пјље®ћдѕ‹е¦д№ жќЋеЌ« 11:00 AM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” дё»жЊЃдєєпјљRoxana Mehran и®Ёи®єдё“е®¶пјљDonald E. Cutlip, Ajay J. Kirtane, жќЋеЌ« иѕ©йў�пјљдёЂз±»иЇЇе·®дёЋвЂњжњ‰й”еЉ›зљ„вЂќP<0.05й�€еЂј 12:00 PM -PеЂјж�Їй‡Ќи¦Ѓзљ„вЂ¦е№¶дё”ж�Їжњ‰ж„Џд№‰зљ„пјЃ Donald E. Cutlip 12:12 PM - PеЂјзљ„ж„Џд№‰ењЁе‡Џе°‘пјЃ Ajay J. Kirtane 12:24 PM - дё“е®¶и®Ёи®є 12:30 PM - дј‘дјљ еЌ€й—ґеЌ«ж�џдјљ еѕ®е€›дё»еЉћ ж„џеЏ—зЃ«й№°пјЊй”Ѓе®љжњЄжќҐ 12:40 PM-1:55 PM дё»еёпјљMartin B. Leon е…±еђЊдё»еёпјљFausto Feres, й©¬й•їз”џ, жІ€еЌ«еі°, еѕђжіў 12:40 PM - ејЂењєи‡ґиѕћ 12:43 PM - FIREHAWKз”џз‰©еЏЇеђёж”¶иЃљеђ€з‰© иҐїиЋ«зЅ—еЏёжґ—и„±ж”Їжћ¶пјљй¦–ж¬ЎдєєдЅ“з ”з©¶гЂЃ TARGET IеЏЉTARGET IIиЇ•йЄЊжњЂж–°иї›е±• й«�ж¶¦йњ– 12:58 PM - TARGET IиЇ•йЄЊдёFIREHAWKеЇ№жЇ” XIENCE Vж”Їжћ¶зљ„иЎЂз®Ўй•њеЏ‘зЋ° й™€з»Ќи‰Ї 8:56 AM - иґЁй‡ЏжЋ§е€¶гЂЃз›‘жџҐи®їи§†еЏЉзЁЅж ёпјљ жЇЏдёЂдЅЌз ”з©¶иЂ…еї…йЎ»дє†и§Јд»Ђд№€пјџ Jenny Zhen Qin 11:05 AM - йќћеЉЈж•€и®ѕи®Ўи§Јй‡Ље’ЊвЂњжЏйњІвЂќпјљ еє”з”Ёе’Њж»Ґз”Ё Donald E. Cutlip 9:08 AM - SFDAй’€еЇ№е®ћж–ЅдёґеєЉз ”з©¶еЌ•дЅЌзљ„ и§„з« е’Њи¦Ѓж±‚ еЏІж–°з«‹ 11:15 AM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 1:13 PM - TARGET IиЇ•йЄЊдёFIREHAWKж”Їжћ¶зљ„ иЎЂз®Ўе†…и¶…еЈ°еЏ‘зЋ° еј з‘ћеІ© 11:20 AM - дёґеєЉиЇ•йЄЊдёдєљз»„е€†жћђдёЋйЈЋй™©з»„ зѕ¤пјљеє”з”Ёе’Њж»Ґз”Ё Davide Capodanno 1:28 PM - FIREHAWKеЌ•дёеїѓз»ЏйЄЊеЏЉжќҐи‡Є TARGETзі»е€—иЇ•йЄЊзљ„зІѕеЅ©з—…дѕ‹ йџ©й›…зЋІ 11:30 AM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 1:43 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 11:35 AM - е…Ёзђѓе®ћж–Ѕз ”з©¶жњ‰е€©жњ‰ејЉ Roxana Mehran 1:55 PM - дј‘дјљ 9:20 AM - жЂЋж · жњ‰ ж•€ењ°еЏ‘ иЎЁе’Њ е…¬еёѓдЅ зљ„ з ”з©¶пјџ Ajay J. Kirtane 9:32 AM - дё“е®¶и®Ёи®єпјљиЃљз„¦дєЋиЋ·еѕ—йЎ№з›®ж€ђ еЉџз‰№е®љзљ„жЊ‘ж€�дёЋжЉЂе·§ 106 CIT 2012 www.citmd.com 2012е№ґ3жњ€15ж—Ґ ж�џжњџе›› д»‹е…Ґе€›ж–°еі°дјљ 2:00 PM-6:15 PM 4:00 PM - дё“е®¶и®Ёи®єпјљиЌЇз‰©жґ—и„±ж”Їжћ¶е€›ж–°зљ„ жњєйЃ‡дёЋжЊ‘ж€�пјљдјЃдёљи§‚з‚№ з¬¬дёЂйѓЁе€†пјљз‰№и‰Іжј”и®І и®Ёи®єдё“е®¶пјљKeith D. Dawkins, зЅ—дёѓдёЂ, и’Іеї жќ°, Martin T. Rothman, еЏІж–°з«‹, Charles A. Simonton, зЋ‹еђ‰ж€ђ, еѕђжіў дё»жЊЃдєєпјљMartin B. Leon дё»жЊЃдєєпјљй«�ж¶¦йњ–, Martin B. Leon 2:00 PM - е€›ж–°е±•жњ›пјљиї‡еЋ»гЂЃзЋ°ењЁе’ЊжњЄжќҐ Martin B. Leon 2:15 PM - дё“е®¶и®Ёи®єпјље€›ж–°з–—жі•еЇ№е…Ёзђѓе’Њж–° е…ґеё‚ењєзљ„е†Іе‡»е’ЊжњєйЃ‡ з¬¬дё‰йѓЁе€†пјљж–°з–—жі•пј€йќћиЌЇз‰©жґ—и„±ж”Їжћ¶пј‰ дё»жЊЃдєєпјљEberhard Grube, жІ€еЌ«еі°, й™€йџµеІ±, иґѕеЃҐй›„ и®Ёи®єдё“е®¶пјљAlexandre Abizaid, Yaron Almagor, Eberhard Grube, Ian T. Meredith, Patrick W. Serruys, ж±Єз«‹, жќЁи·ѓиї› 4:15 PM - з»Џзљ®дё»еЉЁи„‰з“ЈжІ»з–— Michael A. Mussallem з¬¬дєЊйѓЁе€†пјљиЌЇз‰©жґ—и„±ж”Їжћ¶е€›ж–° 4:25 PM - з»Џзљ®дєЊе°–з“ЈжІ»з–— Maurice Buchbinder дё»жЊЃдєєпјљMartin B. Leon, еЏІж–°з«‹, еѕђжіў 2:30 PM - з”џз‰©еЏЇеђёж”¶иЃљеђ€з‰©иЌЇз‰©жґ—и„±ж”Їжћ¶ жЉЂжњЇзљ„е®‰е…ЁжЂ§е’Њжњ‰ж•€жЂ§иЂѓи™‘ Stephan Windecker 2:40 PM - ж— иЃљеђ€з‰©иЌЇз‰©жґ—и„±ж”Їжћ¶жЉЂжњЇзљ„е®‰ е…ЁжЂ§е’Њжњ‰ж•€жЂ§иЂѓи™‘ Adnan Kastrati 2:50 PM - еє”з”Ёе®Ње…Ёз”џз‰©еЏЇеђёж”¶иЌЇз‰©жґ—и„±ж”Ї жћ¶зљ„иЎЂз®Ўдї®е¤Ќз–—жі•ж�ЇжњЄжќҐд№‹и·ЇпјЃжў¦жѓіиѓЊ еђЋзљ„з§‘е¦ Patrick W. Serruys 3:00 PM - жњЄжќҐзљ„ж–°ж”Їжћ¶жЉЂжњЇпјљй›…еџ№иЎЂз®Ўдє§ е“Ѓзєї Charles A. Simonton 3:10 PM - жњЄжќҐзљ„ж–°ж”Їжћ¶жЉЂжњЇпјљжіўеЈ«йЎїз§‘е¦ дє§е“Ѓзєї Keith D. Dawkins 3:20 PM - жњЄжќҐзљ„ж–°ж”Їжћ¶жЉЂжњЇпјљзѕЋж•¦еЉ›дє§ е“Ѓзєї Martin T. Rothman 3:30 PM - жњЄжќҐзљ„ж–°ж”Їжћ¶жЉЂжњЇпјљеђ‰еЁЃе’Њз™ѕз›› дє§е“Ѓзєї зЋ‹еђ‰ж€ђ 3:40 PM - жњЄжќҐзљ„ж–°ж”Їжћ¶жЉЂжњЇпјљд№ђж™®дє§е“Ѓзєї и’Іеї жќ° 3:50 PM - жњЄжќҐзљ„ж–°ж”Їжћ¶жЉЂжњЇпјљеѕ®е€›дє§е“Ѓзєї зЅ—дёѓдёЂ 107 4:35 PM - йЎЅе›єжЂ§й«�иЎЂеЋ‹зљ„з»ЏеЇјз®ЎеЋ»и‚ѕзҐћз»Џ еЊ–пјљеЅ“е‰Ќи§‚з‚№ Markus P. Schlaich 4:45 PM - йЎЅе›єжЂ§й«�иЎЂеЋ‹зљ„з»ЏеЇјз®ЎеЋ»и‚ѕзҐћз»Џ еЊ–пјљжњЄжќҐжњџжњ› Horst Sievert 4:55 PM - жІ»з–—й«�иЎЂеЋ‹зљ„е¤–йѓЁе’Њйќћдѕµе…ҐжЂ§зљ„ з–з•Ґ Michael Gertner 5:05 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 5:55 PM - дёґеєЉз ”з©¶дёЋиЅ¬еЊ–еЊ»е¦зљ„иЊѓдѕ‹пјљдё е›ЅеЊ»её€ењЁеЊ»з–—е™Ёжў°дјЃдёљдёзљ„и§’и‰І Jie Wang 6:05 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” и®Ёи®єдё“е®¶пјљFrank Ahmann, й™€йџµеІ±, иґѕеЃҐй›„, Ferdinand Kiemeneij, жІ€еЌ«еі°, Johan H. C. Reiber, Jason H. Rogers, Jie Wang дё»жЊЃдєєпјљEberhard Grube 6:15 PM - дј‘дјљ дёЂе±‚е¤љеЉџиѓЅBеЋ… з¬¬дєЊе±Љдёж—ҐеЏ‹еҐЅд»‹е…Ґеїѓи„Џз—…е¦и®єеќ› CCT at CIT 8:25 AM-6:00 PM 8:25 AM - ејЂе№•и‡ґиѕћ Eisho Kyo, й«�ж¶¦йњ– з¤єж•™жј”з¤є1 ж…ўжЂ§е®Ње…Ёй—еЎћ ж—Ґжњ¬дё°жЎҐеїѓи„Џдёеїѓ 8:30 AM-10:00 AM и®Ёи®єдё“е®¶пјљMaurice Buchbinder, й™€йџµеІ±, Michael Gertner, иґѕеЃҐй›„, Michael A. Mussallem, Markus P. Schlaich, жІ€еЌ«еі°, Horst Sievert, Jie Wang дё»жЊЃдєєпјљEberhard Grube дё»жЊЃдєєпјљOsamu Katoh, йњЌе‹‡ и®Ёи®єдё“е®¶пјљиЌ†е…Ёж°‘, жќЋдјџжќ°, жќЋж‚¦, Motomaru Masutani, е®‹зЋ°ж¶›, Kinzo Ueda, Yuichi Ujiie, зЋ‹е®€еЉ›, зЋ‹з¦№, йѓ‘й‡‘е€љ жњЇиЂ…пјљTakahiko Suzuki, Yoshihisa Kinoshita, Kenya Nasu 5:15 PM - жІ»з–—иї›е±•жЂ§еїѓиЎ°зљ„еџєдєЋз”џз‰©иЃљеђ€ з‰©зљ„е·¦е®¤жњєжў°дї®е¤Ќ Frank Ahmann и®Іеє§е’Њз—…дѕ‹жЉҐе‘Љпј€дёЂпј‰ ж…ўжЂ§е®Ње…Ёй—еЎћ 5:25 PM - е‹ѓиµ·еЉџиѓЅйљњзўЌзљ„иЎЂз®Ўе†…з–—жі•пјљ ZENдёґеєЉиЇ•йЄЊз»“жћњ Jason H. Rogers дё»жЊЃдєєпјљEisho Kyo, еђ•ж ‘й“® и®Ёи®єдё“е®¶пјљй™€зєЄиЁЂ, Osamu Katoh, Toshiya Muramatsu, Yuichi Ujiie, зЋ‹жµ·ж�Њ, еђґж°ёеЃҐ, Hiroyoshi Yokoi, е‘ЁзЋ‰жќ° 5:35 PM - жњЄжќҐзљ„еЇјз®Ўе®¤е’ЊйЃҐжЋ§ж“ЌдЅњзі»з»џ Ferdinand Kiemeneij 5:45 PM - з»Џзљ®е† и„‰д»‹е…Ґдёдё‰з»ґQCAдёЋIVUS ж€–OCTзљ„ићЌеђ€ Johan H. C. Reiber 10:00 AM - дё»ж—Ёжј”и®Іпјљд»Ћж—Ґжњ¬ж…ўжЂ§е®Ње…Ёй— еЎћд»‹е…ҐжІ»з–—зљ„еЋ†еЏІж€‘д»¬иѓЅе¦е€°д»Ђд№€пјџ Osamu Katoh 10:30 AM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 10:35 AM - ж€‘е¤„зђ†ж…ўжЂ§е®Ње…Ёй—еЎћзљ„ж–№жі•пјљ з—…дѕ‹жЉҐе‘Љ Toshiya Muramatsu CIT 2012 www.citmd.com 2012е№ґ3жњ€15ж—Ґ ж�џжњџе›› 10:50 AM - йЂ†еђ‘жЉЂжњЇиЎЊж…ўжЂ§е®Ње…Ёй—еЎћд»‹е…Ґ жІ»з–—зљ„дёґеєЉз»“жћњпјљжќҐи‡ЄйЂ†еђ‘еі°дјљзљ„ж—Ґжњ¬ з™»и®°ж•°жЌ® Yuichi Ujiie 11:05 AM - дёе›Ѕж…ўжЂ§е®Ње…Ёй—еЎћд»‹е…ҐжІ»з–—еЏЉ з—…дѕ‹жЉҐе‘Љ й™€зєЄиЁЂ 11:20 AM - е¤–е‘Ёи…”е†…ж…ўжЂ§е®Ње…Ёй—еЎће’Ње¤Ќжќ‚ з—…еЏ� Hiroyoshi Yokoi 11:35 AM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” з¤єж•™жј”з¤є2 ж…ўжЂ§е®Ње…Ёй—еЎћ е¤Ќж—¦е¤§е¦й™„е±ћдёе±±еЊ»й™ў 11:45 AM-1:15 PM дё»жЊЃдєєпјљKinzo Ueda, йўњзєўе…µ и®Ёи®єдё“е®¶пјљж–№е”ЇдёЂ, е…‰й›Єеі°, йѓж–‡жЂЎ, Nae Hee Lee, е€�е¦жіў, Toshiya Muramatsu, Masaaki Okutsu, Toshiro Shinke, Wasan Udayachalerm, Wei-Hsian Yin жњЇиЂ…пјљи‘›еќ‡жіў, EtsuoTsuchikane, Alfredo R. Galassi и®Іеє§е’Њз—…дѕ‹жЉҐе‘Љпј€дєЊпј‰ е¤Ќжќ‚з—…еЏ�д»‹е…ҐжІ»з–—дёеЅ±еѓЏе’Њз”џзђ†е¦зљ„ еє”з”Ё дё»жЊЃдєєпјљMotomaru Masutani, й’±иЏЉи‹± и®Ёи®єдё“е®¶пјљй™€жҐж�џ, й™€з»Ќи‰Ї, з›–йІЃзІ¤, е€�жѓ дє®, Masaaki Okutsu, й’±жќ°, Toshiro Shinke 1:15 PM - з”џзђ†е¦пјљFFR / еЋ‹еЉ›еЇјдёќ Toshiro Shinke 1:28 PM - IVUS Motomaru Masutani з¤єж•™жј”з¤є3 ж…ўжЂ§е®Ње…Ёй—еЎћ е›Ѕе®¶еїѓиЎЂз®Ўз—…дёеїѓй�ње¤–еЊ»й™ў 2:45 PM-4:45 PM дё»жЊЃдєєпјљEisho Kyo, жќЁи·ѓиї› и®Ёи®єдё“е®¶пјљи‘›й›·, е‚…е›Ѕиѓњ, Hweung Kon Hwang, Ping-Han Lo, William L. Lombardi, ж ѕиЌЈеЌЋ, зЅ—е»єж–№, Yoshinobu Murasato, Fuminobu Yoshimachi, еј ж–Њ жњЇиЂ…пјљOsamu Katoh, Shigeru Saito, Satoru Sumitsuji IVUSи§ЈиЇґдё“е®¶пјљYuichi Ujiie и®Іеє§е’Њз—…дѕ‹жЉҐе‘Љпј€дё‰пј‰ е¤Ќжќ‚з»Џзљ®е† и„‰д»‹е…ҐжІ»з–— дё»жЊЃдєєпјљMasahiko Ochiai, й™€ж–№ и®Ёи®єдё“е®¶пјљYoshinobu Murasato, иЃ‚з»Ќе№і, Kenji Wagatsuma, зЋ‹е»єе®‰, Fuminobu Yoshimachi, еј еҐ‡ 4:45 PM - е¤Ќжќ‚е€†еЏ‰з—…еЏ� Yoshinobu Murasato 5:00 PM - е¤Ќжќ‚з—…еЏ�дёеє”з”ЁSlenderеЇјз®Ў зі»з»џ Fuminobu Yoshimachi 5:15 PM - дёҐй‡Ќй’™еЊ–з—…еЏ�зљ„ж—‹зЈЁжњЇ зЋ‹е»єе®‰ 5:30 PM - з»ЏжЎЎеЉЁи„‰йЂ”еѕ„е† и„‰д»‹е…ҐжІ»з–—еЉ ејє ж”Їж’‘еЉ›жЉЂжњЇ еј еҐ‡ 5:45 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 6:00 PM - дј‘дјљ 8:38 AM - и®Ёи®є 8:42 AM - AS-0209: Protection of Cellular Repressor of E1A Stimulated Genes Against TNF-О± Mediated Inflammatory Injury of Endothelial Cells ж®µеІ© 8:50 AM - и®Ёи®є 8:54 AM - AS-0210: Association Between Polymorphism in the Cytochrome P450 3A5 Gene rs3800959 and Clopidogrel Resistance in Chinese Han Population е†Їй›Єз‘¶ 9:02 AM - и®Ёи®є 9:06 AM - AS-0213: Downregulation of Adiponectin Induced by Tumor Necrosis Factor О± Is Involved in the Aggravation of Post-Traumatic Myocardial Ischemia/ Reperfusion Injury е€�е°‘дјџ 9:14 AM - и®Ёи®є 9:18 AM - AS-0218: CREG Prevents Human Umbilical Vein Endothelial Cell from Apoptosis by Inhibiting p38 MAPK Activation зЋ‹еЁњ 9:26 AM - и®Ёи®є 1:41 PM - OCT й’±жќ° з¬¬дєЊењєпјљеїѓеѕ‹е¤±еёё 1:54 PM - CT Masaaki Okutsu дё‰е±‚306Aдјљи®®е®¤ 2:07 PM - ж—‹иЅ¬йЂ еЅ± е€�жѓ дє® и®єж–‡дє¤жµЃз¬¬дёЂйѓЁе€† 8:30 AM-12:30 PM 2:20 PM - иЎЂз®Ўй•њ й™€з»Ќи‰Ї з¬¬дёЂењєпјљеџєзЎЂз ”з©¶ 2:33 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 8:30 AM - AS-0196: FTY720 Protects Cardiac Microvessels of Diabetic Rats via Suppression of the PKCОІII-Dependant Signaling Pathway by Regulating S1P1 and S1P3 е°№еї—е‹‡ дё»жЊЃдєєпјљжќЋе»єе†›, Jie Wang, Dongming Hou, иўЃжґЄ дё»жЊЃдєєпјљеђґеЌ°з”џ, е™и‹±иґ¤, жµ¦д»‹йєџ 9:30 AM - AS-0156: NOS1AP Variations and Idiopathic Ventricular Tachycardia (IVT) еј иЌЈеі° 9:38 AM - и®Ёи®є 9:42 AM - AS-0234: Left Atrial Epicardial Adipose Tissue and Atrial Fibrillation е€�жґЃз…њ 108 CIT 2012 www.citmd.com 2012е№ґ3жњ€15ж—Ґ ж�џжњџе›› 9:50 AM - и®Ёи®є 11:14 AM - и®Ёи®є 9:54 AM - AS-0242: The Electrophysiologic Characteristics and Radiofrequency Catheter Ablation of Idiopathic Ventricular Arrhythmias Originating from the Papillary Muscles жќЋдё–еЂЌ 11:18 AM - AS-0167: Understanding the Effects of Psychological Intervention in Patients with Coronary Heart Disease жќЋжЈ®жћ— 10:02 AM - и®Ёи®є з¬¬е››ењєпјље† еїѓз—…пј€дє”пј‰ 10:06 AM - AS-0430: Comparative Study of Pocket Hemorrhage After Pacemaker Implantation in Patients with Warfarin Anticoagulation жќЋз»§ж–‡ 10:14 AM - и®Ёи®є 10:18 AM - AS-0523: Clinical Analysis of Arrhythmia in 297 Ebstein's Anomaly Patients дѕЇз…њ 10:26 AM - и®Ёи®є 11:26 AM - и®Ёи®є дё»жЊЃдєєпјље‚…еђ‘еЌЋ, Kai Huat Lam, еѕђж ‡ 11:30 AM - AS-0212: A Gene Polymorphism Inhibits the Therapeutic Actions of Clopidogrel in Chinese After Drug-Eluting Stent Implantation жўЃжЊЇжґ‹ 11:38 AM - и®Ёи®є 11:42 AM - AS-0239: Relationship Between Renal Dysfunction and Severity of Coronary Artery Disease in a Large Cohort of Catheterized Patients еј зЈЉ 11:50 AM - и®Ёи®є з¬¬дё‰ењєпјљз»“жћ„жЂ§еїѓи„Џз—…дёЋе¤–е‘ЁиЎЂз®Ўз–ѕз—… дё»жЊЃдєєпјљиµµдё–еЌЋ, жќЋж–°ж�Ћ, и’‹й›„дє¬ 10:30 AM - AS-0262: Transcatheter Closure of Membraneous Ventricular Septal Defects in Children жњ±йІњй�і 10:38 AM - и®Ёи®є 11:54 AM - AS-0489: The Value of Combining CYP2C19*2 Polymorphism with Classic Risk Factors in Prediction of Clinical Prognosis in Acute Coronary Syndrome Patients еѕђеЋџе®Ѓ 12:02 PM - и®Ёи®є 10:42 AM - AS-0403: Transcatheter Closure of Coronary Artery Fistula with Coil Device or Occluder жќЋжќѕеЌЋ 12:06 PM - AS-0027: Safety and Efficacy of Anisodamine on Prevention of Contrast Induced Nephropathy in Patients with Acute Coronary Syndrome е‚…еђ‘еЌЋ 10:50 AM - и®Ёи®є 12:14 PM - и®Ёи®є 10:54 AM - AS-0327: Carotid Artery Stenting in Surgically High-Risk Patients: Early and Long-Term Results и‘ЈеѕЅ 12:18 PM - AS-0619: A Multicenter Randomized Comparison of Drug-Eluting Balloon plus Bare Metal Stent vs. Bare Metal Stent vs. Drug-Eluting Stent in Primary Percutaneous Coronary Intervention: 6-Month Angiographic, Intravascular, Functional and Clinical Results of the DEBAMI Trial Pieter R. Stella 11:02 AM - и®Ёи®є 11:06 AM - AS-0190: Transcatheter Renal Denervation for the Treatment of Refractory Hypertension: Early China Experience еЌўж€ђеї— 109 12:26 PM - и®Ёи®є 12:30 PM - дј‘дјљ CITйќ’е№ґеЊ»её€з ”з©¶еҐ–е†іиµ› 2:00 PM-4:20 PM дё»жЊЃдєєпјљRoxana Mehran иЇ„е®Ўдё“е®¶пјљJoseph D. Babb, Davide Capodanno, Donald E. Cutlip, Liliana R. Grinfeld, Fumiaki Ikeno, Spencer B. King III, Ajay J. Kirtane, Mitchell W. Krucoff, Yean-Leng Lim, Jean Marco 2:00 PM - з”іиЇ·дєєж±‡жЉҐ и‘›й›· дёЉжµ·е¤Ќж—¦е¤§е¦й™„е±ћдёе±±еЊ»й™ў 2:12 PM - й—®з” 2:20 PM - з”іиЇ·дєєж±‡жЉҐ дѕЇйќ™жіў е“€е°”ж»ЁеЊ»з§‘е¤§е¦з¬¬дєЊй™„е±ћеЊ»й™ў 2:32 PM - й—®з” 2:40 PM - з”іиЇ·дєєж±‡жЉҐ й«�е±• е›Ѕе®¶еїѓиЎЂз®Ўз—…дёеїѓй�ње¤–еїѓиЎЂз®Ўз—…еЊ»й™ў 2:52 PM - й—®з” 3:00 PM - з”іиЇ·дєєж±‡жЉҐ йѓе®Ѓ иҐїе®‰дє¤йЂље¤§е¦з¬¬дёЂй™„е±ћеЊ»й™ў 3:12 PM - й—®з” 3:20 PM - з”іиЇ·дєєж±‡жЉҐ еј еҐ‡ дёЉжµ·дє¤йЂље¤§е¦еЊ»е¦й™ўй™„е±ћз‘ћй‡‘еЊ»й™ў 3:32 PM - й—®з” 3:40 PM - з”іиЇ·дєєж±‡жЉҐ еѕђе‡Ї жІ€й�іе†›еЊєжЂ»еЊ»й™ў 3:52 PM - й—®з” 4:00 PM - з”іиЇ·дєєж±‡жЉҐ зЄ¦е…‹йќћ е›Ѕе®¶еїѓиЎЂз®Ўз—…дёеїѓй�ње¤–еїѓиЎЂз®Ўз—…еЊ»й™ў 4:12 PM - й—®з” 4:20 PM - дј‘дјљ CIT 2012 www.citmd.com 2012е№ґ3жњ€15ж—Ґ ж�џжњџе›› з¬¬дєЊењєпјље† еїѓз—…пј€дєЊпј‰ 9:30 AM - AS-0056: A Meta-Analysis of Early Percutaneous Coronary Intervention within 24 Hours of Thrombolysis in Acute STSegment Elevation Myocardial Infarction еј жҐж�Ґ 10:42 AM - AS-0183: Double Kissing (DK) Crush vs. Culotte Stenting for the Treatment of Unprotected Distal Left main Bifurcation Lesions: DKCRUSH-III, A Multicenter Randomized Study Comparing Double-Stent Techniques й™€з»Ќи‰Ї 9:38 AM - и®Ёи®є 10:50 AM - и®Ёи®є 9:42 AM - AS-0142: Effect of the Chronic Kidney Disease on Formation of Coronary Collateral Vessels in Patients with Acute Myocardial Infarction жќњж¶¦ 10:54 AM - AS-0295: TIVOLI BiodegradablePolymer-Based Sirolimus-Eluting Stents in Treating Patients with Coronary Artery Disease: 8-Month Angiographic and 3-Year Clinical Follow-up Results - A Prospective, Parallel Control, Multicenter Study зЄ¦е…‹йќћ дё»жЊЃдєєпјљй™€еђ›жџ±, дЅ•е›ЅзҐҐ, з›–йІЃзІ¤ дё‰е±‚306Bдјљи®®е®¤ и®єж–‡дє¤жµЃз¬¬дєЊйѓЁе€† 8:30 AM-12:30 PM з¬¬дёЂењєпјље† еїѓз—…пј€дёЂпј‰ дё»жЊЃдєєпјље€�е›Ѕж ‘, жѓ ж°ёж�Ћ, еј д»ЈеЇЊ 8:30 AM - AS-0102: Multimodality Imaging Evaluation of Functional and Clinical Benefits of Percutaneous Coronary Intervention in Patients with Chronic Total Occlusion Lesion: Role of SPECT/CTCA Fusion Imaging as a Gatekeeper to Evaluate LAD CTO PatientsвЂ™ Outcomes е™е†¬е†¬ 8:38 AM - и®Ёи®є 8:42 AM - AS-0174: Angioscopy Study from a Large Patient Population Comparing Sirolimus-Eluting Stent with Biodegradable vs. Durable Polymer й™€з»Ќи‰Ї 8:50 AM - и®Ёи®є 8:54 AM - AS-0204: Natural History of Dissection and Tissue Prolapse Following Sirolimus-Eluting Stent: 6-Month OCT Follow-up Study й»„е№ёж¶› 9:02 AM - и®Ёи®є 9:06 AM - AS-0555: Characterization of Coronary Plaque Assessed by Optical Coherence Tomography in Diabetic Subjects with Coronary Artery Disease й«�й№Џ 9:50 AM - и®Ёи®є 9:54 AM - AS-0275: Clinical Investigation of Effects of Intravenous vs. Intracoronary Injection of Tirofiban During Primary PCI й©¬йў–и‰і 10:02 AM - и®Ёи®є 10:06 AM - AS-0573: Beneficial Effects of Intracoronary Tirofiban Bolus Administration Following Upstream Intravenous Treatment in Patients with ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: The ICT-AMI Study жњ±е¤©еҐ‡ 11:02 AM - и®Ёи®є 11:06 AM - AS-0286: Incidence, Predictors, and Clinical Outcome of Stent Thrombosis After Stent Implantation еј жќѓе®‡ 11:14 AM - и®Ёи®є 11:18 AM - AS-0168: Distal Protection Devices in Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials й‡‘жіў 11:26 AM - и®Ёи®є 10:14 AM - и®Ёи®є 10:18 AM - AS-0622: Influence of Dietary Patterns on the Risk of Acute Myocardial Infarction (AMI) in China Population: The INTERHEART China Study йѓж™‹ 10:26 AM - и®Ёи®є 9:14 AM - и®Ёи®є з¬¬дё‰ењєпјље† еїѓз—…пј€дё‰пј‰ 9:18 AM - AS-0140: Decreased Serum дё»жЊЃдєєпјљжІ€еЌ«еі°, жќЋе»єе†›, ж±џж—¶жЈ® esRAGE Level Is Associated with Coronary Artery Remodeling in Patients with Type 2 Diabetes: An Intravascular Ultrasound Study жќњж¶¦ 10:30 AM - AS-0293: NOYA I: A Prospective Randomized Trial of NOYA Sirolimus -Eluting Stent with Biodegradable Coating Compared to FIREBIRD 2 Sirolimus-Eluting Stent with Durable Coating in Patients with Coronary Artery Disease: 9-Month Angiographic and 18-Month Clinical Results зЄ¦е…‹йќћ 9:26 AM - и®Ёи®є 10:38 AM - и®Ёи®є з¬¬е››ењєпјље† еїѓз—…пј€е››пј‰ дё»жЊЃдєєпјљйЅђеђ‘е‰Ќ, зЋ‹й•їи°¦, жџіиЊµ 11:30 AM - AS-0284: Long-Term Efficacy of PCI vs. CABG for Patients with Multiple Coronary Chronic Total Occlusions еј е‰‘ 11:38 AM - и®Ёи®є 11:42 AM - AS-0028: Effect of High Dose Rosuvastatin Loading Before Percutaneous Coronary Intervention in Female Patients with Non-ST-Segment Elevation Acute Coronary Syndrome й«�иїњ 11:50 AM - и®Ёи®є 110 CIT 2012 www.citmd.com 2012е№ґ3жњ€15ж—Ґ ж�џжњџе›› 11:54 AM - AS-0266: Effects of Intensive Antiplatelet Therapy for Patients with High On-Treatment Platelet Reactivity After Coronary Stent Implantation е…із»Ќд№‰ 12:02 PM - и®Ёи®є 12:06 PM - AS-0068: Same-Day Discharge Following Effective PCI: 10 Year Single Center Experience Zhihua Zhang 12:14 PM - и®Ёи®є 12:18 PM - AS-0066: Risk Score for Prediction of Contrast Induced Nephropathy in Patients underwent Percutaneous Coronary Intervention й‡‘е†¬йњћ 2:58 PM - и®Ёи®є з¬¬дєЊењє дё»жЊЃдєєпјљж›№дё°, U Po Lam, жњ±ж°ёе®Џ 3:00 PM - й‡‘е±ћиЈёж”Їжћ¶жњЇе‰Ќеє”з”ЁиЌЇз‰©ж¶‚е±‚зђѓ е›Љпјљжґћж‚‰PIONEERиЇ•йЄЊ Pieter C. Smits 3:10 PM - и®Ёи®є 5:00 PM - з»Џе† и„‰еѕ®еЇјз®Ўжµ‹е®љFFRжЉЂжњЇзљ„дёґ еєЉеє”з”Ё зЋ‹е®Ѓе¤« 3:34 PM - и®Ёи®є PCIжЉЂжњЇдёЋз–—ж•€з ”з©¶дё“ењє 2:00 PM-6:00 PM 3:36 PM - ж…ўжЂ§е®Ње…Ёй—еЎћд»‹е…ҐжІ»з–—дёзљ„еЇ№еђ» еѕ®еЇјз®ЎжЉЂжњЇ Wasan Udayachalerm з¬¬дёЂењє 3:46 PM - и®Ёи®є дё»жЊЃдєєпјљдЅ•е›ЅзҐҐ, Wei-Kung Tseng, зЄ¦е…‹йќћ 3:48 PM - зјєиЎЂжЂ§еїѓи‚Њз—…зљ„з»Џзљ®е† и„‰д»‹е…Ґ жІ»з–— Thach Nguyen 3:58 PM - и®Ёи®є 2:10 PM - и®Ёи®є 2:12 PM - ж”Їжћ¶иЎЂж “пјљ2012е№ґе®ѓиї�ж�ЇдёЂдёЄ й‡Ќи¦Ѓзљ„и®®йў�еђ—пјџ Chris Kwok-Yiu Wong з¬¬дё‰ењєпј€иЇиЁЂпјљдёж–‡пј‰ 2:22 PM- и®Ёи®є 4:00 PM - е† и„‰е¤§иЎЂз®Ўз—…еЏ�иЌЇз‰©ж”Їжћ¶дёЋиЈёж”Ї жћ¶зљ„е€©дёЋејЉ ж–№е”ЇдёЂ 2:34 PM - и®Ёи®є 2:36 PM - иЌЇз‰©ж”Їжћ¶е№ґд»Јж—‹зЈЁжњЇењЁе¤Ќжќ‚дёЋж…ў жЂ§е®Ње…Ёй—еЎћз—…еЏ�д»‹е…Ґдёзљ„еє”з”Ё Wen-Lieng Lee дё»жЊЃдєєпјљйќіз«‹е†›, з§¦е¦ж–‡, жћ—и‹±еї 4:10 PM - и®Ёи®є 4:12 PM - е°ЏиЎЂз®Ўз—…еЏ�зљ„д»‹е…ҐжІ»з–—иї›е±• й©¬ж №е±± 4:22 PM - и®Ёи®є 2:46 PM - и®Ёи®є 4:24 PM - йќ™и„‰жЎҐиЎЂз®Ўзљ„д»‹е…ҐжІ»з–—з–з•Ґ е€�еЇ… 2:48 PM - е¤„зђ†е† и„‰з©їе”зљ„жЉЂе·§дёЋиЇЂзЄЌ Sundeep Mishra 4:34 PM - и®Ёи®є 111 4:58 PM - и®Ёи®є 3:22 PM - и®Ёи®є 12:30 PM - дј‘дјљ 2:24 PM - еїѓи‚ЊжЎҐеЇ№е† и„‰д»‹е…ҐжІ»з–—зљ„еЅ±е“Ќ Shih-Pu Wang 4:48 PM - еїѓеЉџиѓЅдёЌе…Ёж‚ЈиЂ…ењЁPCIжњЇдёзљ„ иЋ·з›Љ йѓж–‡жЂЎ з¬¬е››ењєпј€иЇиЁЂпјљдёж–‡пј‰ 12:26 PM - и®Ёи®є жў—ж»дїќеЃҐзі»з»џзљ„жЊ‘ж€� Thomas Alexander 4:46 PM - и®Ёи®є 3:12 PM - PAPAиЇ•йЄЊж›ґж–°пјљжЂҐжЂ§еїѓи‚Њжў—ж» дёеє”з”ЁиЌЇз‰©ж¶‚е±‚зђѓе›Љ Ferdinand Kiemeneij 3:24 PM - еє”з”Ё6Fдё»еЉЁи„‰зђѓе›ЉеЏЌжђЏжіµеЇјз®Ўзљ„ дёґеєЉз»ЏйЄЊ Akihiko Takahashi 2:00 PM - ењЁеЌ°еє¦еЏ‘е±•дёЂйЎ№STж®µжЉ¬й«�ећ‹еїѓи‚Њ 4:36 PM - ж— дїќжЉ¤е·¦дё»е№Із—…еЏ�д»‹е…ҐжІ»з–—зљ„иїњ жњџз–—ж•€ жЁЉе†° дё»жЊЃдєєпјљеЌўж‰Ќд№‰, й™¶иґµе‘Ё, еђґе°Џе‡Ў 5:10 PM - и®Ёи®є 5:12 PM - 450дѕ‹е† еїѓз—…ж‚ЈиЂ…IVUS-VHе›ћйЎѕжЂ§ е€†жћђ зЋ‹з„± 5:22 PM - и®Ёи®є 5:24 PM - еЌ•дёеїѓж…ўжЂ§е®Ње…Ёй—еЎћд»‹е…ҐжІ»з–—з»Џ йЄЊпјљжЂҐжЂ§жњџз»“жћњеЏЉй•їжњџдёґеєЉз–—ж•€ жќЋе¦еҐ‡ 5:34 PM - и®Ёи®є 5:36 PM - жЂҐжЂ§еїѓи‚Њжў—ж»дёиҐїеЊ»з»“еђ€дёґеєЉи·Ї еѕ„зљ„жћ„е»єе’ЊиЇ„д»·з ”з©¶ еј ж•Џе·ћ 5:46 PM - и®Ёи®є 5:48 PM - й«�еЋ‹еђЋж‰©еј ењЁиЌЇз‰©ж”Їжћ¶ж¤Ќе…Ґдёзљ„ й‡Ќи¦ЃжЂ§ еЌўж‰Ќд№‰ 5:58 PM - и®Ёи®є 6:00 PM - дј‘дјљ CIT 2012 www.citmd.com 2012е№ґ3жњ€15ж—Ґ ж�џжњџе›› иЇЉж–ж€–д»‹е…ҐжњЇе‰ЌIVUSеє”з”Ёзљ„е®ћдѕ‹жЉҐе‘Љпј€жЇЏ дёЄз—…дѕ‹жЉҐе‘ЉеЏЉй—®з”15е€†й’џпј‰ дё‰е±‚307ABдјљи®®е®¤ з—…дѕ‹ж—©й¤ђдјљпј€дёЂпј‰ жЂҐжЂ§е† и„‰з»јеђ€еѕЃ 7:00 AM-8:00 AM дё»жЊЃдєєпјљи‘›й›·, е†Їз‡•е…‰, й©¬е€©е№і 7:00 AM - CS-0067пјљдёЂдѕ‹жЂҐжЂ§еїѓи‚Њжў—ж»е№¶ дё‰еЏ‰иЎЂж “з—…еЏ�зљ„е¤„зђ† еѕђдєљдјџ 7:10 AM - и®Ёи®є 9:00 AM - з—…дѕ‹1пјљжЂҐжЂ§е† и„‰з»јеђ€еѕЃж‚ЈиЂ… йѓе®Ѓ 9:15 AM - з—…дѕ‹2пјљи‡ЄеЏ‘е¤№е±‚ж‚ЈиЂ… й’±жќ° 9:30 AM - з—…дѕ‹3пјљзі–е°їз—…ж‚ЈиЂ… жќЁеі»йќ’ 9:45 AM - з—…дѕ‹4пјље† зЉ¶еЉЁи„‰з�¤зљ„иЇ„д»· еђґе°Џе‡Ў 10:00 AM - з—…дѕ‹5пјљйЂ еЅ±е……з›€зјєжЌџзљ„иЇ„д»· е€�е¦жіў 12:15 PM - з—…дѕ‹11пјље·¦дё»е№Іжњ«з«Їе€†еЏ‰з—…еЏ� ж”Їжћ¶жњЇ иґєе‹‡ 12:30 PM - дј‘дјљ еЌ€й—ґеЌ«ж�џдјљ йЂљз”Ёз”µж°”иЌЇдёљдё»еЉћ еїѓи‚ѕдїќжЉ¤пјЊд»‹е…Ґй¦–йЂ‰ 12:40 PM-1:55 PM дё»еёпјљзЋ‹жµ·ж�Њ, еѕђдєљдјџ 12:40 PM - ејЂењєи‡ґиѕћ 12:45 PM - е…іжіЁзі–е°їз—…ж‚ЈиЂ…еЇ№жЇ”е‰‚еїѓи‚ѕйЈЋй™© йџ©й›…зЋІ 7:12 AM - CS-0070пјљжЂҐиЇЉPCIжњЇдёдЅїз”ЁZEEK иЎЂж “жЉЅеђёеЇјз®ЎйЃїе…ЌиїЃеѕ™жЂ§ж “еЎћ зҐќй‡‘ж�Ћ 10:15 AM - и™љж‹џз»„з»‡е¦еЏЉе…¶дёґеєЉеЉџз”Ё William Kongto Hau 7:22 AM - и®Ёи®є д»‹е…ҐеЅ±еѓЏ - й‡Ќз‚№иЃљз„¦ 1:35 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 7:24 AM - CS-0285пјљж— дїќжЉ¤е·¦дё»е№Ізљ„з›ґжЋҐ д»‹е…ҐжІ»з–— Sanjay Kumar дё»жЊЃдєєпјљFina Mauri, Gary S. Mintz и®Ёи®єдё“е®¶пјљTakashi Akasaka, Costantino O. Costantini, Soo-Jin Kang, Satoru Sumitsuji 1:50 PM - и¦Ѓз‚№жЂ»з»“ 10:30 AM - е·¦дё»е№Іе† зЉ¶еЉЁи„‰д»‹е…ҐжІ»з–—дё IVUSзљ„еє”з”Ё Soo-Jin Kang OCTеџ№и®иЇѕзЁ‹з¬¬дёЂйѓЁе€† 2:00 PM-6:00 PM 7:34 AM - и®Ёи®є 7:36 AM - CS-0289пјље†ЌйЂљдёЋе†ЌзЃЊжіЁпјљжЂҐжЂ§ е‰ЌеЈЃеїѓжў—жЂҐиЇЉPCIж— е¤ЌжµЃдёЂдѕ‹ дїЎж “еЉ› 7:46 AM - и®Ёи®є 10:45 AM - IVUSеј•еЇјзљ„ж”Їжћ¶зЅ®е…ҐжњЇеЏЉе№¶еЏ‘ з—‡зљ„еЏ‘зЋ°е’ЊиЇ„д»· Costantino O. Costantini 7:48 AM - CS-0356пјљжЂҐжЂ§еїѓи‚Њжў—ж»пјљиЎЂж “ е¦‚дЅ•е¤„зђ†пјџ й™€дїЉ д»‹е…ҐжІ»з–—жњЇдёIVUSеє”з”Ёзљ„е®ћдѕ‹жЉҐе‘Љпј€жЇЏдёЄ з—…дѕ‹жЉҐе‘ЉеЏЉй—®з”15е€†й’џпј‰ 7:58 AM - и®Ёи®є 11:00 AM - з—…дѕ‹6пјљеёёи§„зљ„ж”Їжћ¶е¤§е°Џжµ‹й‡Џ еѕђе‡Ї 8:00 AM - дј‘дјљ IVUSеџ№и®иЇѕзЁ‹з¬¬дёЂйѓЁе€† 8:30 AM-12:30 PM 11:15 AM - з—…дѕ‹7пјљеє”з”ЁIVUS иЇ†е€«е’Њи§Је†і жЂҐжЂ§и†ЁиѓЂдёЌе…Ё йѓе†› д»‹е…ҐжњЇе‰ЌIVUS 11:30 AM - з—…дѕ‹8пјљеє”з”ЁIVUS иЇ†е€«е’Њи§Је†і жЂҐжЂ§иґґеЈЃдёЌи‰Ї е€�еЃҐ дё»жЊЃдєєпјљJavier Escaned, Philip Hung-Chung Wong и®Ёи®єдё“е®¶пјљWilliam Kongto Hau, Soo-Jin Kang, Gary S. Mintz 11:45 AM - з—…дѕ‹9пјљж”Їжћ¶ж¤Ќе…Ґж€–зЁЌеђЋеЏ‘з”џ зљ„жЂҐжЂ§й—еЎћ еЌ•е®€жќ° 8:30 AM - д»‹е…ҐжњЇе‰ЌIVUS Gary S. Mintz 12:00 PM - з—…дѕ‹10пјљз©їе” еѕђиїЋдЅі 1:15 PM - еЇ№жЇ”е‰‚зљ„еїѓи„Џе®‰е…ЁжЂ§ зЋ‹д№ђдё° 1:55 PM - дј‘дјљ д»‹е…ҐжњЇе‰Ќе’ЊжњЇдёOCT дё»жЊЃдєєпјљTakashi Akasaka, William F. Fearon и®Ёи®єдё“е®¶пјљй™€йџµеІ±, Javier Escaned, Michael Kang-Yin Lee, Yoshinobu Onuma, Ron Waksman 2:00 PM - OCTеЅ±еѓЏи§ЈиЇ»зљ„еџєжњ¬и¦Ѓзґ Takashi Akasaka 2:20 PM - иЇЉж–е’Њд»‹е…ҐжњЇе‰Ќеє”з”ЁOCT Yoshinobu Onuma 2:40 PM - OCTеј•еЇјдё‹зљ„д»‹е…ҐжІ»з–—еЏЉе№¶еЏ‘з—‡ иЇ„д»· й™€йџµеІ± 3:00 PM - дё“е®¶и®Ёи®єпјљд»‹е…ҐжњЇдёIVUSиї�ж�Ї OCT - ж€‘еє”иЇҐеє”з”Ёе“ЄдёЂдёЄпјџ 3:15 PM - иЊ¶ж‡ 112 CIT 2012 www.citmd.com 2012е№ґ3жњ€15ж—Ґ ж�џжњџе›› иЇЉж–ж€–д»‹е…ҐжњЇе‰Ќж€–жњЇдёOCTеє”з”Ёзљ„е®ћдѕ‹жЉҐ е‘Љпј€жЇЏдёЄз—…дѕ‹жЉҐе‘ЉеЏЉй—®з”15е€†й’џпј‰ дё»жЊЃдєєпјљGary S. Mintz, Ron Waksman и®Ёи®єдё“е®¶пјљTakashi Akasaka, Javier Escaned, Seung-Ho Hur, Stephen Wai-Luen Lee, Yoshinobu Onuma 3:30 PM - з—…дѕ‹1 дѕЇйќ™жіў 3:45 PM - з—…дѕ‹2 й’±жќ° 4:00 PM - з—…дѕ‹3 е®‹зЋ°ж¶› 4:15 PM - з—…дѕ‹4 е‘Ёж–Ње…Ё 4:30 PM - з—…дѕ‹5 з”°еі° 4:45 PM - з—…дѕ‹6 еЌўж€ђеї— 5:00 PM - з—…дѕ‹7 еЏ¶йЈћ 7:10 AM - и®Ёи®є 7:12 AM - CS-0153пјљејЂеЏЈз—…еЏ�PCIзљ„Szabo жЉЂжњЇ жќЁиѓње€© 7:22 AM - и®Ёи®є 5:45 PM - з—…дѕ‹10 й«�йњЏ 6:00 PM - дј‘дјљ дё‰е±‚308дјљи®®е®¤ з—…дѕ‹ж—©й¤ђдјљпј€дєЊпј‰ е€†еЏ‰з—…еЏ� 7:00 AM-8:00 AM дё»жЊЃдєєпјљж ѕиЌЈеЌЋ, е€�е…Ё, и‚–зєЇ 7:00 AM - CS-0112пјље¤Ќжќ‚е¤ље€†еЏ‰з—…дѕ‹дёЂдѕ‹ дєЋж·® 113 дё»жЊЃдєєпјљAlexandre Abizaid, й™€зєЄиЁЂ 9:30 AM - е·¦дё»е№Іж”Їжћ¶жњЇпјљIVUSеє”з”ЁдєЋж‰Ђжњ‰ з—…дѕ‹ Costantino R. Costantini 7:24 AM - CS-0208пјљи‡Єе€¶6Fж— йћ�жЊ‡еј•еЇјз®Ў з»ЏжЎЎеЉЁи„‰жІ»з–—е¤Ќжќ‚ејЂеЏЈз—…еЏ� е‘Ёж–Ње…Ё 9:45 AM - е·¦дё»е№Іж”Їжћ¶жњЇпјљйЂ‰ж‹©жЂ§еє”з”ЁIVUS Fausto Feres 7:34 AM - и®Ёи®є 10:00 AM - е·¦дё»е№Іж”Їжћ¶жњЇз—…дѕ‹жЉҐе‘Љ е‚…е›Ѕиѓњ 7:36 AM - CS-0272пјљй«�дѕ§еЈЃеїѓжў—зґЇеЏЉз¬¬дёЂ еЇ№и§’ж”Їе’Ње‰Ќй™Ќж”Їж…ўжЂ§й—еЎћзљ„вЂњиЈ™иЈ¤вЂќж”Ї жћ¶жњЇ и’‹еі» 7:46 AM - и®Ёи®є 10:15 AM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” и®Ёи®єдё“е®¶пјљCostantino O. Costantini, Costantino R. Costantini, Fausto Feres, е‚…е›Ѕиѓњ, Sema GГјneri 7:48 AM - CS-0371пјљжЂҐжЂ§еїѓи‚Њжў—ж»жЂҐиЇЉPCI зљ„е€†еЏ‰з—…еЏ�жЊ¤еЋ‹ж”Їжћ¶жњЇ еј жњќй�і HKSTENT at CIT 10:30 AM-12:30 PM 7:58 AM - и®Ёи®є дё»жЊЃдєєпјљMichael Kang-Yin Lee, Martin B. Leon, Eberhard Grube 8:00 AM - дј‘дјљ 5:15 PM - з—…дѕ‹8 Kelvin Chan 5:30 PM - з—…дѕ‹9 и°ўжґЄж™є з¬¬дєЊйѓЁе€†пјље·¦дё»е№Ізљ„дє‰и®® 10:30 AM - HKSTENTпјљж€‘д»¬и·Їеђ‘дЅ•ж–№пјџ Michael Kang-Yin Lee SOLACI at CIT 8:30 AM-10:30 AM з¬¬дёЂйѓЁе€†пјљеїѓи„ЏеЅ±еѓЏе’Њз”џзђ†е¦ з¬¬дёЂйѓЁе€†пјљз»ЏеЇјз®Ўдё»еЉЁи„‰з“ЈзЅ®жЌў 10:35 AM - FFRењЁдёґеєЉе®ћи·µдёзљ„еє”з”Ё Chi-Kin Chan дё»жЊЃдєєпјљMartin B. Leon, Liliana R. Grinfeld 10:47 AM - и®Ёи®є 8:30 AM - жЂЋж ·ж”№е–„з»ЏеЇјз®Ўдё»еЉЁи„‰з“ЈзЅ®жЌў жњЇзљ„е®‰е…ЁжЂ§пјџ Alexandre Abizaid 10:50 AM - OCTи§‚з‚№еЇ№е† и„‰д»‹е…ҐжІ»з–—е®ћи·µ дёЋз ”з©¶зљ„еЅ±е“Ќ Stephen Wai-Luen Lee 8:45 AM - ж–°йў–зљ„з»ЏеЇјз®Ўдё»еЉЁи„‰з“ЈзЅ®жЌўе™Ёжў° Eberhard Grube 11:02 AM - и®Ёи®є 9:00 AM - з»ЏеЇјз®Ўдё»еЉЁи„‰з“ЈзЅ®жЌўз—…дѕ‹жЉҐе‘Љ Michael Kang-Yin Lee 11:05 AM - еЅ“е‰ЌPCIе®ћи·µдёFFRгЂЃIVUSеЏЉ OCTзљ„еє”з”Ё Philip Hung-Chung Wong 9:15 AM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” и®Ёи®єдё“е®¶пјљAlexandre Abizaid, й™€йџµеІ±, Eberhard Grube, Michael Kang-Yin Lee, Sudhir Rathore, еђґж°ёеЃҐ 11:17 AM - и®Ёи®є 11:20 AM - и¦Ѓз‚№жЂ»з»“ Martin B. Leon CIT 2012 www.citmd.com 2012е№ґ3жњ€15ж—Ґ ж�џжњџе›› 2:12 PM - е·¦дё»е№ІдёЋйќће·¦дё»е№Іе€†еЏ‰з—…еЏ�жЂЋж · з‹¬з‰№еЏЉе…¶жЂЋж ·еЅ±е“Ќд»‹е…Ґж“ЌдЅњпјљеЅ±еѓЏе¦жґћеЇџ Gary S. Mintz 4:28 PM - з—…дѕ‹жЉҐе‘Љпјље€†ж”ЇдїќжЉ¤з–з•Ґ - йў„ж‰© еј иї�ж�Їд»…д»…еЋ‹дЅЏеЇјдёќпјџ Kam-Tim Chan 4:34 PM - и®Ёи®є CICF2012жњЂе…·ж•™и‚Іж„Џд№‰е№¶еЏ‘з—‡з—…дѕ‹1 2:24 PM - е† и„‰е€†еЏ‰з—…еЏ�жІ»з–—пјљж¬§жґІе€†еЏ‰з—… еЏ�дї±д№ђйѓЁжњЂж–°дїЎжЃЇ Goran Stankovic 11:25 AM - з—…дѕ‹жЉҐе‘ЉпјљвЂњдёЌзђ†жѓівЂќзљ„ејЂеЏЈ ж”Їжћ¶ж¤Ќе…ҐдёЂдѕ‹ Kin-Lam Tsui 2:36 PM - е·¦дё»е№ІдёЋйќће·¦дё»е№Іе€†еЏ‰з—…еЏ�еЌ•ж€– еЏЊж”Їжћ¶жњЇеђЋе†Ќз‹зЄ„дёЋиЎЂж “зљ„йў„жµ‹е› зґ Antonio Colombo 11:30 AM - дё“е®¶и®Ёи®єпјљж€‘е°†жЂЋж ·еЃљпјџ 2:48 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” и®Ёи®єдё“е®¶пјљAntonio Colombo, Gary S. Mintz, Goran Stankovic, Renu Virmani 4:52 PM - з—…дѕ‹жЉҐе‘ЉпјљжЂЋж ·е¤„зђ†еЏ—жЌџзљ„е€†ж”Їпјџ Chris Kwok-Yiu Wong з¬¬дєЊењєпјље€†еЏ‰з—…еЏ�зљ„и§Је‰–дёЋиЇЉж–иЂѓй‡Џ з¬¬дё‰ењєпјље¤Ќжќ‚йќће·¦дё»е№Іе€†еЏ‰з—…еЏ�зљ„е¤„зђ† дё»жЊЃдєєпјљй™€з»Ќи‰Ї, Jean Fajadet и®Ёи®єдё“е®¶пјљKam-Tim Chan, Alexandra J. Lansky, Thach Nguyen, Teguh Santoso, Dobrin Vassilev, Chris Kwok-Yiu Wong дё»жЊЃдєєпјљй™€зєЄжћ—, Marie-Claude Morice и®Ёи®єдё“е®¶пјљTamzeed Ahmed, Yaron Almagor, й™€и‰Їйѕ™, Antonio Colombo, жџіж™ЇеЌЋ, Yasuhiro Makita з¬¬дєЊйѓЁе€†пјљHKSTENTеїѓиЎЂз®Ўд»‹е…Ґе№¶еЏ‘з—‡и®є еќ›пј€CICFпј‰2012 - дЅ е°†жЂЋж ·еЃљпјџ и®Ёи®єдё“е®¶пјљKam-Tim Chan, Antonio Colombo, йњЌе‹‡, Kin-Lam Tsui, Ping-Tim Tsui, жќЁи·ѓиї› 11:40 AM - ж€‘ж�ЇжЂЋж ·еЃљзљ„пјџ Kin-Lam Tsui CICF2012жњЂе…·ж•™и‚Іж„Џд№‰е№¶еЏ‘з—‡з—…дѕ‹2 11:45 AM - з—…дѕ‹жЉҐе‘ЉпјљвЂњйЂ†еђ‘вЂќд»‹е…ҐжІ»з–— е№¶еЏ‘з—‡дёЂдѕ‹ Tei-Kei Ng 11:50 AM - дё“е®¶и®Ёи®єпјљж€‘е°†жЂЋж ·еЃљпјџ 12:00 PM - ж€‘ж�ЇжЂЋж ·еЃљзљ„пјџ Tei-Kei Ng CICF2012жњЂе…·ж•™и‚Іж„Џд№‰е№¶еЏ‘з—‡з—…дѕ‹3 12:05 PM - з—…дѕ‹жЉҐе‘ЉпјљдёЂдѕ‹ж�‚иґµзљ„д»‹е…Ґ жІ»з–— Michael Chan 12:10 PM - дё“е®¶и®Ёи®єпјљж€‘е°†жЂЋж ·еЃљпјџ 12:20 PM - ж€‘ж�ЇжЂЋж ·еЃљзљ„пјџ Michael Chan 12:25 PM - HKSTENTжњЄжќҐйЎ№з›®еЏЉз»“иЇ Li-Wah Tam 12:30 PM - дј‘дјљ е·¦дё»е№Іе’Ње€†еЏ‰з—…еЏ�еі°дјљз¬¬дёЂйѓЁе€† 2:00 PM-6:07 PM з¬¬дёЂењєпјљж ёеїѓж¦‚еїµ дё»жЊЃдєєпјљAlexandra J. Lansky, зЋ‹жµ·ж�Њ 2:00 PM - е·¦дё»е№ІдёЋйќће·¦дё»е№Іе€†еЏ‰з—…еЏ�жЂЋж · з‹¬з‰№еЏЉе…¶жЂЋж ·еЅ±е“Ќд»‹е…Ґж“ЌдЅњпјљз—…зђ†е¦жґћеЇџ Renu Virmani 2:58 PM - жµЃдЅ“еЉЁеЉ›е¦гЂЃе‰Єе€‡еЉ›еЏЉж–‘еќ—е€† еёѓпјљеЇ№е€†еЏ‰з—…еЏ�жІ»з–—з–з•ҐгЂЃжЂҐжЂ§жњџеЏЉй•ї жњџе®‰е…ЁжЂ§дёЋжњ‰ж•€жЂ§зљ„еђЇз¤є Thach Nguyen 3:10 PM - еёёи§„йЂ еЅ±зљ„е±Ђй™ђжЂ§пјљж–°йў–зљ„дё‰з»ґ йЂ еЅ±еЏЉе…¶д»–жЉЂжњЇ Alexandra J. Lansky 4:40 PM - з—…дѕ‹жЉҐе‘ЉпјљеЇјдёќй‡Ќж–°иї›е…ҐдёЋжњЂз»€ зђѓе›ЉеЇ№еђ»зљ„жЉЂе·§дёЋиЇЂзЄЌ жџіж™ЇеЌЋ 4:46 PM - и®Ёи®є 4:58 PM - и®Ёи®є 5:04 PM - е¤§её€жј”и®Іпјљж€‘е¤„зђ†е¤Ќжќ‚йќће·¦дё»е№І е€†еЏ‰з—…еЏ�зљ„еЌЃйЎ№йЎ¶зє§жЉЂжњЇ Antonio Colombo 5:19 PM - з—…дѕ‹жЉҐе‘Љпјљж€‘ж�ЇжЂЋж ·е¤„зђ†иї™дёЄе¤Ќ жќ‚йќће·¦дё»е№Іе€†еЏ‰з—…еЏ�пјџпј€Medinaе€†ећ‹111пј‰ Sundeep Mishra 5:25 PM - и®Ёи®є 3:22 PM - е€†еЏ‰з—…еЏ�дёе®Њж€ђе’Њи§ЈиЇ»иЇЉж–жЂ§ FFRзљ„е®ћи·µжЂ§ж–№жі• й™€з»Ќи‰Ї 5:31 PM - з—…дѕ‹жЉҐе‘Љпјљж€‘ж�ЇжЂЋж ·е¤„зђ†иї™дёЄе¤Ќ жќ‚йќће·¦дё»е№Іе€†еЏ‰з—…еЏ�пјџ жќЋжЂЎ 3:34 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 5:37 PM - и®Ёи®є 3:44 PM - е€†еЏ‰и§’еє¦еЏЉе…¶еЇ№з–—ж•€зљ„жљ—з¤є Teguh Santoso 5:43 PM - з—…дѕ‹жЉҐе‘Љпјљж€‘ж�ЇжЂЋж ·е¤„зђ†иї™дёЄе¤Ќ жќ‚йќће·¦дё»е№Іе€†еЏ‰з—…еЏ�пјџпј€Medinaе€†ећ‹011пј‰ жќЋдёЅ 3:54 PM - з—…дѕ‹жЉҐе‘ЉпјљзЄ„е¤№и§’зљ„е€†еЏ‰з—…еЏ�еЏЉ жЉЂжњЇйЂ‰ж‹©пј€Medinaе€†ећ‹111пј‰ жќйќ–е®‡ 4:00 PM - и®Ёи®є 4:06 PM - з—…дѕ‹жЉҐе‘Љпјље®Ѕе¤№и§’зљ„е€†еЏ‰з—…еЏ�еЏЉ жЉЂжњЇйЂ‰ж‹©пј€Medinaе€†ећ‹111пј‰ еј дїЉжќ° 4:12 PM - и®Ёи®є 5:49 PM - и®Ёи®є 5:55 PM - з—…дѕ‹жЉҐе‘ЉпјљTж”Їжћ¶еЏЉеЇ№еђ»жЉЂжњЇжІ» з–—и‚ќз»†иѓћз™Њж‚ЈиЂ…ж— дїќжЉ¤е·¦дё»е№Із—…еЏ� Tamzeed Ahmed 6:01 PM - и®Ёи®є 6:07 PM - дј‘дјљ 4:18 PM - ж”Їжћ¶и„Љ / ж–‘еќ—з§»дЅЌеЏЉе…¶еЇ№з–—ж•€зљ„жљ—з¤є Dobrin Vassilev 114 CIT 2012 www.citmd.com 2012е№ґ3жњ€15ж—Ґ ж�џжњџе›› 8:25 AM - Q&A дё‰е±‚309Aдјљи®®е®¤ з—…дѕ‹ж—©й¤ђдјљпј€дё‰пј‰ е·¦дё»е№Із—…еЏ� 7:00 AM-8:00 AM дё»жЊЃдєєпјљжќЋдјџжќ°, й»„зџіе®‰, е”ђи‰Їз§‹ 7:00 AM - CS-0068пјљJR4еЇјеј•еЇјз®ЎењЁе·¦дё»е№І ејЂеЏЈд»‹е…Ґдёзљ„еє”з”Ё й©¬е‡Њ 7:10 AM - и®Ёи®є 7:12 AM - CS-0195пјљдё‰ж”Їз—…еЏ�зґЇеЏЉе·¦дё»е№І зљ„з®ЂеЌ•е¤„зђ† йѓйќ–ж¶› 7:22 AM - и®Ёи®є 7:24 AM - CS-0264пјљIVUSжЊ‡еЇјдё‹е·¦дё»е№Іе€† еЏ‰з—…еЏ�еђ€е№¶дёҐй‡Ќдё‰ж”Їз—…еЏ�PCIдёЂдѕ‹ зҐЃз‚њзЅЎ 7:34 AM - и®Ёи®є 7:36 AM - CS-0284пјље·¦дё»е№Іеђ€е№¶е† и„‰дё‰ж”Ї з—…еЏ�д»‹е…ҐжІ»з–—дёЂдѕ‹ е”ђи‰Їз§‹ 7:46 AM - и®Ёи®є 7:48 AM - CS-0369пјље·¦дё»е№Іе€†еЏ‰з—…еЏ�зљ„д»‹ е…ҐжІ»з–—дёЂдѕ‹ е§њз«‹жё… 7:58 AM - и®Ёи®є 8:00 AM - дј‘дјљ CITжњЂе…·ж•™и‚Іж„Џд№‰з—…дѕ‹з«ћиµ› з¬¬дёЂйѓЁе€† 8:15 AM-12:30 PM з¬¬дёЂењє дё»жЊЃдєєпјљд№”ж ‘е®ѕ з‚№иЇ„дё“е®¶пјљи”Ўе°љйѓЋ, е…‰й›Єеі°, е€�еђЊеє“, й™¶иґµе‘Ё, жќЁж�Ћ, ж›ѕзЋ‰жќ° 8:15 AM - CS-0219пјље† и„‰з©їе”дёЂдѕ‹ Takuro Takama 115 8:30 AM - CS-0030пјљеїѓжў—еђЋдёЂвЂњжіўвЂќдё‰вЂњжЉ�вЂќ ж®·е…†иЉі 8:40 AM - и®Ёи®є 8:45 AM - CS-0031пјље† и„‰е†…еЇјеј•еЇјдёќж–иЈ‚ еђЋж€ђеЉџжЉ“жЌ•дёЂдѕ‹ е™е…†йќ’ 8:55 AM - и®Ёи®є 9:00 AM - CS-0046пјљжЂҐжЂ§еїѓи‚Њжў—еЎћеђ€е№¶е®¤ й—ґйљ”з©їе”е°Ѓе µе™ЁжІ»з–—дёЂдѕ‹ й»„е…љз”џ 9:10 AM - и®Ёи®є 9:15 AM - CS-0048пјљдё»еЉЁи„‰е¤№е±‚и‡ґе·¦дё»е№І й—еЎћдёЂдѕ‹жЉҐе‘Љ еј еї—е›Ѕ 9:25 AM - и®Ёи®є 9:30 AM - CS-0066пјље·¦е† е›ћж—‹ж”ЇејҐжј«жЂ§й‡Ќ еє¦з�¤ж ·ж‰©еј е№¶еЏіж€їз��е°Ѓе µжњЇдёЂдѕ‹ зЋ‹зєўе‹‡ 9:40 AM - и®Ёи®є 9:45 AM - CS-0081пјље“Єж”ЇиЎЂз®Ўж�Їеїѓи‚Њжў—ж» зљ„зЅЄзЉЇиЎЂз®Ўпјџ дѕЇйќ™жіў 9:55 AM - и®Ёи®є 10:00 AM - CS-0090пјљжЂҐжЂ§еїѓи‚Њжў—ж»жє¶ж “жІ» з–—ж— ж•€еђЋжЂҐиЇЉPCIпјљдёЂж¬Ўе®Њж€ђиЎЂиїђй‡Ќе»єпјџ еђґй“ї 10:10 AM - и®Ёи®є 10:15 AM - CS-0092пјље† еїѓз—…еђ€е№¶зІ’з»†иѓћ зјєд№Џ йљЏж°ёе€љ 10:25 AM - и®Ёи®є з¬¬дєЊењє дё»жЊЃдєєпјљзЋ‹дјџж°‘ з‚№иЇ„дё“е®¶пјљй™€зЋ‰е›Ѕ, йѓќжЃ’е‰‘, й©¬з¤јеќ¤, е®‹иЂЂж�Ћ, зЋ‹еє†иѓњ, еј д»ЈеЇЊ 10:30 AM - CS-0111пјљжў…жЇ’жЂ§е† зЉ¶еЉЁи„‰з‚Ћ PCIдёЂдѕ‹ жџіе…ў 10:40 AM - и®Ёи®є 10:45 AM - CS-0140пјљRCAж…ўжЂ§е®Ње…Ёй—еЎћд»‹ е…Ґиї‡зЁ‹дёзљ„е›°йљѕе’Њеє”еЇ№з–з•Ґ е‘Ёе›Ѕдјџ 10:55 AM - и®Ёи®є 11:00 AM - CS-0146пјљйЂ†еђ‘жЉЂжњЇејЂйЂљLADж…ў жЂ§е®Ње…Ёй—еЎћ й©¬е‰‘и‹± 11:10 AM - и®Ёи®є 11:15 AM - CS-0154пјљдє§еђЋAMIж‚ЈиЂ…е·¦дё»е№І е€†еЏ‰з—…еЏ�еЏЌеђ‘Crushж”Їжћ¶жњЇ жќЁиѓње€© 11:25 AM - и®Ёи®є 11:30 AM - CS-0160пјљйЂ†еђ‘RendezvousжЉЂ жњЇж€ђеЉџжІ»з–—LADж…ўжЂ§е®Ње…Ёй—еЎћдёЂдѕ‹ Tse-Min Lu 11:40 AM - и®Ёи®є 11:45 AM - CS-0169пјљдёЂдѕ‹CABGеђЋLMејЂеЏЈ дёҐй‡Ќй’™еЊ–з—…еЏ�зљ„ж—‹зЈЁе’ЊCrushж”Їжћ¶ и’‹еі» 11:55 AM - и®Ёи®є 12:00 PM - CS-0190пјљй’™еЊ–з—…еЏ�ж”Їжћ¶и„±иЅЅ дёЂдѕ‹ е…із‘ћй”¦ 12:10 PM - и®Ёи®є 12:15 PM - CS-0191пјљFFRеј•еЇјзљ„е¤љж”ЇиЎЂз®ЎPCI еј ж°ёзЏЌ 12:25 PM - и®Ёи®є 12:30 PM - дј‘дјљ CIT 2012 www.citmd.com 2012е№ґ3жњ€15ж—Ґ ж�џжњџе›› CITжњЂе…·ж•™и‚Іж„Џд№‰з—…дѕ‹з«ћиµ› з¬¬дєЊйѓЁе€† 2:00 PM-6:00 PM з¬¬е››ењє з¬¬дё‰ењє дё»жЊЃдєєпјљжќЋдёєж°‘ з‚№иЇ„дё“е®¶пјљзЁ‹е† ж�Њ, е§њдёњз‚¬, жќЋе‡Њ, зЋ‹з¦№, и–›зЋ‰з”џ, иµµе…ґиѓњ дё‰е±‚309Bдјљи®®е®¤ дё»жЊЃдєєпјљйѓж–‡жЂЎ з‚№иЇ„дё“е®¶пјљзЁ‹ж ‡, еђ•е®‰жћ—, еЅе»єе†›, е”ђи‰Їз§‹, зЋ‹е®€еЉ›, еј ж ‘жћ— 4:00 PM - CS-0342пјљеїѓиЎ°еђ€е№¶и‚ѕиЎ°е† и„‰д»‹ е…ҐжІ»з–—дёЂдѕ‹ е…іжЂЂж•Џ з—…дѕ‹ж—©й¤ђдјљпј€е››пј‰ е№¶еЏ‘з—‡ 7:00 AM-8:00 AM 2:00 PM - CS-0339пјљIVUSжЊ‡еЇјзљ„ејҐж•ЈLAD ж…ўжЂ§е®Ње…Ёй—еЎћз—…еЏ�PCI е§љд№‰е®‰ 4:10 PM - и®Ёи®є дё»жЊЃдєєпјље…із‘ћй”¦, жќйќ–е®‡, з§¦й›· 4:15 PM - CS-0349пјљIVUSеЇји‡ґжЂҐжЂ§е·¦дё»е№І еЉЁи„‰й—еЎћ You-Chun Huang 7:00 AM - CS-0003пјљAMIжЂҐиЇЉPCIеђЋзЊќж»пјЊ и°Ѓж�ЇзЅЄйЃзҐёй¦–пјџ й‚“дёйѕ™ 4:25 PM - и®Ёи®є 7:10 AM - и®Ёи®є 4:30 PM - CS-0363пјљRCAејЂеЏЈдєЋLADзљ„е€†еЏ‰ з—…еЏ� жќЁжё… 7:12 AM - CS-0004пјљжЉЅе‡єи„±иђЅж”Їжћ¶зљ„ж–° ж–№жі• е†Їй‡‘еЌЋ 4:40 PM - и®Ёи®є 7:22 AM - и®Ёи®є 4:45 PM - CS-0365пјљй‡Ќеє¦й’™еЊ–ж€ђи§’з—…еЏ�еђ€ е№¶е† и„‰з©їе”дёЂдѕ‹ з”°д№ѓдє® 7:24 AM - CS-0023пјљPCIжњЇе‰Ќе† и„‰е†…зљ„е¤§ иЎЂж “ иЅ¦дє¬жґҐ 4:55 PM - и®Ёи®є 7:34 AM - и®Ёи®є 5:00 PM - CS-0366пјљIABPеђЋи…№йѓЁе¤љж”ЇиЎЂз®Ў дёҐй‡ЌиЎЂж “еЅўж€ђи‡ґж»дєЎдёЂдѕ‹ ж›Іж¶› 7:36 AM - CS-0028пјљеЏЌе¤Ќж”Їжћ¶е†…иЎЂж “дёЂдѕ‹ зЋ‹ж�Ґжў… 2:10 PM - и®Ёи®є 2:15 PM - CS-0142пјљжЂҐжЂ§RCAй—еЎће№¶еЏ‘LAD ж”Їжћ¶е†…жЂҐжЂ§й—еЎћж‚ЈиЂ…дёЂдѕ‹ е™ж�Љ 2:25 PM - и®Ёи®є 2:30 PM - CS-0252пјљйЂ†иЎЊеЇјдёќжЉ“жЌ•жЉЂжњЇжІ» з–—еЏіе† зЉ¶еЉЁи„‰иµ·жєђеј‚еёёеђ€е№¶CTOз—…еЏ� жґЄжµЄ 2:40 PM - и®Ёи®є 2:45 PM - CS-0257пјљзЊќж»е№ёе�иЂ…дјґеЏіе† дёҐ й‡Ќз‹зЄ„гЂЃе‰Ќй™Ќж”ЇCTOзљ„е·¦дё»е№Ідё‰е€†еЏ‰з—…еЏ� PCIдёЂдѕ‹ жќЋи™Ћ 2:55 PM - и®Ёи®є 3:00 PM - CS-0268пјље·¦дё»е№Ідё‰е€†еЏ‰з—…еЏ�д»‹ е…ҐпјљеђЊж—¶дё‰зђѓе›Љж‰©еј жЉЂжњЇ Anek Kanoksilp 3:10 PM - и®Ёи®є 3:15 PM - CS-0282пјљLADд»‹е…ҐжњЇеђЋеЏіе† и„‰ е¤№е±‚дёЂдѕ‹ дѕЇе‡¤йњћ 3:25 PM - и®Ёи®є 3:30 PM - CS-0326пјљз»ЏеђЊеђ‘дѕ§жћќйЂ†еђ‘е®Њж€ђ LADж…ўжЂ§е®Ње…Ёй—еЎћз—…еЏ�зљ„е†Ќж¬Ўд»‹е…ҐжІ»з–— иЌ†е…Ёж°‘ 3:40 PM - и®Ёи®є 3:45 PM - CS-0242пјљж”Їжћ¶зєµеђ‘еЏ�еЅўдёЂдѕ‹ Tamon Kato 5:10 PM - и®Ёи®є 5:15 PM - CS-0373пјљACSзљ„е›°еўѓпјљй«�еЌ±зґ§ жЂҐж‰‹жњЇзљ„жЉ‰ж‹© е€�еЃҐ 5:25 PM - и®Ёи®є 5:30 PM - CS-0375пјљеє”з”ЁйЂ†еђ‘PCIжЉЂжњЇжІ»з–— зђѓе›Љж— жі•йЂљиї‡з—…еЏ� еј ж–Њ 5:40 PM - и®Ёи®є 5:45 PM - CS-0354пјљзјєиЎЂжЂ§еїѓи‚Њз—…е·¦дё»е№І е®Ње…Ёй—еЎћз—…еЏ�дёЂдѕ‹ Ping-Han Lo 5:55 PM - и®Ёи®є 6:00 PM - дј‘дјљ 7:46 AM - и®Ёи®є 7:48 AM - CS-0052пјље† зЉ¶еЉЁи„‰еЈЃе†…е»¶иїџиЎЂ и‚їз—…дѕ‹жЉҐе‘Љ ж–ЅйёїжЇ“ 7:58 AM - и®Ёи®є 8:00 AM - дј‘дјљ иЌЇз‰©е¦з ”и®Ёдјљ иµ›иЇєиЏІеЌЏеЉћ 2:00 PM-4:00 PM дё»жЊЃдєєпјљйњЌе‹‡, жќЋе°Џй№°, й™€зєЄиЁЂ, йѓйќ™иђ±, й«�з‚њ 2:00 PM - ејЂењєи‡ґиѕћ 2:05 PM - BARCе‡єиЎЂе®љд№‰еЏЉйў„й�Іе‡єиЎЂз–з•Ґ Thomas Cuisset 3:55 PM - Q&A 116 CIT 2012 www.citmd.com 2012е№ґ3жњ€15ж—Ґ ж�џжњџе›› 8:50 AM - PET/CTж— е€›жЈЂжµ‹ж�“жЌџж–‘еќ—ж–°иї›е±• иµµе…Ёж�Ћ 2:30 PM - ACC/AHAдёЋESCе…ідєЋACSжЉ—ж “жІ» з–—жњЂж–°жЊ‡еЌ—и§ЈиЇ» йѓйќ™иђ± 2:50 PM - STEMIжЉ—е‡ќжІ»з–—ж–°иї›е±• иўЃж™‹йќ’ дё‰е±‚310дјљи®®е®¤ 3:10 PM - дј�еЊ–PCIе›ґж‰‹жњЇжњџжЉ—ж “жІ»з–—з–з•Ґ еј жЉ’ж‰¬ з—…дѕ‹ж—©й¤ђдјљпј€дє”пј‰ е№¶еЏ‘з—‡ 7:00 AM-8:00 AM 3:30 PM - ACSжЉ—ж “жІ»з–—дёґеєЉиЋ·з›ЉдёЋе‡єиЎЂйЈЋ й™©е№іиЎЎ й™€йџµеІ± 3:50 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” иЌЇз‰©е¦з ”и®Ёдјљ ж‹њиЂіеЌЏеЉћ 4:00 PM-5:30 PM дё»жЊЃдєєпјљй«�ж¶¦йњ–, йџ©й›…зЋІ 4:00 PM - ејЂењєи‡ґиѕћ й«�ж¶¦йњ– 4:05 PM - е…·жњ‰еїѓжў—еЏІзљ„ж€їйў¤ж‚ЈиЂ…еЌ’дёйў„й�І ж–°иї›е±•пјљROCKET AFдєљз»„е€†жћђеё¦жќҐзљ„еђЇз¤є еј жѕЌ дё»жЊЃдєєпјљиЌ†е…Ёж°‘, и‹Џж™ћ, з®Ўе†› 7:00 AM - CS-0096пјље°Ѓе µе† и„‰з©їе”зљ„дёЂдёЄ ж–°ж–№жі• жќЁеі»йќ’ 7:10 AM - и®Ёи®є 7:12 AM - CS-0099пјљж€ђеЉџеЏ–е‡єжЎЎеЉЁи„‰д»‹е…Ґ ж—¶жЋ‰е…Ґе† и„‰е†…зљ„еЇјдёќ й©¬дѕќеЅ¤ 7:22 AM - и®Ёи®є 7:24 AM - CS-0113пјљOCTдёЋIVUSиЃ”еђ€еє”з”Ё иЇЉж–PCIжњЇеђЋжЂҐжЂ§й—еЎћдёЂдѕ‹ йџ©еї—е€љ 7:36 AM - CS-0128пјљж”Їжћ¶жњЇдёж— е¤ЌжµЃеЏЉ вЂњз”µйЈЋжљґвЂќдёЂдѕ‹ еј и•ѕ 4:45 PM - д»ЋжњЂж–°жЊ‡еЌ—жЋЁиЌђзњ‹й�їеЏёеЊ№жћ—ењЁе›ґ ж‰‹жњЇжњџзљ„еє”з”Ё дЅ•еҐ” 7:46 AM - и®Ёи®є 7:48 AM - CS-0134пјљPCIжњЇеђЋйЎЅе›єжЂ§дЅЋиЎЂеЋ‹ дёЂдѕ‹ е‘Ёз‚іе‡¤ 7:58 AM - и®Ёи®є 5:25 PM - и¦Ѓз‚№жЂ»з»“ йџ©й›…зЋІ 8:00 AM - дј‘дјљ 5:30 PM - дј‘дјљ еїѓиЎЂз®Ўж— е€›еЅ±еѓЏз ”и®Ёдјљ 8:30 AM-12:30 PM з¬¬дёЂењє дё»жЊЃдєєпјљдЅ•дЅњзҐҐ, зЋ‹жµ©, иµµдё–еЌЋ, еј е†›, еђ•з§Ђз« 8:30 AM - йЃµеѕЄе…±иЇ†дёЋжЊ‡еЌ—пјљдїѓиї›ж€‘е›Ѕеїѓ иЎЂз®ЎеЅ±еѓЏе¦ж–°жЉЂжњЇзљ„и§„иЊѓеЊ–еЏ‘е±• иµµдё–еЌЋ 8:45 AM - и®Ёи®є 117 9:10 AM - жЂҐжЂ§иѓёз—›иЇЉж–пјљд»Ћи¶…еЈ°еїѓеЉЁе›ѕ еѕ—е€°д»Ђд№€пјџ й™€и‰Їйѕ™ 9:25 AM - и®Ёи®є 9:30 AM - и¶…еЈ°еїѓеЉЁе›ѕењЁж€їгЂЃе®¤й—ґйљ”зјєжЌџ д»‹е…Ґе°Ѓе µжІ»з–—дёзљ„дЅњз”Ё еђ•з§Ђз« 9:45 AM - и®Ёи®є 9:50 AM - е®ћж—¶дё‰з»ґи¶…еЈ°еїѓеЉЁе›ѕењЁе…€еїѓз—… д»‹е…Ґе°Ѓе µжІ»з–—дёзљ„дЅњз”Ё еј е†› 10:05 AM - и®Ёи®є 10:10 AM - з»“жћ„жЂ§еїѓи„Џз—…д»‹е…ҐжІ»з–—дёе¤љз§Ќ еЅ±еѓЏзљ„ж•ґеђ€еє”з”Ё Carlos E. Ruiz 10:25 AM - и®Ёи®є 7:34 AM - и®Ёи®є 4:25 PM - ACSдєЊзє§йў„й�Ізљ„зЋ°зЉ¶е’ЊжњЄжќҐпјљ ATLAS ACS 2 TIMI 51з ”з©¶её¦жќҐзљ„еђЇз¤є е‘ЁзЋ‰жќ° 5:05 PM - й�їеЏёеЊ№жћ—жЉ—еЉЁи„‰зІҐж ·зЎ¬еЊ–дЅњз”Ёжњє е€¶зљ„жЋўи®Ё жќЋе°Џй№° 9:05 AM - и®Ёи®є з¬¬дєЊењє дё»жЊЃдєєпјљеђ•ж»Ё, Michael Lim, Shih-Pu Wang, й™€жҐж�џ, еєћж–‡и·ѓ 10:30 AM - е† зЉ¶еЉЁи„‰з—‰жЊ›зљ„е€›дј¤жЂ§еЏЉйќће€› дј¤жЂ§иЇЉж–ж–№жі•иї›е±• еђ‘е®љж€ђ 10:45 AM - и®Ёи®є 10:50 AM - е† зЉ¶еЉЁи„‰CTAењЁдёе›Ѕзљ„еє”з”Ёпјљ жЉЂжњЇеє”з”Ёиї‡еє¦пјЊдїЎжЃЇе€©з”ЁдёЌи¶і йўњзєўе…µ 11:05 AM - и®Ёи®є 11:10 AM - й‡‡з”ЁCTAжЊ‡еЇјPCIд»ҐжЏђй«�е…¶з–—ж•€ еЏЉй™ЌдЅЋе№¶еЏ‘з—‡ Michael Lim 11:25 AM - и®Ёи®є 11:30 AM - й‡‡з”Ёе¤љжЋ’ићєж—‹CTи‡ЄеЉЁиЇ„дј°е† зЉ¶ еЉЁи„‰ж–‘еќ— Johan H. C. Reiber CIT 2012 www.citmd.com 2012е№ґ3жњ€15ж—Ґ ж�џжњџе›› 11:45 AM - и®Ёи®є 11:50 AM - жЂҐжЂ§иѓёз—›и°ѓжџҐз ”з©¶пјљеїѓи„ЏCTеўћ ејєж‰«жЏЏзљ„ж•€з”Ё Ian T. Meredith 12:05 AM - и®Ёи®є 2:05 PM - жќҐи‡Єж¬§жґІзљ„и§‚з‚№пјљиЌЇз‰©ж¶‚е±‚зђѓе›Љ зљ„дёґеєЉеє”з”Ё Franz Weidinger 2:25 PM - жќҐи‡Єдёе›Ѕзљ„и§‚з‚№пјљиЌЇз‰©ж¶‚е±‚зђѓе›Љ зљ„дёґеєЉеє”з”Ё зЋ‹е»єе®‰ 5:10 PM - ж”Їжћ¶иЎЂж “дёЂдѕ‹ е–»еЌ“ 5:20 PM - и®Ёи®є 5:25 PM - е°ЏиЎЂз®Ўе€†еЏ‰з—…еЏ�дёЂдѕ‹ и‹Џж™ћ 2:40 PM - и®Ёи®є 5:35 PM - и®Ёи®є 12:25 AM - и®Ёи®є 2:45 PM - ж”Їжћ¶е†…е†Ќз‹зЄ„зљ„зЋ°зЉ¶еЏЉиЌЇз‰©зђѓе›Љ е€ќжҐеє”з”ЁдЅ“дјљ еђґж°ёеЃҐ 5:40 PM - ж”Їжћ¶е†…е†Ќз‹зЄ„з—…еЏ�е¤„зђ†дєЊдѕ‹ жќЋж‚¦ 12:30 AM - дј‘дјљ 3:00 PM - и®Ёи®є 12:10 AM - з»ЏеЇјз®ЎдєЊе°–з“ЈзЋЇж€ђеЅўжњЇпјљMSCT иЇ„д»·е† зЉ¶йќ™и„‰зЄ¦еЏЉз›ёй‚»з»“жћ„ж�Їеђ¦еї…и¦Ѓпјџ жќЋж–°ж�Ћ еЌ€й—ґеЌ«ж�џдјљ иҐїй—ЁеђеЊ»з–—дё»еЉћ еЅ±еѓЏжЊ‡еЇјдё‹зљ„з»Џзљ®еїѓиЎЂз®Ўд»‹е…ҐжІ»з–—пјљд»Ћ иЇЉж–е€°жІ»з–—гЂЃд»ЋжІ»з–—е€°йў„еђЋ 12:40 PM-1:55 PM 3:05 PM - иЌЇз‰©зђѓе›ЉжІ»з–—ж”Їжћ¶е†…е†Ќз‹зЄ„9дёЄ жњ€йљЏи®їдёЂдѕ‹ й‡‘зђґиЉ± 3:20 PM - ж”Їжћ¶жњЇеђЋиѕ№ж”Їе†Ќз‹зЄ„зљ„е¤„зђ† е®‹зЋ°ж¶› 12:40 PM - ејЂењєи‡ґиѕћ 3:30 PM - и®Ёи®є 12:45 PM - еЏЊжєђCTењЁе† зЉ¶еЉЁи„‰з–ѕз—…иЇЉж–еЏЉ жІ»з–—дёзљ„еє”з”Ё еђґи®їе®Џ 3:35 PM - е¤љеЏ‘ж”Їжћ¶е†…иЎЂж “е¤„зђ† йЅђеђ‘е‰Ќ 1:25 PM - иҐїй—Ёеђе®ћж—¶дё‰з»ґеЅ±еѓЏж•ґдЅ“и§Је†іж–№ жЎ€ењЁеїѓеЇјз®Ўе®¤дёзљ„еє”з”Ё Janina Beilner 1:45 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 1:55 PM - дј‘дјљ дёж¬§д»‹е…Ґеїѓи„Џз—…е¦зѓз‚№и®єеќ› иґќжњ—дёЋж‹њиЂіеЌЏеЉћ 2:00 PM-6:00 PM з¬¬дёЂйѓЁе€† дё»жЊЃдєєпјљFranz Weidinger, еђ•ж ‘й“® и®Ёи®єдё“е®¶пјљдЅ•еҐ”, жџіж™ЇеЌЋ, д№”ж ‘е®ѕ, е‘ЁзЋ‰жќ° 2:00 PM - з›®зљ„з®Ђд»‹ еђ•ж ‘й“® 5:55 PM - и¦Ѓз‚№жЂ»з»“ йњЌе‹‡ 6:00 PM - дј‘дјљ 3:15 PM - и®Ёи®є дё»еёпјљи’‹дё–и‰Ї 1:05 PM - ж ёзЈЃе…±жЊЇж€ђеѓЏжЉЂжњЇењЁеїѓи„Џз–ѕз—…дё зљ„дёґеєЉж„Џд№‰ зЋ‹еї 5:50 PM - и®Ёи®є 3:45 PM - и®Ёи®є 3:50 PM - е¤Ќжќ‚е€†еЏ‰з—…еЏ�дёЂдѕ‹ е€�е¦жіў 4:00 PM - и®Ёи®є 4:05 PM - и¦Ѓз‚№жЂ»з»“ еђ•ж ‘й“® з¬¬дєЊйѓЁе€† дё»жЊЃдєєпјљMartin MГ¶ckel, йњЌе‹‡ и®Ёи®єдё“е®¶пјљзЋ‹жµ·ж�Њ, зЋ‹д№ђдё°, йЏз›џ 4:10 PM - з›®зљ„з®Ђд»‹ йњЌе‹‡ 4:15 PM - еЇ№жЇ”е‰‚и‚ѕз—…еЏ‘з—…жњєе€¶ж–°иї›е±• Martin MГ¶ckel 4:50 PM - и®Ёи®є дё‰е±‚311Aдјљи®®е®¤ з—…дѕ‹ж—©й¤ђдјљпј€е…пј‰ е№¶еЏ‘з—‡ 7:00 AM-8:00 AM дё»жЊЃдєєпјљжќЋжµЄ, йџ©з«‹е®Є, е”ђз–ѕйЈћ 7:00 AM - CS-0163пјљиЌЇз‰©ж”Їжћ¶ж–иЈ‚ж‰Ђи‡ґиїџ еЏ‘ж™љжњџж”Їжћ¶иЎЂж “еј•иµ·зљ„STж®µжЉ¬й«�жЂ§еїѓи‚Њ жў—ж» жќЋжµЄ 7:10 AM - и®Ёи®є 7:12 AM - CS-0199пјљж”Їжћ¶ж–иЈ‚з»§еЏ‘иїџеЏ‘ж™љ жњџж”Їжћ¶иЎЂж “дёЂдѕ‹ е€�иїЋеЌ€ 7:22 AM - и®Ёи®є 7:24 AM - CS-0215пјљPCIжњЇдёеЏіе† зЉ¶еЉЁи„‰е¤№ е±‚дёЂдѕ‹ е€�зєўж— 7:34 AM - и®Ёи®є 4:55 PM - ж”№и‰ЇвЂњиЈ™иЈ¤вЂќејЏж”Їжћ¶жњЇдёЂдѕ‹ е®‰жЇ… 7:36 AM - CS-0223пјље‰Ќй™Ќж”ЇејЂеЏЈй—еЎћз—…еЏ� ејЂйЂљеђЋе·¦дё»е№ІеЏЉе›ћж—‹ж”ЇиЎЂж “ з±ЌжЊЇе›Ѕ 5:05 PM - и®Ёи®є 7:46 AM - и®Ёи®є 118 CIT 2012 www.citmd.com 2012е№ґ3жњ€15ж—Ґ ж�џжњџе›› 7:48 AM - CS-0307пјљж™љжњџж”Їжћ¶иЎЂж “PCIжњЇдё ж— е¤ЌжµЃдёЂдѕ‹ й‡‘зђґиЉ± 7:58 AM - и®Ёи®є 8:00 AM - дј‘дјљ еїѓеЇјз®ЎжњЇеџєзЎЂз¬¬дёЂйѓЁе€† 8:30 AM-12:30 PM з¬¬дёЂењє дё»жЊЃдєєпјљзЋ‹дјџж°‘, з§¦е¦ж–‡, е§њдёњз‚¬, жќЋеє· 8:30 AM - еїѓиЎЂз®Ўи§Је‰–дёЋз”џзђ†е¦ж¦‚иї° и‘›й›· 8:45 AM - и®Ёи®є 8:50 AM - е† зЉ¶еЉЁи„‰йЂ еЅ±жњЇйЂ‚еє”иЇЃдёЋз¦ЃеїЊиЇЃ е‘Ёйў–зЋІ 9:05 AM - и®Ёи®є 9:10 AM - жЎЎеЉЁи„‰з©їе€єеџєжњ¬жЉЂе·§гЂЃеёёи§Ѓе›° йљѕеЏЉе№¶еЏ‘з—‡ е‚…еђ‘еЌЋ 9:25 AM - и®Ёи®є 9:30 AM - з»ЏжЎЎеЉЁи„‰е…Ґи·ЇеЇјз®Ўж“ЌдЅњзљ„жЉЂе·§ дёЋиЇЂзЄЌ й™€зЏЏ 10:45 AM - и®Ёи®є 1:48 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 10:50 AM - е¦‚дЅ•еє”з”ЁдёЋи§ЈиЇ»IVUSпјџ еђґе°Џе‡Ў 1:55 PM - дј‘дјљ 11:05 AM - и®Ёи®є еїѓеЇјз®ЎжњЇеџєзЎЂз¬¬дєЊйѓЁе€† 2:00 PM-6:00 PM 11:10 AM - е¦‚дЅ•еє”з”ЁдёЋи§ЈиЇ»OCTпјџ дѕЇйќ™жіў з¬¬дё‰ењє 11:25 AM - и®Ёи®є дё»жЊЃдєєпјљеґ”й•їзђ®, й«�иїћеђ›, дё›жґЄи‰Ї, иЊѓдёжќ° 11:30 AM - е¦‚дЅ•еє”з”ЁдёЋи§ЈиЇ»FFRпјџ зЋ‹иґµжќѕ 2:00 PM - й”ЃйЄЁдё‹йќ™и„‰з©їе€єжЉЂе·§еЏЉе№¶еЏ‘з—‡ е§љз„° 11:45 AM - и®Ёи®є 2:15 PM - и®Ёи®є 11:50 AM - IABPйЂ‚еє”иЇЃеЏЉж“ЌдЅњи¦Ѓз‚№ жќЋж€ђзҐҐ 2:20 PM - ж€їй—ґйљ”з©їе€єеџєжњ¬жЉЂе·§ жќЋе¦ж–Њ 12:05 PM - и®Ёи®є 2:35 PM - и®Ёи®є 12:10 PM - иЎЂж “жЉЅеђёеЇјз®Ўзљ„дЅїз”ЁжЉЂе·§ зЋ‹д№ђдё° 2:40 PM - еЏіеїѓеЇјз®ЎжњЇеЏЉдёґеєЉж„Џд№‰ еј ж€€е†› 12:25 PM - и®Ёи®є 2:55 PM - и®Ёи®є 12:30 PM - дј‘дјљ 3:00 PM - еєЉж—ЃиЎЂж¶ІеЉЁеЉ›е¦з›‘жµ‹пјљжЊ‡иЇЃгЂЃж“Ќ дЅњи¦Ѓз‚№еЏЉдёґеєЉж„Џд№‰ дё›жґЄи‰Ї еЌ€й—ґеЌ«ж�џдјљ й›…еџ№иЎЂз®Ўд»Єе™ЁйѓЁдё»еЉћ жЊ‘ж€�CTOпјЊй›…еџ№еЉ©ж‚Ёж— ж‰Ђз•Џжѓ§ 12:40 PM-1:55 PM 3:15 PM - и®Ёи®є дё»еёпјљй™€зєЄиЁЂ, дЅ•еҐ”, зЋ‹дјџж°‘, е‘ЁзЋ‰жќ° 3:20 PM - еїѓе†…и†њжґ»жЈЂеџєжњ¬жЉЂе·§пјљйЂ‚еє”иЇЃгЂЃ ж“ЌдЅњеЏЉе№¶еЏ‘з—‡ жІ€зЏ е†› 12:40 PM - ејЂењєи‡ґиѕћ 3:35 PM - и®Ёи®є 10:05 AM - и®Ёи®є 12:43 PM - ж…ўжЂ§е®Ње…Ёй—еЎћиЎЂз®Ўж€ђеЅўжњЇпјљжЈ еђ‘иї�ж�ЇйЂ†еђ‘пјџдЅ•ж—¶д»ҐеЏЉе¦‚дЅ•еЃље‡єжЉ‰ж‹©пјџ William L. Lombardi 3:40 PM - е®‰иЈ…дёґж—¶иµ·жђЏе™Ёзљ„йЂ‚еє”иЇЃдёЋеџєжњ¬ жЉЂе·§ й™€жџЇиђЌ 10:10 AM - е¦‚дЅ•жЈзЎ®й�…иЇ»е† зЉ¶еЉЁи„‰йЂ еЅ±пјџ ж›Іж–°е‡Ї 12:58 PM - TREKзђѓе›Љпјљж— ж‰Ђз•Џжѓ§ жќЋе»єе№і 3:55 PM - и®Ёи®є 10:25 AM - и®Ёи®є 1:13 PM - PROGRESSеЇјдёќпјљж”»е…‹CTOз—…еЏ� зљ„ж–°ж¦е™Ё жќЋжµЄ 9:45 AM - и®Ёи®є 9:50 AM - е† и„‰еЏ�еј‚ж‚ЈиЂ…е† и„‰йЂ еЅ±жЉЂе·§ иЃ‚з»Ќе№і з¬¬дєЊењє дё»жЊЃдєєпјљй«�з‚њ, еј е¤§дёњ, еђґе…¶ж�Ћ, з§¦е‹¤ 10:30 AM - е¦‚дЅ•иї›иЎЊе®љжЂ§е’Ње®љй‡Џе† зЉ¶еЉЁи„‰ йЂ еЅ±е€†жћђпјџ е¤Џз„¶ 119 1:28 PM - ж…ўжЂ§е®Ње…Ёй—еЎћз»Џе…ёз—…дѕ‹е€†дє«пј€дёЂпј‰ зЄ¦е…‹йќћ 1:38 PM - ж…ўжЂ§е®Ње…Ёй—еЎћз»Џе…ёз—…дѕ‹е€†дє«пј€дєЊпј‰ еЏ¶йЈћ з¬¬е››ењє дё»жЊЃдєєпјљд№”ж ‘е®ѕ, жќЋеЌ е…Ё, еґ”иїћзѕ¤, йѓ‘жќЁ 4:00 PM - и‚ҐеЋљжў—й�»ећ‹еїѓи‚Њз—…ж¶€ићЌпјљж‚ЈиЂ…йЂ‰ ж‹©гЂЃж“ЌдЅњжЉЂе·§еЏЉе№¶еЏ‘з—‡ е°¤еЈ«жќ° 4:15 PM - и®Ёи®є 4:20 PM - еЇ№жЇ”е‰‚и‚ѕз—…зљ„йў„й�ІдёЋз®Ўзђ† е€�е®Џж–Њ CIT 2012 www.citmd.com 2012е№ґ3жњ€15ж—Ґ ж�џжњџе›› 4:35 PM - и®Ёи®є 4:40 PM - еїѓеЇјз®ЎжњЇдёXзєїй�ІжЉ¤ зЋ‹е®€еЉ› 4:55 PM - и®Ёи®є 5:00 PM - еђ„з§ЌиЎЂз®Ўй—еђ€пј€еЋ‹иї«пј‰иЈ…зЅ®зљ„дЅї з”ЁжЉЂе·§еЏЉж“ЌдЅњи¦Ѓз‚№ жџіеј� 5:15 PM - и®Ёи®є 5:20 PM - еЇјз®Ўе®¤еёёи§Ѓе№¶еЏ‘з—‡зљ„иЇ†е€«дёЋй�ІжІ» иґѕз»Ќж–Њ 5:35 PM - и®Ёи®є 7:36 AM - CS-0353пјљPCIжњЇдёжЊ‡еј•еЇјз®Ўи‡ґе¤№ е±‚дёЂдѕ‹ Bei Ge 10:45 AM - жЂҐжЂ§еїѓи‚Њжў—ж»еђ€е№¶жќџж”Їдј еЇјй�» ж»ћзљ„еїѓз”µе›ѕж”№еЏ�е’ЊдёґеєЉж„Џд№‰ й©¬и™№ 7:46 AM - и®Ёи®є 11:00 AM - Jжіўз»јеђ€еѕЃзљ„з ”з©¶иї›е±• еј иђЌ 7:48 AM - CS-0360пјљCTOз—…еЏ�ејЂйЂљеђЋж”Їжћ¶ е†…дєљжЂҐжЂ§иЎЂж “еЅўж€ђдёЂдѕ‹ ж±ќзЈЉз”џ 7:58 AM - и®Ёи®є 8:00 AM - дј‘дјљ зЋ°д»Јеїѓз”µе›ѕе¦ 8:30 AM-12:30 PM 5:40 PM - зЋ°д»ЈеЊ–еЇјз®Ўе®¤дїЎжЃЇеЊ–е»єи®ѕзљ„ж–° жЁЎејЏ е€�еЃҐ з¬¬дёЂењє 5:55 PM - и®Ёи®є 8:30 AM - CRTиµ·жђЏеїѓз”µе›ѕеј‚еёёзљ„иЇ†е€«дёЋ е¤„зђ† Yat-Sun Chan 6:00 PM - дј‘дјљ дё»жЊЃдєєпјљж–№дё•еЌЋ, жќЁй’§е›Ѕ, й©¬и™№ 8:45 AM - иµ·жђЏеїѓз”µе›ѕеЏЉж•…йљње€†жћђе¤„зђ† еЌЋдјџ 9:00 AM - жўЇеЅўе›ѕењЁеїѓеѕ‹е¤±еёёиЇЉж–дёзљ„еє”з”Ё зЋ‹еї—жЇ… дё‰е±‚311Bдјљи®®е®¤ з—…дѕ‹ж—©й¤ђдјљпј€дёѓпј‰ е№¶еЏ‘з—‡ 7:00 AM-8:00 AM дё»жЊЃдєєпјљж±џжґЄ, жќЋж‚¦, ж±ќзЈЉз”џ 7:00 AM - CS-0308пјљLADж…ўжЂ§е®Ње…Ёй—еЎћз—… еЏ�д»‹е…ҐжњЇдёе№¶еЏ‘е·¦дё»е№ІжЂҐжЂ§иЎЂж “еЅўж€ђеЏЉ дј‘е…‹дёЂдѕ‹ е‘Ёе›Ѕдјџ 9:15 AM - йЈџз®Ўз”µз”џзђ†жЈЂжџҐиЇЉж–еї«йЂџжЂ§еїѓ еѕ‹е¤±еёё жќЋеї жќ° 9:30 AM - йў„жїЂз»јеђ€еѕЃзљ„ж–°и®¤иЇ† е€�д»Ѓе…‰ 9:45 AM - е®ЅQRSжіўеїѓеЉЁиї‡йЂџзљ„еїѓз”µе›ѕиЇЉж– еј жµ·жѕ„ 10:00 AM - зЄ„QRSжіўеїѓеЉЁиї‡йЂџзљ„еїѓз”µе›ѕиЇЉж– ж–№е…Ё 11:15 AM - Tжіўз ”з©¶зЋ°зЉ¶дёЋиї›е±• зЋ‹зєўе®‡ 11:30 AM - еїѓи„ЏзЊќж»з»јеђ€еѕЃеїѓз”µе›ѕ жќЁй’§е›Ѕ 11:45 AM - жЂҐжЂ§и‚єж “еЎћеЌ±й‡Ќеє¦зљ„еїѓз”µе›ѕ иЇ„дј° жќЋе№їе№і 12:00 PM - еїѓи„ЏжЂ§зЊќж»зљ„еЌ±й™©жЂ§е€†е±‚дёеёё з”Ёзљ„ж— е€›жЂ§еїѓз”µе›ѕе¦ж–№жі•жЇ”иѕѓ ж–№дё•еЌЋ 12:15 PM - еђ¬дј—й—®з” 12:30 PM - дј‘дјљ еЌ€й—ґеЌ«ж�џдјљ д№ђж™®дё»еЉћ ж–°ећ‹иЌЇз‰©ж”Їжћ¶зљ„еЏ‘е±•ж–№еђ‘ 12:40 PM-1:55 PM дё»еёпјљзЁ‹ж™“ж›™, иЃ‚е¦‚зђј, еђґж°ёеЃҐ, еј е®Џ 12:40 PM - дёґеєЉе®ћи·µдёиЌЇз‰©жґ—и„±ж”Їжћ¶йЂ‰ж‹© зљ„е¤љй‡ЌиЂѓи™‘ жћ—и‹±еї 12:55 PM - ж— иЅЅдЅ“иЌЇз‰©жґ—и„±ж”Їжћ¶NANOењЁ дёґеєЉеє”з”Ёдёзљ„дј�еј‚иЎЁзЋ° е®«е‰‘ж»Ё 1:10 PM - иЌЇз‰©жґ—и„±ж”Їжћ¶зљ„еЏ‘е±•ж–№еђ‘ жџіж™ЇеЌЋ 10:15 AM - еђ¬дј—й—®з” 7:12 AM - CS-0323пјљеЇјдёќиї�ж�Їе…€е¤©жЂ§з��еЇј и‡ґзљ„е† и„‰з©їе”пјџ е…із»Ќд№‰ 1:25 PM - NANOж— иЅЅдЅ“иЌЇз‰©жґ—и„±ж”Їжћ¶е¤§и§„ жЁЎдёґеєЉиЇ•йЄЊд»‹з»Ќ жќЁж�Ћ з¬¬дєЊењє 1:40 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 7:22 AM - и®Ёи®є дё»жЊЃдєєпјљYat-Sun Chan, е€�д»Ѓе…‰, еј жµ·жѕ„ 1:55 PM - дј‘дјљ 7:24 AM - CS-0334пјље‰Ќй™Ќж”Їж”Їжћ¶ж–иЈ‚дёЂдѕ‹ е™зЎ• 10:30 AM - еїѓи‚Њжў—ж»зљ„еїѓз”µе›ѕиЇЉж– зЋ‹ж–Њ 7:10 AM - и®Ёи®є 7:34 AM - и®Ёи®є 120 CIT 2012 www.citmd.com 2012е№ґ3жњ€15ж—Ґ ж�џжњџе›› еїѓеѕ‹е¤±еёёз¬¬дёЂйѓЁе€† ж¶€ићЌжЉЂжњЇ 2:00 PM-6:00 PM з¬¬дёЂењє дё»жЊЃдєєпјљзЋ‹зҐ–з¦„, й©¬еќљ, е™и‹±иґ¤, е€�ж–Њ, й’џе›Ѕејє 2:00 PM - з‰№ж®Љз±»ећ‹е®¤дёЉйЂџзљ„иЇЉж–йљѕз‚№дёЋеЇј з®Ўж¶€ићЌ е€�е…ґй№Џ 2:15 PM - и®Ёи®є 2:20 PM - е¤љж¬ЎеЇјз®Ўж¶€ићЌжІ»з–—ж€їйў¤зљ„ж–№жі•е’Њ жЉЂе·§ е€�ж— 2:35 PM - и®Ёи®є 2:40 PM - ж€їйў¤еЇјз®Ўж¶€ићЌзљ„иїњжњџз–—ж•€е’Ње¤ЌеЏ‘ еЋџе› е€†жћђ й©¬еќљ 2:55 PM - и®Ёи®є 3:00 PM - ж…ўжЂ§ж€їйў¤еЇјз®Ўж¶€ићЌдј�еЊ–з–з•Ґ и‘Је»єеўћ 3:15 PM - и®Ёи®є 3:20 PM - з‰№ж®Љж€їжЂ§еїѓеЉЁиї‡йЂџзљ„ж ‡жµ‹е’Њж¶€ићЌ е€�е°‘зЁі 3:35 PM - и®Ёи®є 3:40 PM - ж€їйў¤еЇјз®Ўж¶€ићЌеђЋж€їйЂџж ‡жµ‹дёЋж¶€ићЌ з–з•Ґ дёЃз‡•з”џ 3:55 PM - и®Ёи®є з¬¬дєЊењє дё»жЊЃдєєпјљдёЃз‡•з”џ, е€�ж—, е€�е…ґй№Џ, й«�иїћеђ›, жўЃе…†е…‰ 4:00 PM - з‰№ж®ЉйѓЁдЅЌе®¤йЂџзљ„иЇ†е€«дёЋж¶€ићЌ зЋ‹зҐ–з¦„ 4:15 PM - и®Ёи®є 4:20 PM - е™ЁиґЁжЂ§е®¤йЂџзљ„з»„з»‡е¦еџєзЎЂдёЋж¶€ићЌ ж–№жі• еђґд№¦жћ— 121 4:35 PM - и®Ёи®є 4:40 PM - е€†ж”ЇжЂ§е®¤йЂџж¶€ићЌеђЋзљ„е¤ЌеЏ‘з±»ећ‹ е§љз„° 4:55 PM - и®Ёи®є 5:00 PM - еїѓи‚Њжў—ж»еђЋе®¤йЂџзљ„еЇјз®Ўж¶€ићЌжІ»з–— й™€ж�Ћйѕ™ 5:15 PM - и®Ёи®є 5:20 PM - ICDж¤Ќе…Ґж‚ЈиЂ…еЇјз®Ўж¶€ићЌзљ„ж—¶жњєдёЋ з–з•Ґ жќЁе№ізЏЌ 5:35 PM - и®Ёи®є 5:40 PM - е®¤йў¤з”µз”џзђ†жњєе€¶еЏЉеЇјз®Ўж¶€ићЌ ж±џжґЄ 5:55 PM - и®Ёи®є 6:00 PM - дј‘дјљ CIT 2012 www.citmd.com 2012е№ґ3жњ€16ж—Ґ ж�џжњџдє” 9:40 AM - дё“е®¶и®Ёи®єпјљдёґеєЉз‰№еѕЃиµ„ж–™гЂЃ ж•™и‚ІеЏЉз ”з©¶ з¬¬дє”йѓЁе€† - жњЄжќҐи§†з‚№пјљдё‹дёЂжҐж�Їд»Ђд№€пјџ е››е±‚е¤§дјље ‚AеЊє з¬¬дєЊйѓЁе€† - жЂҐжЂ§еїѓи‚Њжў—ж»пјљжњЂж–°иї›е±• з‰№ж®Љз—…дѕ‹з¤єж•™жј”з¤є 8:00 AM-8:35 AM дё»жЊЃдєєпјљGregg W. Stone, Harry Suryapranata и®Ёи®єдё“е®¶пјљJoseph D. Babb, Kenneth Chin, Fausto Feres, йњЌе‹‡, Mitchell W. Krucoff, Alexandra J. Lansky, Sameer Mehta, жІ€еЌ«еі°, Pieter C. Smits, Alan C. Yeung йЎЅе›єжЂ§й«�иЎЂеЋ‹зљ„з»ЏеЇјз®ЎеЋ»и‚ѕзҐћз»ЏеЊ– е›Ѕе®¶еїѓиЎЂз®Ўз—…дёеїѓй�ње¤–еЊ»й™ў дё»жЊЃдєєпјљMartin B. Leon и®Ёи®єдё“е®¶пјљй™€з»Ќи‰Ї, й«�ж¶¦йњ–, David E. Kandzari, Steven Li, зЅ—е»єж–№, Martin T. Rothman, Markus P. Schlaich, Alan C. Yeung, Robaayah Zambahari, еј з‘ћеІ© жњЇиЂ…пјљHorst Sievert, и’‹й›„дє¬ CIT2012ејЂе№•ејЏ 8:35 AM-9:40 AM дё»жЊЃдєєпјљй«�ж¶¦йњ–, Martin B. Leon и®Ёи®єдё“е®¶пјљи‘›еќ‡жіў, иѓЎе¤§дёЂ, иѓЎз››еЇї, йњЌе‹‡, Osamu Katoh, еђ•ж ‘й“®, Jean Marco, Seung-Jung Park, Patrick W. Serruys, Gregg W. Stone, жќЁи·ѓиї›, еј жѕЌ 8:35 AM - ејЂе№•е®Јдј з‰‡пјљCITеЌЃе№ґе›ћзњё 8:45 AM - ж¬ўиїЋи‡ґиѕћ 10:10 AM - з—…дѕ‹жЉҐе‘Љ е€�еЃҐ 10:15 AM - дё“е®¶и®Ёи®є 10:40 AM - и¦Ѓз‚№з»јеђ€ Gregg W. Stone з¬¬дё‰йѓЁе€† - еЏЊй‡ЌжЉ—иЎЂе°Џжќїй—®йў�пјљд»‹е…ҐжІ»з–— еђЋжЊЃз»й—ґжњџе’Ње·¦еЏідёєйљѕд№‹е¤„ 10:45 AM - з—…дѕ‹жЉҐе‘Љ й‡‘жіЅе®Ѓ жІ»з–—еЏ‘е±•д№‹и·Ї й«�ж¶¦йњ– 10:50 AM - дё“е®¶и®Ёи®є 9:15 AM - з»Џзљ®е† и„‰д»‹е…ҐжІ»з–—зљ„еЋ†еЏІпјљж€‘ д»¬еє”иЇҐд»Ћиї‡еЋ»35е№ґеЏ‘е±•дёдє†и§Јд»Ђд№€пјџ Spencer B. King III 11:15 AM - и¦Ѓз‚№з»јеђ€ Roxana Mehran 9:30 AM - дё“е®¶и®Ёи®є з¬¬е››йѓЁе€† - е¤Ќжќ‚з»Џзљ®е† и„‰д»‹е…ҐжІ»з–—пјљж…ўжЂ§ е®Ње…Ёй—еЎћгЂЃе€†еЏ‰з—…еЏ�еЏЉе¤љж”ЇиЎЂз®Ўз—…еЏ� CIT-TCTе…ЁдЅ“е¤§дјљ 9:40 AM-12:30 PM дё»жЊЃдєєпјљAntonio Colombo, David E. Kandzari, Jeffrey W. Moses и®Ёи®єдё“е®¶пјљMaurice Buchbinder, Costantino R. Costantini, Jean Fajadet, и‘›еќ‡жіў, Osamu Katoh, William L. Lombardi, Marie-Claude Morice, Charles A. Simonton, Etsuo Tsuchikane, жќЁи·ѓиї› дё»жЊЃдєєпјљMartin B. Leon, Patrick W. Serruys и®Ёи®єдё“е®¶пјљChung-Seung Chiang, й«�ж¶¦йњ–, Yean-Leng Lim, Sundeep Mishra, Masahiko Ochiai, Seung-Jung Park, Teguh Santoso, Huay Cheem Tan, Damras Tresukosol, Robaayah Zambahari дё»жЊЃдєєпјљGary S. Mintz, Eberhard Grube е…±еђЊдё»жЊЃдєєпјљMartin B. Leon и®Ёи®єдё“е®¶пјљAlexandre Abizaid, й™€з»Ќи‰Ї, Keith D. Dawkins, William F. Fearon, Ian T. Meredith, Martin T. Rothman, RenuVirmani, RonWaksman, зЋ‹жµ·ж�Њ, John G.Webb 11:55 AM - з—…дѕ‹жЉҐе‘Љ Eberhard Grube 12:00 PM - дё“е®¶и®Ёи®є 12:25 PM - и¦Ѓз‚№з»јеђ€ Martin B. Leon 12:30 PM - дј‘дјљ е…ЁдЅ“ж¬ўиїЋж™ље®ґжљЁйўЃеҐ–д»ЄејЏ 6:45 PM-9:00 PM дё»жЊЃдєєпјљRoxana Mehran, Stephan Windecker и®Ёи®єдё“е®¶пјљй™€зєЄиЁЂ, Donald E. Cutlip, Liliana R. Grinfeld, йџ©й›…зЋІ, David E. Kandzari, Adnan Kastrati, Ajay J. Kirtane, Jean Marco, Samuel K. Mathew, David X. M. Zhao 9:00 AM - CITеЌЃе№ґпјљдёе›Ѕз»Џзљ®еїѓиЎЂз®Ўд»‹е…Ґ з¬¬дёЂйѓЁе€† - дєље¤Єењ°еЊєпјљеїѓиЎЂз®Ўд»‹е…ҐжІ»з–—е¦ еЏ‘е±•е’Њйў†е†›е…Ёзђѓзљ„ж–°е…ґдёеїѓпјЃ 11:50 AM - и¦Ѓз‚№з»јеђ€ Antonio Colombo дёЂе±‚е¤љеЉџиѓЅAеЋ… з¤єж•™жј”з¤є4 е¤–е‘ЁиЎЂз®Ўд»‹е…ҐжІ»з–— е›Ѕе®¶еїѓиЎЂз®Ўз—…дёеїѓй�ње¤–еЊ»й™ў 9:30 AM-11:00 AM дё»жЊЃдєєпјљNeil E. Strickman, зЅ—е»єж–№ и®Ёи®єдё“е®¶пјљеЊ…дїЉж•Џ, W. Britton Eaves, Haizal Haron Kamar, Elias Kassab, Carlos Mena, Jihad Mustapha, Aravinda Nanjundappa, зЋ‹з„±, еј з‘ћеІ©, й‚№и‹±еЌЋ жњЇиЂ…пјљCraig M. Walker, Raghotham R. Patlola, и’‹й›„дє¬ 11:20 AM - з—…дѕ‹жЉҐе‘Љ и‘›й›· 11:25 AM - дё“е®¶и®Ёи®є 122 CIT 2012 www.citmd.com 2012е№ґ3жњ€16ж—Ґ ж�џжњџдє” з¤єж•™жј”з¤є5 з»“жћ„жЂ§еїѓи„Џз—…д»‹е…ҐжІ»з–— е›Ѕе®¶еїѓиЎЂз®Ўз—…дёеїѓй�ње¤–еЊ»й™ў 11:00 AM-12:30 PM дё»жЊЃдєєпјљJan Kovac, и’‹дё–и‰Ї и®Ёи®єдё“е®¶пјљKelvin Chan, Pham Manh Hung, Atilla Iyisoy, е”зҐҐжё…, Jason H. Rogers, Carlos E. Ruiz, Witold Ruzyllo, еј ж™єдјџ, иµµд»™е…€ жњЇиЂ…пјљHorst Sievert, Jacek Bialkowski, Malgorzata Szkutnik, еѕђд»Іи‹± еЌ€й—ґеЌ«ж�џдјљ жіўеЈ«йЎїз§‘е¦дё»еЉћ й“‚й“¬еђ€й‡‘зљ„еЉ›й‡Џпјљејєе¤§еѕЄиЇЃеЊ»е¦жЈЂйЄЊпјЊ еЌ“и¶Љзњџе®ћдё–з•Њеє”з”Ё 12:40 PM-1:55 PM дё»еёпјљJean Marco, жќЁи·ѓиї›, й™€ж–№, й»„еѕ·е�‰, жњ±е»єеЌЋ 12:40 PM - ејЂењєи‡ґиѕћ 12:45 PM - й“‚й“¬еђ€й‡‘зљ„еЉ›й‡ЏпјљеѕЄиЇЃеЊ»е¦зљ„ иЇ•йЄЊйЄЊиЇЃ Ian T. Meredith з¤єж•™жј”з¤є7 ж…ўжЂ§е®Ње…Ёй—еЎћд»‹е…ҐжІ»з–—еЏЉз»ЏеЇјз®Ўдё»еЉЁи„‰ з“ЈзЅ®жЌў дёе›Ѕе›Ѕз«‹еЏ°ж№ѕе¤§е¦еЊ»й™ў 3:30 PM-5:00 PM дё»жЊЃдєєпјљи‘›еќ‡жіў, Eberhard Grube и®Ёи®єдё“е®¶пјљPaul TL Chiam, жќњеї—ж°‘, Ching-Chang Fang, Richard Lim, е€�жѓ дє®, Masahiko Ochiai, Sudhir Rathore, Etsuo Tsuchikane, зЋ‹д№ђдё°, John G. Webb жњЇиЂ…пјљPaul Hsien-Li KaoеЏЉеђЊдє‹ з¤єж•™жј”з¤є8 е·¦дё»е№Іе€†еЏ‰з—…еЏ�д»‹е…ҐжІ»з–— е›Ѕе®¶еїѓиЎЂз®Ўз—…дёеїѓй�ње¤–еЊ»й™ў 5:00 PM-6:30 PM дё»жЊЃдєєпјљJeffrey W. Moses, Ajay J. Kirtane и®Ёи®єдё“е®¶пјљGiuseppe De Luca, дЅ•еҐ”, дѕЇзЋ‰жё…, Kai Huat Lam, Imad Sheiban, Goran Stankovic, Pieter R. Stella, Seung-Jea Tahk, зЋ‹й›·, еј ж–Њ жњЇиЂ…пјљAntonio Colombo, Seung-Jung Park, жќЁи·ѓиї› IVUSи§ЈиЇґдё“е®¶пјљGary S. Mintz 1:05 PM - PROMUS Elementпјљзњџе®ћдё–з•Њеє” з”Ёз»ЏйЄЊдёЋдЅїз”ЁжЉЂе·§ Huay Cheem Tan 1:25 PM - е€›ж–°пјље»єз«‹иЌЇз‰©ж”Їжћ¶ж–°ж ‡е‡†пјЊејЂ ж‹“д»‹е…Ґеїѓи„Џз—…е¦ж–°йў†еџџ Keith D. Dawkins 1:45 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 1:55 PM - дј‘дјљ з¤єж•™жј”з¤є6 йќће·¦дё»е№Іе€†еЏ‰з—…еЏ�ж€–ејЂеЏЈз—…еЏ�д»‹е…ҐжІ»з–— е›Ѕе®¶еїѓиЎЂз®Ўз—…дёеїѓй�ње¤–еЊ»й™ў 2:00 PM-3:30 PM дё»жЊЃдєєпјљGregg W. Stone, Alan C. Yeung и®Ёи®єдё“е®¶пјљAlexandre Abizaid, Thomas Alexander, Donald E. Cutlip, е‚…еђ‘еЌЋ, Adnan Kastrati, е€�еЃҐ, Fina Mauri, Pieter C. Smits, Franz Weidinger, Stephan Windecker жњЇиЂ…пјљJeffrey W. Moses, Maurice Buchbinder, Yaron Almagor IVUSи§ЈиЇґдё“е®¶пјљGary S. Mintz дё»жЊЃдєєпјљJean Marco, й«�ж¶¦йњ– и®Ёи®єдё“е®¶пјљй™€з»Ќи‰Ї, й™€йџµеІ±, Thomas Cuisset, и‘›еќ‡жіў, Kari NiemelГ¤, Goran Stankovic 2:00 PM - з›®зљ„з®Ђд»‹ Jean Marco з—…дѕ‹1пјље¤љж”ЇиЎЂз®Ўз—…еЏ�зљ„жЂҐжЂ§е† и„‰з»јеђ€еѕЃ ж‚ЈиЂ…зґЇеЏЉе€†еЏ‰/е·¦дё»е№Із—…еЏ� 2:05 PM - з—…дѕ‹жЉҐе‘Љ1 й™€йџµеІ± 2:10 PM - ж€‘е°†жЂЋж ·еЃљпјџ й™€з»Ќи‰Ї 2:17 PM - ж€‘е°†жЂЋж ·еЃљпјџ Goran Stankovic 2:24 PM - ж€‘ж�ЇжЂЋж ·еЃљзљ„пјџ й™€йџµеІ± 2:29 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 2:41 PM - е…±иЇ† дёЂе±‚е¤љеЉџиѓЅBеЋ… еЌ€й—ґеЌ«ж�џдјљ еђ‰еЁЃдё»еЉћ й™Ќи§Је€°е¤©з„¶и€¬зљ„еЃҐеє· 12:40 PM-1:55 PM дё»еёпјљAntonio Colombo, й«�ж¶¦йњ–, Eberhard Grube, зЋ‹жµ·ж�Њ 12:40 PM - ејЂењєи‡ґиѕћ 12:45 PM - LEADERSиЇ•йЄЊ4е№ґйљЏи®їз»“жћњ Stephan Windecker 1:05 PM - CREATEжіЁе†Њз™»и®°з ”з©¶5е№ґйљЏи®їз»“жћњ йџ©й›…зЋІ 1:25 PM - OCTењЁиЌЇз‰©жґ—и„±ж”Їжћ¶ж—¶д»Јзљ„еє”з”Ё й™€йџµеІ± 1:45 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 1:55 PM - дј‘дјљ 123 PCR at CIT ж€‘еє”жЂЋж ·жІ»з–—й«�еЌ±жЂҐжЂ§е† и„‰з»јеђ€еѕЃж‚ЈиЂ… еђ€е№¶е¤љж”ЇиЎЂз®Ўз—…еЏ� 2:00 PM-3:30 PM з—…дѕ‹2пјље¤љж”ЇиЎЂз®Ўз—…еЏ�зљ„жЂҐжЂ§е† и„‰з»јеђ€еѕЃ ж‚ЈиЂ…зґЇеЏЉдёЂе¤„ж…ўжЂ§е®Ње…Ёй—еЎћз—…еЏ� 2:46 PM - з—…дѕ‹жЉҐе‘Љ2 Thomas Cuisset 2:51 PM - ж€‘е°†жЂЋж ·еЃљпјџ и‘›еќ‡жіў 2:58 PM - ж€‘е°†жЂЋж ·еЃљпјџ Kari NiemelГ¤ 3:05 PM - ж€‘ж�ЇжЂЋж ·еЃљзљ„пјџ Thomas Cuisset 3:10 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 3:25 PM - е…±иЇ† CIT 2012 www.citmd.com 2012е№ґ3жњ€16ж—Ґ ж�џжњџдє” з”џз‰©еЏЇеђёж”¶ж”Їжћ¶з ”и®Ёеі°дјљ 3:30 PM-5:00 PM дё»жЊЃдєєпјљй«�ж¶¦йњ–, Ian T. Meredith и®Ёи®єдё“е®¶пјљй™€зєЄиЁЂ, Fausto Feres, Yoshinobu Onuma, Patrick W. Serruys, Renu Virmani, Ron Waksman, е‘ЁзЋ‰жќ° 3:30 PM - з›®зљ„з®Ђд»‹ Ian T. Meredith 3:32 PM - дёєд»Ђд№€з”џз‰©еЏЇеђёж”¶ж”Їжћ¶е°†еЏ–д»Јй‡‘ е±ћиЌЇз‰©жґ—и„±ж”Їжћ¶пјџ Patrick W. Serruys 3:39 PM - з”џз‰©еЏЇеђёж”¶ж”Їжћ¶зљ„еёЊжњ›дёЋжЊ‘ж€�пјљ з—…зђ†е¦з ”з©¶еЏ‘зЋ°пјЃ Renu Virmani 3:49 PM - иЌЇз‰©жґ—и„±з”џз‰©еЏЇеђёж”¶й‡‘е±ћж”Їжћ¶зљ„ дёґеєЉе‰Ќе’ЊдёґеєЉиЇ„д»· Ron Waksman 3:59 PM - з”џз‰©еЏЇеђёж”¶ж”Їжћ¶зљ„еЅ±еѓЏе¦пјљ IVUSгЂЃVHгЂЃOCTгЂЃCTAеЏЉе…¶е®ѓ Yoshinobu Onuma 4:09 PM - ж”Їжћ¶з”џз‰©еђёж”¶еђЋж™љжњџе†…зљ®еЉџиѓЅдї® е¤Ќзљ„иЇ„д»·еЏЉжЅњењЁдёґеєЉиЋ·з›Љ Ian T. Meredith 5:00 PM - TRACK-DпјљиЇ„д»·зі–е°їз—…ж‚ЈиЂ…дёеє” з”Ёз‘ћи€’дјђд»–ж±Ђд»Ґйў„й�ІеЇ№жЇ”е‰‚еј•еЏ‘жЂҐжЂ§и‚ѕ жЌџдј¤зљ„е®‰е…ЁжЂ§дёЋжњ‰ж•€жЂ§зљ„е¤§и§„жЁЎгЂЃе¤љдё еїѓгЂЃйљЏжњєеЇ№з…§иЇ•йЄЊ йџ©й›…зЋІ 5:12 PM - и®Ёи®є 4:44 PM - дё“е®¶и®Ёи®є 4:58 PM - и¦Ѓз‚№жЂ»з»“ й«�ж¶¦йњ– 1:50 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 5:34 PM - и®Ёи®є е† и„‰д»‹е…Ґе®ћз”Ёж•™зЁ‹з¬¬дёЂйѓЁе€† жЂЋж ·жІ»з–—пјџ 2:00 PM-6:00 PM 5:44 PM - DOCA-TRIпјљиЇ„д»·5иї›6еЏЊеЇјз®ЎжЉЂ жњЇењЁз»ЏжЎЎеЉЁи„‰жІ»з–—е¤Ќжќ‚е† и„‰з—…еЏ�дёж•€з”Ё зљ„йљЏжњєеЇ№з…§иЇ•йЄЊ еј еҐ‡ 5:54 PM - и®Ёи®є 6:00 PM - SUIT-AMIпјљиЇ„д»·жЂҐжЂ§еїѓи‚Њжў—ж»ж‚Ј иЂ…дёжў—ж»з›ёе…іеЉЁи„‰й«�еє¦йЂ‰ж‹©жЂ§жіЁе…Ґж›їзЅ— йќћзЏеЇ№еїѓи‚Ње†ЌзЃЊжіЁдёЋе‡єиЎЂе№¶еЏ‘з—‡еЅ±е“Ќзљ„ е¤љдёеїѓгЂЃйљЏжњєеЇ№з…§иЇ•йЄЊ йўњзєўе…µ 6:10 PM - и®Ёи®є 6:15 PM - дј‘дјљ дё»жЊЃдєєпјљMartin B. Leon, Patrick W. Serruys, Gregg W. Stone и®Ёи®єдё“е®¶пјљй™€з»Ќи‰Ї, Donald E. Cutlip, Jean Fajadet, Adnan Kastrati, Mitchell W. Krucoff, Roxana Mehran, Ian T. Meredith, Marie-Claude Morice, Stephan Windecker 1:55 PM - дј‘дјљ з¬¬дёЂењє дё»жЊЃдєєпјљй™€зєЄжћ—, йўњзєўе…µ и®Ёи®єдё“е®¶пјљй™€и‰Їйѕ™, йќіз«‹е†›, е€�еЇ…, зЋ‹е‡Ї, еѕђжіЅеЌ‡, ж›ѕе’Њжќѕ з—…дѕ‹1пјљејЂеЏЈз—…еЏ� 2:00 PM - з—…еЏІд»‹з»Ќ дёЃйЈЋеЌЋ 2:05 PM - ж€‘е°†жЂЋж ·еЃљпјџ й™€и‰Їйѕ™ 2:10 PM - ж€‘е°†жЂЋж ·еЃљпјџ йќіз«‹е†› 2:15 PM - з—…дѕ‹жЉҐе‘Љпјљж€‘ж�ЇжЂЋж ·еЃљзљ„пјџ дёЃйЈЋеЌЋ дёЂе±‚е¤љеЉџиѓЅCеЋ… еЌ€й—ґеЌ«ж�џдјљ иµ›иЇєеЊ»з–—дёЋз¦Џеџєй�іе…‰дё»еЉћ BuMAпјљдЅїз”ЁжЂ§иѓЅеЌ“и¶ЉгЂЃе†ЌзЋ°е®ЊзѕЋе†…зљ®еЊ– зљ„иЌЇз‰©жґ—и„±ж”Їжћ¶ 12:40 PM-1:55 PM дё»еёпјљйњЌе‹‡, Renu Virmani, еђґж°ёеЃҐ, е§њй“Ѓж°‘ жњЂж–°дёґеєЉиЇ•йЄЊдёЋз‰№и‰Із ”з©¶й¦–ж¬Ўе…¬еёѓпј€дёЂпј‰ 5:00 PM-6:15 PM 1:35 PM - BuMAж€ђеЉџжЊ‘ж€�е¤Ќжќ‚з—…еЏ�жЎ€дѕ‹з»Џ йЄЊе€†дє«2 жё©е°љз…њ 5:22 PM - DK-CRUSH IIIпјљеЇ№жЇ”еЏЊжЊ¤еЋ‹ж”Їжћ¶ жњЇдёЋиЈ™иЈ¤ж”Їжћ¶жњЇжІ»з–—ж— дїќжЉ¤е·¦дё»е№Іжњ«з«Ї е€†еЏ‰з—…еЏ�зљ„е¤љдёеїѓгЂЃйљЏжњєеЇ№з…§иЇ•йЄЊ й™€з»Ќи‰Ї 4:19 PM - з®ЂеЌ•з—…еЏ�дёеє”з”ЁBVSпјљй�џе€—Aз ” з©¶5е№ґе’Њй�џе€—Bз ”з©¶2е№ґз»“жћњ - ж•°жЌ®зљ„з»јеђ€ йў†ж‚џ Patrick W. Serruys 4:34 PM - е¤Ќжќ‚з—…еЏ�дёеє”з”ЁBVSпјљABSORB Extendз ”з©¶зљ„ж—©жњџз»“жћњ Fausto Feres 1:20 PM - BuMAж€ђеЉџжЊ‘ж€�е¤Ќжќ‚з—…еЏ�жЎ€дѕ‹з»Џ йЄЊе€†дє«1 жґЄй•їж±џ 2:20 PM - жІ»з–—е† и„‰ејЂеЏЈз—…еЏ�зљ„жЉЂе·§дёЋиЇЂзЄЌ й™€зєЄжћ— 2:30 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” з—…дѕ‹2пјљеЇЊеђ«иЎЂж “з—…еЏ� 12:40 PM - ејЂењєи‡ґиѕћ 2:40 PM - з—…еЏІд»‹з»Ќ жќЋж‚¦ 12:45 PM - жЇ”иѕѓдёЌеђЊDESж¤Ќе…ҐеђЋзљ„е†…зљ®еЏЌеє” Renu Virmani 2:45 PM - ж€‘е°†жЂЋж ·еЃљпјџ е€�еЇ… 1:05 PM - й¦–ж¬ЎжЉҐйЃ“пјљйЂљиї‡OCTж–№жі•и§‚еЇџ BuMAеЇ№жЇ”XIENCE Vж¤Ќе…ҐеђЋ3дёЄжњ€е†…зљ®еЊ–жѓ…е†µ дєЋжіў 2:50 PM - ж€‘е°†жЂЋж ·еЃљпјџ ж›ѕе’Њжќѕ 2:55 PM - з—…дѕ‹жЉҐе‘Љпјљж€‘ж�ЇжЂЋж ·еЃљзљ„пјџ жќЋж‚¦ 124 CIT 2012 www.citmd.com 2012е№ґ3жњ€16ж—Ґ ж�џжњџдє” 3:00 PM - жІ»з–—еЇЊеђ«иЎЂж “з—…еЏ�зљ„жЉЂе·§дёЋиЇЂзЄЌ йўњзєўе…µ 3:10 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” з¬¬дё‰ењє дё»жЊЃдєєпјљеђ•ж ‘й“®, зЋ‹дјџж°‘ и®Ёи®єдё“е®¶пјљжґЄжµЄ, и’‹й‡‘жі•, жќЋжµЄ, ж–Ѕжµ·ж�Ћ, зЋ‹ж…§еі°, и®ёеЉ›и€’ з¬¬дєЊењє з—…дѕ‹5пјљй’™еЊ–з—…еЏ� дё‰е±‚306ABдјљи®®е®¤ е¤§её€и®Іеє§пј€дёЂпј‰ й™€зєЄиЁЂж•™жЋ€з»Џе…ёз—…дѕ‹й›†й”¦ JCICеЌЏеЉћ 7:00 AM-7:45 AM дё»жЊЃдєєпјљж–№е”ЇдёЂ, д№”ж ‘е®ѕ и®Ёи®єдё“е®¶пјљй™€з«№еђ›, йѓж–‡жЂЎ, е€�жњќдё, е€�зєўж—, иЃ‚е¦‚зђј, еј е¤§дёњ 4:40 PM - з—…еЏІд»‹з»Ќ еј дїЉжќ° з—…дѕ‹3пјље°ЏиЎЂз®Ўз—…еЏ� 4:45 PM - ж€‘е°†жЂЋж ·еЃљпјџ и’‹й‡‘жі• 3:20 PM - з—…еЏІд»‹з»Ќ жќйќ–е®‡ 4:50 PM - ж€‘е°†жЂЋж ·еЃљпјџ жґЄжµЄ 3:25 PM - ж€‘е°†жЂЋж ·еЃљпјџ еј е¤§дёњ 4:55 PM - з—…дѕ‹жЉҐе‘Љпјљж€‘ж�ЇжЂЋж ·еЃљзљ„пјџ еј дїЉжќ° 12:40 PM - ејЂењєи‡ґиѕћ 3:30 PM - ж€‘е°†жЂЋж ·еЃљпјџ йѓж–‡жЂЎ 5:00 PM - жІ»з–—й’™еЊ–з—…еЏ�зљ„жЉЂе·§дёЋиЇЂзЄЌ зЋ‹дјџж°‘ 3:35 PM - з—…дѕ‹жЉҐе‘Љпјљж€‘ж�ЇжЂЋж ·еЃљзљ„пјџ жќйќ–е®‡ 12:45 PM - е¤Ќжќ‚е† и„‰д»‹е…ҐжІ»з–—дёзљ„еЅ±еѓЏжЊ‡ еЇјеє”з”Ё Marie-Claude Morice 5:10 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 3:40 PM - жІ»з–—е°ЏиЎЂз®Ўз—…еЏ�зљ„жЉЂе·§дёЋиЇЂзЄЌ д№”ж ‘е®ѕ з—…дѕ‹6пјљиЌЇз‰©жґ—и„±ж”Їжћ¶е†…е†Ќз‹зЄ„ 3:50 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 5:20 PM - з—…еЏІд»‹з»Ќ е®‹зЋ°ж¶› з—…дѕ‹4пјљејҐжј«жЂ§й•їз—…еЏ� 4:00 PM - з—…еЏІд»‹з»Ќ жќЋе¦Ќ 5:25 PM - ж€‘е°†жЂЋж ·еЃљпјџ жќЋжµЄ 5:30 PM - ж€‘е°†жЂЋж ·еЃљпјџ ж–Ѕжµ·ж�Ћ 4:05 PM - ж€‘е°†жЂЋж ·еЃљпјџ е€�жњќдё 5:35 PM - з—…дѕ‹жЉҐе‘Љпјљж€‘ж�ЇжЂЋж ·еЃљзљ„пјџ е®‹зЋ°ж¶› 4:10 PM - ж€‘е°†жЂЋж ·еЃљпјџ иЃ‚е¦‚зђј 5:40 PM - жІ»з–—иЌЇз‰©жґ—и„±ж”Їжћ¶е†…е†Ќз‹зЄ„зљ„жЉЂ е·§дёЋиЇЂзЄЌ еђ•ж ‘й“® 4:15 PM - з—…дѕ‹жЉҐе‘Љпјљж€‘ж�ЇжЂЋж ·еЃљзљ„пјџ жќЋе¦Ќ 4:20 PM - жІ»з–—ејҐжј«жЂ§й•їз—…еЏ�зљ„жЉЂе·§дёЋиЇЂзЄЌ ж–№е”ЇдёЂ 4:30 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 5:50 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 6:00 PM - дј‘дјљ еЌ€й—ґеЌ«ж�џдјљ йЂљз”Ёз”µж°”еЊ»з–—дё»еЉћ еЌ“и¶Љеј•йў†вЂњеїѓвЂќи§†з•Њпјље¤Ќжќ‚ж‰‹жњЇзљ„й«�зє§ еЅ±еѓЏжЉЂжњЇеє”з”Ё 12:40 PM-1:55 PM дё»еёпјљдЅ•йќ’, Marie-Claude Morice 1:05 PM - ж…ўжЂ§е®Ње…Ёй—еЎћз—…еЏ�дёе¤љеЅ±еѓЏжЉЂжњЇ иЃ”еђ€еє”з”Ё и‘›еќ‡жіў 1:25 PM - дё‰з»ґеЅ±еѓЏд»‹е…ҐжЉЂжњЇиѕ…еЉ©з»“жћ„жЂ§еїѓ и„Џз—…зљ„жІ»з–—з–з•Ґ Ashok Tirouvanziam 1:45 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 1:55 PM - дј‘дјљ е¤–е‘Ёе’Њи…”е†…иЎЂз®ЎжІ»з–— NCVH at CIT 2:00 PM-6:00 PM дё»жЊЃдєєпјљCraig M. Walker, Raghotham R. Patlola и®Ёи®єдё“е®¶пјљChip B. Hance, Aravinda Nanjundappa 2:00 PM - ејЂе№•и‡ґиѕћ / дё»ж—Ёжј”и®Іпјљдёєд»Ђд№€жЇЏ дЅЌеїѓи„Џз—…дё“е®¶еє”иЇҐзђ†и§Је’Ње№Ійў„е¤–е‘ЁеЉЁи„‰ з–ѕз—…пјџ Craig M. Walker 2:15 PM - дё»еЉЁи„‰-й«‚еЉЁи„‰д»‹е…ҐжІ»з–—пјљжЉЂ е·§гЂЃиЇЂзЄЌеЏЉдїќжЉ¤жЋЄж–Ѕ Raghotham R. Patlola 2:30 PM - дё»еЉЁи„‰д»‹е…ҐжІ»з–—пјљз—…дѕ‹жЉҐе‘Љ ж™ЇењЁе№і 125 CIT 2012 www.citmd.com 2012е№ґ3жњ€16ж—Ґ ж�џжњџдє” 3:00 PM - з—…дѕ‹2 йѓдёЅеђ› 2:40 PM - дё»еЉЁи„‰-й«‚еЉЁи„‰д»‹е…ҐжІ»з–—пјљдё“е®¶и®Ёи®є 2:45 PM - з©їиї‡е®Ње…Ёй—еЎћпјље†…и†њдё‹еЇ»еѕ„гЂЃжІ» з–—е·Ґе…·еЏЉе…Ґи·Їзљ„й‡Ќи¦ЃжЂ§ Jihad Mustapha 3:00 PM - и‚Ўжµ…еЉЁи„‰/ и…їејЇйѓЁеЉЁи„‰з»Џзљ®и…”е†… ж–‘еќ—ж—‹е€‡жњЇ Elias Kassab 3:15 PM - и‚Ўжµ…еЉЁи„‰/ и…їејЇйѓЁеЉЁи„‰ж”Їжћ¶жњЇпјљ ж–°ећ‹ж”Їжћ¶и®ѕи®ЎгЂЃи¦†и†њж”Їжћ¶гЂЃиЌЇз‰©жґ—и„±ж”Ї жћ¶еЏЉз”џз‰©еЏЇеђёж”¶ж”Їжћ¶ Carlos Mena 3:30 PM - и‚Ўжµ…еЉЁи„‰/ и…їејЇйѓЁеЉЁи„‰д»‹е…ҐжІ» з–—пјљз—…дѕ‹жЉҐе‘Љ и’‹й›„дє¬ 3:40 PM - и‚Ўжµ…еЉЁи„‰/ и…їејЇйѓЁеЉЁи„‰д»‹е…ҐжІ» з–—пјљдё“е®¶и®Ёи®є 3:45 PM - и†ќдё‹еЉЁи„‰д»‹е…ҐжІ»з–—пјљи¶ійѓЁе…Ґи·Їзљ„ дЅњз”ЁгЂЃи¶іеј“еЉЁи„‰й‡Ќе»єеЏЉз»Џдѕ§жћќејЂйЂљ Jihad Mustapha дё‰е±‚307ABдјљи®®е®¤ 3:15 PM - з—…дѕ‹3 зЋ‹е®Ѓе¤« е¤§её€и®Іеє§пј€дєЊпј‰ и‘›еќ‡жіўж•™жЋ€з»Џе…ёз—…дѕ‹й›†й”¦ JCICеЌЏеЉћ 7:00 AM-7:45 AM 3:30 PM - з—…дѕ‹4 еЏ¶йЈћ еЌ€й—ґеЌ«ж�џдјљ еЌљиЋ±з§‘дїЎи°Љдё»еЉћ д»‹е…ҐжІ»з–—дёеЇ№жЇ”е‰‚е®‰е…ЁжЂ§жњЂж–°з ”з©¶иї›е±• 12:40 PM-1:55 PM 4:00 PM - иЊ¶ж‡ дё»еёпјљжІ€еЌ«еі° 12:40 PM - ејЂењєи‡ґиѕћ 12:45 PM - еЇ№жЇ”е‰‚жЂҐжЂ§еЏЉиїџеЏ‘жЂ§дёЌи‰ЇеЏЌеє” зљ„йў„й�ІдёЋе¤„зђ† й’±иЏЉи‹± 3:45 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” жњЄжќҐеЏ‘е±• дё»жЊЃдєєпјљWilliam F. Fearon, еђґж°ёеЃҐ и®Ёи®єдё“е®¶пјљJavier Escaned, жќЋе»єе№і, Sidney Tsz Ho Lo, Bon-Kwon Koo 4:15 PM - iFRж�Їд»Ђд№€пјџе®ѓе°†жЂЋж ·дЅїеїѓиЎЂз®Ў д»‹е…ҐеЏ�еѕ—ж›ґе®№ж�“пјџ Javier Escaned 4:30 PM - CT-FFRж�ЇжњЄжќҐеђ—пјџ Bon-Kwon Koo 4:00 PM - и†ќдё‹еЉЁи„‰д»‹е…ҐжІ»з–—пјљз—…дѕ‹жЉҐе‘Љ йѓдјџ 1:15 PM - ж…ўжЂ§и‚ѕз—…ж‚ЈиЂ…PCIе›ґж‰‹жњЇжњџз®Ў зђ†пјљ2011е№ґACC/AHAжЊ‡еЌ—и§ЈиЇ» йўњзєўе…µ 4:10 PM - и†ќдё‹еЉЁи„‰д»‹е…ҐжІ»з–—пјљдё“е®¶и®Ёи®є 1:45 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 4:15 PM - иїњз«ЇдїќжЉ¤дёЋиЎЂж “жЉЅеђёзљ„дЅњз”Ё W. Britton Eaves 1:55 PM - дј‘дјљ 5:00 PM - з—…дѕ‹6 иЃ‚е¦‚зђј 4:30 PM - йў€еЉЁи„‰д»‹е…ҐжІ»з–— Elias Kassab FFRеџ№и®иЇѕзЁ‹ 2:00 PM-6:00 PM 5:15 PM - з—…дѕ‹7 зЋ‹иґµжќѕ 4:45 PM - йў€еЉЁи„‰д»‹е…ҐжІ»з–—пјљз—…дѕ‹жЉҐе‘Љ зЅ—е»єж–№ еЅ“е‰Ќиї›е±• дё»жЊЃдєєпјљJavier Escaned, Seung-Jea Tahk и®Ёи®єдё“е®¶пјљWilliam F. Fearon, Bon-Kwon Koo, Seung-Jung Park 5:30 PM - з—…дѕ‹8 еђґж°ёеЃҐ 2:00 PM - дё»ж—Ёжј”и®Іпјљж€‘жЂЋж ·е’Њдёєд»Ђд№€дЅїз”Ё FFRпјџеџєжњ¬еЋџзђ†гЂЃе®ћи·µеЏЉй™·й�± William F. Fearon 6:00 PM - дј‘дјљ 4:55 PM - йў€еЉЁи„‰д»‹е…ҐжІ»з–—пјљдё“е®¶и®Ёи®є 5:00 PM - и‚ѕеЉЁи„‰ж”Їжћ¶жњЇдёЋи‚ѕеЉЁи„‰еЋ»зҐћз»ЏеЊ– Raghotham R. Patlola 5:15 PM - и‚ѕеЉЁи„‰д»‹е…ҐжІ»з–—пјљз—…дѕ‹жЉҐе‘Љ еј з‘ћеІ© 5:25 PM - и‚ѕеЉЁи„‰д»‹е…ҐжІ»з–—пјљдё“е®¶и®Ёи®є з—…дѕ‹жЉҐе‘Љпј€жЇЏдёЄз—…дѕ‹жЉҐе‘ЉеЏЉй—®з”15е€†й’џпј‰ 4:45 PM - з—…дѕ‹5 жІ€зЏ е†› 5:45 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 2:15 PM - еє”з”ЁFFRд»Ґе»¶зј“д»‹е…ҐжІ»з–— Seung-Jung Park 5:30 PM - й”ЃйЄЁдё‹еЉЁи„‰дёЋж¤ЋеЉЁи„‰д»‹е…ҐжІ»з–— Carlos Mena 2:30 PM - д»‹е…ҐжњЇдёеє”з”ЁFFRпјљд»Ће¤љж”ЇиЎЂз®Ў з—…еЏ�е€°е€†еЏ‰з—…еЏ� Bon-Kwon Koo 5:45 PM - й”ЃйЄЁдё‹еЉЁи„‰д»‹е…ҐжІ»з–—пјљз—…дѕ‹жЉҐе‘Љ зЋ‹з„± з—…дѕ‹жЉҐе‘Љпј€жЇЏдёЄз—…дѕ‹жЉҐе‘ЉеЏЉй—®з”15е€†й’џпј‰ 5:55 PM - й”ЃйЄЁдё‹еЉЁи„‰д»‹е…ҐжІ»з–—пјљдё“е®¶и®Ёи®є 2:45 PM - з—…дѕ‹1 зЋ‹е»єе®‰ 6:00 PM - й—е№•и‡ґиѕћ / дј‘дјљ 126 CIT 2012 www.citmd.com 2012е№ґ3жњ€16ж—Ґ ж�џжњџдє” 2:27 PM - жЂҐжЂ§е† и„‰з»јеђ€еѕЃж‚ЈиЂ…зљ„е·¦дё»е№Із–ѕ з—…пјљPCIиї�ж�ЇCABGпјџ Imad Sheiban дё‰е±‚308дјљи®®е®¤ е¤§её€и®Іеє§пј€дё‰пј‰ йџ©й›…зЋІж•™жЋ€з»Џе…ёз—…дѕ‹й›†й”¦ JCICеЌЏеЉћ 7:00 AM-7:45 AM еЌ€й—ґеЌ«ж�џдјљ ж�џиї›еЊ»з–—дёЋAsahiдё»еЉћ ж‰‹жњЇж€ђеЉџзљ„дёЂеЌЉеЏ–е†ідєЋе™Ёжў°пјљAsahiе™Ёжў° дЅїз”Ёз»ЏйЄЊе€†дє« 12:40 PM-1:55 PM дё»еёпјљй™€зєЄиЁЂ, зЋ‹д№ђдё°, зЋ‹е»єе®‰ 12:40 PM - ејЂењєи‡ґиѕћ 12:45 PM - ж…ўжЂ§е®Ње…Ёй—еЎћйЂ†еђ‘жЉЂжњЇзљ„жЉЂе·§ дёЋиЇЂзЄЌ Etsuo Tsuchikane 12:55 PM - Corsairеѕ®еЇјз®Ўзљ„иїђз”Ё Osamu Katoh 1:05 PM - Asahi Inteccж–°дёЂзєїеЇјдёќ Eisho Kyo 1:15 PM - AsahiеЇјдёќењЁPCIдёґеєЉдёзљ„иїђз”Ё й™€ж™– 1:30 PM - Asahiж–°е™Ёжў°дЅїз”Ёз»ЏйЄЊе€†дє« и‘›еќ‡жіў 2:39 PM - еђ€е№¶й‡Ќеє¦й’™еЊ–зљ„е·¦дё»е№Іе€†еЏ‰з—… еЏ�пјљPCIиї�ж�ЇCABGпјџ Teguh Santoso 2:51 PM - д»‹е…ҐжІ»з–—еЏЇд»ҐдЅњдёєе¤§е¤љж•°е·¦дё»е№І з–ѕз—…зљ„ж›їд»ЈжІ»з–—пјљжќҐи‡Єдёе›Ѕд»‹е…ҐеЊ»з”џзљ„ е®ћи·µи§‚з‚№ й’±иЏЉи‹± 3:03 PM - еЇ№зђ†жѓійЈЋй™©е€†е±‚е·Ґе…·зљ„ж·±жЂќпјљжЇ” Syntaxи®°е€†иµ°еѕ—ж›ґиїњ Davide Capodanno 3:15 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” и®Ёи®єдё“е®¶пјљDavide Capodanno, David E. Kandzari, Marie-Claude Morice, й’±иЏЉи‹±, Teguh Santoso, Imad Sheiban з¬¬дє”ењєпјљеЊєеџџзљ„е·¦дё»е№Ід»‹е…ҐжІ»з–—з»ЏйЄЊ дё»жЊЃдєєпјљй™€ж–№, Thach Nguyen, Sema GГјneri 3:25 PM - е·¦дё»е№Іж”Їжћ¶жњЇпјљеЌ°еє¦з»ЏйЄЊеЏЉй•їжњџз–—ж•€ Debabrata Dash 3:37 PM - е·¦дё»е№Іж”Їжћ¶жњЇпјље·ґиҐїз»ЏйЄЊеЏЉй•їжњџз–—ж•€ Costantino R. Costantini 3:49 PM - е·¦дё»е№Іж”Їжћ¶жњЇпјљдёе›Ѕе¤§ећ‹еЌ•дёеїѓ з»ЏйЄЊеЏЉй•їжњџз–—ж•€ иЌ†е…Ёж°‘ 1:55 PM - дј‘дјљ 4:01 PM - е·¦дё»е№Іж”Їжћ¶жњЇпјљдёе›Ѕе¤§ећ‹еЌ•дёеїѓ з»ЏйЄЊеЏЉй•їжњџз–—ж•€ зЋ‹жµ·ж�Њ е·¦дё»е№Іе’Ње€†еЏ‰з—…еЏ�еі°дјљз¬¬дєЊйѓЁе€† 2:00 PM-6:02 PM 4:13 PM - дёЌеђЊиЌЇз‰©жґ—и„±ж”Їжћ¶жІ»з–—е·¦дё»е№Іе€† еЏ‰з—…еЏ�зљ„жЇ”иѕѓ Wei-Hsian Yin 1:45 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” з¬¬е››ењєпјље·¦дё»е№Іе†ЌиЎЂз®ЎеЊ–пјљPCIеЇ№жЇ”CABG дё»жЊЃдєєпјљEberhard Grube, йџ©й›…зЋІ 2:00 PM - е·¦дё»е№Із–ѕз—…зљ„PCIдёЋCABGеЇ№жЇ”пјљ еЅ“д»ЉйљЏжњєеЇ№з…§иЇ•йЄЊдёЋе¤§и§„жЁЎжіЁе†Њз™»и®°з ” з©¶ж•°жЌ® Marie-Claude Morice 2:15 PM - е·¦дё»е№Ізљ„PCIдёЋCABGпјљзѕЋе›Ѕи¶‹еЉї David E. Kandzari 127 4:25 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” и®Ёи®єдё“е®¶пјљCostantino R. Costantini, Debabrata Dash, иЌ†е…Ёж°‘, зЋ‹жµ·ж�Њ, Wei-Hsian Yin з¬¬е…ењєпјље·¦дё»е№Іе€†еЏ‰з—…еЏ�д»‹е…ҐжІ»з–— дё»жЊЃдєєпјљй™€зєЄжћ—, Kenneth Chin и®Ёи®єдё“е®¶пјљAkihiko Takahashi, Joo-Young Yang 4:35 PM - еЌ•гЂЃеЏЊж”Їжћ¶еЇ№жЇ”пјљеѕЄиЇЃеЊ»е¦дёЋеЇј з®Ўе®¤е®ћз”ЁжЂ§ Jean Fajadet 4:47 PM - IVUSиѓЅеђ¦её®еЉ©зЎ®е®љеЌ•гЂЃеЏЊж”Їжћ¶жњЇејЏпјџ еЌ•е®€жќ° 4:59 PM - FFRиѓЅеђ¦её®еЉ©зЎ®е®љеЌ•гЂЃеЏЊж”Їжћ¶жњЇејЏпјџ Bon-Kwon Koo 5:11 PM - з—…дѕ‹жЉҐе‘Љпјље¤Ќжќ‚е·¦дё»е№Ід»‹е…ҐжІ»з–— дёиЃ”еђ€еє”з”ЁIVUSдёЋFFR еЏ¶йЈћ 5:17 PM - и®Ёи®є 5:23 PM - еЏЊж”Їжћ¶жЉЂжњЇзі»е€—пј€еЏЉжЂЋж ·йЂ‰ж‹©жњЇејЏпј‰ е‚…е›Ѕиѓњ 5:38 PM - з—…дѕ‹жЉҐе‘ЉпјљжЂЋж ·жІ»з–—иї™дѕ‹е¤Ќжќ‚е·¦ дё»е№Ідё‰е€†еЏ‰з—…еЏ�пјџ Teguh Santoso 5:44 PM - и®Ёи®є 5:50 PM - е·¦дё»е№Іе€†еЏ‰з—…еЏ�дё“з”Ёж”Їжћ¶пјљдѕќ жЌ®гЂЃж–°дє§е“ЃеЏЉдЅїз”Ёз»ЏйЄЊ Dobrin Vassilev 6:02 PM - дј‘дјљ CIT 2012 www.citmd.com 2012е№ґ3жњ€16ж—Ґ ж�џжњџдє” 2:45 PM - з—…дѕ‹жЉҐе‘ЉпјљIIећ‹зі–е°їз—…ж‚ЈиЂ…д»‹е…Ґ жІ»з–—еЏЉжњЇеђЋз®Ўзђ† е€�е¦жіў дё‰е±‚309Aдјљи®®е®¤ 2:55 PM - и®Ёи®є еЌ€й—ґеЌ«ж�џдјљ ејєз”џеЊ»з–—дё»еЉћ д»ЋеџєзЎЂе€°еЌ“и¶Љпјљж–°йў†еџџпјЊж–°жЂќи·ЇпјЊж–°Cordis 12:40 PM-1:55 PM 3:00 PM - з—…дѕ‹жЉҐе‘Љпјљзі–е°їз—…еђ€е№¶е€†еЏ‰з—…еЏ� д»‹е…ҐжІ»з–—дёЂдѕ‹ е№Іе¦дёњ дё»еёпјљд№”ж ‘е®ѕ, е‚…е›Ѕиѓњ 12:40 PM - ејЂењєи‡ґиѕћ 12:45 PM - ж€ђеЉџеџєзџіпјљз»ЏжЎЎеЉЁи„‰д»‹е…ҐжІ»з–—е¦‚ дЅ•йЂ‰ж‹©еђ€йЂ‚зљ„жЊ‡еј•еЇјз®Ўпјџпј€еђ«з—…дѕ‹е€†дє«пј‰ жќЋж‚¦ 1:05 PM - дЅ•ж—¶дЅ•е¤„пјље¦‚дЅ•иїђз”Ёй«�еЋ‹зђѓе›ЉжќҐдїќ йљњд»‹е…ҐжІ»з–—е®‰е…ЁеЏЉжњ‰ж•€пјџпј€еђ«з—…дѕ‹е€†дє«пј‰ е‘Ёж–Ње…Ё 1:25 PM - вЂњжЎЎвЂќжњ‰жґће¤©пјље¦‚дЅ•з»ЏжЎЎеЉЁи„‰ејЂ е±•и‚ѕеЉЁи„‰д»‹е…ҐжІ»з–—пјџпј€еђ«з—…дѕ‹е€†дє«пј‰ еѕђдєљдјџ 1:45 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 1:55 PM - дј‘дјљ еїѓиЎЂз®Ўз–ѕз—…еђ€е№¶зі–е°їз—…ж‚ЈиЂ…зљ„з»јеђ€з®Ўзђ† зѕЋж•¦еЉ›еЌЏеЉћ 2:00 PM-6:00 PM 5:45 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 5:55 PM - и¦Ѓз‚№жЂ»з»“ иўЃзҐ–иґ» 6:00 PM - дј‘дјљ 3:10 PM - и®Ёи®є 3:15 PM - з—…дѕ‹жЉҐе‘Љпјљзі–е°їз—…и¶ідё‹и‚ўеЉЁи„‰з—… еЏ�д»‹е…ҐжІ»з–— еє„з™ѕжєЄ 3:30 PM - з—…дѕ‹жЉҐе‘Љпјљзі–е°їз—…и¶ідё‹и‚ўеЉЁи„‰з—… еЏ�д»‹е…ҐжІ»з–— еЊ…дїЉж•Џ дё‰е±‚309Bдјљи®®е®¤ 3:45 PM - и®Ёи®є еЌ€й—ґеЌ«ж�џдјљ й›·з§‘еЊ»з–—дё»еЉћ зѕЋе›Ѕй›·з§‘е…¬еЏёж–°ећ‹еЇјдёќжЉЂжњЇеє”еЇ№е¤Ќжќ‚з—…еЏ� 12:40 PM-1:55 PM з¬¬дєЊйѓЁе€† дё»еёпјљеђ•ж ‘й“®, е‘Ёйў–зЋІ, дё‡еѕЃ, дЅ•еҐ”, зєЄеѕЃ, ж›№е®‡ дё»жЊЃдєєпјљй«�дј зЋ‰, йѓдёЅеђ›, зЋ‹е»єе®‰, иўЃзҐ–иґ» и®Ёи®єдё“е®¶пјљйѓе®Ѓ, жќЋе…‰дјџ, жќЋз»§з¦Џ, жќЋеї—еї , ж…•жњќдјџ, Alan C. Yeung 4:00 PM - еїѓиЎЂз®Ўз–ѕз—…еђ€е№¶зі–е°їз—…ж‚ЈиЂ…зљ„з»ј еђ€з®Ўзђ†пјљиЇЃжЌ®дёЋе®ћи·µ жќЋе…‰дјџ 4:20 PM - жњЂж–°еЅ±еѓЏе¦жЉЂжњЇеЇ№зі–е°їз—…ж‚ЈиЂ…иЎЂ з®Ўжѓ…е†µзљ„е€¤ж–еЏЉд»‹е…ҐжІ»з–—зљ„жЊ‡еЇј йѓе®Ѓ з¬¬дёЂйѓЁе€† 4:35 PM - и®Ёи®є дё»жЊЃдєєпјљй™€зєЄиЁЂ, дЅ•еҐ”, еЌўж‰Ќд№‰, е™з¦Џж€ђ и®Ёи®єдё“е®¶пјљеЊ…дїЉж•Џ, е№Іе¦дёњ, жќЋж�Ґйњ–, е€�е¦жіў, еђґж°ёеЃҐ, еє„з™ѕжєЄ 4:40 PM - з—…дѕ‹жЉҐе‘Љпјљзі–е°їз—…еђ€е№¶ж…ўжЂ§е®Ње…Ё й—еЎћз—…еЏ�д»‹е…ҐжІ»з–—дёЂдѕ‹ ж…•жњќдјџ 2:00 PM - ејЂењєжј”и®Іпјљи·Ёе¦з§‘еђ€дЅњз»јеђ€з®Ўзђ† зі–е°їз—…ж—¶д»Јзљ„е€°жќҐ й™€зєЄиЁЂ 4:50 PM - и®Ёи®є 2:05 PM - еїѓиЎЂз®Ўз—…дёЌеђЊеЌ±й™©е€†е±‚ж‚ЈиЂ…зљ„иЎЂ зі–з®Ўзђ† жќЋж�Ґйњ– 5:25 PM - зі–е°їз—…ж‚ЈиЂ…е† и„‰д»‹е…ҐжІ»з–—иї›е±• Alan C. Yeung 4:55 PM - з—…дѕ‹жЉҐе‘ЉпјљйќћSTж®µжЉ¬й«�ећ‹жЂҐжЂ§е† и„‰з»јеђ€еѕЃж‚ЈиЂ…еђ€е№¶зі–е°їз—…д»‹е…ҐжІ»з–—дёЂдѕ‹ жќЋеї—еї 5:05 PM - и®Ёи®є 2:25 PM - е† зЉ¶еЉЁи„‰йЂ еЅ±и§‚еЇџпјљзі–е°їз—…ж‚ЈиЂ… зљ„иЎЂз®ЎиЇ„д»·еЏЉPCIз–з•Ґ еђґж°ёеЃҐ 5:10 PM - з—…дѕ‹жЉҐе‘ЉпјљSTж®µжЉ¬й«�ећ‹жЂҐжЂ§еїѓи‚Њ жў—ж»ж‚ЈиЂ…еђ€е№¶зі–е°їз—…д»‹е…ҐжІ»з–—дёЂдѕ‹ жќЋз»§з¦Џ 2:40 PM - и®Ёи®є 5:20 PM - и®Ёи®є 12:40 PM - ејЂењєи‡ґиѕћ 12:45 PM - зѕЋе›Ѕй›·з§‘е…¬еЏёж–°ећ‹еЇјдёќжЉЂжњЇеє” еЇ№е¤Ќжќ‚з—…еЏ� Ron Amanda 12:55 PM - Regattaе·ҐдЅњеЇјдёќжЊ‘ж€�е¤Ќжќ‚з—…еЏ� й™€дїЉ 1:10 PM - Regatta SB DeflectorжЉЂжњЇиЅ»жќѕеє” еЇ№е¤Ќжќ‚е€†еЏ‰з—…еЏ� зЅ—е»єж–№ 1:25 PM - Regatta HSж–°ећ‹WedgeжЉЂжњЇи·Ёи¶Љ CTOз—…еЏ� зєЄеѕЃ 1:40 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 1:55 PM - дј‘дјљ еџєзЎЂдёЋиЌЇз‰©з¬¬дёЂйѓЁе€† 2:00 PM-6:00 PM з¬¬дёЂењє дё»жЊЃдєєпјљй™€зЃЏзЏ , жњ±ж–‡зЋІ, й™€еђ›жџ±, и’‹е®ќзђ¦, з›–йІЃзІ¤, жќЋе№їе№і 128 CIT 2012 www.citmd.com 2012е№ґ3жњ€16ж—Ґ ж�џжњџдє” 2:40 PM - еЌµењ†е”жњЄй—е°Ѓе µжњЇйў„й�Іи„‘еЌ’дё David X. M. Zhao 2:00 PM - дёеїѓеЏ‘иЁЂпјљеЉЁи„‰зІҐж ·зЎ¬еЊ–еЏ‘з”џжњє е€¶ - 2011е№ґе›ћйЎѕ е”ђжњќжћў 2:25 PM - иЎЂз®Ўе†…зљ®дї®е¤ЌиѓЅеЉ›зљ„еџєе› и°ѓжЋ§ й™¶е†› дё‰е±‚310дјљи®®е®¤ 2:40 PM - еџєдєЋз‚Ћз—‡жњєе€¶зљ„еЉЁи„‰зІҐж ·зЎ¬еЊ–з”џ з‰©ж ‡еї—з‰© з”°й‡Ћ е¤§её€и®Іеє§пј€е››пј‰ еђ•ж ‘й“®ж•™жЋ€з»Џе…ёз—…дѕ‹й›†й”¦ JCICеЌЏеЉћ 7:00 AM-7:45 AM 2:55 PM - и®Ёи®є 3:00 PM - дёеїѓеЏ‘иЁЂпјљи„‚д»Ји°ўеј‚еёёдёЋдёґеєЉ 2011е№ґе›ћйЎѕ жќЋе»єе†› 3:25 PM - дЅЋеЇ†еє¦и„‚и›‹з™Ѕиѓ†е›єй†‡дёЋеЉЁи„‰зІҐж · зЎ¬еЊ–зљ„ж–°и§‚з‚№ еЏ¶е№і 3:40 PM - й«�еЇ†еє¦и„‚и›‹з™Ѕиѓ†е›єй†‡дёЋеЉЁи„‰зІҐж · зЎ¬еЊ–зљ„ж–°и®¤иЇ† й™€зєў 3:55 PM - и®Ёи®є з¬¬дєЊењє дё»жЊЃдєєпјљй»„еѕ·е�‰, жџЇе…ѓеЌ—, й»„жЊЇж–‡, еѕђж ‡, еј ж�Ћ, ж›№дё° 4:00 PM - дёеїѓеЏ‘иЁЂпјљеїѓи‚ЊзјєиЎЂдёЋжў—ж» - 2:55 PM - и®Ёи®є 3:00 PM - Watchmanе·¦ж€їиЂійѓЁе°Ѓе µе™Ёзљ„дёґ еєЉеє”з”Ё Dominic Allocco 3:15 PM - и®Ёи®є еЌ€й—ґеЌ«ж�џдјљ е…€еЃҐз§‘жЉЂдё»еЉћ е…€е¤©жЂ§еїѓи„Џз—…д»‹е…ҐжІ»з–—зљ„йќ©е‘Ѕ 12:40 PM-1:55 PM 3:20 PM - з“Је‘ЁжјЏзљ„е°Ѓе µжњЇ жЅ�ж¬Ј дё»еёпјљи’‹дё–и‰Ї 3:40 PM - з©їе€єж€їй—ґйљ”з»Џе·¦е®¤йЂ”еѕ„д»‹е…ҐжІ»з–— з»“жћ„жЂ§еїѓи„Џз—… Carlos E. Ruiz 12:40 PM - ејЂењєи‡ґиѕћ 12:45 PM - FuStarеЏЇи°ѓејЇйћ�ењЁз»“жћ„жЂ§еїѓи„Џ з—…д»‹е…ҐжІ»з–—дёзљ„еє”з”Ё Yat-Yin Lam 1:05 PM - Ceraе°Ѓе µе™ЁењЁдёе›Ѕзљ„йљЏи®їз»“жћњеЏЉ е…ЁзђѓдЅїз”Ёжѓ…е†µ еј ж™єдјџ 1:25 PM - еЉЁи„‰еЇјз®ЎжњЄй—е°Ѓе µжњЇз»ЏйЄЊе’Њйљѕйў� Manoj Kumar Rohit 1:45 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 3:35 PM - и®Ёи®є 3:55 PM - и®Ёи®є 4:00 PM - з»Џзљ®дєЊе°–з“Јж€ђеЅўжњЇдёзђѓе›ЉдёЌиѓЅжЉЅ з�ЄпјљдёЂдѕ‹зЅ•и§Ѓе№¶еЏ‘з—‡ Vikas Bisne 4:15 PM - и®Ёи®є з¬¬дєЊењє дё»жЊЃдєєпјљи’‹дё–и‰Ї, Pham Gia Khai, жќЋеЌЋжі°, зЋ‹е№їд№‰, еј ж€€е†›, Ajit G. Desai и®Ёи®єдё“е®¶пјљXiwei Deng, Pham Manh Hung, Hweung Kon Hwang, Witold Ruzyllo, Malgorzata Szkutnik 2011е№ґе›ћйЎѕ дЅ•еҐ” 1:55 PM - дј‘дјљ 4:25 PM - зјєиЎЂйў„йЂ‚еє”дёЋеђЋйЂ‚еє”зљ„дёґеєЉеє”з”Ё жќЁеђ‘е†› з»“жћ„жЂ§еїѓи„Џз—…з¬¬дёЂйѓЁе€† 2:00 PM-6:00 PM 4:40 PM - е† и„‰ж— е¤ЌжµЃзЋ°и±Ўзљ„е€†еђжњєе€¶дёЋдёґ еєЉе№Ійў„ й»„еІљ з¬¬дёЂењє 4:35 PM - и®Ёи®є дё»жЊЃдєєпјље‘Ёз€±еЌї, Carlos E. Ruiz, е”зҐҐжё…, иµµдё–еЌЋ, Dongming Hou, Atilla Iyisoy и®Ёи®єдё“е®¶пјљDominic Allocco, Jacek Bialkowski, жЅ�ж¬Ј, Horst Sievert, David X. M. Zhao 4:40 PM - й‡‡з”ЁInoueзђѓе›ЉйЎєиЎЊдё»еЉЁи„‰з“Јзђѓ е›Љж€ђеЅўжњЇ Hweung Kon Hwang 4:55 PM - и®Ёи®є 5:00 PM - дёеїѓеЏ‘иЁЂпјље№Із»†иѓћжІ»з–— - 2011е№ґ е›ћйЎѕ и‘›еќ‡жіў 5:25 PM - е№Із»†иѓћжІ»з–—зљ„й”™иЇЇж¦‚еїµ Jie Wang 5:40 PM - зјєиЎЂжЂ§еїѓи‚Њз—…зљ„е№Із»†иѓћжІ»з–— жќЁеї—еЃҐ 2:00 PM - е·¦ж€їиЂійѓЁе°Ѓе µжњЇзљ„зЋ°зЉ¶ Horst Sievert 2:15 PM - и®Ёи®є 2:20 PM - дё»еЉЁи„‰ж”Їжћ¶ж¤Ќе…ҐжњЇжІ»з–—дё»еЉЁи„‰зј© 4:20 PM - дё»еЉЁи„‰зЄ¦з�¤з ґиЈ‚зљ„д»‹е…ҐжІ»з–— Malgorzata Szkutnik 4:55 PM - и®Ёи®є 5:00 PM - з»Џзљ®и‚єеЉЁи„‰з“Јж¤Ќе…ҐжњЇ Witold Ruzyllo 5:15 PM - и®Ёи®є 5:55 PM - и®Ёи®є зЄ„пјљжіўе…°з»ЏйЄЊ Jacek Bialkowski 5:20 PM - з»Џзљ®дєЊе°–з“Јзђѓе›Љж€ђеЅўжњЇпјљи¶ЉеЌ—зљ„зЋ°зЉ¶ Pham Manh Hung 6:00 PM - дј‘дјљ 2:35 PM - и®Ёи®є 5:35 PM - и®Ёи®є 129 CIT 2012 www.citmd.com 2012е№ґ3жњ€16ж—Ґ ж�џжњџдє” 5:40 PM - й‡‡з”Ёењ€еҐ—е™Ёе¦‚дЅ•е¤„зђ†д»‹е…ҐжњЇдёзљ„ е№¶еЏ‘з—‡пјџ Xiwei Deng 2:03 PM - дєљжґІSTж®µжЉ¬й«�ећ‹еїѓи‚Њжў—ж»пјљиї…йЂџ еўћй•їзљ„жµЃиЎЊз—… Robaayah Zambahari 5:55 PM - и®Ёи®є 2:15 PM - дёе›ЅSTж®µжЉ¬й«�ећ‹еїѓи‚Њжў—ж»жІ»з–—зЋ° зЉ¶еЏЉжЊ‡еЌ—ж›ґж–°и§ЈиЇ» жІ€еЌ«еі° 6:00 PM - дј‘дјљ 2:27 PM - е¦‚дЅ•ж”№иї›D2Bз»“жћњпјџ Sameer Mehta дё‰е±‚311Aдјљи®®е®¤ е¤§её€и®Іеє§пј€дє”пј‰ зЋ‹дјџж°‘ж•™жЋ€з»Џе…ёз—…дѕ‹й›†й”¦ JCICеЌЏеЉћ 7:00 AM-7:45 AM еЌ€й—ґеЌ«ж�џдјљ й‡‘з‘ће‡Їе€©дё»еЉћ е…Ёеїѓзљ„ејЂе§‹пјљжµ·е€©ж¬§ж–Ї 12:40 PM-1:55 PM дё»еёпјљжќЋеЌ е…Ё, зЋ‹дјџж°‘, ж–№е”ЇдёЂ 12:40 PM - ејЂењєи‡ґиѕћ 12:45 PM - HOPEпјљжµ·е€©ж¬§ж–Їз”џз‰©еЏЇй™Ќи§Ј иЃљеђ€з‰©иҐїиЋ«зЅ—еЏёжґ—и„±ж”Їжћ¶е‰Ќзћ»жЂ§гЂЃе¤љдё еїѓгЂЃйљЏжњєеЇ№з…§дёґеєЉиЇ•йЄЊ - 24дёЄжњ€йљЏи®їз»“жћњ еђ•ж ‘й“® 2:42 PM - жќҐи‡ЄHORIZONS-AMIиЇ•йЄЊзљ„е…ій”® жЂ§з»ЏйЄЊпјљжЇ”дјђеЌўе®ље’ЊиЌЇз‰©жґ—и„±ж”Їжћ¶ Roxana Mehran 2:57 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” STж®µжЉ¬й«�ећ‹еїѓи‚Њжў—ж»е…Ёзђѓй�ІжІ»иї›е±• дё»жЊЃдєєпјљYean-Leng Lim, й«�з‚њ и®Ёи®єдё“е®¶пјљJoseph D. Babb, Chung-Seung Chiang, йњЌе‹‡, Harry Suryapranata, Huay Cheem Tan, Chuen-Den Tseng 3:07 PM - ж¬§жґІз»ЏйЄЊ Harry Suryapranata 3:19 PM - зѕЋе›Ѕз»ЏйЄЊ Joseph D. Babb 3:31 PM - дєљжґІз»ЏйЄЊ Huay Cheem Tan 1:15 PM - дёе›Ѕз¬¬дёЂдёЄиЌЇз‰©жґ—и„±ж”Їжћ¶з±»йљЏжњє иЇ•йЄЊпјљз»џи®Ўе¦иЂѓи™‘ жќЋеЌ« 3:43 PM - дёе›ЅжЂҐжЂ§еїѓи‚Њжў—ж»и§„иЊѓеЊ–ж•‘жІ»йЎ№ з›®жњЂж–°иї›е±• йњЌе‹‡ 1:35 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 3:55 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 1:55 PM - дј‘дјљ STж®µжЉ¬й«�ећ‹еїѓи‚Њжў—ж»д»‹е…ҐжІ»з–—з—…дѕ‹е›ћйЎѕпјљ е®ћдѕ‹е¦д№ STж®µжЉ¬й«�ећ‹еїѓи‚Њжў—ж»еі°дјљ AICTдёЋLUMENеЌЏеЉћ 2:00 PM-6:05 PM дё»жЊЃдєєпјљSameer Mehta, йўњзєўе…µ и®Ёи®єдё“е®¶пјљDevang Desai, Seung-Ho Hur, Mohammad Ishaq, Rajneesh Jain, Vincent On-Hing Kwok, Muhammad Munawar, Quang Tuan Nguyen STж®µжЉ¬й«�ећ‹еїѓи‚Њжў—ж»з»ји§€ дё»жЊЃдєєпјљиѓЎе¤§дёЂ, жІ€еЌ«еі°, Huay Cheem Tan и®Ёи®єдё“е®¶пјљGiuseppe De Luca, Roxana Mehran, Sameer Mehta, Damras Tresukosol, зЋ‹д№ђдё°, Robaayah Zambahari 2:00 PM - ејЂе№•и‡ґиѕћ иѓЎе¤§дёЂ, Huay Cheem Tan 4:30 PM - и®Ёи®є 4:35 PM - е·¦дё»е№ІжЂҐжЂ§й—еЎћ Rosli Mohd Ali 4:45 PM - и®Ёи®є 4:50 PM - STж®µжЉ¬й«�ећ‹еїѓи‚Њжў—ж»еђ€е№¶е¤љж”ЇиЎЂ з®Ўз—…еЏ� йЏз›џ 5:00 PM - и®Ёи®є 5:05 PM - иЎЂж “жЉЅеђё йўњзєўе…µ 5:15 PM - и®Ёи®є 5:20 PM - йќ™и„‰жЎҐ Praveer Agarwal 5:30 PM - и®Ёи®є иѕ©и®єпјљSTж®µжЉ¬й«�ећ‹еїѓи‚Њжў—ж»жІ»з–—зљ„жњЂдЅі ж•ґдЅ“з–з•Ґж�Їд»Ђд№€пјџ дё»жЊЃдєєпјљSameer Mehta, Huay Cheem Tan и®Ёи®єдё“е®¶пјљLiliana R. Grinfeld, зЋ‹д№ђдё° 5:35 PM - з›ґжЋҐд»‹е…ҐжІ»з–—д»Ќз„¶ж�Їй‡‘ж ‡е‡† зЋ‹д№ђдё° 5:45 PM - иЃ”еђ€иЌЇз‰©-д»‹е…Ґе¤„зђ†е°†ж€ђдёєй¦–йЂ‰ зљ„е†ЌзЃЊжіЁз–з•Ґ Liliana R. Grinfeld 5:55 PM - дё“е®¶и®Ёи®єеЏЉи¦Ѓз‚№жЂ»з»“ 6:05 PM - дј‘дјљ 4:05 PM - еїѓеЋџжЂ§дј‘е…‹ Praveen Chandra 4:15 PM - и®Ёи®є 4:20 PM - ж— е¤ЌжµЃ Fazila Tun Nesa Malik 130 CIT 2012 www.citmd.com 2012е№ґ3жњ€16ж—Ґ ж�џжњџдє” 2:15 PM - и®Ёи®є дё‰е±‚311Bдјљи®®е®¤ е¤§её€и®Іеє§пј€е…пј‰ жќЁи·ѓиї›ж•™жЋ€з»Џе…ёз—…дѕ‹й›†й”¦ JCICеЌЏеЉћ 7:00 AM-7:45 AM еЌ€й—ґеЌ«ж�џдјљ зѕЋж•¦еЉ›дё»еЉћ дїЎеїѓй¦–йЂ‰пјЊж€ђе°±йќће‡Ў 12:40 PM-1:55 PM дё»еёпјљMartin B. Leon е…±еђЊдё»еёпјљй™€з»Ќи‰Ї, Martin T. Rothman, еѕђжіў, е‘ЁзЋ‰жќ° 12:40 PM - ејЂењєи‡ґиѕћ 12:43 PM - RESOLUTEж”Їжћ¶пјљзі–е°їз—…ж‚ЈиЂ…зљ„ й¦–йЂ‰ жџіж™ЇеЌЋ 1:03 PM - з—…дѕ‹жЉҐе‘Љ1пјљзі–е°їз—…ж‚ЈиЂ…е† и„‰д»‹ е…ҐжІ»з–— зЋ‹з„± 1:15 PM - з—…дѕ‹жЉҐе‘Љ2пјљзі–е°їз—…ж‚ЈиЂ…е† и„‰д»‹ е…ҐжІ»з–— йЏз›џ 1:27 PM- RESOLUTEдёґеєЉеѕЄиЇЃж•°жЌ®дёЋд»‹е…Ґ еїѓи„Џз—…е¦зљ„жњЄжќҐ David E. Kandzari 1:42 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 1:55 PM - дј‘дјљ 2:20 PM - еїѓж€їйў¤еЉЁжЉ—е‡ќжІ»з–—ж–°иї›е±• еј жѕЌ 2:35 PM - и®Ёи®є 2:40 PM - еїѓж€їйў¤еЉЁеЇјз®Ўж¶€ићЌжІ»з–—зљ„йљѕз‚№дёЋ жњЄжќҐ й©¬й•їз”џ 3:00 PM - еїѓж€їйў¤еЉЁеЇјз®Ўж¶€ићЌжІ»з–—зљ„ж–°жЉЂжњЇ е’Њж–°з–з•Ґ жќЁе»¶е®— 3:15 PM - и®Ёи®є 3:20 PM - ж€їйў¤жіЁе†Њз ”з©¶дёєж€‘д»¬её¦жќҐд»Ђд№€пјџ еђґд№¦жћ— 3:35 PM - и®Ёи®є 3:40 PM - иЊ¶ж‡ з¬¬дєЊењє дё»жЊЃдєєпјљеј жѕЌ, й©¬й•їз”џ, жќЁе»¶е®—, йѓ‘ејєиЌЄ, ж›І з§ЂиЉ¬ 4:00 PM - и‚єеЉЁи„‰з“ЈдёЉе®¤жЂ§еїѓеѕ‹е¤±еёёпјљеїѓз”µ е›ѕгЂЃж ‡жµ‹дёЋеЇјз®Ўж¶€ићЌ ж›№е…‹е°† 4:15 PM - и®Ёи®є 4:20 PM - е®¤жЂ§еїѓеЉЁиї‡йЂџжІ»з–—зЋ°зЉ¶ жќЁж–°ж�Ґ 4:40 PM - Brugadaз»јеђ€еѕЃе®¤йЂџзљ„еЇјз®Ўж¶€ићЌ е§љз„° 4:55 PM - и®Ёи®є з¬¬дёЂењє дё»жЊЃдєєпјљзЋ‹ж–№жЈ, й»„д»Ћж–°, ж›№е…‹е°†, жќЁж–°ж�Ґ, еѕђдєљдјџ 2:00 PM - дёе›Ѕеїѓж€їйў¤еЉЁеЇјз®Ўж¶€ићЌзљ„зЋ°зЉ¶е’Њ жњЄжќҐ й»„д»Ћж–° 5:00 PM - еЉџиѓЅжЂ§е®¤жЂ§ж—©жђЏе†ЌиЇ„д»·еЏЉе¤„зђ†з–з•Ґ жќЁжќ°ељ 5:15 PM - и®Ёи®є 5:20 PM - е®¤жЂ§ж—©жђЏдёЋеїѓиЎ° ж–№е…Ё 5:35 PM - и®Ёи®є 131 5:55 PM - и®Ёи®є 6:00 PM - дј‘дјљ 2:55 PM - и®Ёи®є 4:35 PM - и®Ёи®є еїѓеѕ‹е¤±еёёз¬¬дєЊйѓЁе€† ж€їжЂ§дёЋе®¤жЂ§еїѓеЉЁиї‡йЂџзљ„иЇЉз–—з–з•Ґ 2:00 PM-6:00 PM 5:40 PM - е®¤йЂџж¶€ићЌжІ»з–—з›®е‰Ќйќўдёґзљ„й—®йў�е’Њ жЂќиЂѓ жќЋжЇ…е€љ дё‰е±‚жЉҐе‘ЉеЋ… иЌЇз‰©е¦з ”и®Ёдјљ иѕ‰з‘ћеЌЏеЉћ е† еїѓз—…ж‚ЈиЂ…дј�еЊ–д»–ж±ЂжІ»з–—зљ„зђ†еїµжЋўзґўдёЋе®ћи·µ 2:00 PM-4:00 PM дё»жЊЃдєєпјљжњ±е›Ѕи‹±, еђ•ж ‘й“®, еј жЉ’ж‰¬ 2:00 PM - ејЂењєи‡ґиѕћпјљи§„иЊѓиЌЇз‰©жІ»з–—пјЊиї›дёЂ жҐж”№е–„ж‚ЈиЂ…йў„еђЋ еђ•ж ‘й“® 2:05 PM - PCIе›ґжњЇжњџд»–ж±ЂејєеЊ–жІ»з–—зљ„дёе›Ѕ еѕЄиЇЃ жќЋе»єе№і 2:30 PM - д»–ж±ЂиЋ·з›Љзљ„ж—¶й—ґз›ІеЊєдёЋзЄЃз ґ й™†е›Ѕе№і 2:55 PM - еє”з”Ёи™љж‹џз»„з»‡е¦жЉЂжњЇиЇ„дј°д»–ж±ЂдёЋ ж–‘еќ—зљ„зЁіе®љдёЋйЂ†иЅ¬ еЏ¶йЈћ 3:15 PM - д»–ж±ЂдёЋеЇ№жЇ”е‰‚и‚ѕз—…зљ„й�ІжІ»з–з•Ґ зЋ‹дјџж°‘ 3:35 PM - иЋ·з›Љж—¶й—ґпјљй«�еЌ±ж‚ЈиЂ…д»–ж±ЂжІ»з–—е†і з–жЂќиЂѓ й™€йџµеІ± 3:55 PM - и¦Ѓз‚№жЂ»з»“ CIT 2012 www.citmd.com 2012е№ґ3жњ€16ж—Ґ ж�џжњџдє” иЌЇз‰©е¦з ”и®Ёдјљ й�їж–Їе€©еє·еЌЏеЉћ PCIе›ґж‰‹жњЇжњџиЌЇз‰©жІ»з–—зљ„ж–°жЋўзґў 4:00 PM-5:30 PM дё»жЊЃдєєпјљиѓЎе¤§дёЂ, жІ€еЌ«еі° 4:00 PM - ејЂењєи‡ґиѕћ 4:05 PM - 2011е№ґNSTEMI/UAжІ»з–—жЊ‡еЌ—е›ћйЎѕ жІ€еЌ«еі° 4:25 PM - жЉ—иЎЂе°ЏжќїиЌЇз‰©жІ»з–—зљ„ж–°йЂ‰ж‹© йџ©й›…зЋІ 4:45 PM - PCIдёЋОІеЏ—дЅ“й�»ж»ће‰‚ й™€йџµеІ± 5:05 PM - иЎЂи„‚жњЂж–°иї›е±•е›ћйЎѕ еј жЉ’ж‰¬ 5:25 PM - и¦Ѓз‚№жЂ»з»“ 5:30 PM - дј‘дјљ 132 CIT 2012 www.citmd.com 2012е№ґ3жњ€17ж—Ґ ж�џжњџе… дёЂе±‚е¤љеЉџиѓЅAеЋ… CRT at CIT е¤љж”ЇиЎЂз®Ўз—…еЏ�е¤„зђ† 8:00 AM-9:30 AM дё»жЊЃдєєпјљRon Waksman, й«�ж¶¦йњ– 8:00 AM - е¤љж”ЇиЎЂз®Ўз—…еЏ�пјљSyntaxи®°е€†еЇ№иЎЂ з®Ўй‡Ќе»єжІ»з–—йЂ‰ж‹©зљ„еЅ±е“Ќ Patrick W. Serruys 8:12 AM - дёєдЅ•ењЁе¤љж”ЇиЎЂз®Ўз—…еЏ�жІ»з–—дёж€‘ дёЌз”ЁSyntaxи®°е€†пјџ Maurice Buchbinder 8:24 AM - е¤љж”ЇиЎЂз®Ўз—…еЏ�жІ»з–—пјљж€‘д»¬еє”иЇҐ е€†жњџе®Њж€ђеђ—пјџ Imad Sheiban 8:36 AM - е¤љж”ЇиЎЂз®Ўз—…еЏ�пјљFFRзљ„еє”з”Ёиµ·й‡Ќ и¦ЃдЅњз”Ёеђ—пјџ Ron Waksman 8:48 AM - е¤љж”ЇиЎЂз®Ўз—…еЏ�жІ»з–—зљ„жњЄжќҐж–№еђ‘пјљ з¬¬дєЊд»ЈиЌЇз‰©жґ—и„±ж”Їжћ¶е°†ж”№еЏ�з–—ж•€еђ—пјџ Gregg W. Stone 9:00 AM - е¤љж”ЇиЎЂз®Ўз—…еЏ�жІ»з–—зљ„жњЄжќҐж–№еђ‘пјљ жќ‚дє¤иЎЂз®Ўй‡Ќе»єжњЇе°†еЏ‘жЊҐй‡Ќи¦ЃдЅњз”Ёеђ—пјџ иѓЎз››еЇї 9:12 AM - дё“е®¶и®Ёи®є и®Ёи®єдё“е®¶пјљMaurice Buchbinder, иѓЎз››еЇї, Patrick W. Serruys, Imad Sheiban, Gregg W. Stone з¤єж•™жј”з¤є10 е·¦дё»е№Іе€†еЏ‰з—…еЏ�д»‹е…ҐжІ»з–— й¦–йѓЅеЊ»з§‘е¤§е¦й™„е±ће®‰иґћеЊ»й™ў 9:30 AM-11:00 AM дё»жЊЃдєєпјљPatrick W. Serruys, й™€зєЄиЁЂ и®Ёи®єдё“е®¶пјљеґ”иїћзѕ¤, William F. Fearon, Sema GГјneri, Yangsoo Jang, Mitchell W. Krucoff, д№”ж ‘е®ѕ, Eak-Kyun Shin, е™з¦Џж€ђ, Dobrin Vassilev жњЇиЂ…пјљMarie-Claude Morice, еђ•ж ‘й“®, Imad Sheiban 133 Angioplasty Summit - TCTAP at CIT е·¦дё»е№Іе’Ње€†еЏ‰з—…еЏ�ж”Їжћ¶жњЇпјљйЂљиї‡еє”з”ЁFFR дёЋIVUSиѕѕе€°жІ»з–—жњЂдј�еЊ– 11:00 AM-12:30 PM дё»жЊЃдєєпјљSeung-Jung Park, Gregg W. Stone 11:00 AM - ж¬ўиїЋи‡ґиѕће’ЊиЇѕзЁ‹з®Ђд»‹ Seung-Jung Park 11:03 AM - IVUSдёЋFFRжЊ‡еЇјйќће·¦дё»е№Іе€†еЏ‰ з—…еЏ�PCI Soo-Jin Kang 11:15 AM - е·¦дё»е№Іжњ«з«Їе€†еЏ‰з—…еЏ�з—…дѕ‹зі»е€— пј€дёЂпј‰пјљж€‘зљ„и§Је†іж–№жЎ€ Marie-Claude Morice 11:27 AM - е·¦дё»е№Іжњ«з«Їе€†еЏ‰з—…еЏ�з—…дѕ‹зі»е€— пј€дєЊпј‰пјљж€‘зљ„и§Је†іж–№жЎ€ Jeffrey W. Moses 11:39 AM - IVUSдёЋFFRжЊ‡еЇје·¦дё»е№Іе€†еЏ‰з—… еЏ�PCIпјљжІ»з–—е†із–дёЋжњЂдј�еЊ– Seung-Jung Park 11:51 AM - з»јеђ€дёґеєЉиЇ•йЄЊз»“жћњд»ҐжґћеЇџе·¦дё» е№Ід»‹е…ҐжІ»з–—зљ„йЂ‚еЅ“жЂ§ Patrick W. Serruys 12:03 PM - EXCELиЇ•йЄЊ Gregg W. Stone 12:15 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” и®Ёи®єиЂ…пјљSoo-Jin Kang, Patrick W. Serruys, Marie-Claude Morice, Jeffrey W. Moses 12:30 PM - дј‘дјљ еЌ€й—ґеЌ«ж�џдјљ й›…еџ№иЎЂз®Ўд»Єе™ЁйѓЁдё»еЉћ DESй«�еі°и®єеќ›пјље€†дє«е…Ёзђѓдё“е®¶и§‚з‚№ 12:40 PM-1:55 PM дё»еёпјљжќЁи·ѓиї›, и‘›еќ‡жіў, й™€ж–№, жќњеї—ж°‘ 12:40 PM - ејЂењєи‡ґиѕћ 12:45 PM - иЌЇз‰©жґ—и„±ж”Їжћ¶зљ„еЏ‘е±•дёЋжњЄжќҐ Patrick W. Serruys 1:00 PM - дёж–еЏЊй‡ЌжЉ—иЎЂе°ЏжќїжІ»з–—пјљж‰Ђжњ‰зљ„ ж”Їжћ¶йѓЅдёЂж ·е®‰е…Ёеђ—пјџ Gregg W. Stone 1:15 PM - ж–°зљ„ж”Їжћ¶и®ѕи®ЎдёЂе®љж›ґеҐЅеђ—пјџ Mitchell W. Krucoff 1:30 PM - SEEDSжіЁе†Њз™»и®°з ”з©¶иї›е±• жќЁи·ѓиї› 1:45 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 1:55 PM - дј‘дјљ з¤єж•™жј”з¤є12 е¤љж”ЇиЎЂз®Ўз—…еЏ�гЂЃйќ™и„‰жЎҐиЎЂз®Ўз—…еЏ�еЏЉй’™еЊ– з—…еЏ�д»‹е…ҐжІ»з–— й¦–йѓЅеЊ»з§‘е¤§е¦й™„е±ће®‰иґћеЊ»й™ў 2:00 PM-3:30 PM дё»жЊЃдєєпјљJean Fajadet, йџ©й›…зЋІ и®Ёи®єдё“е®¶пјљPraveer Agarwal, Brigadier S. Aziz, Praveen Chandra, дЅ•йќ’, й»Ћиѕ‰, йЅђеђ‘е‰Ќ, Li-Wah Tam, Renu Virmani, Franz Weidinger, й‚№й�іж�Ґ жњЇиЂ…пјљSamuel K. Mathew, Robaayah Zambahari, Mitchell W. Krucoff з¤єж•™жј”з¤є14 дёЌеёёи§Ѓзљ„е¤Ќжќ‚з—…еЏ�д»‹е…ҐжІ»з–— й¦–йѓЅеЊ»з§‘е¤§е¦й™„е±ћжњќй�іеЊ»й™ў 3:30 PM-5:00 PM дё»жЊЃдєєпјљй™€з»Ќи‰Ї, Liliana R. Grinfeld и®Ёи®єдё“е®¶пјљChung-Seung Chiang, зЄ¦е…‹йќћ, иґєе‹‡, жќЋдјџж�Ћ, Sidney Tsz Ho Lo, Quang Tuan Nguyen, Gustavo Samaja, еј еҐ‡, еј й’І, е‘Ёж–Ње…Ё жњЇиЂ…пјљDavid E. Kandzari, Costantino R. Costantini, Fausto Feres IVUSи§ЈиЇґдё“е®¶пјљCostantino O. Costantini з—…дѕ‹и®Ёи®єпјљдёЋCITе’ЊTCTе¤§её€йќўеЇ№йќў 5:00 PM-6:00 PM дё»жЊЃдєєпјљй«�ж¶¦йњ–, Jeffrey W. Moses и®Ёи®єдё“е®¶пјљи‘›еќ‡жіў, йџ©й›…зЋІ, David E. Kandzari, Roxana Mehran, Gary S. Mintz, Alan C. Yeung 5:00 PM - CS-0217пјље·¦дё»е№Із—…еЏ�зљ„з›ґжЋҐPCI дёЂдѕ‹жЉҐйЃ“ йѓе®Ѓ 5:15 PM - CS-0232пјљзґ§жЂҐ5иї›6еЏЊеЇјз®ЎжЉЂжњЇ ењЁйЂ†еђ‘жІ»з–—е¤Ќжќ‚CTOдёзљ„еє”з”ЁдёЂдѕ‹ еј еҐ‡ CIT 2012 www.citmd.com 2012е№ґ3жњ€17ж—Ґ ж�џжњџе… 5:30 PM - CS-0170пјљдёЂдѕ‹дёЋж”Їжћ¶ж–иЈ‚жњ‰е…і зљ„еЉЁи„‰з�¤еЅўж€ђж‰Ђи‡ґзљ„иїџеЏ‘ж™љжњџж”Їжћ¶иЎЂж “ еј дїЉжќ° 5:45 PM - CS-0377пјљжЂҐжЂ§еїѓи‚Њжў—ж»д»‹е…ҐжњЇеђЋ иґІй—ЁзІ�и†њж’•иЈ‚ж‰Ђи‡ґдёЉж¶€еЊ–йЃ“е¤§е‡єиЎЂдёЂдѕ‹ еђґж°ёеЃҐ 6:00 PM - дј‘дјљ 10:00 AM - FOCUSпјљFIREBIRD 2й’ґй“¬еђ€й‡‘й›· её•йњ‰зґ жґ—и„±ж”Їжћ¶е‰Ќзћ»жЂ§гЂЃе¤§и§„жЁЎгЂЃе¤љдё еїѓжіЁе†Њз™»и®°з ”з©¶ - 2е№ґдёґеєЉз»“жћњ и‘›еќ‡жіў 10:10 AM - и®Ёи®є 10:15 AM - NOYA IпјљNOYAз”џз‰©еЏЇй™Ќи§Јж¶‚е±‚ й›·её•йњ‰зґ жґ—и„±ж”Їжћ¶еЇ№жЇ”FIREBIRD 2жЊЃд№…ж¶‚ е±‚й›·её•йњ‰зґ жґ—и„±ж”Їжћ¶жІ»з–—е† зЉ¶еЉЁи„‰з—…еЏ� зљ„е¤љдёеїѓгЂЃйљЏжњєеЇ№з…§иЇ•йЄЊ - 2е№ґдёґеєЉз»“жћњ жќЁи·ѓиї› 10:25 AM - и®Ёи®є дёЂе±‚е¤љеЉџиѓЅBеЋ… з¤єж•™жј”з¤є9 йќће·¦дё»е№Іе€†еЏ‰з—…еЏ�ж€–ејЂеЏЈз—…еЏ�д»‹е…ҐжІ»з–— й¦–йѓЅеЊ»з§‘е¤§е¦й™„е±ћжњќй�іеЊ»й™ў 8:00 AM-9:30 AM дё»жЊЃдєєпјљYean-Leng Lim, Roxana Mehran и®Ёи®єдё“е®¶пјљJoseph D. Babb, I-Chang Hsieh, е§њй“Ѓж°‘, жќЋжЂЎ, Sameer Mehta, Rosli Mohd Ali, й‚±ж�Ґе…‰, Harry Suryapranata, иўЃзҐ–иґ», е‘Ёж—ж™Ё жњЇиЂ…пјљзЋ‹д№ђдё°, Alan C. Yeung, Teguh Santoso 10:30 AM - FIRE2-DIABETESпјљиЇ„д»·зі–е°їз—… ж‚ЈиЂ…дёеє”з”ЁFIREBIRD 2й’ґй“¬еђ€й‡‘й›·её•йњ‰зґ жґ—и„±ж”Їжћ¶жІ»з–—е¤Ќжќ‚е† и„‰з—…еЏ�жњ‰ж•€жЂ§дёЋе®‰ е…ЁжЂ§зљ„е‰Ќзћ»жЂ§гЂЃе¤љдёеїѓжіЁе†Њз™»и®°з ”з©¶ - 6 дёЄжњ€дёґеєЉз»“жћњ жќЋе¦Ќ дё»жЊЃдєєпјљDonald E. Cutlip, Alexandra J. Lansky и®Ёи®єдё“е®¶пјљFausto Feres, Liliana R. Grinfeld, Jan Kovac, жќЋеЌ«, жІ€еЌ«еі°, еЏІж–°з«‹, Huay Cheem Tan, Damras Tresukosol, Ron Waksman 9:30 AM - CREATEпјљEXCELз”џз‰©еЏЇй™Ќи§ЈиЃљеђ€ з‰©иЌЇз‰©жґ—и„±ж”Їжћ¶е‰Ќзћ»жЂ§гЂЃе¤§и§„жЁЎгЂЃе¤љдё еїѓжіЁе†Њз™»и®°з ”з©¶ - жњЂз»€5е№ґдёґеєЉз»“жћњ йџ©й›…зЋІ 9:40 AM - и®Ёи®є 9:45 AM - TARGET Iй•їж”Їжћ¶й�џе€—пјљиЇ„д»· FIREHAWKз”џз‰©еЏЇй™Ќи§ЈиЃљеђ€з‰©й›·её•йњ‰зґ йќ¶ еђ‘жґ—и„±ж”Їжћ¶жІ»з–—е† зЉ¶еЉЁи„‰й•їз—…еЏ�е®‰е…ЁжЂ§ е’Њжњ‰ж•€жЂ§зљ„е‰Ќзћ»жЂ§гЂЃе¤љдёеїѓз ”з©¶ - 9дёЄжњ€ йЂ еЅ±дёЋ1е№ґдёґеєЉз»“жћњ й«�ж¶¦йњ– 9:55 AM - и®Ёи®є дё»еёпјљй™€зєЄиЁЂ, д№”ж ‘е®ѕ, зЋ‹д№ђдё° 12:40 PM - ејЂењєи‡ґиѕћ 12:45 PM - NOYAиЌЇз‰©жґ—и„±ж”Їжћ¶жЉЂжњЇз‰№жЂ§ зЋ‹ж�ЉйЈћ 1:05 PM - NOYA IпјљNOYAз”џз‰©еЏЇй™Ќи§Јж¶‚е±‚ й›·её•йњ‰зґ жґ—и„±ж”Їжћ¶еЇ№жЇ”FIREBIRD 2жЊЃд№…ж¶‚ е±‚й›·её•йњ‰зґ жґ—и„±ж”Їжћ¶жІ»з–—е† зЉ¶еЉЁи„‰з—…еЏ� зљ„е¤љдёеїѓгЂЃйљЏжњєеЇ№з…§иЇ•йЄЊ - 2е№ґдёґеєЉз»“жћњ еѕђжіў 1:25 PM - NOYAиЌЇз‰©жґ—и„±ж”Їжћ¶ењЁдёґеєЉдёзљ„ еє”з”Ё й™€йџµеІ± 10:40 AM - и®Ёи®є 1:45 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 10:45 AM - SERY IпјљYINYIж— иЃљеђ€з‰©зґ«жќ‰й†‡ жґ—и„±ж”Їжћ¶жІ»з–—е† еїѓз—…зљ„е‰Ќзћ»жЂ§гЂЃе¤љдёеїѓ жіЁе†Њз™»и®°з ”з©¶ - 2е№ґдёґеєЉз»“жћњ жІ€еЌ«еі° 1:55 PM - дј‘дјљ 10:55 AM - и®Ёи®є жњЂж–°дёґеєЉиЇ•йЄЊдёЋз‰№и‰Із ”з©¶й¦–ж¬Ўе…¬еёѓпј€дєЊпј‰ 9:30 AM-11:00 AM еЌ€й—ґеЌ«ж�џдјљ дё‡з‘ћйЈћйёїдё»еЉћ е°Џж”Їжћ¶е¤§еЅ±е“Ќ 12:40 PM-1:55 PM з¤єж•™жј”з¤є11 ж…ўжЂ§е®Ње…Ёй—еЎћд»‹е…ҐжІ»з–— е›Ѕе®¶еїѓиЎЂз®Ўз—…дёеїѓй�ње¤–еЊ»й™ў 11:00 AM-12:30 PM дё»жЊЃдєєпјљMaurice Buchbinder, David E. Kandzari и®Ёи®єдё“е®¶пјљChi-Kin Chan, й™€з»Ќи‰Ї, й™€йџµеІ±, Tetsuya Hata, Duncan Hung-Kwong Ho, Fumiaki Ikeno, Eisho Kyo, зЋ‹е»єе®‰, йЏз›џ, Joo-Young Yang жњЇиЂ…пјљEtsuo Tsuchikane, Masahiko Ochiai, William L. Lombardi з¤єж•™жј”з¤є13 дёЌеёёи§Ѓзљ„е¤Ќжќ‚з—…еЏ�д»‹е…ҐжІ»з–— з¬¬е››е†›еЊ»е¤§е¦й™„е±ћиҐїдє¬еЊ»й™ў 2:00 PM-3:30 PM дё»жЊЃдєєпјљIan T. Meredith, зЋ‹жµ·ж�Њ и®Ёи®єдё“е®¶пјљDebabrata Dash, Mohammad Ishaq, жќЋе¦Ќ, е€�жµ·жіў, Kenan Ovunc, Teguh Santoso, и°е®Ѓ, Chee-Wo Wu, Chiung-Jen Wu, и®ёй”‹ жњЇиЂ…пјљToshiya Muramatsu, йѓж–‡жЂЎеЏЉеђЊдє‹ жњЂж–°дёґеєЉиЇ•йЄЊдёЋз‰№и‰Із ”з©¶й¦–ж¬Ўе…¬еёѓпј€дё‰пј‰ 3:30 PM-5:00 PM дё»жЊЃдєєпјљJean Marco, Alan C. Yeung и®Ёи®єдё“е®¶пјљWilliam F. Fearon, Fumiaki Ikeno, Michael Lim, Richard Lim, Thach Nguyen, Imad Sheiban, Pieter C. Smits, Pieter R. Stella, Chuen-Den Tseng, Yee Guan Yap 3:30 PM - CREST-MIж›ґж–°пјљжЂҐжЂ§STж®µжЉ¬ й«�ећ‹еїѓи‚Њжў—ж»ж‚ЈиЂ…дёеЇ№жЇ”CYPHERдёЋ ENDEAVORж”Їжћ¶е®‰е…ЁжЂ§дёЋжњ‰ж•€жЂ§зљ„е¤љдё еїѓгЂЃйљЏжњєеЇ№з…§иЇ•йЄЊ зЋ‹д№ђдё° 3:40 PM - и®Ёи®є 134 CIT 2012 www.citmd.com 2012е№ґ3жњ€17ж—Ґ ж�џжњџе… 3:45 PM - иЇ„д»·жЂҐжЂ§STж®µжЉ¬й«�ећ‹еїѓи‚Њжў—ж»ж‚Ј иЂ…жЂҐиЇЉд»‹е…ҐжІ»з–—е‰Ќеє”з”Ёй‡Ќз»„дєєз±»е°їжїЂй…¶е®‰ е…ЁжЂ§дёЋжњ‰ж•€жЂ§зљ„е¤љдёеїѓгЂЃйљЏжњєеЇ№з…§иЇ•йЄЊ еѕђе‡Ї 3:55 PM - и®Ёи®є 4:00 PM - е®љй‡ЏйЂ еЅ±дёЋиЎЂз®Ўе†…и¶…еЈ°еЏ‚ж•°зљ„иЇЉ ж–зІѕзЎ®жЂ§д»Ґйў„жµ‹еЌ•е¤„еЋџеЏ‘з—…еЏ�еЉџиѓЅж„Џд№‰ зљ„е‰Ќзћ»жЂ§гЂЃе¤љдёеїѓз ”з©¶ еј дїЉжќ° 4:10 PM - и®Ёи®є 4:15 PM - еЏ‘е±•дёе›Ѕе®¶е·¦дё»е№Іе† зЉ¶еЉЁи„‰з—…еЏ� д»‹е…ҐжІ»з–—зљ„еЌ•дёеїѓжіЁе†Њз™»и®°з ”з©¶ Fazila Tun Nesa Malik 4:25 PM - и®Ёи®є 4:30 PM - иЌЇз‰©жґ—и„±ж”Їжћ¶ж¤Ќе…ҐеђЋе»¶й•їж°ЇеђЎж ј й›·дЅїз”Ёзљ„еЌ•дёеїѓжіЁе†Њз™»и®°з ”з©¶ й™€ж–№ з—…дѕ‹4 дёЂе±‚е¤љеЉџиѓЅCеЋ… дё»жЊЃдєєпјљдЅ•еҐ” з‚№иЇ„дё“е®¶пјљй»„и¶…иЃ”, еђ•еђ‰е…ѓ, ж›Ій№Џ, е‘Ёз«‹еђ› е† и„‰д»‹е…Ґе®ћз”Ёж•™зЁ‹з¬¬дєЊйѓЁе€† дє‰и®®з—…дѕ‹дё“ењєпјљдёєд»Ђд№€пјџдЅ•ж—¶пјџжЂЋж ·пјџ 8:30 AM-12:30 PM 10:30 AM - CS-0274пјљжЂҐжЂ§е№їжі›е‰ЌеЈЃеїѓи‚Њ жў—ж»жњЇдёе·¦дё»е№ІиЎЂж “еЅўж€ђе№¶еЏ‘еїѓи„ЏйЄ¤еЃњ д»‹е…ҐжІ»з–—дёЂдѕ‹ иґєзЋ‰жі‰ з—…дѕ‹1 10:40 AM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” дё»жЊЃдєєпјљи‘›еќ‡жіў з‚№иЇ„дё“е®¶пјљз™Ѕй”‹, жќЋдјџж�Ћ, и°е®Ѓ, еј з‘ћеІ© 11:05 AM - и¦Ѓз‚№жЂ»з»“ дЅ•еҐ” 8:30 AM - CS-0037пјљзЅ•и§ЃејЂеЏЈеђ€е№¶жћЃеє¦ејЇ ж›Із—…еЏ�зљ„д»‹е…ҐжІ»з–— ж€ґе†› з—…дѕ‹5 8:40 AM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” дё»жЊЃдєєпјљйњЌе‹‡ з‚№иЇ„дё“е®¶пјље€�жѓ дє®, е€�еЃҐ, еђґж·і, и®ёй”‹ 9:05 AM - и¦Ѓз‚№жЂ»з»“ иґѕе›Ѕи‰Ї 11:10 AM - CS-0034пјљIVUSдЅњдёєй‡Ќи¦Ѓе·Ґе…·иѕ… еЉ©е·¦дё»е№ІејЂеЏЈе®Ње…Ёй—еЎћз—…еЏ�зљ„д»‹е…ҐжІ»з–— зЋ‹и™№ з—…дѕ‹2 11:20 AM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” дё»жЊЃдєєпјљзЋ‹дјџж°‘ з‚№иЇ„дё“е®¶пјљиѓЎж‰їжЃ’, ж±ќзЈЉз”џ, еѕђе»¶ж•Џ, жќЁиѓње€© 11:45 AM - и¦Ѓз‚№жЂ»з»“ йњЌе‹‡ 9:10 AM - CS-0352пјље‰Ќй™Ќж”Їе¤ље€†еЏ‰еЏЉеЏіе† и„‰й«�еє¦иї‚ж›Ізљ„д»‹е…ҐжІ»з–— еЌўж‰Ќд№‰ з—…дѕ‹6 з¤єж•™жј”з¤є15 з»ЏжЎЎеЉЁи„‰д»‹е…ҐжІ»з–—гЂЃж”Їжћ¶е†…е†Ќз‹зЄ„д»‹е…Ґ жІ»з–—еЏЉзЈЃеЇји€Єиѕ…еЉ©д»‹е…ҐжІ»з–— й¦–йѓЅеЊ»з§‘е¤§е¦й™„е±ће®‰иґћеЊ»й™ў 5:00 PM-6:30 PM 9:20 AM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” дё»жЊЃдєєпјљй™€зєЄиЁЂ з‚№иЇ„дё“е®¶пјљи‘Је№іж “, й»„дјџе‰‘, еђ•е®‰жћ—, еЏ¶йЈћ 9:45 AM - и¦Ѓз‚№жЂ»з»“ зЋ‹дјџж°‘ 11:50 AM - CS-0057пјљдёЂдѕ‹вЂњиў«жђће¤Ќжќ‚вЂќ зљ„CTO зЋ‹жћ— дё»жЊЃдєєпјљJean Marco, Ron Waksman и®Ёи®єдё“е®¶пјљж›№дё°, й«�е±•, Paul Hsien-Li Kao, Marie-Claude Morice, ж›Іж–°е‡Ї, I Gde Rurus Suryawan, Huay Cheem Tan, Mujeeb Ul-Haq, Yee Guan Yap, жњ±ж°ёе®Џ жњЇиЂ…пјљJean Fajadet, Ferdinand Kiemeneij з—…дѕ‹3 12:00 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” дё»жЊЃдєєпјљжњ±е›Ѕи‹± з‚№иЇ„дё“е®¶пјљжµ¦еҐЋ, з§¦е¦ж–‡, е”ђеЏ‘е®Ѕ, жќЁж°ёеЃҐ 12:25 PM - и¦Ѓз‚№жЂ»з»“ й™€зєЄиЁЂ 9:50 AM - CS-0224пјљPCIеђЋзЊќж»дёЂдѕ‹ ж±Єи”љйќ’ 12:30 PM - дј‘дјљ 4:40 PM - и®Ёи®є 4:45 PM - иЇ„д»·е·¦е®¤еЉџиѓЅдЅЋдё‹еЇ№е† и„‰дё‰ж”Їз—… еЏ�д»‹е…ҐжІ»з–—дёґеєЉз–—ж•€еЅ±е“Ќзљ„е¤§и§„жЁЎгЂЃеЌ• дёеїѓз ”з©¶ й«�е±• 4:55 PM - и®Ёи®є 10:00 AM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 10:25 AM - и¦Ѓз‚№жЂ»з»“ жњ±е›Ѕи‹± 135 CIT 2012 www.citmd.com 2012е№ґ3жњ€17ж—Ґ ж�џжњџе… еЌ€й—ґеЌ«ж�џдјљ ж�“з”џз§‘жЉЂдё»еЉћ и§ЃиЇЃвЂњз€±з«‹вЂќж—¶е€»пјЊдЅ“йЄЊз§‘жЉЂе€›ж–° 12:40 PM-1:55 PM дё»еёпјљйџ©й›…зЋІ, зЋ‹жµ·ж�Њ, жќЋе¦еҐ‡ 12:40 PM - ејЂењєи‡ґиѕћ 12:45 PM - е¤љз§ЌжЉЂжњЇиЃ”еђ€иїђз”ЁејЂйЂљLADж…ў жЂ§е®Ње…Ёй—еЎћдёЂдѕ‹ е‘Ёе›Ѕдјџ 1:00 PM - зІѕеЅ©з—…дѕ‹е€†дє« еєћж–‡и·ѓ 1:15 PM - еЏЇй™Ќи§Јж¶‚е±‚DESиѓЅе‡Џе°‘ж™љжњџж”Їжћ¶ иґґеЈЃдёЌи‰Їеђ—пјџ еј еі° 1:30 PM - з€±з«‹жЊ‘ж€�е¤Ќжќ‚з—…еЏ�пјљRCAж…ўжЂ§е®Њ е…Ёй—еЎћеђ€е№¶е·¦дё»е№Ід»‹е…ҐжІ»з–—дёЂдѕ‹ жќЋе¦Ќ 1:45 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 1:55 PM - дј‘дјљ е† и„‰д»‹е…Ґе®ћз”Ёж•™зЁ‹з¬¬дё‰йѓЁе€† ж…ўжЂ§е®Ње…Ёй—еЎћз—…еЏ� 2:00 PM-6:00 PM 3:00 PM - ж…ўжЂ§е®Ње…Ёй—еЎће†ЌиЎЂз®ЎеЊ–зљ„е¤Ќеђ€жЉЂжњЇ William L. Lombardi 3:15 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” з¬¬дєЊењєпјљж…ўжЂ§е®Ње…Ёй—еЎћд»‹е…ҐеџєзЎЂ дё»жЊЃдєєпјљзЋ‹е»єе®‰, еґ”иїћзѕ¤ и®Ёи®єдё“е®¶пјљжќЋдїќ, зЋ‹е®€еЉ›, жё©е°љз…њ, дїЎж “еЉ› 3:30 PM - ж…ўжЂ§е®Ње…Ёй—еЎћд»‹е…ҐжІ»з–—зљ„еѕЄиЇЃеЊ» е¦ж №жЌ® жќњеї—ж°‘ 3:42 PM - и®Ёи®є 3:45 PM - ж…ўжЂ§е®Ње…Ёй—еЎћзљ„з—…зђ†ж”№еЏ�еЇ№ж‰‹жњЇ з–з•Ґзљ„еЅ±е“Ќ зЋ‹жµ·ж�Њ 5:15 PM - IVUSеЇ№ж…ўжЂ§е®Ње…Ёй—еЎћд»‹е…Ґзљ„еј•еЇј дЅњз”Ё й’±жќ° 5:27 PM - и®Ёи®є 5:30 PM - ж…ўжЂ§е®Ње…Ёй—еЎћд»‹е…Ґзљ„еёёи§Ѓй”™иЇЇе€†жћђ й™€зєЄиЁЂ 5:42 PM - и®Ёи®є 5:45 PM - еЇ№дѕ§йЂ еЅ±зљ„й‡Ќи¦ЃжЂ§еє”й‡Ќз‚№ејєи°ѓпјЃ еѕђдєљдјџ 5:57 PM - и®Ёи®є 6:00 PM - дј‘дјљ 3:57 PM - и®Ёи®є 4:00 PM - ж…ўжЂ§е®Ње…Ёй—еЎћд»‹е…ҐжІ»з–—еЇјдёќзљ„йЂ‰ж‹© зЋ‹е»єе®‰ дё‰е±‚306ABдјљи®®е®¤ 4:12 PM - и®Ёи®є 4:15 PM - зђѓе›ЉдёЌиѓЅйЂљиї‡ж…ўжЂ§е®Ње…Ёй—еЎћз—…еЏ� ж—¶зљ„е¤„зђ† зЋ‹е®€еЉ› ж—©й¤ђдјљ жіўеЈ«йЎїз§‘е¦дё»еЉћ е¤Ќжќ‚е·¦дё»е№ІдёЋй’™еЊ–з—…еЏ�д»‹е…ҐжІ»з–—з–з•ҐеЏЉ ж–№жі• 7:00 AM-8:00 AM 4:27 PM - и®Ёи®є дё»еёпјљзЋ‹дјџж°‘, йЏз›џ, дєЋжіў 4:30 PM - ж…ўжЂ§е®Ње…Ёй—еЎћд»‹е…Ґе№¶еЏ‘з—‡зљ„е¤„зђ† е‘ЁзЋ‰жќ° 7:00 AM - ејЂењєи‡ґиѕћ дё»жЊЃдєєпјљй™€зєЄиЁЂ, Hweung Kon Hwang и®Ёи®єдё“е®¶пјљWilliam L. Lombardi, Jeffrey W. Moses, Etsuo Tsuchikane, Sudhir Rathore 4:42 PM - и®Ёи®є 7:03 AM - е¤Ќжќ‚з—…еЏ�PCIдёе¦‚дЅ•йЂ‰ж‹©зђ†жѓізљ„ жЊ‡еј•еЇјз®Ўпјџ е‚…е›Ѕиѓњ 2:00 PM - ж…ўжЂ§е®Ње…Ёй—еЎћиЎЂз®Ўж€ђеЅўжњЇдѕќжЌ®дёЋ жЉЂжњЇиї›е±• Jeffrey W. Moses дё»жЊЃдєєпјљй™€ж–№, е§њй“Ѓж°‘ и®Ёи®єдё“е®¶пјљй‡‘жѓ ж №, жќЋз”°ж�Њ, зЋ‹й•їи°¦, жќЁж ‘жЈ® з¬¬дёЂењєпјљж…ўжЂ§е®Ње…Ёй—еЎћиЎЂз®Ўж€ђеЅўжњЇ 2012пјље¤§её€и§‚з‚№ 2:15 PM - ж…ўжЂ§е®Ње…Ёй—еЎћиЎЂз®Ўж€ђеЅўжњЇйЂ†еђ‘жЉЂ жњЇж›ґж–° Etsuo Tsuchikane 2:30 PM - дёе›Ѕе№ґеє¦вЂњжЊ‘ж€�жЂ§вЂќз—…дѕ‹пјљж€ђеЉџ жЈеђ‘ејЂйЂље‰Ќй™Ќж”Їж…ўжЂ§е®Ње…Ёй—еЎћдёЂдѕ‹пј€CS0364пј‰ и‘›еќ‡жіў з¬¬дё‰ењєпјљж…ўжЂ§е®Ње…Ёй—еЎћд»‹е…Ґз–з•Ґ 4:45 PM - е¦‚дЅ•йЂљиї‡е† и„‰йЂ еЅ±иµ„ж–™е€¶е®љж…ўжЂ§ е®Ње…Ёй—еЎћд»‹е…Ґз–з•Ґпјџ зЋ‹дјџж°‘ 4:57 PM - и®Ёи®є 5:00 PM - CTAеЇ№ж…ўжЂ§е®Ње…Ёй—еЎћд»‹е…ҐжІ»з–—зљ„её®еЉ© з›–йІЃзІ¤ 7:18 AM - дёе›ЅиЎЂз®Ўе†…и¶…еЈ°е¦й™ўдё“е®¶е…± иЇ†пјље·¦дё»е№ІPCIдёIVUSеє”з”Ёдёєд»Ђд№€е…·жњ‰е…і й”®жЂ§ - иЇ•йЄЊиї›е±•дёЋз—…дѕ‹е€†дє« й’±жќ° 7:33 AM - ж—‹зЈЁжІ»з–—з»ЏйЄЊеЏЉз—…дѕ‹е€†дє« зЅ—е»єж–№ 7:48 AM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 8:00 AM - дј‘дјљ 5:12 PM - и®Ёи®є 2:45 PM - йЂ†еђ‘ж…ўжЂ§е®Ње…Ёй—еЎћжЉЂжњЇпјљж€ђеЉџдёЋ е¤±иґҐзљ„йў„жµ‹е› зґ Sudhir Rathore 136 CIT 2012 www.citmd.com 2012е№ґ3жњ€17ж—Ґ ж�џжњџе… е¤–е‘Ёе’Њи…”е†…иЎЂз®ЎжІ»з–—з¬¬дёЂйѓЁе€† 8:30 AM-12:30 PM йў€еЉЁи„‰з–ѕз—… дё»жЊЃдєєпјљNeil E. Strickman, и’‹й›„дє¬ 8:30 AM - йў€еЉЁи„‰з–ѕз—…иЇЉжІ»и¦Ѓзґ пјљжЊ‡еЌ—гЂЃ иЇ„д»·еЏЉз–—ж•€ и’‹й›„дє¬ 8:45 AM - йў€еЉЁи„‰ж”Їжћ¶жњЇ2012пјљж€‘д»¬д»Ће“Є й‡ЊжќҐпјџеЋ»еђ‘дЅ•ж–№пјџ Neil E. Strickman 9:00 AM - жЎЎеЉЁи„‰и·Їеѕ„ж— йћ�жЉЂжњЇиЎЊйў€еЉЁи„‰ ж”Їжћ¶жњЇ Chiung-Jen Wu 9:15 AM - жЂЋж ·ејЂйЂљйў€еЉЁи„‰е®Ње…Ёй—еЎћпјџ Aravinda Nanjundappa 9:30 AM - йў€еЉЁи„‰ж”Їжћ¶жњЇз”ЁдєЋж ‡е‡†ж‰‹жњЇйЈЋ й™©ж‚ЈиЂ…пјљCRESTиЇ•йЄЊж›ґж–° Charles A. Simonton 9:45 AM - ж�Їеђ¦еє”иЇҐеЇ№жЂҐжЂ§зјєиЎЂжЂ§дёйЈЋе®ћ ж–Ѕд»‹е…ҐжІ»з–—пјџ зЋ‹з„± 10:00 AM - Jasperз”µи§ЈеЏЇи„±жЂ§еј№з°§ењ€жІ»з–— йў…е†…еЉЁи„‰з�¤ Erol Akgul 10:15 AM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” и®Ёи®єдё“е®¶пјљErol Akgul, Aravinda Nanjundappa, Charles A. Simonton, зЋ‹з„±, Chiung-Jen Wu 11:30 AM - дє¤ж„џзҐћз»Џзі»з»џдёЋеїѓи‚ѕз–ѕз—… Markus P. Schlaich 11:45 AM - йЎЅе›єжЂ§й«�иЎЂеЋ‹д»‹е…ҐжІ»з–—иї›е±• й‚№и‹±еЌЋ 12:00 PM - йЎЅе›єжЂ§й«�иЎЂеЋ‹зљ„з»ЏеЇјз®ЎеЋ»и‚ѕзҐћ з»ЏеЊ–пјљж—©жњџз»ЏйЄЊдёЋз—…дѕ‹жЉҐе‘Љ еЌўж€ђеї— 12:15 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” и®Ёи®єдё“е®¶пјљи’‹й›„дє¬, еЌўж€ђеї—, зЅ—е»єж–№, Markus P. Schlaich, еј з‘ћеІ© 12:30 PM - дј‘дјљ еЌ€й—ґеЌ«ж�џдјљ зЃ«е±±дё»еЉћ е† и„‰д»‹е…ҐеЅ±еѓЏжЉЂжњЇж–°иї›е±• 12:40 PM-1:55 PM дё»еёпјљй™€з»Ќи‰Ї, йўњзєўе…µ, йѓдёЅеђ›, Gary S. Mintz 12:40 PM - ејЂењєи‡ґиѕћ 12:45 PM - еЇјз®Ўе®¤зЄЃз ґжЂ§д»‹е…ҐеЅ±еѓЏпјљиЎЂз®Ў е†…и¶…еЈ°гЂЃи¶…еЈ°и™љж‹џз»„з»‡е¦еЏЉе…‰е¦е№Іж¶‰ж– е±‚ж€ђеѓЏз‰еЅ±еѓЏзљ„еђ€зђ†еє”з”Ё Gary S. Mintz 1:05 PM - iFRпјљдёЌдѕќиµ–и…єи‹·зљ„ж–°еЋ‹еЉ›жЈЂжµ‹ жЉЂжњЇд»ҐиЇ„дј°з‹зЄ„дёҐй‡ЌжЂ§ Javier Escaned 2:30 PM - и‚Ўжµ…еЉЁи„‰з—…еЏ�д»‹е…Ґдёзђѓе›Љж€ђеЅў жњЇгЂЃй‡‘е±ћиЈёж”Їжћ¶гЂЃиЌЇз‰©жґ—и„±ж”Їжћ¶еЏЉиЌЇз‰© ж¶‚е±‚зђѓе›Љзљ„жЇ”иѕѓ Haizal Haron Kamar 2:45 PM - и†ќдё‹еЉЁи„‰д»‹е…ҐжІ»з–—пјљдёґеєЉз»ЏйЄЊеЏЉ вЂњжЊ‘ж€�жЂ§вЂќз—…дѕ‹е›ћйЎѕ Rosli Mohd Ali 3:00 PM - жЎЎеЉЁи„‰еѕ„и·Їе¤–е‘ЁиЎЂз®Ўд»‹е…ҐиЇЉз–—зљ„ зЋ°зЉ¶дёЋжњЄжќҐ жќЁж€ђж�Ћ 3:15 PM - иЎЂз®Ўеѕ„и·Їе№¶еЏ‘з—‡ Aravinda Nanjundappa 3:30 PM - и¶…еЈ°жЊ‡еј•дё‹дё‹и…”йќ™и„‰ж»¤е™ЁзЅ®е…Ґпјљ ж—¶жњєгЂЃж–№жі•еЏЉж“ЌдЅњиЂ… Joseph Varon 3:45 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” и®Ёи®єдё“е®¶пјљHaizal Haron Kamar, Rosli Mohd Ali, Aravinda Nanjundappa, Joseph Varon, зЋ‹ж•€еўћ, жќЁж€ђж�Ћ дё»еЉЁи„‰з–ѕз—… дё»жЊЃдєєпјљйѓдјџ, з¬¦дјџе›Ѕ 4:00 PM - TEVARжІ»з–—дё»еЉЁи„‰е¤№е±‚зљ„е…ій”®й—®йў� з¬¦дјџе›Ѕ 4:15 PM - дё»еЉЁи„‰з–ѕз—…и…”е†…еѕ®е€›жІ»з–—зЋ°зЉ¶е’Њ иї›е±• ж™ЇењЁе№і 1:25 PM - иЎЂз®Ўе†…и¶…еЈ°е°„йў‘ж•°жЌ®е€†жћђењЁдёґеєЉ дёЉзљ„еє”з”Ёд»·еЂј William Kongto Hau 4:30 PM - и…”е†…й‡Ќе»єе†…и„ЏеЉЁи„‰пјљж–№жі•дёЋз»“жћњ йѓдјџ и‚ѕеЉЁи„‰з–ѕз—… 1:45 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” дё»жЊЃдєєпјљAravinda Nanjundappa, й‚№и‹±еЌЋ 1:55 PM - дј‘дјљ 4:45 PM - дё»еЉЁи„‰еј“з—…еЏ�е¤–з§‘дёЋи…”е†…зљ„иЃ”еђ€ дї®е¤ЌпјљеЌіе€»з–—ж•€дёЋе№¶еЏ‘з—‡ Eak-Kyun Shin 10:30 AM - и‚ѕеЉЁи„‰з–ѕз—…иЇЉжІ»и¦Ѓзґ пјљжЊ‡еЌ—гЂЃ иЇ„д»·еЏЉз–—ж•€ еј з‘ћеІ© 10:45 AM - 2012е№ґи‚ѕеЉЁи„‰ж”Їжћ¶жњЇзљ„и§’и‰І Aravinda Nanjundappa е¤–е‘Ёе’Њи…”е†…иЎЂз®ЎжІ»з–—з¬¬дєЊйѓЁе€† 2:00 PM-6:00 PM дё‹и‚ўеЉЁи„‰з–ѕз—…еЏЉйќ™и„‰з–ѕз—… дё»жЊЃдєєпјљй™€еї , Craig M. Walker 11:00 AM - йЂ‰ж‹©жЂ§дёҐй‡Ќи‚ѕеЉЁи„‰зІҐж ·зЎ¬еЊ–ж‚Ј иЂ…дёи‚ѕеЉЁи„‰ж”Їжћ¶жњЇж�Їжњ‰ж•€зљ„пјљеЌ•дёеїѓе… е№ґйљЏи®їз–—ж•€ и’‹й›„дє¬ 2:00 PM - дё‹и‚ўеЉЁи„‰з–ѕз—…иЇЉжІ»и¦Ѓзґ пјљжЊ‡еЌ—гЂЃ иЇ„д»·еЏЉз–—ж•€ зЋ‹ж•€еўћ 11:15 AM - е¦‚дЅ•еЃљеҐЅз»ЏжЎЎеЉЁи„‰и‚ѕеЉЁи„‰д»‹е…Ґ жІ»з–—пјџ зЅ—е»єж–№ 2:15 PM - и¶іиѓЊеЉЁи„‰е’Њдѕ§жћќеѕ„и·ЇењЁд»‹е…ҐжІ»з–— дёҐй‡Ќи‚ўдЅ“еЉЁи„‰зјєиЎЂдёзљ„дЅњз”Ё Craig M. Walker 137 5:00 PM - е®Ње…Ёд»‹е…ҐжЉЂжњЇе®Њж€ђдё»еЉЁи„‰з�¤дї®е¤Ќ(EVAR) Neil E. Strickman 5:15 PM - дјґдёҐй‡Ќйў€йѓЁж€ђи§’и…№дё»еЉЁи„‰з�¤дї®е¤Ќ дёи‚ѕдёЉж–№е›єе®ље™Ёжў°зљ„еє”з”ЁпјљеЋџзђ†гЂЃж“ЌдЅњ жЉЂе·§еЏЉз—…дѕ‹е›ћйЎѕ Won-Heum Shim 5:30 PM - е† еїѓз—…еђ€е№¶дё»еЉЁи„‰е¤№е±‚зљ„е¤„зђ† ж›ѕе’Њжќѕ 5:45 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” и®Ёи®єдё“е®¶пјљж™ЇењЁе№і, Won-Heum Shim, Eak-Kyun Shin, Neil E. Strickman, ж›ѕе’Њжќѕ 6:00 PM - дј‘дјљ CIT 2012 www.citmd.com 2012е№ґ3жњ€17ж—Ґ ж�џжњџе… е…Ґи·ЇзЇ‡ дё»жЊЃдєєпјље€�жѓ дє®, жќЋе»єе№і, иЃ‚з»Ќе№і, йЅђж™“е‹‡ дё‰е±‚307ABдјљи®®е®¤ ж—©й¤ђдјљ жі°е°”иЊ‚дё»еЉћ TRI и§Је†іж–№жЎ€пјље¦‚дЅ•HOLDдЅЏз»ЏжЎЎеЉЁи„‰е¤„ зђ†е¤Ќжќ‚з—…еЏ�пјџ 7:00 AM-8:00 AM 8:42 AM - д»Ћз›®е‰ЌиЇЃжЌ®зњ‹жЎЎеЉЁи„‰еЏЇд»Ґж€ђдёє д»‹е…ҐжІ»з–—зљ„й¦–йЂ‰и·Їеѕ„еђ—пјџ жќЋдёєж°‘ 8:52 AM - и®Ёи®є дё»еёпјљзЋ‹жµ·ж�Њ, Chiung-Jen Wu, е‘ЁзЋ‰жќ° 8:54 AM - з»Џе°єеЉЁи„‰д»‹е…ҐжІ»з–—ж�Їд»‹е…ҐеЊ»з”џ зљ„еџєжњ¬еЉџеђ—пјџ е‚…еђ‘еЌЋ 7:00 AM - ејЂењєи‡ґиѕћ 9:04 AM - и®Ёи®є 7:03 AM - е¦‚дЅ•holdдЅЏз»ЏжЎЎеЉЁи„‰е¤„зђ†е·¦дё»е№І з—…еЏ�пјџ еђґж°ёеЃҐ 9:06 AM - жЂЋж ·е…‹жњЌжЎЎеЉЁи„‰е…Ґи·ЇйљњзўЌж€ђеЉџ е®Њж€ђз»ЏжЎЎеЉЁи„‰йЂ еЅ±дёЋд»‹е…ҐжІ»з–—пјџ иЌ†е…Ёж°‘ 7:18 AM - е¦‚дЅ•holdдЅЏз»ЏжЎЎеЉЁи„‰е¤„зђ†е€†еЏ‰з—…еЏ�пјџ еј жё… 7:33 AM - е¦‚дЅ•holdдЅЏз»ЏжЎЎеЉЁи„‰ж— йћ�жЉЂжњЇе¤„ зђ†е¤Ќжќ‚е† и„‰з—…еЏ�пјџ иґєе‹‡ 7:48 AM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” TRIдї±д№ђйѓЁ 8:00 AM-12:30 PM з‰№и‰Іжј”и®І дё»жЊЃдєєпјљFina Mauri, д№”ж ‘е®ѕ, е‘ЁзЋ‰жќ° и®Ёи®єдё“е®¶пјљFerdinand Kiemeneij, Mitchell W. Krucoff, жќЁи·ѓиї› 8:00 AM - з»ЏжЎЎеЉЁи„‰д»‹е…ҐжІ»з–—20е‘Ёе№ґпјљж—ў еѕЂж€ђе°±дёЋжњЄжќҐжњєйЃ‡ Ferdinand Kiemeneij 8:12 AM - дёе›Ѕз»ЏжЎЎеЉЁи„‰е¤Ќжќ‚д»‹е…ҐжІ»з–—пјљ и·Їеђ‘дЅ•ж–№пјџ жќЁи·ѓиї› 8:24 AM - зѕЋе›Ѕз»ЏжЎЎеЉЁи„‰д»‹е…ҐжІ»з–—пјљйњЂи¦Ѓ д»Ђд№€ж•°жЌ®пјџ Mitchell W. Krucoff 8:36 AM - дё“е®¶и®Ёи®є 9:16 AM - и®Ёи®є 9:18 AM - жЎЎеЉЁи„‰е…Ґи·ЇиЎЂз®ЎејЇж›Іж‚ЈиЂ…дёеє” з”Ёе† и„‰еЇјдёќзљ„вЂњжЉЂе·§вЂќ Gustavo Samaja 9:28 AM - и®Ёи®є жЊ‘ж€�зЇ‡ дё»жЊЃдєєпјљжќЋеЌ е…Ё, жќЋз”°ж�Њ, ж€ґе†›, жѓ ж°ёж�Ћ, ж›ѕе’Њжќѕ, иµµиїЋж–° 9:30 AM - з»ЏеЏЊдѕ§жЎЎеЉЁи„‰ж— йћ�зі»з»џе¤„зђ†ж…ў жЂ§е®Ње…Ёй—еЎћз—…еЏ� Chiung-Jen Wu 9:40 AM - и®Ёи®є 9:42 AM - з»ЏжЎЎеЉЁи„‰е·¦дё»е№Із—…еЏ�д»‹е…ҐжІ»з–— з—…дѕ‹иЌџиђѓ еѕђдєљдјџ 9:52 AM - и®Ёи®є 9:54 AM - з»ЏжЎЎеЉЁи„‰е€†еЏ‰з—…еЏ�д»‹е…ҐжІ»з–—з—… дѕ‹иЌџиђѓ Josef Ludwig 10:04 AM - и®Ёи®є 10:06 AM - з»ЏжЎЎеЉЁи„‰жЎҐиЎЂз®Ўз—…еЏ�д»‹е…ҐжІ»з–— з—…дѕ‹иЌџиђѓ е‚…е›Ѕиѓњ 10:16 AM - и®Ёи®є 10:18 AM - дёЌеёёи§Ѓе¤Ќжќ‚з»ЏжЎЎеЉЁи„‰д»‹е…ҐжІ»з–— з—…дѕ‹иЌџиђѓ Ramazan Г–zdemir 10:28 AM - и®Ёи®є 10:30 AM - з»ЏжЎЎеЉЁи„‰з›ґжЋҐд»‹е…ҐжІ»з–—е¤„зђ†ST ж®µжЉ¬й«�ећ‹еїѓи‚Њжў—ж»зљ„з›®е‰ЌиЇЃжЌ®дёЋе®ћи·µз»ЏйЄЊ зЋ‹й›· 10:40 AM - и®Ёи®є е™Ёжў°зЇ‡ дё»жЊЃдєєпјљзЋ‹д№ђдё°, жґЄжµЄ, иґѕз»Ќж–Њ, еєћж–‡и·ѓ, и’‹й‡‘жі• 10:42 AM - з»ЏжЎЎеЉЁи„‰д»‹е…ҐжІ»з–—еЇјеј•еЇјз®ЎйЂ‰ ж‹©и¦Ѓз‚№ е§љж°‘ 10:52 AM - и®Ёи®є 10:54 AM - жЇЌеђеЇјз®ЎжЉЂжњЇењЁз»ЏжЎЎеЉЁи„‰д»‹е…Ґ жІ»з–—дёзљ„еє”з”Ё Kenji Wagatsuma 11:04 AM - и®Ёи®є 11:06 AM - жЎЎеЉЁи„‰е¤„зђ†е·¦дё»е№І/е€†еЏ‰з—…еЏ�зљ„ е™Ёжў°йЂ‰ж‹©еЏЉж“ЌдЅњжЉЂе·§ д№”ж ‘е®ѕ 11:16 AM - и®Ёи®є 11:18 AM - дёҐй‡Ќй’™еЊ–з—…еЏ�з»ЏжЎЎеЉЁи„‰ж—‹зЈЁжІ» з–—зљ„еє”з”Ё е§њй“Ѓж°‘ 11:28 AM - и®Ёи®є е‘µжЉ¤зЇ‡ дё»жЊЃдєєпјљй«�дј зЋ‰, е€�ж–Њ, йЅђе›Ѕе…€, ж›ѕзЋ‰жќ°, и‹—з«‹е¤« 11:30 AM - жЎЎеЉЁи„‰е№¶еЏ‘з—‡зљ„йў„й�ІеЏЉе¤„зђ† е‘ЁзЋ‰жќ° 11:40 AM - и®Ёи®є 11:42 AM - з»ЏжЎЎеЉЁи„‰д»‹е…ҐжІ»з–—зљ„дё»и¦Ѓй—® йў�пјљз—‰жЊ›гЂЃеЌ’дёеЏЉж”ѕе°„зєїжЌџдј¤ зЋ‹жµ·ж�Њ 11:52 AM - и®Ёи®є 138 CIT 2012 www.citmd.com 2012е№ґ3жњ€17ж—Ґ ж�џжњџе… 11:54 AM - з»ЏжЎЎеЉЁи„‰дёҐй‡Ќе‡єиЎЂе№¶еЏ‘з—‡зљ„йў„ й�ІеЏЉе¤„зђ† жќЋжµЄ 12:04 PM - и®Ёи®є 12:06 PM - е¦‚дЅ•йЃїе…ЌжЎЎеЉЁи„‰жЌџдј¤е’Њй—еЎћпјџ й™€зЏЏ 2:50 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” з—…дѕ‹жЉҐе‘Љпј€жЇЏдёЄз—…дѕ‹жЉҐе‘ЉеЏЉй—®з”15е€†й’џпј‰ 3:00 PM - з—…дѕ‹1пјљж—©жњџж”Їжћ¶иЎЂж “ й’±жќ° 12:16 PM - и®Ёи®є 3:15 PM - з—…дѕ‹2пјљиґґеЈЃдёЌи‰Їеј•иµ·зљ„ж™љжњџж€– иїџеЏ‘ж™љжњџж”Їжћ¶иЎЂж “ й‡‘зђґиЉ± 12:18 PM - з»ЏжЎЎеЉЁи„‰д»‹е…ҐжІ»з–—е№¶еЏ‘з—‡е¤„зђ† з—…дѕ‹иЌџиђѓ жќњеї—ж°‘ 3:30 PM - з—…дѕ‹3пјљж–°з”џе†…и†њз ґиЈ‚еј•иµ·зљ„ж™љ жњџж€–иїџеЏ‘ж™љжњџж”Їжћ¶иЎЂж “ дїћжў¦и¶Љ 12:28 PM - и®Ёи®є 3:45 PM - иЊ¶ж‡ 12:30 PM - дј‘дјљ дё»жЊЃдєєпјљй™€йџµеІ±, Yangsoo Jang и®Ёи®єдё“е®¶пјљй™€жҐж�џ, е‚…е›Ѕиѓњ, жќЋеЌ е…Ё еЌ€й—ґеЌ«ж�џдјљ жі°е°”иЊ‚дё»еЉћ CTOи§Је†іж–№жЎ€пјље¦‚дЅ•HOLDдЅЏCTOпјџ 12:40 PM-1:55 PM дё»еёпјље‚…е›Ѕиѓњ, дѕЇзЋ‰жё…, еђ•ж ‘й“® 12:40 PM - ејЂењєи‡ґиѕћ 12:45 PM - вЂњж€�е‰ЌвЂќпјљCTOжњЇе‰Ќе‡†е¤‡ и‘›й›· 1:05 PM - вЂњж€�ж—¶вЂќпјљCTOеёёи§„жЉЂжњЇ й™€з»ѓ 1:25 PM - вЂњж€�еђЋвЂќпјљCTOе¤±иґҐзљ„еЋџе› е€†жћђ жќЋжµЄ 4:00 PM - з—…дѕ‹4пјљж–°з”џе†…и†њеўћз”џеј•иµ·зљ„ж”Ї жћ¶е†…е†Ќз‹зЄ„ дѕЇйќ™жіў дё‰е±‚308дјљи®®е®¤ з—…дѕ‹ж—©й¤ђдјљпј€е…«пј‰ е¤–е‘Ёе’Њи…”е†…иЎЂз®Ўз–ѕз—… 7:00 AM-8:00 AM дё»жЊЃдєєпјљж™ЇењЁе№і, еј з‘ћеІ©, е€�е»єе№і 7:00 AM - CS-0094пјљиѓёдё»еЉЁи„‰з�¤и…”е†…дї®е¤Ќ жњЇпј€EVARпј‰дёе€©з”ЁIVUSиЇЃе®ћзњџи…” й»„ж–‡ж™– 7:12 AM - и®Ёи®є 7:15 AM - CS-0135пјљи‚ѕеЉЁи„‰ж”Їжћ¶ж¤Ќе…ҐжњЇеђЋ е†ЌеЏ‘йЎЅе›єжЂ§й«�иЎЂеЋ‹ зЅ—ж·ће…ѓ 7:27 AM - и®Ёи®є 4:15 PM - з—…дѕ‹5пјљж”Їжћ¶ж–иЈ‚еј•иµ·зљ„ж”Їжћ¶е†… е†Ќз‹зЄ„ Yangsoo Jang 7:30 AM - CS-0299пјљеє”з”Ёеїѓе†…з§‘д»‹е…Ґж‰‹ж®µ жІ»з–—е¤–е‘ЁCTOз—…еЏ�пјљж”Їжћ¶зј“и§Јз—‡зЉ¶ Andrew D. Wisneski 4:30 PM - з—…дѕ‹6пјљж…ўжЂ§ж”Їжћ¶и†ЁиѓЂдёЌе…Ёеј•иµ· зљ„ж”Їжћ¶е†…е†Ќз‹зЄ„ е‚…е›Ѕиѓњ 7:42 AM - и®Ёи®є 4:45 PM - з—…дѕ‹7пјљж”Їжћ¶е†…ж–°з”џзІҐж ·зЎ¬еЊ–еј• иµ·зљ„ж”Їжћ¶е†…е†Ќз‹зЄ„ йѓе†› 7:45 AM - CS-0340пјљеє”з”Ёж— йћ�еЇјз®Ўз»ЏжЎЎеЉЁ и„‰иЎЊз»Џзљ®йў€еЉЁи„‰ж”Їжћ¶ж¤Ќе…ҐжњЇ е‘Ёж–Ње…Ё 7:57 AM - и®Ёи®є 5:00 PM - з—…дѕ‹8пјљж”Їжћ¶иЎЂж “зљ„е¤„зђ† еЌўж€ђеї— 8:00 AM - дј‘дјљ 1:55 PM - дј‘дјљ 5:15 PM - з—…дѕ‹9пјљж”Їжћ¶е†…е†Ќз‹зЄ„зљ„е¤„зђ† жќЁеЈ«дјџ е·¦дё»е№Іе’Ње€†еЏ‰з—…еЏ�еі°дјљз¬¬дё‰йѓЁе€† 8:30 AM-12:30 AM OCTеџ№и®иЇѕзЁ‹з¬¬дєЊйѓЁе€† 2:00 PM-6:00 PM 5:30 PM - з—…дѕ‹10пјљж™љжњџж”Їжћ¶е№¶еЏ‘з—‡ Simon Cheung-Chi Lam з¬¬дёѓењєпјље·¦дё»е№Ід»‹е…ҐжІ»з–—жЉЂжњЇ ж™љжњџж”Їжћ¶е№¶еЏ‘з—‡ 5:45 PM -дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” дё»жЊЃдєєпјљYangsoo Jang, жќЁи·ѓиї› и®Ёи®єдё“е®¶пјљKelvin Chan, й’±жќ°, дєЋжіў 6:00 PM - дј‘дјљ 1:45 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 2:00 PM - ж”Їжћ¶иЎЂж “зљ„OCTиЇ„д»· дєЋжіў 2:25 PM - ж”Їжћ¶е†…е†Ќз‹зЄ„е’Њж–°з”џзІҐж ·зЎ¬еЊ–зљ„ OCTиЇ„д»· Yangsoo Jang 139 дё»жЊЃдєєпјљй™€з»Ќи‰Ї, Davide Capodanno 8:30 AM - е‰Ќй™Ќж”Їж€–е›ћж—‹ж”ЇејЂеЏЈз—…еЏ�зљ„е¤„ зђ†пјљж€‘зљ„ж–№жі• й™€зєЄжћ— 8:45 AM - й’™еЊ–е·¦дё»е№Із—…еЏ�е‡†е¤‡пјљж™®йЂљзђѓ е›ЉгЂЃе€»з—•зђѓе›ЉеЏЉж—‹зЈЁзљ„жЇ”иѕѓ Samuel K. Mathew 9:00 AM - иЎЂж¶ІеЉЁеЉ›е¦ж”ЇжЊЃзљ„иЂѓй‡Џпјљдёґж—¶ ењ°дёЋйў„й�ІжЂ§ењ°еє”з”ЁеЇ№жЇ” Yuji Hamazaki CIT 2012 www.citmd.com 2012е№ґ3жњ€17ж—Ґ ж�џжњџе… 9:12 AM - е·¦дё»е№Іеђ€е№¶е¤љж”ЇиЎЂз®Ўз—…еЏ�ж‚ЈиЂ… дёж–ЅиЎЊе€†жњџдёЋвЂњжќ‚дє¤вЂќж‰‹жњЇзљ„и§’и‰І David X. M. Zhao 9:24 AM - е·¦дё»е№Ід»‹е…ҐжІ»з–—еђЋйљЏи®їз›‘и§†пјљ йЂ еЅ±дёЋиїђеЉЁиЇ•йЄЊеЇ№жЇ”гЂЃж—¶жњєеЏЉйЃїе…ЌдёЌеї… и¦Ѓзљ„е†Ќж¬Ўд»‹е…Ґ жџіж™ЇеЌЋ 9:36 AM - е·¦дё»е№Іж”Їжћ¶е†…е†Ќз‹зЄ„зљ„е¤„зђ†еЏЉ з–—ж•€ Gim-Hooi Choo 9:48 AM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” и®Ёи®єдё“е®¶пјљй™€зєЄжћ—, Gim-Hooi Choo, Yuji Hamazaki, жџіж™ЇеЌЋ, Samuel K. Mathew, David X. M. Zhao з¬¬е…«ењєпјље·¦дё»е№Ід»‹е…ҐжІ»з–—з—…дѕ‹е›ћйЎѕпј€дёЂпј‰пјљ и§Је†із–‘йљѕй—®йў�ж€–е№¶еЏ‘з—‡пј€иЇиЁЂпјљдёж–‡пј‰ дё»жЊЃдєєпјљзЋ‹дјџж°‘, ж–№е”ЇдёЂ и®Ёи®єдё“е®¶пјљж›№й›Єж»Ё, йѓќжЃ’е‰‘, жќЋе›Ѕеє†, е€�жµ·жіў, жџіж™ЇеЌЋ, еј й’І 10:00 AM - е·¦дё»е№Ід»‹е…ҐжІ»з–—вЂњжЊ‘ж€�жЂ§вЂќз—…дѕ‹1 е‘Ёж—ж™Ё 10:10 AM - и®Ёи®є 10:15 AM - е·¦дё»е№Ід»‹е…ҐжІ»з–—вЂњжЊ‘ж€�жЂ§вЂќз—…дѕ‹2 й©¬ж №е±± 10:25 AM - и®Ёи®є 10:30 AM - е·¦дё»е№Ід»‹е…ҐжІ»з–—вЂњжЊ‘ж€�жЂ§вЂќз—…дѕ‹3 е€�еђЊеє“ 10:40 AM - и®Ёи®є 10:45 AM - е·¦дё»е№Ід»‹е…ҐжІ»з–—вЂњжЊ‘ж€�жЂ§вЂќз—…дѕ‹4 еј е¤§дёњ з¬¬д№ќењєпјље·¦дё»е№Ід»‹е…ҐжІ»з–—з—…дѕ‹е›ћйЎѕпј€дєЊпј‰пјљ и§Је†із–‘йљѕй—®йў�ж€–е№¶еЏ‘з—‡пј€иЇиЁЂпјљдёж–‡пј‰ 1:30 PM - е€†еЏ‰еѕ®еЇјз®ЎењЁPCIдёзљ„еє”з”Ё Eisho Kyo дё»жЊЃдєєпјљеј е¤§дёњ, и°е®Ѓ и®Ёи®єдё“е®¶пјљж€ґе†›, жЁЉе†°, йѓй‡‘ж€ђ, жќЋж‹Ґе†›, еђґй“ї, жќЁдёЅйњћ 1:45 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 11:15 AM - е·¦дё»е№Ід»‹е…ҐжІ»з–—вЂњжЊ‘ж€�жЂ§вЂќз—…дѕ‹6 й©¬з¤јеќ¤ 11:25 AM - и®Ёи®є е·¦дё»е№Іе’Ње€†еЏ‰з—…еЏ�еі°дјљз¬¬е››йѓЁе€† 2:00 PM-6:00 PM 11:30 AM - е·¦дё»е№Ід»‹е…ҐжІ»з–—вЂњжЊ‘ж€�жЂ§вЂќз—…дѕ‹7 еј дїЉжќ° з¬¬еЌЃењєпјљйќће·¦дё»е№Іе€†еЏ‰з—…еЏ�д»‹е…ҐжІ»з–—е№¶ еЏ‘з—‡ 11:40 AM - и®Ёи®є дё»жЊЃдєєпјљжІ€еЌ«еі°, Yean-Teng Lim и®Ёи®єдё“е®¶пјљDevang Desai, и‘›й›·, е€�еЃҐ, Goran Stankovic, зЋ‹иґµжќѕ, жќЁеєж ‘ 11:45 AM - е·¦дё»е№Ід»‹е…ҐжІ»з–—вЂњжЊ‘ж€�жЂ§вЂќз—…дѕ‹8 е‘Ёж–Ње…Ё 11:55 AM - и®Ёи®є 12:00 PM - е·¦дё»е№Ід»‹е…ҐжІ»з–—вЂњжЊ‘ж€�жЂ§вЂќз—…дѕ‹9 ж›Іж–°е‡Ї 12:10 PM - и®Ёи®є 12:15 PM - е·¦дё»е№Ід»‹е…ҐжІ»з–—вЂњжЊ‘ж€�жЂ§вЂќз—…дѕ‹10 еєћж–‡и·ѓ 12:25 PM - и®Ёи®є 12:30 PM - дј‘дјљ еЌ€й—ґеЌ«ж�џдјљ ж�џиї›еЊ»з–—дёЋKanekaдё»еЉћ ж‰‹жњЇж€ђеЉџзљ„дёЂеЌЉеЏ–е†ідєЋе™Ёжў°пјљKanekaе™Ё жў°дЅїз”Ёз»ЏйЄЊе€†дє« 12:40 PM-1:55 PM дё»еёпјљй»„дјџе‰‘, й©¬ж №е±±, зЋ‹дјџж°‘ 10:55 AM - и®Ёи®є 12:40 PM - ејЂењєи‡ґиѕћ 11:00 AM - е·¦дё»е№Ід»‹е…ҐжІ»з–—вЂњжЊ‘ж€�жЂ§вЂќз—…дѕ‹5 еђ•е®‰жћ— 12:45 PM - иЎЂж “жЉЅеђёеЇјз®Ўпј€Thrombuster IIпј‰ењЁжЂҐжЂ§еїѓи‚Њжў—ж»дёзљ„еє”з”Ё еј е¤§дёњ 11:10 AM - и®Ёи®є 1:55 PM - дј‘дјљ 1:00 PM - иЎЂж “жЉЅеђёеЇјз®ЎењЁжІ»з–—STж®µжЉ¬й«�ећ‹ еїѓи‚Њжў—ж»дёзљ„еє”з”Ё йѓй‡‘ж€ђ 1:15 PM - иЎЂж “жЉЅеђёеЇјз®ЎењЁжЂҐжЂ§STж®µжЉ¬й«�ећ‹ еїѓи‚Њжў—ж»дёзљ„еє”з”Ёпјљз—…дѕ‹е›ћйЎѕ жќЋжЂЎ 2:00 PM - жЂЋж ·йў„й�Ійќће·¦дё»е№Іе€†еЏ‰з—…еЏ�д»‹е…Ґ жІ»з–—жњЇдёдёЋжњЇеђЋе№¶еЏ‘з—‡пјџ Goran Stankovic 2:15 PM - з—…дѕ‹жЉҐе‘Љпјље€†еЏ‰з—…еЏ�ж¤Ќе…Ґ Nilepaxдё“з”Ёж”Їжћ¶пј€Medinaе€†ећ‹111пј‰ Devang Desai 2:21 PM - и®Ёи®є 2:27 PM - жЊ‡еЇје€†еЏ‰з—…еЏ�ж”Їжћ¶жњЇзљ„IVUSж ‡ е‡†пјљж”Їжћ¶еЇ№з§°жЂ§гЂЃе›ћзј©дёЋи†ЁиѓЂеЏЉе…¶еЇ№е®‰ е…ЁжЂ§дёЋжњ‰ж•€жЂ§з–—ж•€зљ„жЅњењЁеЅ±е“Ќ Gary S. Mintz 2:42 PM - з—…дѕ‹жЉҐе‘ЉпјљMedinaе€†ећ‹110з—…еЏ� зљ„вЂњеЌіе…ґвЂќж”Їжћ¶жњЇ и‘›й›· 2:48 PM - и®Ёи®є 2:54 PM - MurrayдёЋFinetе€†еЏ‰е…¬ејЏзљ„ж•€з”Ёпјљ дёґеєЉеє”з”ЁеЏЉе…¶еЇ№е€†еЏ‰з—…еЏ�е¤„зђ†дёЋз–—ж•€зљ„ жЅњењЁеЅ±е“Ќ Sidney Tsz Ho Lo 3:09 PM - з—…дѕ‹жЉҐе‘ЉпјљдёЂдѕ‹е‰Ќй™Ќж”Ї / еЇ№и§’ж”Ї Medinaе€†ећ‹111е€†еЏ‰з—…еЏ�жЂЋж ·йЂ‰ж‹©ж”Їжћ¶е¤§ е°Џпјџпј€з›®жµ‹гЂЃQCAеЏЉIVUSзљ„е·®еј‚пј‰ е€�еЃҐ 3:15 PM - и®Ёи®є 3:21 PM - дёєд»Ђд№€ж”Їжћ¶е†…е†Ќз‹зЄ„з»ЏеёёењЁе€†еЏ‰ з—…еЏ�йѓЁдЅЌеЇ№дѕ§иЎЂз®ЎеЈЃеЏ‘з”џпјџ Gim-Hooi Choo 140 CIT 2012 www.citmd.com 2012е№ґ3жњ€17ж—Ґ ж�џжњџе… 3:36 PM - з—…дѕ‹жЉҐе‘Љпјље€†ж”Їж”Їжћ¶е†…е†Ќз‹зЄ„ Wan Azman Wan Ahmad 3:42 PM - и®Ёи®є 3:48 PM - е€†еЏ‰з—…еЏ�и§Је‰–дёЋж–‘еќ—иґџиЌ·еЇ№д»‹е…Ґ жІ»з–—е№¶еЏ‘з—‡зљ„еЅ±е“Ќ Dobrin Vassilev 4:03 PM - з—…дѕ‹жЉҐе‘Љпјљдё»ж”Їж”Їжћ¶ж¤Ќе…ҐеђЋе€†ж”Ї дёўе¤±пј€Medinaе€†ећ‹110пј‰ Sufia Rahman 5:42 PM - и®Ёи®є 5:48 PM - з—…дѕ‹жЉҐе‘ЉпјљжЂҐжЂ§еїѓи‚Њжў—ж»зґЇеЏЉзњџ жЂ§е€†еЏ‰з—…еЏ� й©¬йў–и‰і 5:54 PM - и®Ёи®є 6:00 PM - дј‘дјљ дё»жЊЃдєєпјљAlexandra J. Lansky, жќЋжµЄ и®Ёи®єдё“е®¶пјљдё›жґЄи‰Ї, Giuseppe De Luca, Josef Ludwig, Jayesh S. Prajapati, жІ€зЏ е†›, Swee Choon Ng 4:15 PM - е€†еЏ‰з—…еЏ�вЂњеЌіе…ґвЂќж”Їжћ¶жњЇеЇ№жЇ”еЏЊ ж”Їжћ¶жњЇзљ„иЌџиђѓе€†жћђпјљз—…дѕ‹йЂ‰ж‹©дёЋз–—ж•€ Jan Kovac 4:30 PM - е€†ж”ЇвЂњз›‘з¦ЃвЂќпјљи°Ѓе¤„ењЁйЈЋй™©дёеЏЉ е…¶жЂЋж ·еЅ±е“Ќз–—ж•€пјџ Alexandra J. Lansky 4:45 PM - з—…дѕ‹жЉҐе‘Љпјљж�Їеђ¦еЇ№еђ»пјџ пј€Medinaе€†ећ‹111, дё»ж”Їж”Їжћ¶ж¤Ќе…ҐеђЋпј‰ жќЋдёЅ 4:51 PM - и®Ёи®є 4:57 PM - DK-CRUSHзі»е€—иЇ•йЄЊпјљзђ†и§Је…ій”® з»“жћњеЏЉе…¶дёЋдёґеєЉе®ћи·µзљ„з›ёе…іжЂ§ еј дїЉжќ° 5:12 PM - з—…дѕ‹жЉҐе‘ЉпјљдЅ е°†жЂЋж ·е¤„зђ†еђЊдёЂж‚Ј иЂ…е¤ље¤„е€†еЏ‰з—…еЏ�пјџ и°е®Ѓ дё‰е±‚309Aдјљи®®е®¤ EAPCI-EuroPCR/ESC at CIT йќћSTж®µжЉ¬й«�ећ‹еїѓи‚Њжў—ж»-жЂҐжЂ§е† и„‰з»јеђ€еѕЃ зљ„еЅ“д»Јз®Ўзђ† 8:30 AM-10:30 AM дё»жЊЃдєєпјљJean Fajadet, йўњзєўе…µ 8:30 AM - з›®зљ„з®Ђд»‹ Jean Fajadet 8:35 AM - йЈЋй™©е€†е±‚ Kari NiemelГ¤ 8:47 AM - й’€еЇ№дёЌеђЊж‚ЈиЂ…зљ„жЉ—иЎЂе°ЏжќїжІ»з–— Thomas Cuisset 8:59 AM - жњ‰е€›е№Ійў„зљ„ж—¶жњєе’Њз»“жћњ Goran Stankovic 9:11 AM - дёе›ЅйќћSTж®µжЉ¬й«�ећ‹еїѓи‚Њжў—ж»-жЂҐ жЂ§е† и„‰з»јеђ€еѕЃзљ„еЅ“д»Јз®Ўзђ† ж¦й�ідё° 9:23 AM - Live in-a-BoxзІѕи‡ґзј–иѕ‘з—…дѕ‹еЏЉи®Ёи®є и®Ёи®єиЂ…пјљThomas Cuisset, дЅ•еҐ”, Yean-Teng Lim, Kari NiemelГ¤, Goran Stankovic, Franz Weidinger 5:18 PM - и®Ёи®є 10:13 AM - жЊ‡еЌ—и§ЈиЇ» Franz Weidinger 5:24 PM - з—…дѕ‹жЉҐе‘ЉпјљMedinaе€†ећ‹101е€†еЏ‰ з—…еЏ�й‡‡з”ЁеЌ•ж”Їжћ¶иї�ж�ЇеЏЊж”Їжћ¶пјџ еЏ¶йЈћ 10:25 AM - и¦Ѓз‚№жЂ»з»“ Jean Fajadet 5:30 PM - и®Ёи®є 5:36 PM - з—…дѕ‹жЉҐе‘Љпјље‰Ќй™Ќж”Їж…ўжЂ§е®Ње…Ёй—еЎћ иї‘з«ЇMedinaе€†ећ‹111е€†еЏ‰з—…еЏ� жІ€зЏ е†› 141 дё»жЊЃдєєпјљй«�з‚њ, й’±иЏЉи‹± и®Ёи®єдё“е®¶пјљYuji Hamazaki, Chien-Ming Huang, Wen-Lieng Lee, Samuel K. Mathew, з”°е†›, жё© е°љз…њ, Wei-Hsian Yin, Robaayah Zambahari 10:30 AM - ж—‹зЈЁжњЇењЁе¤Ќжќ‚е† и„‰з—…еЏ�д»‹е…ҐжІ» з–—дёзљ„дЅњз”Ё Robaayah Zambahari 10:42 AM - ж—‹зЈЁжњЇзљ„ж“ЌдЅњжЉЂе·§ й«�з‚њ 4:09 PM - и®Ёи®є з¬¬еЌЃдёЂењєпјљйќће·¦дё»е№Іе€†еЏ‰з—…еЏ�ж”Їжћ¶жњЇ - д»Ћ дёґеєЉиЇ•йЄЊе¦е€°дє†д»Ђд№€пјџ з¬¬дё‰е±Љж—‹зЈЁжЉЂжњЇе°Џећ‹з ”и®Ёдјљ 10:30 AM-12:30 PM 10:54 AM - ж—‹зЈЁе№¶еЏ‘з—‡зљ„е¤„зђ† Samuel K. Mathew зІѕеЅ©з—…дѕ‹е›ћйЎѕ 11:06 AM - з—…дѕ‹1пјље¤Ќжќ‚й’™еЊ–з—…еЏ�дёеє”з”Ё ж—‹зЈЁ Yuji Hamazaki 11:16 AM - и®Ёи®є 11:19 AM - з—…дѕ‹2пјљзђѓе›ЉдёЌиѓЅйЂљиї‡зљ„з—…еЏ� дёеє”з”Ёж—‹зЈЁ жё©е°љз…њ 11:29 AM - и®Ёи®є 11:32 AM - з—…дѕ‹3пјље¤Ќжќ‚ж…ўжЂ§е®Ње…Ёй—еЎћз—… еЏ�дёеє”з”Ёж—‹зЈЁ Wen-Lieng Lee 11:42 AM - и®Ёи®є 11:45 AM - з—…дѕ‹4пјље°ЏиЎЂз®Ўз—…еЏ�дёеє”з”Ёж—‹зЈЁ з”°е†› 11:55 AM - и®Ёи®є 11:58 AM - з—…дѕ‹5пјљз»ЏжЎЎеЉЁи„‰иЎЊе† и„‰ж—‹зЈЁжњЇ Chien-Ming Huang 12:08 PM - и®Ёи®є 12:11 PM - з—…дѕ‹6пјљжЂЋж ·ж”¶е›ћж— жі•з§»еЉЁзљ„ ж—‹зЈЁе¤ґпјџ Wei-Hsian Yin 12:21 PM - и®Ёи®є 12:24 PM - еђ¬дј—й—®з”еЏЉи¦Ѓз‚№жЂ»з»“ 12:30 PM - дј‘дјљ CIT 2012 www.citmd.com 2012е№ґ3жњ€17ж—Ґ ж�џжњџе… еЌ€й—ґеЌ«ж�џдјљ ењЈзЉ№иѕѕдё»еЉћ OCTе’ЊFFRпјљй±је’Њз†ЉжЋЊпјџ 12:40 PM-1:55 PM 3:40 PM - еђ€е№¶и‚ѕеЉџиѓЅдёЌе…Ёзљ„жЂҐжЂ§е† и„‰з»јеђ€ еѕЃж‚ЈиЂ…жЉ—е‡ќжІ»з–— й™€йџµеІ± дё»еёпјљWilliam F. Fearon, еђґж°ёеЃҐ, й’±иЏЉи‹±, е‘Ёйў–зЋІ 4:00 PM - еђ€е№¶з»€жњ«жњџи‚ѕз—…зљ„жЂҐжЂ§е† и„‰з»јеђ€ еѕЃж‚ЈиЂ…иЎЂиїђй‡Ќе»єжІ»з–— еј з‘ћеІ© 12:40 PM - ејЂењєи‡ґиѕћ 4:20 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 12:45 PM - FFRе’ЊOCTзљ„дёґеєЉеЉџз”Ё William F. Fearon з¬¬дё‰ењєпјљд»‹е…ҐдёЋдёґеєЉпјљејҐеђ€иЈ‚з—• 1:05 PM - OCTз—…дѕ‹е›ћйЎѕ й’±жќ° 1:20 PM - FFRз—…дѕ‹е›ћйЎѕ еј дїЉжќ° 1:30 PM - FFRз—…дѕ‹е›ћйЎѕ зЅ—е»єж–№ 1:40 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 1:55 PM - дј‘дјљ CCC/CISC at CIT зЄЃз ґдёґеєЉе®ћи·µзљ„е›°еўѓ - з–‘йљѕз—…дєєзљ„е¤„зђ† 2:00 PM-6:00 PM дё»жЊЃдєєпјљжњ±е›Ѕи‹±, жІ€жЅћеЌЋ, жќЋи™№дјџ, жќЋе¦еҐ‡ 4:40 PM - еђ€е№¶иЎЂе°Џжќїе‡Џе°‘ж€–з™Ѕз»†иѓће‡Џе°‘зљ„ е† еїѓз—…ж‚ЈиЂ…иЎЂиїђй‡Ќе»єжІ»з–— жќЋе»єе№і 5:00 PM - еђ€е№¶жЃ¶жЂ§и‚їз�¤зљ„е† еїѓз—…ж‚ЈиЂ…зљ„иЎЂ иїђй‡Ќе»єжІ»з–— зЋ‹иґµжќѕ 5:20 PM - е† и„‰д»‹е…ҐжњЇеђЋеђ€е№¶ж€їйў¤зљ„е† еїѓз—… ж‚ЈиЂ…зљ„жЉ—ж “жІ»з–— е€�е®‡ж‰¬ 5:40 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 9:25 AM - и®Ёи®є 9:30 AM - дёеїѓеЏ‘иЁЂпјљжЂҐжЂ§е† и„‰з»јеђ€еѕЃиЌЇ з‰©жІ»з–— - 2011е№ґе›ћйЎѕ й«�з‚њ 9:55 AM - IIb/IIIaеЏ—дЅ“ж‹®жЉ—е‰‚ењЁжЂҐжЂ§е† и„‰з»ј еђ€еѕЃзљ„еє”з”Ё жќЁж–°ж�Ґ 10:10 AM - йќћSTж®µжЉ¬й«�жЂ§жЂҐжЂ§е† и„‰з»јеђ€еѕЃ зљ„жЉ—ж “жІ»з–— й©¬дѕќеЅ¤ 10:25 AM - и®Ёи®є з¬¬дєЊењє дё»жЊЃдєєпјљжЇ›иЉ‚ж�Ћ, жњ±е»єеЌЋ, еЂЄе№јж–№, й»Ћиѕ‰, Kai Wang, е§љжњ±еЌЋ 10:30 AM - дёеїѓеЏ‘иЁЂпјљPCIжњЇеђЋиЌЇз‰©жІ»з–— 2011е№ґе›ћйЎѕ й©¬и™№ 10:55 AM - PCIжњЇеђЋзљ„дј�еЊ–иЌЇз‰©жІ»з–— е€�жў…жћ— з¬¬дёЂењєпјље‡єиЎЂдёЋиЎЂж “пјље¦‚дЅ•и§„йЃїйЈЋй™©пјџ 11:10 AM - ж–°ећ‹жЉ—иЎЂе°ЏжќїиЌЇз‰©ењЁPCIжІ»з–—дё зљ„еє”з”Ё Kai Wang дё»жЊЃдєєпјљеђ•ж ‘й“®, йЎѕе¤Ќз”џ, й«�з‚њ, еј жѕЌз”° 11:25 AM - и®Ёи®є 2:00 PM - еђ€е№¶дёЉж¶€еЊ–йЃ“е‡єиЎЂзљ„жЂҐжЂ§е† и„‰з»ј еђ€еѕЃж‚ЈиЂ…жЉ—е‡ќжЉ—ж “жІ»з–— еј жЉ’ж‰¬ 11:30 AM - дёеїѓеЏ‘иЁЂпјље† зЉ¶еЉЁи„‰з–ѕз—…зљ„з‰№ ж®ЉзЋ°и±Ў жњ±е»єеЌЋ 2:20 PM - еђ€е№¶е‡єе‡ќиЎЂеј‚еёёзљ„е† еїѓз—…ж‚ЈиЂ…зљ„ жЉ—ж “жІ»з–— иµµж°ёејє 2:40 PM - е† и„‰д»‹е…ҐжњЇеђЋйњЂи¦Ѓзґ§жЂҐйќћеїѓи„Џе¤– з§‘ж‰‹жњЇзљ„е† еїѓз—…ж‚ЈиЂ…жЉ—ж “жІ»з–— иўЃж™‹йќ’ 3:00 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” з¬¬дєЊењєпјљеїѓи„‘и‚ѕдё‰ж–№еЇ№иЇќ дё»жЊЃдєєпјљйѓйќ™иђ±, жќЋе°Џй№°, й»„еІљ 3:20 PM - еђ€е№¶и„‘еЌ’дёзљ„жЂҐжЂ§е† и„‰з»јеђ€еѕЃж‚Ј иЂ…жЉ—е‡ќжЉ—ж “жІ»з–— йЅђж™“е‹‡ 6:00 PM - дј‘дјљ дё‰е±‚309Bдјљи®®е®¤ еџєзЎЂдёЋиЌЇз‰©з¬¬дєЊйѓЁе€† 8:30 AM-12:30 PM з¬¬дёЂењє дё»жЊЃдєєпјљжћ—ж›™е…‰, ж›ѕе®ље°№, жќЋж·‘жў…, дЅ•йќ’, е‘Ёйў–зЋІ, иґѕе¤§жћ— 8:30 AM - дёеїѓеЏ‘иЁЂпјље† еїѓз—…жЉ—е‡ќдёЋжЉ—ж‹ґ жІ»з–— - 2011е№ґе›ћйЎѕ еђ•ж ‘й“® 11:55 AM - е† зЉ¶еЉЁи„‰ж…ўиЎЂжµЃзЋ°и±Ўзљ„дёґеєЉж„Џд№‰ иЃ‚з»Ќе№і 12:10 PM - е† зЉ¶еЉЁи„‰з—‰жЊ›зљ„еЏ‘з”џжњєе€¶дёЋдёґеєЉ еђ‘е®љж€ђ 12:25 PM - и®Ёи®є 12:30 PM - дј‘дјљ 8:55 AM - жЉ—е‡ќжІ»з–—дёзљ„иЌЇз‰©з›ёдє’дЅњз”Ё жќЁе¤©дј¦ 9:10 AM - ж°ЇеђЎж јй›·жІ»з–—зљ„дё¤йќўжЂ§пјљжЉ—зјє иЎЂдёЋе‡єиЎЂ иўЃж™‹йќ’ 142 CIT 2012 www.citmd.com 2012е№ґ3жњ€17ж—Ґ ж�џжњџе… иЌЇз‰©е¦з ”и®Ёдјљ з¬¬дёЂдё‰е…±еЌЏеЉћ д»ЋдёґеєЉиЇ•йЄЊе€°дёґеєЉе®ћи·µпјљжЂҐжЂ§е† и„‰з»јеђ€ еѕЃиЌЇз‰©жЉ—иЎЂе°ЏжќїжІ»з–—и®єеќ› 2:00 PM-4:00 PM дё»жЊЃдєєпјље‘ЁзЋ‰жќ°, еј жЉ’ж‰¬, й™€йџµеІ± 2:00 PM - ејЂењєи‡ґиѕћ 2:05 PM - жЂҐжЂ§е† и„‰з»јеђ€еѕЃз»јеђ€з®Ўзђ† й™€йџµеІ± 2:25 PM - 2011жЂҐжЂ§е† и„‰з»јеђ€еѕЃжЊ‡еЌ—ж›ґж–°з»јиї° е‘ЁзЋ‰жќ° 2:45 PM - STEMI/PCIжЉ—иЎЂе°ЏжќїжІ»з–—иї›е±•пјљ еЏЇйў„и§Ѓзљ„дёґеєЉиЋ·з›Љ е€�йњ‡е®‡ 3:05 PM - UA/NSTEMIд»‹е…ҐжІ»з–—зљ„жЉ—ж “дїќжЉ¤ жќЋе»єе№і 3:25 PM - ACSжЉ—ж “жІ»з–—е±•жњ› еђґж°ёеЃҐ 3:45 PM - й—®з”дёЋжЉЅеҐ– з¬¬дєЊйѓЁе€†пјљз—…дѕ‹и®Ёи®є дё»жЊЃдєєпјљеђ•ж ‘й“®, д№”ж ‘е®ѕ, йўњзєўе…µ 5:00 PM - з—…дѕ‹жЉҐе‘ЉпјљPCIжњЇеђЋе°Џи„‘е‡єиЎЂдёЂдѕ‹ еј дє¬жў… 5:10 PM - и®Ёи®є 5:15 PM - з—…дѕ‹жЉҐе‘Љпјљй«�йѕ„CTOдё‰ж”Їз—…еЏ�дёЂдѕ‹ еј иђЊ 7:57 AM - и®Ёи®є 5:25 PM - и®Ёи®є 5:30 PM - з—…дѕ‹жЉҐе‘Љпјљй¦–ж¬ЎPCIе¤№е±‚пјЊжі°е�‰ ејєеЊ–жЉ—иЎЂе°ЏжќїжІ»з–—еђЋдёЂе‘Ёе†Ќж¬ЎPCIж€ђеЉџ д»�д№ѓе®Ѕ 5:40 PM - и®Ёи®є 5:45 PM - з—…дѕ‹жЉҐе‘ЉпјљжЂҐжЂ§еїѓжў—жЂҐиЇЉPCIе¤§ й‡ЏиЎЂж “иґџиЌ·ж‚ЈиЂ…дёЂдѕ‹ е€�еї— 5:55 PM - и®Ёи®є 6:00 PM - дј‘дјљ з»“жћ„жЂ§еїѓи„Џз—…з¬¬дєЊйѓЁе€† 8:00 AM-12:30 PM з¬¬дёЂењє дё»жЊЃдєєпјљи’‹дё–и‰Ї, дєЋжіў, жќЋеҐ‹, й‡‘жў…, жќЋиґµеЏЊ, ж�“еІ‚е»є, зЋ‹зЋ‰жћ—, зЋ‹йњ‡ 8:00 AM - е°Џе„їи†ње‘ЁйѓЁе®¤й—ґйљ”зјєжЌџд»‹е…ҐжІ» з–—зљ„и¦Ѓз‚№ жњ±йІњй�і 8:15 AM - и®Ёи®є 8:20 AM - е·¦еїѓе®¤жµЃе‡єйЃ“е®¤й—ґйљ”зјєжЌџзљ„д»‹ е…ҐжІ»з–— з§¦ж°ёж–‡ 8:35 AM - и®Ёи®є иЌЇз‰©е¦з ”и®Ёдјљ дїЎз«‹жі°еЌЏеЉћ д»Ћжі°е�‰е€°жі°еЉ е®Ѓ 4:00 PM-6:00 PM дё‰е±‚310дјљи®®е®¤ з¬¬дёЂйѓЁе€†пјљдё“йў�и®Іеє§ з—…дѕ‹ж—©й¤ђдјљпј€д№ќпј‰ з»“жћ„жЂ§еїѓи„Џз—… 7:00 AM-8:00 AM дё»жЊЃдєєпјљжќЁи·ѓиї›, жќЁжќ°ељ, еј жЉ’ж‰¬ дё»жЊЃдєєпјљи’Іж™“зѕ¤, еѕђд»Іи‹±, зЋ‹й»Ћж�Ћ 4:00 PM - ејЂењєи‡ґиѕћ 7:00 AM - CS-0220пјљCPж”Їжћ¶ж€ђеЉџжІ»з–—е·¦и‚є еЉЁи„‰з‹зЄ„е¤–з§‘жњЇеђЋе†Ќз‹зЄ„еђ€е№¶еЏіи‚єеЉЁи„‰ зјєе¦‚дёЂдѕ‹ еѕђд»Іи‹± 4:30 PM - ж°ЇеђЎж јй›·з”џз‰©е€©з”Ёеє¦з ”з©¶ з”°и•ѕ 7:12 AM - и®Ёи®є 4:50 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 7:15 AM - CS-0302пјљзІ—е¤§жњЄй—еЉЁи„‰еЇјз®Ўд»‹ е…Ґе°Ѓе µжњЇеђЋжє¶иЎЂдёЂдѕ‹ й‡‘жў… 7:27 AM - и®Ёи®є 143 7:42 AM - и®Ёи®є 7:45 AM - CS-0372пјљеє”з”Ёе† и„‰еЇјдёќиѕ…еЉ©д»‹ е…ҐжІ»з–—е®¤й—ґйљ”зјєжЌџ еђґз‚ізҐҐ 3:55 PM - и¦Ѓз‚№жЂ»з»“ 4:05 PM - жЇ”дјђеЌўе®љзљ„ж—¶д»Је€°жќҐдє†пјЃ йўњзєўе…µ 7:30 AM - CS-0341пјљеє”з”ЁADO2иЎЂз®Ўж “е‰Ќеђ‘ е°Ѓй—еЏіе®¤е† зЉ¶еЉЁи„‰з�� Manoj Kumar Rohit 8:40 AM - е…€еїѓз—…д»‹е…ҐжІ»з–—е°Ѓе µе™Ёи„±иђЅзљ„ е¤„зђ† еѕђд»Іи‹± 8:55 AM - и®Ёи®є 9:00 AM - е…€е¤©жЂ§еїѓи„Џз—…еђ€е№¶й‡Ќеє¦и‚єеЉЁи„‰ й«�еЋ‹зљ„д»‹е…ҐжІ»з–—пјљз¬¬дё‰е†›еЊ»е¤§е¦иҐїеЌ—еЊ» й™ўз»ЏйЄЊ е®‹жІ»иїњ 9:10 AM - и®Ёи®є 9:15 AM - е…€е¤©жЂ§еїѓи„Џз—…еђ€е№¶й‡Ќеє¦и‚єеЉЁи„‰ й«�еЋ‹зљ„д»‹е…ҐжІ»з–—пјљиҐїе®‰дє¤йЂље¤§е¦з¬¬дёЂй™„ е±ћеЊ»й™ўз»ЏйЄЊ еј зЋ‰йЎє 9:25 AM - и®Ёи®є 9:30 AM - е…€е¤©жЂ§еїѓи„Џз—…еђ€е№¶й‡Ќеє¦и‚єеЉЁи„‰ й«�еЋ‹зљ„д»‹е…ҐжІ»з–—пјље“€е°”ж»ЁеЊ»з§‘е¤§е¦з¬¬дёЂ еЊ»й™ўз»ЏйЄЊ еђґз‚ізҐҐ CIT 2012 www.citmd.com 2012е№ґ3жњ€17ж—Ґ ж�џжњџе… 9:40 AM - и®Ёи®є 9:45 AM - е…€е¤©жЂ§еїѓи„Џз—…еђ€е№¶й‡Ќеє¦и‚єеЉЁи„‰ й«�еЋ‹зљ„д»‹е…ҐжІ»з–—пјље№їдёњзњЃдєєж°‘еЊ»й™ўз»ЏйЄЊ еј ж™єдјџ 9:55 AM - и®Ёи®є 10:00 AM - е…€е¤©жЂ§еїѓи„Џз—…еђ€е№¶й‡Ќеє¦и‚єеЉЁи„‰ й«�еЋ‹зљ„д»‹е…ҐжІ»з–—пјље››е·ќе¤§е¦еЌЋиҐїдєЊй™ўз»ЏйЄЊ еЌЋз›Љж°‘ 10:10 AM - и®Ёи®є з¬¬дєЊењє дё»жЊЃдєєпјљжњ±йІњй�і, иµµд»™е…€, е‘Ёиѕѕж–°, еј зЋ‰йЎє, еѕђеІ©, и¦ѓе†›, жІ€еђ‘е‰Ќ, жЅ�ж¬Ј 10:15 AM - е…€е¤©жЂ§еїѓи„Џз—…еђ€е№¶й‡Ќеє¦и‚єеЉЁи„‰ й«�еЋ‹зљ„д»‹е…ҐжІ»з–—пјљеЌ—дє¬еЊ»з§‘е¤§е¦з¬¬дёЂй™„ е±ћеЊ»й™ўз»ЏйЄЊ е”зҐҐжё… 10:25 AM - и®Ёи®є 10:30 AM - е…€е¤©жЂ§еїѓи„Џз—…еђ€е№¶й‡Ќеє¦и‚єеЉЁи„‰ й«�еЋ‹зљ„д»‹е…ҐжІ»з–—пјљж–°з–†еЊ»з§‘е¤§е¦з¬¬дёЂй™„ е±ћеЊ»й™ўз»ЏйЄЊ й©¬дѕќеЅ¤ 10:40 AM - и®Ёи®є 10:45 AM - е…€е¤©жЂ§еїѓи„Џз—…еђ€е№¶й‡Ќеє¦и‚єеЉЁи„‰ й«�еЋ‹зљ„д»‹е…ҐжІ»з–—пјље№їиҐїеЊ»з§‘е¤§е¦з¬¬дёЂй™„ е±ћеЊ»й™ўз»ЏйЄЊ дјЌдјџй”‹ 10:55 AM - и®Ёи®є 11:00 AM - е…€е¤©жЂ§еїѓи„Џз—…еђ€е№¶й‡Ќеє¦и‚єеЉЁи„‰ й«�еЋ‹зљ„д»‹е…ҐжІ»з–—пјљиґµе·ћзњЃдєєж°‘еЊ»й™ўз»ЏйЄЊ жќЁе¤©е’Њ 11:10 AM - и®Ёи®є 11:15 AM - е…€е¤©жЂ§еїѓи„Џз—…еђ€е№¶й‡Ќеє¦и‚єеЉЁи„‰ й«�еЋ‹зљ„д»‹е…ҐжІ»з–—пјљдє‘еЌ—ж�†ж�Ће»¶е®‰еЊ»й™ўз»ЏйЄЊ еј дјџеЌЋ 11:25 AM - и®Ёи®є 11:30 AM - е…€е¤©жЂ§еїѓи„Џз—…еђ€е№¶й‡Ќеє¦и‚єеЉЁи„‰ й«�еЋ‹зљ„д»‹е…ҐжІ»з–—пјље››е·ќе¤§е¦еЌЋиҐїеЊ»й™ўз»ЏйЄЊ ж›ѕж™є 11:45 AM - е…€е¤©жЂ§еїѓи„Џз—…еђ€е№¶й‡Ќеє¦и‚єеЉЁи„‰ й«�еЋ‹зљ„д»‹е…ҐжІ»з–—пјљеЌ—ж�Ње¤§е¦й™„дєЊй™ўз»ЏйЄЊ зЁ‹еє”жЁџ з»“жћ„жЂ§еїѓи„Џз—…з¬¬дё‰йѓЁе€† з»ЏеЇјз®Ўз“Ји†њжІ»з–— 2:00 PM-6:00 PM 11:55 AM - и®Ёи®є з¬¬дёЂењєпјљдё»еЉЁи„‰з“Јз‹зЄ„зљ„ж›їд»ЈжІ»з–— 12:00 PM - е…€е¤©жЂ§еїѓи„Џз—…еђ€е№¶й‡Ќеє¦и‚єеЉЁи„‰ й«�еЋ‹зљ„д»‹е…ҐжІ»з–—пјљжµ™ж±џе„їз«ҐеЊ»й™ўз»ЏйЄЊ йѕљж–№ж€љ 12:10 PM - и®Ёи®є 12:15 PM - е…€е¤©жЂ§еїѓи„Џз—…еђ€е№¶й‡Ќеє¦и‚єеЉЁи„‰ й«�еЋ‹зљ„д»‹е…ҐжІ»з–—пјље±±дёњдёґжІ‚дєєж°‘еЊ»й™ўз»ЏйЄЊ дѕЇеђе±± 12:25 PM - и®Ёи®є дё»жЊЃдєєпјљEberhard Grube, й«�ж¶¦йњ– 2:00 PM - дёе›Ѕеїѓе¤–з§‘дё»еЉЁи„‰з“ЈзЅ®жЌўжњЇзЋ°зЉ¶ иѓЎз››еЇї 2:10 PM - дёе›Ѕдё»еЉЁи„‰з“Јз‹зЄ„е¤љдёеїѓи°ѓжџҐпјљ дё»еЉЁи„‰з“Јзђѓе›Љж€ђеЅўжњЇйЂ‚еє”иЇЃеЏЉе€ќжњџз»ЏеЇј з®Ўдё»еЉЁи„‰з“ЈзЅ®жЌўз»ЏйЄЊ еђґж°ёеЃҐ 12:30 PM - дј‘дјљ 2:20 PM - жќҐи‡Єиї‘жњџдё»еЉЁи„‰з“Јзђѓе›Љж€ђеЅўжњЇз ” з©¶зљ„еђЇз¤єпјље…¶дёґеєЉз–—ж•€дёЋз»ЏеЇјз®Ўдё»еЉЁи„‰ з“ЈзЅ®жЌўж—¶д»Јзљ„вЂње¤Ќе…ґвЂќ Ron Waksman еЌ€й—ґеЌ«ж�џдјљ з€±еѕ·еЌЋдё»еЉћ з»ЏеЇјз®Ўдё»еЉЁи„‰з“ЈзЅ®жЌўзљ„зЋ°зЉ¶еЏЉж€ђеЉџи¦Ѓзґ 12:40 PM-1:55 PM 2:30 PM - дј�еЊ–з»ЏеЇјз®Ўдё»еЉЁи„‰з“ЈзЅ®жЌўз–—ж•€йњЂ и¦Ѓе¤ље¦з§‘вЂњеїѓи„Џз“Ји†њжІ»з–—е›ўй�џвЂќзљ„ж”ЇжЊЃ Jan Kovac дё»еёпјљй«�ж¶¦йњ–, иѓЎз››еЇї 2:40 PM - е€›е»єдёЂйЎ№ж€ђеЉџзљ„е…Ёзђѓз»ЏеЇјз®Ўдё»еЉЁ и„‰з“Ји®Ўе€’зљ„и§‚з‚№пјљвЂњи‹¦жЃјдёЋзҐћеѕЂвЂќ Michael A. Mussallem 12:40 PM - ејЂењєи‡ґиѕћ 12:45 PM - е›ћйЎѕдёЋе±•жњ›з€±еѕ·еЌЋз»ЏеЇјз®Ўдё»еЉЁ и„‰з“ЈзЅ®жЌўдёґеєЉйЎ№з›®зљ„еЏ‘е±• Martin B. Leon 2:50 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” и®Ёи®єдё“е®¶пјљиѓЎз››еЇї, Jan Kovac, Michael A. Mussallem, Ron Waksman, еђґж°ёеЃҐ, еј з‘ћеІ© 1:05 PM - з»ЏеЇјз®Ўдё»еЉЁи„‰з“ЈзЅ®жЌўйЎ№з›®зљ„ж€ђеЉџ и¦Ѓзґ еЏЉе…¶ењЁеЊ—зѕЋжґІзљ„жЁЎејЏ John G. Webb з¬¬дєЊењєпјљз»ЏеЇјз®Ўдё»еЉЁи„‰з“ЈзЅ®жЌўдёґеєЉж•°жЌ® ж›ґж–° 1:25 PM - дєљжґІеђЇеЉЁз»ЏеЇјз®Ўдё»еЉЁи„‰з“ЈзЅ®жЌўдёґ еєЉйЎ№з›®зљ„иїњж™Ї Seung-Jung Park 1:45 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 1:55 PM - дј‘дјљ дё»жЊЃдєєпјљJohn G. Webb, и‘›еќ‡жіў 3:00 PM - и‡Єи†ЁиѓЂећ‹з»ЏеЇјз®Ўдё»еЉЁи„‰з“ЈзЅ®жЌўдёґ еєЉз–—ж•€ж¦‚е†µ Eberhard Grube 3:10 PM - зђѓе›Љж‰©еј ећ‹з»ЏеЇјз®Ўдё»еЉЁи„‰з“ЈзЅ®жЌў дёґеєЉз–—ж•€ж¦‚е†µ John G. Webb 3:20 PM - з»ЏеЇјз®Ўдё»еЉЁи„‰з“ЈзЅ®жЌўжњЇеђЋе№¶еЏ‘ з—‡пјљеЏ‘з”џзЋ‡дёЋдёґеєЉй‡Ќи¦ЃжЂ§ Patrick W. Serruys 3:30 PM - иЎЂз®Ўе…Ґи·ЇдёЋиѕ…еЉ©еЅ±еѓЏпј€и¶…еЈ°дёЋе¤љ жЋ’CTпј‰пјљж�Їж€ђеЉџзљ„з»ЏеЇјз®Ўдё»еЉЁи„‰з“ЈзЅ®жЌў зљ„еџєзџіеђ—пјџ Stephan Windecker 11:40 AM - и®Ёи®є 144 CIT 2012 www.citmd.com 2012е№ґ3жњ€17ж—Ґ ж�џжњџе… 3:40 PM - ж–°ећ‹з»ЏеЇјз®Ўдё»еЉЁи„‰з“ЈзЅ®жЌўе™Ёжў°ж¦‚и§‚ Ian T. Meredith 3:50 PM - еЌіе°†жќҐдёґзљ„з»ЏеЇјз®Ўдё»еЉЁи„‰з“ЈзЅ®жЌў дёґеєЉиЇ•йЄЊж¦‚и§‚ Patrick W. Serruys 4:00 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” и®Ёи®єдё“е®¶пјљEberhard Grube, Ian T. Meredith, Patrick W. Serruys, Stephan Windecker 5:40 PM - ж–°ећ‹з»ЏеЇјз®ЎдєЊе°–з“ЈжІ»з–—ж¦‚и§‚пјљжњЄ жќҐзљ„йЎ№з›® Maurice Buchbinder 8:15 AM - дЅђд»–иЋ«еЏёжґ—и„±ж”Їжћ¶пјљиї‡еЋ»гЂЃзЋ° ењЁеЏЉжњЄжќҐ David E. Kandzari 5:50 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” и®Ёи®єдё“е®¶пјљPham Manh Hung, Jason H. Rogers, Charles A. Simonton, ж›ѕж™є 8:27 AM - дѕќз»ґиЋ«еЏёжґ—и„±ж”Їжћ¶пјљиї‡еЋ»гЂЃзЋ° ењЁеЏЉжњЄжќҐ Pieter C. Smits 6:00 PM - дј‘дјљ 8:39 AM - з”џз‰©еЏЇй™Ќи§ЈиЃљеђ€з‰©Biolimus A9жґ— и„±ж”Їжћ¶пјљиї‡еЋ»гЂЃзЋ°ењЁеЏЉжњЄжќҐ Stephan Windecker 8:51 AM - ж”Їжћ¶иЎЁйќўж”№жЂ§ж�ЇйЃїе…ЌиЌЇз‰©жґ—и„± ж°ёд№…иЃљеђ€з‰©зљ„з”жЎ€еђ—пјџ Adnan Kastrati з¬¬дё‰ењєпјљз»ЏеЇјз®Ўдё»еЉЁи„‰з“ЈзЅ®жЌўжЊ‘ж€�жЂ§з—… дѕ‹дёЋеЊєеџџз»ЏйЄЊ дё»жЊЃдєєпјљEberhard Grube, йџ©й›…зЋІ 4:10 PM - еЏ°ж№ѕзљ„з»ЏеЇјз®Ўдё»еЉЁи„‰з“ЈзЅ®жЌўе€ќжҐ з»ЏйЄЊ Paul Hsien-Li Kao 4:20 PM - еҐіжЂ§з»ЏеЇјз®Ўдё»еЉЁи„‰з“ЈзЅ®пјљж¬§жґІз»ЏйЄЊ Marie-Claude Morice 4:30 PM - жЊ‘ж€�жЂ§з—…дѕ‹пјљз»Џдё»еЉЁи„‰е…Ґи·ЇиЎЊз»Џ еЇјз®Ўдё»еЉЁи„‰з“ЈзЅ®жЌўпј€з—…дѕ‹дёЋдё»йў�е›ћйЎѕпј‰ David X. M. Zhao 4:40 PM - жЊ‘ж€�жЂ§з—…дѕ‹пјљжњ‰дё¤е°–е¤ґзљ„дё»еЉЁи„‰ з“ЈиЎЊз»ЏеЇјз®Ўдё»еЉЁи„‰з“ЈзЅ®жЌў Paul TL Chiam 4:50 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” и®Ёи®єдё“е®¶пјљPaul TL Chiam, Paul Chien-Li Kao, е”зҐҐжё…, Marie-Claude Morice, David X. M. Zhao з¬¬е››ењєпјљз»ЏеЇјз®ЎдєЊе°–з“ЈжІ»з–— дё»жЊЃдєєпјљMaurice Buchbinder, жќЁи·ѓиї› 5:00 PM - з»Џзљ®дєЊе°–з“Јж€ђеЅўжњЇпј€дёЂпј‰пјљйЂ‚еє” иЇЃдёЋз»“жћњпј€зџжњџдёЋй•їжњџпј‰- дёе›Ѕз»ЏйЄЊ ж›ѕж™є 5:10 PM - з»Џзљ®дєЊе°–з“Јж€ђеЅўжњЇпј€дєЊпј‰пјљдј�еЊ– ж€ђеЉџзљ„жњЇдёжЉЂе·§дёЋиЇЂзЄЌ Pham Manh Hung 5:20 PM - з»Џзљ®вЂњиѕ№еЇ№иѕ№вЂќдєЊе°–з“Јдї®иЎҐпјљ MitraClipжЉЂжњЇзЋ°зЉ¶ Charles A. Simonton 5:30 PM - жЊ‘ж€�жЂ§з—…дѕ‹пјљMitraClipжІ»з–—й«�еЌ± еЉџиѓЅжЂ§дєЊе°–з“Јиї”жµЃпј€з—…дѕ‹дёЋдё»йў�е›ћйЎѕпј‰ Jason H. Rogers 145 дё‰е±‚311Aдјљи®®е®¤ ж—©й¤ђдјљ еђ‰еЁЃдё»еЉћ ж€ђз†џжЉЂжњЇеј•йў†жњЄжќҐ 7:00 AM-8:00 AM дё»еёпјљжќњеї—ж°‘, д№”ж ‘е®ѕ 7:00 AM - ејЂењєи‡ґиѕћ 7:03 AM - е¤Ќжќ‚з—…еЏ�з—…дѕ‹е€†дє« жЇ›еЁЃ 7:18 AM - е¤Ќжќ‚з—…еЏ�з—…дѕ‹е€†дє« й‚±ж�Ґе…‰ 7:33 AM - иЎЂз®Ўй•њи§‚еЇџEXCELеЏЇй™Ќи§ЈиЃљеђ€з‰© й›·её•йњ‰зґ жґ—и„±ж”Їжћ¶дёЋCYPHERжЊЃд№…иЃљеђ€з‰© й›·её•йњ‰зґ жґ—и„±ж”Їжћ¶иЎЂз®Ўе†…зљ®и¦†з›–е¤§и§„жЁЎ еЇ№з…§з ”з©¶ й™€з»Ќи‰Ї 7:48 AM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” иЌЇз‰©жґ—и„±ж”Їжћ¶еі°дјљз¬¬дёЂйѓЁе€† еЅ“е‰ЌиЌЇз‰©жґ—и„±ж”Їжћ¶е№іеЏ° 8:00 AM-12:30 PM еЅ“е‰Ќе…ЁзђѓиЌЇз‰©жґ—и„±ж”Їжћ¶е№іеЏ°ж›ґж–° дё»жЊЃдєєпјљIan T. Meredith, зЋ‹жµ·ж�Њ и®Ёи®єдё“е®¶пјљGiuseppe De Luca, Eberhard Grube, David E. Kandzari, Adnan Kastrati, Pieter C. Smits, Stephan Windecker 8:00 AM - ејЂе№•жј”и®І - иЌЇз‰©жґ—и„±ж”Їжћ¶еЏ‘е±•зљ„ еЋ†еЏІи§‚з‚№пјљиї‡еЋ»гЂЃзЋ°ењЁеЏЉжњЄжќҐ Ian T. Meredith 9:03 AM - Cre8ж— иЃљеђ€з‰©иЌЇз‰©жґ—и„±ж”Їжћ¶ Giuseppe De Luca 9:15 AM - BioFreedomж— иЃљеђ€з‰©иЌЇз‰©жґ—и„± ж”Їжћ¶ Eberhard Grube 9:27 AM - дё“е®¶и®Ёи®єпјљйЂљиї‡ж‰Ђжњ‰ж•°жЌ®жЂЋж · ењЁе…ЁзђѓиЊѓе›ґе†…йЂ‰ж‹©иЌЇз‰©жґ—и„±ж”Їжћ¶пјџ еЅ“е‰Ќдёе›Ѕе›Ѕдє§зљ„иЌЇз‰©жґ—и„±ж”Їжћ¶е№іеЏ°пјљдЅ еї…йЎ»дє†и§Јеѕ—ж›ґе¤љ дё»жЊЃдєєпјљAjay J. Kirtane, еѕђжіў и®Ёи®єдё“е®¶пјљзЄ¦е…‹йќћ, и‘›й›·, йѓе®Ѓ, й‡‘жіЅе®Ѓ, жќЋжµЄ, жќЋе¦Ќ, е€�е¦жіў, е®‹зЋ°ж¶›, еј еҐ‡ 9:42 AM - FIREBIRD 2пјљжЊЃд№…иЃљеђ€з‰©й’ґй“¬еђ€ й‡‘иҐїиЋ«зЅ—еЏёжґ—и„±ж”Їжћ¶ жќЋе¦Ќ 9:52 AM - EXCELпјљз”џз‰©еЏЇй™Ќи§ЈиЃљеђ€з‰©иҐїиЋ« зЅ—еЏёжґ—и„±ж”Їжћ¶ е€�е¦жіў 10:02 AM - PARTNERпјљжЊЃд№…иЃљеђ€з‰©иҐїиЋ«зЅ— еЏёжґ—и„±ж”Їжћ¶ йѓе®Ѓ 10:12 AM - YINYIпјљж— иЃљеђ€з‰©зґ«жќ‰й†‡жґ—и„±ж”Їжћ¶ еј еҐ‡ 10:22 AM - TIVOLIпјљз”џз‰©еЏЇй™Ќи§ЈиЃљеђ€з‰©й’ґ й“¬еђ€й‡‘иҐїиЋ«зЅ—еЏёжґ—и„±ж”Їжћ¶ и‘›й›· 10:32 AM - BuMAпјљз”џз‰©еЏЇй™Ќи§ЈиЃљеђ€з‰©иҐї иЋ«зЅ—еЏёжґ—и„±ж”Їжћ¶ е®‹зЋ°ж¶› CIT 2012 www.citmd.com 2012е№ґ3жњ€17ж—Ґ ж�џжњџе… 10:42 AM - NANOпјљж— иЃљеђ€з‰©иҐїиЋ«зЅ—еЏёжґ— и„±ж”Їжћ¶ жќЋжµЄ 10:52 AM - HELIOSпјљз”џз‰©еЏЇй™Ќи§ЈиЃљеђ€з‰©иҐї иЋ«зЅ—еЏёжґ—и„±ж”Їжћ¶ й‡‘жіЅе®Ѓ 11:02 AM - NOYAпјљз”џз‰©еЏЇй™Ќи§ЈиЃљеђ€з‰©й’ґй“¬ еђ€й‡‘иҐїиЋ«зЅ—еЏёжґ—и„±ж”Їжћ¶ зЄ¦е…‹йќћ 11:12 AM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 1:00 PM - FIREBIRD 2й’ґй“¬еђ€й‡‘иҐїзЅ—иЋ«еЏёжґ— и„±ж”Їжћ¶ењЁзі–е°їз—…е¤Ќжќ‚е† и„‰з—…еЏ�дёзљ„жњ‰ж•€ жЂ§еЏЉе®‰е…ЁжЂ§з ”з©¶пј€FIRE-DIABETESпј‰пјљ6дёЄ жњ€йљЏи®їз»“жћњ жќЋе¦Ќ 1:15 PM - й�їж №е»·FIRE2-DIABETESжіЁе†ЊиЇ•йЄЊ зљ„ж–№жЎ€и®ѕи®Ўе’Ње€ќжҐж•°жЌ® Liliana R. Grinfeld 1:30 PM - FOCUS-TжіЁе†Њз™»и®°з ”з©¶пјљFIREBIRD 2ж”Їжћ¶ењЁSirirajеЊ»й™ўзљ„дё¤е№ґдёґеєЉз»“жћњ Suwatchai Pornrattanarungsri 1:45 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” вЂњеЇ№жЉ—вЂќиЌЇз‰©жґ—и„±ж”Їжћ¶пјљиЌЇз‰©ж¶‚е±‚зђѓе›Љ дё»жЊЃдєєпјљJean Marco, д№”ж ‘е®ѕ и®Ёи®єдё“е®¶пјљж›№дё°, Kenneth Chin, Gim-Hooi Choo, Rosli Mohd Ali, Pieter R. Stella, Renu Virmani 11:27 AM - иЌЇз‰©ж¶‚е±‚зђѓе›ЉдёЋиЌЇз‰©жґ—и„±ж”Їжћ¶ жЉЂжњЇзљ„з›ёдјјеЏЉе…ій”®дёЌеђЊз‚№ Renu Virmani 11:39 AM - 2012е№ґзєµи§€иЌЇз‰©ж¶‚е±‚зђѓе›ЉйЎ№з›® дёЋж—ўеѕЂдёґеєЉж•°жЌ® Pieter R. Stella 11:54 AM - иЌЇз‰©ж¶‚е±‚зђѓе›Љеє”з”Ёз–з•Ґз—…дѕ‹е›ћ йЎѕпј€ж”Їжћ¶е†…е†Ќз‹зЄ„гЂЃе€†еЏ‰з—…еЏ�гЂЃе°ЏиЎЂз®Ў еЏЉеЋџеЏ‘з—…еЏ�пј‰ Kenneth Chin 12:06 PM - иЌЇз‰©ж¶‚е±‚зђѓе›Ље¤–е‘ЁиЎЂз®Ўеє”з”Ёз– з•Ґз—…дѕ‹е›ћйЎѕ Rosli Mohd Ali 12:18 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 12:30 PM - дј‘дјљ еЌ€й—ґеЌ«ж�џдјљ еѕ®е€›дё»еЉћ йЎєз•…еїѓи„‰пјЊдїЎиЂЊжњ‰иЇЃпјљFIREBIRD 2ж”Їжћ¶ж•° жЌ®дёЋз»ЏйЄЊе€†дє« 12:40 PM-1:55 PM дё»еёпјљйњЌе‹‡, е‘ЁзЋ‰жќ°, дєЋжіў, Costantino R. Costantini, е€�еЇ… 12:40 PM - ејЂењєи‡ґиѕћ 12:45 PM - FOCUSдёґеєЉз ”з©¶дё¤е№ґйљЏи®їз»“жћњ и‘›еќ‡жіў 1:55 PM - дј‘дјљ иЌЇз‰©жґ—и„±ж”Їжћ¶еі°дјљз¬¬дєЊйѓЁе€† иЌЇз‰©жґ—и„±ж”Їжћ¶зљ„дёґеєЉдЅїз”Ё 2:00 PM-6:00 PM е¤Ќжќ‚з—…еЏ�дёеє”з”ЁиЌЇз‰©жґ—и„±ж”Їжћ¶ дё»жЊЃдєєпјљйњЌе‹‡, Fina Mauri и®Ёи®єдё“е®¶пјљдѕЇзЋ‰жё…, жџіж™ЇеЌЋ, Ju-Pin Pan, I Gde Rurus Suryawan, Mujeeb Ul-Haq, Kai Wang 3:00 PM - STж®µжЉ¬й«�ећ‹еїѓи‚Њжў—ж»ж‚ЈиЂ…дёдЅ•ж—¶ еє”иЇҐеє”з”ЁиЌЇз‰©жґ—и„±ж”Їжћ¶пјџ Fina Mauri 3:12 PM - з—…дѕ‹жЉҐе‘Љ4пјљSTж®µжЉ¬й«�ећ‹еїѓи‚Њжў— ж»з®ЂеЌ•з—…еЏ�дёеє”з”ЁиЌЇз‰©жґ—и„±ж”Їжћ¶ Richard Lim 3:20 PM - и®Ёи®є 3:27 PM - з—…дѕ‹жЉҐе‘Љ5пјљSTж®µжЉ¬й«�ећ‹еїѓи‚Њжў— ж»е¤Ќжќ‚з—…еЏ�дёеє”з”ЁиЌЇз‰©жґ—и„±ж”Їжћ¶ иѓЎеҐ‰зЋЇ 3:35 PM - и®Ёи®є 3:42 PM - е¤Ќжќ‚дёґеєЉжѓ…е†µдё‹еє”з”ЁиЌЇз‰©жґ—и„±ж”Ї жћ¶пјљйќћеїѓи„Џж‰‹жњЇгЂЃе‡єиЎЂй«�еЌ±еЏЉй•їжњџйќўдёґ йљѕйў� Roxana Mehran дё»жЊЃдєєпјљй™€зєЄжћ—, Duncan Hung-Kwong Ho и®Ёи®єдё“е®¶пјљHeng-Chia Chang, Swee Choon Ng, Sufia Rahman, е”ђз–ѕйЈћ, Wan Azman Wan Ahmad, е‘Ёж—ж™Ё 3:54 PM - иЌЇз‰©жґ—и„±ж”Їжћ¶ж¤Ќе…ҐеђЋдёжўеЏЊй‡ЌжЉ— иЎЂе°Џжќїзљ„еЅ“е‰ЌиЇЃжЌ® Alexandra J. Lansky 2:00 PM - е¤Ќжќ‚з—…еЏ�дёж€‘дЅ•ж—¶дёЋжЂЋж ·йЂ‰ж‹©иЌЇ з‰©жґ—и„±ж”Їжћ¶пјџ Marie-Claude Morice 4:06 PM - з—…дѕ‹жЉҐе‘Љ6пјљж‹©жњџйќћеїѓи„Џж‰‹жњЇе‰Ќ зљ„д»‹е…ҐжІ»з–— жќЋжЂЎ 2:12 PM - з—…дѕ‹жЉҐе‘Љ1пјље¤љж”ЇиЎЂз®Ўз—…еЏ�дёеє” з”ЁиЌЇз‰©жґ—и„±ж”Їжћ¶пј€йќће·¦дё»е№Ідё”еЊ…еђ«дёЂе¤„ ж…ўжЂ§е®Ње…Ёй—еЎћпј‰ Chien-Ming Huang 4:14 PM - и®Ёи®є 2:20 PM - и®Ёи®є 2:27 PM - з—…дѕ‹жЉҐе‘Љ2пјље·¦дё»е№Із—…еЏ�дёеє”з”Ё иЌЇз‰©жґ—и„±ж”Їжћ¶ Wen-Lieng Lee 4:21 PM - з—…дѕ‹жЉҐе‘Љ7пјље‡єиЎЂй«�еЌ±ж‚ЈиЂ…е¤Ќжќ‚ з—…еЏ�д»‹е…ҐжІ»з–— жџіж™ЇеЌЋ 4:29 PM - и®Ёи®є 4:36 PM - и¦Ѓз‚№жЂ»з»“ йњЌе‹‡ 2:35 PM - и®Ёи®є 2:42 PM - з—…дѕ‹жЉҐе‘Љ3пјље¤Ќжќ‚й•їз—…еЏ�дёеє”з”Ё иЌЇз‰©жґ—и„±ж”Їжћ¶ й™€зЏЏ 2:50 PM - и®Ёи®є 2:57 PM - и¦Ѓз‚№жЂ»з»“ й™€зєЄжћ— иЌЇз‰©жґ—и„±ж”Їжћ¶е¤±иґҐ дё»жЊЃдєєпјљжќЋдёєж°‘, Tak-Fu Tse и®Ёи®єдё“е®¶пјљBrigadier S. Aziz, Wai-Kwong Chan, жќйќ–е®‡, жќЋж‚¦, Chee-Wo Wu, еј жІ› 4:41 PM - иЌЇз‰©жґ—и„±ж”Їжћ¶е¤±иґҐж—¶зљ„е¤„зђ†пј€еЊ… ж‹¬ж”Їжћ¶е†…е†Ќз‹зЄ„гЂЃиЎЂж “еЏЉе…¶е®ѓеЉ›е¦й—®йў�пј‰ Jeffrey W. Moses й«�еЌ±ж‚ЈиЂ…дёеє”з”ЁиЌЇз‰©жґ—и„±ж”Їжћ¶ 146 CIT 2012 www.citmd.com 2012е№ґ3жњ€17ж—Ґ ж�џжњџе… 4:56 PM - з—…дѕ‹жЉҐе‘Љ8пјљиЌЇз‰©жґ—и„±ж”Їжћ¶е†Ќз‹ зЄ„пј€еЏЌе¤ЌеЏ‘з”џпј‰ Sema GГјneri 5:04 PM - и®Ёи®є 5:11 PM - з—…дѕ‹жЉҐе‘Љ9пјљиЌЇз‰©жґ—и„±ж”Їжћ¶е†Ќз‹ зЄ„/иЎЂж “пј€ж”Їжћ¶жќ†ж–иЈ‚еј•иµ·пј‰ й’±иЏЉи‹± 5:19 PM - и®Ёи®є 7:38 AM - NC Sprinterпјљдј�еЊ–ж”Їжћ¶ж¤Ќе…Ґж•€жћњ й’±иЏЉи‹± 7:50 AM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 8:00 AM - дј‘дјљ еїѓеѕ‹е¤±еёёз¬¬дё‰йѓЁе€† ж¤Ќе…Ґе™Ёжў° 8:30 AM-12:30 PM 5:26 PM - з—…дѕ‹жЉҐе‘Љ10пјљдєљжЂҐжЂ§ж”Їжћ¶иЎЂж “ пј€ж”Їжћ¶и†ЁиѓЂдёЌе…Ёеј•иµ·пј‰ Chris Kwok-Yiu Wong з¬¬дёЂењєпјљжЊ‡еЌ—и§ЈиЇ» 5:34 PM - и®Ёи®є 8:30 AM - д»ЋABCе€°CABпјљжЉўж•‘зЊќж»вЂњеїѓвЂќе…€ иЎЊ - 2010е№ґAHAеїѓи‚єе¤Ќи‹ЏдёЋжЂҐж•‘жЊ‡еЌ—и§ЈиЇ» й»„еѕ·е�‰ 5:41 PM - з—…дѕ‹жЉҐе‘Љ11пјљж™љжњџ/иїџеЏ‘ж™љжњџж”Ї жћ¶иЎЂж “пј€дёЌж�ЋеЋџе› пј‰ Brigadier S. Aziz 5:49 PM - и®Ёи®є 5:56 PM - и¦Ѓз‚№жЂ»з»“ жќЋдёєж°‘ 6:00 PM - дј‘дјљ дё»жЊЃдєєпјљзЋ‹ж–№жЈ, й™€ж�Ће“І, е‘ЁиѓњеЌЋ, еђґж�Ћ ж—©й¤ђдјљ зѕЋж•¦еЉ›дё»еЉћ дјљеЅ“вЂњй›¶вЂќз»ќйЎ¶пјЊдёЂи§€дј—е±±е°Џ 7:00 AM-8:00 AM дё»еёпјљжќЁи·ѓиї›, й™€ж–№, й™€йџµеІ±, жќЋз»§з¦Џ 7:00 AM - ејЂењєи‡ґиѕћ 7:02 AM - йќ©е‘ЅжЂ§зљ„й›¶жЉ�еЏ жЉЂжњЇпјљејЂе€›зђѓ е›Љж–°зєЄе…ѓ й™€йџµеІ± 7:14 AM - Sprinter Legendж‹Їж•‘иѕ№ж”ЇжЉЂжњЇ жќЋж€ђзҐҐ 7:26 AM - Sprinter Legend OTWпјљжЊ‘ж€�жћЃз«Ї е¤Ќжќ‚з—…еЏ�зљ„е€©е™Ё еђ‘е®љж€ђ 147 дё»йў�жј”и®І дё»жЊЃдєєпјљй»„еІљ, йѓ‘ејєиЌЄ, е€�е…ґж–Њ, и”Ўзђі 10:30 AM - CRT-Pж›ґжЌўпјљж�Їеђ¦еЌ‡зє§дёє CRT-Dпјџ зЋ‹е†¬жў… 10:45 AM - еїѓиЎ°дјґж€їйў¤зљ„CRTжІ»з–—пјљж€їе®¤ з»“ж¶€ићЌзљ„ењ°дЅЌеЏЉиЇ„д»· е®їз‡•еІ— 11:00 AM - CRTжњЇеђЋи†€зҐћз»Џе€єжїЂпјљж‰‹жњЇд№‹ е¤–пјЊжњ‰и®ЎеЏЇж–Ѕ жІ€жі•иЌЈ 11:15 AM - CRTж— еЏЌеє”пјљеЋџе› еЏЉеє”еЇ№ й™€жџЇиђЌ 8:45 AM - иЅ»дёеє¦еїѓиЎ°ж‚ЈиЂ…пјљICDиї�ж�Ї CRT-DпјџESC2010еїѓеЉ›иЎ°з«е™Ёжў°жІ»з–—жЊ‡еЌ— и§ЈиЇ» еЌЋдјџ з—…дѕ‹и®Ёи®є - CRTж¤Ќе…ҐжЉЂжњЇпјље›°йљѕдёЋжЊ‘ж€� 9:00 AM - д»Ћз»ЏйЄЊе€°и§„иЊѓпјљиµ·жђЏе™ЁеЏЉICDж¤Ќ е…ҐжњЇеђЋж„џжџ“зљ„е¤„зђ† - 2010е№ґAHAжЊ‡еЌ—и§ЈиЇ» й©¬еќљ 11:30 AM - з—…дѕ‹1 и”Ўзђі 9:15 AM - еїѓи„ЏжЂ§зЊќж»дёЂзє§йў„й�ІпјљжЊ‡еЌ—дёЋ зЋ°е®ћ Kathy Lai Fun Lee дё‰е±‚311Bдјљи®®е®¤ з¬¬дё‰ењєпјљCRTжІ»з–—дё“ењє з¬¬дєЊењєпјљжЊ‡еЌ—дёЋе®ћи·µ - з—…дѕ‹е¤§и®Ёи®є дё»жЊЃдєєпјљжІ€жі•иЌЈ, е®їз‡•еІ—, жќЋиЋ‰, еј жµ·жѕ„ дё»жЊЃдєєпјљдёҐжїЂ, и®ёйќ™, й‚±ж�Ґе…‰, жџіиЊµ 11:40 AM - и®Ёи®є 11:45 AM - з—…дѕ‹2 зЋ‹дёњзђ¦ 11:55 AM - и®Ёи®є 12:00 PM - з—…дѕ‹3 жўЃе»¶ж�Ґ 9:30 AM - з—…дѕ‹1пјљеїѓжў—еђЋдјґдЅЋEFпјљICDж�Ї й›ЄдёйЂЃз‚пјЊиї�ж�Їй”¦дёЉж·»иЉ±пјџ еѕђдјџ з‚№иЇ„дё“е®¶пјљеј жѕЌ, еђґз«‹зѕ¤ 12:10 PM - и®Ёи®є 10:00 AM - з—…дѕ‹2пјљеїѓи‚Њжў—ж»дјґе®¤йЂџпјљPCI ж€–ICDпјџ - е†із–дёЋж—¶жњє й‚№е»єе€љ з‚№иЇ„дё“е®¶пјљй»„еѕ·е�‰, жќЋе№їе№і 12:25 PM - и®Ёи®є 12:15 PM - з—…дѕ‹ 4 е€�е…ґж–Њ 12:30 PM - дј‘дјљ CIT 2012 www.citmd.com 2012е№ґ3жњ€17ж—Ґ ж�џжњџе… еЌ€й—ґеЌ«ж�џдјљ д№ђж™®дё»еЉћ е¤Ќжќ‚е…€еїѓз—…д»‹е…ҐжІ»з–—дёзљ„е™Ёжў°йЂ‰ж‹©жЉЂе·§ 12:40 PM-1:55 PM 3:30 PM - з—…дѕ‹3 иЊѓжґЃ 3:40 PM - и®Ёи®є дё‰е±‚жЉҐе‘ЉеЋ… дё»еёпјљи’‹дё–и‰Ї, жњ±йІњй�і, еј зЋ‰йЎє, еј ж™єдјџ 3:45 PM - з—…дѕ‹4 жЇ›е®¶дє® 12:40 PM - з‰№ж®Љз±»ећ‹ж€їй—ґйљ”зјєжЌџзљ„д»‹е…ҐжІ»з–— з§¦ж°ёж–‡ 3:55 PM - и®Ёи®є з¬¬дёѓе±ЉжЉ¤еЈ«е’ЊжЉЂжњЇдєєе‘�з ”и®Ёдјљ 8:25 AM-5:00 PM 12:55 PM - еЉЁи„‰еЇјз®ЎжњЄй—зљ„д»‹е…ҐжІ»з–—и¦Ѓз‚№ иµ·жђЏжІ»з–—дё“ењє - дё»йў�жј”и®І 8:25 AM ж¬ўиїЋи‡ґиѕћ еѕђжіў й«�дјџ дё»жЊЃдєєпјљзЋ‹ж™Їеі°, и‹Џж™ћ, й™€зЃї, еђґз«‹иЌЈ 1:10 PM - ењ€еҐ—е™ЁењЁе°Ѓе µе™Ёз§»дЅЌдёзљ„еє”з”Ё е‘Ёиѕѕж–° 1:25 PM - е„їз«Ґе®¤й—ґйљ”зјєжЌџд»‹е…ҐжІ»з–—з—…дѕ‹йЂ‰ж‹© еЌЋз›Љж°‘ 1:40 PM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 1:55 PM - дј‘дјљ еїѓеѕ‹е¤±еёёз¬¬е››йѓЁе€† 2:00 PM-6:00 PM 4:00 PM -IIеє¦ж€їе®¤дј еЇјй�»ж»ћпјљдЅ•ж—¶иµ·жђЏжІ»з–—пјџ еѕђиЂ• 4:15 PM - ж€їйў¤дјґй•їй—ґж‡пјље¦‚дЅ•жЋЊжЏЎиµ·жђЏйЂ‚ еє”иЇЃпјџ й™€жћ— 4:30 PM - еЏіе®¤й—ґйљ”иµ·жђЏпјљйЂ‚еє”иЇЃгЂЃж—¶жњєеЏЉдЅЌзЅ® дёҐжїЂ 4:45 PM - иµ·жђЏзљ„иїњзЁ‹йљЏи®їпјљжњЄжќҐзљ„ж–№еђ‘ ж±¤е®ќй№Џ ICDе№¶еЏ‘з—‡е¤„зђ†дё“ењє - дё»йў�жј”и®І дё»жЊЃдєєпјљйѓз»§йёї, йЅђж™“е‹‡, жќЋиЋ‰, ж›Із§ЂиЉ¬ 2:00 PM - ICDжњЇеђЋз”µйЈЋжљґзљ„е¤„зђ† еђґз«‹зѕ¤ 2:15 PM - ICDж¤Ќе…ҐжњЇдёDFTеЌ‡й«�зљ„еє”еЇ№з–з•Ґ зЋ‹ж™Їеі° 2:30 PM - е¦‚дЅ•е‡Џе°‘ICDзљ„дёЌйЂ‚еЅ“ж”ѕз”µпјџ й™€жі—жћ— 2:45 PM - ICDжњЇеђЋж„џжџ“еђЋе†Ќж¤Ќе…ҐпјљеЋџдЅЌиї� ж�ЇеЇ№дѕ§пјџ йѓж¶› ICDе№¶еЏ‘з—‡е¤„зђ†дё“ењє - з—…дѕ‹и®Ёи®є дё»жЊЃдєєпјљеЌЋдјџ, й™€жі—жћ—, е€�дїЉж�Ћ, йѓж¶› 3:00 PM - з—…дѕ‹1 дєЋжіў иµ·жђЏе™Ёе№¶еЏ‘з—‡иѕ©и®є з¬¬дёЂењєпјљдё»ж—Ёжј”и®І дё»жЊЃдєєпјљйѓйќ™иђ±, жўЃж¶›, е€�з„± 8:30 AM - жњЄжќҐзљ„ж–°е…ґд»‹е…ҐжЉЂжњЇпјљиЃљз„¦з”џ з‰©еЏЇеђёж”¶ж”Їжћ¶гЂЃз»ЏеЇјз®Ўдё»еЉЁи„‰з“ЈзЅ®жЌўеЏЉ йЎЅе›єй«�иЎЂеЋ‹з»ЏеЇјз®ЎеЋ»и‚ѕзҐћз»ЏеЊ– е€�еЃҐ 8:55 AM - и®Ёи®є з¬¬дєЊењєпјље›Ѕй™…дє¤жµЃ дё»жЊЃдєєпјљйѓйќ™иђ±, жўЃж¶›, е€�з„± дё»жЊЃдєєпјљи‘ЈеђЃй’ў, дё‡еѕЃ и®Ёи®єдё“е®¶пјљй©¬еќљ, зЁ‹ж™“ж›™ 9:05 AM - еЇјз®Ўе®¤зљ„дєєе‘�з®Ўзђ† и”ЎдЅ©еІљ иѕ©и®єдё»йў�пјљж‰Ђжњ‰иµ·жђЏе™Ёе›Љиў‹ж„џжџ“еї…йЎ»ж‹” й™¤еЇјзєї 9:20 AM - з»ЏеЇјз®Ўдё»еЉЁи„‰з“ЈзЅ®жЌўз»ЏйЄЊпј€Core Valveпј‰ Chan Kim 5:00 PM - жЈж–№ жќЋе¦ж–Њ 5:10 PM - еЏЌж–№ е€�е…µ 9:35 AM - е† и„‰е†…зђѓе›Љж–иЈ‚ Myeong-Bo Shim 9:50 AM - и®Ёи®є 5:20 PM - дё“е®¶и®Ёи®є 10:00 AM - иЊ¶ж‡ иµ·жђЏе™Ёе№¶еЏ‘з—‡з—…дѕ‹е›ћйЎѕ з¬¬дё‰ењєпјљдё“е®¶и®Іеє§ дё»жЊЃдєєпјљдєЋжіў, е€�еђЇж�Ћ, еј еЌ«жіЅ 5:30 PM - з—…дѕ‹1 д»»е¦е†› 3:10 PM - и®Ёи®є 5:40 PM - з—…дѕ‹2 и®ёйќ™ 3:15 PM - з—…дѕ‹2 йѓ‘и‰ЇиЌЈ 5:50 PM - з—…дѕ‹3 жќЋиї°еі° 3:25 PM - и®Ёи®є 6:00 PM - дј‘дјљ дё»жЊЃдєєпјљжќЁзЋ‰зЏЌ, жќЋиЏІ, е€�жґЄ 10:20 AM - дёе›Ѕд»‹е…ҐжЉ¤зђ†зљ„еЏ‘е±•зЋ°зЉ¶ дѕЇжЎ‚еЌЋ 10:40 AM - ж•°жЌ®з®Ўзђ†еЏЉйљЏи®їжЉЂе·§ и®ёдє® 11:00 AM - ж€‘ж�Їе¦‚дЅ•еЃљиЎЂз®Ўе†…и¶…еЈ°ж•°жЌ®е€† жћђзљ„пјџ й�љйќ™ 148 CIT 2012 www.citmd.com 2012е№ґ3жњ€17ж—Ґ ж�џжњџе… 11:20 AM - жЉ¤зђ†з§‘з ”и®єж–‡зљ„д№¦е†™ и°ўиґћ 3:15 PM - ж”Їжћ¶и„±иЅЅжЉ¤зђ†з»ЏйЄЊе€†дє« еІіз»§еЌЋ 11:40 AM - и®Ёи®є 3:30 PM - з”µз”џзђ†з—…з‰№ж®Љз—…дѕ‹ е€�еђ› з¬¬е››ењєпјљеЌ€й¤ђдјљ 3:45 PM - жЂҐиЇЉPCIжњЇдёе№¶еЏ‘еїѓеѕ‹е¤±еёё й‚±жњ€зєў дё»жЊЃдєєпјљдѕЇжЎ‚еЌЋ, е€�з„± 12:00 PM - еЇјз®Ўе®¤иЎЂж¶ІеЉЁеЉ›е¦з›‘жµ‹ зЋ‹и‹± 12:25 PM - и®Ёи®є 12:30 PM - IABPзљ„еє”з”Ё й‡‘е»єиЉ¬ 12:55 PM - и®Ёи®є 1:00 PM - еЇ№жЇ”е‰‚зљ„дЅїз”Ё иЌЇзґ жЇ“ 1:25 PM - и®Ёи®є з¬¬дє”ењєпјљеЇјз®Ўе®¤з®Ўзђ† дё»жЊЃдєєпјљжќЋжќ°, е†ЇзҐє, жќЋжѓ зЏ 1:30 PM - еЇјз®Ўе®¤дєєеЉ›иµ„жєђз®Ўзђ† е€�з„± 1:50 PM - еЇјз®Ўе®¤жЉ¤еЈ«зљ„еЋ‹еЉ›жєђе€†жћђ иѕње°ЏиЉі 2:10 PM - еЇјз®Ўе®¤зљ„йЈЋй™©з®Ўзђ† еј зєўжў… 2:30 PM - еЇјз®Ўе®¤е’Њз—…ж€їзљ„дє¤жЋҐз®Ўзђ† з«Ґзґ жў… 2:50 PM - и®Ёи®є з¬¬е…ењєпјљз»ЏйЄЊдє¤жµЃ дё»жЊЃдєєпјљиµµйњћ, зЋ‹ж™“з‡•, жќЋжњќиѕ‰ 3:00 PM - е°Џе„їе† и„‰йЂ еЅ±зљ„й…Ќеђ€ е€�йќ™ 149 4:00 PM - ж€їйў¤е°„йў‘е№¶еЏ‘еїѓи„Џз©їе”жЉ¤зђ†еЇ№з– жќЋиЋ‰ 4:15 PM - жЂҐиЇЉз—…дєєзљ„дє¤жЋҐ жќЋж·‘иЌЈ 4:30 PM - и®Ёи®є 4:50 PM - и¦Ѓз‚№жЂ»з»“ е€�з„±, дѕЇжЎ‚еЌЋ 5:00 PM - дј‘дјљ CIT 2012 www.citmd.com 2012е№ґ3жњ€18ж—Ґ ж�џжњџж—Ґ з¬¬дєЊењє дёЂе±‚е¤љеЉџиѓЅAеЋ… з¬¬е››е±Ље† и„‰д»‹е…ҐжІ»з–—вЂњзІѕйЂ‰вЂќе№¶еЏ‘з—‡и®єеќ› 8:30 AM-12:30 PM дё»жЊЃдєєпјљжќЁи·ѓиї›, еђ•ж ‘й“®, зЋ‹дјџж°‘, й™€йџµеІ±, еђґж°ёеЃҐ, жњ±е»єеЌЋ, йѓдёЅеђ›, е€�е®‡ж‰¬ дёЂе±‚е¤љеЉџиѓЅBеЋ… 10:30 AM - з—…дѕ‹7пјљиЌЇз‰©жґ—и„±ж”Їжћ¶жњЇеђЋе¤љ е¤„ж”Їжћ¶ж–иЈ‚е’ЊиЋ·еѕ—жЂ§иґґеЈЃдёЌи‰Їе№¶жћЃж™љжњџ ж”Їжћ¶е†…иЎЂж “ й’±иЏЉи‹± GAP-CCBC at CIT жЊ‡еЌ—е’Ње®ћи·µ - дёґеєЉз—…дѕ‹и®Ёи®єдјљ 8:30 AM-12:30 PM 10:38 AM - и®Ёи®є з¬¬дёЂењє 10:50 AM - з—…дѕ‹8пјљдёЂдёЄй—Єе¤±еј•еЏ‘зљ„дёЂзі» е€—йє»зѓ¦ е€�е¦жіў дё»жЊЃдєєпјљжќЁи·ѓиї›, Chung-Seung Chiang, й™€е‡¤иЌЈ, еѕђдєљдјџ, дЅ•еҐ”, еј иђЌ, е¤Џдє‘йѕ™, е”ђз† иѕѕ з¬¬дёЂењє дё»жЊЃдєєпјљжњ±е›Ѕи‹±, Yean-Leng Lim, е‘ЁзЋ‰жќ°, и°е®Ѓ, жё©е°љз…њ, е€�жµ·жіў, иЃ‚з»Ќе№і, е°¤еЈ«жќ° 8:30 AM - з—…дѕ‹1пјљж“ЌдЅњдёЌеЅ“еј•иµ·ж”Їжћ¶и„±иЅЅ дёЂдѕ‹ зЋ‹жџЏеЅ± 8:38 AM - и®Ёи®є 8:50 AM - з—…дѕ‹2пјље† и„‰е¤№е±‚ж„€жј”ж„€зѓ€пјљиЇҐ е¦‚дЅ•еє”еЇ№пјџ дёЃйЈЋеЌЋ 8:58 AM - и®Ёи®є 9:10 AM - з—…дѕ‹3пјљеЉЁи„‰з�¤дјґж”Їжћ¶ж–иЈ‚и‡ґж™љ жњџж”Їжћ¶е†…иЎЂж “еЅўж€ђдёЂдѕ‹ еј дїЉжќ° 9:18 AM - и®Ёи®є 9:30 AM - з—…дѕ‹4пјљж…ўжЂ§е®Ње…Ёй—еЎћз—…еЏ�д»‹е…Ґ жњЇдёжЊ‡еј•еЇјдёќдёЌиѓЅж’¤е‡єзљ„е¤„зђ† е®‹зЋ°ж¶› 9:38 AM - и®Ёи®є 9:50 AM - з—…дѕ‹5пјљTRIе№¶йЄЁз‹и†ње®¤з»јеђ€еѕЃдёЂдѕ‹ жќЋжµЄ 10:58 AM - и®Ёи®є 11:10 AM - з—…дѕ‹9пјљж— дїќжЉ¤е·¦дё»е№Іж”Їжћ¶ж¤Ќ е…ҐжњЇеђЋдёЌд№…еїѓз»ћз—›е†ЌеЏ‘дёЂдѕ‹ жќЋж‚¦ 11:18 AM - и®Ёи®є 11:30 AM - з—…дѕ‹10пјљAngiosealе°Ѓе µе™Ёдјљжњ‰ иї™ж ·зљ„е№¶еЏ‘з—‡д№€пјџ иµµжќ° 11:38 AM - и®Ёи®є 11:50 AM - з—…дѕ‹11пјљеЇјз®Ўе®¤зљ„иќґиќ¶ж•€еє” жґЄжµЄ 11:58 AM - и®Ёи®є 12:10 PM - з—…дѕ‹12пјље† и„‰д»‹е…ҐжњЇеђЋиЎЂз®ЎжЂҐ жЂ§й—еЎћзљ„ж·±е±‚жЂќиЂѓ й‚±еЋџе€љ 12:18 PM - и®Ёи®є 9:58 AM - и®Ёи®є 10:10 AM - з—…дѕ‹6пјље·¦дё»е№Іи‡ЄеЏ‘е¤№е±‚иї�ж�Ї еЇјз®ЎжЌџдј¤пјџ иЌ†е…Ёж°‘ 10:18 AM - и®Ёи®є 8:30 AM - з—…дѕ‹1пјљи…°з—›дјґиЎЂе°їгЂЃиЎЂдѕїеЏЉе‘ј еђёе›°йљѕж‚ЈиЂ…дёЂдѕ‹ е€�ж�џ 8:50 AM - з—…дѕ‹2пјљиµ·жђЏе™ЁжњЇеђЋеЏЌе¤Ќж€їж‰‘ дёЂдѕ‹ еёёиїћиЉі 9:10 AM - з—…дѕ‹3пјље·¦дё»е№ІејЂеЏЈй‡Ќеє¦з‹зЄ„е№¶ е‰Ќй™Ќж”ЇеЏЉеЏіе† й—еЎћзљ„д»‹е…ҐжІ»з–—дёЂдѕ‹ е‘Ёз‚іе‡¤ 9:30 AM - з—…дѕ‹4пјљз»ЏйЄЊз§ЇзґЇеђЋзљ„й†’ж‚џ еј е»єе†› 9:50 AM - з—…дѕ‹5пјљжЂҐжЂ§еїѓи‚Њжў—ж»дєљжЂҐжЂ§еїѓ и„Џз ґиЈ‚дёЂдѕ‹ еј еі» 10:10 AM - з—…дѕ‹6пјљIIb/IIIaеЏ—дЅ“ж‹®жЉ—е‰‚еј•иµ· дёҐй‡ЌиЎЂе°Џжќїе‡Џе°‘з—‡дёЂдѕ‹пјљжІ»з–—з–з•ҐеЏЉеЋџ е› и§Јжћђ е”ђз† иѕѕ з¬¬дєЊењє CIT2012й—е№•ејЏ 12:30 PM-12:45 PM дё»жЊЃдєєпјљй™€зєў, Chuen-Den Tseng, еЌўй•їжћ—, зЋ‹з„±, з”°е†›, еј е»єе†›, еђґеІіе№і, жќЁиї›е€љ дё»жЊЃдєєпјљеѕђжіў иЃ”еђ€дё»еёпјљй™€зєЄиЁЂ, й™€з»Ќи‰Ї, й«�ж¶¦йњ–, и‘›еќ‡жіў, йџ©й›…зЋІ, и’‹дё–и‰Ї, еђ•ж ‘й“®, зЋ‹дјџж°‘, жќЁи·ѓиї›, жњ±е›Ѕи‹± 10:30 AM - з—…дѕ‹7пјље№ґиЅ»еҐіжЂ§иѓёз—›дјґж™•еЋҐ дёЂдѕ‹ й«�и‹± 12:30 PM - CIT2012жЂ»з»“еЏЉCIT2013е®Јеёѓ й«�ж¶¦йњ– 12:45 PM - дј‘дјљ 10:50 AM - з—…дѕ‹8пјљз–‘дјјдё»еЉЁи„‰е¤№е±‚еЇји‡ґ зљ„жЂҐжЂ§дё‹еЈЃеїѓжў—и‡ґж»дёЂдѕ‹ еє„е°‘дјџ 11:10 AM - з—…дѕ‹9пјљдёЌж�ЋеЋџе› й�µеЏ‘жЂ§иѓё з—›гЂЃж™•еЋҐдёЂдѕ‹пјљиЇЉж–дёЋжІ»з–— й™€и‰Їйѕ™ 150 CIT 2012 www.citmd.com 2012е№ґ3жњ€18ж—Ґ ж�џжњџж—Ґ 11:30 AM - з—…дѕ‹10пјље¤Ќжќ‚е† и„‰е’Ње¤–е‘ЁеЉЁи„‰ зІҐж ·зЎ¬еЊ–ж‚ЈиЂ…зљ„д»‹е…ҐжІ»з–—ж–№жЎ€йЂ‰ж‹© зЋ‹з„± 11:50 AM - з—…дѕ‹11пјљеЋџеЏ‘жЂ§й†›е›єй…®еўће¤љз—‡ дјґеЏ‘зѓж‚ЈиЂ…дёЂдѕ‹ д»»ж™ЇжЂЎ з¬¬дє”ењєпјљйЂ†еђ‘жЉЂжњЇ дё»жЊЃдєєпјљи‘›еќ‡жіў, ж–№е”ЇдёЂ и®Ёи®єдё“е®¶пјљжќЋз”°ж�Њ, ж…•жњќдјџ, зЋ‹дёњзђ¦, еј й’І 10:00 AM - йЂ‚еє”иЇЃдёЋе™Ёжў°е‡†е¤‡ е‚…е›Ѕиѓњ 12:10 PM - з—…дѕ‹12пјљеє”жїЂжЂ§еїѓи‚Њз—…дёЂдѕ‹ зЅ—ж™“дє® 10:15 AM - и®Ёи®є 12:30 PM - дј‘дјљ 10:18 AM - йЂ†еђ‘йЂљйЃ“зљ„йЂ‰ж‹© и‘›й›· 10:36 AM - е¦‚дЅ•ж“ЌжЋ§еЇјдёќйЂљиї‡дѕ§ж”ЇиЎЂз®Ўпјџ й™€зєЄиЁЂ з—…дѕ‹ж—©й¤ђдјљпј€еЌЃпј‰ ж…ўжЂ§е®Ње…Ёй—еЎћ 7:00 AM-8:00 AM е† и„‰д»‹е…Ґе®ћз”Ёж•™зЁ‹з¬¬е››йѓЁе€† ж…ўжЂ§е®Ње…Ёй—еЎћз—…еЏ� 8:30 AM-12:30 PM 10:54 AM - еЇјдёќйЂљиї‡дѕ§ж”ЇеђЋзљ„е¤„зђ†пјљеЇјдёќ еЇ№еђ»гЂЃCARTгЂЃеЏЌеђ‘CARTгЂЃвЂњзє¦дјљвЂќеЏЉе…¶ д»–жЉЂжњЇ еј ж–Њ 8:30 AM - иї›е…Ґз‚№зљ„е€¤ж–е’ЊеЇјдёќйЂљиї‡жЉЂжњЇ еђ•ж ‘й“® 9:03 AM - и®Ёи®є 9:06 AM - еЇјдёќйЂљиї‡з©їе‡єз‚№пјље¤љи§’еє¦и§‚еЇџ зљ„й‡Ќи¦ЃжЂ§ зЅ—е»єж–№ 9:21 AM - и®Ёи®є 9:24 AM - еЇјдёќиї›е…ҐеЃ‡и…”еёёи§Ѓеђ—пјџе¦‚дЅ•иї› иЎЊе€¤ж–пјџ й™€з»Ќи‰Ї 9:39 AM - и®Ёи®є 7:00 AM - CS-0043пјљйЂ†еђ‘еЇјдёќжЉЂжњЇејЂйЂљ CTOз—…еЏ�зљ„жЉЂе·§ и‘Ји±Єеќљ 7:10 AM - и®Ёи®є 11:12 AM - жЈеђ‘дёЋйЂ†еђ‘е†із–еЇ№жЇ”пјљвЂњжќ‚ дє¤вЂќиЂѓй‡ЏдёЋж”№еЏ�вЂњи€Єеђ‘вЂќ и‘›еќ‡жіў 7:12 AM - CS-0065пјљз»ЏжЎЎеЉЁи„‰ејЂйЂљCTOз—… еЏ�пјљдёЌеђЊжЊ‡еј•еЇјдёќзљ„йЂ‰ж‹© й»„ж¦•зїЂ 11:27 AM - и®Ёи®є 7:22 AM - и®Ёи®є з¬¬е…ењєпјљжЊ‘ж€�жЂ§ж…ўжЂ§е®Ње…Ёй—еЎћз—…дѕ‹е›ћйЎѕ 7:24 AM - CS-0186пјљз»Џеїѓе¤–и†њйЂ†еђ‘CTOд»‹ е…ҐжІ»з–— йѓе®Ѓ дё»жЊЃдєєпјљй™€зєЄиЁЂ, йџ©й›…зЋІ и®Ёи®єдё“е®¶пјљжќЋж€ђзҐҐ, жќЋе¦еҐ‡, жќЋж‚¦, йѓ‘й‡‘е€љ 11:30 AM - ж€‘вЂњжњЂвЂќе…·жЊ‘ж€�ж…ўжЂ§е®Ње…Ёй—еЎћ дёЂдѕ‹ жќЋе¦еҐ‡ 11:40 AM - и®Ёи®є 11:45 AM - ж€‘вЂњжњЂвЂќе…·жЊ‘ж€�ж…ўжЂ§е®Ње…Ёй—еЎћ дёЂдѕ‹ йѓ‘й‡‘е€љ 11:55 AM - и®Ёи®є 9:42 AM - еЏЊеЇјдёќжЉЂжњЇзљ„еє”з”Ё еђґж°ёеЃҐ 12:00 PM - ж€‘вЂњжњЂвЂќе…·жЊ‘ж€�ж…ўжЂ§е®Ње…Ёй—еЎћ дёЂдѕ‹ жќЋж€ђзҐҐ 9:57 AM - и®Ёи®є 12:10 PM - и®Ёи®є 151 дё»жЊЃдєєпјљи°е®Ѓ, иґѕе¤§жћ—, жќЋжЂЎ 11:09 AM - и®Ёи®є 8:45 AM - и®Ёи®є 8:48 AM - е¦‚дЅ•ж“ЌжЋ§еЇјдёќйЂљиї‡з—…еЏ�пјљж‰‹ж„џ й‡Ќи¦Ѓиї�ж�Їж–№еђ‘й‡Ќи¦Ѓпјџ йџ©й›…зЋІ 12:30 PM - дј‘дјљ дё‰е±‚306ABдјљи®®е®¤ 10:51 AM - и®Ёи®є дё»жЊЃдєєпјљжІ€еЌ«еі°, зЋ‹жµ·ж�Њ и®Ёи®єдё“е®¶пјљиґѕз»Ќж–Њ, зЋ‹е®€еЉ›, зЋ‹з¦№, е‘Ёж—ж™Ё 12:25 PM - и®Ёи®є 10:33 AM - и®Ёи®є дёЂе±‚е¤љеЉџиѓЅCеЋ… з¬¬е››ењєпјљжЈеђ‘жЉЂжњЇ 12:15 PM - ж€‘вЂњжњЂвЂќе…·жЊ‘ж€�ж…ўжЂ§е®Ње…Ёй—еЎћ дёЂдѕ‹ жќЋж‚¦ 7:34 AM - и®Ёи®є 7:36 AM - CS-0201пјљйЂ†еђ‘RendezvousжЉЂжњЇ й±јйѕ™жµ© 7:46 AM - и®Ёи®є 7:48 AM - CS-0213пјље‰Ќеђ‘жЉЂжњЇејЂйЂљCABGжњЇ еђЋеЌЃе№ґж‚ЈиЂ…е‰Ќй™Ќж”ЇCTOдёЂдѕ‹ й»„дёњ 7:58 AM - и®Ёи®є 8:00 AM - дј‘дјљ CIT 2012 www.citmd.com 2012е№ґ3жњ€18ж—Ґ ж�џжњџж—Ґ е¤–е‘Ёе’Њи…”е†…иЎЂз®ЎжІ»з–—з¬¬дё‰йѓЁе€† дё»еЉЁи„‰з�¤д»‹е…Ґи®єеќ› 8:30 AM-12:00 PM дё»жЊЃдєєпјљеёёи°¦, еј з‘ћеІ©, и€’з•…, з¬¦дјџе›Ѕ, йѓдјџ, й™€еї 8:30 AM - й�ње¤–еїѓиЎЂз®Ўз—…еЊ»й™ўдёґеєЉз»ЏйЄЊеЏЉ вЂњжЊ‘ж€�жЂ§вЂќз—…дѕ‹е›ћйЎѕ еёёи°¦ 9:00 AM - дёЉжµ·дє¤йЂље¤§е¦еЊ»е¦й™ўй™„е±ћз‘ћй‡‘ еЊ»й™ўдёґеєЉз»ЏйЄЊеЏЉвЂњжЊ‘ж€�жЂ§вЂќз—…дѕ‹е›ћйЎѕ еј з‘ћеІ© 9:30 AM - ж№–еЌ—ж№�й›…дєЊй™ўдёґеєЉз»ЏйЄЊеЏЉвЂњжЊ‘ ж€�жЂ§вЂќз—…дѕ‹е›ћйЎѕ и€’з•… 10:00 AM - е¤Ќж—¦е¤§е¦й™„е±ћдёе±±еЊ»й™ўдёґеєЉз»Џ йЄЊеЏЉвЂњжЊ‘ж€�жЂ§вЂќз—…дѕ‹е›ћйЎѕ з¬¦дјџе›Ѕ 10:30 AM - и§Јж”ѕе†›жЂ»еЊ»й™ўдёґеєЉз»ЏйЄЊеЏЉвЂњжЊ‘ ж€�жЂ§вЂќз—…дѕ‹е›ћйЎѕ йѓдјџ 7:22 AM - и®Ёи®є 7:24 AM - CS-0245пјљйЂ†еђ‘PCIдѕ§ж”ЇиЎЂз®Ўз ґиЈ‚ дёЂдѕ‹ йѓ‘еїѓз”° 7:34 AM - и®Ёи®є 7:36 AM - CS-0319пјље№іиЎЊеЇјдёќжЉЂжњЇејЂйЂљеЏі е† и„‰CTO зЋ‹ж–Њ 7:46 AM - и®Ёи®є 7:48 AM - CS-0336пјљLADжЂҐжЂ§й—еЎћеђ€е№¶ж…ў жЂ§й—еЎћдёЂдѕ‹ йўњзєўе…µ 10:30 AM - з—…дѕ‹5пјљж”Їжћ¶ж–иЈ‚еј•иµ·зљ„ж”Їжћ¶ е†…е†Ќз‹зЄ„ еЌње†› 10:45 AM - з—…дѕ‹6пјљж…ўжЂ§ж”Їжћ¶и†ЁиѓЂдёЌе…Ёеј• иµ·зљ„ж”Їжћ¶е†…е†Ќз‹зЄ„ й«�з«‹е»є 11:00 AM - з—…дѕ‹7пјљж”Їжћ¶ж–иЈ‚е’Њж”Їжћ¶е†Ќз‹зЄ„ еј еЇ… 11:15 AM - з—…дѕ‹8пјљвЂњи‡ЄеЏ‘вЂќе¤№е±‚е’ЊиЎЂж “ жќЁжЇ…е®Ѓ 7:58 AM - и®Ёи®є 11:30 AM - з—…дѕ‹9пјљж–‘еќ—з ґиЈ‚ зЋ‹жћ— 8:00 AM - дј‘дјљ 11:45 AM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 12:00 PM - дј‘дјљ IVUSеџ№и®иЇѕзЁ‹з¬¬дєЊйѓЁе€† 8:30 AM-12:00 PM ж”Їжћ¶е№¶еЏ‘з—‡ 11:00 AM - й¦–йѓЅеЊ»з§‘е¤§е¦й™„е±ће®‰иґћеЊ»й™ўдёґ еєЉз»ЏйЄЊеЏЉвЂњжЊ‘ж€�жЂ§вЂќз—…дѕ‹е›ћйЎѕ й™€еї дё»жЊЃдєєпјљGary Mintz, Jeffrey W. Moses и®Ёи®єдё“е®¶пјљйѓе®Ѓ, иґєе‹‡, е€�е¦жіў, й’±иЏЉи‹± 11:30 AM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 8:30 AM - ж”Їжћ¶е†…е†Ќз‹зЄ„зљ„IVUSиЇ„д»· й’±жќ° 12:00 PM - дј‘дјљ дё»жЊЃдєєпјљGary Mintz, Jeffrey W. Moses и®Ёи®єдё“е®¶пјље€�еЃҐ, й’±жќ°, еђґе°Џе‡Ў, еѕђе‡Ї 8:50 AM - ж”Їжћ¶иЎЂж “зљ„IVUSиЇ„д»· е€�еЃҐ з—…дѕ‹жЉҐе‘Љпј€жЇЏдёЄз—…дѕ‹жЉҐе‘ЉеЏЉй—®з”15е€†й’џпј‰ дё‰е±‚308дјљи®®е®¤ з—…дѕ‹ж—©й¤ђдјљпј€еЌЃдєЊпј‰ е·¦дё»е№ІдёЋеЅ±еѓЏ 7:00 AM-8:00 AM дё»жЊЃдєєпјљжќЋе›Ѕеє†, з±ЌжЊЇе›Ѕ, еѕђжіЅеЌ‡ 7:00 AM - CS-0064пјљеЏідЅЌеїѓе№¶е·¦дё»е№Із—…еЏ� д»‹е…ҐжІ»з–—дёЂдѕ‹ жќЋж‹Ґе†› дё‰е±‚307ABдјљи®®е®¤ 9:10 AM - з—…дѕ‹1пјљж”Їжћ¶дєљжЂҐжЂ§иЎЂж “еЅўж€ђ еґ”е‡Ї з—…дѕ‹ж—©й¤ђдјљпј€еЌЃдёЂпј‰ ж…ўжЂ§е®Ње…Ёй—еЎћ 7:00 AM-8:00 AM 9:25 AM - з—…дѕ‹2пјљиґґеЈЃдёЌи‰Їеј•иµ·зљ„иїџеЏ‘ж™љ жњџж”Їжћ¶иЎЂж “ е€�йњ‡е®‡ 7:12 AM - CS-0139пјљжЂҐжЂ§е·¦дё»е№Ій—еЎћжЉўж•‘ ж€ђеЉџдёЂдѕ‹ е°№еЉ› дё»жЊЃдєєпјљеђґй“ї, еј еҐ‡, иґѕж°ёе№і 9:40 AM - з—…дѕ‹3пјљиїџеЏ‘ж™љжњџиЎЂж “еЅўж€ђ ж±Єж�Ћжѓ 7:22 AM - и®Ёи®є 7:00 AM - CS-0239пјљжЂҐиЇЉCTOз—…дѕ‹дёЂдѕ‹ жќҐж™Џ 7:10 AM - и®Ёи®є 7:12 AM - CS-0241пјље¤Ќжќ‚е¤љж”Їз—…еЏ�еђ€е№¶ CTO иѓЎж¶› 9:55 AM - з—…дѕ‹4пјљж”Їжћ¶ж–иЈ‚гЂЃе†Ќз‹зЄ„еЏЉиЎЂ ж “еЅўж€ђ иµµиїЋж–° 10:10 AM - иЊ¶ж‡ 7:10 AM - и®Ёи®є 7:24 AM - CS-0280пјљIVUSе’ЊFFRењЁPCIдёзљ„ еє”з”Ё е‚…еђ‘еЌЋ 7:34 AM - и®Ёи®є 152 CIT 2012 www.citmd.com 2012е№ґ3жњ€18ж—Ґ ж�џжњџж—Ґ 7:36 AM - CS-0331пјљдёґз•Њз—…еЏ�зљ„PCIжІ»з–—дёЂдѕ‹ жћ—ж°ёйќ’ 7:46 AM - и®Ёи®є 7:48 AM - CS-0332пјље·¦дё»е№ІжЂҐжЂ§й—еЎћжЂҐиЇЉ д»‹е…ҐжІ»з–—дёЂдѕ‹ еѕђжіЅеЌ‡ 7:58 AM - и®Ёи®є 8:00 AM - дј‘дјљ еѕЃй›†з—…дѕ‹и®Ёи®єз¬¬дёЂйѓЁе€† 8:30 AM-12:30 PM з¬¬дёЂењєпјљжЂҐжЂ§е† и„‰з»јеђ€еѕЃ дё»жЊЃдєєпјље‚…еђ‘еЌЋ з‚№иЇ„дё“е®¶пјље®‰жЇ…, з™Ѕй”‹, ж›№й›Єж»Ё, еђґеђЊжћњ, е§љжњ±еЌЋ, еј ж•Џе·ћ 8:30 AM - CS-0061пјљй…·дјјжЂҐжЂ§еїѓи‚Њжў—ж»зљ„ Tako-Tsuboeз»јеђ€еѕЃ й«�иїњ 8:40 AM - и®Ёи®є 8:45 AM - CS-0091пјљжЂҐиЇЉе№Ійў„е¤§йљђйќ™и„‰жЎҐ иЎЂз®Ўй—еЎћдёЂдѕ‹ е™ж�Љ 8:55 AM - и®Ёи®є 9:00 AM - CS-0093пјљеїѓжў—еђЋ3е¤©пјЊиЎЂз®Ўиї�йњЂ и¦ЃејЂйЂљеђ—пјџ жќЁеі»йќ’ 9:55 AM - и®Ёи®є 12:10 PM - и®Ёи®є 10:00 AM - CS-0338пјљй«�еЌ±ACSж‚ЈиЂ…зљ„д»‹е…Ґ жІ»з–—дёЂдѕ‹ жІ€ж•Џ 12:15 PM - CS-0328пјљIVUSжЊ‡еЇјзљ„SKSжЉЂжњЇ жІ»з–—е·¦дё»е№Іе€†еЏ‰дёЂдѕ‹ еѕђе‡Ї 10:10 AM - и®Ёи®є 12:25 PM - и®Ёи®є 10:15 AM - CS-0346пјљжЂҐжЂ§еїѓи‚Њжў—ж»жІ»з–— з–з•Ґ е§љжњ±еЌЋ 12:30 PM - дј‘дјљ 10:25 AM - и®Ёи®є з¬¬дєЊењєпјље·¦дё»е№ІгЂЃе€†еЏ‰з—…еЏ�еЏЉеЅ±еѓЏ дё‰е±‚309Aдјљи®®е®¤ дё»жЊЃдєєпјље‚…е›Ѕиѓњ з‚№иЇ„дё“е®¶пјљй™€з«№еђ›, е…љзѕ¤, и‘Је№іж “, еѕђе»¶ж•Џ, жќЁдёЅйњћ, жќЁж ‘жЈ® з—…дѕ‹ж—©й¤ђдјљпј€еЌЃдё‰пј‰ з‰№ж®Љз—…дѕ‹ 7:00 AM-8:00 AM 10:30 AM - CS-0044пјљж— дїќжЉ¤е·¦дё»е№Іж”Їжћ¶жњЇ Chong-Guan Chan дё»жЊЃдєєпјљзЋ‹е®Ѓе¤«, жќЋжЅћ, дїЎж “еЉ› 10:40 AM - и®Ёи®є 7:00 AM - CS-0035пјљж‰©еј жњџи‚ҐеЋљећ‹еїѓи‚Њз—… дёЂдѕ‹ зЋ‹е¦ж–‡ 10:45 AM - CS-0007пјљж— дїќжЉ¤е·¦дё»е№ІеЏЉе¤љж”Ї иЎЂз®Ўз—…еЏ�д»‹е…ҐжІ»з–—з–з•ҐеЏЉжЉЂжњЇ еѕђе»¶ж•Џ 10:55 AM - и®Ёи®є 11:00 AM - CS-0133пјљвЂње‘Ѕж‚¬дёЂзєївЂќпјље·¦ дё»е№ІеЏЉдё‰ж”Їз—…еЏ�е†Ќж¬ЎиЎЂиїђй‡Ќе»є е…іжЂЂж•Џ 11:10 AM - и®Ёи®є 9:10 AM - и®Ёи®є 11:15 AM - CS-0165пјље·¦дё»е№Іе€†еЏ‰з—…еЏ�зљ„еЏЊ жЊ¤еЋ‹ж”Їжћ¶жњЇ жќЋжµЄ 9:15 AM - CS-0174пјљдё»еЉЁи„‰Aећ‹е¤№е±‚еЇји‡ґ зљ„жЂҐжЂ§еїѓи‚Њжў—ж»пјљж€ђеЉџжЉўж•‘дёЂдѕ‹ й›·ж–°е†› 11:25 AM - и®Ёи®є 9:25 AM - и®Ёи®є 9:30 AM - CS-0235пјљжЂЋж ·е¤„зђ†STEMIз—…дєєзЅЄ зЉЇиЎЂз®Ўзљ„е·Ёе¤§иЎЂж “пјџ еј еҐ‡ 9:40 AM - и®Ёи®є 9:45 AM - CS-0296пјље† и„‰з—‰жЊ›и‡ґжЂҐжЂ§дё‹еЈЃ еїѓи‚Њжў—ж» зЋ‹еЏЇ 153 11:30 AM - CS-0185пјљDESе†…йљѕжІ»ж–‘еќ—е’ЊиЎЂ ж “ еЏ¶зєўеЌЋ 11:40 AM - и®Ёи®є 11:45 AM - CS-0305пјљз•™зЅ®зђѓе›ЉжЉЂжњЇе’ЊеЏЌеђ‘ жЊ¤еЋ‹ж”Їжћ¶жњЇ й‡‘зђґиЉ± 11:55 AM - и®Ёи®є 12:00 PM - CS-0324пјљLADдё‰е€†еЏ‰з—…еЏ�д»‹е…ҐдёЂдѕ‹ иЌ†е…Ёж°‘ 7:10 AM - и®Ёи®є 7:12 AM - CS-0082пјљдёЂдѕ‹и‡ЄеЏ‘жЂ§е† зЉ¶еЉЁи„‰ е¤№е±‚з—…дєєзљ„жЉ¤зђ† ж®µдїЉж»” 7:22 AM - и®Ёи®є 7:24 AM - CS-0086пјљй…·дјјжЂҐжЂ§еїѓи‚Њжў—ж»зљ„ й‡Ќз—‡еїѓи‚Њз‚ЋдёЂдѕ‹ й™€з« ејє 7:34 AM - и®Ёи®є 7:36 AM - CS-0109пјље† еїѓз—…еђ€е№¶еїѓиЎ°е¤–жєђ BNPжІ»з–—зљ„дѕќиµ– зЋ‹е®Ѓе¤« 7:46 AM - и®Ёи®є 7:48 AM - CS-0118пјљйќћеїѓи‚Њжў—ж»дёи‚Њй’™и›‹ з™ЅеЌ‡й«�дёЂдѕ‹ жќЋжЈ®жћ— 7:58 AM - и®Ёи®є 8:00 AM - дј‘дјљ CIT 2012 www.citmd.com 2012е№ґ3жњ€18ж—Ґ ж�џжњџж—Ґ еѕЃй›†з—…дѕ‹и®Ёи®єз¬¬дєЊйѓЁе€† 8:30 AM-12:30 PM з¬¬дёЂењєпјљй’™еЊ–з—…еЏ�дёЋж…ўжЂ§е®Ње…Ёй—еЎћ дё»жЊЃдєєпјљй«�з‚њ з‚№иЇ„дё“е®¶пјљиѓЎж‰їжЃ’, жќЋеє·, жќЋж‹Ґе†›, зЋ‹ж�Ћз”џ, еђґж·і, жќЁж°ёеЃҐ 8:30 AM - CS-0005пјљ74еІЃиЂЃе№ґж‚ЈиЂ…дё‰ж”Їе† и„‰з—…еЏ�еђ€е№¶ејҐжј«дёҐй‡Ќй’™еЊ– е€�е…µ 8:40 AM - и®Ёи®є 8:45 AM - CS-0006пјљдёҐй‡Ќй’™еЊ–з—…еЏ�PCI з”�ж¶¦йџ¬ 8:55 AM - и®Ёи®є 9:00 AM - CS-0147пјљеѕ®еЇјз®Ўдјљеё€жЉЂжњЇйЂ†еђ‘ ејЂйЂљCTOдёЂдѕ‹ дѕЇзЈЉ 9:10 AM - и®Ёи®є 9:15 AM - CS-0159пјљйЂ†еђ‘CARTејЂйЂљеЏіе† CTOдёЂдѕ‹ еј еЉ±еє 9:25 AM - и®Ёи®є 9:30 AM - CS-0246пјљз»Џеїѓе¤–и†њеЉЁи„‰йЂ†еђ‘жЉЂ жњЇжІ»з–—CTO йѓдёЅеђ› 9:40 AM - и®Ёи®є 9:45 AM - CS-0287пјљ5FеЇјз®Ўз»ЏеЏЊдѕ§жЎЎеЉЁи„‰ ж€ђеЉџејЂйЂљCTOдёЂдѕ‹ Yoshihide Fujimoto 9:55 AM - и®Ёи®є 10:00 AM - CS-0329пјљCTOе…Ёж”»з•ҐжІ»з–—е¤љж”Ї иЎЂз®Ўй—еЎћдёЂдѕ‹ жќЁжЇ…е®Ѓ 10:10 AM - и®Ёи®є 10:15 AM - CS-0345пјљCrusadeеЇјз®ЎжІ»з–—ж€ђ и§’CTOз—…еЏ� еЏ¶йЈћ 10:25 AM - и®Ёи®є з¬¬дєЊењєпјљз‰№ж®Љз—…дѕ‹ дё»жЊЃдєєпјљй™€ж–№ з‚№иЇ„дё“е®¶пјљеђ•еђ‰е…ѓ, и‹—з«‹е¤«, жµ¦еҐЋ, зЋ‹ж…§еі°, жќЁеї—еЃҐ, иµµе…Ёж�Ћ дё‰е±‚309Bдјљи®®е®¤ 10:30 AM - CS-0020пјљз›ёиѕ…з›ёж€ђпјџдёЂдѕ‹ CABGеђЋзљ„PCI жќЋжў¦зђ¦ з—…дѕ‹ж—©й¤ђдјљпј€еЌЃе››пј‰ з‰№ж®Љз—…дѕ‹ 7:00 AM-8:00 AM 10:40 AM - и®Ёи®є дё»жЊЃдєєпјљеЏ¶йЈћ, е€�е’Ње№і, жќЁиђЌ 10:45 AM - CS-0021пјљй«�е‡ќзЉ¶жЂЃж‰Ђи‡ґеїѓжў— еЏЉдєљжЂҐжЂ§ж”Їжћ¶е†…иЎЂж “ зЋ‹еЂ© 7:00 AM - CS-0127пјље¤љеЏ‘жЂ§е¤§еЉЁи„‰з‚ЋдёЂдѕ‹ дєЋжіў 10:55 AM - и®Ёи®є 11:00 AM - CS-0079пјљд»‹е…ҐжІ»з–—й‡‘ж ‡е‡†пјљ йЂ еЅ±пјџIVUSпјџFFRпјџ дї®е»єж€ђ 11:10 AM - и®Ёи®є 11:15 AM - CS-0166пјљRCAиЎЂж “з—…еЏ�PCIдёЂдѕ‹ е°№ж ‹ 11:25 AM - и®Ёи®є 11:30 AM - CS-0198пјљдёЂдѕ‹иЎЂз®Ўе†…е¤№е±‚зљ„ PCIжІ»з–— е‘Ёж™Їж�± 11:40 AM - и®Ёи®є 11:45 AM - CS-0209пјље¤–дј¤ж‰Ђи‡ґеїѓи‚Њжў—ж» дёЂдѕ‹ жќЁеЈ«дјџ 11:55 AM - и®Ёи®є 12:00 PM - CS-0256пјљPTCAеЇјдёќиѕ…еЉ©ж€ђеЉџ е®¤й—ґйљ”зјєжЌџе°Ѓе µжњЇдёЂдѕ‹ й©¬дёњж�џ 12:10 PM - и®Ёи®є 7:10 AM - и®Ёи®є 7:12 AM - CS-0168пјљPCIзЊќж»жЉўж•‘ж€ђеЉџдёЂдѕ‹ жЇ›ж‡ї 7:22 AM - и®Ёи®є 7:24 AM - CS-0197пјљиµ·жєђеј‚еёёRCAжЂҐиЇЉPCI жњЇеђЋдЅЋж°§иЎЂз—‡ еѕђжµ© 7:34 AM - и®Ёи®є 7:36 AM - CS-0221пјљеїѓжў—еђЋе®¤еЈЃз�¤дјґй™„еЈЃ иЎЂж “зљ„е¤„зђ† зЋ‹еє†иѓњ 7:46 AM - и®Ёи®є 7:48 AM - CS-0227пјљеїѓи‚Њж·ЂзІ‰ж ·еЏ�еЊ–дёЂдѕ‹ е‘ЁзЋ‰жќ° 7:58 AM - и®Ёи®є 8:00 AM - дј‘дјљ иЌЇз‰©е¦з ”и®Ёдјљ ж–Ѕз»ґй›…еЌЏеЉћ е† еїѓз—…ж‚ЈиЂ…зљ„д»Ји°ўжІ»з–— 8:30 AM-10:30 AM 12:15 PM - CS-0317пјљеє”з”ЁйЂ еЅ±еЇјз®Ўеј•еЇј PTCAеЇјдёќиї›е…ҐеЏіе† дёЂдѕ‹ зЋ‹иЂї дё»жЊЃдєєпјљй«�ж¶¦йњ– 12:25 PM - и®Ёи®є 8:35 AM - е† еїѓз—…д»Ји°ўжІ»з–—иї›е±• жќЋе°Џй№° 12:30 PM - дј‘дјљ 8:30 AM - ејЂењєи‡ґиѕћ 9:00 AM - д»Ји°ўжІ»з–—ењЁPCIж‚ЈиЂ…зљ„еє”з”Ё й™€йџµеІ± 154 CIT 2012 www.citmd.com 2012е№ґ3жњ€18ж—Ґ ж�џжњџж—Ґ 9:25 AM - д»Ји°ўжІ»з–—ењЁLVDж‚ЈиЂ…зљ„еє”з”Ё иѓЎз”іж±џ 9:50 AM - дё‡з€ЅеЉ›зј“й‡Љз‰‡пјљж”№е–„еїѓи‚Њзјє иЎЂпјЊй™ЌдЅЋжё…ж™ЁйЈЋй™© е‘Ёж™“иЉі 10:15 AM - дё“е®¶и®Ёи®єеЏЉеђ¬дј—й—®з” 10:30 AM - дј‘дјљ дё‰е±‚310дјљи®®е®¤ з»“жћ„жЂ§еїѓи„Џз—…з¬¬е››йѓЁе€† 8:00 AM-12:26 PM 9:48 AM - и®Ёи®є з¬¬дёЂењє 9:52 AM - е…€е¤©жЂ§еїѓи„Џз—…еђ€е№¶й‡Ќеє¦и‚єеЉЁи„‰й«� еЋ‹зљ„д»‹е…ҐжІ»з–—пјљж№–еЌ—е¤§е¦ж№�й›…дєЊй™ўз»ЏйЄЊ жІ€еђ‘е‰Ќ дё»жЊЃдєєпјљз§¦ж°ёж–‡, еј зЋ‰йЎє, еѕђд»Іи‹±, е®‹жІ»иїњ, еЌЋз›Љж°‘, еј ж™єдјџ, еђґз‚ізҐҐ, з››е›Ѕе¤Є 10:02 AM - и®Ёи®є 8:00 AM - е…€е¤©жЂ§еїѓи„Џз—…еђ€е№¶й‡Ќеє¦и‚єеЉЁи„‰ й«�еЋ‹зљ„д»‹е…ҐжІ»з–—пјљз¬¬дєЊе†›еЊ»е¤§е¦й•їжµ·еЊ» й™ўз»ЏйЄЊ иµµд»™е…€ 10:06 AM - е…€е¤©жЂ§еїѓи„Џз—…еђ€е№¶й‡Ќеє¦и‚єеЉЁи„‰ й«�еЋ‹зљ„д»‹е…ҐжІ»з–—пјљдёЉжµ·дє¤йЂље¤§е¦иѓёз§‘еЊ» й™ўз»ЏйЄЊ жЅ�ж¬Ј 8:10 AM - и®Ёи®є 10:16 AM - и®Ёи®є 8:14 AM - е…€е¤©жЂ§еїѓи„Џз—…еђ€е№¶й‡Ќеє¦и‚єеЉЁи„‰ й«�еЋ‹зљ„д»‹е…ҐжІ»з–—пјљй�ње¤–еЊ»й™ўз»ЏйЄЊ еј ж€€е†› з¬¬дєЊењє 8:24 AM - и®Ёи®є дё»жЊЃдєєпјљж›ѕж™є, и’‹дё–и‰Ї, й©¬дѕќеЅ¤, дјЌдјџй”‹, дѕЇеђе±±, еј дјџеЌЋ, жќЁе¤©е’Њ, йѕљж–№ж€љ дё»жЊЃдєєпјљеј ж–Њ, е€�ж…§, жќЁеї—ж�Ћ 8:28 AM - е…€е¤©жЂ§еїѓи„Џз—…еђ€е№¶й‡Ќеє¦и‚єеЉЁи„‰ й«�еЋ‹зљ„д»‹е…ҐжІ»з–—пјљдёЉжµ·дёе±±еЊ»й™ўз»ЏйЄЊ е‘Ёиѕѕж–° 10:20 AM - е…€е¤©жЂ§еїѓи„Џз—…еђ€е№¶й‡Ќеє¦и‚єеЉЁи„‰ й«�еЋ‹зљ„д»‹е…ҐжІ»з–—пјљи§Јж”ѕе†›жЂ»еЊ»й™ўз»ЏйЄЊ зЋ‹е№їд№‰ 7:00 AM - CS-0250пјљеЋџеЏ‘жЂ§й†›е›єй…®еўће¤љз—‡ PCIдёЂдѕ‹ еґ”жќѕ 8:38 AM - и®Ёи®є 10:30 AM- и®Ёи®є 8:42 AM - е…€е¤©жЂ§еїѓи„Џз—…еђ€е№¶й‡Ќеє¦и‚єеЉЁи„‰ й«�еЋ‹зљ„д»‹е…ҐжІ»з–—пјље“€еЊ»е¤§дєЊй™ўз»ЏйЄЊ дєЋжіў 10:34 AM - е…€е¤©жЂ§еїѓи„Џз—…еђ€е№¶й‡Ќеє¦и‚єеЉЁи„‰ й«�еЋ‹зљ„д»‹е…ҐжІ»з–—пјљдёЉжµ·е„їз«ҐеЊ»е¦дёеїѓз»ЏйЄЊ жќЋеҐ‹ 8:52 AM - и®Ёи®є 10:44 AM - и®Ёи®є 7:24 AM - CS-0294пјљеє”жїЂжЂ§еїѓи‚Њз—…дёЂдѕ‹ е€�е…€е®ќ 8:56 AM - е…€е¤©жЂ§еїѓи„Џз—…еђ€е№¶й‡Ќеє¦и‚єеЉЁи„‰ й«�еЋ‹зљ„д»‹е…ҐжІ»з–—пјље®‰еѕЅеЊ»з§‘е¤§е¦й™„дёЂй™ў з»ЏйЄЊ еѕђеІ© 10:48 AM - е…€е¤©жЂ§еїѓи„Џз—…еђ€е№¶й‡Ќеє¦и‚єеЉЁи„‰ й«�еЋ‹зљ„д»‹е…ҐжІ»з–—пјљеЊ—дє¬е®‰иґћеЊ»й™ўз»ЏйЄЊ й‡‘жў… 7:34 AM - и®Ёи®є 9:06 AM- и®Ёи®є 7:36 AM - CS-0310пјље† зЉ¶еЉЁи„‰з—‰жЊ›дёЂдѕ‹ й©¬иЊ‚е„’ 9:10 AM - е…€е¤©жЂ§еїѓи„Џз—…еђ€е№¶й‡Ќеє¦и‚єеЉЁи„‰ й«�еЋ‹зљ„д»‹е…ҐжІ»з–—пјљз¬¬дё‰е†›еЊ»е¤§е¦ж–°жЎҐеЊ» й™ўз»ЏйЄЊ и¦ѓе†› з—…дѕ‹ж—©й¤ђдјљпј€еЌЃдє”пј‰ з‰№ж®Љз—…дѕ‹ 7:00 AM-8:00 AM 7:10 AM - и®Ёи®є 7:12 AM - CS-0255пјље‰Ќй™Ќж”Їе¤№е±‚з—…дѕ‹ иѓЎеҐ‰зЋЇ 7:22 AM - и®Ёи®є 7:46 AM - и®Ёи®є 7:48 AM - CS-0320пјљдёЂдѕ‹иї‡й‡Џеђёзѓџйќ’е№ґеҐі жЂ§зљ„е† и„‰иЎЂз®Ўз—…еЏ� е€�жµ·дјџ 7:58 AM - и®Ёи®є 9:20 AM - и®Ёи®є 9:24 AM - е…€е¤©жЂ§еїѓи„Џз—…еђ€е№¶й‡Ќеє¦и‚єеЉЁи„‰ й«�еЋ‹зљ„д»‹е…ҐжІ»з–—пјљжІ€й�іе†›еЊєжЂ»еЊ»й™ўз»ЏйЄЊ жњ±йІњй�і 9:34 AM - и®Ёи®є 9:38 AM - е…€е¤©жЂ§еїѓи„Џз—…еђ€е№¶й‡Ќеє¦и‚єеЉЁи„‰ й«�еЋ‹зљ„д»‹е…ҐжІ»з–—пјљйќ’жµ·еїѓиЎЂз®Ўз—…дё“з§‘еЊ» й™ўз»ЏйЄЊ зЋ‹й»Ћж�Ћ 155 10:58 AM - и®Ёи®є 11:02 AM - е…€е¤©жЂ§еїѓи„Џз—…еђ€е№¶й‡Ќеє¦и‚єеЉЁи„‰ й«�еЋ‹зљ„д»‹е…ҐжІ»з–—пјље±±дёњйЅђйІЃеЊ»й™ўз»ЏйЄЊ жќЋиґµеЏЊ 11:12 AM - и®Ёи®є 11:16 AM - е…€е¤©жЂ§еїѓи„Џз—…еђ€е№¶й‡Ќеє¦и‚єеЉЁи„‰ й«�еЋ‹зљ„д»‹е…ҐжІ»з–—пјљй‡Ќеє†е„їз«ҐеЊ»й™ўз»ЏйЄЊ ж�“еІ‚е»є 11:26 AM - и®Ёи®є 11:30 AM - е…€е¤©жЂ§еїѓи„Џз—…еђ€е№¶й‡Ќеє¦и‚єеЉЁи„‰ й«�еЋ‹зљ„д»‹е…ҐжІ»з–—пјље±±дёњзњЃдєєж°‘еЊ»й™ўз»ЏйЄЊ зЋ‹зЋ‰жћ— 11:40 AM - и®Ёи®є CIT 2012 www.citmd.com 2012е№ґ3жњ€18ж—Ґ ж�џжњџж—Ґ 11:44 AM - е…€е¤©жЂ§еїѓи„Џз—…еђ€е№¶й‡Ќеє¦и‚єеЉЁи„‰ й«�еЋ‹зљ„д»‹е…ҐжІ»з–—пјљжІіеЊ—еЊ»з§‘е¤§е¦з¬¬дёЂеЊ» й™ўз»ЏйЄЊ зЋ‹йњ‡ 11:54 AM - и®Ёи®є 11:58 AM - е…€е¤©жЂ§еїѓи„Џз—…еђ€е№¶й‡Ќеє¦и‚єеЉЁи„‰ й«�еЋ‹зљ„д»‹е…ҐжІ»з–—пјљж±џиҐїзњЃдєєж°‘еЊ»й™ўз»ЏйЄЊ з››е›Ѕе¤Є 12:08 PM - и®Ёи®є 12:12 PM - е…€е¤©жЂ§еїѓи„Џз—…еђ€е№¶й‡Ќеє¦и‚єеЉЁи„‰ й«�еЋ‹зљ„д»‹е…ҐжІ»з–—пјљж№–еЌ—е¤§е¦ж№�й›…еЊ»й™ўз»ЏйЄЊ и’Іж™“зѕ¤ 12:22 PM - и®Ёи®є 12:26 PM - дј‘дјљ 7:48 AM - CS-0298пјље±‹жјЏеЃЏйЂўиїћй�ґй›ЁпјљдёЂ ењєи‰°и‹¦зљ„й’™еЊ–йЃйЃ‡ж€� еј ж…§е№і 10:15 AM - CS-0238пјљжЂҐжЂ§еїѓи‚Њжў—ж»еђ€е№¶ еїѓе®¤з”µйЈЋжљґ д»»е€©иѕ‰ 7:58 AM - и®Ёи®є 10:25 AM - и®Ёи®є 8:00 AM - дј‘дјљ з¬¬дєЊењєпјље№¶еЏ‘з—‡дёЋзЅ•и§Ѓз—…дѕ‹ еѕЃй›†з—…дѕ‹и®Ёи®єз¬¬дё‰йѓЁе€† 8:30 AM-12:30 PM з¬¬дёЂењєпјље№¶еЏ‘з—‡дёЋзЅ•и§Ѓз—…дѕ‹ дё»жЊЃдєєпјљжќЋдёєж°‘ з‚№иЇ„дё“е®¶пјљж€ґе†›, иѓЎеҐ‰зЋЇ, еЌўй•їжћ—, йЅђе›Ѕе…€, з§¦е‹¤, е°љж™“ж�Ћ 8:30 AM - CS-0025пјље¤Ќжќ‚PCIжњЇжЉ—ж “жІ»з–—дёЂдѕ‹ зЅ—дєљзЋ® 8:40 AM - и®Ёи®є 8:45 AM - CS-0029пјљж”Їжћ¶и„±иЅЅеµЊйЎїдєЋеЏіе† зЉ¶еЉЁи„‰еЏЈйѓЁдёЂдѕ‹еЏЉе¤„зђ† еєћж–‡и·ѓ дё‰е±‚311Aдјљи®®е®¤ 8:55 AM - и®Ёи®є з—…дѕ‹ж—©й¤ђдјљпј€еЌЃе…пј‰ зЅ•и§Ѓе¤Ќжќ‚з—…дѕ‹ 7:00 AM-8:00 AM 9:00 AM - CS-0059пјље† зЉ¶еЉЁи„‰з ґиЈ‚дёЂдѕ‹ иµµз‘ће№і дё»жЊЃдєєпјљй‡‘жѓ ж №, еј дїЉжќ°, иўЃе‹‡ 9:10 AM - и®Ёи®є 7:00 AM - CS-0019пјљдёЂе±‚иЎЂз®Ўдє”е±‚ж”Їжћ¶ жќЋжќѕеЌЋ 7:10 AM - и®Ёи®є 7:12 AM - CS-0049пјље…€жґ»жЈЂиї�ж�ЇPCIпјџдё¤йљѕ жЉ‰ж‹© жќЋдјџж�Ћ 7:22 AM - и®Ёи®є 7:24 AM - CS-0200пјљдёЂз«™ејЏжќ‚дє¤ж‰‹жњЇе¤„зђ† е¤Ќжќ‚е† и„‰з—…еЏ� иѓЎж–°е¤® 7:34 AM - и®Ёи®є 7:36 AM - CS-0253пјљдёЂж¬Ўе№¶дёЌе¤ЄйЎєе€©зљ„жЂҐ иЇЉPCI еђґй“® 7:46 AM - и®Ёи®є 9:15 AM - CS-0132пјљеїѓи‚ЊжЎҐж”Їжћ¶ж¤Ќе…ҐеђЋеЏ‘ з”џе† и„‰з�¤еЏЉж”Їжћ¶ж–иЈ‚ й™†жµ© 9:25 AM - и®Ёи®є 9:30 AM - CS-0162пјљеЊ»жєђжЂ§е·¦дё»е№Іе¤№е±‚ дёЂдѕ‹ жќЁж€ђж�Ћ 9:40 AM - и®Ёи®є 9:45 AM - CS-0202пјљPCIжњЇеђЋжЂҐжЂ§еїѓеЊ…еЎ«еЎћ дёЂдѕ‹ зЁ‹е®‡еЅ¤ 9:55 AM - и®Ёи®є 10:00 AM - CS-0237пјљж—‹зЈЁжІ»з–—LADж…ўжЂ§е®Њ е…Ёй—еЎћй’™еЊ–з—…еЏ�зЈЁе¤ґеµЊйЎїдёЂдѕ‹ зЋ‹ж–Њ дё»жЊЃдєєпјљй™€з»Ќи‰Ї з‚№иЇ„дё“е®¶пјљй»„и¶…иЃ”, ж›Ій№Џ, ж±ќзЈЉз”џ, еј жІ›, йѓ‘жќЁ, е‘Ёз«‹еђ› 10:30 AM - CS-0251пјљиЌЇз‰©ж¶‚е±‚зђѓе›ЉењЁж”Ї жћ¶е†…е†Ќз‹зЄ„дёзљ„еє”з”Ё е€�е…€е®ќ 10:40 AM - и®Ёи®є 10:45 AM - CS-0267пјљжЂҐжЂ§ж”Їжћ¶еђЋе†…и†њдё‹ иЎЂи‚їдёЂдѕ‹ зҐЃз‚њзЅЎ 10:55 AM - и®Ёи®є 11:00 AM - CS-0297пјљPCIжњЇдёжЊ‡еј•еЇјз®Ўи‡ґ дё»еЉЁи„‰з“Јиї”жµЃеј•иµ·е№їжі›еїѓи‚ЊзјєиЎЂдёЂдѕ‹ и‚–ж–№жЇ… 11:10 AM - и®Ёи®є 11:15 AM - CS-0205пјљAMIж‚ЈиЂ…иЌЇз‰©жґ—и„±ж”Ї жћ¶ж¤Ќе…ҐеђЋеЏЌе¤ЌдєљжЂҐжЂ§ж”Їжћ¶е†…иЎЂж “еЅўж€ђдёЂдѕ‹ е‘ЁзЋ‰жќ° 11:25 AM - и®Ёи®є 11:30 AM - CS-0315пјље† и„‰йЂ еЅ±жњЇдёе®¤йў¤ дёЂдѕ‹ зЋ‹ж•€еўћ 11:40 AM - и®Ёи®є 11:45 AM - CS-0327пјљеїѓи‚Њжў—ж»е®¤й—ґйљ”з©ї е”е°Ѓе µжњЇеЏЉPCIдёЂдѕ‹ й©¬йў–и‰і 11:55 AM - и®Ёи®є 12:00 PM - CS-0337пјљж€ђеЉџеЏ–е‡єж–иЈ‚дєЋйћ�з®Ў е†…зљ„жЊ‡еј•еЇјз®ЎдёЂдѕ‹ й™¶иґµе‘Ё 12:10 PM - и®Ёи®є 10:10 AM - и®Ёи®є 156 CIT 2012 www.citmd.com 2012е№ґ3жњ€18ж—Ґ ж�џжњџж—Ґ 12:15 PM - CS-0361пјљд»‹е…ҐжІ»з–—ж”Їжћ¶иїњж®µићє ж—‹е¤№е±‚дёЂдѕ‹з»ЏйЄЊдёЋж•™и® йЅђж™“е‹‡ еїѓеѕ‹е¤±еёёз¬¬дє”йѓЁе€† еїѓеѕ‹е¤±еёёиї›е±•дёЋз—…дѕ‹и®Ёи®є 8:00 AM-12:30 PM 12:25 PM - и®Ёи®є з¬¬дёЂењєпјљж–°иї›е±• 12:30 PM - дј‘дјљ дё»жЊЃдєєпјљжµ¦д»‹йєџ, жќЋе№їе№і, ж®·и·ѓиѕ‰, ж±ЄиЉі, й»„й№¤ 11:10 AM - и®Ёи®є 8:30 AM - и‡ґж»жЂ§еїѓеѕ‹е¤±еёёеЏ‘з”џж–°жњєе€¶ жµ¦д»‹йєџ 8:45 AM - и®Ёи®є дё‰е±‚311Bдјљи®®е®¤ з—…дѕ‹ж—©й¤ђдјљпј€еЌЃдёѓпј‰ зЅ•и§Ѓе¤Ќжќ‚з—…дѕ‹ 7:00 AM-8:00 AM дё»жЊЃдєєпјље€�е¦жіў, й©¬еє·еЌЋ, еј й«�ж�џ 7:00 AM - CS-0301пјље¤ље¤„и‡ЄеЏ‘жЂ§е† и„‰е¤№е±‚ еЇји‡ґзљ„жЂҐжЂ§еїѓи‚Њжў—ж»дёЂдѕ‹ жќЋеЌље®‡ 7:10 AM - и®Ёи®є 7:12 AM - CS-0306пјљд»¤дєєдёєйљѕзљ„е¤Ќжќ‚з—…еЏ� е€�е¦жіў 8:50 AM - еїѓж€їйў¤еЉЁеЏ‘з”џжњєе€¶ж–°иї›е±• зЋ‹зЋ‰е ‚ 9:05 AM - и®Ёи®є 9:10 AM - е†·е†»ж¶€ићЌжІ»з–—ж€їйў¤зљ„ж–°иї›е±• ж–№дё•еЌЋ 9:25 AM - и®Ёи®є 9:30 AM - зЈЃеЇји€ЄжЉЂжњЇдёЋз”µз”џзђ†д»‹е…ҐжІ»з–— иї›е±• жќЁе…µ 9:45 AM - и®Ёи®є 7:22 AM - и®Ёи®є 9:50 AM - еїѓе¤–и†њеЇјз®Ўж¶€ићЌжІ»з–—е®¤жЂ§еїѓеѕ‹ е¤±еёё й‚“еЌЋ 7:24 AM - CS-0313пјљдёҐй‡Ќй’™еЊ–ж€ђи§’з—…еЏ�и‡ґ еЇјдёќйЂљиї‡е›°йљѕз—…дѕ‹ иўЃй“ 10:05 AM - и®Ёи®є 7:34 AM - и®Ёи®є 7:36 AM - CS-0335пјље¤љж”ЇејҐжј«й«�еЌ±PCIдёЂдѕ‹ иґєе‹‡ 10:10 AM - еЇјз®Ўж¶€ићЌжІ»з–—ж€їжЂ§еїѓеЉЁиї‡йЂџзљ„ з ”з©¶иї›е±• дЅ•е»єжЎ‚ 10:25 AM - и®Ёи®є 7:46 AM - и®Ёи®є з¬¬дєЊењєпјљз—…дѕ‹и®Ёи®є 7:48 AM - CS-0367пјљдёҐй‡Ќй’™еЊ–з—…еЏ�зљ„е¤„зђ† иµµжќ° 7:58 AM - и®Ёи®є 8:00 AM - дј‘дјљ дё»жЊЃдєєпјљжќЋжЇ…е€љ, дЅ•е»єжЎ‚, еј еЌ«жіЅ, еґ”дїЉзЋ‰, жҐље»єж°‘ 10:30 AM - з—…дѕ‹1 еј еЉІжћ— 10:40 AM - и®Ёи®є 10:45 AM - з—…дѕ‹2 й»„й№¤ 10:55 AM - и®Ёи®є 157 11:00 AM - з—…дѕ‹3 жќЁе…µ 11:15 AM - з—…дѕ‹4 е€�еђЇж�Ћ 11:25 AM - и®Ёи®є 11:30 AM - з—…дѕ‹5 е¤Џдє‘йѕ™ 11:40 AM - и®Ёи®є 11:45 AM - з—…дѕ‹6 з‰›е›Ѕж ‹ 11:55 AM - и®Ёи®є 12:00 PM - з—…дѕ‹7 и’‹ж™Ёй�і 12:10 PM - и®Ёи®є 12:15 PM - з—…дѕ‹8 е”ђй—Ѕ 12:25 PM - и®Ёи®є 12:30 PM - дј‘дјљ CIT 2012 www.citmd.com CIT HANDS-ON CENTER е®ћд№ дёеїѓ 2012 CIT Crossroads Institute-in-a-box Hands-on Training Center Date Mar 15th, Thursday Time Items Faculty Room 09:30 ~ 11:10 Virtual Simulator - MVD Module training N/A 301A 13:00 ~ 14:40 Virtual Simulator - STEMI training N/A 301A 15:00 ~ 16:40 Virtual Simulator вЂ“ STEMI training N/A 301A 09:30 ~ 11:10 Hybrid Model вЂ“ Standardized PCI &Bifurcation LI Chong-jian 301B 13:00 ~ 14:40 Hybrid Model вЂ“ Bifurcation Stent training HONG Lang 301B 15:00 ~ 16:40 Hybrid Model вЂ“ Bifurcation Stent training CUI Jin-gang 301B Time Items Faculty Room 09:30 ~ 11:10 Virtual Simulator - MVD Module training N/A 301A 13:00 ~ 14:40 Virtual Simulator - Peripheral vascular intervention N/A 301A 15:00 ~ 16:40 Virtual Simulator вЂ“ Peripheral vascular intervention N/A 301A 09:30 ~ 11:10 Hybrid Model вЂ“ Standardized PCI &Bifurcation ZHAO Jing-lin 301B 13:00 ~ 14:40 Hybrid Model вЂ“ CTO Module training LI Hu 301B 15:00 ~ 16:40 Hybrid Model вЂ“ CTO Module training ZENG He-song 301B Time Items Faculty Room 09:30 ~ 11:10 Virtual Simulator - MVD Module training N/A 301A 13:00 ~ 14:40 Virtual Simulator CTO Module training N/A 301A 09:30 ~ 11:10 Hybrid Model вЂ“ Standardized PCI &Bifurcation YAO Dao-kuo 301B 13:00 ~ 14:40 Hybrid Model вЂ“ Trouble shooting training XIA Zhi-gang 301B Date Mar 16th , Friday Date Mar 17th пјЊSaturday If you have any problem, pls contact with Abbott Crossroads Program Coordinator Eric Xia at your convenient (cell phone:18017226222 , email: [email protected]пј‰ 158 CIT 2012 www.citmd.com CIT HANDS-ON CENTER е®ћд№ дёеїѓ 2012CITи·Ёи¶Љд№‹и·ЇвЂўй›…еџ№е¦жњЇдёеїѓ е®ћи·µи®з»ѓж“ЌдЅњзЏ ж—Ґжњџпјљ 3жњ€15ж—ҐпјЊж�џжњџе›› ж—¶й—ґ ж“ЌдЅњйЎ№з›® жЊ‡еЇјиЂЃеё€ ж€їй—ґ 09:30 ~ 11:10 и®Ўз®—жњєжЁЎж‹џе™Ёе®ћи·µж“ЌдЅњ вЂ“ е¤љж”Їз—…еЏ�ж“ЌдЅњи®з»ѓ ж— 301A 13:00 ~ 14:40 и®Ўз®—жњєжЁЎж‹џе™Ёе®ћи·µж“ЌдЅњ вЂ“ жЂҐиЇЉPCIж“ЌдЅњи®з»ѓ ж— 301A 15:00 ~ 16:40 и®Ўз®—жњєжЁЎж‹џе™Ёе®ћи·µж“ЌдЅњ вЂ“ жЂҐиЇЉPCIж“ЌдЅњи®з»ѓ ж— 301A 09:30 ~ 11:10 д»їзњџиЎЂз®Ўе®ћи·µж“ЌдЅњ вЂ“ и§„иЊѓеЊ–PCI&е€†еЏ‰з—…еЏ� жќЋеґ‡е‰‘ 301B 13:00 ~ 14:40 д»їзњџиЎЂз®Ўе®ћи·µж“ЌдЅњ вЂ“ е€†еЏ‰з—…еЏ�ж”Їжћ¶жњЇи®з»ѓ жґЄжµЄ 301B 15:00 ~ 16:40 д»їзњџиЎЂз®Ўе®ћи·µж“ЌдЅњ вЂ“ е€†еЏ‰з—…еЏ�ж”Їжћ¶жњЇи®з»ѓ еґ”й”¦е€љ 301B ж—¶й—ґ ж“ЌдЅњйЎ№з›® жЊ‡еЇјиЂЃеё€ ж€їй—ґ 09:30 ~ 11:10 и®Ўз®—жњєжЁЎж‹џе™Ёе®ћи·µж“ЌдЅњ вЂ“ е¤љж”Їз—…еЏ�ж“ЌдЅњи®з»ѓ ж— 301A 13:00 ~ 14:40 и®Ўз®—жњєжЁЎж‹џе™Ёе®ћи·µж“ЌдЅњ вЂ“ е¤–е‘ЁиЎЂз®Ўд»‹е…Ґи®з»ѓ ж— 301A 15:00 ~ 16:40 и®Ўз®—жњєжЁЎж‹џе™Ёе®ћи·µж“ЌдЅњ вЂ“ е¤–е‘ЁиЎЂз®Ўд»‹е…Ґи®з»ѓ ж— 301A 09:30 ~ 11:10 д»їзњџиЎЂз®Ўе®ћи·µж“ЌдЅњ вЂ“ и§„иЊѓеЊ–PCI&е€†еЏ‰з—…еЏ� иµµдє¬жћ— 301B 13:00 ~ 14:40 д»їзњџиЎЂз®Ўе®ћи·µж“ЌдЅњ вЂ“ ж…ўжЂ§й�»еЎћжЂ§з—…еЏ�ж“ЌдЅњи®з»ѓ жќЋи™Ћ 301B 15:00 ~ 16:40 д»їзњџиЎЂз®Ўе®ћи·µж“ЌдЅњ вЂ“ ж…ўжЂ§й�»еЎћжЂ§з—…еЏ�ж“ЌдЅњи®з»ѓ ж›ѕе’Њжќѕ 301B ж—¶й—ґ ж“ЌдЅњйЎ№з›® жЊ‡еЇјиЂЃеё€ ж€їй—ґ 09:30 ~ 11:10 и®Ўз®—жњєжЁЎж‹џе®ћи·µж“ЌдЅњ вЂ“ е¤љж”Їз—…еЏ�ж“ЌдЅњи®з»ѓ ж— 301A 13:00 ~ 14:40 и®Ўз®—жњєжЁЎж‹џе®ћи·µж“ЌдЅњ вЂ“ж…ўжЂ§й�»еЎћжЂ§з—…еЏ�ж“ЌдЅњ ж— 301A 09:30 ~ 11:10 д»їзњџиЎЂз®Ўе®ћи·µж“ЌдЅњ вЂ“ и§„иЊѓеЊ–PCI&е€†еЏ‰з—…еЏ� е§љйЃ“й�” 301B 13:00 ~ 14:40 д»їзњџиЎЂз®Ўе®ћи·µж“ЌдЅњ вЂ“ е№¶еЏ‘з—‡е¤„зђ†и®з»ѓ е¤Џеї—е€љ 301B ж—Ґжњџпјљ 3жњ€16ж—ҐпјЊж�џжњџдє” ж—Ґжњџпјљ 3жњ€17ж—ҐпјЊж�џжњџе… е¦‚жћњж‚Ёжњ‰д»»дЅ•й—®йў�пјЊиЇ·иЃ”зі»й›…еџ№е¦жњЇдёеїѓйЎ№з›®иґџиґЈдєєе¤Џеї—е€љпј€18017226222, [email protected]пј‰ 159 CIT 2012 www.citmd.com CIT HANDS-ON CENTER е®ћд№ дёеїѓ й‚ЂиЇ·е‡Ѕ е°Љж•¬зљ„еЊ»з”џпјљ ж‚ЁеҐЅ! йљЏзќЂеїѓе†…з§‘жЉЂжњЇзљ„дёЌж–ж·±е…ҐпјЊи¶ЉжќҐи¶Ље¤љзљ„й‡Ќз—‡йљѕйў�иў«ж€‘д»¬ж‰ЂеѕЃжњЌпјЊж€‘д»¬д№џи¶ЉжќҐи¶ЉйњЂи¦Ѓжё…ж™°ж·±е…Ґзљ„и§†з•ЊгЂ‚дёЌд»…д»…ж�Їе®�и…”еЅўжЂЃпјЊиЎЂз®Ўе†…и¶… еЈ°иї�иѓЅдёєж‚Ёж�ѕз¤єз®ЎеЈЃз»“жћ„пјЊдє†и§Јз®ЎеЈЃз—…еЏ�зљ„жЂ§иґЁпјЊе› ж¤иў«и®¤дёєж�ЇиЎЂз®ЎжЈЂжџҐзљ„ж–°вЂњй‡‘ж ‡е‡†вЂќгЂ‚ жњ¬ж¬Ўз”±жіўз§‘е…¬еЏёжЏђдѕ›зљ„иЎЂз®Ўе†…и¶…еЈ°еџєзЎЂеџ№и®е°†дёєж‚ЁжЏђдѕ›пјљ 1. IVUSи®Іи§ЈпјЊи®©ж‚ЁењЁжњЂзџж—¶й—ґе†…дє†и§ЈиЎЂз®Ўе†…и¶…еЈ°зљ„еЋџзђ†пјЊз§Ќз±»пјЊж“ЌдЅњи¦Ѓйў†пјЊйЂ‚еє”з—‡пјЊд»ҐеЏЉеџєжњ¬иЇ†е›ѕ 2. иµ„ж·±дё“е®¶е®ћжњєж“ЌдЅњдёєж‚Ёз”з–‘и§Јжѓ‘ ењєењ°пјљ е›Ѕе®¶дјљи®®дёеїѓпјЊ 302Aе®¤ еџ№и®её€пјљжіўз§‘е…¬еЏёIVUSиµ„ж·±дє§е“Ѓз»Џзђ† ж—¶й—ґпјљ 2012е№ґ3жњ€15ж—Ґ-3жњ€17ж—Ґ з¬¬дёЂењє 9:00-10:15 з¬¬дєЊењє 10:30-11:45 з¬¬дё‰ењє 14:15-15:30 з¬¬е››ењє 15:45-17:00 дёєдїќиЇЃжњ¬ж¬Ўеџ№и®жЇЏдЅЌе¦е‘�йѓЅиѓЅеѕ—е€°жњЂжњ‰ж•€зљ„жЊ‡еЇјпјЊжЇЏж‰№е¦й™ўй™ђе®љ10-15дєєпјЊиЇ·еђ„дЅЌеЊ»з”џењЁе·ҐдЅњдєєе‘�е¤„йў†еЏ–е…ҐењєеЌ·пјЊжЊ‰з…§з§©еєЏпјЊе‡еЌ·е…ҐењєгЂ‚ жЋЁиЌђе¦е‘�пјљ еЇ№IVUSж„џе…ґи¶ЈпјЊдЅ†дёЌеЌЃе€†дє†и§Јж€–жњ‰е€ќжҐдє†и§ЈдЅ†жњЄз†џз»ѓжЋЊжЏЎзљ„йќ’е№ґеЊ»её€гЂ‚ еёЊжњ›иї›иЎЊIVUSе®ћж“Ќе№¶дє†и§ЈжіЁж„Џдє‹йЎ№зљ„еЊ»её€гЂ‚ ж€‘д»¬иЇљжЊљзљ„жњџеѕ…ж‚Ёзљ„е€°жќҐпјЊе№¶еёЊжњ›еЇ№ж‚Ёжњ‰ж‰Ђеё®еЉ©пјЃ дё“дёљж€ђе°±жњЄжќҐ жіўз§‘дјґж‚Ёж€ђй•ї жіўеЈ«йЎїз§‘е¦е›Ѕй™…жњ‰й™ђе…¬еЏё 160 CIT 2012 www.citmd.com CIT HANDS-ON CENTER е®ћд№ дёеїѓ Invitations Dear Doctor: With the deepening development of the Department of Cardiology, more and more severe problems that we conquer, we also increasingly need to clear and in-depth vision. Not just bureaucratic form, IVUS can show you the wall structure, the nature of the understanding of wall lesions, so that new blood vessels to check the "gold standard". The intravascular ultrasound basic training provided by Boston Scientific Corporation will provide you with: 1. The IVUS explain, so that you understand the principle of intravascular ultrasound in the shortest time, type, operating essentials, indications, and basic knowledge map 2. 2 senior expert hands-on to answer your questions Venue: National Convention Center, Room 302A, Trainer: Boston Scientific Company, IVUS, Senior Product Manager Time: March 15, 2012 - March 17, 2012 The first field 9:00-10:15 The second field 10:30-11:45 The third field 14:15-15:30 The fourth field 15:45-17:00 In order to ensure each participant can be the most effective guidance in the training, each batch of the Institute is limited to 10-15 people, please ask for admission tickets from the staff, in accordance with the order, with the involvement of field. Recommended participants: Young doctors who interested in IVUS, but do not fully understand or have a preliminary understanding but did not masterIVUS. Physicians who want to actual operate IVUS and learn the note of IVUS operation. We sincerely look forward to your arrival, and I hope we can help! Professional accomplishments the future The Boston Scientific with your growing Boston Scientific International Co., Ltd. 161 CIT 2012 www.citmd.com CIT HANDS-ON CENTER е®ћд№ дёеїѓ й‚ЂиЇ·е‡Ѕ е°Љж•¬зљ„еЊ»з”џпјљ ж‚ЁеҐЅ! йљЏзќЂеЊ»з–—жЉЂжњЇзљ„дёЌж–жЏђй«�пјЊе† зЉ¶еЉЁи„‰ж—‹зЈЁжњЇе·Із»Џи¶ЉжќҐи¶ЉеЏ—е€°еїѓе†…з§‘еЊ»з”џзљ„й‡Ќи§†пјЊењЁдёЂдє›з‰№ж®Љз—…еЏ�е¦‚дёҐй‡Ќй’™еЊ–з—…еЏ�пјЊж—‹зЈЁжЉЂжњЇе‡ д№Ћж�Їз»Џ зљ®е† зЉ¶еЉЁи„‰д»‹е…Ґж‰‹жњЇпј€PCIпј‰йЎєе€©е®Њж€ђдёЌеЏЇзјєе°‘зљ„дёЂй—ЁжЉЂжњЇгЂ‚ жњ¬ж¬Ўз”±жіўз§‘е…¬еЏёжЏђдѕ›зљ„ж—‹зЈЁе®ћж“Ќеџ№и®е°†дёєж‚ЁжЏђдѕ›пјљ 1. йЂљиї‡дё“дёљзљ„й’™еЊ–з—…еЏ�жЁЎж‹џе™ЁпјЊз”Ёж—‹зЈЁд»Єе®ћй™…дёЉж‰‹ж“ЌдЅњпјЊи®©ж‚ЁењЁжЈејЏж‰‹жњЇе‰Ќзњџе€‡й›¶и·ќз¦»дє†и§Јж—‹зЈЁе№¶дЅ“йЄЊж—‹зЈЁзљ„й…еЉ›гЂ‚ 2. зѕЋе›Ѕиµ„ж·±дё“е®¶зЋ°ењєи®Іи§ЈпјЊдёєж‚Ёж—‹зЈЁиї›й�¶з”з–‘и§Јжѓ‘гЂ‚ ењєењ°пјљ е›Ѕе®¶дјљи®®дёеїѓпјЊ 302Aе®¤ еџ№и®её€пјљ Paul BeckerпјЊ жіўеЈ«йЎїз§‘е¦ е›Ѕй™…еџ№и®з»Џзђ† ж—¶й—ґпјљ 2012е№ґ3жњ€15ж—Ґ-3жњ€17ж—Ґ з¬¬дёЂењє 9:00-10:15 з¬¬дєЊењє 10:30-11:45 з¬¬дё‰ењє 14:15-15:30 з¬¬е››ењє 15:45-17:00 дёєдїќиЇЃжњ¬ж¬Ўеџ№и®жЇЏдЅЌе¦е‘�йѓЅиѓЅеѕ—е€°жњЂжњ‰ж•€зљ„жЊ‡еЇјпјЊжЇЏж‰№е¦й™ўй™ђе®љ10-15дєєпјЊиЇ·еђ„дЅЌеЊ»з”џењЁе·ҐдЅњдєєе‘�е¤„йў†еЏ–е…ҐењєеЌ·пјЊжЊ‰з…§з§©еєЏпјЊе‡еЌ·е…ҐењєгЂ‚ жЋЁиЌђе¦е‘�пјљ еЇ№ж—‹зЈЁж„џе…ґи¶ЈпјЊжњ‰е€ќжҐдє†и§ЈдЅ†жњЄж“ЌдЅњз†џз»ѓзљ„йќ’е№ґеЊ»её€гЂ‚ еЇ№ж—‹зЈЁжЉЂжњЇжњ‰дёЂе®љдє†и§ЈпјЊеёЊжњ›иѓЅиї›й�¶е¦д№ е’Њдё“е®¶жЋўи®Ёзљ„еЊ»её€пј€и¦Ѓж±‚жњ‰дёЂе®љи‹±ж–‡ж°ґе№іпј‰гЂ‚ ж€‘д»¬иЇљжЊљзљ„жњџеѕ…ж‚Ёзљ„е€°жќҐпјЊе№¶еёЊжњ›еЇ№ж‚Ёжњ‰ж‰Ђеё®еЉ©пјЃ дё“дёљж€ђе°±жњЄжќҐ жіўз§‘дјґж‚Ёж€ђй•ї жіўеЈ«йЎїз§‘е¦е›Ѕй™…жњ‰й™ђе…¬еЏё 162 CIT 2012 www.citmd.com CIT HANDS-ON CENTER е®ћд№ дёеїѓ Invitations Dear Doctor: As medical technology continues to improve, Rota has been more and more important to heart physician's attention, in some special lesions such as severe calcification, rotational technique is almost surgery after percutaneous coronary intervention (PCI) successfully completed can not be lack of a technology. The Rotablator practical operation of the training provided by Boston Scientific company will provide you with: 1. Through professional calcification Simulator, the rotational instrument actually handed operation, allowing you to truly in a formal preoperative distance, rotational and experience the charm of the rotational 2. A senior U.S. expert on-site to explain the rotational Advanced FAQ. Venue: National Convention Center, Room 302A, Trainer: Paul Becker, Boston Scientific International Training Manager Time: March 15, 2012 - March 17, 2012 The first field 9:00-10:15 The second field 10:30-11:45 The third field 14:15-15:30 The fourth field 15:45-17:00 In order to ensure the training each participant can be the most effective guidance, each batch of the Institute is limited to 10-15 people, please ask for admission tickets from the staff, in accordance with the order, with the involvement of field. Recommended participants: Young physician who interesting in Rota but not operate skilled on it. Physicians who hope to advanced learning and experts to explore with Rota (which requires a certain standard of English). We sincerely look forward to your arrival, and I hope we can help! Professional achievement the future The Boston Scientific with your growing Boston Scientific International Co., Ltd. 163 CIT 2012 www.citmd.com CIT HANDS-ON CENTER е®ћд№ дёеїѓ е°Љж•¬зљ„еЊ»з”џпјљ вЂњж™®еЏЉеїѓиЎЂз®Ўд»‹е…ҐжЉЂжњЇе’ЊжЋЁе№їд»‹е…Ґж–°жЉЂжњЇвЂќж�ЇзѕЋж•¦еЉ›е¤§е¦Innovation CathLabиЇѕзЁ‹зљ„е®—ж—ЁгЂ‚дЅњдёєеїѓиЎЂз®Ўйў†еџџзљ„е€›ж–°еј•йў†иЂ…пјЊж€‘д»¬е°†иЃ�иЇ· дё“дёљзљ„жЁЎж‹џе™ЁеЇјеё€пјЊй’€еЇ№дёЌеђЊз±»ећ‹зљ„з—…дѕ‹пјЊиї›иЎЊж‰‹жњЇз–з•Ґе’Ње™Ёжў°йЂ‰ж‹©ж–№йќўзљ„жЊ‡еЇјгЂ‚е№¶дё”йЂљиї‡е€›ж–°зљ„дє§е“ЃжЁЎећ‹е±•з¤єпјЊи®©ж‚Ёж›ґз›ґи§‚зљ„дЅ“йЄЊеїѓ иЎЂз®Ўд»‹е…ҐжІ»з–—зљ„е‰ЌжІїз§‘жЉЂгЂ‚ жЁЎж‹џе™Ёж—ҐзЁ‹пјљ 3жњ€15ж—Ґ 3жњ€16ж—Ґ 3жњ€17ж—Ґ 14:00-16:00 з®ЂеЌ•з—…еЏ�зљ„е¤„зђ†з–з•ҐеЏЉжЉЂе·§ 09:30-11:30 е·¦дё»е№Із—…еЏ�зљ„е¤„зђ†з–з•ҐеЏЉжЉЂе·§ 14:00-16:00 CTOз—…еЏ�зљ„е¤„зђ†з–з•ҐеЏЉжЉЂе·§ 09:30-11:30 ејҐжј«жЂ§й’™еЊ–з—…еЏ�зљ„е¤„зђ†з–з•ҐеЏЉжЉЂе·§ 14:00-16:00 е¤љж”Їз—…еЏ�зљ„е¤„зђ†з–з•ҐеЏЉжЉЂе·§ ењ°з‚№пјљ еЊ—дє¬е›Ѕе®¶дјљи®®дёеїѓ302B 164 CIT 2012 www.citmd.com CIT HANDS-ON CENTER е®ћд№ дёеїѓ CIT 2012 Learning Center -- TRI Training Course CIT 2012 е®ћд№ дёеїѓвЂ”TRI жЁЎж‹џе™Ёжј”з¤єдјљењє Date: ж—Ґжњџ: Venue: ењ°з‚№: March 15-17, 2012 2012е№ґ3жњ€15ж—Ґи‡і17ж—Ґ Room 303A, 3rd Floor, China National Convention Center, Beijing еЊ—дє¬ CNCCе›Ѕе®¶дјљи®®дёеїѓдё‰е±‚303A жі°е°”иЊ‚TRIжЁЎж‹џе™ЁпјЊж�Їз›®е‰Ќдё–з•ЊдёЉе”ЇдёЂзљ„з»ЏжЎЎеЉЁи„‰еїѓи„Џд»‹е…ҐжЁЎж‹џ е™ЁпјЊеЏЇд»Ґе…ЁзЁ‹жЁЎж‹џTRIж‰‹жњЇиї‡зЁ‹пјЊжњ‰дёЌеђЊе¤Ќжќ‚зЁ‹еє¦зљ„20дЅ™дёЄз—…дѕ‹еЏЇ йЂ‰пјЊеЊ…ж‹¬RCAпјЊLADпјЊLCXз—…еЏ�пјЊж›ґжњ‰жЎЎеЉЁи„‰з•ёеЅўзљ„зњџе®ћжЁЎж‹џз—…дѕ‹гЂ‚ ж€‘д»¬е°†й‚ЂиЇ·и‘—еђЌTRIдё“е®¶пјЊдёєж‚ЁзЋ°ењєд»‹з»Ќе’ЊжЊ‡еЇјжЁЎж‹џе™Ёж“ЌдЅњпјЊдёЋж‚Ё йќўеЇ№йќўдє¤жµЃTRIз»ЏйЄЊгЂ‚ жі°е°”иЊ‚TRIжЁЎж‹џе™ЁеЏЇд»Ґеё®еЉ©ж‚Ёж›ґеї«зљ„з†џж‚‰жЎЎеЉЁи„‰е…Ґи·Їзљ„з‰№з‚№пјЊе°ќиЇ• еђ„з§Ќдё“дёєз»ЏжЎЎеЉЁи„‰д»‹е…Ґи®ѕи®Ўзљ„е™Ёжў°пјЊжњ‰ж•€зј©зџж‚Ёзљ„е¦д№ ж›ІзєїпјЊдёєж‚Ё ж—©ж—Ґж€ђдёєе‡єи‰Ізљ„TRIдё“е®¶еЉ©дёЂи‡‚д№‹еЉ›пјЃ March 15 3жњ€15ж—Ґ March 17жі°е°”иЊ‚пјЊе‡еЂџз‹¬з‰№е…€иї›жЉЂжњЇпјЊе®ћзЋ°дєєжЂ§еЊ–жё©й¦ЁеЊ»з–—гЂ‚ 3жњ€17ж—Ґ 10:00-10:30 Introduction of Terumo TRI Simulator жі°е°”иЊ‚жЎЎеЉЁи„‰жЁЎж‹џе™Ёи®ѕи®Ўзђ†еїµд»‹з»Ќ 9:00-10:00 Demonstration of Complex Lesion Treatment by TRI with Instruction з»ЏжЎЎеЉЁи„‰е¤„зђ†е¤Ќжќ‚з—…еЏ�з—…дѕ‹жј”з¤єеЏЉжЊ‡еЇј 10:30-11:00 Demonstration of Simple Lesion Treatment by TRI with Instruction з®ЂеЌ•з—…еЏ�TRIж‰‹жњЇжЁЎж‹џжј”з¤єеЏЉжЊ‡еЇј 10:00-12:00 Hands-on: Complex Lesion Treatment by TRI еЉЁж‰‹еЃљвЂ”вЂ”з»ЏжЎЎеЉЁи„‰е¤„зђ†е¤Ќжќ‚з—…еЏ�жЁЎж‹џз—…дѕ‹ 11:00-12:00 Hands-on: Simple Lesion Treatment by TRI еЉЁж‰‹еЃљвЂ”вЂ”з»ЏжЎЎеЉЁи„‰е¤„зђ†з®ЂеЌ•з—…еЏ�жЁЎж‹џз—…дѕ‹ 14:00-15:00 Demonstration of Complex Lesion Treatment by TRI with Instruction з»ЏжЎЎеЉЁи„‰е¤„зђ†е¤Ќжќ‚з—…еЏ�з—…дѕ‹жј”з¤єеЏЉжЊ‡еЇј 14:00-14:30 Demonstration of Simple Lesion Treatment by TRI with Instruction з®ЂеЌ•з—…еЏ�TRIж‰‹жњЇжЁЎж‹џжј”з¤єеЏЉжЊ‡еЇј 15:00-16:30 Hands-on: Complex Lesion Treatment by TRI еЉЁж‰‹еЃљвЂ”вЂ”з»ЏжЎЎеЉЁи„‰е¤„зђ†е¤Ќжќ‚з—…еЏ�жЁЎж‹џз—…дѕ‹ 14:30-16:30 Hands-on: Simple Lesion Treatment by TRI еЉЁж‰‹еЃљвЂ”вЂ”з»ЏжЎЎеЉЁи„‰е¤„зђ†з®ЂеЌ•з—…еЏ�жЁЎж‹џз—…дѕ‹ March 16 3жњ€16ж—Ґ иЎ·еїѓж¬ўиїЋж‚ЁиЋ…дёґеЏ‚и§‚дёЋжЊ‡еЇјпјЃ 9:00-10:00 Demonstration of Complex Lesion Treatment by TRI with Expert Instruction з»ЏжЎЎеЉЁи„‰е¤„зђ†е¤Ќжќ‚з—…еЏ�з—…дѕ‹жј”з¤єеЏЉдё“е®¶жЊ‡еЇј 10:00-12:00 Hands-on: Complex Lesion Treatment by TRI еЉЁж‰‹еЃљвЂ”вЂ”з»ЏжЎЎеЉЁи„‰е¤„зђ†е¤Ќжќ‚з—…еЏ�жЁЎж‹џз—…дѕ‹ 14:00-14:30 Demonstration of CTO Lesion Treatment by TRI with Expert Introduction з»ЏжЎЎеЉЁи„‰е¤„зђ†CTOз—…еЏ�з—…дѕ‹жј”з¤єеЏЉдё“е®¶жЊ‡еЇј By Prof. Masahiko Ochiai иђЅеђ€й›…еЅ¦ 14:30-16:30 Hands-on: Complex Lesion Treatment by TRI еЉЁж‰‹еЃљвЂ”вЂ”з»ЏжЎЎеЉЁи„‰е¤„зђ†е¤Ќжќ‚з—…еЏ�жЁЎж‹џз—…дѕ‹ 165 ењЁжі°е°”иЊ‚TRIе®ћд№ дёеїѓпјЊж€‘д»¬иї�е‡†е¤‡дє†TRIдёґеєЉзџҐиЇ†е…‰з›�з‰иµ е“ЃпјЊеёЊ жњ›еЇ№ж‚Ёзљ„е·ҐдЅњжњ‰ж‰Ђеё®еЉ©гЂ‚ жі°е°”иЊ‚еЊ»з–—дє§е“Ѓпј€дёЉжµ·пј‰жњ‰й™ђе…¬еЏё 2012е№ґ3жњ€ CIT 2012 www.citmd.com EXHIBIT FLOOR PLAN B001 B005 TLD09 24 CMT C F( A )D 10 8 28 . S H TF (A ) D10 24 TF (A ) D15 24 Main Entrance CCRF TD1 524 TF (C )D 15 1 5 CRF/TCT B004 Speaker Ready Room Faculty Lounge TF (A ) D20 27 A010 Daiichi Sankyo Medtronic A013 A015/A030 Pп¬Ѓzer A108 A151 MicroPort Abbott Vascular 3449.4 5000 EEC Boston Scientiп¬Ѓc A198 A233 PTS Sanoп¬Ѓ -Aventis Lake Region Medical A229 A226 St. Jude A244 PTS A268 A290 Huaren A291 A277 J&J Medical A283 TCTAP Lifetech A284 CCT A285 International Circulation 365 A324 A316 A317 A318 Salubris еЌЋиѕ°еє·еЃҐ OCC2012 Cyber Station Ziehm Medical Poster Exhibit Area TD0 824 TF (A ) P D24 27 TF (A ) P D24 27 TF (A ) P D20 27 TF (A ) P D20 27 TF (A ) P D20 27 TF (A ) P D20 27 TF (A ) P D20 27 TF (A ) P D18 27 TLD09 24 TF (C )D 07 1 5 TF (C )D 15 1 5 TLD09 24 TG F ( B )D 15 2 4 Stereotaxis Merit A270 TF (A ) D10 24 Tyco A275-A276 A269 EuroPCR CHC2012 GW-ICC TF (A ) D10 24 TG F ( A) D1 82 4 A273 A286 A240 TF (A ) P D20 27 TF (A ) P D20 27 A271 A225 йѕ™и„‰ Allian A264 Kelida A223 TF (A ) D12 27 A197 Demax ж°ёйЂљиЃ”еђ€ Agfa TF (A ) P D20 27 A196 Kinhely JW Medical TF (A ) D12 27 Essen A180-A181 A178 A174 TD1 21 0 0 A170 A166 Promed OrbusNeich TF (A ) P D20 27 TF (A ) P D20 27 TF (A ) P D20 27 Main Entrance B003 A165 4449.2 Great Dragon Star Progress A163-A164 Beilu Pharmaceutical A153-A154 BraccoSine B002 Kindly A118 TF (C )D 15 1 5 TF (C )D 07 1 5 Sino Medical pie Medical Imaging A158 Terumo Siemens A104 A103 A099 A106 Philips TF (A ) D12 27 Lepu Medical A058 TD1 21 0 0 Bayer /B.Braun /Medrad Medfavour TF (A ) P D20 27 TF (A ) P D20 27 A050 TF (A ) D12 27 A047 TG F ( B )D 15 2 4 TF (A ) P D20 27 A039 TG F ( A) D1 82 4 A009 A005 Liaoning Biomedical 21000 TF (C )D 12 2 3 TF (C )D 12 2 3 TF (C )D 12 2 3 TF (C )D 06 2 3 TF (C )D 12 2 3 A002 5000 TF (A ) P D20 27 TF (A ) P D20 27 TF (A ) P D20 27 TF (A ) D20 27 Shimadzu 3000 TF (A ) D20 27 Haemonetics 4000 eleva t or TF (A ) D20 27 TF (A ) D20 27 24000 TG F ( B )D 15 2 4 TLD09 24 TLD09 24 TG F ( A) D1 82 4 166 CIT 2012 www.citmd.com EXHIBITORS еЏ‚е±•еЌ•дЅЌ Company Name е…¬еЏёеђЌз§° Booth Number е±•дЅЌеЏ· Company Name е…¬еЏёеђЌз§° Booth Number е±•дЅЌеЏ· Liaoning Biomedical Materials R&D Center Co., Ltd. иѕЅе®Ѓз”џз‰©еЊ»е¦жќђж–™з ”еЏ‘дёеїѓжњ‰й™ђе…¬еЏё A002 Star Progress Medical Co.,Ltd. дёЉжµ·ж�џеі°е·Ґиґёжњ‰й™ђе…¬еЏё A118 Medtronic (Shanghai) Management Co., Ltd. зѕЋж•¦еЉ›(дёЉжµ·)з®Ўзђ†жњ‰й™ђе…¬еЏё A005 Sino Medical Sciences Technology Inc. иµ›иЇєеЊ»з–—з§‘е¦жЉЂжњЇжњ‰й™ђе…¬еЏё A151 Daiichi Sankyo (China) Holdings Co., Ltd. з¬¬дёЂдё‰е…±е€¶иЌЇ(дёЉжµ·)жњ‰й™ђе…¬еЏё A009 Shanghai Bracco Sine Pharmaceutical Corp. Ltd. дёЉжµ·еЌљиЋ±з§‘дїЎи°ЉиЌЇдёљжњ‰й™ђиґЈд»»е…¬еЏё Haemonetics Corporation зѕЋе›ЅиЎЂж¶ІжЉЂжњЇ(дёе›Ѕ)е…¬еЏё A010 еѕ®е€›еЊ»з–—е™Ёжў°(дёЉжµ·)жњ‰й™ђе…¬еЏё иѕ‰з‘ће€¶иЌЇжњ‰й™ђе…¬еЏё A013 Beijing Beilu Pharmaceutical Co., Ltd. еЊ—дє¬еЊ—й™†иЌЇдёљи‚Ўд»Ѕжњ‰й™ђе…¬еЏё Shimadzu (China) Co., Ltd. еІ›жґҐдјЃдёљз®Ўзђ†(дёе›Ѕ)жњ‰й™ђе…¬еЏё A015/ A030 A153-A154 A158 A163-A164 Eastern Enterprise Corporation еЊ—дє¬жЃ’ж¶¦жі°еЊ»иЌЇз§‘жЉЂжњ‰й™ђе…¬еЏё A165 Medfavour(Beijing)Medical Co.,Ltd дё‡з‘ћйЈћйёї(еЊ—дє¬)еЊ»з–—е™Ёжќђжњ‰й™ђе…¬еЏё A039 Essen Technology(Beijing) Co., Ltd. ж�“з”џз§‘жЉЂ(еЊ—дє¬)жњ‰й™ђе…¬еЏё A166 ж‹њиЂіеЊ»иЌЇдїќеЃҐжњ‰й™ђе…¬еЏё A047 JW Medical Systems Ltd. еђ‰еЁЃеЊ»з–—е€¶е“Ѓжњ‰й™ђе…¬еЏё A170 B.Braun Medical (Shanghai) International Trading Co., Ltd иґќжњ—еЊ»з–—(дёЉжµ·)е›Ѕй™…иґёж�“жњ‰й™ђе…¬еЏё A047 BSC Int'l Medical Trading(Shanghai) Co., Ltd. жіўз§‘е›Ѕй™…еЊ»з–—иґёж�“(дёЉжµ·)жњ‰й™ђе…¬еЏё A174 MEDRAD Medical Equipment Trading Company, Beijing зѕЋеѕ·з‘ћиѕѕеЊ»з–—е™Ёжў°иґёж�“(еЊ—дє¬)жњ‰й™ђе…¬еЏё A047 Kinhely Bio-tech co.,Ltd ж·±ењіеё‚й‡‘з‘ће‡Їе€©з”џз‰©з§‘жЉЂжњ‰й™ђе…¬еЏё A178 Lepu Medical Technology (Beijing) Co., Ltd д№ђж™®(еЊ—дє¬)еЊ»з–—е™Ёжў°и‚Ўд»Ѕжњ‰й™ђе…¬еЏё A050 Promed Medical Tech. (Suzhou) Co., Ltd. е¤©еЃҐеЊ»з–—з§‘жЉЂ(и‹Џе·ћ)жњ‰й™ђе…¬еЏё Philips Healthcare йЈће€©жµ¦еЊ»з–—дїќеЃҐ A058 Beijing Demax Medical Technology Co., Ltd. еЊ—дє¬иїЄзЋ›е…‹еЊ»иЌЇз§‘жЉЂжњ‰й™ђе…¬еЏё A196 Abbott Medical Devices Trading (Shanghai) Co., Ltd й›…еџ№еЊ»з–—е™Ёжў°иґёж�“(дёЉжµ·)жњ‰й™ђе…¬еЏё A099 Bejin Yongton Unted Technology Co., Ltd. еЊ—дє¬ж°ёйЂљиЃ”еђ€з§‘жЉЂжњ‰й™ђе…¬еЏё A197 Pie Medical Imaging A103 Agfa HealthCare (Shanghai) Co., Ltd. з€±е…‹еЏ‘еЊ»з–—зі»з»џи®ѕе¤‡(дёЉжµ·)жњ‰й™ђе…¬еЏё A198 Shanghai Kindly Enterprise Development Group Medical Instruments Co., Ltd. дёЉжµ·еє·еѕ·иЋ±дјЃдёљеЏ‘е±•й›†е›ўеЊ»з–—е™Ёжў°жњ‰й™ђе…¬еЏё A104 Lake Region Medical й›·з§‘еЊ»з–— A223 Siemens Ltd. China Healthcare Sector иҐїй—Ёеђ(дёе›Ѕ)жњ‰й™ђе…¬еЏёеЊ»з–—зі»з»џй›†е›ў A106 D-Pulse Medical (Beijing) Co., Ltd. йѕ™и„‰еЊ»з–—е™Ёжў°(еЊ—дє¬)жњ‰й™ђе…¬еЏё A225 Terumo Medical (Shanghai) CO., LTD. жі°е°”иЊ‚еЊ»з–—дє§е“Ѓ(дёЉжµ·)жњ‰й™ђе…¬еЏё A108 Sanofi (Hangzhou) Pharmaceuticals Co., Ltd. иµ›иЇєиЏІ(жќе·ћ)е€¶иЌЇжњ‰й™ђе…¬еЏё A226 167 A180-A181 CIT 2012 www.citmd.com EXHIBITORS еЏ‚е±•еЌ•дЅЌ Company Name е…¬еЏёеђЌз§° Booth Number е±•дЅЌеЏ· PTS Co., Ltd. дёЉжµ·зђµжі°зЏЉеЊ»й™ўжЉ•иµ„з®Ўзђ†жњ‰й™ђе…¬еЏё Company Name е…¬еЏёеђЌз§° Booth Number е±•дЅЌеЏ· A229/ A240 Ziehm Medical Shanghai Co., Ltd. еҐ‡з›®еЊ»з–—е™Ёжў°иґёж�“(дёЉжµ·)жњ‰й™ђе…¬еЏё A324 ењЈзЉ№иѕѕеЊ»з–—з”Ёе“Ѓ(дёЉжµ·)жњ‰й™ђе…¬еЏё A233 Cardiovascular Research Foundation B001 Beijing Allian Medical Devices Co., Ltd. еЊ—дє¬ж¬§иЋ±иЃ”еђ€еЊ»з–—е™Ёжў°жњ‰й™ђе…¬еЏё A244 Beijing Great Dragon Scientific Instrument Trade Co., Ltd. еЊ—дє¬дјџйѕ™з§‘д»Єиґёж�“жњ‰й™ђе…¬еЏё B002 ејєз”џ(дёе›Ѕ)еЊ»з–—е™Ёжў°жњ‰й™ђе…¬еЏё A264 OrbusNeich ж·±ењідёљиЃље®ћдёљжњ‰й™ђе…¬еЏё B003 PCR A268 CCRF ж°ёй“иЇљйЃ“(еЊ—дє¬)е’ЁиЇўжњ‰й™ђе…¬еЏё B004 CHC2012 дёе›Ѕеїѓи„Џз—…е¤§дјљ A269 GE Healthcare Group йЂљз”Ёз”µж°”еЊ»з–—й›†е›ў й•їеџЋе›Ѕй™…еїѓи„Џз—…е¦дјљи®® A270 Beijing Kelida Medical Equipment Developing Co., Ltd. еЊ—дє¬з§‘е€©иѕѕеЊ»з–—и®ѕе¤‡еЏ‘е±•жњ‰й™ђе…¬еЏё A271 Covidien жі°з§‘еЊ»з–—е™Ёжќђе›Ѕй™…иґёж�“(дёЉжµ·)жњ‰й™ђе…¬еЏё A273 Merit Medical Beijing Co., Ltd. йє¦з‘ћйЂљеЊ»з–—е™Ёжў°(еЊ—дє¬)жњ‰й™ђе…¬еЏё дё‰е±‚и§‚ж™Ї е¤§еЋ… A275-A276 Lifetech Scientific (Shenzhen) Co., Ltd. е…€еЃҐз§‘жЉЂ(ж·±ењі)жњ‰й™ђе…¬еЏё A277 ANGIOPLASTY SUMMIT-TCTAP A283 Complex Cardiovascular Therapeutics (CCT) A284 Stereotaxis зѕЋе›ЅжЂќз‘ћжі°еїѓе›Ѕй™…е…¬еЏё A286 Beijing Huaren Health Science&Technology Developing Co.,Ltd. еЊ—дє¬её‚еЌЋд»Ѓз›Љеє·з§‘жЉЂеЏ‘е±•жњ‰й™ђе…¬еЏё A290 Shenzhen Salubris ж·±ењідїЎз«‹жі°иЌЇдёљи‚Ўд»Ѕжњ‰й™ђе…¬еЏё A316 Beijing Huachenkangjian Health Company Ltd. еЊ—дє¬еЌЋиѕ°еє·еЃҐз§‘жЉЂеЏ‘е±•жњ‰й™ђе…¬еЏё A317 168 CIT 2012 www.citmd.com EXHIBITORS' DIRECTORY Liaoning Biomedical Materials R&D Center Co., Ltd. иѕЅе®Ѓз”џз‰©еЊ»е¦жќђж–™з ”еЏ‘дёеїѓжњ‰й™ђе…¬еЏё Medtronic (Shanghai) Management Co., Ltd. зѕЋж•¦еЉ›(дёЉжµ·)з®Ўзђ†жњ‰й™ђе…¬еЏё Booth Number / е±•дЅЌеЏ·: A002 Booth Number / е±•дЅЌеЏ·: A005 Address: No.8-11, Hanzheng Road, Guangming Street, Jinzhou District, Dalian ењ°еќЂпјљ е¤§иїћеё‚й‡‘е·ћеЊєе…‰ж�ЋиЎ—йЃ“ж±‰жЈи·Ї8-11еЏ· 0411-8713 9238 Tel: 0411-8713 9322 Fax: Email: [email protected] Address: Block 11, No.3000 Long Dong Avenue, Pudong, Shanghai 201203, P.R.China ењ°еќЂпјљ дёЉжµ·её‚жµ¦дёњйѕ™дёње¤§йЃ“3000еЏ·11еЏ·жҐј 021-2032 5330 Tel: 021-5080 1357 Fax: Email: [email protected] Liaoning Biomedical Materials R&D Center Co., Ltd (LBC) was founded in October 2004. Today LBC is the coronary stent industrialization demonstration base of China. LBC has about 170 employees and owns a professional expert team. LBC have developed the first Polymer-free Microporous Drug Eluting Stent in the world. The product owns the first authorized invention patent in China DES field, which fills the domestic gap. It is the first polymer-free DES on China market and the first Paclitaxel-eluting stent made in China. зѕЋе›ЅзѕЋж•¦еЉ›е…¬еЏё(Medtronic, Inc.)жЂ»йѓЁдЅЌдєЋзѕЋе›Ѕж�Ће°ји‹Џиѕѕе·ћж�Ће°ј й�їжіўе€©ж–Їеё‚пјЊж�Їе…Ёзђѓйў†е…€зљ„еЊ»з–—з§‘жЉЂе…¬еЏёпјЊи‡ґеЉ›дєЋдёєж…ўжЂ§з–ѕз—… ж‚ЈиЂ…жЏђдѕ›з»€иє«зљ„жІ»з–—ж–№жЎ€гЂ‚е…¶дё»и¦Ѓдє§е“Ѓи¦†з›–еїѓеѕ‹е¤±еёёгЂЃеїѓиЎ°гЂЃ иЎЂз®Ўз–ѕз—…гЂЃеїѓи„Џз“Ји†њзЅ®жЌўгЂЃдЅ“е¤–еїѓи„Џж”ЇжЊЃгЂЃеѕ®е€›еїѓи„Џж‰‹жњЇгЂЃжЃ¶ жЂ§еЏЉйќћжЃ¶жЂ§з–јз—›гЂЃиїђеЉЁе¤±и°ѓгЂЃзі–е°їз—…гЂЃиѓѓи‚ з–ѕз—…гЂЃжіЊе°їзі»з»џз–ѕ з—…гЂЃи„Љж¤Ћз–ѕз—…гЂЃзҐћз»Џзі»з»џз–ѕз—…еЏЉдє”е®�з§‘ж‰‹жњЇжІ»з–—з‰йў†еџџгЂ‚жЇЏ4з§’ й’џпјЊдё–з•ЊдёЉе°±жњ‰дёЂеђЌз—…дєєе› дёєзѕЋж•¦еЉ›зљ„дє§е“ЃиЂЊе‡ЏиЅ»з—…з—›пјЊжЃўе¤Ќ еЃҐеє·пјЊе»¶й•їеЇїе‘ЅгЂ‚ The company has gained 27 national projects and owns 22 national technique patents. LBC has independently developed YINYIВ® Metal Stent, YINYIВ® Metal Stent System, YINYIВ® Polymer-free Microporous Drug-eluting Coronary Stent System, YINYIВ® PTCA Balloon Catheter and other series of cutting-edge medical products. The company is becoming one of the most innovative companies in the field of interventional medical device in China. LBC owns 3 purifying workshops, possesses various standardized production line and testing lines, ranges from stents sculpting, drug coating, catheter manufacturing, product assembly to package sterilization. LBC's production R&D area amounts to 5000m2, which leads to a production capacity of over 100,000 sets. In July 2007, LBC got the certificates of ISO9001 & ISO13485. In Jan 2011, Metal Stent System and PTCA Balloon Catheter were CE marked. Daiichi Sankyo (China) Holdings Co., Ltd. з¬¬дёЂдё‰е…±е€¶иЌЇ(дёЉжµ·)жњ‰й™ђе…¬еЏё We have regional sales office in Beijing, Shanghai, Guangzhou and Xi'an, cooperate with more than 90 master distributors, the marketing network covers over 30 provinces and areas including more than 500 hospitals. A new production base is under construction. It covers an area of 24,000 sq.m, while the increased production R&D area is up to 23,500 sq.m. It is an optimistic blueprint that within 3 to 4 years, LBC will become a leading center of manufacturing, testing and R&D on high-end implantable & interventional products in China. Booth Number / е±•дЅЌеЏ·: A009 Address: 500 Juli Rd. Zhangjiang High-tech Park, Pudong New Area, Shanghai ењ°еќЂпјљ дёЉжµ·её‚жµ¦дёњж–°еЊєеј ж±џй«�з§‘е±…й‡Њи·Ї500еЏ· 021-5080 3338 Tel: 021-5080 3102 Fax: [email protected] Email: Daiichi Sankyo's mission is "to contribute to the enrichment of quality of life around the world through the creation of innovative pharmaceuticals and through the provision of pharmaceuticals addressing diverse medical needs." Internal and external forces continue to reshape the pharmaceuticals sector as we know it. Therefore, we are deploying a Hybrid Business Model to materialize our vision of вЂњbecoming a Global Pharma Innovator." We will satisfy unmet medical needs as an innovative pharmaceuticals manufacturer. We will also deliver comprehensive healthcare services by developing a new business model that extends beyond a conventional pharmaceuticals business to vaccines, generic drugs, and over-the-counter treatments. We have two key duties as a member of the healthcare industry. The first is to improve our operating results and contribute to the economy. The second is to assume an active role in the healthcare system. We intend to fulfill these duties to the absolute best of our ability as we earnestly do our utmost as a leading Japanese and world-class enterprise to earn the trust of all our stakeholders. 169 CIT 2012 www.citmd.com EXHIBITORS' DIRECTORY Haemonetics Corporation зѕЋе›ЅиЎЂж¶ІжЉЂжњЇ(дёе›Ѕ)е…¬еЏё Shimadzu (China) Co., Ltd. еІ›жґҐдјЃдёљз®Ўзђ†(дёе›Ѕ)жњ‰й™ђе…¬еЏё Booth Number / е±•дЅЌеЏ·: A010 Booth Number / е±•дЅЌеЏ·: A015/A030 Address: й‚®зј–: ењ°еќЂпјљ Tel: Fax: Email: Address: 14/F,Life Tower,No.16 Chaoyang Men Wai Street, Chao Yang District,Beijing China ењ°еќЂпјљ еЊ—дє¬её‚жњќй�іеЊєжњќе¤–е¤§иЎ—16еЏ·дёе›ЅдєєеЇїе¤§еЋ¦14F 010 8525 2407 Tel: 010 8525 2376 Fax: Email: [email protected] 200031 дёЉжµ·её‚ж·®жµ·дёи·Ї1325еЏ·з€±зѕЋй«�е¤§еЋ¦1103-06е®¤ +852-2116 1278 +852-2801 4380 [email protected] зѕЋе›ЅиЎЂж¶ІжЉЂжњЇе…¬еЏё(Haemonetics Corporation)е€›е»єдєЋ1971е№ґпјЊ ж�ЇзєЅзє¦иЇЃе€ёдє¤ж�“ж‰ЂдёЉеё‚зљ„дё“дёљеЊ–е€›ж–°е…¬еЏёпјЊжЂ»йѓЁи®ѕењЁзѕЋе›Ѕйє» зњЃжіўеЈ«йЎїпјЊењЁ21дёЄе›Ѕе®¶и®ѕжњ‰е€†йѓЁгЂ‚2007е№ґ11жњ€жЈејЏж”¶иґдє† Haemoscopeе…¬еЏёпјЊиЇҐе…¬еЏёдє«жњ‰з››иЄ‰зљ„TEGиЎЂж “еј№еЉ›е›ѕ - ж�Їиї„д»Љ дёєжўдё–з•ЊдёЉжњЂе®Њж•ґзљ„е‡ќиЎЂз®Ўзђ†зі»з»џгЂ‚ еІ›жґҐе€¶дЅњж‰Ђи‡Є1875е№ґе€›дёљд»ҐжќҐпјЊе§‹з»€еќљжЊЃеђ‘ж—¶д»Јзљ„е°–з«ЇжЉЂжњЇжЊ‘ ж€�,ењЁеЊ»з–—е™Ёжў°гЂЃз”џе‘Ѕз§‘е¦гЂЃзЋЇеўѓдїќжЉ¤з‰йў†еџџдёЌж–й’»з ”ж–°жЉЂжњЇпјЊ ејЂеЏ‘ж–°дє§е“ЃгЂ‚е°¤е…¶ењЁXзєїиЇЉж–и®ѕе¤‡зљ„ејЂеЏ‘дёдёЂз›ґиµ°ењЁдё–з•Њзљ„е‰Ќ е€—пјЊе№¶е€¶ж€ђдё–з•Њй¦–еЏ°з›ґжЋҐиЅ¬жЌўећ‹FPDж•°е—еЊ–иЎЂз®ЎжњєгЂ‚ вЂњдёєдє†дєєз±»е’Њењ°зђѓзљ„еЃҐеє·вЂќпјЊеІ›жґҐе…¬еЏёж„їдёЋе¤§е®¶е…±еђЊе‰Ќиї›пјЊеЋ» е®ћзЋ°дєєз±»зљ„зѕЋеҐЅзђ†жѓігЂ‚ Pfizer Pharmaceutical Ltd. иѕ‰з‘ће€¶иЌЇжњ‰й™ђе…¬еЏё Booth Number / е±•дЅЌеЏ·: A011/A026,A013 Address: 10/F, Tower B, 5th Square No. 3-7 North Chao Yang Men Ave., ењ°еќЂпјљ еЊ—дє¬ 010-8516 7759 Tel: 010-8516 7072 Fax: [email protected] Email: Pfizer has a broad and diversified global product portfolio to improve health and well-being at every stage of life No.1 multinational R&D-based biopharmaceutical company in China Over 9000 employees distributed in business, R&D, production and other areas in China.About $ 1 billon investment in China to date and 2 world class R&D centers in Shanghai and Wuhan, 8 state-ofthe-art plants in Dalian, Suzhou and WuxiPfizer's business in China was divided, our business in China was divided into two business units, similar to the setup at Pfizer Global. These two units are the bio-pharmaceutical business (WBB) and the diversified business (PDB):The bio-pharmaceutical business at Pfizer is divided into six business units:For high blood pressure, high cholesterol, diabetes, and other diseases. Major products include Lipitor and Norvasc. Shimadzu cooperation was founded in 1875.Form then on,we had been persisting in challenging the high- tech up to the minute. We are keeping ahead to research new technique and to develop new product in the area of medical instrument, life sciences,environment protecting, especially in developing x-ray diagnostic equipment. And we already pruduced the first direct-transforming FPD digital blood vessel equipment in the world. For the sake of the health of all the hunmen beings and our earth,we,shimadzu corperation ,hope to make progress with all of u here and make our ideal come ture. Medfavour(Beijing)Medical Co.,Ltd дё‡з‘ћйЈћйёї(еЊ—дє¬)еЊ»з–—е™Ёжќђжњ‰й™ђе…¬еЏё Booth Number / е±•дЅЌеЏ·: A039 Address: F14,Trends Tower, Block C, The Place, NO9, Guanghua Road, Chaoyang District, Beijing, China ењ°еќЂпјљ еЊ—дє¬её‚жњќй�іеЊєе…‰еЌЋи·Ї9еЏ·дё–иґёе¤©й�¶ж—¶е°ље¤§еЋ¦Cеє§14е±‚ 010-6587 2805 Tel: 010-6587 2806 Fax: Email: [email protected] дё‡з‘ћйЈћйёї(еЊ—дє¬)еЊ»з–—е™Ёжќђжњ‰й™ђе…¬еЏёе€›з«‹дєЋ2005е№ґпјЊз”±еЇЊжњ‰з»ЏйЄЊзљ„ её‚ењєиђҐй”ЂгЂЃиЎЊж”їз®Ўзђ†гЂЃиґўеЉЎз®Ўзђ†д»ҐеЏЉдєєеЉ›иµ„жєђз®Ўзђ†дєєе‘�з»„ж€ђпјЊ и‡ґеЉ›дєЋж€ђдёєеѕЄзЋЇзі»з»џд»‹е…ҐжІ»з–—йў†еџџдёЂжµЃеЊ»з–—е™Ёжќђзљ„з”џдє§дѕ›еє”е•† еЏЉжњЌеЉЎе•†гЂ‚дЅњдёєеЊ—дє¬её‚й«�ж–°з§‘жЉЂдјЃдёљпјЊдё‡з‘ћйЈћйёїз›®е‰Ќе·Іе…·жњ‰е¤љ йЎ№и‡Єдё»зџҐиЇ†дє§жќѓзљ„дё“е€©жЉЂжњЇгЂ‚д»ЉеђЋдјЃдёље°†ж¶‰еЏЉж¤Ќе…Ґз±»еЊ»з–—е™Ё жќђгЂЃеѕЄзЋЇд»‹е…Ґй«�е€†еђз±»е™ЁжќђгЂЃеѕЄзЋЇд»‹е…ҐеЊ»з–—е™Ёжќђз ”з©¶й™ўгЂЃз”џз‰© е€¶е‰‚е››е¤§дє§дёљгЂ‚ 170 CIT 2012 www.citmd.com EXHIBITORS' DIRECTORY дє§е“ЃжЉЂжњЇ е…¬еЏёдёЋж¬§зѕЋе¤ље®¶еЊ»з–—е™Ёжќђз”џдє§еЏЉз ”еЏ‘жњєжћ„еђ€дЅњз ”еЏ‘еїѓи„ЏеЏЉйў…е†…д»‹ е…Ґдє§е“ЃпјЊе№¶дёЋжё…еЌЋе¤§е¦еђ€дЅње€›з«‹дє†з”џз‰©еЊ»з–—жќђж–™еЏЉзєіз±іжќђж–™еђ€дЅњ е®ћйЄЊе®¤пјЊе…·жњ‰е®Ње–„зљ„з‰©зђ†жЈЂжµ‹з ”еЏ‘дёеїѓгЂЃеЊ–е¦жЈЂжµ‹з ”еЏ‘дёеїѓеЏЉз”џ з‰©жЈЂжµ‹з ”еЏ‘дёеїѓгЂ‚з”џдє§иЅ¦й—ґе·ІйЂљиї‡е›Ѕе®¶дё‡зє§еЏЉз™ѕзє§жґЃе‡ЂзЋЇеўѓи®¤ иЇЃпјЊдё»и¦Ѓз”џдє§еЏЉз ”еЏ‘жЈЂжµ‹и®ѕе¤‡еќ‡з”±й«�з«Їдё“дёљдѕ›еє”е•†жЏђдѕ›гЂ‚ е…¬еЏёж„їж™Ї ж€‘д»¬е°†ж°ёиїњи‡ґеЉ›дєЋзј”йЂ дёЂе®¶дёєдё–дєєж‰Ђж™Їд»°зљ„е…¬еЏёгЂ‚ Medfavour (Beijing) Medical Co., Ltd was founded in Beijing in 2005. The company is composed of experienced marketing and sales department, administrative department, financial department and human resource department. We determine to become the leading manufacturers and suppliers of medical devices in the field of interventional therapy. As one of the high-tech companies in Beijing, we have a number of patents of independent intellectual property rights. In the future, we will devote ourselves to the field of implanted medical devices, interventional macromolecule devices, research of interventional medical devices and biopreparate. Technology We cooperate with several American medical equipment R&D institutions to research and develop coronary interventional products, and created a biomedical materials cooperative laboratory with Tsinghua University. We have perfect physicalпјЊ chemical and biological quality testing R&D centers. The manufacturing environment is in the class 10000 cleanroom and 100 cleanroom which have been certified by the government. The main manufacture and R&D testing equipments are all provided by world famous suppliers. Our Credo We will forever devote ourselves to creating an admired company by people. ж‹њиЂіеЊ»иЌЇдїќеЃҐжњ‰й™ђе…¬еЏё Booth Number / е±•дЅЌеЏ·: A047 Address: ењ°еќЂпјљ з”µиЇќпјљ дј зњџпјљ Emailпјљ Dong San Huan Zhong Road No.7 Beijing еЊ—дє¬дёњдё‰зЋЇдёи·Ї7еЏ·иґўеЇЊдёеїѓе†™е—жҐј 010-5921 8929 010-5921 8699 [email protected] Bayer HealthCare, subgroup of Bayer AG, is one of the worldвЂ™s leading, innovative companies in the healthcare and medical industry and is based in Leverkusen, Germany, with more than 53,400 employees worldwide. Bayer HealthCare is committed to research, develop, manufacture and market innovative products that improve the health of people and animals throughout the world. In 2009, Bayer HealthCare's sales revenue worldwide reached 15.9 billion Euros, with 1.85 billion Euros spent on R&D, making up 67.3% of BayerвЂ™s total R&D expenditures. 171 The relationship between Bayer HealthCare and China dates back to early 20th century. In 1936, Bayer established its first production company in China, which manufactured a series of products including the world famous pain killer Aspirin. Currently, Bayer HealthCare has about 4,600 employees in China and is headquartered in Beijing with facilities in Beijing, Guangzhou, and Chengdu. The company is composed of four major business units: Bayer Schering Pharma, Consumer Care, Medical Care, and Animal Health. Bayer Schering Pharma, the largest division of Bayer Healthcare, is the merger of Bayer HealthCare Pharma division and Schering Pharmaceutical Co. (Guangzhou). With presence in more than 70 cities, the product line of Bayer Schering Pharma covers general medicine, womenвЂ™s health, specialty medicine and diagnostic imaging. In July 2008, Bayer HealthCareвЂ™s Consumer Care Division acquired the western over-the-counter (OTC) portfolio of Topsun Science and Technology Qidong Gaitianli Pharmaceutical Co., Ltd. In 2008, Bayer HealthCare completed the expansion of the facility in Yizhuang of Beijing with an investment of 220 million RMB. The new production lines in this Beijing-based facility use the most advanced equipment in Asia, quadrupling its production capacity. Besides from the investment in hardware system, this facility also introduces an advanced software management systems including a fully-automatic weighing system and a logistics management system that help further improve the drug quality. In early 2009, Bayer HealthCare built its global R&D center in Beijing, the company's fourth R&D center in the world. This move not only demonstrates our resolution and confidence in seeking long-term development in China but also lays a solid foundation for Bayer HealthCare to become a leader in AsiaвЂ™s pharmaceutical sector. BHC China has been the biggest driving force of Bayer global for the past 3-5 years, in 2009 around 25% of global growth for BHC is come from China. BSP China was upgraded to an independant region reported to the headquaters starting in January 2010, which is an envidence that China will play more important role in the future, and it will help create a new growth era for the China organization. Bayer HealthCare has always emphasized on social responsibility in its business decisioins by actively cooperating with all social parties. In November 2008, it launched the Health and Safety Training Program for Rural to Urban Migrant Worker with China Association for Employment Promotion, which will provide health and safety employment training and offer transfer for 30,000 rural surplus workers in three years. Despite the global financial crisis, we will continue to pay attention to those disadvantaged populations in need of help. In order to promote and improve the overall medical services of the county-level hospitals in Central and West China, Bayer HealthCare successfully launched the вЂњ10,000 Healthcare Professionals TrainingвЂќ for the вЂњGo WestвЂќ project by cooperating with the Ministry of Health. The government attaches CIT 2012 www.citmd.com EXHIBITORS' DIRECTORY great importance and provides support for this project, listing it as a part of the вЂњBringing Culture/Science and Technology/Hygienic Health to the CountrysideвЂќ program organized by the Publicity Department of the Central Committee of the Chinese Communist Party. B.Braun Medical (Shanghai) International Trading Co., Ltd иґќжњ—еЊ»з–—(дёЉжµ·)е›Ѕй™…иґёж�“жњ‰й™ђе…¬еЏё Booth Number / е±•дЅЌеЏ·: A047 Address: Rm.1908, CBD internaitonal Mansion No.16 Yong An Dong Li, Chaoyang District, 100022 , China ењ°еќЂпјљ еЊ—дє¬её‚жњќй�іеЊєж°ёе®‰дёњй‡Њ16еЏ·CBDе›Ѕй™…е¤§еЋ¦1908е®¤ 010-5763 2919 Tel: 010-6599 5587 Fax: Email: [email protected] B. BRAUN MELSUNGEN AG is a German private family-owned stock company with a tradition of more than 160 years. The company's headquarters is at Melsungen, right in the middle of Germany and Europe, approximately 180 km north of Frankfurt/Main. With about 27,500 employees world-wide and an annual turnover of almost USD 2,1 billion during the present business year B. Braun Melsungen AG can be considered as one of the biggest hospital health care suppliers in Europe. The company continuously developed from a pharmacy acquired in 1839 to its present size and image. Also outside Europe the name B. Braun stands for high-quality products which have gained universal acceptance by the medical profession for many decades. Through intensive research and development work B. Braun decisively contributes to find new ways in clinical therapy, to improve and create new techniques in surgery and intensive care and last but not least has greatly influenced the rapid progress of disposable plastic products in the medical field all over the world. The company's largest subsidiaries outside Europe are to be found in the US, Malaysia and Brazil. All over the world Centers of Excellence have specialised in research, manufacturing and marketing of medical products. Regarding itself as вЂћone true companyвЂњ, B. Braun is and has been a real pacesetter and pioneer in medicine. Enormous efforts in research and development have created new milestones in health care and have become the basis for the company's international reputation of reliability and responsibility. The driving forces behind B. Braun's continued progress and success are: ethical commitment, reliability, creativity, foresight and last but not least a wealth of experience acquired during many years in research and development of health care products. The company's activities are subdivided into four separate Product Divisions, i.e. Hospital Care Division (e.g. Disposable plastic products for infusion/transfusion, infusion solutions, catheterisation/ venipuncture, anaesthesia, intravenous solutions for water and electrolyte therapy, complete parenteral nutrition), Aesculap Division (e.g. Surgical instruments, surgical sutures, vascular and bone grafts), Medtech Division (e.g. Dialysis machines and accessories) and OPM (Out Patient Market) Division with products tailored to the specific requirements of the outpatient market. MEDRAD Medical Equipment Trading Company, Beijing зѕЋеѕ·з‘ћиѕѕеЊ»з–—е™Ёжў°иґёж�“(еЊ—дє¬)жњ‰й™ђе…¬еЏё Booth Number / е±•дЅЌеЏ·: A047 Address: Rm 401-402, Air China Plaza, No. 36 Xiaoyun Road, Beijing, China ењ°еќЂпјљ еЊ—дє¬её‚жњќй�іеЊєйњ„дє‘и·Ї36еЏ·е›Ѕи€Єе¤§еЋ¦401-402 010-8447 5288-807 Tel: 010-8447 5292 Fax: Email: [email protected] MEDRAD is a worldwide leading provider of medical devices and services that enable and enhance imaging procedures of the human body. Used in diagnostic imaging, MEDRAD's product offerings include a comprehensive line of vascular injection systems and patient care products, and equipment services. MEDRAD is a 2003 and 2010 recipient of the Malcolm Baldrige National Quality Award, the top honor a U.S. company can receive for quality and business excellence. The company's world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD is an affiliate of Bayer AG. The injector systems include Vistron CT injector system, Stellant Sx and Stellant D CT injector system, Spectris Solaris EP MR injector system, Mark V ProVis DSA injector system and Avanta cardiac vascular injector system. More details, please refer to www.medrad.com MEDRADж�ЇдёЂе®¶е…Ёзђѓйў†е…€зљ„еЊ»з–—и®ѕе¤‡е’ЊжњЌеЉЎдѕ›еє”е•†пјЊжЏђдѕ›еЏЇе®ћ зЋ°ж”№е–„дєєдЅ“ж€ђеѓЏе’ЊжІ»з–—иї‡зЁ‹зљ„дє§е“ЃдёЋжњЌеЉЎгЂ‚ ењЁиЇЉж–ж€ђеѓЏйў†еџџпјЊ MEDRADеЏЇжЏђдѕ›еЊ…ж‹¬е…Ёзі»е€—зљ„йЂ еЅ±е‰‚жіЁе°„зі»з»џе’Њж‚ЈиЂ…жЉ¤зђ†дє§е“Ѓ з‰дє§е“Ѓд»ҐеЏЉи®ѕе¤‡жњЌеЉЎгЂ‚е…¬еЏёиї�жЏђдѕ›иЎЂз®Ўд»‹е…Ґз›ёе…ідє§е“ЃгЂ‚2003 е№ґ е’Њ2010е№ґпјЊMEDRAD иЌЈиЋ·вЂњй©¬е°”з§‘е§†вЂўйІЌеѕ·й‡ЊеҐ‡е›Ѕе®¶иґЁй‡ЏеҐ–вЂќпјЊ иї™ж�ЇзѕЋе›Ѕе…¬еЏёеЏЇиЋ·еѕ—зљ„иґЁй‡Џе’Ње•†дёљж€ђе°±ж–№йќўзљ„жњЂй«�иЌЈиЄ‰гЂ‚ е…¬ еЏёзљ„е…ЁзђѓжЂ»йѓЁдЅЌдєЋзѕЋе›Ѕе®ѕе¤•жі•е°јдєље·ћеЊ№е…№е Ўй™„иї‘гЂ‚MEDRAD ж�Ї Bayer AG зљ„еђе…¬еЏёгЂ‚ е…·дЅ“йЂ еЅ±е‰‚жіЁе°„зі»з»џеЊ…ж‹¬пјљVistron CTйЂ еЅ±е‰‚жіЁе°„зі»з»џпјЊStellant Sxе’ЊStellant DйЂ еЅ±е‰‚жіЁе°„зі»з»џпјЊSpectris Solaris EP MRйЂ еЅ±е‰‚жіЁ е°„зі»з»џпјЊMark V ProVis DSAйЂ еЅ±е‰‚жіЁе°„зі»з»џпјЊAvanta еїѓиЎЂз®ЎйЂ еЅ± е‰‚жіЁе°„зі»з»џгЂ‚ иЇ¦з»†жѓ…е†µпјЊиЇ·з™»еЅ•www.medrad.comжџҐиЇўгЂ‚ 172 CIT 2012 www.citmd.com EXHIBITORS' DIRECTORY Lepu Medical Technology (Beijing) Co., Ltd д№ђж™®(еЊ—дє¬)еЊ»з–—е™Ёжў°и‚Ўд»Ѕжњ‰й™ђе…¬еЏё Philips Healthcare йЈће€©жµ¦еЊ»з–—дїќеЃҐ Booth Number / е±•дЅЌеЏ·: A050 Booth Number / е±•дЅЌеЏ·: A058 Address: 20F,Tower2,No.1 Xizhimenwai Street,Xihuan plaza, Xicheng District,Beijing ењ°еќЂпјљ еЊ—дє¬её‚иҐїеџЋеЊєиҐїз›ґй—Ёе¤–е¤§иЎ—1еЏ·иҐїзЋЇе№їењєT2еє§20е±‚ 010-5830 5025 Tel: 010-5830 5100 Fax: Email: [email protected] Address: 9F,The Palce Tower,No.9,Guanghua Road,Chaoyang District, Beijing ењ°еќЂпјљ еЊ—дє¬её‚жњќй�іеЊєе…‰еЌЋи·Ї9еЏ·дё–иґёе¤©й�¶е¤§еЋ¦9е±‚ 010-8527 3289 Tel: 010-8527 3234 Fax: Email: [email protected] Established in 1999, Lepu Medical Technology (Beijing) Co., Ltd is a leading Chinese enterprise specializing in research & development, production, sales and service of high-tech interventional medical devices. In October of 2009, Lepu medical was successful in listing on the GEM in China (stock code: 300003). Philips is among the top three in the healthcare technology market alongside General Electric (GE) and Siemens. Philips' current activities can be divided in four businesses: Imaging Systems, Patient Care and Clinical Informatics, Customer Services and Home Healthcare. Lepu medical has become an industrialized and collectivized enterprise focusing on cardiac therapy, which manages six wholly-owned subsidiaries and one joint stock company. The headquarters of Lepu medical is located in Changping Technology Park, Beijing; the marketing center is in Xihuan Plaza, Beijing. Philips is unique in its approach to healthcare because we start by looking at the peopleвЂ”patients and care providersвЂ”not the technology. Through gaining insights into how patients and clinicians experience healthcare, we are able to identify larger market and clinical needs. In response we can develop more intuitive, more affordable, and in the end better technology solutions to help take some of the complexity out of healthcare. This helps to drive better diagnosis, more appropriate treatment planning, faster patient recovery and long term health. At Philips, we try to simplify healthcare through combining our unique clinical expertise with human insights to develop innovations that ultimately help to improve the quality of people's lives. Based on the technological advantages and industrialization, Lepu medical strives to be a domestic leading and first-class international enterprise group, providing high-end interventional medical devices with high technology, high curative effect and high cost-effective. д№ђж™®(еЊ—дє¬)еЊ»з–—е™Ёжў°и‚Ўд»Ѕжњ‰й™ђе…¬еЏёе€›з«‹дєЋ1999е№ґпјЊдё“дёљд»Ћдє‹й«�жЉЂ жњЇд»‹е…ҐеЊ»з–—е™Ёжў°з ”еЏ‘гЂЃз”џдє§е’Њй”Ђе”®гЂ‚ж�Їе›Ѕе†…ењЁй«�з«ЇеЊ»з–—е™Ёжў°йў† еџџиѓЅе¤џдёЋе›Ѕе¤–дє§е“ЃеЅўж€ђејєжњ‰еЉ›з«ћдє‰зљ„дёєж•°иѕѓе°‘зљ„дјЃдёљд№‹дёЂпјЊдєЋ 2009е№ґ10жњ€пјЊењЁж·±дє¤ж‰Ђе€›дёљжќїдёЉеё‚(иЇЃе€ёд»Јз Ѓпјљ300003з®Ђз§°:д№ђж™® еЊ»з–—)гЂ‚ д№ђж™®еЊ»з–—е·Іжћ„е»єиµ·е›ґз»•еїѓи„ЏжІ»з–—зљ„й›†е›ўеЊ–дє§дёљеЊ–е№іеЏ°пјЊж——дё‹ж‹Ґ жњ‰6е®¶е…Ёиµ„еђе…¬еЏёпјЊдёЂе®¶еЏ‚и‚Ўе…¬еЏёгЂ‚жЂ»йѓЁдЅЌдєЋеЊ—дє¬дёе…іжќ‘з§‘жЉЂе› еЊєж�Ње№іе›пјЊиђҐй”ЂдёеїѓдЅЌдєЋеЊ—дє¬её‚еЊєиҐїзЋЇе№їењєгЂ‚з›®е‰Ќе·Іж€ђдёєе›Ѕе†… е€ќе…·и§„жЁЎзљ„дє§дёљеџєењ°гЂ‚ д№ђж™®еЊ»з–—з›®е‰ЌжЈдѕќж‰�зЋ°жњ‰жЉЂжњЇдј�еЉїе’Њдє§дёљеЊ–еџєзЎЂпјЊеЉ›ж±‚е°†д№ђж™® еЊ»з–—ж‰“йЂ ж€ђе›Ѕе†…йў†е…€гЂЃе›Ѕй™…дёЂжµЃзљ„вЂњй«�жЉЂжњЇгЂЃй«�з–—ж•€гЂЃй«�жЂ§д»· жЇ”вЂќзљ„й«�з«Їд»‹е…ҐеЊ»з–—е™Ёжў°еЏЉиЇЉз–—и®ѕе¤‡з ”еЏ‘дјЃдёљй›†е›ўгЂ‚ 173 With a growing presence in cardiology, oncology, and women's health, we focus on the fundamental health problems with which people are confronted, such as congestive heart failure, lung and breast cancers and coronary artery disease. Our focus is to deliver value throughout the complete cycle of care: from disease prevention to screening and diagnosis through to treatment, monitoring and health management. Philips is dedicated to making an impact wherever care happens, within the hospital critical care, emergency care and surgery вЂ“ and, as importantly, in the home. CIT 2012 www.citmd.com EXHIBITORS' DIRECTORY Abbott Medical Devices Trading (Shanghai) Co., Ltd й›…еџ№еЊ»з–—е™Ёжў°иґёж�“(дёЉжµ·)жњ‰й™ђе…¬еЏё Booth Number / е±•дЅЌеЏ·: A099 Address: 12th Floor, Phase II Shanghai IFC, No.8, Century Avenue Pudong Shanghai P.R. China ењ°еќЂпјљ дёе›ЅдёЉжµ·жµ¦дёњж–°еЊєдё–зєЄе¤§йЃ“8еЏ·дёЉжµ·е›Ѕй‡‘дёеїѓ2жњџ12жҐј 021-5775 7816 Tel: 021-5775 7899 Fax: Email: [email protected] Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs nearly 91,000 people and markets its products in more than 130 countries. Abbott has been operating in China for nearly 20 years and provides Chinese consumers with a diverse range of nutrition, pharmaceutical and medical products. Abbott has more than 4,000 employees in China and is headquartered in Shanghai. Abbott Vascular, a division of Abbott, is a global leader in cardiac and vascular care with market-leading products and an industryleading pipeline. Headquartered in Northern California, we are committed to advancing patient care by transforming the treatment of vascular disease through medical device innovations, investments in research and development, and physician training and education. й›…еџ№ж�ЇдёЂе®¶е…Ёзђѓйў†е…€зљ„е¤ље…ѓеЊ–еЊ»з–—дїќеЃҐе…¬еЏёпјЊи‡ґеЉ›дєЋиЌЇе“Ѓе’ЊеЊ» з–—дє§е“Ѓзљ„з ”еЏ‘гЂЃз”џдє§е’Њй”Ђе”®пјЊдё»и¦ЃдёљеЉЎж¶‰еЏЉиђҐе…»е“ЃгЂЃе™Ёжў°е’ЊиЇЉ ж–и®ѕе¤‡з‰гЂ‚й›…еџ№ењЁе…Ёзђѓж‹Ґжњ‰91,000е¤љеђЌе‘�е·ҐпјЊдёљеЉЎйЃЌеЏЉ130е¤љдёЄ е›Ѕе®¶е’Њењ°еЊєгЂ‚ й›…еџ№ењЁдёе›ЅејЂе±•дёљеЉЎиї‘20е№ґпјЊдёєдёе›Ѕж¶€иґ№иЂ…жЏђдѕ›еђ„з§ЌиђҐе…»е“ЃгЂЃ иЌЇе“Ѓе’ЊеЊ»з–—дє§е“ЃгЂ‚й›…еџ№дёе›ЅжЂ»йѓЁдЅЌдєЋдёЉжµ·пјЊењЁеЌЋж‹Ґжњ‰4,000е¤љеђЌ е‘�е·ҐгЂ‚ й›…еџ№иЎЂз®Ўд»Єе™ЁйѓЁдЅњдёєй›…еџ№дёљеЉЎйѓЁй—Ёд№‹дёЂпјЊж‹Ґжњ‰её‚ењєйў†е…€зљ„дє§ е“ЃпјЊж�Їе…Ёзђѓеїѓи„Џе’ЊиЎЂз®ЎжЉ¤зђ†зљ„йў†еЇјиЂ…е’ЊиЎЊдёљзї�жҐљгЂ‚й›…еџ№иЎЂз®Ўд»Є е™ЁжЂ»йѓЁдЅЌдєЋзѕЋе›ЅеЉ е€©з¦Џе°јдєље·ћеЊ—йѓЁпјЊи‡ґеЉ›дєЋйЂљиї‡е€›ж–°зљ„еЊ»з–—и®ѕ е¤‡гЂЃжЊЃз»зљ„з ”еЏ‘жЉ•е…Ґд»ҐеЏЉеЊ»еЉЎдєєе‘�зљ„еџ№и®дёЋж•™и‚ІжќҐиЅ¬еЏ�еїѓиЎЂз®Ў з–ѕз—…зљ„жІ»з–—ж–№ејЏпјЊдёєж‚ЈиЂ…её¦жќҐе…€иї›зљ„иЇЉз–—дЅ“йЄЊгЂ‚ Pie Medical Imaging Booth Number / е±•дЅЌеЏ·: A103 Address: Becanusstraat 13d +3143328 1328 Tel: +3143328 1329 Fax: Email: [email protected] Pie Medical Imaging is specialized in developing analytical software for quantification of cardiovascular medical images using automated segmentation. Pie Medical Imaging cooperates with major imaging companies marketing the CAAS software to endusers. We extend our expert knowledge via cooperation with research-groups to learn about changes in treatments influencing the use of Quantitative-Analysis. In doing so we have set a worldstandard. Pie Medical Imaging offers quantitative analysis solutions for X-ray, MRI and IVUS. CT analysis software for Aneurysm and Valve procedures is offered in collaboration with 3mensio Medical Imaging, sister company of PMI. Shanghai Kindly Enterprise Development Group Medical Instruments Co., Ltd. дёЉжµ·еє·еѕ·иЋ±дјЃдёљеЏ‘е±•й›†е›ўеЊ»з–—е™Ёжў°жњ‰й™ђе…¬еЏё Booth Number / е±•дЅЌеЏ·: A104 Address: No.925, Jinyuan Road 1, Jiading district, Shanghai, China ењ°еќЂпјљ дёЉжµ·её‚е�‰е®љеЊєй‡‘е›дёЂи·Ї925еЏ· 021-5911 7599-811 Tel: 021-6900 0013-811 Fax: [email protected] Email: дёЉжµ·еє·еѕ·иЋ±дјЃдёљеЏ‘е±•й›†е›ўеЊ»з–—е™Ёжў°жњ‰й™ђе…¬еЏёж€ђз«‹дєЋ2006е№ґпјЊ и‡ґеЉ›дєЋй«�з«Їд»‹е…ҐеЊ»з–—дє§е“Ѓзљ„з ”еЏ‘гЂЃз”џдє§дёЋй”Ђе”®гЂ‚е…¬еЏёи‡Єж€ђз«‹д»Ґ жќҐпјЊиї…йЂџж•ґеђ€дє†жЁЎе…·и®ѕи®ЎгЂЃжЁЎе…·е€¶йЂ гЂЃдє§е“ЃжіЁеЎ‘гЂЃдє§е“Ѓз»„иЈ…гЂЃ еЊ…иЈ…гЂЃзЃиЏЊз‰иµ„жєђпјЊе…·е¤‡дє†е®Ње–„иЂЊеЃҐе…Ёзљ„з ”еЏ‘гЂЃе€¶йЂ иѓЅеЉ›гЂ‚е…¬ еЏёд»Ґеўћејєи‡Єдё»е€›ж–°иѓЅеЉ›пјЊејЂеЏ‘и‡Єдё»зџҐиЇ†дє§жќѓдє§е“Ѓдёєй‡Ќз‚№еЏ‘е±•ж–№ еђ‘пјЊе…€еђЋе¤љж¬ЎиЋ·еѕ—дє†вЂњдёЉжµ·её‚зЃ«з‚¬и®Ўе€’вЂќгЂЃвЂњдёЉжµ·её‚й«�ж–°ж€ђжћњ иЅ¬еЊ–йЎ№з›®вЂќгЂЃвЂњдёЉжµ·её‚е€›ж–°еџєй‡‘вЂќгЂЃвЂњдёЉжµ·её‚дё“е€©еЏ‘ж�ЋеҐ–вЂќгЂЃ вЂње›Ѕе®¶е€›ж–°еџєй‡‘вЂќз‰йЎ№з›®зљ„ж”ЇжЊЃпјЊж ‘з«‹дє†дё“дёљйў†е…€гЂЃи‡Єдё»е€›ж–° зљ„е“Ѓз‰ЊеЅўи±ЎгЂ‚ 174 CIT 2012 www.citmd.com EXHIBITORS' DIRECTORY Siemens Ltd. China Healthcare Sector иҐїй—Ёеђ(дёе›Ѕ)жњ‰й™ђе…¬еЏёеЊ»з–—зі»з»џй›†е›ў Booth Number / е±•дЅЌеЏ·: A106 Address: No.278, Zhouzhu Road, Pudong New District, Shanghai ењ°еќЂпјљ дёЉжµ·её‚жµ¦дёњж–°еЊєе‘ЁзҐќе…¬и·Ї278еЏ· 021-3889 5766 Tel: 021-3889 5613 Fax: [email protected] Email: The Siemens Healthcare Sector is one of the world's largest suppliers to the healthcare industry and a trendsetter in medical imaging, laboratory diagnostics, medical information technology and hearing aids. Siemens offers its customers products and solutions for the entire range of patient care from a single source вЂ“ from prevention and early detection to diagnosis, and on to treatment and aftercare. By optimizing clinical workflows for the most common diseases, Siemens also makes healthcare faster, better and more cost-effective. Siemens Healthcare employs some 51,000 employees worldwide and operates around the world. In fiscal year 2011 (to September 30), the Sector posted revenue of 12.5 billion euros and profit of around 1.3 billion euros. The Siemens Healthcare Sector is one of the world's largest suppliers to the healthcare industry and a trendsetter in medical imaging, laboratory diagnostics, medical information technology and hearing aids. Siemens offers its customers products and solutions for the entire range of patient care from a single source вЂ“ from prevention and early detection to diagnosis, and on to treatment and aftercare. By optimizing clinical workflows for the most common diseases, Siemens also makes healthcare faster, better and more cost-effective. Siemens Healthcare employs some 51,000 employees worldwide and operates around the world. In fiscal year 2011 (to September 30), the Sector posted revenue of 12.5 billion euros and profit of around 1.3 billion euros. For further information please visit: www.siemens.com/healthcare. Terumo Medical (Shanghai) CO., LTD. жі°е°”иЊ‚еЊ»з–—дє§е“Ѓ(дёЉжµ·)жњ‰й™ђе…¬еЏё Booth Number / е±•дЅЌеЏ·: A108 Address: Room 801, 805 PICC Buiding 2 Jianguomenwai Street Chaoyang District Beijing, 100022, China ењ°еќЂпјљ дёе›ЅеЊ—дє¬её‚жњќй�іеЊєе»єе¤–е¤§иЎ—2еЏ·PICCе¤§еЋ¦801пјЊ805е®¤ 010-6409 6685 Tel: 010-6409 6689 Fax: [email protected] Email: Terumo manufactures high quality interventional cardiology products in Japan. We focus on supporting Chinese doctorвЂ™s training in TRI (Trans-Radial artery Intervention) techniques which is less invasive for patient and CTO (Chronic Total Occlusion) technique which is enhanced patient quality of life. As our 175 contribution to cardiology market, we sponsor many training courses, NPO Sino-Japan TRI seminar in Japan, CTO seminar in core hospitals, satellite activities at interventional congresses and so on. жі°е°”иЊ‚еЊ»з–—дє§е“Ѓ(дёЉжµ·)жњ‰й™ђе…¬еЏёж�Їйљ¶е±ћдєЋж—Ґжњ¬жі°е°”иЊ‚ж ЄејЏдјљз¤ѕгЂ‚ ж—Ґжњ¬жі°е°”иЊ‚ж€ђз«‹дєЋ1921е№ґпјЊе®ѓзљ„з ”еЏ‘гЂЃз”џдє§е’Њй”Ђе”®зЅ‘з»њйЃЌеЏЉе…Ё зђѓ150е¤љдёЄе›Ѕе®¶гЂ‚жі°е°”иЊ‚дє§е“Ѓиї›е…Ґдёе›Ѕе·Іжњ‰20е¤ље№ґзљ„еЋ†еЏІпјЊе№¶ ењЁй•їж�ҐпјЊжќе·ћж€ђз«‹дє†дё¤дёЄеђ€иµ„е·ҐеЋ‚гЂ‚з›®е‰ЌењЁдёе›Ѕй”Ђе”®зљ„дє§е“ЃеЊ… ж‹¬пјљеїѓи„Џд»‹е…Ґдє§е“ЃгЂЃеїѓиЎЂз®Ўдє§е“ЃгЂЃдєєе·ҐиЎЂз®ЎгЂЃдЅ“е¤–еѕЄзЋЇзі»з»џгЂЃ иѕ“иЎЂдє§е“ЃгЂЃCAPD(иїћз»жґ»еЉЁжЂ§и…№и†њйЂЏжћђзі»з»џ)гЂЃдёЂж¬ЎжЂ§еЊ»з–—е™Ё жў°гЂЃзі–е°їз—…жЉ¤зђ†дє§е“ЃгЂЃиЌЇе“ЃгЂЃе®¶еєз”ЁиђҐе…»з–—жі•гЂЃеђёж°§з–—жі•еЏЉи‡Є ж€‘дїќеЃҐдє§е“Ѓз‰гЂ‚ ењЁеїѓи„Џд»‹е…Ґж–№йќўпјЊжі°е°”иЊ‚ж�ЇжЋЁе№їжЎЎеЉЁи„‰зљ„дё“дёље…¬еЏёпјЊи‡ґеЉ›дєЋз ” з©¶ејЂеЏ‘жЎЎеЉЁи„‰д»‹е…Ґзљ„з›ёе…ідє§е“ЃпјЊе№¶ењЁдёе›ЅжЋЁе№їз»ЏжЎЎеЉЁи„‰д»‹е…Ґж‰‹ жњЇпјЊдёЂж–№йќўе‡ЏиЅ»з—…дєєз—›и‹¦пј›еЏ¦дёЂж–№йќўдёєеЊ»з”џжЏђдѕ›ж›ґе¤љд»‹е…ҐйЂ”еѕ„ йЂ‰ж‹©гЂ‚жі°е°”иЊ‚ж‹Ґжњ‰з›®е‰Ќдё–з•ЊдёЉе”ЇдёЂзљ„з»ЏжЎЎеЉЁи„‰еїѓи„Џд»‹е…ҐжЁЎж‹џ е™ЁпјЊеЏЇд»Ґе…ЁзЁ‹жЁЎж‹џз»ЏжЎЎеЉЁи„‰д»‹е…Ґж‰‹жњЇиї‡зЁ‹пјЊдёєдёе›Ѕд»‹е…ҐеЊ»её€жЏђ дѕ›дє†дёЂдёЄеџ№и®е№іеЏ°гЂ‚ жі°е°”иЊ‚е…¬еЏёеёЊжњ›йЂљиї‡ж€‘д»¬дёЌж‡€зљ„еЉЄеЉ›пјЊиѓЅе¤џе®ћзЋ°ж€‘д»¬дёЂиґЇеќљжЊЃ зљ„е®—ж—Ёпјљд»Ґж›ґе®Ње–„зљ„еЊ»з–—дїќеЃҐжќҐеҐ‰зЊ®з¤ѕдјљгЂ‚ Star Progress Medical Co.,Ltd. дёЉжµ·ж�џеі°е·Ґиґёжњ‰й™ђе…¬еЏё Booth Number / е±•дЅЌеЏ·: A118 Address: Suite 7M, Cross Region Plaza, 899 Ling Ling Road ењ°еќЂпјљ дёЉжµ·её‚й›¶й™µи·Ї899еЏ·йЈћжґІе›Ѕй™…е№їењє7Mеє§ 021-5489 1580 Tel: 021-6428 2818 Fax: Email: [email protected] Established in 1996, Star Progress Medical has been making efforts in helping our partners in promoting their State-Of-The-Art technologies, Practices of Medicine and Services to China and other communities in Asia Pacific Region. All of us in the company have been making our best efforts in helping our partners, from all over the world, in creating distribution networks and establishing sales of their products including wide range of Medical Devices and Equipment. With the latest and advanced western business training, well defined mission and vision, excellent communication skills both in terms of language and mindset, and well versatile experience and performances, Star Progress Medical certain serves as your best partner for your presence in Asia Pacific, especially in China. CIT 2012 www.citmd.com EXHIBITORS' DIRECTORY Sino Medical Sciences Technology Inc. иµ›иЇєеЊ»з–—з§‘е¦жЉЂжњЇжњ‰й™ђе…¬еЏё Shanghai Bracco Sine Pharmaceutical Corp. Ltd. дёЉжµ·еЌљиЋ±з§‘дїЎи°ЉиЌЇдёљжњ‰й™ђиґЈд»»е…¬еЏё Booth Number / е±•дЅЌеЏ·: A151 Booth Number / е±•дЅЌеЏ·: A153-A154 Address: 2nd Floor,TEDA Biopharm Res.Building B,#5 4th St. TEDA, Tianjin,China ењ°еќЂпјљ е¤©жґҐз»ЏжµЋжЉЂжњЇејЂеЏ‘еЊєз¬¬е››е¤§иЎ—5еЏ·жі°иѕѕз”џз‰©еЊ»иЌЇз ”еЏ‘ е¤§еЋ¦BеЊє2е±‚ 022-6620 0080 Tel: 022-6200 0060 Fax: [email protected] Email: Address: Rm.610-612 Gangtai Plaza No.700 Yan An East Road, Shanghai China ењ°еќЂпјљ дёЉжµ·её‚е»¶е®‰дёњи·Ї700еЏ·жёЇжі°е№їењє610 021-5385 1100-336 Tel: 021-5385 1020 Fax: [email protected] Email: Beijing SUN Technology Inc.пјЊis headquartered in Beijing Zhongguancun Science Zone. Its main business is focused on interventional medical device products. It is the solo dealer designated by Sino Medical Sciences Technology (Sinomed) in China. In 2007, building on the technologies platform of Beijing Sun Technology Inc, Sinomed Holding Ltd. invested 30 million U.S. dollars established Sino-Medical Science and Technology Co., Ltd. in Tianjin Binhai New Area. It has concentrated its R&D efforts in the developping new devices for the vascular interventional applications, products manufacturing and marketing. Through international cooperation and technological innovation, it has built series products lines, which includes PTCA, PTA balloon catheters, and coronary stent system. Production facilities and product quality has reached international high standards, and balloon catheter has been certified by European Union. At the end of 2011, we have successfully launched a next-generation drug-eluting stents вЂ“BuMATMпјљa new drug eluting stent of excellent performance and perfect re-endothelialization. BuMATM is the first domestic drug eluting stent that has complete Independent intellectual property rights instead of getting rid of copy. It has access to a number of international and domestic patents. Moreover, it was honored asвЂњthe 2011 National Key New ProductвЂќby The Ministry of Science and Technology of the People's Republic of China. The company's mission is: Through our efforts to help more patients to be benefited from technologies innovation, and to build the company into a leading interventional medical device R & D centre and production base in China and for the world. Innovation for health еЌљиЋ±з§‘е…¬еЏёж�ЇеЅ±еѓЏиЇЉж–гЂЃе€¶иЌЇгЂЃеЊ»з–—е™Ёжў°еЏЉдёґеєЉиЇЉж–йў†еџџзљ„е›Ѕ й™…еЊ–еЊ»иЌЇй›†е›ўпјЊе№¶дёЂз›ґи‡ґеЉ›дєЋз ”еЏ‘е’ЊжЏђдѕ›еє”з”ЁдєЋXзєїгЂЃзЈЃе…±жЊЇгЂЃ и¶…еЈ°иЇЉж–е’Њж ёеЊ»е¦зљ„еЇ№жЇ”е‰‚дє§е“ЃдёЋеЊ»з–—и§Је†іж–№жЎ€гЂ‚19дё–зєЄ70е№ґ д»ЈпјЊеЌљиЋ±з§‘з ”еЏ‘ж€ђеЉџе…Ёзђѓй¦–дёЄз›ґжЋҐдЅїз”Ёзљ„ж°ґжє¶жЂ§йќћз¦»еђећ‹зў�еЇ№жЇ” е‰‚вЂ”вЂ”зў�её•й†‡пјЊе№¶дєЋ1988е№ґиµ·ењЁдёе›ЅдёЉеё‚гЂ‚2002е№ґпјЊеЌљиЋ±з§‘дєљжґІ еЅ±еѓЏиЇЉж–е…¬еЏёе’Њдёе›Ѕеђ€дЅњдј™дјґдёЉжµ·дїЎи°ЉиЌЇеЋ‚еђ€иµ„ж€ђз«‹дёЉжµ·еЌљиЋ±з§‘ дїЎи°ЉиЌЇдёљжњ‰й™ђиґЈд»»е…¬еЏёпјЊдё»и¦Ѓд»Ћдє‹еЇ№жЇ”е‰‚дє§е“Ѓзљ„з”џдє§дёЋй”Ђе”®гЂ‚ еѕ®е€›еЊ»з–—е™Ёжў°(дёЉжµ·)жњ‰й™ђе…¬еЏё Booth Number / е±•дЅЌеЏ·: A158 Address: 501 Newton Road, Z.J. Hi-Tech Park, Shanghai 201203 021-3895 4600 Tel: 021-5080 5016 Fax: [email protected] Email: Beijing Beilu Pharmaceutical CO.,LTD еЊ—дє¬еЊ—й™†иЌЇдёљи‚Ўд»Ѕжњ‰й™ђе…¬еЏё Booth Number / е±•дЅЌеЏ·: A163-A164 Address: Floor 7,Tower A, Fenglanguoji Building, No.32,North Street Xizhimen, Haidian Dist,Beijing ењ°еќЂпјљ еЊ—дє¬её‚жµ·ж·ЂеЊєиҐїз›ґй—ЁеЊ—е¤§иЎ—32еЏ·жћ«и“ќе›Ѕй™…Aеє§е†™е—жҐј7е±‚ 010-6262 2266 Tel: 010-8262 6933 Fax: Email: [email protected] еЊ—дє¬еЊ—й™†иЌЇдёљи‚Ўд»Ѕжњ‰й™ђе…¬еЏёж€ђз«‹дєЋ1992е№ґ9жњ€пјЊдё»и¦Ѓд»Ћдє‹еЊ»иЌЇ дє§е“Ѓзљ„з ”еЏ‘гЂЃз”џдє§еЏЉй”Ђе”®гЂ‚дЅњдёєз§‘жЉЂйѓЁгЂЃиґўж”їйѓЁе’ЊзЁЋеЉЎжЂ»е±ЂиЃ” еђ€и®¤е®љзљ„й«�ж–°жЉЂжњЇе€¶иЌЇдјЃдёљгЂ‚2010е№ґе…¬еЏёжЈејЏе…ҐйЂ‰еЊ—дє¬з”џз‰©еЊ» иЌЇдє§дёљи·Ёи¶ЉеЏ‘е±•е·ҐзЁ‹(G20е·ҐзЁ‹)й¦–ж‰№и§„жЁЎдјЃдёљпј›2010е№ґењЁз”±дёе›Ѕ з¤ѕдјљз§‘е¦й™ўгЂЃдёе›ЅеЊ»иЌЇдїЎжЃЇдё“дёље§”е‘�дјљд»ҐеЏЉдёљз•Њзљ„зџҐеђЌдё“е®¶еЏ‚ дёЋиЇ„йЂ‰зљ„жґ»еЉЁдёпјЊиў«иЇ„дёєвЂњеЊ»иЌЇдёЉеё‚е…¬еЏёж ёеїѓз«ћдє‰еЉ›жЋ’иЎЊж¦њ50 ејєвЂќдјЃдёљгЂ‚ 2009е№ґ10жњ€30ж—ҐпјЊжЈејЏењЁж·±ењіиЇЃе€ёдє¤ж�“ж‰Ђе€›дёљжќїжЊ‚ з‰ЊдёЉеё‚пјЊж€ђдёєй¦–ж‰№е€›дёљжќїдёЉеё‚е…¬еЏёгЂ‚ 176 CIT 2012 www.citmd.com EXHIBITORS' DIRECTORY Eastern Enterprise Corporation еЊ—дє¬жЃ’ж¶¦жі°еЊ»иЌЇз§‘жЉЂжњ‰й™ђе…¬еЏё JW Medical Systems Ltd. еђ‰еЁЃеЊ»з–—е€¶е“Ѓжњ‰й™ђе…¬еЏё Booth Number / е±•дЅЌеЏ· A165 Booth Number / е±•дЅЌеЏ·: A170 Address: Room A8G Building A, Chengming Plaza, No. 2 Xizhimen South Street, Xicheng District Beijing. China ењ°еќЂпјљ еЊ—дє¬её‚иҐїеџЋеЊєиҐїз›ґй—ЁеЌ—е¤§иЎ—2еЏ·ж€ђй“е¤§еЋ¦A8Gе®¤ 010-6600 2013 Tel: 010-6600 2103 Fax: [email protected] Email: Address: Foregin Economic & Trade Plaza #912, 22 Fuchengmenwai Avenue, West District, Beijing, P.R.China ењ°еќЂпјљ еЊ—дє¬её‚иҐїеџЋеЊєй�њж€ђй—Ёе¤–е¤§иЎ—22еЏ·е¤–з»Џиґёе¤§еЋ¦9е±‚912 010-6806 8918 Tel: 010-6806 5989 Fax: Email: [email protected] Founded in 2000, Eastern Enterprise Corporation is specialized in medical devices distribution. Its main products involve in anesthesia/operation room, nursing, hematology, surgery, Radiology, ICU, etc.The featured products include patented radial / femoral artery compression device that aim to stop bleeding and achieve hemostasis after radial/femoral artery PTC or coronary arteriography. JW Medical Systems succeeds in producing innovative solutions and enjoys a history of extraordinary achievement in the field of interventional healthcare. Founded by Dr. Jicheng Wang from the United States in the beautiful coastal city of WeiHai, ShanDong, China, JW Medical Systems is an international corporation with investment mainly from China. JW Medical Systems focused on the R & D, manufacturing and commercialization of high tech medical devices. Since August 2003, JW has established branch offices in Beijing, Shanghai, GuangZhou and XiAn. Today, approximately 800 JW employees are dedicating their talents and energy on providing cutting-edge solutions in the field of interventional healthcare. Essen Technology(Beijing) Co.,Ltd. ж�“з”џз§‘жЉЂ(еЊ—дє¬)жњ‰й™ђе…¬еЏё Booth Number / е±•дЅЌеЏ·: A166 Address: 9th Floor,Shangdi Sci-tech Tower 8 Shangdi West Road, Haidian District Beijing ењ°еќЂпјљ еЊ—дє¬её‚жµ·ж·ЂеЊєдёЉењ°иҐїи·Ї8еЏ·й™ў4еЏ·жҐј9е±‚ 010-5885 6668 Tel: 010-5885 9115 Fax: Email: [email protected] ж�“з”џз§‘жЉЂ(еЊ—дє¬)жњ‰й™ђе…¬еЏёж�Їдё“дёљд»Ћдє‹д»‹е…ҐеЊ»з–—е™Ёжў°зљ„з ”еЏ‘гЂЃз”џ дє§гЂЃй”Ђе”®еЏЉжњЌеЉЎзљ„дёзѕЋеђ€иµ„дјЃдёљгЂ‚з€±з«‹(TIVOLI)иЌЇз‰©ж”Їжћ¶з»“еђ€ дє†еЅ“д»Љдј�еј‚зљ„ж”Їжћ¶жЉЂжњЇпјЊй‡‡з”Ёй’ґй“¬еђ€й‡‘ж”Їжћ¶е№іеЏ°пјЊе®Ње…Ёз”џз‰©еЏЇ й™Ќи§Јж¶‚е±‚е’Њй›·её•йњ‰зґ иЌЇз‰©пјЊе…·жњ‰дј�еј‚зљ„иѕ“йЂЃжЂ§иѓЅе’Њиїњжњџз–—ж•€гЂ‚ е®Ње…Ёй™Ќи§ЈиЌЇз‰©иЅЅдЅ“пјЊеЏЇжњ‰ж•€й�Іжўж™љжњџиЎЂж “зљ„еЅўж€ђгЂ‚з€±з«‹(TIVOLI) ж”Їжћ¶ењЁеЊ—дє¬й�ње¤–еЊ»й™ўгЂЃеЊ—дє¬е®‰иґћеЊ»й™ўгЂЃеЊ—е¤§еЊ»й™ўгЂЃдёЉжµ·дёе±±еЊ» й™ўгЂЃе№їе·ћзњЃдєєж°‘еЊ»й™ўз‰е…Ёе›Ѕи‘—еђЌзљ„еЌЃдєЊе®¶еЊ»й™ўиї›иЎЊдє†дёґеєЉиЇ• йЄЊпјЊж”Їжћ¶ж¤Ќе…ҐеђЋдё‰е№ґйљЏи®їз»“жћње……е€†е±•з¤єдє†TIVOLIж”Їжћ¶зљ„дј�и¶ЉжЂ§пјЊ е†Ќз‹зЄ„зЋ‡д»…дёє2.9%гЂ‚ е…¬еЏёеє§иђЅдєЋдёе…іжќ‘й«�з§‘жЉЂе›еЊєпјЊж‹Ґжњ‰ејєе¤§зљ„з ”еЏ‘е’Њз®Ўзђ†е›ўй�џпјЊе›Ѕ й™…дёЂжµЃзљ„з”џдє§и®ѕж–ЅпјЊиї‘дё¤е№ґе…€еђЋиў«иЇ„дёєеЊ—дє¬её‚з”џз‰©еЊ»иЌЇG20е·ҐзЁ‹ жЅњеЉ›дјЃдёљгЂЃжµ·ж·ЂеЊєж ёеїѓеЊєе€›ж–°ећ‹дјЃдёљгЂЃдёе…іжќ‘з™ѕе®¶е€›ж–°ећ‹иЇ•з‚№дјЃ дёљпјЊз€±з«‹TIVOLIиЌЇз‰©ж”Їжћ¶иў«иЇ„дёє2010е№ґG20е·ҐзЁ‹жњЂе…·жЅњеЉ›дє§е“ЃгЂ‚ BSC Int'l Medical Trading(Shanghai) Co.,Ltd жіўз§‘е›Ѕй™…еЊ»з–—иґёж�“(дёЉжµ·)жњ‰й™ђе…¬еЏё Booth Number / е±•дЅЌеЏ·: A174 Address: Unit 4701, Raffles City, No268 Xizang Middle Road, Shanghai ењ°еќЂпјљ дёЉжµ·её‚иҐїи—Џдёи·Ї268еЏ· 021-6141 5901 Tel: 021-6141 5900 Fax: Email: [email protected] Boston Scientific (NYSE: BSX) is a worldwide developer, manufacturer and marketer of medical devices with approximately 25,000 employees and revenue of $7.806 billion in 2010. For more than 30 years, Boston Scientific has advanced the practice of lessinvasive medicine by providing a broad and deep portfolio of innovative products, technologies and services across a wide range of medical specialties. The Company's products help physicians and other medical professionals improve their patients' quality of life by providing alternatives to surgery. For more information, please visit www.bostonscientific.com. MISSION Boston Scientific's mission is to improve the quality of patient care and the productivity of health care delivery through the development and advocacy of less-invasive medical devices and procedures. This is accomplished through the continuing refinement of existing products and procedures and the investigation and development of new technologies which can reduce risk, trauma, cost, procedure time and the need for aftercare. 177 CIT 2012 www.citmd.com EXHIBITORS' DIRECTORY HISTORY Boston Scientific's history began in the late 1960s, when cofounder John Abele acquired an equity interest in Medi-tech, Inc., a research and development company focused on developing alternatives to traditional surgery. Medi-tech's first products, a family of steerable catheters, were introduced in 1969 and were used in some of the first less-invasive procedures. Versions of these steerable catheters are still used today. In 1979, Abele and Pete Nicholas partnered to buy Medi-tech and together formed Boston Scientific Corporation. жіўеЈ«йЎїз§‘е¦е›Ѕй™…жњ‰й™ђе…¬еЏёж�ЇдёЂе®¶е…ЁзђѓжЂ§зљ„еЊ»з–—жЉЂжњЇдє§е“Ѓз ”еЏ‘гЂЃз”џ дє§гЂЃиђҐй”Ђе…¬еЏёпјЊзЋ°жњ‰25,000еђЌй›‡е‘�пјЊ2010е№ґзљ„й”Ђе”®ж”¶е…Ґдёє78.06дєї зѕЋй‡‘гЂ‚ењЁиї‡еЋ»зљ„30е¤ље№ґдёпјЊе…¬еЏёдёєе№їжі›зљ„еЊ»з–—жЉЂжњЇйў†еџџжЏђдѕ›дє†е…· жњ‰ж·±еє¦е’Ње№їеє¦зљ„дј—е¤љйќ©ж–°дє§е“ЃзєїпјЊд»ЋиЂЊжЋЁеЉЁдє†еѕ®е€›д»‹е…Ґдє§е“Ѓзљ„е®ћ и·µе’ЊеЏ‘е±•гЂ‚е…¬еЏёзљ„дє§е“ЃйЂљиї‡жЏђдѕ›дј з»џе¤–з§‘ж‰‹жњЇзљ„ж›їд»Јдє§е“ЃпјЊеё®еЉ© еЊ»з”џе’Ње…¶д»–еЊ»з–—иЎЊдёље·ҐдЅњиЂ…ж”№е–„з—…дєєзљ„з”џе‘ЅиґЁй‡ЏгЂ‚ е…ідєЋж›ґиЇ¦з»†зљ„дїЎжЃЇпјЊиЇ·еЏ‚й�…www.bostonscientific.com. ж€‘д»¬зљ„дЅїе‘Ѕ йЂљиї‡еЂЎеЇје’ЊеЏ‘е±•еѕ®е€›д»‹е…ҐжЉЂжњЇпјЊжЏђй«�з—…дєєзљ„жЉ¤зђ†иґЁй‡ЏеЏЉеЊ»з–—дє‹ дёљзљ„з”џдє§еЉ›гЂ‚ж€‘д»¬зљ„дЅїе‘Ѕж�ЇйЂљиї‡жЊЃз»ж”№е–„зЋ°жњ‰дє§е“ЃпјЊдёЌж–з ”еЏ‘ иѓЅе¤џе‡Џе°‘йЈЋй™©гЂЃжЌџдј¤гЂЃиґ№з”ЁгЂЃж‰‹жњЇж—¶й—ґе’ЊжњЇеђЋжЉ¤зђ†зљ„ж–°жЉЂжњЇжќҐ иѕѕе€°зљ„гЂ‚ е…¬еЏёеЋ†еЏІ жіўеЈ«йЎїз§‘е¦е›Ѕй™…жњ‰й™ђе…¬еЏёзљ„еЋ†еЏІд»ЋдєЊеЌЃдё–зєЄ60е№ґд»Јж™љжњџејЂе§‹пјЊеЅ“ ж—¶иЃ”еђ€е€›е§‹дєєJohn Abeleе…€з”џж”¶иґдє†Medi-techе…¬еЏёпјЊж¤е…¬еЏёж�ЇдёЂ е®¶дё“жіЁдєЋеЏ‘е±•дј з»џе¤–з§‘ж‰‹жњЇж›їд»Јдє§е“Ѓзљ„з ”еЏ‘ећ‹е…¬еЏёгЂ‚Medi-techе…¬ еЏёзљ„з¬¬дёЂдёЄдє§е“ЃвЂ”вЂ”еЇјеј•еЇјз®Ўзі»е€—пјЊдєЋ1969е№ґжЋЁеђ‘её‚ењєпјЊе№¶ењЁдёЂ дє›ж—©жњџзљ„еѕ®е€›ж‰‹жњЇдёиў«дЅїз”ЁгЂ‚еЅ“ж—¶иї™дє›еЇјеј•еЇјз®Ўзљ„йѓЁе€†дє§е“Ѓиї„д»Љ д»Ќз„¶иў«дЅїз”ЁгЂ‚1979е№ґпјЊAbeleе…€з”џе’ЊPete Nicholasе…€з”џеђ€дј™ж”¶иґдє† Medi-techе…¬еЏёе№¶дёЂиµ·з»„ж€ђдє†жіўеЈ«йЎїз§‘е¦е›Ѕй™…е…¬еЏёгЂ‚ Kinhely Bio-tech co.,Ltd ж·±ењіеё‚й‡‘з‘ће‡Їе€©з”џз‰©з§‘жЉЂжњ‰й™ђе…¬еЏё Booth Number / е±•дЅЌеЏ·: A178 Address: Floor6,House402,CaiDian Industral Park, North Huanggang Rd.,Futian,Shenzhen. ењ°еќЂпјљ ж·±ењіеё‚з¦Џз”°еЊєзљ‡еІ—еЊ—и·ЇеЅ©з”µе·ҐдёљеЊєдёЋ402ж ‹6жҐј 021-6413 6730 Tel: 021-6413 6370 Fax: [email protected] Email: ж€‘д»¬зљ„дЅїе‘Ѕ е…¬еЏёд»ҐвЂњдёєйЎѕе®ўжЏђдѕ›е®‰е…ЁгЂЃе…·жњ‰з–—ж•€зљ„дє§е“ЃпјЊд»Ґж»Ўи¶ійЎѕе®ўзљ„жњЂ е¤§йњЂж±‚вЂќдёєдЅїе‘ЅпјЊд»ҐдёҐи°Ёзљ„з§‘е¦жЂЃеє¦пјЊе…€иї›зљ„з®Ўзђ†еЏЉжЉЂжњЇе’Њй«� зґ иґЁзљ„е›ўй�џз”џдє§й«�иґЁй‡Џзљ„дє§е“ЃпјЊж»Ўи¶ійЎѕе®ўзљ„йњЂж±‚пјЊдє‰еЏ–еЌ“и¶ЉпјЊ е€›е»єдёЂжµЃзљ„ж°‘ж—ЏдјЃдёљгЂ‚ иґЁй‡Џж–№й’€пјљд»Ґжі•еѕ‹дёєе‡†з»іпјЊи§†иґЁй‡Џдёєз”џе‘Ѕпј› ж‰“йЂ е®‰е…Ёи€’еїѓдє§е“ЃпјЊе€›е»єйЎѕе®ўдїЎд»»дјЃдёљгЂ‚ й‡‘з‘ће‡Їе€©ж�ЇдёЂдёЄе……ж»Ўиї›еЏ–зІѕзҐћзљ„е№ґиЅ»е…¬еЏёгЂ‚е…¬еЏёеЂЎеЇјвЂњдєєжњ¬гЂЃ е€›ж–°гЂЃеЌ“и¶ЉгЂЃе°Љй‡ЌвЂќзљ„зђ†еїµпј›д»ҐвЂње®‰е…ЁгЂЃиґЁй‡ЏгЂЃж•€зЋ‡гЂЃж€ђжњ¬вЂќ дёєж—Ґеёёе·ҐдЅње‡†е€™пј›д»ҐвЂњдёєдєєз±»еЃҐеє·иґЎзЊ®ж‰Ќж™єдёЋжЉЂжњЇвЂќдёєдЅїе‘ЅпјЊ е€›е»єе№¶дїќжЊЃдјЃдёљзљ„ж ёеїѓз«ћдє‰еЉ›гЂ‚ иЇ¦жѓ…иЇ·еЏ‚й�…пјљwww.kinhely.com Promed Medical Tech. (Suzhou) Co., Ltd. е¤©еЃҐеЊ»з–—з§‘жЉЂ(и‹Џе·ћ)жњ‰й™ђе…¬еЏё Booth Number / е±•дЅЌеЏ·: A180-A181 Address: No. 25 Xing Nan Road, Wu Zhong District, Suzhou, 215128, P.R.China ењ°еќЂпјљ дёе›Ѕи‹Џе·ћеђґдёеЊєе…ґеЌ—и·Ї25еЏ· 0512-6658 6669 Tel: 0512-6561 3885 Fax: [email protected] Email: Beijing Demax Medical Technology Co., Ltd. еЊ—дє¬иїЄзЋ›е…‹еЊ»иЌЇз§‘жЉЂжњ‰й™ђе…¬еЏё Booth Number / е±•дЅЌеЏ·: A196 Address: 1st Floor, Building No.1, No.8 Hongdabei road, BDA, Beijing China ењ°еќЂпјљ еЊ—дє¬её‚з»ЏжµЋжЉЂжњЇејЂеЏ‘еЊєе®Џе¤§еЊ—и·Ї8еЏ·1еЏ·еЋ‚ж€ї1е±‚ 010-5778 0251-802 Tel: 010-5778 0398 Fax: Email: [email protected] ж·±ењіеё‚й‡‘з‘ће‡Їе€©з”џз‰©з§‘жЉЂжњ‰й™ђе…¬еЏёд»Ћ2006е№ґејЂе§‹з№е¤‡пјЊдєЋ2007 е№ґе€ќжЈејЏж€ђз«‹пјЊж�ЇдёЂдёЄдё“й—Ёд»Ћдє‹еїѓи„Џд»‹е…ҐеЊ»з–—дє§е“Ѓзљ„з ”е€¶е’ЊејЂ еЏ‘еЏЉз”џдє§е’ЊжњЌеЉЎзљ„е…¬еЏёпјЊе…¬еЏёз”џдє§еџєењ°и®ѕењЁж·±ењіеё‚з¦Џз”°еЊєеЅ©з”µ е·Ґдёље›еЊєе†…пј›е…¬еЏёе›ўй�џз”±еЊ»з–—гЂЃеЊ–е·ҐгЂЃз”џз‰©гЂЃжњєжў°гЂЃе€¶иЌЇе’ЊдїЎ жЃЇз®Ўзђ†з‰дё“дёљж–№йќўзљ„дєєж‰Ќз»„ж€ђгЂ‚ Headquartered in Australia, Demax Medical manufactures medical devices used in Interventional CardiologyпјЊincluding Balloon Dilatation Catheter, Inflation Device, Introducer Sheath Kit, Y Connector Kit, Manifold, Control Syringe etc. Demax Medical has marked its presence in the market relying on excellent technical engineering, state-of-art production equipment, high standard raw materials selection and strict quality management system. Based on clients' requirement, Demax Medical will continually update products range. We are devoted to achieving the highest standardвЂ”вЂњZero Defection productsвЂќ in the Interventional Cardiology Industry. е…¬еЏёз ”еЏ‘зљ„жµ·е€©ж¬§ж–ЇиЌЇз‰©ж”Їжћ¶зі»з»џе·ІйЂљиї‡жіЁе†ЊеЅўејЏжЈЂйЄЊе’ЊеЉЁз‰© е®ћйЄЊпјЊжЈењЁиї›иЎЊе›Ѕе†…й¦–дёЄеЊ»з–—е™Ёжў°йљЏжњєеЌ•з›Іе№іиЎЊеЇ№з…§дёґеєЉйЄЊиЇЃ иЇ•йЄЊгЂ‚ иїЄзЋ›е…‹еЊ»иЌЇз§‘жЉЂжњ‰й™ђе…¬еЏёж�Їз”±жѕіжґІиїЄзЋ›е…‹жЉ•иµ„.е…¬еЏёдё“й—Ёд»Ћдє‹дєЋ еїѓе†…д»‹е…ҐеЊ»з–—е™Ёжў°з ”еЏ‘дёЋз”џдє§пјЊдє§е“ЃеЊ…ж‹¬PTCAзђѓе›Љж‰©еј еЇјз®Ў, еЋ‹ еЉ›жіµпјЊиЎЂз®Ўйћ�з»„д»¶пјЊвЂњYвЂќжЋҐе¤ґз»„д»¶пјЊиїћйЂљжќїпјЊд»ҐеЏЉжЋЁжіЁе™Ёз‰дє§ 178 CIT 2012 www.citmd.com EXHIBITORS' DIRECTORY е“ЃгЂ‚е‡еЂџдј�з§Ђзљ„жЉЂжњЇдєєе‘�гЂЃйЎ¶зє§зљ„з”џдє§и®ѕе¤‡гЂЃй«�ж ‡е‡†зљ„еЋџж–™йЂ‰ жќђгЂЃдёҐи°Ёзљ„е€¶дЅње·Ґи‰єеЏЉз®Ўзђ†дЅ“зі»иї…йЂџењЁеїѓе†…д»‹е…ҐеЊ»з–—е™Ёжў°зљ„е€¶ йЂ дёљеЏ‘е±•гЂ‚иїЄзЋ›е…‹д»ҐеЊ»з–—йњЂж±‚дёєж №жњ¬, д»Ґе“ЃиґЁдёєж ёеїѓпјЊеЉЄеЉ›е®ћзЋ° дє§е“Ѓй›¶зјєй™·зљ„ж–№й’€дёєе‡†е€™пјЊе°†дёЌж–ејЂеЏ‘ж›ґеҐЅзљ„дє§е“Ѓж»Ўи¶іеЊ»з”Ёеё‚ ењєзљ„йњЂи¦Ѓ. Bejin Yongton Unted Technology Co.Led. еЊ—дє¬ж°ёйЂљиЃ”еђ€з§‘жЉЂжњ‰й™ђе…¬еЏё Booth Number / е±•дЅЌеЏ·: A197 Address: No 6 Xiaozhuang Chaoyangmeiwai Ave Beijing ењ°еќЂпјљ еЊ—дє¬её‚жњќй�іеЊєжњќе¤–е°Џеє„6еЏ· 010-6506 2339 Tel: 010-6506 2339 Fax: [email protected] Email: еЊ—дє¬ж°ёйЂљиЃ”еђ€з§‘жЉЂжњ‰й™ђе…¬еЏёж�Їдёе›Ѕдё“дёљйў†еџџйў†е…€зљ„еЊ»з–—дє§е“Ѓе…¬ еЏёгЂ‚е…¬еЏёй›†з ”еЏ‘гЂЃжіЁе†ЊгЂЃз”џдє§гЂЃеё‚ењєй”Ђе”®дєЋдёЂдЅ“пјЊењЁжІ€й�іењ°еЊє ж‹Ґжњ‰дё¤е®¶дё“дёљеЊ»з–—е™Ёжў°з”џдє§еЋ‚пјЊж¶‰еЏЉж”ѕе°„д»‹е…ҐгЂЃжіЊе°їгЂЃеїѓи„Џд»‹ е…ҐгЂЃеїѓи„Џе¤–з§‘з‰е¤љдёЄеЊ»е¦йў†еџџпјЊењЁе…Ёе›Ѕж‹Ґжњ‰е®Ње–„зљ„иђҐй”ЂзЅ‘з»њгЂ‚ еЊ—дє¬ж°ёйЂљиЃ”еђ€з§‘жЉЂжњ‰й™ђе…¬еЏёй™¤и‡Єдё»з ”еЏ‘з”џдє§дє§е“Ѓе¤–пјЊдёЌж–еј•иї› жќҐи‡Єж¬§гЂЃзѕЋзІѕйЂ‰й«�е“ЃиґЁеЊ»з–—е™Ёжў°д№џж�Їе…¬еЏёзљ„дё»и¦ЃдёљеЉЎгЂ‚е…¬еЏёе®ћ дЅ“еЏЉе…¶ж€ђе‘�дёєе…¶й•їиѕѕ 10 е№ґзљ„д»Ћдёљз»ЏйЄЊдёЋйЄ„дєєдёљз»©ж·±ж„џи‡Єи±ЄгЂ‚ е…¬еЏёз§‰ж‰ївЂње®ўж€·и‡ідёЉпјЊе‘�е·Ґдј�е…€вЂќзљ„е…¬еЏёе®—ж—ЁпјЊеќљжЊЃдё“дёљжњЌ еЉЎпјЊе¦жњЇе…€еЇјзљ„её‚ењєеЋџе€™пјЊењЁзІѕеїѓж”ЇжЊЃеђ„ењ°з»Џй”Ђе•†зљ„еџєзЎЂдёЉпјЊ дёєеЊ»й™ўдё“дёљз§‘е®¤жЏђдѕ›е…Ёйќўзљ„дё“дёљжЉЂжњЇж”ЇжЊЃпјЊеЏЉж—¶дј ж’дё–з•Ње…€иї› еЊ»з–—жЉЂжњЇе€°е…Ёе›Ѕеђ„ењ°пјЊдёЋдј—е¤ље¤§дёећ‹еЊ»з–—жњєжћ„з»“дё‹и‰ЇеҐЅеЏ‹и°ЉгЂ‚ е…¬еЏёе°†жЊЃз»иїЅиёЄе№¶жЋЁе№їдё–з•Ње…€иї›еЊ»з–—жЉЂжњЇпјЊеЉ з›џе›Ѕй™…еЊ»з–—иЎЊ дёљеЌЏдјљпјЊе№¶еј•йў†дёе›ЅеЊ»з–—дё“дёљиЎЊдёљеЌЏдјљдёЋдё–з•Њзљ„жІџйЂљдёЋдє¤ жµЃпјЊиµ„еЉ©ж–°жЉЂжњЇдє§е“Ѓзљ„з ”еЏ‘дёЋдє§дёљеЊ–пјЊж€ђдёєдєєз±»еЃҐеє·дє‹дёљд№‹ и·Їзљ„иЂ•иЂ�иЂ…гЂ‚ Agfa HealthCare (Shanghai) Co., Ltd. з€±е…‹еЏ‘еЊ»з–—зі»з»џи®ѕе¤‡(дёЉжµ·)жњ‰й™ђе…¬еЏё Booth Number / е±•дЅЌеЏ·: A198 Address: 15F, No. 388 West Nanjing Road ењ°еќЂпјљ дёЉжµ·её‚еЌ—дє¬иҐїи·Ї388еЏ·д»™д№ђж–Їе№їењє15жҐј 021-2412 2000 Tel: 021-2412 2067 Fax: Email: [email protected] About Agfa HealthCare Agfa HealthCare, a member of the Agfa-Gevaert Group, is a leading provider of IT-enabled clinical workflow and diagnostic image management solutions, and state-of-the-art systems for capturing and processing images in hospitals and healthcare facilities. Agfa HealthCare has over a century of healthcare experience related to diagnostic imaging and has been a pioneer on the healthcare IT market since the early 1990's. 179 Agfa HealthCare has sales offices and representatives in over 100 markets worldwide. Sales for Agfa HealthCare in 2010 were 1,180 million Euro. Delivering solutions Agfa HealthCare today offers its customers an extensive portfolio of solutions, including Hospital Information Systems (HIS), Clinical Information Systems (CIS), Radiology Information Systems (RIS), Picture Archiving and Communications Systems (PACS), Laboratory Information Systems (LIS), Cardiology Information and Image Management Systems, solutions for reporting, enterprise scheduling, decision support, and data storage as well as Digital Radiography, Computed Radiography, print solutions, film and associated products. Over the years, Agfa HealthCare has demonstrated its capacity for successfully support its customers' technological challenges, and transitioning them from analog to digital to IT solutions. This success has made Agfa HealthCare a global Imaging Informatics leader with over 2000 installations (PACS, RIS, CVIS) worldwide, and European healthcare Enterprise IT leader with systems installed in 1200 European hospitals and 1000 laboratories. IT solutions developed and implemented by Agfa HealthCare work across departmental disciplines to integrate information and streamline the workflows and operations of hospitals, imaging centers and other healthcare facilities, enabling a more effective and efficient healthcare offering. Agfa HealthCare is a leader in the fast growing market of IT systems that span the entire healthcare enterprise and through which significant gains can be made in quality of care, speed and cost effectiveness. Imaging systems developed and implemented by Agfa HealthCare capture, process, and manage diagnostic images from a multitude of sources within and beyond the healthcare enterprise, integrating these into a variety of workflows and systems. These systems are designed to bring vital information to medical practitioners regardless of their location. Agfa HealthCare's solutions serve a multitude of medical specialties and departments including radiology, cardiology, orthopaedics, women's care and intensive care units. Lake Region Medical й›·з§‘еЊ»з–— Booth Number / е±•дЅЌеЏ·: A223 Address: Suite A 22nd Floor, 1800 Zhongshan West Rd ењ°еќЂпјљ дёе±±иҐїи·Ї1800еЏ·е…†дё°е¤§еЋ¦22A 021-3353 2850 Tel: 021-6440 3173 Fax: [email protected] Email: Lake Region Medical is a global leader in OEM devices, specializing in minimally-invasive technologies, such as guidewires. With extensive industry knowledge, technical expertise and portfolio CIT 2012 www.citmd.com EXHIBITORS' DIRECTORY of patented technologies, Lake Region is dedicated to the development of innovative products for minimally-invasive therapies for cardiovascular, cardiac rhythm management, neurovascular and peripheral vascular applications. D-Pulse Medical (Beijing) Co., Ltd. йѕ™и„‰еЊ»з–—е™Ёжў°(еЊ—дє¬)жњ‰й™ђе…¬еЏё Booth Number / е±•дЅЌеЏ·: A225 Address: 2,5th KeChuang(E)St., OPTO-Mechatronics Industrial Park, TongZhou District, Beijing ењ°еќЂпјљ еЊ—дє¬её‚йЂље·ћеЊєе…‰жњєз”µдёЂдЅ“еЊ–дє§дёљеџєењ°з§‘е€›дёњдє”иЎ—2еЏ· 010-5211 6868 Tel: 010-5211 6802 Fax: [email protected] Email: йѕ™и„‰еЊ»з–—е™Ёжў°(еЊ—дє¬)жњ‰й™ђе…¬еЏёпјЊдЅЌдєЋеЊ—дє¬её‚йЂље·ћеЊєе…‰жњєз”µдёЂдЅ“еЊ– дє§дёљеџєењ°пјЊж�ЇдёЂж‰Ђдё“дёљд»Ћдє‹д»‹е…Ґдє§е“Ѓзљ„з ”еЏ‘гЂЃз”џдє§гЂЃй”Ђе”®еЏЉе”® еђЋжњЌеЉЎдёєдёЂдЅ“зљ„дјЃдёљгЂ‚ е…¬еЏёдѕќйќ дёЂж”Їй«�е±‚ж¬Ўзљ„з§‘жЉЂй�џдјЌпјЊе…€еђЋејЂеЏ‘дє†дёЂзі»е€—PCIд»‹е…Ґй…Ќ д»¶дє§е“ЃгЂ‚и‡ЄиЎЊз ”еЏ‘зљ„Yећ‹иїћжЋҐе™Ёз»„д»¶гЂЃеЋ‹еЉ›жіµгЂЃиЌЇз‰©жґ—и„±ж”Їжћ¶гЂЃ е† и„‰ж”Їжћ¶з‰иЌЈиЋ·е…йЎ№е›Ѕе®¶дё“е€©гЂ‚2009е№ґпјЊе…¬еЏёйЂљиї‡дє†ISO13485 еЊ»з–—е™Ёжў°иґЁй‡Џз®Ўзђ†дЅ“зі»и®¤иЇЃгЂ‚ е…¬еЏёжіЁй‡Ќд»ҐжЉЂжњЇе€›ж–°дёєз›®ж ‡пјЊд»Ґз ”еЏ‘е’ЊеЉ е·ҐдёєдёЂдЅ“пјЊдё“дёље€¶йЂ еђ„з§Ќд»‹е…Ґй…Ќд»¶дє§е“ЃгЂ‚д»ҐвЂње®‰е…Ёжњ‰ж•€гЂЃйЎѕе®ўж»Ўж„ЏгЂЃи§„иЊѓз®Ўзђ†гЂЃзІѕ з›Љж±‚зІѕвЂќдёєиґЁй‡Џж–№й’€пјЊз§‰жЊЃвЂњдё“жіЁеЃҐеє·пјЊе€›ж–°й©±еЉЁвЂќзљ„з»ЏиђҐзђ† еїµпјЊдёєз”Ёж€·жЏђдѕ›е®Ње–„зљ„е”®е‰Ќе’ЁиЇўе’Ње”®еђЋжњЌеЉЎгЂ‚ е‡еЂџзќЂй›„еЋљзљ„з§‘з ”еЉ›й‡ЏпјЊе®Ње–„зљ„з®Ўзђ†дЅ“зі»е’Њи‰ЇеҐЅзљ„дјЃдёљеЅўи±ЎпјЊ ж€‘д»¬дёЌж–е€›ж–°пјЊејЂж‹“иї›еЏ–пјЊеЉЄеЉ›е€›йЂ е±ћдєЋи‡Єе·±зљ„з‰№и‰Ідє§е“ЃгЂ‚ D-Pulse Medical (Beijing) Co., Ltd. is located in OPTO-Mechatronics Industrial Park, TongZhou District, Beijing, which majored in the PCI accessories products manufacturing. It has 2500 m2 10,000 grade clean room with advanced manufacturing equipments, nicer manufacturing environment, strict physics and chemistry lab. D-Pulse has been built a practical quality control management system from raw materials to finishedproduct. We have the strict production operations management, and standardized induction training system to ensure the quality of products. With the well educated team, we have developed a series of PCI accessory products, and we could provide formulation research and development according to customer's requirements to ensure customer satisfaction. We obtained the certificate of ISO13485 Quality Management System for Medical Device, Sanofi (Hangzhou) Pharmaceuticals Co., Ltd. иµ›иЇєиЏІ(жќе·ћ)е€¶иЌЇжњ‰й™ђе…¬еЏё Booth Number / е±•дЅЌеЏ·: A226 Address: Floor 31-32 Office Bldg.,Plaza 66,NO.1266,Nanjing Rd. West,Shanghai ењ°еќЂпјљ дёЉжµ·её‚еЌ—дє¬иҐїи·Ї1266еЏ·жЃ’йљ†е№їењєеЉће…¬жҐј31-32е±‚ 021-6288 1616-6915 Tel: 021-6288 2335 Fax: Email: [email protected] Sanofi is one of the first foreign pharmaceutical companies to open offices in China. It is also one of the fastest growing healthcare companies in China, with 6,000 people in more than 200 cities across China. A long heritage and expanding footprint In 1982, Sanofi became one of the first foreign pharmaceutical companies to open offices in China. Today, Sanofi has one of the largest workforce in the Chinese healthcare industry. Sanofi's China headquarters are in Shanghai, supported by 11 regional offices in Beijing, Tianjin, Shenyang, Shanghai, Hangzhou, Nanjing, Wuhan, Chengdu, Guangzhou, Jinanand Urumqi. Uniquely positioned to address public health needs in China Г� Disease Prevention вЂ“ Sanofi Pasteur, the vaccines division of Sanofi, is a worldwide leader of vaccines. Sanofi Pasteur has a broad portfolio to meet pediatric and adult immunization requirements in China, including influenza (Vaxigrip), pediatric diseases (IPV), Rabies (Verorab). SP expects to launch Pentaxim, the first pediatric 5-in-1 vaccine in China, in 2011. Г� Consumer Healthcare вЂ“ In October 2010, Sanofi entered the consumer healthcare market in China, with the establishment of Hangzhou Sanofi Minsheng Consumer Healthcare Co., Ltd, which focuses on Vitamins and Mineral Supplements (VMS). Sanofi has a majority equity stake in this joint venture with Minsheng Pharmaceutical Group. In Feb 2011,Sanofi successfully completed the acquisition of BMP Sunstone, which allows Sanofi to own China's most recognized children cough&cold brand: вЂњHao Wa WaвЂќ (GoodBaby). These collaborations provide Sanofi a strong position in both Vitamins & Minerals Supplements and Cough&Cold, the two largest categories of ChinaOTC market. Г� Key Therapeutic Areas вЂ“ China has over 92 million diabetes patients1. With Lantus and Amaryl, Sanofi is the fastest growing company in diabetes2. вЂ“ Plavix, our anti-platelet drug for PCI / ACS / Stroke is the largest Rx product in China2. вЂ“ China has 200 million hypertension patients3, and ARB is the fastest growing class. Aprovel is the #1 ARB drug by volume2. вЂ“ Approximately 10% of the Chinese population is affected by the fatty liver disease4. Essentiale is the #1 oral hepatic protector2. вЂ“ Cancer remains the number one cause of death in China. Eloxatin and Taxotere address a broad range of cancer types. New industrial investment to better meet the growing demand of the Chinese market Sanofi currently has three manufacturing 180 CIT 2012 www.citmd.com EXHIBITORS' DIRECTORY facilities in Beijing, Hangzhou, and Shenzhen. In addition, the company is building three new facilities, all scheduled to begin commercial production in 2012. This includes: Г� Expanding the current manufacturing facility in Beijing to build pre-filled injection production lines for LantusВ® (Insulin Glargine) SoloSTARВ® Г� Building a new manufacturing site in Binjiang New Development Zone in Hangzhou to replace the current facility in downtown Hangzhou Г� Building a hi-tech manufacturing facility in Shenzhen to produce VaxigripВ® for the prevention of seasonal influenza and to contribute to pandemic readiness in China Integrated and Collaborative R&D Sanofi is engaged in integrated R&D in China from drug target identification to late stage clinical studies. Its China R&D Center and Asia Pacific R&D Center are based in Shanghai, supported by branches in Beijing and Chengdu. Since 2008, Sanofi has established over ten strategic collaborations on the discovery front with top scientific institutions in China in cutting-edge research in cancer, stem cell, diabetes and age-related diseases. PTS Co. Ltd. дёЉжµ·зђµжі°зЏЉеЊ»й™ўжЉ•иµ„з®Ўзђ†жњ‰й™ђе…¬еЏё е¤љеђЌе‘�е·Ґдёє100е¤љдёЄе›Ѕе®¶зљ„е®ўж€·жЏђдѕ›дј�иґЁзљ„дє§е“Ѓе’ЊжњЌеЉЎпјЊеё®еЉ©е…Ё зђѓжІ»з–—еїѓи„Џз—…гЂЃзҐћз»Џз–ѕз—…е’Њж…ўжЂ§з–јз—›зљ„еЊ»з”џжЏђй«�жІ»з–—зљ„жЋЊжЋ§иѓЅ еЉ›пјЊи‡ґеЉ›дєЋйЂљиї‡е…Ёж–№дЅЌй™ЌдЅЋеЏЇиѓЅзљ„еЊ»з–—йЈЋй™©жќҐжЏђй«�еЊ»з–—е®ћи·µж°ґ е№іпјЊеђЊж—¶дёєжЇЏдёЂдЅЌж‚ЈиЂ…зљ„и‰ЇеҐЅйў„еђЋдЅње‡єиґЎзЊ®гЂ‚ Beijing Allian Medical Devices Co., Ltd. еЊ—дє¬ж¬§иЋ±иЃ”еђ€еЊ»з–—е™Ёжў°жњ‰й™ђе…¬еЏё Booth Number / е±•дЅЌеЏ·: A244 Address: Building 4,DongQu International,Ci Yunsi 1st courtyard, ењ°еќЂпјљ еЊ—дє¬её‚жњќй�іеЊєж…€дє‘еЇєдёЂеЏ·й™ў4еЏ·жҐј 010-6489 9016 Tel: 010-6489 9028 Fax: Email: [email protected] еЊ—дє¬ж¬§иЋ±иЃ”еђ€еЊ»з–—е™Ёжў°жњ‰й™ђе…¬еЏёж�Їдёе›Ѕдё“дёљйў†еџџйў†е…€зљ„еЊ»з–—дє§ е“Ѓе…¬еЏёпјЊе…¬еЏёеЏЉе…¶дё‹е±ће…¬еЏёе·Із»Џж€ђеЉџдёЋзѕЋе›Ѕеє“е…‹гЂЃзѕЋе›ЅInfadгЂЃ еѕ·е›ЅMIз‰е…¬еЏёеђ€дЅњпјЊдё»и¦Ѓз»ЏиђҐжќҐи‡Єж¬§гЂЃзѕЋзљ„зІѕйЂ‰й«�е“ЃиґЁеЊ»з–—е™Ё жў°,ењЁж”ѕе°„д»‹е…Ґйў†еџџгЂЃеЊ»з”Ёй�ІжЉ¤йў†еџџдёЋж”ѕе°„еЊ»е¦и®ѕе¤‡йў†еџџж‹Ґжњ‰и‡Є е·±зљ„её‚ењєдёЋд»ЅйўќгЂ‚ е…¬еЏёз§‰ж‰ївЂњењЁйЂ з¦Џз¤ѕдјљд№‹иї‡зЁ‹дёпјЊе®ћзЋ°дјЃдёљзђ†жѓівЂќзљ„е®—ж—ЁпјЊењЁ зІѕеїѓж”ЇжЊЃеђ„ењ°з»Џй”Ђе•†зљ„еџєзЎЂдёЉпјЊдёєеЊ»й™ўдё“дёљз§‘е®¤жЏђдѕ›е…Ёйќўзљ„дё“ дёљжЉЂжњЇж”ЇжЊЃпјЊеЏЉж—¶дј ж’дё–з•Ње…€иї›еЊ»з–—жЉЂжњЇе€°е…Ёе›Ѕеђ„ењ°гЂ‚ Booth Number / е±•дЅЌеЏ·: A229/A240 Address: B-802, Nanzheng Building, 580 Nanjing west street, Shanghai ењ°еќЂпјљ дёЉжµ·её‚еЌ—дє¬иҐїи·Ї580еЏ·еЌ—иЇЃе¤§еЋ¦B-802е®¤ +86-21-5160 0165 Tel: +86-21-5228 2099 Fax: [email protected] Email: ењЈзЉ№иѕѕеЊ»з–—з”Ёе“Ѓ(дёЉжµ·)жњ‰й™ђе…¬еЏё Booth Number / е±•дЅЌеЏ·: A233 Address: 20th Floor, Xuhuiyuan Mansion No.1089, 2nd South Zhongshan Road Xuhui District, Shanghai, China ењ°еќЂпјљ дёЉжµ·её‚еѕђж±‡еЊєдёе±±еЌ—дєЊи·Ї1089еЏ·еѕђж±‡и‹‘е¤§еЋ¦20жҐј 021-2306 7551 Tel: 021-6422 4838 Fax: [email protected] Email: ењЈзЉ№иѕѕеЊ»з–—(St. Jude Medical)ж€ђз«‹дєЋ1976е№ґпјЊжЂ»йѓЁдЅЌдєЋиў«з§°дёєеЊ»з–— з§‘жЉЂд№‹йѓЅзљ„зѕЋе›Ѕж�Ће°ји‹ЏиѕѕењЈдїќзЅ—её‚(St. Paul Minnesota)гЂ‚дё‰еЌЃдЅ™е№ґ жќҐпјЊйЂљиї‡и‡Єдё»е€›ж–°д»ҐеЏЉж€�з•Ґе№¶иґпјЊд»ЋеЌ•зєЇзљ„еїѓи„Џз“Ји†њз”џдє§е•†еЏ‘е±• ж€ђдёЂдёЄдёєдј—е¤љдё“дёљеЊ»з–—йў†еџџжЏђдѕ›з»јеђ€и§Је†іж–№жЎ€зљ„йў†е…€зљ„е›Ѕе®¶еЊ–дё“ дёље…¬еЏёгЂ‚з›®е‰ЌпјЊж€‘д»¬зљ„з ”еЏ‘гЂЃз”џдє§е’ЊжњЌеЉЎдё“жіЁдєЋеїѓи„ЏиЉ‚еѕ‹з®Ўзђ†гЂЃ еїѓи„Џз”µз”џзђ†гЂЃеїѓи„Џе¤–з§‘гЂЃеїѓиЎЂз®Ўд»‹е…ҐиЇЉз–—е’ЊзҐћз»Џи°ѓжЋ§дє”е¤§йў†еџџгЂ‚ ж€‘д»¬зљ„дє§е“ЃеЊ…ж‹¬пјљеїѓи„Џиµ·жђЏе™ЁгЂЃICDгЂЃCRT/DгЂЃз”µз”џзђ†дё‰з»ґж ‡жµ‹зі» з»џгЂЃж¶€ићЌеЏЉиЇЉж–еЇјз®ЎгЂЃдєєе·Ґеїѓи„Џз“Ји†њеЏЉдї®иЎҐдє§е“ЃгЂЃиЎЂз®Ўе°Ѓеђ€е™ЁгЂЃ FFRеЋ‹еЉ›еЇјдёќгЂЃOCTд»ҐеЏЉзҐћз»Џе€єжїЂд»Єз‰гЂ‚2008е№ґиђҐдёљйўќиѕѕ44дєїзѕЋ й‡‘зљ„ењЈзЉ№иѕѕеЊ»з–—з›®е‰ЌењЁе…Ёзђѓж‹Ґжњ‰20е¤ље¤„ж‰§иЎЊе’Ње€¶йЂ жњєжћ„пјЊ13,000 181 ејєз”џ(дёе›Ѕ)еЊ»з–—е™Ёжў°жњ‰й™ђе…¬еЏё Booth Number / е±•дЅЌеЏ·: A264 Address: 7F, #355 Hongqiao Rd. Chengkai International Tower, Shanghai ењ°еќЂпјљ дёЉжµ·её‚и™№жЎҐи·Ї355еЏ·еџЋејЂе¤§еЋ¦7жҐј 021-2205 8922 Tel: 021-2205 9253 Fax: [email protected] Email: CIT 2012 www.citmd.com EXHIBITORS' DIRECTORY PCR й•їеџЋе›Ѕй™…еїѓи„Џз—…е¦дјљи®® Booth Number / е±•дЅЌеЏ·: A268 Booth Number / е±•дЅЌеЏ·: A270 Address: Toulouse cedex 6 19, allГ©es Jean JaurГЁs +33 (0)5 34 45 26 45 Tel: +33 (0)5 61 42 00 09 Fax: [email protected] Email: ењ°еќЂпјљ PCR is an organisation dedicated to education and information in the field of cardiovascular therapies, most notably for cardiovascular intervention and interventional medicine. CHC2012 дёе›Ѕеїѓи„Џз—…е¤§дјљ Booth Number / е±•дЅЌеЏ·: A269 Address: A 167 Beilishi Road, Xicheng District, Fuwai Hospital ењ°еќЂпјљ еЊ—дє¬её‚иҐїеџЋеЊєеЊ—з¤јеЈ«и·Ї167еЏ·й�ње¤–еЊ»й™ў 010-8839 6164 Tel: 010-8831 6064 Fax: [email protected] Email: The China Heart Congress (CHC) as well the Forum is organized by the National Center for Cardiovascular Diseases, China (NCCD), and jointly sponsored by all Chinese societies in cardiovascular field. The theme of the congress is вЂ�Healthy Heart, Better LifeвЂ” Prevention, Translation and Cooperation'. With strong supports from our most knowledgeable national and international experts and colleagues, the Chinese government and the industrial sections as well, the International Heart Forum Beijing has become the most comprehensive conference in cardiovascular field in Asia Pacific region. This year, the China Heart Congress will follow the success of the previous forums. Distinguished scientists will be invited to share their groundbreaking research, present their original scientific works and clinicians will debate the hottest topics for day to day clinical practice. In addition, the congress will offer cardiologists a wealth of opportunities to exchange information on education, recent findings, and the challenges that confront us in cardiovascular care. Tel: Fax: Email: дёе›ЅеЊ—дє¬иҐїз›ґй—ЁеЌ—е¤§иЎ—11еЏ· еЊ—дє¬е¤§е¦дєєж°‘еЊ»й™ў й•їеџЋе›Ѕй™… еїѓи„Џз—…е¦дјљи®®з»„е§”дјљ +86 10-88381733 -8006 +86 10-88381733 [email protected] The Great Wall International Congress of Cardiology (GWICC) The Great Wall International Congress of Cardiology (GWICC) is one of the most influential and successful comprehensive cardiovascular Congress with the most complete subject in the Asia Pacific region. This yearвЂ™s Great Wall International Congress of Cardiology ( GWICC) will develop a more extensive academic exchange and a tighter cooperation with the most influential international medical societies and groups such as ACC, ESCпјЊAPHAпјЊWHFпјЊISCP пјЊESH and JCS etc and will unite more than 10 thousand cardiologists and scholars come from the hospitals throughout the country to have an in-depth exchange and extensive communication. Nowadays the GWICC has developed into a multi-functional organization .Integrating the comprehensive function of international cooperation, knowledge promotion, professional training, academic exchange and interdisciplinary research. GWICC will join hands with the top academic societies or organizations to strengthen medical research and disease control, to promote the healthy development of the cardiology and international community. й•їеџЋе›Ѕй™…еїѓи„Џз—…е¦дјљи®®(й•їеџЋдјљ)ж�Їдєље¤Єењ°еЊєи§„жЁЎжњЂе¤§гЂЃж¶‰еЏЉе¦з§‘ жњЂйЅђе…ЁгЂЃжњЂе…·еЅ±е“ЌеЉ›д№‹дёЂзљ„еїѓиЎЂз®Ўз—…з»јеђ€жЂ§е¦жњЇз››дјљпјЃ д»Ље№ґзљ„й•їеџЋдјљдёЋACCгЂЃESCгЂЃAPHAгЂЃWHFгЂЃISCPгЂЃESHгЂЃJCSз‰е›Ѕ й™…жњЂе…·е¦жњЇеЅ±е“ЌеЉ›зљ„еЊ»е¦з»„з»‡е’Ње›ўдЅ“е±•ејЂдє†ж›ґеЉ е№їжі›иЂЊзґ§еЇ†зљ„ еђ€дЅње’Њдє¤жµЃпјЊиЃ”еђ€дё‡дЅ™еђЌжќҐи‡Єе…Ёе›Ѕеђ„ењ°гЂЃеђ„зє§еЊ»й™ўеїѓиЎЂз®ЎеЏЉе…¶ з›ёе…ідё“дёљзџҐеђЌзљ„дё“е®¶гЂЃе¦иЂ…пјЊж·±е…Ґдє¤жµЃгЂЃе№їжі›жЋўи®ЁгЂ‚ й•їеџЋдјљй›†е›Ѕй™…еђ€дЅњгЂЃзџҐиЇ†жЋЁе№їгЂЃдё“дёљеџ№и®гЂЃе¦жњЇдє¤жµЃгЂЃдє¤еЏ‰з ” з©¶дєЋдёЂдЅ“пјЊдёЋе›Ѕе†…е›Ѕй™…йЎ¶зє§е¦жњЇз»„з»‡е’Ње›ўдЅ“дёЂиµ·пјЊејєеЊ–еЊ»е¦з ” з©¶е’Њз–ѕз—…жЋ§е€¶пјЊе…±еђЊжЋЁеЉЁдё–з•Њеїѓи„Џз—…е¦зљ„еЏ‘е±•пјЊдїѓиї›е›Ѕй™…з¤ѕдјљ еЃҐеє·еЏ‘е±•гЂ‚ In order to better communicate and introduce the latest cardiovascular news and developments, the congress includes approximately 30 sessions, such as Fundamental Research, Epidemiology and Prevention, Cardiovascular Imaging, Cardiology, Interventional Cardiology, Cardiovascular Surgery and Nursing, just to name a few. Sessions are presented in the form of lectures, debates, interviews, workshops, posters and satellite symposiums. This will be a high-profile congress and we look forward to seeing you in August at the China Heart Congress & International. 182 CIT 2012 www.citmd.com EXHIBITORS' DIRECTORY Beijing Kelida Medical Equipment Developing Co.,Ltd. еЊ—дє¬з§‘е€©иѕѕеЊ»з–—и®ѕе¤‡еЏ‘е±•жњ‰й™ђе…¬еЏё Booth Number / е±•дЅЌеЏ·: A271 Address: F606 Zizhu Garden No.88 Zizhuyuan Road Haidian Beijing ењ°еќЂпјљ еЊ—дє¬её‚жµ·ж·ЂеЊєзґ«з«№й™ўи·Ї88еЏ·зґ«з«№иЉ±е›F606 010-8855 2106 Tel: 010-8855 2107 Fax: Email: [email protected] Kelida Medical Equipment Co., Ltd. is a high-tech joint-venture company specializing in R&D, production and sales of medical equipment. After establishment in 1988, Kelida dedicated to R&D, production and sales of medical x-ray protective aprons, protective shield systems, medical image equipment and accessories. All X-ray protective products manufactured in Kelida meet the international standards with high quality and good look. With development recent years, Kelida became the largest manufacturer of X-ray protective aprons and X-ray barriers as well as X-ray protective accessories including lead glasses in China. We are proud to announce that Kelida now is certified according to the general quality management system standard ISO 9001:2000, and also thanks to the high quality, the X-ray protective products manufactured in Kelida obtained the CE mark and FDA approval. Due to the leading market position, Kelida has the most recognized brands in the X-ray protective products in China. So far KelidaвЂ™s products are sold worldwide through our network of distribution partners. Covidien жі°з§‘еЊ»з–—е™Ёжќђе›Ѕй™…иґёж�“(дёЉжµ·)жњ‰й™ђе…¬еЏё Booth Number / е±•дЅЌеЏ·: A273 Address: ROOM 1806-1810 TOWER A OCEAN INTERNA TIONAL CENTGRE ењ°еќЂпјљ еЊ—дє¬её‚жњќй�іеЊєдёње››зЋЇдёи·Їиїњжґ‹е›Ѕй™…дёеїѓAеє§1806-1810 010-5963 1200 Tel: 010-5963 1212 Fax: [email protected] Email: жі°з§‘еЊ»з–—Tyco Healthcareж�Їжі°з§‘е›Ѕй™…й›†е›ўдє”е¤§дёљеЉЎзі»з»џд№‹дёЂпјЊ ж�Їе…Ёзђѓдё»и¦ЃеЊ»з–—и®ѕе¤‡е’ЊдёЂж¬ЎжЂ§еЊ»з–—дє§е“Ѓзљ„з”џдє§е•†гЂ‚жі°з§‘еЊ»з–—зљ„ дё»и¦ЃдёљеЉЎеЊ…ж‹¬е€†дёєеЊ»з–—е™Ёжў°пјЊ еЅ±еѓЏпјЊиЌЇе“ЃпјЊеЊ»з–—з”Ёе“ЃпјЊй›¶е”® дє§е“Ѓдє”е¤§дёљеЉЎйѓЁй—ЁгЂ‚дЅњдёєе…ЁзђѓеЊ»з–—дїќеЃҐдёљжЏђдѕ›дє§е“ЃжњЂдёєе№їжі›зљ„ дё–з•Њзє§дѕ›еє”е•†д№‹дёЂпјЊжі°з§‘еЊ»з–—йЃЌеёѓе…Ёдё–з•Њ50е¤љдёЄе›Ѕе®¶е’Њењ°еЊєзљ„ 43,000еђЌе‘�е·ҐењЁ2006е№ґеє¦е€›йЂ е‡єиї‘100дєїзѕЋе…ѓиђҐдёљйўќгЂ‚е®ѓзљ„дє§е“Ѓ й”ЂеѕЂ130е¤љдёЄе›Ѕе®¶е’Њењ°еЊєгЂ‚ жі°з§‘еЊ»з–—зљ„дЅїе‘Ѕеђ‘е…ЁзђѓеЊ»еЉЎдєєе‘�жЏђ дѕ›дј�и‰Їе€›ж–°зљ„еЊ»з–—дє§е“ЃпјЊи®©ж‚ЈиЂ…иѓЅе¤џдє«еЏ—й«�иґЁй‡Џзљ„еЊ»з–—жњЌеЉЎгЂ‚ 2007е№ґ6жњ€30ж—Ґжі°з§‘й›†е›ўиў«ж‹†е€†дёєдё‰е®¶з‹¬з«‹дёЉеё‚зљ„е…¬еЏёпјЊеЋџжі°з§‘ еЊ»з–—Tyco Healthcareиў«жЈејЏж›ґеђЌдёєCovidienгЂ‚Covidienз»§з»з§‰ж‰ї еЋ†еЏІиѕ‰з…Њж€ђдёєдёЂе®¶дё–з•Њйў†е…€зљ„еЊ»з–—дє§е“Ѓе…¬еЏёпјЊжЏђдѕ›иЇёе¤љдє«иЄ‰дё– з•Њзљ„Nellcor, Puritan-Bennett, Mallinckrodt, US Surgical, Kendallд»Ґ еЏЉ ValleyLabз‰ж——дё‹дє§е“ЃгЂ‚ Covidienзљ„дЅїе‘Ѕж�ЇдёЋеЊ»е¦дё“дёљдєєе‘�е…± еђЊејЂеЏ‘пјЊе€›йЂ е’ЊжЏђдѕ›е€›ж–°зљ„еЊ»з–—и§Је†іж–№жЎ€пјЊж”№е–„ж‚ЈиЂ…зљ„з”џжґ»иґЁ 183 й‡ЏпјЊдёєе®ўж€·е’Њи‚Ўдёње€›йЂ ж›ґеЌ“и¶Љзљ„ж€ђз»©гЂ‚Covidienд»Ґе…¶ењЁеЊ»з–—дє§ е“ЃдёЉзљ„дё“й—ЁжЉЂжњЇпјЊиЇҐиЎЊдёљзљ„з«ћдє‰еЉ›д»ҐеЏЉењЁз ”еЏ‘дёзљ„дёЌж–жЉ•е…ҐпјЊ е†ЌеЉ д№‹е®ѓе……е€†еЌЏи°ѓдє†е…¶е…ЁзђѓеЊ–й”Ђе”®е’Ње€†й”ЂзЅ‘з»њпјЊдЅїе…¶ењЁеЊ»з–—йў† еџџж€ђдёєеђ„з±»е®ўж€·зљ„й¦–йЂ‰дј™дјґгЂ‚йљЏзќЂдёе›Ѕз»ЏжµЋзљ„й«�йЂџеўћй•їе’ЊдёЌж– еўћй•їзљ„еЌ«з”џйњЂж±‚пјЊдєєд»¬ж›ґиї«е€‡йњЂи¦Ѓе…€иї›зљ„еЊ»з–—и®ѕе¤‡гЂ‚иї™дїѓдЅї CovidienењЁдёе›Ѕе»єз«‹е€¶йЂ еЋ‚д»ҐжЏђдѕ›дёЌж–е€›ж–°зљ„гЂЃж›ґе…·з«ћдє‰еЉ›зљ„еЊ» з–—и®ѕе¤‡гЂ‚жі°з§‘еЊ»з–—е™Ёжќђе€¶йЂ (дёЉжµ·)жњ‰й™ђе…¬еЏё ж�ЇCovidienењЁдёе›ЅжЉ• иµ„4еЌѓе¤љдё‡зѕЋй‡‘ж€ђз«‹зљ„е…Ёиµ„еђе…¬еЏёгЂ‚е…¬еЏёж€ђз«‹дєЋ2006е№ґ11жњ€гЂ‚ењЁ 2006е№ґ1жњ€ејЂе§‹еЋ‚ж€їзљ„е»єи®ѕпјЊе№¶дєЋ2007е№ґ4жњ€жђ¬е…ҐдёЉжµ·её‚й—µиЎЊеЊє жµ¦ж±џй•‡жј•жІіжіѕе‡єеЏЈеЉ е·ҐеЊєе†…гЂ‚ Merit Medical Beijing Co., Ltd йє¦з‘ћйЂљеЊ»з–—е™Ёжў°(еЊ—дє¬)жњ‰й™ђе…¬еЏё Booth Number / е±•дЅЌеЏ·: A275-A276 Address: Room1105,11/F, Nuo An Ji Building, No.Jia 14 Guanghua Road, Chaoyang District, Beijing ењ°еќЂпјљ еЊ—дє¬её‚жњќй�іеЊєе…‰еЌЋи·Їз”І14еЏ·иЇєе®‰еџєй‡‘е¤§еЋ¦11е±‚1105е®¤ 010-6593 4476 Tel: 010-6593 4470 Fax: [email protected] Email: Merit Medical is a worldwide company specialized in the development, manufacture and distribution of medical device used in inter ventional and diagnostic procedures. Merit Medical Systems' products address the needs of cardiologists and radiologists around the world, enabling them to perform diagnostic and interventional procedures such as angiography, angioplasty, stent placement, AAA (stent grafts), discography, thrombolysis and other procedures. Merit Medical's product lines include balloon inflation devices and accessories, diagnostic and therapeutic catheters and guide wires, pressure monitoring disposables, fluid delivery systems, non-vascular stents (tracheal, bronchial, esophageal, and biliary), medication syringes, safety products, and needles. We take prides in providing high quality and innovative products to serve clinicians and patients around the world. CIT 2012 www.citmd.com EXHIBITORS' DIRECTORY Lifetech Scientific (Shenzhen) Co., Ltd. е…€еЃҐз§‘жЉЂ(ж·±ењі)жњ‰й™ђе…¬еЏё Booth Number / е±•дЅЌеЏ·: A277 Address: Floor 1-3, Cybio electronic building Langshan 2nd Street, Nanshan Shenzhen ењ°еќЂпјљ ж·±ењіеё‚еЌ—е±±еЊєй«�ж–°жЉЂжњЇдє§дёље›еЊ—еЊєжњ—е±±дєЊи·Їиµ›йњёз§‘з ”жҐј1-3е±‚ 0755-8602 6250 Tel: 0755-8602 6251 Fax: [email protected] Email: Lifetech is a developer, manufacturer and marketer of advanced minimally invasive surgical medical devices for cardiovascular and peripheral vascular diseases and disorders. Lifetech was founded in 1999 and is now the second largest provider worldwide of congenital heart defects occluders and the leading developer and manufacturer of minimally invasive surgical medical devices in China. In 2011, Lifetech listed on the Hong Kong Stock Exchange. Lifetech has a leading market position for occluders, a device for congenital heart defects. Lifetech is now the second largest provider worldwide of occluders for congenital heart defects, and the largest provider of occluders for congenital heart defects in BRIC countries. Lifetech has a broad portfolio of proprietarily developed minimally invasive cardiovascular and peripheral medical devices. As a national high-tech enterprise and a Post-doctoral Research Workstation in China, Lifetech has an experienced research and development team and has established long term and close cooperative relationships with reputable scientific advisors and third party institutions and universities. Lifetech has conducted and is conducting over 10 government-sponsored research and development projects, including one research project of China National Basic Research Program, two research projects of China National High-Tech Research and Development Program, and two research projects co-sponsored by the Guangdong province and the Ministry of Education of the PRC. Lifetech Scientific Corporation is located in Shenzhen and has over 10 subsidiaries, branches and sales offices in Shenzhen, Beijing, Shanghai, Guangzhou, Hong Kong and India. A distribution network has been established for all products, consisting of over 150 distributors located internationally. ANGIOPLASTY SUMMIT-TCTAP Booth Number / е±•дЅЌеЏ·: A283 Address: 388-1, Pungnap-2dong, Songpa-gu, Seoul 2F, Asan Institute for Education & Research 82-2-3010-4749 Tel: 82-2-475-6898 Fax: [email protected] Email: ANGIOPLASTY SUMMIT-TCTAP organized by CardioVascular Research Foundation(CVRF) is one of the largest educational conferences in Asia Pacific specializing in inter ventional cardiovascular medicine. It is played a significant role as a leading player in this filed to educate physicians and other health care professionals from all over the would. Complex Cardiovascular Therapeutics (CCT) Booth Number / е±•дЅЌеЏ·: A284 Address: Toyohashi, Aichi 1-1-5-2E Maedaminami-machi +81-532-57-1275 Tel: +81-532-52-2883 Fax: [email protected] Email: Complex Cardiovascular Therapeutics (CCT) 2012 will be held from November 2 to 4, 2012 in Kobe, Japan. CCT is a live course that masters complex PCI and hands it down to the next generation. We are looking forward to being reunited with you and we welcome and encourage your active participation. Stereotaxis зѕЋе›ЅжЂќз‘ћжі°еїѓе›Ѕй™…е…¬еЏё Booth Number / е±•дЅЌеЏ·: A286 Address: 4320 Forest Park Avenue,Suite 100, St.Louis,MO 63108 ењ°еќЂпјљ еЊ—дє¬её‚иҐїеџЋеЊєй—№её‚еЏЈе¤§иЎ—1еЏ·Cеє§511е®¤ 010-5852 8545 Tel: 010-5852 8545 Fax: [email protected] Email: зѕЋе›ЅжЂќз‘ћжі°еїѓе…¬еЏёи‡ґеЉ›дєЋдёєе…Ёзђѓзљ„еїѓиЎЂз®Ўдё“дёљеЊ»з”џжЏђдѕ›е®‰е…Ёй«� ж•€зљ„е€›ж–°жЂ§дёґеєЉи§Је†іж–№жЎ€пјЊдЅїеЊ»з”џиѓЅи‡Єе¦‚ењ°жІ»з–—з”Ёдј з»џж–№ејЏж— жі•ж¶‰и¶іж€–ж‰‹жњЇе®‰е…ЁжЂ§ж— жі•дїќиЇЃзљ„иЇёе¤љз–‘йљѕз—…жЎ€гЂ‚ ж€‘д»¬зљ„з›®ж ‡ж�Їе°†е¤Ќжќ‚зљ„еїѓи„Џд»‹е…ҐжІ»з–—еЏ�еѕ—з®ЂдѕїгЂЃе®‰е…ЁиЂЊдё”ж›ґжњ‰ ж•€пјЊж€‘д»¬ж‰Ђз‹¬жњ‰зљ„е…Ёи®Ўз®—жњєжЋ§е€¶зљ„зЈЃеЇји€ЄжЉЂжњЇ(NiobeзЈЃеЇји€Єзі» з»џ)иѓЅе¤џй«�еє¦зІѕеЇ†еЏЉе®‰е…Ёењ°жЋ§е€¶еЇјз®ЎеЏЉеїѓиЎЂз®Ўд»‹е…ҐжІ»з–—дёзљ„дё» и¦Ѓиї‡зЁ‹пјЊе№¶дё”йЂљиї‡е…Ёйќўж•ґеђ€зљ„еЇјз®Ўе®¤дёґеєЉдїЎжЃЇзі»з»џ(Odysseyзі» з»џ)пјЊиѓЅе¤џејЂе±•ењЁзєїиЅ¬ж’еЏЉдёґеєЉз¤єж•™пј›и‡Єд»ЋжЂќз‘ћжі°еїѓе…¬еЏё2004е№ґ жЋЁе‡єе…Ёзђѓз¬¬дёЂеЏ°дёґеєЉзЈЃеЇји€Єзі»з»џд»ҐжќҐпјЊе·Із»Џеё®еЉ©еЊ»з”џдЅїж— ж•°зљ„ 184 CIT 2012 www.citmd.com EXHIBITORS' DIRECTORY ж‚ЈиЂ…ж‘†и„±дє†ж€їйў¤з‰еїѓиЎЂз®ЎйЎЅз–ѕзљ„е›°ж‰°пјЊе…Ёзђѓ27дёЄе›Ѕе®¶зљ„зџҐеђЌеїѓ иЎЂз®Ўдёеїѓеќ‡е·Ій…Ќе¤‡дє†ж€‘д»¬зљ„зЈЃеЇји€Єзі»з»џпјЊзЈЃеЇји€Єд»‹е…ҐжІ»з–—ж–№жі• е·Із»ЏйЂђжёђж€ђдёєдёґеєЉеЊ»её€ж‰ЂжЋЁеґ‡зљ„еёёи§„жІ»з–—ж‰‹ж®µпјЊе…¶дёЌд»…и®©е°„йў‘ ж¶€ићЌжІ»з–—зљ„жњЇеђЋдёЌи‰ЇеЏЌеє”е‡ д№Ћй™Ќдёєй›¶пјЊиЂЊдё”дЅїеЊ»её€е’Њз—…дєєеЏ—ж”ѕ е°„зєїиѕђе°„зљ„ж—¶й—ґе’Ње‰‚й‡Џеќ‡е¤§е¤§й™ЌдЅЋпјЊеђЊж—¶д№џе°†еЊ»з”џд»Ћж‰‹жњЇй—ґи§Ј ж”ѕе€°дє†жЋ§е€¶е®¤пјЊењЁиї™й‡ЊеЊ»з”џеЏЇйЂљиї‡иїњзЁ‹ж“ЌжЋ§жќҐе®Њж€ђж•ґдёЄж‰‹жњЇзљ„ е¤§еЌЉиї‡зЁ‹гЂ‚ Protective Apron HUAREN Brand HR Series of Medical X-ray Protective Apron HUAREN Brand HR Series of Medical X-ray Table Mounted Shield and Overhead Suspended Shield HUAREN Brand HR Series of Medical X-ray Protective Mask HUAREN Brand FG Series of Medical X-ray Protective Glasses HUAREN Brand HR Series of Medical X-ray Radiographic Stand. жЂќз‘ћжі°еїѓе…¬еЏёйќћеёёжіЁй‡ЌеЇ№е®ўж€·зљ„дёґеєЉеє”з”Ёеџ№и®пјЊеђЊж—¶е®ўж€·зљ„дёґ еєЉдЅїз”ЁдЅ“дјље’ЊеЏЌй¦€еЏ€ж�Їж€‘д»¬ж”№иї›дёЋе€›ж–°зљ„й‡Ќи¦ЃзЃµж„џжќҐжєђпјЊж€‘д»¬ зљ„еЏ¦е¤–дёЂдёЄй‡Ќи¦Ѓи§Је†іж–№жЎ€Odysseyж•ґеђ€дёґеєЉдїЎжЃЇзі»з»џдѕїжќҐжєђдєЋ ж¤пјЊд»ЋиЂЊдЅїд»ҐеЇјз®Ўе®¤дёєд»ЈиЎЁзљ„дёґеєЉеЌ•е…ѓиѓЅе¤џиЅ»жќѕењ°е®ћж—¶ж�ѕз¤єгЂЃ ж“ЌжЋ§гЂЃи®°еЅ•е№¶иЅ¬ж’е…ЁйѓЁдёґеєЉдїЎжЃЇгЂ‚ еЊ—дє¬её‚еЌЋд»Ѓз›Љеє·з§‘жЉЂеЏ‘е±•жњ‰й™ђе…¬еЏёж�ЇдЅЌдєЋеЊ—дє¬дёе…іжќ‘з§‘жЉЂе›еЊє зљ„дёЂе®¶дё“дёљз ”еЏ‘гЂЃз”џдє§гЂЃз»ЏиђҐеЊ»з”ЁXе°„зєїй�ІжЉ¤з”Ёе“ЃгЂЃXе°„зєїй�ІжЉ¤ иЈ…зЅ®еЏЉж ёеЊ»е¦й�ІжЉ¤иЈ…зЅ®зљ„е›Ѕе®¶зє§й«�ж–°жЉЂжњЇдјЃдёљгЂ‚жњ¬е…¬еЏёдёЂиґЇз§‰ ж‰їи‡Єдё»е€›ж–°гЂЃжЉЂжњЇйў†е…€зљ„дјЃдёљеЏ‘е±•е®—ж—ЁгЂ‚ењЁе›Ѕе†…зЋ‡е…€й‡‡з”Ёе¤ље±‚ и–„ећ‹й�ІжЉ¤жќђж–™з»„еђ€ејЏXе°„зєїй�ІжЉ¤жњЌз”џдє§е·Ґи‰єпј›зЋ‡е…€ејЂеЏ‘е‡єж‚¬жЊ‚й�І жЉ¤е±Џпј›ењЁе›Ѕй™…дёЉй¦–е€›е‡єXе°„зєїй�ІжЉ¤йќўзЅ©гЂ‚з›®е‰Ќж€‘е…¬еЏёе·ІеЏ–еѕ—е›Ѕе®¶ зє§дё“е€©13йЎ№пјЊе№¶дєЋ2011е№ґ12жњ€иў«з¬¬дё‰ж¬Ўи®¤е®љдёєе›Ѕе®¶зє§й«�ж–°жЉЂжњЇ дјЃдёљгЂ‚ ж€‘д»¬иї�дёЋеїѓиЎЂз®Ўд»‹е…Ґйў†еџџзљ„е…¶д»–е…ЁзђѓзџҐеђЌеЋ‚е•†жњ‰еЇ†е€‡зљ„еђ€дЅњпјЊ е¦‚иҐїй—ЁеђгЂЃйЈће€©жµ¦гЂЃејєз”џпјЊдЅїеѕ—ж€‘д»¬зљ„е®ўж€·иѓЅе¤џдє«еЏ—е€°ж— зјќй“ѕ жЋҐзљ„еїѓиЎЂз®Ўд»‹е…ҐжІ»з–—и§Је†іж–№жЎ€пјЊе…¶дёзЈЃеЇји€Єдё“з”Ёзљ„е°„йў‘ж¶€ићЌеЇј з®ЎеЌідёєжЂќз‘ћжі°еїѓе…¬еЏёдєЋејєз”џе…¬еЏёж‰Ђе…±еђЊејЂеЏ‘гЂ‚ ж€‘д»¬зљ„дЅїе‘ЅпјљйЂљиї‡ж‹“е±•й«�еє¦зІѕеЇ†дёЋе®‰е…Ёзљ„дёґеєЉжІ»з–—ж‰‹ж®µпјЊжќҐж‹Ї ж•‘ж›ґе¤љзљ„з—…дєєпјЃ Beijing Huaren Health Science&Technology Developing Co.,Ltd. еЊ—дє¬её‚еЌЋд»Ѓз›Љеє·з§‘жЉЂеЏ‘е±•жњ‰й™ђе…¬еЏё Booth Number / е±•дЅЌеЏ·: A290 Address: Room 205, Building 2, No.45 Xizhimen North Street, Haidian District, Beijing, P.R. China ењ°еќЂпјљ еЊ—дє¬её‚жµ·ж·ЂеЊєиҐїз›ґй—ЁеЊ—е¤§иЎ—45еЏ·2еЏ·жҐј205е®¤ 010-6222 2212 Tel: 010-6222 2022 Fax: [email protected] Email: Beijing Huaren Health&Technology Developing Co.,Ltd is a hi-tech enterprise that specializes in developing, manufacturing and selling X-ray protective products, devices and other X-ray accessories. This company adheres to the tenet of independent innovation and advanced technology, and it is the first one who adopt the technique of combining multiple layers of thin material to become a protective apron and is also the first one to device the overhead suspended shields inland, and it is the pioneer to develop the X-ray protective mask in the world. Untill now, we have obtained 13 items of national patent. In December of 2011, our company was identified as National Hi-tech Enterprise for the third time. Huaren X-ray protection series in accordance with the MDD 93/42EEC of EU and the standard IEC61331-3:1998, and obtained FDA certificate(registration No.: 3005517128) .Recently, our products has been sold to more than 30 contries, for example, Germany, England, Italy, Korea, Pakistan, Kenya. Huaren brand takes the reputation in the region of medical X-ray indoor and outdoor. Our main products: HUAREN Brand HR Series of Medical X-ray Export Lead-free 185 еЌЋд»Ѓз‰Њзі»е€—й�ІжЉ¤дє§е“Ѓз¬¦еђ€ж¬§е…±дЅ“еЊ»з–—е™Ёжў°93/42/EECжЊ‡д»¤ е’ЊIEC61331-3пјљ1998ж ‡е‡†пј›иЋ·еѕ—зѕЋе›ЅFDAи®¤иЇЃ(жіЁе†ЊеЏ·пјљ 3005517128)пјЊдє§е“Ѓи‡ЄжЉ•е…Ґеё‚ењєд»ҐжќҐи¶ЉжќҐи¶ЉеЏ—е€°е›Ѕе†…е¤–еђ„з•Ње®ўж€· и®¤еЏЇпјЊз›®е‰Ќдє§е“Ѓе·Іиїњй”Ђи‡іеѕ·е›ЅгЂЃи‹±е›ЅгЂЃзѕЋе›ЅгЂЃж„Џе¤§е€©гЂЃйџ©е›ЅгЂЃ е·ґеџєж–Їеќ¦гЂЃи‚Їе°јдєљз‰дё‰еЌЃдЅ™дёЄе›Ѕе®¶пјЊеЏ–еѕ—дє†йЄ„дєєзљ„её‚ењєдёљз»©гЂ‚ ж€‘д»¬зљ„дё»и¦Ѓдє§е“Ѓе¦‚дё‹пјљ гЂЂгЂЂеЌЋд»Ѓз‰ЊHRзі»е€—еЊ»з”ЁXе°„зєїж— й“…ж›ґиЅ»ећ‹й�ІжЉ¤жњЌпј› гЂЂгЂЂеЌЋд»Ѓз‰ЊHRзі»е€—еЊ»з”ЁXе°„зєїй�ІжЉ¤жњЌпј› гЂЂгЂЂеЌЋд»Ѓз‰ЊHRзі»е€—еЊ»з”ЁXе°„зєїз§»еЉЁејЏй�ІжЉ¤е±Џпј› гЂЂгЂЂеЌЋд»Ѓз‰ЊHRеЊ»з”ЁXе°„зєїй�ІжЉ¤иЈ…зЅ®зі»з»џпј› гЂЂгЂЂеЌЋд»Ѓз‰ЊHRзі»е€—еЊ»з”ЁXе°„зєїй�ІжЉ¤йќўзЅ©пј› гЂЂгЂЂеЌЋд»Ѓз‰ЊFGзі»е€—еЊ»з”ЁXе°„зєїй�ІжЉ¤зњјй•њпј› гЂЂгЂЂеЌЋд»Ѓз‰ЊHRзі»е€—ж‘„з‰‡жћ¶гЂЃйЂЏи§†жњєй�ІжЉ¤иЈ…зЅ®пј› гЂЂгЂЂеЌЋд»Ѓз‰ЊHRзі»е€—ж ёеЊ»е¦й�ІжЉ¤дє§е“Ѓпј› Shenzhen Salubris ж·±ењідїЎз«‹жі°иЌЇдёљи‚Ўд»Ѕжњ‰й™ђе…¬еЏё Booth Number / е±•дЅЌеЏ·: A316 Address: Beijing City, Chaoyang District, 39 East Third Ring Road outside the SOHO3 No. 1101 ењ°еќЂпјљ еЊ—дє¬её‚жњќй�іеЊєдёњдё‰зЋЇдёи·Ї39еЏ·е»єе¤–SOHO3еЏ·жҐј1101 010-5869 1059 Tel: 010-5869 0218 Fax: [email protected] Email: ж·±ењідїЎз«‹жі°иЌЇдёљи‚Ўд»Ѕжњ‰й™ђе…¬еЏё(Salubris)дёєењЁдёе›Ѕдё»жќїдёЉеё‚гЂЃж‰Ћ ж №дєЋдёе›Ѕзљ„й«�з§‘жЉЂж–°ећ‹иЌЇдёљгЂ‚е…¬еЏёе¤§еЉ›жЋЁиї›з§‘з ”ејЂеЏ‘пјЊе№¶е’Ње›Ѕ е†…е¤–йЎ¶е°–з§‘з ”жњєжћ„зґ§еЇ†еђ€дЅњпјЊе®ћж–Ѕи‡Єдё»зџҐиЇ†дє§жќѓж€�з•Ґе’ЊеђЌз‰Њж€� з•ҐгЂ‚дё“жіЁдєЋжЉ—е‡ќжЉ—ж “з‰еїѓиЎЂз®ЎиЌЇе“Ѓзљ„з ”еЏ‘гЂ‚ е…¬еЏёж‹Ґжњ‰дё–з•Њж°ґе№ізљ„зЋ°д»ЈеЊ–з”џдє§еЋ‚ж€їеЏЉе…€иї›зљ„и®ѕе¤‡е’ЊжЈЂжµ‹д»Є е™ЁпјЊе…·жњ‰й«�иґЁз”џдє§еђ„з§Ќе‰‚ећ‹иЌЇе“Ѓзљ„иѓЅеЉ›гЂ‚ е‡єи‰Ідё“дёљзљ„иђҐй”Ђе›ўй�џеђ‘е№їе¤§зљ„еЊ»з”џжЏђдѕ›дє§е“Ѓдё“дёље¦жњЇжњЌеЉЎгЂ‚е…¬ еЏёзљ„дє§е“ЃењЁе›Ѕе†…е¤–зљ„е¤§дёећ‹еЊ»й™ўз›ёе…ійў†еџџе№їжі›еє”з”ЁпјЊе№¶еѕ—е€°дє† CIT 2012 www.citmd.com EXHIBITORS' DIRECTORY дё“е®¶еЊ»з”џзљ„е¦жњЇи®¤еЏЇгЂ‚2007е№ґе§‹е…¬еЏёиї›е…Ґдёе›ЅеЊ»й™ўз”ЁиЌЇ50ејєгЂ‚ е…¬еЏёењЁеЏ‘е±•иї‡зЁ‹дёеЏ–еѕ—е¤љйЎ№ж€ђз»©пјЊиЋ·еѕ—вЂњ*AAA-*иµ„дїЎз‰зє§иЇЃ д№¦вЂќпј›дёєвЂњж·±ењіеё‚е…€иї›жЉЂжњЇдјЃдёљвЂќгЂЃвЂњж·±ењіеё‚й«�ж–°жЉЂжњЇдјЃдёљвЂќ еЏЉж·±ењіиЎЊдёљ10ејєдјЃдёљпј›е…€еђЋиў«вЂњдёе›ЅдјЃдёљи‡Єдё»е€›ж–°йў†е…€е“Ѓз‰ЊвЂќ е’ЊвЂњдёе›Ѕ100ејєдёЉеё‚дјЃдёљвЂќгЂ‚ дёєдёе›Ѕж‚ЈиЂ…жЏђдѕ›й«�жЂ§д»·жЇ”зљ„дј�з§ЂиЌЇе“Ѓж�Їе…¬еЏёзљ„е®—ж—ЁпјЃ жі°е�‰(зЎ«й…ёж°ўж°ЇеђЎж јй›·з‰‡)ж�ЇдїЎз«‹жі°е…¬еЏёж‹Ґжњ‰и‡Єдё»зџҐиЇ†дє§жќѓзљ„жЉ—иЎЂ е°ЏжќїиЌЇз‰©пјЊе®ѓењЁдёе›Ѕз»ќе¤§йѓЁе€†е¤§еЊ»й™ўеѕ—е€°е№їжі›еє”з”ЁгЂ‚жі°е�‰е‰‚й‡Џ йЂ‚еђ€дёе›Ѕж‚ЈиЂ…еє”з”ЁпјЊж‹Ґжњ‰е¤§й‡Џдёе›Ѕж‚ЈиЂ…еђ„е±‚ж¬ЎдёґеєЉиЇ•йЄЊдј�з§Ђзљ„ ж°ЇеђЎе’Їй›·пјЊиґЁй‡Џж ‡е‡†й«�дєЋзѕЋе›ЅUSP31ж ‡е‡†пјЊе®ѓдёєдёе›Ѕж‚ЈиЂ…её¦жќҐй«� жЂ§д»·жЇ”зљ„з›Ље¤„пјЊжЊЅж•‘ж›ґе¤љзљ„з”џе‘ЅгЂ‚ Beijing Huachenkangjian Health Company Ltd. еЊ—дє¬еЌЋиѕ°еє·еЃҐз§‘жЉЂеЏ‘е±•жњ‰й™ђе…¬еЏё Cardiovascular Research Foundation Booth Number / е±•дЅЌеЏ·: B001 Address: New York, NY 111 East 59th Street, 11th Floor 646-434-4386 Tel: 646-434-4713 Fax: Email: [email protected] The Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education. Since its inception in 1990, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies and therapies in the subspecialty of interventional cardiology and endovascular medicine. Booth Number / е±•дЅЌеЏ·: A317 ењ°еќЂпјљ еЊ—дє¬дё°еЏ°еЊєиЏњж€·иђҐдёњиЎ—з”І88еЏ·й№Џж¶¦е®¶е›и±Єе›Aеє§903 010-6333 2999 Tel: [email protected] Email: Beijing Great Dragon Scientific Instrument Trade Co.,Ltd еЊ—дє¬дјџйѕ™з§‘д»Єиґёж�“жњ‰й™ђе…¬еЏё Booth Number / е±•дЅЌеЏ·: B002 Ziehm Medical Shanghai Co.,Ltd еҐ‡з›®еЊ»з–—е™Ёжў°иґёж�“(дёЉжµ·)жњ‰й™ђе…¬еЏё Booth Number / е±•дЅЌеЏ·: A324 Address: Rm2506-07,No.83,Loushanguan Rd.Shanghai ењ°еќЂпјљ дёЉжµ·её‚й•їе®ЃеЊєеЁ„е±±е…іи·Ї83еЏ·2506-07е®¤ 021-6236 9903 Tel: 021-6236 9916 Fax: [email protected] Email: Ziehm Imaging is the specialist for mobile X-ray based imaging. For about 40 years, our systems have been delivering superb image quality, while minimizing radiation levels. We work closely with our clinical partners and, as a medium size company, have the agility needed to develop tailored solutions. We feel a strong sense of responsibility for both medical staff and patients. еѕ·е›ЅеҐ‡з›®ж€ђеѓЏZiehm Imaging ж�Їз§»еЉЁејЏCи‡‚дє§е“Ѓзљ„е…ЁзђѓзџҐеђЌдјЃдёљ д№‹дёЂпјЊе››еЌЃе№ґжќҐж€‘д»¬е§‹з»€и‡ґеЉ›дєЋCи‡‚Xе°„зєїзі»з»џзљ„з ”еЏ‘гЂЃз”џдє§дёЋ й”Ђе”®пјЊе№¶йЂљиї‡дёЋе›Ѕй™…и‘—еђЌе¤§е¦гЂЃз ”з©¶дёеїѓеЏЉеЊ»й™ўзљ„еЇ†е€‡еђ€дЅњпјЊ дёЌж–ејЂеЏ‘е‡єзЄЃз ґжЂ§зљ„е…€иї›жЉЂжњЇе№¶дЅЌдєЋж™єиѓЅд»‹е…ҐеЅ±еѓЏйў†еџџзљ„жњЂе‰Ќ жІїгЂ‚еҐ‡з›®е€¶йЂ зљ„Cи‡‚дє§е“Ѓд»ҐжЉЂжњЇе€›ж–°дёєеј•еЇјпјЊдёєе®ўж€·её¦жќҐж›ґе¤§зљ„ д»·еЂјпјЊеђЊж—¶д№џдїќйљњдє†еЊ»её€е’Њж‚ЈиЂ…зљ„е®‰е…ЁгЂ‚ Address: Room 818, 59 GaoliangqiaoxieStreet,Haidian District, Beijing, China. ењ°еќЂпјљ еЊ—дє¬её‚жµ·ж·ЂеЊєиҐїз›ґй—Ёй«�зІ±жЎҐж–њиЎ—59еЏ·дёеќ¤е¤§еЋ¦818е®¤ 010-8221 1330-128 Tel: 010-6223 7063 Fax: [email protected] Email: Great Dragon Medical System Ltd, registered in HK and China's mainland, has been agent of many advanced medical equipment manufactures all over the world, such as GE MARQUETTE(GEMS-IT), TYCO HEALTHCARE (Ventilator), SUNLIGHT (Omnisense), I.E.M(Mobil Blood Pressure Recorders), Swemac Imaging(G-arm) etc. In Chia's medical industry field, Great Dragon Medical System Ltd. has obtained good creditability and established steady relationship with customers. We have set up an excellent sales network of more than 50 sub-dealers. A staff of 60 are working in our offices in Beijing, Shijiazhuang, Taiyuan, Inner Mongolia, Tianjing, Guizhou, Nanjin etc. During the long-term co-operation with China's government bodies, we have built very close and good relationships with SDA (State Drug Administration), MOPH (Ministry of Public Health) and Logisty of the PLA. We are one of the major equipment suppliers for the hospitals of the PLA. We are seeking for good, advanced medical products for China's market and are expecting to co-operate with manufactures of those products. Great Dragon is a terrific company worthy of your attention, with whom you can share profit and make progress together. We can be reached at ADD: Room 0158, Block B, Xiqing Apartment, 101 Lian Hui Road, 186 CIT 2012 www.citmd.com EXHIBITORS' DIRECTORY OrbusNeich ж·±ењідёљиЃље®ћдёљжњ‰й™ђе…¬еЏё GE Healthcare Group йЂљз”Ёз”µж°”еЊ»з–—й›†е›ў Booth Number / е±•дЅЌеЏ·: B003 Booth Number / е±•дЅЌеЏ·: дё‰е±‚и§‚ж™Їе¤§еЋ… Address: F-501, Fuhua Mansion,NO.8 Chaoyangmen Street, Dongcheng District,Beijing ењ°еќЂпјљ еЊ—дє¬её‚дёњеџЋеЊєеЇЊеЌЋе¤§еЋ¦Fеє§501 010-6554 2003 Tel: 010-6554 4808 Fax: [email protected] Email: Address: No.1 Huatuo Rd, Shanghai, P.R.China ењ°еќЂпјљ дёЉжµ·еЌЋдЅ—и·Ї1еЏ· 21-3877 4141 Tel: 21-3877 4141 Fax: Email: [email protected] OrbusNeichж�ЇдёЂе®¶и®ѕи®ЎгЂЃз ”еЏ‘гЂЃз”џдє§гЂЃй”Ђе”®еїѓиЎЂз®Ўд»‹е…Ґдє§е“Ѓзљ„ е…¬еЏёпјЊе…¶е‰Ќиє«ж�ЇCordis-NeichгЂЃNeich Medicalе’ЊOrbus MTпјЊд»Ћдє‹ еїѓиЎЂз®Ўйў†еџџеЊ»з–—дє§е“ЃжњЌеЉЎиї‘дё‰еЌЃе№ґпјЊењЁдєље¤ЄеЊ»з–—з•Њдє«жњ‰з››иЄ‰гЂ‚ Neichе…¬еЏё1979е№ґж€ђз«‹дєЋй¦™жёЇпјЊ2005е№ґе€ќпјЊNeichе№¶иґдє†й•їжњџеђ€ дЅњдј™дјґOrbusеЊ»з–—з§‘жЉЂе…¬еЏёеђЋж›ґеђЌдёєOrbusNeichеЊ»з–—е™Ёжў°е…¬еЏёгЂ‚ дЅњдёєдёЂе®¶е…ЁзђѓжЂ§зљ„е…¬еЏёпјЊOrbusNeichе…¬еЏёжЂ»йѓЁи®ѕењЁй¦™жёЇпјЊењЁзѕЋ е›Ѕе’Њдёе›Ѕи®ѕжњ‰з ”еЏ‘дёеїѓпјЊењЁдёе›Ѕе’ЊиЌ·е…°е»єжњ‰е·ҐеЋ‚пјЊењЁй¦™жёЇе’ЊиЌ· е…°и®ѕжњ‰з‰©жµЃе’Ње€†й”ЂдёеїѓпјЊдє§е“Ѓдѕ›еє”и¶…иї‡70дёЄе›Ѕе®¶е’Њењ°еЊєгЂ‚ With the strong R&D ability, perfect management system and good corporate image, we are continuously developing distinctive products in our characteristics with great creativity. Sincerely welcome customers to set up partnership with us. CCRF ж°ёй“иЇљйЃ“(еЊ—дє¬)е’ЁиЇўжњ‰й™ђе…¬еЏё Booth Number / е±•дЅЌеЏ·: B004 Address: Shimao International Center Office Building One, Room 806 Gongti North Road, Chaoyang District ењ°еќЂпјљ жњќй�іеЊєе·ҐдЅ“еЊ—и·Їдё–иЊ‚е›Ѕй™…дёеїѓ1еЏ·жҐј806 010-8405 9198 Tel: 010-8409 4958 Fax: [email protected] Email: CCRF is a leading clinical full services company based in Beijing, China, specialized in medical devices, particularly in interventional cardiology related technologies and products.We are one of the top players in clinical trial management, data management, core lab (QCA, IVUS and OCT), quality assurance, medical writing, IT innovation and medical communication in the arena of medical devices in China.We strive to promote, through strong partnerships, the safe and successful development of therapies aimed at improving patient care.CCRF has partnered with global institutes in the area of clinical research and services since 2009 and determined to deliver quality services for customers. 187 GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, GE Healthcare partners with healthcare leaders, striving to support advances in global policy necessary to implement successful and sustainable healthcare systems. GE Global GE (NYSE: GE) works on things that matter. The best people and the best technologies taking on the toughest challenges. Finding solutions in energy, health and home, transportation and finance. Building, powering, moving and curing the world. Not just imagining. Doing. GE works. For more information, visit the company's website at www.ge.com. CIT 2012 www.citmd.com Acknowledgment 1 CIT organization is a year round effort. Many people play a part in its success by contributing their experience and expertise. The Board of Directors, CIT wishes to give special thanks to all the members of CIT Working Group, who work tirelessly and with great dedication to our mission. Bin Liu Chun Liang Honghua Ye Jie Qian Junqing Yang Lei Ge Qinhua Jin Wei Song Xiaojun Bai Yingjia Xu Yue Li Zhiqi Sun Bin Zhang Chunyu Fan Ji Xu Jingang Zheng Juying Qian Ning Guo Rongchong Huang Weixian Yang Xinkai Qu Yong He Zening Jin Zhujun Shen Binquan Zhou Fei Ye Jian An Jingbo Hou Kai Xu Ning Tan Ruqiong Nie Wenyue Pang Xuebo Liu Yong Zeng Zhan Gao Takeshi Sakamoto Yide Zhang Chen Yun Dong Jinping Feng Zhiyong Gao Yan Liu Bei Yin Yuanyuan Sheryl Ong Dou Linlin Wang Lei Wang Wenjuan Liu Hualin Xu Shanshan Luo Yukun Sebastian Fritsche CIT overseas live case transmission coordinator, Japan CIT overseas case transmission coordinator, Taiwan, China Graphic designer Coordinator, CIT live case transmission Coordinator, CIT scientific Coordinator, CIT scientific Coordinator, CNCC Coordinator, CNCC Coordinator, CIT-Chien Foundation Exhibit services Manager, A/V services Coordinator, CIT live case transmission CCRF CEO, Web & Media support Manager, Media support Manager, Media support M-Events Management Bo Xu Feng Cao Jian Liu Jingyu Hang Kefei Dou Peng Zhao Tao Ye Xiantao Song Yan Li Yonghong Zhu Zheng Wu Chaowei Mu Guisong Wang Jianqiang Li Junjie Zhang Lang Li Qi Zhang Tianzhu Yi Xiaofan Wu Yi Li Yonghong Zhu Zhenyu Liu The Organizing Committee of CIT 2012 wishes to thank Chien Foundation for its educational grant to the CIT-Chien Foundation Young Investigator Award. CIT2012 Official Media Partners: 188 CIT 2012 www.citmd.com Sponsored Services The Organizing Committee wishes to thank the following companies for sponsoring the following Congress services Faculty Lounge & Speaker Ready Room, Mini-program, Signage CIT2012 Best Educational Case Award Name badge & Signage Staff waistcoat , Mineral water, & Pocket progam Internet Station & Poster Boards Registration Area, CIT On-demand Service 189 CIT 2012 www.citmd.com Acknowledgement 2 Board of Directors, China Interventional Therapeutics, wishes to give special thanks to the following companies for their participation and support to this Congress: Abbott Medical Devices Trading (Shanghai) Co., Ltd. Lepu Medical Technology (Beijing) Co., Ltd Agfa HealthCare (Shanghai) Co., Ltd. Liaoning Biomedical Materials R&D Center Co., Ltd. ANGIOPLASTY SUMMIT-TCTAP Lifetech Scientific (Shenzhen) Co., Ltd. AstraZeneca Medfavour(Beijing)Medical Co.,Ltd B.Braun Medical (Shanghai) International Trading Co., Ltd. MEDRAD Medical Equipment Trading Company ? Beijing Bayer Healthcare Medtronic (Shanghai) Management Co., Ltd. Beijing Allian Medical Devices Co., Ltd. Merit Medical Beijing Co., Ltd Beijing Beilu Pharmaceutical Co., Ltd. Microport Medical(Shanghai)Co., Ltd Beijing Demax Medical Technology Co., Ltd. OCC Beijing Great Dragon Scientific Instrument Trade Co., Ltd. OrbusNeich Beijing Huaren Health Science & Technology Developing Co., Ltd. PCR Beijing Huachenkangjian Health Company Ltd. Pfizer Pharmaceutical Ltd. Beijing Kelida Medical Equipment Developing Co., Ltd. Philips Healthcare Bejin Yongton Unted Technology Co., Ltd. Pie Medical Imaging BSC Int'l Medical Trading(Shanghai) Co., Ltd. Promed Medical Tech. (Suzhou) Co., Ltd. Cardiovascular Research Foundation PTS Co. Ltd. CCRF Sanofi (Hangzhou) Pharmaceuticals Co., Ltd. CHC2012 Servier(Tianjin) Pharmaceutical Co., Ltd. Complex Cardiovascular Therapeutics (CCT) Shanghai Bracco Sine Pharmaceutical Corp. Ltd. Covidien Shanghai Kindly Enterprise Development Group Medical Instruments Co., Ltd. Daiichi Sankyo (China) Holdings Co., Ltd. D-Pulse Medical (Beijing) Co., Ltd. Eastern Enterprise Corporation Edwards Lifesciences Essen Technology(Beijing) Co., Ltd. GE Healthcare (Shanghai) Ltd. GE Healthcare Group GW-ICC Haemonetics Corporation Johnson & Johnson JW Medical Systems Ltd. Shenzhen Salubris Pharmaceuticals Co., Ltd. Shimadzu (China) Co., Ltd. Siemens Ltd. China Healthcare Sector Sino Medical Sciences Technology Inc. St. Jude Medical (Shanghai) Co., Ltd. Star Progress Medical Co., Ltd. Stereotaxis Terumo Medical (Shanghai) Co., Ltd. The Medicines Company Ziehm Medical Shanghai Co., Ltd. Kinhely Bio-tech co.,Ltd Lake Region Medical 190 CIT 2012 www.citmd.com Acknowledgment 3 Top Sponsor Premier Sponsor Double Platinum Sponsors Diamond Sponsor Platinum Sponsors Gold Sponsors Silver Sponsors Bronze Sponsors 191 CIT 2012 www.citmd.com MAP ењ°е›ѕ N еЊ—жІ™ж»©жЎҐ Beishatan Qiao AE exit ењ°й“Ѓ8еЏ·зєї еҐҐжћ—еЊ№е…‹е…¬е›з«™ дЅ“и‚ІењєеЊ—и·Ї е›Ѕе®¶дЅ“и‚Ій¦† National Indoor Stadium ж°ґз«‹ж–№ йёџе·ў National Stadium (BirdвЂ™s Nest) China National Aquatics Center (Water Cube) зЋЇ и·Ї еЊ—иѕ°иҐїжЎҐ Beichenxi Qiao дєљиїђжќ‘ Asian Games Village Anli Road Subway Line 8 Olympic Green Station е®‰з«‹ и·Ї еЃҐзї”жЎҐ Jianxiang Qiao е›› China National Convention Center Beichen Eest Road еЊ— е›Ѕе®¶дјљи®®дёеїѓ Tianchen East Road y swa pres ll Ex t Wa Beichen West Road Grea Pangu Hotel Tianchen West Road йЂџ з›�еЏ¤дёѓж�џ Datun Road еЊ— иѕ° дёњ и·Ї е¤©иѕ°иҐї и·Ї еІй«� е›Ѕе®¶дјљи®®дёеїѓ е¤§й…’еє— CNCC Grand Hotel и·Ї е¤©иѕ°дёњ и·Ї е±Ї еЊ— иѕ° иҐї и·Ї е…«иѕѕ е¤§ North 4th Ring Road еЊ—иѕ°жЎҐ Beichen Qiao е®‰ж…§жЎҐ Anhui Qiao 192 дј ж‰їдј�ж•€ жЊЃз»е€›ж–°